<SEC-DOCUMENT>0001213900-21-032158.txt : 20210611
<SEC-HEADER>0001213900-21-032158.hdr.sgml : 20210611
<ACCEPTANCE-DATETIME>20210611171706
ACCESSION NUMBER:		0001213900-21-032158
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		21
FILED AS OF DATE:		20210611
DATE AS OF CHANGE:		20210611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Regencell Bioscience Holdings Ltd
		CENTRAL INDEX KEY:			0001829667
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-254571
		FILM NUMBER:		211012301

	BUSINESS ADDRESS:	
		STREET 1:		11/F FIRST COMMERCIAL BUILDING
		STREET 2:		33-35 LEIGHTON ROAD, CAUSEWAY BAY
		CITY:			HONG KONG
		STATE:			K3
		ZIP:			999077
		BUSINESS PHONE:		852 2155 0823

	MAIL ADDRESS:	
		STREET 1:		11/F FIRST COMMERCIAL BUILDING
		STREET 2:		33-35 LEIGHTON ROAD, CAUSEWAY BAY
		CITY:			HONG KONG
		STATE:			K3
		ZIP:			999077
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>ea142369-f1a2_regencellbio.htm
<DESCRIPTION>AMENDMENT NO. 2 TO FORM F-1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>As filed with the Securities and Exchange
Commission on June 11, 2021</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"> <B>Registration No. 333-254571</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>AMENDMENT NO. 2 TO</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM F-1</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGENCELL BIOSCIENCE HOLDINGS LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified
in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cayman
    Islands</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2833</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not
    Applicable</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of<BR>
    incorporation or organization)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary
    Standard Industrial<BR>
    Classification Code Number)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer<BR>
    Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">11/F First Commercial Building</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">33-35 Leighton Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Causeway Bay, Hong Kong</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">+ 852 2155 0823</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code, and telephone
number, including area code, of registrant&rsquo;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Puglisi &amp; Associates</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">850 Library Avenue, Suite 204</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Newark, Delaware 19711</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">302-738-6680</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code, and
telephone number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>With a Copy to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 40%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Joan
                                         Wu, Esq.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Arila Zhou, Esq.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Hunter Taubman Fischer &amp; Li
        LLC</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">800 Third Avenue, Suite 2800</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">New York, NY 10022</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tel: 212.530.2208</P></TD>
    <TD STYLE="vertical-align: bottom; width: 20%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 40%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Mitchell
                                         Nussbaum, Esq.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Angela M. Dowd, Esq.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Loeb &amp; Loeb LLP</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">345 Park Avenue</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">New York, NY 10154</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tel: 212.407.4000</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Approximate date of commencement of proposed sale to the
public:</B> Promptly after the effective date of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If any of the securities being registered on this Form are
to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box:
&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is filed to register additional securities for
an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is a post-effective amendment filed pursuant to
Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company &#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company that prepares its financial statements
in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt"> <B>&nbsp;</B> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Title of Each Class of Securities to Be Registered</B> </P></TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed
    Maximum<BR>
    Aggregate Offering<BR>
    Price<SUP>(1)(2)</SUP></B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount
    of<BR>
    Registration<BR>
    Fee<SUP>(6)</SUP></B></FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 76%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary shares, par value $0.00001
    per share<SUP>(1) (3)</SUP></FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,772,500.00</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,029.98</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriter&rsquo;s Warrants<SUP>(4)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary shares, par value $0.00001 per share, underlying
    Underwriter&rsquo;s Warrants<SUP>(5)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">763,743.75</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">83.32</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,536,243.75</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,113.30</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Estimated solely for purposes of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. Includes the offering price of ordinary shares that the underwriter has the option to purchase to cover over-allotments, if any.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In accordance with Rule 416(a), the Registrant is also registering an indeterminate number of additional Ordinary Shares that shall be issuable pursuant to Rule 416 to prevent dilution resulting from share splits, share dividends or similar transactions.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Estimated solely for the purpose of determining the amount of registration fee in accordance with Rule 457(o) under the Securities Act.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(4)</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">No separate fee is required pursuant to Rule 457(i) of the Securities Act. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT> </TD>
    <TD><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> The Registrant will issue to the underwriter warrants to purchase
        a number of Ordinary Shares equal to an aggregate of 2.5% of the total number of ordinary shares (the &ldquo;Underwriter Warrants&rdquo;)
        sold in the offering. The Underwriter Warrants will have an exercise price of 110% of the public offering price per ordinary
        shares sold in the offering. The Underwriter Warrants are exercisable commencing six (6) months immediately following the closing
        of this offering for a period of five (5) years after the closing of this offering, at any time, and from time to time, in whole
        or in part. As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities
        Act. Resales of ordinary shares issuable upon exercise of the Underwriter Warrants on a delayed or continuous basis pursuant
        to Rule 415 under the Securities Act are also registered hereby. </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT> </TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> The registration fee of US$3,113.30 is calculated in accordance
        with Rule 457(o) of the Securities Act. On March 22, 2021, the Registrant made the initial filing of this Registration Statement
        on Form F-1 (File No. 333- 254571), or the Initial Registration Statement, relating to a proposed maximum aggregate offering
        price of $ 17,724,375 (calculated in accordance with the aggregate gross proceeds), and paid a registration fee of US$1,933.73
        calculated in accordance with Rule 457(o) of the Securities Act. Therefore, an additional registration fee of US$1,179.57 due
        relating to the revised proposed maximum aggregate offering price for the securities offered by this amendment to the Initial
        Registration Statement has been paid with respect to this offering. </P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Registrant hereby amends this registration statement
on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the
Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities
and Exchange Commission, acting pursuant to such Section 8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>EXPLANATORY NOTE</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> On May 31, 2021, we effectuated a forward
split at a ratio of 1,000-for-1 to increase our authorized capital shares from 100,000,000 Ordinary Shares with a par value of $0.01
per share to 100,000,000,000 Ordinary Shares with a par value of $0.00001 per share (the &ldquo;2021 Forward Split&rdquo;). As a result
of the 2021 Forward Split, we now have 10,000,000 Ordinary Shares issued and outstanding as of the date hereof. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> All share numbers, option numbers, warrant numbers, other derivative
security numbers and exercise prices appearing in this registration statement have been adjusted to give effect to the 2021 Forward Split,
unless otherwise indicated or unless the context suggests otherwise. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Red"><B>The information in this prospectus
is not complete and may be changed. We may not sell the securities until the registration statement filed with the Securities
and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting
any offer to buy these securities in any jurisdiction where such offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Red"><B>SUBJECT TO
COMPLETION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="color: Red"><B>PRELIMINARY PROSPECTUS
DATED JUNE 11, 2021</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B><I>2,300,000 Ordinary Shares</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGENCELL BIOSCIENCE HOLDINGS LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> This is an initial public offering of our ordinary
shares. We are offering on a firm commitment basis, 2,300,000 ordinary shares, $0.00001 par value per share (&ldquo;Ordinary Shares&rdquo;).
The estimated initial public offering price per Ordinary Share is between $8.50 and $10.50. We have applied to list our Ordinary Shares
on the Nasdaq Capital Market under the symbol &ldquo;RGC.&rdquo; There can be no assurance that we will be successful in listing our
Ordinary Shares on the Nasdaq Capital Market; however, we will not complete this offering unless we receive approval for listing on Nasdaq
Capital Market. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Investing in our Ordinary Shares involves
a high degree of risk, including the risk of losing your entire investment. See &ldquo;Risk Factors&rdquo; beginning on page&nbsp;14
to read about factors you should consider before buying our Ordinary Shares.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Neither the Securities and Exchange
Commission nor any state securities commission nor any other regulatory body has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are an &ldquo;emerging growth company&rdquo;
as defined under the federal securities laws and will be subject to reduced public company reporting requirements. Please read
the disclosures beginning on page&nbsp;iii of this prospectus for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mr. Yat-Gai Au, our founder, director, and
Chief Executive Officer (the &ldquo;CEO&rdquo;), currently owns approximately 100% of our Ordinary Shares. Upon the closing of
this offering, Mr. Yat-Gai Au will continue to own a controlling interest in us and we will meet the definition of a &ldquo;controlled
company&rdquo; under the corporate governance standards for Nasdaq listed companies and we will be eligible to utilize certain
exemptions from the corporate governance requirements of the Nasdaq Stock Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
    Share</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 78%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public offering price</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 8%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 8%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriter discount (1)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds to us, before expenses</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have agreed to reimburse the underwriter for certain expenses. See the section titled &ldquo;Underwriting&rdquo; beginning on page 104 of this prospectus for additional disclosure regarding underwriter compensation and offering expenses.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have granted the underwriter an option to
purchase from us, at the public offering price, up to additional&nbsp;345,000&nbsp;Ordinary Shares, less the underwriting discounts and
commissions, within&nbsp;45 days from the date of this prospectus to cover over-allotments, if any. If the representative of the underwriters
exercises the option in full, the total underwriting discounts and commissions payable will be $_______, and the total proceeds to us,
before expenses, will be $_______. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The underwriter expects to deliver the
shares to purchasers in the offering on or about ______, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Sole Book-Running Manager</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Maxim Group LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus dated [&#9679;],
2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 92%; padding-left: 9pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DISCLOSURE
    REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">iii</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
    SUMMARY</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">1</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
    OFFERING</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">12</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RISK
    FACTORS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">14</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENFORCEABILITY
    OF CIVIL LIABILITY</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">35</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>USE
    OF PROCEEDS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">36</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIVIDEND
    POLICY</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">37</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CAPITALIZATION</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">38</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DILUTION</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">39</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MANAGEMENT
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">40</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDUSTRY
    OVERVIEW</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">49</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OUR
    BUSINESS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">53</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGULATIONS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">71</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MANAGEMENT</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">76</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXECUTIVE
    COMPENSATION</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">81</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRINCIPAL
    SHAREHOLDERS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">83</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RELATED
    PARTY TRANSACTIONS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">84</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
    OF SHARE CAPITAL</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">86</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHARES
    ELIGIBLE FOR FUTURE SALE</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">99</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TAXATION</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">100</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDERWRITING</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">104</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LEGAL
    MATTERS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">112</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_023"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHANGES
    IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">112</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_024"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXPERTS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">112</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_025"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INTEREST
    OF NAMED EXPERTS AND COUNSEL</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">112</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_026"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DISCLOSURE
    OF COMMISSION POSITION ON INDEMNIFICATION</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">112</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_027"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHERE
    YOU CAN FIND MORE INFORMATION</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">112</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_028"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>EXPENSES
    RELATING TO THIS OFFERING</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">113</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#RB_DRS_029"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEX
    TO FINANCIAL STATEMENTS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-1</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>About this Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We and the underwriter have not authorized
anyone to provide any information or to make any representations other than those contained in this prospectus or in any free
writing prospectuses prepared by us or on our behalf or to which we have referred you. We take no responsibility for, and can
provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to
sell only the Ordinary Shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. We
are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted or where the person
making the offer or sale is not qualified to do so or to any person to whom it is not permitted to make such offer or sale. The
information contained in this prospectus is current only as of the date on the front cover of the prospectus. Our business, financial
condition, results of operations and prospects may have changed since that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Other Pertinent Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless otherwise indicated or the context
requires otherwise, references in this prospectus to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-left: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;China&rdquo;
    or the &ldquo;PRC&rdquo; are to the People&rsquo;s Republic of China, excluding Taiwan and the special administrative regions
    of Hong Kong and Macau for the purposes of this prospectus only;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Hong Kong&rdquo; is to the Hong Kong
    Special Administrative Region of the People&rsquo;s Republic of China for the purposes of this prospectus only;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>&ldquo;HK$&rdquo; refers to the legal currency of Hong Kong;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Regencell Bioscience Holdings&rdquo;
    is to Regencell Bioscience Holdings Limited, a Cayman Islands exempted company incorporated under the laws of Cayman Islands;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Regencell Bioscience Limited&rdquo; is to Regencell Bioscience Limited, a Hong Kong limited liability company organized under the laws of Hong Kong and a wholly-owned subsidiary of Regencell Bioscience Holdings Limited;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Regencell (BVI) Limited&rdquo; is to Regencell (BVI) Limited, a British Virgin Islands business company organized under the laws of British Virgin Islands;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Regencell Limited&rdquo; is to Regencell Limited, a Hong Kong limited liability company organized under the laws of Hong Kong and a wholly-owned subsidiary of Regencell Bioscience Holdings Limited;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"> &nbsp; </TD>
<TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
<TD> &ldquo;Shares&rdquo;, &ldquo;shares&rdquo; or &ldquo;Ordinary Shares&rdquo; are to the Ordinary Shares of Regencell Bioscience
Holdings Limited, par value $0.00001 per share; </TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;TCM&rdquo; refers to Traditional Chinese Medicine; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;The TCM Practitioner&rdquo; or &ldquo;our TCM Practitioner&rdquo; refers to our strategic TCM research partner, Mr. Sik-Kee Au, father of our Chief Executive Officer and director; and</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We&rdquo;, &ldquo;us&rdquo;, &ldquo;RGC&rdquo;,
    the &ldquo;Company&rdquo; or the &ldquo;Group&rdquo; are to one or more of Regencell Bioscience Holdings and its affiliated entities.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business is conducted in Hong Kong
through our Hong Kong subsidiary Regencell Bioscience Limited since our inception, using Hong Kong dollars, the currency of
Hong Kong. In October 2020, we opened our California office. Currently, we are not actively developing the U.S. market and
will conduct preliminary market research once our TCM products obtain regulatory approvals and achieve success in Hong Kong.
Our consolidated financial statements are presented in United States dollars. In this prospectus, we refer to assets,
obligations, commitments and liabilities in our consolidated financial statements in United States dollars. These dollar
references are based on the exchange rate of Hong Kong dollars to United States dollars, determined as of a specific date or
for a specific period. Changes in the exchange rate will affect the amount of our obligations and the value of our assets in
terms of United States dollars which may result in an increase or decrease in the amount of our obligations (expressed in
dollars) and the value of our assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On May 31, 2021, we effectuated
a forward split at a ratio of 1,000-for-1 to increase our authorized capital shares from 100,000,000 Ordinary Shares with a par value
of $0.01 per share to 100,000,000,000 Ordinary Shares with a par value of $0.00001 per share (the &ldquo;2021 Forward Split&rdquo;).
As a result of the 2021 Forward Split, we now have 10,000,000 Ordinary Shares issued and outstanding as of the date hereof. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in"> All share numbers, option
numbers, warrant numbers, other derivative security numbers and exercise prices appearing in this registration statement have been adjusted
to give effect to the 2021 Forward Split, unless otherwise indicated or unless the context suggests otherwise. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_001"></A><B>FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have made statements in this prospectus,
including under &ldquo;Prospectus Summary,&rdquo; &ldquo;Risk Factors,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations,&rdquo; &ldquo;Our Business&rdquo; and elsewhere that constitute forward-looking
statements. Forward-looking statements involve risks and uncertainties, such as statements about our plans, objectives, expectations,
assumptions or future events. In some cases, you can identify forward-looking statements by terminology such as &ldquo;anticipate,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;project,&rdquo; &ldquo;continuing,&rdquo; &ldquo;ongoing,&rdquo; &ldquo;expect,&rdquo;
&ldquo;we believe,&rdquo; &ldquo;we intend,&rdquo; &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;could&rdquo;
and similar expressions denoting uncertainty or an action that may, will or is expected to occur in the future. These statements
involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ
materially from any future results, performances or achievements expressed or implied by the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Examples of forward-looking statements
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of the development of future services;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">projections of revenue, earnings, capital structure
    and other financial items;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the development of future company-owned branches;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">statements regarding the capabilities of our
    business operations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">statements of expected future economic performance;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">statements regarding competition in our market;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assumptions underlying statements regarding
    us or our business.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ultimate correctness of these forward-looking
statements depends upon a number of known and unknown risks and events. We discuss our known material risks under the heading
&ldquo;Risk Factors&rdquo; below. Many factors could cause our actual results to differ materially from those expressed or implied
in our forward-looking statements. Consequently, you should not place undue reliance on these forward-looking statements. The
forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation
to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to
reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the
extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any
forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
    <DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_002"></A><B>PROSPECTUS
SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>The following summary is qualified in
its entirety by, and should be read in conjunction with, the more detailed information and financial statements included elsewhere
in this prospectus. In addition to this summary, we urge you to read the entire prospectus carefully, especially the risks of
investing in our Ordinary Shares, discussed under &ldquo;Risk Factors,&rdquo; before deciding whether to buy our Ordinary Shares.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are an early-stage bioscience company
that focuses on research, development and commercialization of TCM for the treatment of neurocognitive disorders and degeneration,
specifically Attention Deficit Hyperactivity Disorder (&ldquo;ADHD&rdquo;) and Autism Spectrum Disorder (&ldquo;ASD&rdquo;). Our
goal is to improve the lives of ADHD and ASD patients, their families and caregivers and become a market leader for the best treatment
of ADHD and ASD globally. We started in Hong Kong in 2014 with main operation and assets in Hong Kong. We aim to launch three liquid-based
standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients in Hong Kong first and subsequently to
other markets as we deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We strategically partner with Mr. Sik-Kee Au,
our TCM Practitioner, the father of our CEO and director. We have three standardized TCM formulae candidates under development targeting
mild, moderate and severe ADHD and ASD conditions. We plan to commence our second research study using the three standardized TCM formulae
candidates in the third quarter of 2021. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our TCM formulae candidates are derived from
a TCM base formula and an adjustable formula developed by our TCM Practitioner based on his TCM brain theory, known as &ldquo;Sik-Kee
Au TCM Brain Theory&trade;&rdquo;, and has demonstrated reduced severity in patients&rsquo; ADHD and ASD conditions, as reflected in
lower ATEC, GARS, VADRS and SNAP-IV-26 assessment scores, using the personalized TCM formula in our first research study. The activity
and specificity of the TCM base formula have been optimized by the TCM Practitioner in his prior ADHD and ASD treatments. As of the date
hereof, the TCM Practitioner has standardized the adjustable formula into three fixed formulae (&ldquo;Fixed Adjusted Formula&rdquo;)
for mild, moderate and severe ADHD and ASD conditions. The TCM brain theory is not recognized in general literature of TCM or elsewhere.
However, the TCM Practitioner has prescribed the TCM base formula based on his TCM brain theory for over 30 years to treat ADHD, ASD
and many neurological illnesses, disorders and degeneration and obtained satisfactory clinical treatment results. Such clinical treatment
results are not supported by controlled clinical data or trials. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have been headquartered in Hong Kong
since our inception. In October 2020, we opened our California office. Currently, we are not actively developing the U.S. market
and will conduct preliminary market research once our TCM products obtain regulatory approvals and achieve success in Hong Kong.
We have been keeping books and records in Hong Kong since our inception. Our research study and supply of TCM raw materials are
in Hong Kong. As we are still at the stage of conducting TCM research, we have not applied for regulatory approvals, we have no
sales, marketing or distribution capabilities or experience and no granted patents or pending patent applications, and we have
not generated revenues since inception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Business Plan and Growth Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our goal is to improve the lives of ADHD
and ASD patients, their families and caregivers and become a market leader for the best treatment of ADHD and ASD globally. The
TCM Practitioner has been treating ADHD and ASD patients for over 30 years and we intend to commercialize the TCM formulae utilized
in his treatment first in Hong Kong and subsequently globalize the use of such TCM formulae in order to address the unmet medical
needs of the growing ADHD and ASD patient population in other countries such as the U.S. We aim to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">show in a quantifiable and systematic way that the personalized
TCM formulae is effective for the treatment of ADHD and ASD in our first research study;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">file patent applications in Hong Kong and abroad;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">verify the effectiveness of the standardized TCM formulae in
our second research study;</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid"><P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">set up centralized production facilities to streamline our
production and support our application for the approval and registration of our proprietary Chinese medicine (&ldquo;pCm&rdquo;);</P>   </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">brand and commercialize our standardized TCM formulae candidates;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">expand to other locations globally; and</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">conduct further research and development on the TCM base formula
for other applications.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT="" STYLE="width: 650px; height: 322px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 5pt 0 0pt; text-indent: 0.5in">The projected timeline above is what we
aim to achieve but there is no guarantee that any of the listed milestones will be met in the time noted or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of the date hereof, we have completed our
first research study with the TCM Practitioner and have three standardized TCM formulae candidates under development targeting mild,
moderate and severe ADHD and ASD patients. We plan to commence our second research study using the three standardized TCM formulae candidates
in the third quarter of 2021. We intend to conduct further investigation and research on the application of the TCM base formula for
other neurological illnesses, disorders and degeneration. We will also commercialize our standardized TCM formulae candidates by building
our own specialized sales and marketing organization initially in Hong Kong after obtaining necessary approvals from Hong Kong regulatory
agencies. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TCM Industry in Hong Kong</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We conduct our research and operation in
Hong Kong and plan to commercialize our standardized TCM formulae candidates for ADHD and ASD patients in the Hong Kong market
first. Whilst Hong Kong is part of the PRC, the TCM industry and regulations in the PRC are inapplicable to us in Hong Kong because
Hong Kong and the PRC are regarded as two separate markets and jurisdictions in law. Under the &ldquo;One Country, Two Systems&rdquo;,
Hong Kong retains its own systems and way of life after the handover of sovereignty to the PRC in 1997. The Legislative Council
of Hong Kong, Chinese Medicine Council, Chinese Medicines Board and Chinese Medicine Regulatory Office of Department of Health
of Hong Kong are independent and separate entities from the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Hong Kong Basic Law (the &ldquo;Basic
Law&rdquo;), being Hong Kong&rsquo;s constitutional document, gives legal effect to the &ldquo;One Country, Two Systems&rdquo;
policy. Pursuant to the Basic Law, the laws previously in force in Hong Kong, that is, the common law, rules of equity, ordinances,
subordinate legislation and customary law shall be maintained, except for any that contravene the Basic Law, and subject to any
amendment by the Legislative Council of Hong Kong. The socialist system and policies shall not be practiced in Hong Kong, and
the previous capitalist system and way of life shall remain unchanged for 50 years. Hence, within Hong Kong&rsquo;s legal system,
the laws and regulations of the PRC do not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

</DIV>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>TCM Industry</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">TCM has a long history in Hong Kong. The
TCM industry in Hong Kong is regulated by the Hong Kong Chinese Medicine Ordinance (&ldquo;HKCMO&rdquo;), which was passed by the
Legislative Council of Hong Kong in July 1999. <FONT STYLE="background-color: white">The Chinese Medicine Council of Hong Kong,
or the Council, is a statutory body established in September 1999 under the Hong Kong Chinese Medicine Ordinance. The Council is
responsible for implementing regulatory measures for Chinese medicine. </FONT>The Council implemented the licensing system of TCM
traders and the registration system of proprietary Chinese medicine (&ldquo;pCm&rdquo;) by phases. The role of TCM is now well
established and the dispensation, storage and labeling of Chinese herbal medicines have been regulated since 2003. The safety,
efficacy and quality of pCm will be assessed by the Hong Kong Chinese Medicines Board, which was established in 1999 under the
HKCMO, before the products being allowed to be registered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of June 2020, there were over 10,000
TCM practitioners in Hong Kong, compared with 14,600 doctors of western medicine. These TCM practitioners have an important role
to contribute to Hong Kong&rsquo;s health care system. Since the supportive initiatives were launched by the Hong Kong government
in 1997, the TCM industry has grown into one of the main industries in the healthcare sector. According to the list on the website
of the Council, as of December 2020, there are over 6,000 TCM stores, wholesalers and other distribution channels in Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Hong Kong Government is committed to
promoting TCM, and has implemented measures including creation of a network of institutions of high standing for research and
development work, development of new drugs for enhancement of the competitiveness of the Chinese medicine industry, and setting
up of research funds for the support of research in Chinese medicine. Under the Hong Kong Government&rsquo;s policy direction
to promote the development of &ldquo;evidence-based&rdquo; TCM and out-patient TCM services in the public sector, as well as to
provide training placements for local TCM degree program graduates, the Hong Kong Hospital Authority was tasked to establish a
total of 18 Chinese Medicine Centers for Training and Research (&ldquo;CMCTRs&rdquo;) in each of the 18 districts of Hong Kong
since 2003. In 2018, the total number of attendances at the 18 CMCTRs was about 1.2 million. In the 2018-19 Hong Kong Government
Budget, a Chinese Medicine Development Fund of HK$500 million was set up to facilitate applied research and Chinese medicine specialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Key Differences between Regulated Pharmaceutical Industry
and TCM Industry in Hong Kong </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Currently in Hong Kong, there are several
U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) and Hong Kong Pharmacy and Poisons Board approved drugs available to treat
ADHD and ASD symptoms that are manufactured by global pharmaceutical companies. However, we are a TCM bioscience company focusing on
TCM holistic treatments and do not compete directly with those pharmaceutical companies. Although both pharmaceutical drugs and TCM
are regulated by the Import and Export Ordinance and the Undesirable Medical Advertisements Ordinance, there are several key
differences between the regulated pharmaceutical drug industry and the TCM industry in Hong Kong. For example, pharmaceutical drugs
are principally regulated under the Pharmacy and Poisons Ordinance (&ldquo;PPO&rdquo;) and the Antibiotics Ordinance and Dangerous
Drugs Ordinance, while TCM is principally regulated by the HKCMO. Furthermore, all pharmaceutical manufacturers with manufacturing
capability in Hong Kong must comply with the Hong Kong Good Manufacturing Practices (&ldquo;GMP&rdquo;), whereas TCM manufacturers
are not required to have GMP certifications. In terms of registration, pharmaceutical drugs sold in the Hong Kong market must be
registered with the Hong Kong Pharmacy and Poisons Board, while pCm formulae products are registered with the Hong Kong Chinese
Medicines Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Based on research provided
by Persistence Market Research, no large TCM companies are providing similar ADHD and ASD products in the Hong Kong market. As
such, the TCM ADHD and ASD markets are highly fragmented and there is no large TCM competitor in our target market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Research and Competitive Strengths </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our TCM Practitioner</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We strategically partner with the TCM Practitioner,
the father of Mr. Yat-Gai Au, our CEO and director. Pursuant to the strategic partnership agreement and the supplemental agreement
(collectively, the &ldquo;Partnership Agreements&rdquo;) we have with the TCM Practitioner, we have exclusive rights and ownership
of (1) all his TCM formulae and (2) the intellectual property rights of the TCM formulae, including research and development, trademark,
copyright, patent and any other intellectual property rights in relation to the TCM formulae that the TCM Practitioner develops.
Pursuant to the Partnership Agreements, the TCM Practitioner is responsible for research and development of TCM formulae for ADHD
and ASD patients, however, any inventions, TCM formulae, utilities, improvements, research, discoveries, designs, processes, methods
of manufacture and products conceived or made by the TCM Practitioner in relation to his TCM research shall be the sole and exclusive
property of us. To support the TCM Practitioner&rsquo;s continued research, we undertake to pay for all reasonable costs and expenses
incurred by the TCM Practitioner in conducting research, testing, attending meetings/seminars, compiling records, or performing
any similar acts in relation to the development of the TCM formulae. In furtherance of our research, development and commercialization
of TCM formulae candidates, we have direct supervision and control over the TCM Practitioner&rsquo;s TCM formulae research pursuant
to the Partnership Agreements. We have full discretion to assign, refine, update, or redesign the TCM Practitioner&rsquo;s research
tasks from time-to-time pursuant to the Partnership Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The TCM Practitioner has been practicing
TCM under the guidance of the HKCMO in his clinic in Hong Kong since 1999 and has accumulated in-depth experience of TCM research
and clinical practice. For over 30 years the TCM Practitioner has focused his TCM study on TCM thesis of his father, who was a
renowned TCM doctor in Hong Kong in the 1950s, and other traditional treatises of TCM. He is experienced in treating patients suffering
from a wide range of neurocognitive disorders and degeneration. In particular, the TCM Practitioner has treated many children afflicted
with ADHD and ASD during his practice. He has always been passionate about treating patients and giving back to society. He decided
to dedicate all his efforts to treat people afflicted with incurable diseases, illnesses and disorders. Prior to starting his TCM
clinical practice, the TCM Practitioner founded a successful technology and property business in California. The TCM Practitioner
graduated from the University of California, Berkeley with Bachelor&rsquo;s and Master&rsquo;s Degrees in Electrical Engineering
in Circuit Design and Network Theory. He was the pioneer who invented the prototype high-density recording drive on flexible media
while working at IBM, which later became known as Iomega Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>TCM Research Studies and Standardized TCM Formulae Candidates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>TCM Research Study</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Seven (7) of the TCM Practitioner&rsquo;s
patients in Hong Kong, who were clinically diagnosed with ADHD or ASD by their healthcare professionals at different levels of
severity, voluntarily consented through their parents or guardians to participate in our first research study in November 2018
and March 2019. In the first research study, the TCM Practitioner treated the enrolled patients with the use of the personalized
TCM formulae. The personalized TCM formulae were comprised of two formula components, a base formula and an adjustable formula
targeting different severity of symptoms. The base TCM formula is the product of Sik-Kee Au TCM Brain Theory&trade;, which is used
to treat ADHD and ASD by the TCM Practitioner over his 30 years of practice. The adjustable formula is &ldquo;personalized&rdquo;
to each patient for different severity of symptoms. The enrolled patients&rsquo; ages ranged from five to twelve years old. Six
of the enrolled patients completed a three-month treatment and one completed a two-month treatment. Under the treatment by the
TCM Practitioner, the enrolled patients consumed liquid-based TCM twice a day, which was prepared based on personalized TCM formulae
by our TCM Practitioner, and temporarily stopped consuming any other medicines. All the enrolled patients and their parents were
required to meet with the TCM Practitioner in his clinic weekly and provide regular reports to update the patients&rsquo; symptoms
and conditions by phone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We used globally accepted assessment tools
such as Autism Treatment Evaluation Checklist (&ldquo;ATEC&rdquo;), Gilliam Autism Rating Scale (&ldquo;GARS&rdquo;), Vanderbilt ADHD
Diagnostic Parent Rating Scale (&ldquo;VADRS&rdquo;) and Swanson, Nolan, and Pelham (SNAP)-IV 26-item Parent Rating Scale (&ldquo;SNAP-IV-26&rdquo;),
together with additional assessments, written observations, photos, videos and parent testimonials to track the enrolled patients&rsquo;
progress. Within three months of using our TCM formulae, our research showed that the enrolled patients had attained better speech, communication,
sociability, cognition and behavioral abilities. The enrolled patients using the personalized TCM formulae prescribed by the TCM Practitioner
also experienced better bowel movement, sweating and temporary fatigue as part of the improvement process. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



</DIV>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Standardized TCM Formulae Candidates and Second Research
Study</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of the date hereof,
the TCM Practitioner has standardized the adjustable formula into three fixed formulae for mild, moderate and severe conditions. As a
result, we have three standardized TCM formulae candidates under development targeting mild, moderate and severe ADHD and ASD patients,
each consisting of a standard base formula and a fixed adjusted formula. We plan to commence our second research study using the three
standardized TCM formulae candidates in the third quarter of 2021. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The standardized TCM formulae candidates
were developed on the premise of Sik-Kee Au TCM Brain Theory&trade;, which explains why a healthy brain is essential in restoring
the body&rsquo;s systems to normal from disorders and illnesses such as ADHD and ASD. The TCM brain theory is not recognized in
general literature of TCM or elsewhere. However, the TCM Practitioner has prescribed the TCM base formulae based on his TCM brain
theory for over 30 years to treat ADHD, ASD and many neurological illnesses, disorders and degeneration and obtained satisfactory
clinical treatment results. Such clinical treatment results are not supported by controlled clinical data or trials. According
to the TCM brain theory, the blockage of or reduced blood flow, and damage of the interconnecting central nervous system, endocrine
system and blood circulatory system disrupt the production of hormones and transmission of neurotransmitters, such as melatonin,
dopamine and norepinephrine, leading to a defective encoding and decoding of functions and resulting in deficient or abnormal social
behaviors that are the hallmarks of ADHD and ASD. Our standardized TCM formulae candidates aim to address the fundamental cause
of the disorders to achieve an optimal outcome compared to available stimulant and non-stimulant medications currently available
in the market. The fundamental properties and treatment process of TCM are different from the mainstream stimulant and non-stimulant
medications. TCM takes a holistic approach, using natural ingredients to treat different elements within the body. Every bodily
function is taken into consideration when preparing the TCM formulae for the patients so that the optimal results of the treatment
could be reached. This explains the improvements in both their symptoms and overall health. As provided in the Partnership Agreements,
we continue to work closely with the TCM Practitioner to include those treatments in our future development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We seek to protect our standardized TCM
formulae candidates, including the TCM base formula and the fixed adjusted TCM formulae, and technology that we consider commercially
important by filing patent applications in Hong Kong and abroad. In addition, we also rely on trade secrets or TCM related regulatory
protection to protect our intellectual property. Our trade secrets and confidential information include unpatented know-how, technology
and other proprietary information, to maintain our competitive position and to protect our TCM formulae candidates. We seek to
protect these trade secrets and confidential information, in part, by entering into non-disclosure and confidentiality agreements
with parties that have access to them. Further, we also rely on or intend to rely on our trademarks, trade names and brand names
to distinguish our products from the products of our competitors, and have registered or will apply to register a number of these
trademarks. We have received trademark certificates for &ldquo;&#33126;&#36996;&#21407;<SUP>&reg;</SUP>&rdquo; (directly translates
as &ldquo;brain restoration&rdquo;) and &ldquo;RGC Regencell<SUP>&reg;</SUP>&rdquo; from the Hong Kong Registrar of Trade Marks
in July 2020. We also filed a trademark application for &ldquo;Sik-Kee Au TCM Brain Theory&trade;&rdquo; in January 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Regulatory Approvals Prior to Commercialization in Hong
Kong</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the outcome of further research
and development, if we commercialize our TCM formulae candidates in Hong Kong, the Company will need to receive a manufacturer
license issued by the Hong Kong Chinese Medicines Board. Once we receive the license and complete pCm registrations for our standardized
TCM formulae candidates, our standardized pCm formulae products can be manufactured and sold over the counter without the supervision
and prescription of a TCM practitioner in Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When applying for registration of pCm in
Hong Kong, we will be required to provide sufficient documents to show the safety, stability, quality and efficacy of our pCm
formulae products to the Hong Kong Chinese Medicines Board. To show the efficacy of our pCm formulae products, documents required
include reference materials in which the claimed therapeutic functions are supported by research studies, interpretation and principle
of formulating a prescription and a summary report on all the product efficacy documents. To prove the safety, stability and quality
of our pCm formulae products, we will work with accredited laboratories, a list of which is provided by the Hong Kong Chinese
Medicines Board, to conduct all the necessary tests, such as heavy metals and toxic element test and pesticide residues test.
As for the application of manufacturer license, the major documents required are a brief floor plan of the premise and a list
of manufacturing equipment. GMP certification is not required for the manufacturing of pCm in Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our current primary roles include recruiting
and arranging patients to be treated by the TCM Practitioner, collecting research data from patients, conducting analysis over
research data, and planning for commercialization of our standardized TCM formulae candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Estimated Time and Cost Prior to the Commercialization of
Our Standardized TCM Formulae Candidates in Hong Kong</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We estimate that it will take us approximately
four years to commercialize our standardized TCM formulae candidates in Hong Kong, including as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately
                                         one year to complete our second research study, including enrollment of qualified patients
                                         for treatment by qualified TCM practitioner(s) with the use of our standardized TCM formulae
                                         candidates, assessment and analysis;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Approximately one year to develop an efficient centralized production
process to manufacture our liquid-based standardized TCM formulae candidates, set up our centralized production facility and apply
for manufacturer license with the Hong Kong Chinese Medicines Board after our second research study;</P></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Approximately one year to prepare for efficacy documents and
conduct tests, including safety, quality and stability tests upon completion of our centralized production process and approval
of manufacturer license; and</P></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately
                                         one year or more for review process of our pCm registration application after submission
                                         of our application to the Hong Kong Chinese Medicines Board.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our estimated costs prior to the commercialization
of our pCm formulae products in Hong Kong aggregate to a total amount of approximately $29 million. We will use the proceeds of this
offering for a second research study of our TCM formulae and products, staff salaries, facilities rental, renovations and equipment,
product and intellectual property registrations, and other general and administrative expenses and working capital. See &ldquo;Use of
Proceeds&rdquo; on page 36 and &ldquo;Our Business - Estimated Time and Cost Prior to the Commercialization of Our Standardized TCM Formulae
Candidates in Hong Kong&rdquo; on page 68 for more information. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Summary Risk Factors</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our prospects should be considered in light of the risks, uncertainties,
expenses and difficulties frequently encountered by similar companies. Below please find a summary of the principal risks we face, organized
under relevant headings. These risks are discussed more carefully in the section titled &ldquo;Risk Factors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Risks Related to Our Financial Position and Need for Capital</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We are an early-stage TCM bioscience company with a limited
operating history and we have incurred operating losses since our formation;</P></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We have not generated revenue or applied for any regulatory
approvals, nor have distribution capabilities or experienced or any granted patents or pending patent applications, and may never
be profitable; and</P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">We have limited sources of working capital and will need substantial additional financing.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Risks Related to Our Product Development, Regulatory
Approval, Manufacturing and Commercialization</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">If we are unable to advance our TCM formulae candidates to final development, meet regulatory requirements, including obtaining regulatory approval, where applicable, or ultimately commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">If we are unable to obtain regulatory approval and ultimately commercialize our standardized TCM formulae candidates or experiences significant delays in doing so, our business, financial condition, results of operations, and prospects will be materially and adversely affected;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Although the assessment tools for assessment of ADHD and ASD are globally recognized, the outcome of our research study may be subject to some biases of parents and caregivers of patients because we relied on the data provided by them;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">If we encounter difficulties enrolling patients in our research studies, our TCM formulae development could be delayed or otherwise adversely affected;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Results of our earlier studies on personalized TCM formulae may not be predictive of future research study results. Failure can occur at any stage of research and development;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Our TCM formulae candidates may cause undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if any;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">If any of our TCM formulae candidates are approved for marketing and commercialization and we are unable to develop manufacture, sales, marketing and distribution capabilities on our own or enter into agreements with third parties to produce and sell our products on acceptable terms, we will be unable to successfully commercialize any such future therapeutics;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Our success depends on our ability to obtain and protect our intellectual property; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Adverse publicity associated with our standardized TCM formulae candidates, ingredients or network marketing program, or those of similar companies, could harm our financial condition and operating results;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Any disruption in the supply chain of raw materials and our products could adversely impact
    our ability to produce and deliver products; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secret.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>General Company Related Risks</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">There is uncertainty regarding our ability to continue as a going concern, indicating the possibility that we may be required to curtail or discontinue our operations in the future. If we discontinue our operations, you may lose all of your investment;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD>Our future operating results are difficult to predict and may
vary significantly from quarter to quarter, which may adversely affect the price of our Ordinary Shares;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Future debt agreements may contain, restrictions that may limit our flexibility in operating our business;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">We are wholly dependent on certain key personnel and our strategic partner, Mr. Sik-Kee
Au, the father of our founder, director, and CEO, and loss of these individuals could have a material adverse effect on our business,
financial condition and results of operations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 5pt; width: 24px">&nbsp;</TD>
    <TD STYLE="padding-bottom: 5pt; width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-bottom: 5pt"><FONT STYLE="font-size: 10pt">We have identified material weaknesses in our internal control over financial reporting. If we fail to develop and maintain an effective system of internal control over financial reporting, we may be unable to accurately report our financial results or prevent fraud;</FONT></TD></TR>
</TABLE>

</DIV>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">We may not be able to compete effectively against our competitors;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">We have broad discretion in the use of the net proceeds from our initial public offering and may not use them effectively;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Our business model may not be sufficient to ensure our success in our intended market; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Our TCM business is subject to inherent risks relating to product liability and personal injury claims.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Risks Related to the Offering and Our Ordinary Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The initial public offering price of our Ordinary Shares may not be indicative of the market price of our Ordinary Shares after this offering. In addition, an active, liquid and orderly trading market for our Ordinary Shares may not develop or be maintained, and our stock price may be volatile;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">If we are a passive foreign investment company for United States federal income tax purposes for any taxable year, United States holders of our Ordinary Shares could be subject to adverse United States federal income tax consequences;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">As a foreign private issuer, we are not subject to certain U.S. securities law disclosure requirements that apply to a domestic U.S. issuer, which may limit the information publicly available to our shareholders;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">We may lose our foreign private issuer status in the future, which could result in significant additional costs and expenses;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Recent joint statements by the SEC and PCAOB, proposed rule changes submitted by Nasdaq, and an act signed into law all call for additional and more stringent criteria to be applied to emerging market companies upon assessing the qualification of their auditors. These developments could add uncertainties to our offering;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">We do not expect to declare or pay any dividends in the foreseeable future;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt">If you purchase Ordinary Shares in this offering, you will experience
immediate and substantial dilution;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">The market price for our Ordinary Shares may be volatile;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Our founder and CEO will continue to own a significant percentage of our Ordinary Shares and will be able to exert significant control over matters subject to shareholder approval; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">As a &ldquo;controlled company&rdquo; under the rules of the Nasdaq Capital Market, we may choose to exempt our company from certain corporate governance requirements that could have an adverse effect on our public shareholders; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our shares, the price and trading volume of our Ordinary Shares could decline.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Risks Related to Doing Business in Hong Kong</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Political risks exist associated with conducting business in Hong Kong </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Because our business is conducted in Hong Kong dollars and the price of our Ordinary Shares is quoted in United States dollars, changes in currency conversion rates may affect the value of your investments; and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Volatility in our Ordinary Shares price may subject us to securities litigation.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we face other risks and uncertainties
that may materially affect our business prospect, financial condition, and operations. You should consider the risks discussed
in &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus before investing in our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On May 31, 2021, we effectuated a forward split
at a ratio of 1,000-for-1 to increase our authorized capital shares from 100,000,000 Ordinary Shares with a par value of $0.01 per share
to 100,000,000,000 Ordinary Shares with a par value of $0.00001 per share. As a result of the 2021 Forward Split, Our authorized share
capital consists of $1,000,000 divided into 100,000,000,000 shares, par value $0.00001 per share. Holders of Ordinary Shares are entitled
to one vote per share. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our principal executive offices are located
at 11/F First Commercial Building, 33-35 Leighton Road, Causeway Bay, Hong Kong, and our phone number is +852 2155 0823. We maintain
a corporate website at https://www.regencellbioscience.com/. The information contained in, or accessible from, our website or any
other website does not constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;</P>


</DIV>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><B>Our Corporate History and Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a holding company incorporated in
the Cayman Islands on October 30, 2014. We have no substantive operations other than holding all of the issued and outstanding
shares of Regencell Bioscience Limited and Regencell Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Regencell Bioscience Holdings Limited owns
100% equity interest of Regencell Bioscience Limited, which was incorporated in Hong Kong on May 12, 2015. Currently, we conduct
research and development activities in the TCM industry through Regencell Bioscience Limited, which has entered Partnership Agreements
with the TCM Practitioner. In October 2020, Regencell Bioscience Limited entered into a leasing agreement with Regus in California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Regencell Bioscience Holdings Limited owns
100% equity interest of Regencell Limited, which was incorporated in Hong Kong on November 20, 2014. Currently, Regencell Limited
has no operation and is reserved for future expansion use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our CEO and director, Mr. Yat-Gai Au, beneficially
owns 100% of Regencell Bioscience Holdings Limited through Regencell (BVI) Limited Regencell (BVI) Limited was incorporated pursuant
to the BVI Business Companies Act, 2004, on May 25, 2017, and has no operation since its inception. Mr. Yat-Gai Au has been the sole
shareholder of Regencell (BVI) Limited since its inception. On September 28, 2020, Regencell (BVI) Limited acquired all equity interest
of Regencell Bioscience Holdings Limited from Mr. Yat-Gai Au. In addition, pursuant to a promissory note (the &ldquo;Note&rdquo;) that
we issued to Mr. Yat-Gai Au on March 18, 2021 that the outstanding principal of $3,250,000 under such note will be converted into 342,105
Ordinary Shares upon the closing of this offering at the same price of the offering (assuming an offering price of $9.50, the midpoint
of the price range set forth on the cover page of this prospectus). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The following diagram illustrates our corporate
structure as of the date of this prospectus, assuming over-allotment is not exercised by the underwriter and including the issuance of
342,105 Ordinary Shares issuable upon the closing of this offering to Regencell (BVI) Limited, Mr. Yat-Gai Au&rsquo;s designee, under
the Note (assuming an offering price of $9.50, the midpoint of the price range set forth on the cover page of this prospectus). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_003.jpg" ALT="" STYLE="width: 650px; height: 275px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our consolidated financial statements as
of and for the years ended June 30, 2020 and 2019 were prepared assuming that we will continue as a going concern and do not include
any adjustments that might be necessary if we are unable to continue as a going concern. There were substantial doubts about our
ability to continue as a going concern at the audit report date of our consolidated financial statement as of and for the years
ended June 30, 2020 and 2019. Our independent registered public accounting firm, Friedman LLP, has issued their opinion with an
explanatory paragraph in connection with the consolidated financial statements for the years ended June 30, 2020 and 2019 included
in our annual report that expresses substantial doubt about our ability to continue as a going concern. As of June 30, 2020, and
2019, we have outstanding shareholder loans amounting to approximately $3.07 million and $2.08 million, respectively, from Mr.
Yat-Gai Au, the founder and CEO. On November 10, 2020, we entered into a loan agreement with Mr. Yat-Gai Au to evidence the existing
loan and document our oral agreements of the terms and conditions of such existing loan when such loan was initially generated.
The loan agreement also sets forth that Mr. Yat-Gai Au will continue to make loan to us for daily operation and research activities.
The use of loan shall be agreed and determined by both parties before granting the loan. All loans shall bear 0% interest per annual.
The maturity date of such loans is June 30, 2021, subject to indefinite extension if agreed by the parties in writing. On February
2, 2021, a loan extension agreement was entered by Mr. Yat-Gai Au and Regencell Bioscience Limited, pursuant to which Mr. Yat-Gai
Au agreed to provide up to $3 million in the form of loan or make payments on behalf of Regencell Bioscience Limited during the
period from January 1, 2021 to June 30, 2022 to support our operations and research activities for the period from January 1, 2021
to June 30, 2022 and further extend the maturity date of the existing loans from June 30, 2021 to December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On March 18, 2021, a supplemental loan agreement
was entered by and between Regencell Bioscience Limited and Mr. Yat-Gai Au, pursuant to which Mr. Yat-Gai Au will waive the amount of
$3.25 million of the outstanding loan upon the receipt of the Note issued by the Company in the principal amount of $3,250,000. On March
18, the Company issued the Note to Mr. Yat-Gai Au in the principal amount of $3,250,000, automatically convertible into Ordinary Shares,
upon the completion of the Company&rsquo;s initial public offering, at the same price as the offering price per Ordinary Shares to be
issued in the initial public offering. The Note does not carry any interest. The Note, if not automatically converted, will mature and
become payable twelve months after the issuance date of the Note and the date when the Company redeems the Note. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Implications of Our Being an &ldquo;Emerging Growth Company&rdquo;
and &ldquo;Foreign Private Issuer&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a company with less than $1.07 billion
in revenue during our last fiscal year, we qualify as an &ldquo;emerging growth company&rdquo; as defined in the Jumpstart Our
Business Startups Act of 2012, or the JOBS Act. An &ldquo;emerging growth company&rdquo; may take advantage of reduced reporting
requirements that are otherwise generally applicable to public companies. In particular, as an emerging growth company, we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may present only two
    years of audited financial statements and only two years of related Management&rsquo;s Discussion and Analysis of Financial
    Condition and Results of Operations, or MD&amp;A;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are not required to provide a detailed narrative
    disclosure discussing our compensation principles, objectives and elements and analyzing how those elements fit with our principles
    and objectives, which is commonly referred to as &ldquo;compensation discussion and analysis&rdquo;;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are not required to obtain an attestation and
    report from our auditors on our management&rsquo;s assessment of our internal control over financial reporting pursuant to
    the Sarbanes-Oxley Act of 2002;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are not required to obtain a non-binding advisory
    vote from our shareholders on executive compensation or golden parachute arrangements (commonly referred to as the &ldquo;say-on-pay,&rdquo;
    &ldquo;say-on frequency&rdquo; and &ldquo;say-on-golden-parachute&rdquo; votes);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are exempt from certain executive compensation
    disclosure provisions requiring a pay-for-performance graph and CEO pay ratio disclosure;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are eligible to claim longer phase-in periods
    for the adoption of new or revised financial accounting standards under &sect;107 of the JOBS Act; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will not be required to conduct an evaluation
    of our internal control over financial reporting for two years.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to take advantage of all of these
reduced reporting requirements and exemptions, including the longer phase-in periods for the adoption of new or revised financial
accounting standards under &sect;107 of the JOBS Act. Our election to use the phase-in periods may make it difficult to compare
our financial statements to those of non-emerging growth companies and other emerging growth companies that have opted out of
the phase-in periods under &sect;107 of the JOBS Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Certain of these reduced reporting requirements
and exemptions were already available to us due to the fact that we also qualify as a &ldquo;smaller reporting company&rdquo;
under SEC rules. For instance, smaller reporting companies are not required to obtain an auditor attestation and report regarding
management&rsquo;s assessment of internal control over financial reporting, are not required to provide a compensation discussion
and analysis, are not required to provide a pay-for-performance graph or CEO pay ratio disclosure, and may present only two years
of audited financial statements and related MD&amp;A disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a foreign private issuer within
the meaning of the rules under the Exchange Act, and as such we are exempt from certain provisions of the securities rules and
regulations in the United States that are applicable to U.S. domestic issuers. Moreover, the information we are required to file
with or furnish to the SEC will be less extensive and less timely compared to that required to be filed with the SEC by U.S. domestic
issuers. In addition, as a company incorporated in the Cayman Islands, we are permitted to adopt certain home country practices
in relation to corporate governance matters that differ significantly from the Nasdaq listing standards. As such, we may rely
on home country practice to be exempted from the corporate governance requirements that we have a majority of independent directors
on our board of directors and the audit committee of our board of directors has a minimum of three members. These practices may
afford less protection to shareholders than they would enjoy if we complied fully with the Nasdaq listing standards. However,
following this offering, we will voluntarily have a majority of independent directors and our audit committee will consist of
three independent directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
</DIV>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Controlled Company</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Upon the completion of this offering, we will
be a &ldquo;controlled company&rdquo; as defined under the Nasdaq Stock Market Rules because we expect that Mr. Yat-Gai Au, our founder,
director and CEO, will beneficially own approximately 10,342,105 Ordinary Shares, or approximately 79.2% of our Ordinary Shares, and
will be able to exercise approximately 79.2% of the total voting power of our issued and outstanding shares, assuming the full exercise
of the over-allotment option by the underwriter and the exercise of the warrants and including the Ordinary Shares issuable to Mr. Yat-Gai
Au or his designees upon the automatic conversion of the Note. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As long as our officers and directors,
either individually or in the aggregate, own at least 50% of the voting power of our Company, we are a &ldquo;controlled company&rdquo;
as defined under Nasdaq Marketplace Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For so as we are a controlled company under
that definition, we are permitted to elect to rely, and may rely, on certain exemptions from corporate governance rules, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from the rule that a majority of
    our board of directors must be independent directors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from the rule that the compensation
    of our CEO must be determined or recommended solely by independent directors; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from the rule that our director
    nominees must be selected or recommended solely by independent directors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a result, you will not have the same
protection afforded to shareholders of companies that are subject to these corporate governance requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although we do not intend to rely on the
&ldquo;controlled company&rdquo; exemption under the Nasdaq listing rules, we could elect to rely on this exemption in the future.
If we elect to rely on the &ldquo;controlled company&rdquo; exemption, a majority of the members of our board of directors might
not be independent directors and our nominating and corporate governance and compensation committees might not consist entirely
of independent directors.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>
</DIV>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_003"></A><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%"> <FONT STYLE="font-size: 10pt"><B>Ordinary Shares offered by us</B></FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 71%"> <FONT STYLE="font-size: 10pt">2,300,000 Ordinary Shares (excluding the over-allotment discussed below).</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt"><B>Price per Ordinary Share</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> We estimate that purchase price will be between $8.50 to $10.50 per Ordinary Share. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt"><B>Over-allotment</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">The underwriter has an option for a period of 45 days to purchase up to&nbsp;345,000 additional
    Ordinary Shares solely to cover over-allotments, if any.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt"><B>Ordinary Shares outstanding prior to completion of this offering</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">10,000,000 Ordinary Shares.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Ordinary Shares outstanding immediately after this offering</B> </P></TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">12,642,105 Ordinary Shares, assuming no exercise of the underwriter&rsquo;s over-allotment option.<SUP>(1)</SUP></FONT> </TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">We intend to use the proceeds from this offering for a second research study of our TCM formulae and products, staff salaries, facilities rental, renovations and equipment, product and intellectual property registrations, and other general and administrative expenses and working capital. See &ldquo;Use of Proceeds&rdquo; on page 36 for more information.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt"><B>Proposed Nasdaq Capital Market Trading Symbol and Listing</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">We have applied to list our Ordinary Shares on the Nasdaq Capital Market under the symbol &ldquo;RGC.&rdquo;
    No assurance can be given that such listing will be approved or that a liquid trading market will develop for our Ordinary Shares;
    however, we will not complete this offering unless we receive approval for listing on Nasdaq Capital Market.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt"><B>Lock-up</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">We and our directors, officers any other holder(s) of three percent (3.0%) or more of our outstanding
    ordinary share have agreed with the representative not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose
    of any of our Ordinary Shares or securities convertible into Ordinary Shares for a period of 180-days after the Initial Public Offering
    (&ldquo;IPO&rdquo;) is completed. See &ldquo;Underwriting&rdquo;.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt"><B>Transfer Agent</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Vstock Transfer, LLC.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Risk Factors</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">The Ordinary Shares offered hereby involve a high degree of risk. You should read &ldquo;Risk Factors,&rdquo; beginning on page 14 for a discussion of factors to consider before deciding to invest in our Ordinary Shares.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The number of Ordinary Shares that are and will be outstanding
immediately before and after this offering as shown above is based on 10,000,000 shares outstanding as of June 9, 2021, which, as used
throughout this prospectus, unless otherwise indicated, excludes (i) the Ordinary Shares issuable upon the exercise of the warrants to
be issued to the representative of the underwriter, and assumes no exercise of over-allotment option by the underwriter and (ii) the
issuance of 1,235,074 Ordinary shares upon the exercise of options granted under our 2021 Share Option Plan,. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> (1) Includes 342,105 Ordinary Shares issuable to Mr. Yat-Gai Au or
his designees upon the automatic conversion of the principal of $3,250,000 under the Note that we issued to Mr. Yat-Gai Au at the same
price in this offering (assuming the offering price of $9.50, the midpoint of the price range set forth on the cover page of this prospectus). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</DIV>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUMMARY CONSOLIDATED FINANCIAL DATA
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In the table below, we provide you with historical
selected financial data for the years ended June 30, 2020 and 2019. This information is derived from our consolidated financial statements
included elsewhere in this prospectus. Historical results are not necessarily indicative of the results that may be expected for any
future period. When you read this historical selected financial data, it is important that you read it along with the historical financial
statements and related notes and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
included elsewhere in this prospectus. The number of shares is presented on a retroactive basis to reflect the 2021 Forward Split. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>For the Years Ended
    <BR>
    June 30,</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>2020</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>2019</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-size: 10pt"><B>Consolidated Statements of Operations and Comprehensive Loss:</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 76%; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Operating Expenses</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">812,371</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">390,990</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Loss from Operations</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">(812,371</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">)&nbsp;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">(390,990</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">)&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Earnings per share, basic and diluted</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">(0.08</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">(0.04</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Weighted average number of Ordinary Shares outstanding</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">10,000,000</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">10,000,000</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<BR>
    2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<BR>
    2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Consolidated Balance Sheet Data:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 9pt">Current assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">386,979</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">243,307</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">514,018</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">243,307</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,164,910</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,081,828</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,164,910</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,081,828</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Shareholder&rsquo;s deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,650,892</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,838,521</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Working capital (deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,777,931</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,838,521</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
</DIV>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_004"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Investment in our securities involves
a high degree of risk. You should carefully consider the risks described below together with all of the other information included
in this prospectus before making an investment decision. The risks and uncertainties described below represent our known material
risks to our business. If any of the following risks actually occurs, our business, financial condition or results of operations
could suffer. In that case, you may lose all or part of your investment. You should not invest in this offering unless you can
afford to lose your entire investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks related to Our Financial Position and Need for Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are an early</I></B>-<B><I>stage TCM bioscience company
with a limited operating history. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are an early-stage TCM bioscience company
with a limited operating history that focuses on research, development and commercialization of TCM for children afflicted by ADHD
and ASD and we have not generated any revenue. We have incurred operating losses since our formation. We incurred total net losses
of $0.81 million and $0.39 million, respectively, for the fiscal years ended June 30, 2020 and 2019. The likelihood of success
of our business plan and growth strategy must be considered in light of the problems, substantial expenses, difficulties, complications
and delays frequently encountered in connection with developing and expanding early-stage businesses and the regulatory and competitive
environment in which we operate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Accordingly, you should consider our prospectus
in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in the early stages of development,
especially early-stage bioscience research companies such as ours. Potential investors should carefully consider the risks and
uncertainties that a company with a limited operating history will face. In particular, potential investors should consider that
we cannot assure you that we will be able to, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">successfully
                                         implement or execute our current business plan, and we cannot assure you that our business
                                         plan is sound;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt">successfully manufacture and commercialize our standardized
liquid-based TCM formulae treatment for mild, moderate and severe ADHD and ASD patients after our second research studies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully complete
    the research studies to obtain regulatory approval for the marketing of our TCM formulae candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-indent: -18.05pt">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">obtain,
                                         secure, maintain and, as necessary, defend our intellectual property rights;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">attract
                                         and retain an experienced management and research team;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">launch
                                         commercial sales of our standardized liquid-based TCM formulae candidates, whether alone
                                         or in collaboration with others;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">raise
                                         sufficient funds in the capital markets or otherwise to effectuate our business plan;
                                         and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">utilize
                                         the funds that we do have and/or raise in this offering or in the future to efficiently
                                         execute our business strategy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we cannot successfully execute any one
of the foregoing, our business may fail and your investment will be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have not generated revenue from any TCM formulae candidates
or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent
applications, and may never be profitable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our ability to become profitable depends
upon our ability to generate revenue. As the date hereof, we have not applied for any regulatory approvals, no granted or pending
patent applications and we have no distribution capabilities or experience, and we have not generated any revenue from our development
stage TCM formulae candidates and we do not know when, or if, we will generate any such revenue. We do not expect to generate significant
revenue unless and until we obtain marketing approval of our standardized TCM formulae candidates, produce and commercialize products
based on such TCM formulae. Our ability to generate future revenue from sales of products based on our TCM formulae depends heavily
on our success in many areas, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining favorable results from and progress
    the research studies of our TCM formulae candidates;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing and obtaining regulatory approval
    for registration for our TCM formulae candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">accurately identifying demand for our product
    candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continued consumer interest in treatments to
    the symptoms of ADHD and ASD;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining market acceptance of our liquid-based
    TCM formulae treatment, if approved for marketing, as viable treatment options for ADHD and ASD;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiating favorable terms in any collaboration,
    licensing or other arrangements into which we may enter; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attracting, hiring and retaining qualified personnel.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have limited sources of working capital and will need
substantial additional financing </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The working capital required to implement
our business plan will most likely be provided by funds obtained through offerings of our equity, debt, debt-linked securities,
and/or equity-linked securities, and, in the future, revenues generated by us. No assurance can be given that we will have revenues
sufficient to sustain our operations or that we would be able to obtain equity/debt financing in the current economic environment.
If we do not have sufficient working capital or raise additional funds, we may delay the completion of or significantly reduce
the scope of our current business plan; delay some of our research and development; postpone the hiring of new personnel; or,
under certain dire financial circumstances, substantially curtail or cease our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our inability to obtain sufficient additional
financing would have a material adverse effect on our ability to implement our business plan and, as a result, could require us
to significantly curtail or potentially cease our operations. Our ability to complete additional financings is dependent on, among
other things, the state of the capital markets at the time of any proposed offering, market reception of the Company and the likelihood
of the success of our business model and offering terms. There is no assurance that we will be able to obtain any such additional
capital through asset sales, equity or debt financing, or any combination thereof, on satisfactory terms or at all. Additionally,
no assurance can be given that any such financing, if obtained, will be adequate to meet our capital needs and to support our
operations. If we do not obtain adequate capital on a timely basis and on satisfactory terms, our revenues and operations and
the value of our Ordinary Shares and Ordinary Share equivalents would be materially negatively impacted and we may cease our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Product Development, Regulatory Approval,
Manufacturing and Commercialization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our standardized TCM formulae candidates for mild, moderate
and severe ADHD and ASD patients are still in development. If we are unable to obtain regulatory approval and ultimately commercialize
our standardized TCM formulae and/or products based on our TCM formulae or experience significant delays in doing so, our business,
financial condition, results of operations, and prospects will be materially and adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Currently, three standardized TCM formulae
candidates for mild, moderate and severe ADHD and ASD patients are under research and development. None of the formulae candidates
are currently in the process of the regulatory approval and commercialization. Our ability to generate revenues from our standardized
TCM formulae candidates are dependent on the completion of our research and development, receipt of regulatory approval and successfully
commercializing products based on such formulae, which may never occur. Each of our TCM formulae candidates will require additional
research and development, regulatory approval in Hong Kong and other jurisdictions where we plan to sell, development of manufacturing
supply and capacity, substantial investment, and significant marketing efforts before we generate any revenue from product sales.
The success of our three standardized TCM formulae candidates for mild, moderate and severe patients will depend on several factors,
including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful enrollment in, and completion of,
    research studies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>receipt of regulatory approvals from applicable regulatory authorities
for planned research studies, future research studies, or drug registrations, manufacturing and commercialization;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful completion
    of all safety studies required to obtain regulatory approval in Hong Kong and other jurisdictions in which our standardized
    TCM formulae candidates intend to sell;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing commercial manufacturing capabilities
    to the specifications for our candidates for clinical supply and commercial manufacturing;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">making and maintaining arrangements with third-party
    TCM raw material suppliers or manufacturers;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>obtaining and maintaining patent, trade secret and other intellectual
property protection and/or regulatory exclusivity for our standardized TCM formula candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching commercial sales of our standardized
    liquid-based TCM formulae treatment, if and when approved, whether alone or in collaboration with others;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance of the standardized liquid-based
    TCM formulae treatment, if and when approved, by patients and the medical community;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectively competing with other therapies and
    alternative drugs, particularly those for ADHD and ASD;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully enforcing and defending intellectual
    property rights and claims; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining a continued acceptable safety profile
    of the standardized TCM formulae candidates following regulatory approval.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The success of our business is highly dependent
upon our ability to develop and commercialize our standardized TCM formulae candidates for ADHD and ASD, of which has research
studies currently on-going. As a result, our business is substantially dependent on our ability to complete the research and development
of, obtain regulatory approval for, and successfully commercialize our standardized liquid-based TCM formulae treatment and other
TCM formulae candidates for ADHD and ASD patients in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We cannot commercialize standardized TCM
formulae candidates in Hong Kong, where we intend to launch our first standardized TCM formulae and products, without first obtaining
regulatory approval from authorities concerned in Hong Kong. The process to develop, obtain regulatory approval for, and commercialize
standardized TCM formulae candidates is long, complex, and costly and approval may not be granted. Obtaining regulatory approval
in one jurisdiction does not mean that regulatory approval will be obtained in any other jurisdiction. Approval processes vary
among countries and can involve additional product testing and validation and additional administrative review periods. No assurance
can be given that we can obtain regulatory approval in Hong Kong, even if our TCM formulae candidates, which to be proved its efficiency,
were to successfully obtain approval from the Hong Kong Chinese Medicines Board, we would still need to seek approval in other
jurisdictions where we plan to market the product. Any safety issues, product recalls, or other incidents related to products approved
and marketed in one jurisdiction may impact the approval of those products by another jurisdiction. If we are unable to obtain
regulatory approval for our standardized TCM formulae candidates in one or more jurisdictions, or any approval contains significant
limitations imposed on certain standardized TCM formulae candidates, we may not be able to obtain sufficient funding or generate
sufficient revenue to continue the development of our TCM formulae candidates or any other TCM formulae candidates that we may
acquire or develop in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our research and development of TCM formulae candidates
is at an early stage of development and all of our TCM formulae candidates may require significant interactions with regulatory
authorities and investments before their respective commercial launches. If we are unable to advance our TCM formulae candidates
to final development, meet regulatory requirements, including obtaining regulatory approval, where applicable, or ultimately commercialize
our product candidates or experience significant delays in doing so, our business will be materially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our research and development of TCM formulae
is at an early stage and will require significant investment and regulatory approvals prior to commercialization. Each of our TCM
formulae candidates will require additional research and development, obtaining regulatory approval, such as obtaining manufacturing
supply, substantial investment and significant marketing efforts before it generates any revenue from product sales. We are not
permitted to market or promote any of our standardized TCM formulae candidates before our receipt of regulatory approval from the
Hong Kong Chinese Medicines Board, or comparable regulatory authorities, and we may never receive such regulatory approval for
any such standardized TCM formulae candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The success of our product candidates will
depend on several factors, including but not limited to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">receipt
                                         of regulatory approvals from applicable regulatory authorities for drug product candidates
                                         or, alternatively, compliance with regulatory requirements applicable to non-drug products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing current
    GMP-compliant supply and commercial manufacturing operations or deciding with GMP-compliant third-party manufacturers for
    supply and commercial manufacturing;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">obtaining
                                         and maintaining patent and trade secret protection or regulatory exclusivity for our
                                         product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">launching
                                         commercial sales of our product candidates, if and when approved or allowed for marketing,
                                         whether alone or in collaboration with others; and </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">maintaining
                                         a continued acceptable safety profile of the product candidates following approval or
                                         commercialization.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We cannot be certain that research and
development of any of our TCM formulae candidates will be successful or that we will obtain regulatory approval or be able to
successfully commercialize any product based on our TCM formulae and generate revenue. Success in our research studies does not
ensure that application of regulatory approval will be successful. Our research studies may fail to demonstrate that our TCM formulae
candidates are safe and effective for their proposed uses. Any such failure could cause us to abandon further development of any
one or more of our TCM formulae candidates and may delay development of other TCM formulae candidates. Any delay in, or termination
of, our development will delay and possibly preclude the filing with regulatory authorities and, ultimately, our ability to commercialize
the TCM formulae candidates and generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Although the assessment tools for assessment of ADHD and
ASD are globally recognized, the outcome of our research study may be subject to some biases of parents and caregivers of patients
because we relied on the data provided by them.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The assessment tools we used in our research
study include Autism Treatment Evaluation Checklist (ATEC), Gilliam Autism Rating Scale (GARS), Vanderbilt ADHD Diagnostic Parent
Rating Scale (VADRS), and Swanson, Nolan, and Pelham (SNAP)-IV 26-item Parent Rating Scale (SNAP-IV-26). These assessment tools
are globally recognized and accepted methods of scoring severity levels of ADHD and ASD patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that these assessment tools serve
a useful purpose in helping us to evaluate whether our TCM formulae candidates are having their intended effects, and that they
may thus enable us to identify additional TCM formulae candidates, to direct our resources efficiently, and to provide data support
for our future application of pCm registrations with the Hong Kong Chinese Medicine Council.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding the foregoing, we rely on
parents or caregivers of patients to provide us with initial data which we cannot guarantee the accuracy. If the parents and caregivers
of enrolled ADHD and ASD patients fail to observe and record accurately, then we will not only fail to realize any benefits from
using these assessment tools, but may also be led to invest time and financial resources inefficiently in attempting to develop
inappropriate TCM formulae candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we encounter difficulties enrolling patients in our
research studies, our TCM formulae development could be delayed or otherwise adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We conduct research studies involving TCM
formulae candidates whose activity and specificity have been optimized by our TCM Practitioner in his prior ADHD and ASD treatments.
Timely completion of research studies in accordance with the protocols depends, among other things, on our ability to enroll a
sufficient number of patients who meet the research study criteria and remain in the study until the conclusion. We may experience
difficulties enrolling and retaining appropriate patients in its research study for a variety of reasons, including but not limited
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size and nature of the patient population;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient eligibility criteria defined in the
    research study protocol;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size of study population required for statistical
    analysis of the study&rsquo;s primary endpoints;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the design of the study and changes to the design
    of the study;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit personnel with the appropriate
    competencies and experience;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing research studies for similar therapies
    or other new therapeutics, which will reduce the number and types of patients available;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients&rsquo; perceptions as to the potential
    advantages and side effects of the TCM formulae being studied in relation to other available therapies, including any new
    drug candidates or treatments that may be approved for the indications we are investigating;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and maintain patient consents;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients enrolled in research study that may
    not complete a research study; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of approved therapies that
    are similar to our TCM formulae candidates.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Even if we are able to enroll a sufficient
number of patients in our research study, delays in patient enrollment may result in increased costs or may affect the timing
or outcome of the planned research studies, which could prevent completion of these studies and adversely affect our ability to
advance the development of our TCM formulae candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Results of our earlier studies on personalized TCM formulae
may not be predictive of future research study results. Failure can occur at any stage of research and development.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The results of research studies of our
personalized TCM formulae may not be predictive of the results of standardized TCM formulae candidates. Standardized TCM formulae
candidates may fail to show the desired safety and efficacy despite positive results of personalized TCM formulae. Based upon
negative or inconclusive results, we, along with our TCM Practitioner or any potential future collaborator may decide, or regulators
may require us, to conduct additional research studies. In addition, data obtained from research studies are susceptible to varying
interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit, or prevent regulatory
approval.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we do not know whether future
research studies will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule,
if at all. Research studies can be delayed or aborted for a variety of reasons, including delay or failure to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recruit suitable patients to participate in
    research studies and have such patients complete the research studies or return for post-treatment follow-up;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">address any patient safety concerns that arise
    during the course of a research study;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensure that patients comply with and complete
    research study protocol;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate or add a sufficient number of research
    study sites;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture sufficient quantities of TCM formulae
    candidate for use in research studies and ensure research study material is provided to research study sites in a timely manner;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain the statistical analysis plan to be used
    to evaluate the research study data.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Qualified patient enrollment is a significant
factor in our research studies and is affected by many factors, including the size and nature of the patient population, the eligibility
criteria for the studies, the design of the research study, competing research studies and patients&rsquo; perceptions as to the
potential advantages of the TCM formulae being studied in relation to other available therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we experience delays in the start or
completion of, or termination of, any research studies of our TCM formulae candidates, the commercial prospects of our TCM formulae
candidates may be affected, and our ability to generate product revenues will be delayed. In addition, any delays in completing
our research studies will increase our costs, slow down our TCM formulae candidates&rsquo; development and approval process and
jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may negatively harm our business,
financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion
of research studies may also ultimately lead to the denial of regulatory approval of our TCM formulae candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our TCM formulae candidates may cause undesirable side
effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in
significant negative consequences following regulatory approval, if any.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Potential undesirable side effects caused
by our TCM formulae candidates may cause it to interrupt, delay, or halt research studies or could cause regulatory authorities
to interrupt, delay, or halt our research studies or could result in a more restrictive label or the delay or denial of regulatory
approval by the Hong Kong Chinese Medicines Board, or other regulatory authorities. We may observe some potential side effects
in future research studies that could affect patient recruitment or the ability of enrolled patients to complete the study or
result in potential product liability claims. Any of these occurrences may harm our business, financial condition, and prospects
significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our research studies assessed a sample
of the potential patient population. With a limited number of patients and duration of exposure, rare and severe side effects
of our TCM formulae candidates may only be uncovered with a large number of patients exposed to the TCM formulae treatment. If
our TCM formulae candidates receive regulatory approval and we, our partners, or others identify undesirable side effects caused
by such standardized liquid-based TCM formulae treatment after such approval, a number of potentially significant negative consequences
could result, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Hong Kong Chinese
    Medicines Board or other comparable regulatory authorities may withdraw or limit their approval of such standardized TCM formulae
    candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to create a medication guide
    outlining the risks of such side effects for distribution to patients;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to change the way such standardized
    TCM formulae candidates are distributed or administered, conduct additional research studies, or change the labeling of our
    TCM formulae treatment;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>the Hong Kong Chinese Medicines Board or other comparable regulatory
authorities may require a risk evaluation and mitigation strategy, plan to mitigate risks, which could include medication guides,
physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and
other risk minimization tools;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be subject to regulatory investigations
    and government enforcement actions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may decide to remove such TCM formulae treatment
    from the marketplace;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held liable for injury
    caused to individuals exposed to or taking our TCM formulae treatment; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reputation may suffer.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any of these events could prevent us from
achieving or maintaining market acceptance of the affected TCM formulae treatment and could substantially increase the costs of
commercializing our TCM formulae treatment, if approved, and significantly impact our ability to successfully commercialize our
TCM formulae candidates and generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If any of our TCM formulae candidates are approved for
marketing and commercialization and we are unable to develop manufacture, sales, marketing and distribution capabilities on our
own or enter into agreements with third parties to produce and sell our products on acceptable terms, we will be unable to successfully
commercialize any such future therapeutics.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We currently have no sales and marketing,
or distribution capabilities or experience. In order to commercialize our standardized TCM formulae candidates, if approved, we
must build marketing and sales capabilities or decide to make arrangements with third parties to produce and sell products, and
we may not be successful in doing so. Building the requisite sales, marketing or distribution capabilities will be expensive and
time-consuming and will require significant attention of our leadership team to manage. Any failure or delay in the development
of our sales, marketing or distribution capabilities would adversely impact the commercialization of our products. The competition
for talented individuals experienced in selling and marketing TCM products is intense, and we cannot assure you that we can assemble
an effective team. Additionally, we may choose to collaborate with third parties on the commercialization of our standardized
TCM formulae candidates. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to
successfully commercialize our standardized TCM formulae candidates if and when we receive regulatory approval or any such commercialization
may experience delays or limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may be subject to additional risks related
to operating in foreign countries either ourselves or through a third-party, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing regulatory requirements in foreign
    countries;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected changes in tariffs, trade barriers,
    price and exchange controls and other regulatory requirements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic weakness, including inflation or political
    instability in particular foreign economies and markets;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with tax, employment, immigration
    and labor laws for employees living or traveling abroad;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign taxes, including withholding of payroll
    taxes;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign currency fluctuations, which could result
    in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties staffing and managing foreign operations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce uncertainty in countries where labor
    unrest is more common than in the United States;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential liability under the Foreign Corrupt
    Practices Act of 1977 or comparable foreign regulations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges enforcing our contractual and intellectual
    property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the
    same extent as the United States;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">production shortages resulting from any events
    affecting raw material supply or manufacturing capabilities abroad; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">business interruptions resulting from geopolitical
    actions, including war and terrorism.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we fail to increase our brand recognition, we may
face difficulty in obtaining new customers or patients.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that developing, maintaining
and enhancing our brand recognition in a cost-effective manner outside of that market is critical to achieving widespread acceptance
of our future products and is an important element in our effort to build our customer or patient base. Successful promotion of
our brand and products in the TCM and medical industry will depend largely on our ability to maintain a sizeable and active customer
or patient base, our marketing efforts and ability to provide reliable and useful products and treatments at competitive prices.
Brand promotion activities may not yield increased revenue in the near future, and even if they do, any increased revenue may
not offset the expenses we will incur in building our brand. If we fail to successfully promote and maintain our brand during
our commercialization period, or if we incur substantial expenses in an unsuccessful attempt to promote and maintain our brand,
we may fail to attract enough customers or patients to the extent necessary to realize a sufficient return on our brand-building
efforts, in which case our business, operating results and financial condition, would be materially adversely affected.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our success depends on our ability to obtain and protect
our intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The TCM formulae are the core of our business
operation and TCM research and development. We seek to protect the TCM formulae candidates and technology that we consider commercially
important by filing patent applications in Hong Kong and abroad or rely on our trade secrets. Although we intend to file for patent
applications with the authorities concerned in Hong Kong, there is no assurance that they will be granted, or that, if granted,
any of our future patents will be held valid and enforceable against third-party infringement, or that our formulae will not infringe
any third-party patent or intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any patents relating to our formulae, if
granted, may not be sufficiently broad to protect them. In addition, our patents, if granted, may be challenged, potentially invalidated
or potentially circumvented. Our patents, if granted, may not afford us protection against competitors with similar formulae or
permit the commercialization of our products without infringing third-party patents or other intellectual property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Further, we also rely on or intend to rely
on our trademarks, trade names and brand names to distinguish our products from the products of our competitors, and have registered
or will apply to register a number of these trademarks. We have received trademark certificates for &ldquo;&#33126;&#36996;&#21407;<SUP>&reg;</SUP>&rdquo;
(directly translates as &ldquo;brain restoration&rdquo;) and &ldquo;RGC Regencell<SUP>&reg;</SUP>&rdquo; from the Hong Kong Registrar
of Trade Marks in July 2020. We also filed a trademark application for &ldquo;Sik-Kee Au TCM Brain Theory&trade;&rdquo; in January
2021. However, third parties may oppose our trademark applications or otherwise challenge our use of the trademarks. Further, our
competitors may infringe our trademarks, or we may not have adequate resources to enforce our trademarks. Effective trademark protection
may not be available or may not be sought in every country in which our products are made available in the future. In the event
that our trademarks or applications are successfully challenged, we could be forced to rebrand our products, which could result
in loss of brand recognition and could require us to devote resources to advertising and marketing these new brands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Third parties
may make claims challenging the inventorship or ownership of our TCM formulae. In addition, we may face claims by third parties
that our agreements with employees, contractors or consultants obligating them to&nbsp;assign&nbsp;intellectual&nbsp;property&nbsp;to
us are ineffective or in conflict with prior or competing contractual obligations of assignment, which could result in ownership
disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial
value of such intellectual property. Litigation may be necessary to resolve an ownership dispute, and if we are not successful,
we may be precluded from using certain intellectual property or may lose our exclusive rights in that intellectual property. Either
outcome could harm our business and competitive position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also rely on trade secrets, including
unpatented know-how, technology and TCM related regulatory protection, to maintain our competitive position in our TCM research.
While our current employment agreements with our employees contain provisions protecting our confidential information, including
the knowledge of proprietary Chinese medicine, prescriptions, techniques, and skills, we may seek to protect, in part, by entering
into separate confidentiality agreements with licensees, suppliers, employees and consultants in the future. These agreements
may be breached and there may not be adequate remedies in the event of a breach. Disputes may arise concerning the ownership of
intellectual property or the applicability of confidentiality agreements. Moreover, our trade secrets and proprietary technology
may otherwise become known or be independently developed by our competitors. If patents are not issued with respect to products
arising from research, we may not be able to maintain the confidentiality of information relating to these products.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Adverse publicity associated with our TCM formulae candidates,
ingredients or network marketing program, or those of similar companies, could harm our financial condition and operating results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The results of our operations may be significantly
affected by the public&rsquo;s perception of our TCM formulae candidates and the overall TCM treatment industry. This perception
is dependent upon opinions concerning:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.65pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the safety and quality of our TCM formulae and
    ingredients;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.65pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the safety and quality of similar products and
    ingredients distributed by other TCM companies; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.65pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our sales force.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Adverse publicity concerning any actual
or purported failure to comply with applicable laws and regulations regarding product claims and advertising, good manufacturing
practices, or other aspects of our business, whether or not resulting in enforcement actions or the imposition of penalties, could
have an adverse effect on our goodwill and could negatively affect our sales and ability to generate revenue. In addition, our
consumers&rsquo; perception of the safety and quality of products and ingredients as well as similar products and ingredients
distributed by other companies can be significantly influenced by media attention, publicized scientific research or findings,
widespread product liability claims and other publicity concerning our TCM formulae candidates or ingredients or similar products
and ingredients distributed by other companies. Adverse publicity, whether or not accurate or resulting from consumers&rsquo;
use or misuse of our TCM formulae treatment, that associates consumption of our TCM formulae treatment or ingredients or any similar
products or ingredients with illness or other adverse effects, questions the benefits of our or similar products or claims that
any such products are ineffective, inappropriately labeled or have inaccurate instructions as to their use, could negatively impact
our reputation or the market demand for our TCM formulae treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Any disruption in the supply chain of raw materials and
our products could adversely impact our ability to produce and deliver products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As to the products we intend to manufacture,
we must manage our supply chain for raw materials and delivery of our products. Our raw material used in research study is currently
sourced by the TCM Practitioner from a Hong Kong vendor under the Hong Kong Chinese Medicine Regulatory Office guideline. Local
administrative bodies and physical infrastructure built to protect local interests pose transportation challenges for raw material
transportation as well as product delivery in Hong Kong. In addition, profitability and volume could be negatively impacted by
limitations inherent within the supply chain, including competitive, governmental, legal, natural disasters, and other events
that could impact both supply and price. Any of these occurrences could cause significant disruptions to our supply chain, manufacturing
capability and distribution system that could adversely impact our ability to produce and deliver some of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our raw materials are not sourced from
endangered species of animals or plants. All of our raw materials are readily available in over 6,000 TCM stores, wholesalers,
and other distribution channels in Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Third parties may assert that
our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">We employ individuals
who previously worked with other companies, including our competitors or potential competitors. Although we try to ensure that
our employees, contractors, or consultants do not use the proprietary information or&nbsp;know-how&nbsp;of others in their work
for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise
used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other
third party. Litigation may be necessary to defend against these claims. If we fail in defending any such claims or settling those
claims, in addition to paying monetary damages or a settlement payment, we may lose valuable intellectual property rights or personnel.
Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We face risks related to health epidemics and outbreaks,
including the SARS-Cov-2 (or COVID-19) pandemic, which could significantly disrupt our ongoing research studies, and therefore
our receipt of necessary regulatory approvals could be delayed or prevented.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">We face risks
related to health epidemics or outbreaks of communicable diseases. For example, the recent outbreak around the world, including
in Hong Kong, the U.S., the European Union members, China and many other countries, of the highly transmissible and pathogenic
COVID-19. The outbreak of such communicable diseases could result in a widespread health crisis that could adversely affect general
commercial activity and the economies and financial markets of many countries, which in the case of COVID-19 has occurred. In
addition, the COVID-19 pandemic may have a severe effect on our ongoing and future research studies of many TCM formulae candidates.
The extent to which the COVID-19 pandemic may impact our research studies will depend on future developments, which are highly
uncertain and cannot be predicted with confidence, such as the duration and geographic reach of the outbreak, the severity of
COVID-19, and the effectiveness of actions to contain and treat COVID-19 in Hong Kong. The continued spread of COVID-19 globally
could adversely impact our research study operations, including our ability to recruit and retain patients if an outbreak outlasts
in Hong Kong. Disruptions or restrictions on our ability to travel to monitor data from our enrolled patients, or to conduct research
studies, or the ability of patients enrolled in our studies to travel, as well as temporary closures of our facilities would negatively
impact our research study activities. As a result, the expected timeline for data readouts of our research studies on enrolled
patients and certain regulatory filings may be negatively impacted, which would adversely affect our ability to obtain regulatory
approval for and to commercialize our product candidates, increase our operating expenses and have a material adverse effect on
our financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General Company Related Risks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have a very limited operating history, which may make
it difficult for you to evaluate the success of our business to date and to assess our future viability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">We commenced our operations in Hong Kong through our wholly-owned
subsidiary Regencell Bioscience Limited in 2015. Our operations to date have been limited to organizing and staffing the company,
partnering with the TCM Practitioner to conduct research studies, identifying potential partnerships and TCM formulae candidates,
acquiring TCM raw materials, and conducting research and development activities for our TCM formulae candidates. We have not yet
demonstrated the ability to successfully complete large-scale, pivotal research studies. We have also not yet applied for or obtained
regulatory approval for, or demonstrated an ability to manufacture or commercialize, any of our TCM formulae candidates. Consequently,
any predictions about our future success, performance, or viability may not be as accurate as they could be if it had a longer
operating history or approved products on the market.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Our limited operating
history, particularly in light of the evolving TCM formulae research and development industry in which we operate, may make it
difficult to evaluate our current business and prospects for future performance. Our short history makes any assessment of our
future performance or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced
by early-stage companies in evolving fields as we seek to transition to a company capable of supporting commercial activities.
In addition, as a new business, we may be more likely to encounter unforeseen expenses, difficulties, complications, and delays
due to limited experience. If we do not address these risks and difficulties successfully, our business will suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>There is uncertainty regarding our ability to continue
as a going concern, indicating the possibility that we may be required to curtail or discontinue our operations in the future.
If we discontinue our operations, you may lose all of your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">We incurred total
net losses of $0.81 million and $0.39 million, respectively, for the fiscal years ended June 30, 2020 and 2019, and have completed
only the preliminary stages of our business plan. We anticipate incurring additional losses before realizing any revenues. We may
need additional financing in order to meet our continuing obligations and ultimately, to attain profitability. The financial statements
do not include any adjustments that might result from the uncertainty about our ability to continue our business. If we are unable
to obtain enough financing from outside sources before we produce enough revenues, we may be forced to sell our assets, or curtail
or discontinue our operations. If this happens, you could lose all or part of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Our future operating results
are difficult to predict and may vary significantly from quarter to quarter, which may adversely affect the price of our Ordinary
Shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Our limited research
progress of our standardized TCM formulae candidates, together with our history of losses, make prediction of future operating
results difficult. You should not rely on our past performance as any indication of future growth rates or operating results.
Our valuation and the price of our securities likely will fall in the event our operating results do not meet the expectations
of analysts and investors. Comparisons of our quarterly operating results are an unreliable indication of our future performance
because they are likely to vary significantly based on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to enroll enough mild-to-moderate
    ADHD and ASD patients into our second research studies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the success of our standardized TCM formulae
    candidates to treat individuals with ADHD or ASD, and the possible future introduction of new products and treatments for
    ADHD or ASD;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the successful completion of future research
    studies, and the possibility that the results of any future study may be adverse to our product and services, or reveal some
    heretofore unknown risk to patients from treatment in the personalized TCM formulae; the failure by us to make professional
    presentation and publication of positive outcomes data from these research studies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to commercialize the standardized
    TCM formulae candidates in Hong Kong once we obtain permission from the Hong Kong Chinese Medicines Board;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expansion and rate of success of our marketing
    and advertising efforts to ADHD and ASD patients, and the rate of success of our direct sales force in Hong Kong;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure of third-party contract manufacturers
    to deliver products or provide services in a cost effective and timely manner;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our failure to compete with other treatment
    for ADHD and ASD;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions relating to ongoing Chinese Medicine
    Ordinance of Hong Kong compliance;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated delays in the development and
    introduction of our future products and/or our inability to control costs;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effects of global or local pandemics or
    epidemics and governmental responses, such as COVID-19; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic conditions as well as those
    specific to our customers and markets.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Therefore, you
should expect that our results of operations will be difficult to predict, which will make an investment in our company uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Future debt agreements may contain, restrictions that
may limit our flexibility in operating our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Documents governing
our future indebtedness, or in connection with additional capital raises, if any, may contain, numerous financial and operating
covenants that limit the discretion of management with respect to certain business matters. Restrictive covenants included in
the above-mentioned credit facility include restrictions on, among others, our ability to&nbsp;incur or permit additional indebtedness
and change the nature of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Our ability to
comply with these and other provisions of the existing loan agreement is dependent on our future performance, which will be subject
to many factors, some of which are beyond our control. The breach of any negative covenants in our current or future agreements
could result in an event of default, as may be defined in such agreements, thereby leading to a potential default interest rate
or immediate repayment of any borrowed amounts. These restrictive covenants which may be in place from time to time and a lack
of compliance by us could limit our flexibility in operating our business. We currently entered into a loan agreement with Mr.
Yat-Gai Au, our CEO and director, which is subject to written amendment by both parties to extend the term of loans. We cannot
guarantee you that we can extend the loans with him in the future without being requested to accept additional restrictions in
connection with our future business operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are wholly dependent on certain key personnel and
our strategic partner, Mr. Sik-Kee Au, the father of our founder, director, and CEO, and loss of these individuals could have
a material adverse effect on our business, financial condition and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our success is, to a certain extent, attributable
to the management, and research and development expertise and potential sales and marketing of key personnel. We are dependent
on the services of Mr. Yat-Gai Au, our founder, director, and CEO, and Dr. Yi-Chung Chao, our Chief Medical Officer (&ldquo;CMO&rdquo;)
and director, for the continued growth and operation of our Company, and critical to our overall management, as well as the continued
development of our strategic direction, due to their experience, personal and business contacts in Hong Kong and the US.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our success of developing standardized TCM
formulae candidates is wholly dependent upon our strategic partnership with Mr. Sik-Kee Au, the TCM Practitioner, the father of
Mr. Yat-Gai Au, our director and CEO, for the continued research and development of the formulae candidates for the Company. The
whole basis of our TCM research is the TCM formulae transferred by the TCM Practitioner, which was developed based on Sik-Kee Au
TCM Brain Theory&trade;&#65039;. We may not be able to retain our partnership with the TCM Practitioner for any given period of
time. We are reliant upon the TCM Practitioner to provide these research services and have little control over his availability
or expertise, except our Partnership Agreements with the TCM Practitioner. Although we have no reason to believe that he will terminate
the partnership relationship with us, the interruption or loss of his services would adversely affect our ability to effectively
run our business and pursue our research on standardized TCM formulae candidates as well as our results of operations. We also
highly rely upon Dr. Yi-Chung Chao&rsquo;s collection and analysis over the research data of our research study. The loss of any
of these individuals could have a material adverse effect upon our business, financial condition, and results of operations. We
do not carry key man life insurance for any of our key personnel, nor do we foresee purchasing such insurance to protect against
the loss of key personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may not be able to hire and retain qualified personnel
to support our growth and if we are unable to retain or hire these personnel in the future, our ability to improve our products
and implement our business objectives could be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We must attract, recruit and retain a sizeable
workforce of technically competent employees. Competition for senior management and personnel in Hong Kong is intense and the
pool of qualified candidates in Hong Kong is very limited. We may not be able to retain the services of our senior executives
or personnel, or attract and retain high-quality senior executives or personnel in the future. This failure could materially and
adversely affect our future growth and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have identified material weaknesses in our internal
control over financial reporting. If we fail to develop and maintain an effective system of internal control over financial reporting,
we may be unable to accurately report our financial results or prevent fraud.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the course of auditing our consolidated
financial statements as of and for the years ended June 30, 2020, and 2019, we and our independent registered public accounting
firm identified two material weaknesses in our internal control over financial reporting as well as other control deficiencies.
As defined in standards established by the PCAOB, a &ldquo;material weakness&rdquo; is a deficiency, or a combination of deficiencies,
in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual
or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses identified relate
to (1) our lack of sufficient skilled staff with U.S. GAAP knowledge and the SEC reporting knowledge for the purpose of financial
reporting as well as the lack in formal accounting policies and procedures manual to ensure proper financial reporting in accordance
with U.S. GAAP and SEC reporting requirements; and (2) our lack of an audit committee and internal audit function to establish
formal risk assessment process and internal control framework.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our management identified material weaknesses
in the design and operation of our internal controls because:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Our lack of sufficient
skilled staff with U.S. GAAP knowledge and the SEC reporting knowledge for the purpose of financial reporting as well as the lack
in formal accounting policies and procedures manual to ensure proper financial reporting in accordance with U.S. GAAP and SEC
reporting requirements; and</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Our lack of an audit
committee and internal audit function to establish formal risk assessment process and internal control framework.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As defined under standards established by
the Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;), a material weakness is a deficiency, or a combination of deficiencies,
in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company&rsquo;s
annual or interim consolidated financial statements will not be prevented or detected on a timely basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a result, we have taken the following
actions to strengthen our U.S. GAAP financial reporting capabilities and our internal audit function:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: left">On December 3, 2020 the board of directors passed
a resolution to appoint three independent directors and form an audit committee comprising three independent directors upon effectiveness
of this registration statement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: left">On January 18, 2021, we hired an experienced CFO with listed
companies&rsquo; financial reporting and internal control experience;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: left">On January 26, 2021, we hired an experienced U.S. GAAP
accountant to manage the company&rsquo;s U.S. GAAP financial reporting process; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD STYLE="text-align: left">The Company has begun searching for an internal control
service provider for the audit committee to consider.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All internal control systems, no matter
how well designed, have inherent limitations including the possibility of human error and the circumvention or overriding of controls.
Further, because of changes in conditions, the effectiveness of internal controls may vary over time. Projections of any evaluation
of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate. Accordingly, even those systems determined to
be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We cannot be certain that these measures
will successfully remediate the material weakness or that other material weaknesses will not be discovered in the future. If our
efforts are not successful or other material weaknesses or control deficiencies occur in the future, we may be unable to report
our financial results accurately on a timely basis or help prevent fraud, which could cause our reported financial results to be
materially misstated and result in the loss of investor confidence or delisting and cause the market price of our Ordinary Shares
to decline. In addition, it could in turn limit our access to capital markets, harm our results of operations, and lead to a decline
in the trading price of our securities. Additionally, ineffective internal control over financial reporting could expose us to
increased risk of fraud or misuse of corporate assets and subject us to potential delisting from the stock exchange on which we
list, regulatory investigations and civil or criminal sanctions. We may also be required to restate our financial statements from
prior periods. Because of our status as an emerging growth company, you will not be able to depend on any attestation from our
independent registered public accountants as to our internal control over financial reporting for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon completion of this offering, we will
become a public company in the United States subject to the Sarbanes-Oxley Act of 2002. Section 404 of the Sarbanes-Oxley Act of
2002 will require that we include a report of management on our internal control over financial reporting in our annual report
on Form 20-F beginning with our first required annual report for the prior fiscal year after completion of this offering. In addition,
once we cease to be an &ldquo;emerging growth company&rdquo; as such term is defined under the JOBS Act, our independent registered
public accounting firm must attest to and report on the effectiveness of our internal control over financial reporting. Our management
may conclude that our internal control over financial reporting is not effective. Moreover, even if our management concludes that
our internal control over financial reporting is effective, our independent registered public accounting firm, after conducting
its own independent testing, may issue a report that is qualified if it is not satisfied with our internal controls or the level
at which our controls are documented, designed, operated or reviewed, or if it interprets the relevant requirements differently
from us. In addition, after we become a public company, our reporting obligations may place a significant strain on our management,
operational and financial resources and systems for the foreseeable future. We may be unable to timely complete our evaluation
testing and any required remediation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the course of documenting and testing our internal control
procedures, in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act of 2002, we may identify other weaknesses
and deficiencies in our internal control over financial reporting. In addition, if we fail to maintain the adequacy of our internal
control over financial reporting, as these standards are modified, supplemented or amended from time to time, we may not be able
to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404
of the Sarbanes-Oxley Act of 2002. Generally, if we fail to achieve and maintain an effective internal control environment, we
could suffer material misstatements in our financial statements and fail to meet our reporting obligations, which would likely
cause investors to lose confidence in our reported financial information. This could in turn limit our access to capital markets,
and harm our results of operations. Additionally, ineffective internal control over financial reporting could expose us to increased
risk of fraud or misuse of corporate assets and subject us to potential delisting from the stock exchange on which we list, regulatory
investigations and civil or criminal sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may not be able to compete effectively against our
competitors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are at the early stage of the development
of our liquid-based TCM formulae treatment and have not sold any products successfully. We expect to face competition in the future
that may result in revenue reductions for the liquid-based TCM formulae treatment that we plan to deliver. We will be at a competitive
disadvantage in obtaining the facilities, employees, financing and other resources required to provide services demanded by prospective
customers. Our opportunity to obtain customers may be limited by our financial resources and other assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The requirements of being a public company may strain
our resources and divert management&rsquo;s attention.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a public company, we will be subject
to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the Sarbanes-Oxley Act,
the Dodd-Frank Act, the listing requirements of the securities exchange on which we list, and other applicable securities rules
and regulations. Compliance with these rules and regulations will nonetheless increase our legal, accounting, and financial compliance
costs and investor relations and public relations costs, make some activities more difficult, time-consuming or costly and increase
demand on our systems and resources, particularly after we are no longer an &ldquo;emerging growth company.&rdquo; As a foreign
private issuer, the Exchange Act requires, among other things, that we file annual and current reports with respect to our business
and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a result of disclosure of information
in this prospectus and in filings required of a public company, our business and financial condition will become more visible,
which we believe may result in threatened or actual litigation, including by competitors and other third parties. If such claims
are successful, our business and operating results could be harmed, and even if the claims do not result in litigation or are resolved
in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management
and adversely affect our business, brand and reputation and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also expect that being a public company
and these new rules and regulations will make it more expensive for us to obtain director and officer liability insurance, and
we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also
make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit
committee and compensation committee, and qualified executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have broad discretion in the use of the net proceeds
from our initial public offering and may not use them effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To the extent (i) we raise more money than
required for the purposes explained in the section titled &ldquo;Use of Proceeds&rdquo; or (ii) we determine that the proposed
uses set forth in that section are no longer in the best interests of our Company, we cannot specify with any certainty the particular
uses of such net proceeds that we will receive from our initial public offering. Our management will have broad discretion in the
application of such net proceeds, including working capital, possible acquisitions, and other general corporate purposes, and we
may spend or invest these proceeds in a way with which our shareholders disagree. The failure by our management to apply these
funds effectively could harm our business and financial condition. Pending their use, we may invest the net proceeds from our initial
public offering in a manner that does not produce income or that loses value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The obligation to disclose information publicly may put
us at a disadvantage to competitors that are private companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon completion of this offering, we will be a publicly listed
company in the United States. As a publicly listed company, we will be required to file periodic reports with the SEC upon the
occurrence of matters that are material to our company and shareholders. In some cases, we will need to disclose material agreements
or results of financial operations that we would not be required to disclose if we were a private company. Our competitors may
have access to this information, which would otherwise be confidential. This may give them advantages in competing with our company.
Similarly, as a U.S.-listed public company, we will be governed by U.S. laws that our non-publicly traded competitors are not required
to follow. To the extent compliance with U.S. laws increases our expenses or decreases our competitiveness against such companies,
our public listing could affect our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our business model may not be sufficient to ensure our
success in our intended market.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our survival is currently dependent upon
the success of our efforts to gain ADHD and ASD patients&rsquo; acceptance of liquid-based TCM formulae treatment that will ultimately
represent a very small segment in our targeted industry when it is completed. Should our target market not be as responsive to
our products as we anticipate, we may not have in place alternate products or services that we can offer to ensure our survival.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our TCM formulae treatment may not be desired
for purchase by patients, or potential competitors may develop services that imitate or compete with ours or prospective offers
and take our targeted revenue stream away from us or reduce our ability to command profitable revenue streams for our products.
If international pharmaceutical companies, develop more successful products to cure ADHD or ASD or offer competitive products
at a lower price, our revenue, margins, and profitability will suffer.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our TCM business is subject to inherent risks relating
to product liability and personal injury claims.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">TCM companies, similar to pharmaceutical
companies, are exposed to risks inherent in the manufacturing and distribution of TCM products, such as with respect to improper
filling of prescriptions, labeling of prescriptions, inadequacy of warnings, and unintentional distribution of counterfeit products.
In addition, product liability claims may be asserted against us with respect to any of the products we sell and as a distributor,
we are required to pay for damages for any successful product liability claim against us, although we may have the right under
applicable Hong Kong laws, rules and regulations to recover from the relevant manufacturer for compensation we paid to our customers
in connection with a product liability claim. We may also be obligated to recall affected products. If we are found liable for
product liability claims, we could be required to pay substantial monetary damages. Furthermore, even if we successfully defend
ourselves against this type of claim, we could be required to spend significant management, financial and other resources, which
could disrupt our business, and our reputation as well as our brand name may also suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to the Offering and Our Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B><I>The initial public offering price
of our Ordinary Shares may not be indicative of the market price of our Ordinary Shares after this offering. In addition, an active,
liquid and orderly trading market for our Ordinary Shares may not develop or be maintained, and our share price may be volatile.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to this offering, our Ordinary Shares
were not traded on any market. An active, liquid and orderly trading market for our Ordinary Shares may not develop or be maintained
after this offering. Active, liquid and orderly trading markets usually result in less price volatility and more efficiency in
carrying out investors&rsquo; purchase and sale orders. The market price of our Ordinary Shares could vary significantly as a
result of a number of factors, some of which are beyond our control. In the event of a drop in the market price of our Ordinary
Shares, you could lose a substantial part or all of your investment in our Ordinary Shares. The initial public offering price
will be determined by us, based on numerous factors and may not be indicative of the market price of our Ordinary Shares after
this offering. Consequently, you may not be able to sell shares of our Ordinary Shares at prices equal to or greater than the
price paid by you in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following factors could affect our
share price:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our operating and financial performance;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">quarterly variations in the rate of growth of
    our financial indicators, such as net income per share, net income and revenues;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the public reaction to our press releases, our
    other public announcements and our filings with the SEC;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">strategic actions by our competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in revenue or earnings estimates, or
    changes in recommendations or withdrawal of research coverage, by equity research analysts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">speculation in the press or investment community;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the failure of research analysts to cover our
    Ordinary Shares;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our Ordinary Shares by us or other
    shareholders, or the perception that such sales may occur;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in accounting principles, policies,
    guidance, interpretations or standards;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures of key management personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions by our shareholders;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">domestic and international economic, legal and
    regulatory factors unrelated to our performance; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the realization of any risks described under
    this &ldquo;Risk Factors&rdquo; section.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The stock markets in general have experienced
extreme volatility that has often been unrelated to the operating performance of particular companies. These broad market fluctuations
may adversely affect the trading price of our Ordinary Shares. Securities class action litigation has often been instituted against
companies following periods of volatility in the overall market and in the market price of a company&rsquo;s securities. Such
litigation, if instituted against us, could result in very substantial costs, divert our management&rsquo;s attention and resources
and harm our business, operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we are a passive foreign investment company for United
States federal income tax purposes for any taxable year, United States holders of our Ordinary Shares could be subject to adverse
United States federal income tax consequences.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A non-United States corporation will be
a passive foreign investment company, or PFIC, for United States federal income tax purposes for any taxable year if either (i)
at least 75% of its gross income for such taxable year is passive income or (ii) at least 50% of the value of its assets (based
on an average of the quarterly values of the assets) during such year is attributable to assets that produce or are held for the
production of passive income. Based on the current and anticipated value of our assets and the composition of our income and assets,
we do not expect to be a PFIC for United States federal income tax purposes for our current taxable year ending June 2021 or in
the foreseeable future. However, the determination of whether or not we are a PFIC according to the PFIC rules is made on an annual
basis and will depend on the composition of our income and assets and the value of our assets from time to time. Therefore, changes
in the composition of our income or assets or the value of our assets may cause us to become a PFIC. The determination of the
value of our assets (including goodwill not reflected on our balance sheet) may be based, in part, on the quarterly market value
of our Ordinary Shares, which is subject to change and may be volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The classification of certain of our income
as active or passive, and certain of our assets as producing active or passive income, and hence whether we are or will become
a PFIC, depends on the interpretation of certain United States Treasury Regulations as well as certain IRS guidance relating to
the classification of assets as producing active or passive income. Such regulations and guidance are potentially subject to different
interpretations. If due to different interpretations of such regulations and guidance the percentage of our passive income or
the percentage of our assets treated as producing passive income increases, we may be a PFIC in one or more taxable years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we are a PFIC for any taxable year during
which a United States person holds Ordinary Shares, certain adverse United States federal income tax consequences could apply
to such United States person. See &ldquo;Taxation&mdash;Passive Foreign Investment Company.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX
ADVISERS ABOUT THE PFIC RULES, THE POTENTIAL APPLICABILITY OF THESE RULES TO THE COMPANY CURRENTLY AND IN THE FUTURE, AND THEIR
FILING OBLIGATIONS IF THE COMPANY IS A PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>For as long as we are an emerging growth company, we
will not be required to comply with certain reporting requirements, including those relating to accounting standards and disclosure
about our executive compensation, that apply to other public companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In April 2012, President Obama signed into
law the JOBS Act. We are classified as an &ldquo;emerging growth company&rdquo; under the JOBS Act. For as long as we are an emerging
growth company, which may be up to five full fiscal years, unlike other public companies, we will not be required to, among other
things, (i) provide an auditor&rsquo;s attestation report on management&rsquo;s assessment of the effectiveness of our system
of internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act, (ii) comply with any new requirements
adopted by the PCAOB requiring mandatory audit firm rotation or a supplement to the auditor&rsquo;s report in which the auditor
would be required to provide additional information about the audit and the financial statements of the issuer, (iii) provide
certain disclosure regarding executive compensation required of larger public companies or (iv) hold nonbinding advisory votes
on executive compensation. We will remain an emerging growth company for up to five years, although we will lose that status sooner
if we have more than $1.07 billion of revenues in a fiscal year, have more than $700 million in market value of our Ordinary Shares
held by non-affiliates, or issue more than $1.0 billion of non-convertible debt over a three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> To the extent that we rely on any of the exemptions
available to emerging growth companies, you will receive less information about our executive compensation and internal control over
financial reporting than issuers that are not emerging growth companies. If some investors find our Ordinary Shares to be less attractive
as a result, there may be a less active trading market for our Ordinary Shares and our share price may be more volatile. </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>As a foreign private issuer, we are not subject to certain
U.S. securities law disclosure requirements that apply to a domestic U.S. issuer, which may limit the information publicly available
to our shareholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a foreign private issuer, we are not
required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act and therefore there
may be less publicly available information about us than if we were a U.S. domestic issuer. For example, we are not subject to
the proxy rules in the United States and disclosure with respect to our annual general meetings will be governed by Cayman Islands
law requirements. In addition, our officers, directors and principal shareholders are exempt from the reporting and &ldquo;short-swing&rdquo;
profit recovery provisions of Section 16 of the Exchange Act and the rules thereunder. Therefore, our shareholders may not know
on a timely basis when our officers, directors and principal shareholders purchase or sell our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may lose our foreign private issuer status in the
future, which could result in significant additional costs and expenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As discussed above, we are a foreign private
issuer, and therefore, we are not required to comply with all of the periodic disclosure and current reporting requirements of
the Exchange Act. The determination of foreign private issuer status is made annually on the last business day of an issuer&rsquo;s
most recently completed second fiscal quarter. We would lose our foreign private issuer status if, for example, more than 50%
of our Ordinary Shares are directly or indirectly held by residents of the U.S. and we fail to meet additional requirements necessary
to maintain our foreign private issuer status. If we lose our foreign private issuer status on this date, we will be required
to file with the SEC periodic reports and registration statements on U.S. domestic issuer forms, which are more detailed and extensive
than the forms available to a foreign private issuer. We will also have to mandatorily comply with U.S. federal proxy requirements,
and our officers, directors and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions
of Section 16 of the Exchange Act. In addition, we will lose our ability to rely upon exemptions from certain corporate governance
requirements under the Nasdaq Stock Market listing rules. As a U.S. listed public company that is not a foreign private issuer,
we will incur significant additional legal, accounting and other expenses that we will not incur as a foreign private issuer,
and accounting, reporting and other expenses in order to maintain a listing on a U.S. securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Recent joint statements by the SEC and PCAOB, proposed
rule changes submitted by Nasdaq, and an act signed into law all call for additional and more stringent criteria to be applied
to emerging market companies upon assessing the qualification of their auditors. These developments could add uncertainties to
our offering.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 21, 2020, SEC Chairman Jay Clayton
and PCAOB Chairman William D. Duhnke III, along with other senior SEC staff, released a joint statement highlighting the risks
associated with investing in companies based in or have substantial operations in emerging markets. The joint statement emphasized
the risks associated with lack of access for the PCAOB to inspect auditors and audit work papers in China and higher risks of
fraud in emerging markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 18, 2020, Nasdaq filed three proposals
with the SEC to (i) apply minimum offering size requirement for companies primarily operating in &ldquo;Restrictive Market&rdquo;,
(ii) adopt a new requirement relating to the qualification of management or board of director for &ldquo;Restrictive Market&rdquo;
companies, and (iii) apply additional and more stringent criteria to an applicant or listed company based on the qualifications
of the company&rsquo;s auditors. The proposed definition of &ldquo;Restrictive Market&rdquo; means a jurisdiction that Nasdaq
determines to have secrecy laws, blocking statutes, national security laws or other laws or regulations restricting access to
information by regulators of U.S.-listed companies in such jurisdictions. Nasdaq may consider the geographic locations of the
company&rsquo;s principal business segments, operations or assets; board and shareholders&rsquo; meetings; headquarters or principal
executive offices; senior management and employees; and books and records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As part of a continued regulatory focus
in the United States on access to audit and other information currently protected by national law, in particular China&rsquo;s,
U.S. President Donald J. Trump signed into law on December 18, 2020 the Holding Foreign Companies Accountable Act, which will
require the SEC to propose rules within 90 days after its enactment to prohibit securities of any registrant from being listed
on any of the U.S. securities exchanges or traded &ldquo;over the counter&rdquo; if the auditor of the registrant&rsquo;s financial
statements is not subject to PCAOB inspection for three consecutive years after the law becomes effective. We could be delisted
if we are unable to cure the situation to meet the PCAOB inspection requirement in time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> The lack of access to the PCAOB inspection in
China prevents the PCAOB from fully evaluating audits and quality control procedures of the auditors based in China. As a result, investors
may be deprived of the benefits of such PCAOB inspections. The inability of the PCAOB to conduct inspections of auditors in China makes
it more difficult to evaluate the effectiveness of these accounting firms&rsquo; audit procedures or quality control procedures as compared
to auditors outside of China that are subject to the PCAOB inspections, which could cause existing and potential investors in our shares
to lose confidence in our audit procedures and reported financial information and the quality of our financial statements. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Enactment of the Holding Foreign Companies
Accountable Act or other efforts to increase U.S. regulatory access to audit information could cause investor uncertainty for affected
issuers, including us, and the market price of the Ordinary Shares could be adversely affected. In addition, enactment of the Holding
Foreign Companies Accountable Act will result in prohibitions on the trading of the Ordinary Shares on The Nasdaq Capital Market or other
U.S. exchange if our auditor fails to be inspected by the PCAOB for three consecutive years.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that we are not subject to the proposed Nasdaq rules
or the Holding Foreign Companies Accountable Act because our business is conducted exclusively in Hong Kong, through our Hong Kong
subsidiary Regencell Bioscience Limited, using Hong Kong dollars. Our senior management and employees are citizens of Hong Kong
and the U.S. and our books and records are managed in Hong Kong. Hong Kong is a special administrative region of the PRC and the
basic policies of the PRC regarding Hong Kong are reflected in the Basic Law, namely, Hong Kong&rsquo;s constitutional document,
which provides Hong Kong with a high degree of autonomy and executive, legislative and independent judicial powers, including that
of final adjudication under the principle of &ldquo;one country, two systems&rdquo;. However, there is no assurance that there
will not be any changes in the economic, political and legal environment in Hong Kong in the future. Since our operation is based
in Hong Kong, any change of such political arrangements may pose immediate threat to the stability of the economy in Hong Kong,
thereby directly and adversely affecting our results of operations and financial positions.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our auditor, Friedman LLP, the independent
registered public accounting firm that issues the audit report included elsewhere in this prospectus, as an auditor of companies
that are traded publicly in the United States and a firm registered with the PCAOB, is subject to laws in the United States pursuant
to which the PCAOB conducts regular inspections to assess our auditor&rsquo;s compliance with the applicable professional standards.
Our auditor is headquartered in Manhattan, New York, and has been inspected by the PCAOB on a regular basis with the last inspection
in June 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">However, the recent developments would
add uncertainties to our offering and we cannot assure you whether Nasdaq or regulatory authorities would apply additional and
more stringent criteria to us after considering our business operation and the effectiveness of our auditor&rsquo;s audit procedures
and quality control procedures, sufficiency of resources, geographic reach or experience as it relates to the audit of our financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We do not intend to pay dividends for the foreseeable
future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We currently intend to retain any future
earnings to finance the operation and expansion of our business, and we do not expect to declare or pay any dividends in the foreseeable
future. As a result, you may only receive a return on your investment in our Ordinary Shares if we are successfully listed and
the market price of our Ordinary Shares increases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The price of the Ordinary Shares and other terms of this
offering have been determined by us along with our underwriter.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you purchase our Ordinary Shares in
this offering, you will pay a price that was not established in a competitive market. Rather, you will pay a price that was determined
by us along with our underwriter. The offering price for our Ordinary Shares may bear no relationship to our assets, book value,
historical results of operations or any other established criterion of value. The trading price, if any, of the Ordinary Shares
that may prevail in any market that may develop in the future, for which there can be no assurance, may be higher or lower than
the price you paid for our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Shares eligible for future sale may adversely affect
the market price of our Ordinary Shares if the shares are successfully listed on Nasdaq or other stock markets, as the future
sale of a substantial number of outstanding shares of Ordinary Shares in the public marketplace could reduce the price of our
Ordinary Shares.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The market price of our shares could decline
as a result of sales of substantial amounts of our shares in the public market, or the perception that these sales could occur. In addition,
these factors could make it more difficult for us to raise funds through future offerings of our Ordinary Shares. An aggregate of 10,000,000
shares will be issued and outstanding before the consummation of this offering all of which, except those held by management, are or
will be freely tradable immediately upon effectiveness of this registration statement. All of the shares sold in the offering will be
freely transferable without restriction or further registration under the Securities Act. The remaining shares will be &ldquo;restricted
securities&rdquo; as defined in Rule 144. These shares may be sold without registration under the Securities Act to the extent permitted
by Rule 144 or other exemptions under the Securities Act. See &ldquo;Shares Eligible for Future Sale.&rdquo;&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If you purchase ordinary shares in this offering, you
will experience immediate and substantial dilution.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The initial public offering price of our shares
is substantially higher than the net tangible book value per share of our Ordinary Shares. Assuming the completion of the minimum offering,
if you purchase shares in this offering, you will incur immediate dilution of approximately $7.95 per share or approximately 83.7% from
the assumed offering price of $9.50 per share, the midpoint of the price range set forth on the cover page of this prospectus, and after
deducting estimated underwriter fees and commissions and estimated offering expenses payable by us. Assuming the completion of the maximum
offering, if you purchase shares in this offering, you will incur immediate dilution of approximately $7.76 or approximately 81.7% from
the assumed offering price of $9.5 per share. Accordingly, if you purchase shares in this offering, you will incur immediate and substantial
dilution of your investment. See &ldquo;Dilution.&rdquo; </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>A sale or perceived sale of a substantial number of shares
of our Ordinary Shares may cause the price of our Ordinary Shares to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If our shareholders sell substantial amounts
of our Ordinary Shares in the public market, the market price of our Ordinary Shares could fall. Moreover, the perceived risk
of this potential dilution could cause shareholders to attempt to sell their shares and investors to short our ordinary shares.
These sales also may make it more difficult for us to sell equity or equity-related securities in the future at a time and price
that we deem reasonable or appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The market price for our Ordinary Shares may be volatile.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The initial public offering price for our
Ordinary Shares may vary from the market price of our Ordinary Shares following our initial public offering. If you purchase our
Ordinary Shares in our initial public offering, you may not be able to resell those shares at or above the initial public offering
price. We cannot assure you that the initial public offering price of our Ordinary Shares, or the market price following our initial
public offering, will equal or exceed prices in privately negotiated transactions of our shares that have occurred from time to
time prior to our initial public offering. The market price for our Ordinary Shares may be volatile and subject to wide fluctuations
due to factors such as:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the financial projections we may provide to
    the public, any changes in these projections or our failure to meet these projections;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated fluctuations in our quarterly
    operating results;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in financial estimates by securities
    research analysts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative publicity, studies or reports;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our capability to catch up with the technological innovations in the industry;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by us or our competitors of acquisitions,
    strategic partnerships, joint ventures or capital commitments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">addition or departure of key personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations of exchange rates between Hong
    Kong dollar and the U.S. dollar; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic or political conditions in
    Hong Kong.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the securities market has
from time to time experienced significant price and volume fluctuations that are not related to the operating performance of particular
companies. These market fluctuations may also materially and adversely affect the market price of our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A possible &ldquo;short squeeze&rdquo;
due to a sudden increase in demand of our Ordinary Shares that largely exceeds supply may lead to price volatility in our Ordinary
Shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Following this offering, investors may
purchase our Ordinary Shares to hedge existing exposure in our Ordinary Shares or to speculate on the price of our Ordinary Shares.
Speculation on the price of our Ordinary Shares may involve long and short exposures. To the extent aggregate short exposure exceeds
the number of shares of our Ordinary Shares available for purchase in the open market, investors with short exposure may have to
pay a premium to repurchase our Ordinary Shares for delivery to lenders of our Ordinary Shares. Those repurchases may in turn,
dramatically increase the price of our Ordinary Shares until investors with short exposure are able to purchase additional common
shares to cover their short position. This is often referred to as a &ldquo;short squeeze.&rdquo; A short squeeze could lead to
volatile price movements in our Ordinary Shares that are not directly correlated to the performance or prospects of our company
and once investors purchase the shares of Ordinary Shares necessary to cover their short position the price of our Ordinary Shares
may decline.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our founder and CEO will continue to own a significant
percentage of our Ordinary Shares and will be able to exert significant control over matters subject to shareholder approval.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Mr. Yat-Gai Au, our founder and CEO, currently
beneficially owns 100% of the Company through Regencell (BVI) Limited, and after this offering is completed the Company will continue
to be controlled by him. Upon the closing of this offering, he will beneficially own approximately 82% of the voting power of our outstanding
Ordinary Shares, or approximately 80% if the underwriter exercises its option to purchase additional Ordinary Shares from us in full.
The Ordinary Shares owned by Mr. Yat-Gai Au upon this closing include 342,105 Ordinary Shares issuable to Mr. Yat-Gai Au or his designees
upon the automatic conversion of the principal of $3,250,000 under the Note that we issued to Mr. Yat-Gai Au at the same price in this
offering (assuming the offering price of $9.50, the midpoint of the price range set forth on the cover page of this prospectus). Therefore,
even after this offering, he will have the ability to substantially influence us through this ownership position. For example, he may
be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or
other major corporate transaction. His interests may not always coincide with our corporate interests or the interests of other shareholders,
and he may act in a manner with which you may not agree or that may not be in the best interests of our other shareholders. So long as
he continues to own a significant amount of our equity, he will continue to be able to strongly influence or effectively control our
decisions. </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>As a &ldquo;controlled company&rdquo; under the rules
of the Nasdaq Capital Market, we may choose to exempt our company from certain corporate governance requirements that could have
an adverse effect on our public shareholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Upon the completion of this offering, we will
be a &ldquo;controlled company&rdquo; as defined under the Nasdaq Stock Market Rules because Mr. Yat-Gai Au, our founder, director and
CEO, will beneficially own 79% of our Ordinary Shares and will be able to exercise 79% of the total voting power of our issued and outstanding
shares, assuming the full exercise of the over-allotment option by the underwriter and the exercise of the warrants and including the
Ordinary Shares issuable to Mr. Yat-Gai Au or his designees upon the automatic conversion of the Note. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As long as our officers and directors,
either individually or in the aggregate, own at least 50% of the voting power of our Company, we are a &ldquo;controlled company&rdquo;
as defined under Nasdaq Market place Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For so long as we are a controlled company
under that definition, we are permitted to elect to rely, and may rely, on certain exemptions from corporate governance rules,
including:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from the rule that a majority of
    our board of directors must be independent directors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from the
    rule that the compensation of our CEO must be determined or recommended solely by independent directors; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from the rule that our director
    nominees must be selected or recommended solely by independent directors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a result, you will not have the same
protection afforded to shareholders of companies that are subject to these corporate governance requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Cayman Islands
law does not impose any fiduciary or other duties on a majority (or controlling) shareholder in respect of the company or any
minority shareholders. For more discussion regarding differences of fiduciary duties under Cayman Islands law and U.S. corporate
law, see &ldquo;&mdash; Description of Share Capital </FONT><FONT STYLE="background-color: white">&mdash;</FONT> <FONT STYLE="font-size: 10pt">Differences
in Corporate Law.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although we do not intend to rely on the
&ldquo;controlled company&rdquo; exemption under the Nasdaq listing rules, we could elect to rely on this exemption in the future.
If we elect to rely on the &ldquo;controlled company&rdquo; exemption, a majority of the members of our board of directors might
not be independent directors and our nominating and corporate governance and compensation committees might not consist entirely
of independent directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If securities or industry analysts do not publish research
or reports about our business, or if they issue an adverse or misleading opinion regarding our shares, the price and trading volume
of our Ordinary Shares could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The trading market for our Ordinary Shares
will be influenced by the research and reports that industry or securities analysts publish about us or our business. If no or few securities
or industry analysts commence coverage of us, the trading price for our securities would be negatively impacted. In the event we obtain
securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our
business model, our intellectual property or our share performance, or if our operating results fail to meet the expectations of analysts,
the price of our securities would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on
us regularly, we could lose visibility in the financial markets, which in turn could cause the price or trading volume of our Ordinary
Shares to decline<B>.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Doing Business in Hong Kong </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Political risks associated with conducting business in
Hong Kong.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our operations are based in Hong Kong. Accordingly, our business
operation and financial conditions will be affected by the political and legal developments in Hong Kong. During the period covered
by the financial information incorporated by reference into and included in this prospectus, we maintain substantially all of our
operations in Hong Kong and, specifically, from Regencell Bioscience Limited. Any adverse economic, social and/or political conditions,
material social unrest, strike, riot, civil disturbance or disobedience, as well as significant natural disasters, may affect the
market may adversely affect the business operations of Regencell Bioscience Limited. Hong Kong is a special administrative region
of the PRC and the basic policies of the PRC regarding Hong Kong are reflected in the Basic Law, namely, Hong Kong&rsquo;s constitutional
document, which provides Hong Kong with a high degree of autonomy and executive, legislative and independent judicial powers, including
that of final adjudication under the principle of &ldquo;one country, two systems&rdquo;. However, there is no assurance that there
will not be any changes in the economic, political and legal environment in Hong Kong in the future. Since our operation is based
in Hong Kong, any change of such political arrangements may pose immediate threat to the stability of the economy in Hong Kong,
thereby directly and adversely affecting our results of operations and financial positions.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Basic Law of the Hong Kong Special
Administrative Region of the People&rsquo;s Republic of China, Hong Kong is exclusively in charge of its internal affairs and
external relations, while the government of the PRC is responsible for its foreign affairs and defense. As a separate customs
territory, Hong Kong maintains and develops relations with foreign states and regions. Based on certain recent development including
the Law of the People&rsquo;s Republic of China on Safeguarding National Security in the Hong Kong Special Administrative Region
issued by the Standing Committee of the PRC National People&rsquo;s Congress in June 2020, the U.S. State Department has indicated
that the United States no longer considers Hong Kong to have significant autonomy from China and President Trump signed an executive
order and Hong Kong Autonomy Act, or HKAA, to remove Hong Kong&rsquo;s preferential trade status and to authorize the U.S. administration
to impose blocking sanctions against individuals and entities who are determined to have materially contributed to the erosion
of Hong Kong&rsquo;s autonomy. The United States may impose the same tariffs and other trade restrictions on exports from Hong
Kong that it places on goods from mainland China. These and other recent actions may represent an escalation in political and
trade tensions involving the U.S, China and Hong Kong, which could potentially harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Given the relatively small geographical
size of Hong Kong, any of such incidents may have a widespread effect on our business operations, which could in turn adversely
and materially affect our business, results of operations and financial condition. It is difficult to predict the full impact
of the HKAA on Hong Kong and companies with operations in Hong Kong like us. Furthermore, legislative or administrative actions
in respect of China-U.S. relations could cause investor uncertainty for affected issuers, including us, and the market price of
our Ordinary Shares could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Because our business is conducted in Hong Kong dollars
and the price of our Ordinary Shares is quoted in United States dollars, changes in currency conversion rates may affect the value
of your investments.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business is conducted in Hong Kong,
our books and records are maintained in Hong Kong dollars, which is the currency of Hong Kong, and the financial statements that
we file with the SEC and provide to our shareholders are presented in United States dollars. Changes in the exchange rate between
the Hong Kong dollar and U.S. dollar affect the value of our assets and the results of our operations in United States dollars.
The value of the Hong Kong dollar against the United States dollar and other currencies may fluctuate and is affected by, among
other things, changes in the Hong Kong&rsquo;s political and economic conditions and perceived changes in the economy of Hong Kong
and the United States. Any significant revaluation of the Hong Kong dollar may materially and adversely affect our cash flows,
revenue and financial condition. Further, our Ordinary Shares offered by this prospectus are denominated in United States dollars,
we will need to convert the net proceeds we receive into Hong Kong dollar in order to use the funds for our business. Changes in
the conversion rate between the United States dollar and the Hong Kong dollar will affect the amount of proceeds we will have available
for our business.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Volatility in our Ordinary Shares price may subject us
to securities litigation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The market for our Ordinary Shares may
have, when compared to seasoned issuers, significant price volatility and we expect that our share price may continue to be more
volatile than that of a seasoned issuer for the indefinite future. In the past, plaintiffs have often initiated securities class
action litigation against a company following periods of volatility in the market price of its securities. We may, in the future,
be the target of similar litigation. Securities litigation could result in substantial costs and liabilities and could divert
management&rsquo;s attention and resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_005"></A><B>ENFORCEABILITY
OF CIVIL LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are incorporated under the laws of the
Cayman Islands as an exempted company with liability limited by shares. We are incorporated in the Cayman Islands because of certain
benefits associated with being a Cayman Islands corporation, such as political and economic stability, an effective judicial system,
a favorable tax system, the absence of exchange control or currency restrictions and the availability of professional and support
services. However, the Cayman Islands has a less developed body of securities laws as compared to the United States and provides
protections for investors to a lesser extent. In addition, Cayman Islands companies may not have standing to sue before the federal
courts of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Substantially all of our assets are located
outside the United States. As a result, it may be difficult for investors to effect service of process within the United States
upon us or such persons or to enforce against them or against us, judgments obtained in United States courts, including judgments
predicated upon the civil liability provisions of the securities laws of the United States or any state thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have appointed Puglisi &amp; Associates
as our agent to receive service of process with respect to any action brought against us in the United States District Court for
the Southern District of New York under the federal securities laws of the United States or of any state in the United States
or any action brought against us in the Supreme Court of the State of New York in the County of New York under the securities
laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Ogier, our counsel to the laws of the Cayman
Islands, and Fairbairn Catley Low &amp; Kong, our counsel to Hong Kong law, have advised us that there is uncertainty as to whether
the courts of the Cayman Islands or Hong Kong would (i) recognize or enforce judgments of United States courts obtained against
us or our directors or officers predicated upon the civil liability provisions of the securities laws of the United States or
any state in the United States or (ii) entertain original actions brought in the Cayman Islands or the Hong Kong against us or
our directors or officers predicated upon the securities laws of the United States or any state in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Ogier has further advised us that there
is currently no statutory enforcement or treaty between the United States and the Cayman Islands providing for enforcement of
judgments. A judgment obtained in the United States, however, may be recognized and enforced in the courts of the Cayman Islands
at common law, without any re-examination on the merits of the underlying dispute, by an action commenced on the foreign judgment
debt in the Grand Court of the Cayman Islands, provided such judgment: (i) is given by a foreign court of competent jurisdiction;
(ii) is final; (iii) is not in respect of taxes, a fine or a penalty; and (iv) was not obtained in a manner and is not of a kind
the enforcement of which is contrary to natural justice or public policy of the Cayman Islands. Furthermore, it is uncertain that
Cayman Islands courts would enforce: (1) judgments of U.S. courts obtained in actions against us or other persons that are predicated
upon the civil liability provisions of the U.S. federal securities laws; or (2) original actions brought against us or other persons
predicated upon the Securities Act. Ogier has informed us that there is uncertainty with regard to Cayman Islands law relating
to whether a judgment obtained from the U.S. courts under civil liability provisions of the securities laws will be determined
by the courts of the Cayman Islands as penal or punitive in nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A judgment of a court in the United States
predicated upon U.S. federal or state securities laws may be enforced in Hong Kong at common law by bringing an action in a Hong
Kong court on that judgment for the amount due thereunder, and then seeking summary judgment on the strength of the foreign judgment,
provided that the foreign judgment, among other things, is (1) for a debt or a definite sum of money (not being taxes or similar
charges to a foreign government taxing authority or a fine or other penalty) and (2) final and conclusive on the merits of the
claim, but not otherwise. Such a judgment may not, in any event, be so enforced in Hong Kong if (a) it was obtained by fraud;
(b) the proceedings in which the judgment was obtained were opposed to natural justice; (c) its enforcement or recognition would
be contrary to the public policy of Hong Kong; (d) the court of the United States was not jurisdictionally competent; or (e) the
judgment was in conflict with a prior Hong Kong judgment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Fairbairn Catley Low &amp; Kong has further
advised us that Hong Kong has no arrangement for the reciprocal enforcement of judgments with the United States. As a result,
there is uncertainty as to the enforceability in Hong Kong, in original actions or in actions for enforcement, of judgments of
United States courts of civil liabilities predicated solely upon the federal securities laws of the United States or the securities
laws of any State or territory within the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_006"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We estimate that we will receive net proceeds
from this offering, after deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable
by us and based upon an assumed initial public offering price of $9.50 per Ordinary Share, the midpoint of the range set forth on the
cover page of this prospectus, of approximately $19.3 million (or approximately $22.3 million if the underwriter exercises its over-allotment
option in full). </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We plan to use the net proceeds we receive
from this offering for the following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%"> <FONT STYLE="font-size: 10pt">Second research study</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 25%; text-align: right"> <FONT STYLE="font-size: 10pt">approximately $2.9 million</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-size: 10pt">Staff salaries</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">approximately $8.2 million</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-size: 10pt">Facilities rental, renovations and equipment </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">approximately $2.7 million</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-size: 10pt">Product and intellectual properties registration </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">approximately $2.3 million</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-size: 10pt">Working capital and other general corporate purposes</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">approximately $3.2 million </FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing represents our current intentions based upon our
present plans and business conditions to use and allocate the net proceeds of this offering. Based on our current projection, we
expect the net proceeds of the offering will provide funds to use for the purposes specified above until December 31, 2023.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">However, we cannot guarantee that if due
to the process of our development, the net proceeds of the offering will be progressed sooner than we expected, or if any additional
financing will be available to us in the terms satisfactory to us, or if any at all. Our management, however, will have significant
flexibility and discretion to apply the net proceeds of this offering. If an unforeseen event occurs or business conditions change,
we may use the proceeds of this offering differently than as described in this prospectus. To the extent that the net proceeds
we receive from this offering are not immediately used for the above purposes, we intend to invest our net proceeds in short-term,
interest-bearing bank deposits or debt instruments.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_007"></A><B>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to keep any future earnings to
finance the expansion of our business, and we do not anticipate that any cash dividends will be paid in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under Cayman Islands law, a Cayman Islands
exempted company may pay a dividend on its shares out of either distributable profits or amounts standing to the credit of the
share premium amount account, provided that in no circumstances may a dividend be paid if this would result in the company being
unable to pay its debts due in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we determine to pay dividends on any of our Ordinary Shares
in the future, as a holding company, we will be dependent on additional debt or equity financing by the holding company and/or
receipt of funds from our HK subsidiary, Regencell Bioscience Limited.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="RB_DRS_008"></A>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The following table sets forth our capitalization
as of December 31, 2020: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on an actual basis;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">on a pro forma basis to give effect to the issuance of 342,105 Ordinary
    Shares upon the automatic conversion of the Note immediately prior to the closing of this offering; and</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in"> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">on a pro forma as adjusted basis to reflect the issuance and sale of 2,300,000 Ordinary Shares
    by us in this offering at the initial public offering price of $9.50 per Ordinary Share, the midpoint of the price range set forth
    on the cover page of this prospectus, after deducting the estimated commissions to the underwriter and the estimated offering expenses
    payable by us.</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You should read this capitalization table
in conjunction with &ldquo;Use of Proceeds,&rdquo; &ldquo;Selected Consolidated Financial and Operating Data,&rdquo; &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and the consolidated financial statements and
the related notes appearing elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Actual</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Pro Forma</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Pro Forma As adjusted<SUP>(1)</SUP></B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; padding-left: 9pt; text-indent: -9pt"> <FONT STYLE="font-size: 10pt">Ordinary shares, $0.00001 par value,
    100,000,000,000 shares authorized, and 10,000,000 shares issued and outstanding as of June 30, 2020, and December 31, 2020</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">100</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">26</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">126</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"> <FONT STYLE="font-size: 10pt">Additional paid-in capital</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">256</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">22,557,511</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">22,557,767</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"> <FONT STYLE="font-size: 10pt">Accumulated deficit</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">(2,985,096</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-&nbsp;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">(2,985,096</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"> <FONT STYLE="font-size: 10pt">Total shareholders&rsquo; deficit</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">(2,984,740</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">22,557,537&nbsp;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">19,572,797</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3pt; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects the sale of Ordinary
    Shares in this offering, excluding (i) the Ordinary Shares issuable upon the exercise of the warrants to be issued to the representative
    of the underwriter, at an assumed initial public offering price of $9.50 per share and (ii) the issuance of 1,235,074 Ordinary shares
    upon the exercise of options granted under our 2021 Share Option Plan, and after deducting the estimated underwriting discounts,
    non-accountable expense allowance, and estimated offering expenses payable by us. The as adjusted information is illustrative only,
    and we will adjust this information based on the actual initial public offering price and other terms of this offering determined
    at pricing, and assuming no exercise of over-allotment option by the underwriter. Additional paid-in capital reflects the net proceeds
    we expect to receive, after deducting the underwriting discounts, non-accountable expense allowance, and estimated offering expenses
    payable by us. We estimate that such net proceeds will be approximately $19,307,537.</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> A $1.00 increase (decrease) in the assumed
initial public offering price of $9.50 per Ordinary Share, the midpoint of the price range set forth on the cover page of this prospectus,
would increase (decrease) each of additional paid-in capital, total shareholders&rsquo; equity and total capitalization by $2.13 million,
assuming the number of Ordinary Shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting
the estimated underwriting discounts and commissions and estimated expenses payable by us. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_009"></A><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you invest in our Ordinary Shares, your
interest will be diluted for each Ordinary Share you purchase to the extent of the difference between the initial public offering
price per Ordinary Share and our net tangible book value per Ordinary Share after this offering. Dilution results from the fact
that the initial public offering price per Ordinary Share is substantially in excess of the net tangible book value per Ordinary
Share attributable to the existing shareholders for our presently outstanding Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our historical net tangible book value as of
December 31, 2020 was $(2,984,740) or $(0.30) per share based upon 10,000,000 outstanding shares. Net tangible book value per share represents
the amount of our total tangible assets, less the amount of our total liabilities, divided by the total number of shares outstanding.
Dilution is determined by subtracting the as adjusted net tangible book value per Ordinary Share from the initial public offering price
per Ordinary Share and after deducting the estimated commissions to the underwriter and the estimated offering expenses payable by us. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our pro forma net tangible book value as of
December 31, 2020 was $(2,984,740), or $(0.29) per share. Pro forma net tangible book value per ordinary share represents the amount
of our total tangible assets less our total liabilities, after giving effect to the conversion of the Note into 342,105 Ordinary Shares
immediately prior to the completion of this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> After giving effect to our issuance and sale
of 2,300,000 Ordinary Shares in this offering, excluding the Ordinary Shares issuable upon the exercise of the warrants to be issued
to the representative of the underwriter, at an assumed offering price of $9.50 per share, the midpoint of the price range set forth
on cover page of this prospectus, assuming no exercise of overallotment and after deducting the estimated underwriting discounts and
offering expenses payable by us, the pro forma as adjusted net tangible book value as of December 31, 2020, would have been $19,572,797
or $1.55 per share. This represents an immediate increase in net tangible book value to existing shareholders of $1.85 per share. Accordingly,
new investors who purchase shares in this Offering will suffer an immediate dilution of their investment of $7.95 per share. The following
table illustrates this per share dilution to the new investors purchasing shares in this Offering: </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 89%; padding-left: 9pt; text-indent: -9pt"> <FONT STYLE="font-size: 10pt">Assumed offering price per ordinary
    share</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 8%; text-align: right"> <FONT STYLE="font-size: 10pt">9.50</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    </TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt"> <FONT STYLE="font-size: 10pt">Net tangible book value
    per ordinary share as of December 31, 2020</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="vertical-align: top; text-align: right"> <FONT STYLE="font-size: 10pt">(0.30</FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    </TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt"> <FONT STYLE="font-size: 10pt">Pro forma tangible book
    value per ordinary share after giving effect to the conversion of the Note as of December 31, 2020</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="vertical-align: top; text-align: right"> <FONT STYLE="font-size: 10pt">(0.29</FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"> <FONT STYLE="font-size: 10pt">Pro forma as adjusted net tangible book value per
    Ordinary Share attributable to payments by new investors</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;1.85</FONT> </TD>
    <TD> &nbsp; </TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"> <FONT STYLE="font-size: 10pt">Net tangible book value per Ordinary Share immediately
    after this offering</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">1.55&nbsp;</FONT> </TD>
    <TD> &nbsp; </TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"> <FONT STYLE="font-size: 10pt">Amount of dilution in net tangible book value per
    Ordinary Share to new investors in the offering</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">7.95&nbsp;</FONT> </TD>
    <TD> &nbsp; </TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"> The following tables summarize, on as adjusted
basis as of December 31, 2020, the differences between existing shareholders and the new investors with respect to the number of Ordinary
Shares purchased from us, the total consideration paid and the average price per Ordinary Share before deducting the estimated underwriting
discounts, non-accountable expense allowance, and the estimated offering expenses payable by us, and assuming no exercise of over-allotment
option by the underwriter. The information above excludes (i) the Ordinary Shares issuable upon the exercise of the warrants to be issued
to the representative of the underwriter, at an assumed initial public offering price of $9.50 per share and (ii) the issuance of 1,235,074
Ordinary shares upon the exercise of options granted under our 2021 Share Option Plan. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Ordinary Shares<BR>
    purchased</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Total consideration</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Average<BR>
    price per<BR>
    Ordinary</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Number</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Percent</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Amount</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Percent</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Share</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="18" STYLE="text-align: center"> <FONT STYLE="font-size: 10pt"><B>($ in thousands)</B></FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 40%"> <FONT STYLE="font-size: 10pt">Existing shareholders</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">10,342,105&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">82&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">%</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">3,250&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">13&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">%</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">0.31&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">New investors</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;2,300,000</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">18&nbsp;</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">%</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">21,850&nbsp;</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">87&nbsp;</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">%</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: right"> <FONT STYLE="font-size: 10pt">9.50&nbsp;</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">Total</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; padding-right: 5pt; text-align: right"> <FONT STYLE="font-size: 10pt">12,642,105&nbsp;</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">100&nbsp;</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">%</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">25,100</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">100&nbsp;</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">%</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt; text-align: right"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The as adjusted information as discussed
above is illustrative only. Our net tangible book value following the completion of this offering is subject to adjustment based
on the actual initial public offering price of our Ordinary Shares and other terms of this offering determined at the pricing.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_010"></A><B>MANAGEMENT
DISCUSSION AND ANALYSIS OF&nbsp;<BR>
FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>The following discussion and analysis
of our financial condition and results of operations should be read in conjunction with our consolidated financial statements
and related notes that appear in this prospectus. In addition to historical consolidated financial information, the following
discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ
materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences
include those discussed below and elsewhere in this prospectus, particularly in &ldquo;Risk Factors&rdquo;. All amounts included
herein with respect to the fiscal years ended June 30, 2020 and 2019 are derived from our audited consolidated financial statements
included elsewhere in this prospectus. The audited consolidated financial statements for the fiscal years ended 2020 and 2019
have been prepared in accordance with U.S. Generally Accepted Accounting Principles, or US GAAP.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We are a holding company incorporated on October
30, 2014, under the laws of the Cayman Islands, and conduct our business in Hong Kong through our wholly-owned subsidiary, Regencell
Bioscience Limited, a company incorporated in Hong Kong on May 12, 2015, and Regencell Limited, a company incorporated in Hong Kong on
November 20, 2014. We are an early-stage bioscience company that focuses on research, development, and commercialization of TCM for the
treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD. Our goal is to improve the lives of ADHD and ASD patients,
their families and caregivers and become a market leader for the best treatment of ADHD and ASD globally. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our TCM formulae candidates are derived from
a TCM base formula and an adjustable formula developed by our TCM Practitioner based on his TCM brain theory, known as &ldquo;Sik-Kee
Au TCM Brain Theory&trade;&rdquo;, and has demonstrated reduced severity in patients&rsquo; ADHD and ASD conditions, as reflected in
lower ATEC, GARS, VADRS and SNAP-IV-26 assessment scores, using the personalized TCM formula in our first research study. The activity
and specificity of the TCM base formula have been optimized by the TCM Practitioner in his prior ADHD and ASD treatments. As of the date
hereof, the TCM Practitioner has standardized the adjustable formula into three Fixed Adjusted Formula for mild, moderate and severe
ADHD and ASD conditions. The TCM brain theory is not recognized in general literature of TCM or elsewhere. However, the TCM Practitioner
has prescribed the TCM base formula based on his TCM brain theory for over 30 years to treat ADHD, ASD and many neurological illnesses,
disorders and degeneration and obtained satisfactory clinical treatment results. Such clinical treatment results are not supported by
controlled clinical data or trials. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We aim to launch three standardized liquid-based
TCM formulae candidates for mild, moderate and severe ADHD and ASD patients in Hong Kong first and subsequently to other markets as we
deem appropriate. We have been headquartered in Hong Kong since inception. In October 2020, we opened our California office. Currently,
we are not actively developing the U.S. market and will conduct preliminary market research once we have successfully developed the Hong
Kong market.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Corporate History and Structure</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Regencell Bioscience Holding Limited is a holding
company incorporated in the Cayman Islands, which has no substantive operations other than holding all of the issued and outstanding
shares of Regencell Bioscience Limited and Regencell Limited.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Regencell Bioscience Holdings Limited owns
100% equity interest of Regencell Bioscience Limited, which was incorporated in Hong Kong on May 12, 2015. Currently, we conduct research
and development activities in the TCM industry through Regencell Bioscience Limited, which has entered Partnership Agreements with the
TCM Practitioner. In October 2020, Regencell Bioscience Limited entered into a leasing agreement with Regus in California. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Regencell Bioscience Holdings Limited owns
100% equity interest of Regencell Limited, which was incorporated in Hong Kong on November 20, 2014. Currently, Regencell Limited has
no operation and is reserved for future expansion needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our CEO and director, Mr. Yat-Gai Au, beneficially owns 100% of Regencell
Bioscience Holdings Limited through Regencell (BVI) Limited, which was incorporated pursuant to the BVI Business Companies Act, 2004 on
May 25, 2017. Mr. Yat-Gai Au has been the sole shareholder of Regencell (BVI) Limited since its inception. On September 28, 2020, Regencell
(BVI) Limited acquired all equity interest of Regencell Bioscience Holdings Limited from Mr. Yat-Gai Au.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On May 31, 2021, we effectuated a forward split
at a ratio of 1,000-for 1 to increase our authorized capital shares from 100,000,000 Ordinary Shares with a par value of $0.01 per share
to 100,000,000,000 Ordinary Shares with a par value of $0.00001 per share. As a result of the 2021 Forward Split, we now have 10,000,000
Ordinary Shares issued and outstanding as of the date hereof, which are owned by Regencell (BVI) Limited. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Strategic Partnership Agreement with TCM Practitioner</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In January 2018, Regencell Bioscience Limited
entered into a Deed of Rights Transfer, Strategic Partnership and Undertaking (the &ldquo;Strategic Partnership Agreement&rdquo;) with
the TCM Practitioner, the father of our CEO and director. Pursuant to the Strategic Partnership Agreement we have with TCM Practitioner,
we have exclusive rights and ownership of (1) all his TCM formulae and (2) the intellectual property rights of the TCM formulae, including
research and development, trademark, copyright, patent and any other intellectual property rights in relation to the TCM formulae that
the TCM Practitioner develops. Pursuant to Strategic Partnership Agreement, the TCM Practitioner is responsible for research and development
of TCM formulae, while, any inventions, TCM formulae, utilities, improvements, research, discoveries, designs, processes, methods of
manufacture and products conceived or made by the TCM Practitioner in relation to TCM shall be the sole and exclusive property of us. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp; &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pursuant to the Strategic Partnership Agreement,
in exchange for the rights, we are required to donate three percent (3.0%) of net revenue that Regencell Bioscience Limited generates
in association with the use and/or commercialization of the TCM formulae treatment to any charitable institutions and/or trusts of a
public character anywhere in the world at the sole and absolute choice of the TCM Practitioner, or his assignee, and in such proportion
at the sole and absolute discretion of the TCM Practitioner on a yearly basis. We also undertake to pay for all reasonable costs and
expenses incurred by the TCM Practitioner in conducting research, testing, attending meetings/seminars, compiling records, or performing
any similar acts in relation to the development of the TCM formulae and TCM inventions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 10, 2020, Regencell Bioscience
Limited entered into a Supplemental Agreement of the Partnership Agreement (the &ldquo;Supplemental Agreement&rdquo; collectively with
the Strategic Partnership Agreement, the &ldquo;Partnership Agreements&rdquo;) with the TCM Practitioner. Under the Supplemental Agreement,
the TCM Practitioner shall provide his research by using his best endeavors on his TCM formulae and TCM inventions under our direction
and supervision. We have authorized the TCM Practitioner, his agents, subcontractors, development team, and affiliates to use TCM formulae
and TCM Inventions to conduct research. However, they shall not directly or indirectly publish, disseminate or otherwise disclose, deliver
or make available to any third party any confidential information, without prior written notice given by the Company. The TCM Practitioner
also shall not be directly or indirectly concerned with or engaged or interested in any other business which is in any respect in competition
with or similar to the TCM business conducted by the Company for two years after the expiration or termination of the Supplemental Agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We shall pay the TCM Practitioner for his expenses
on his TCM research within 30 days upon the receipt of invoice. The Supplemental Agreement shall remain effective until the Strategic
Partnership Agreement is expired or terminated. We can terminate the Supplemental Agreement without cause without any indemnity or damages
being due to TCM Practitioner with 30 days prior written notice. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Financial Operations Overview</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Impact of COVID-19 on Our Business</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The worldwide COVID-19 pandemic may affect
our ability to initiate and complete research studies, delay the initiation of our future research studies, disrupt regulatory activities
or have other adverse effects on our business, results of operations, financial condition and prospects. In addition, the pandemic has
caused substantial disruption in the financial markets and may adversely impact economies worldwide, both of which could adversely affect
our business, operations and ability to raise funds to support our operations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> To date, we have not experienced material business
disruptions or impairments of any of our assets as a result of the pandemic. We are following and plan to continue to follow recommendations
from local governments regarding workplace policies, practices and procedures. We expect to continue to monitor the situation and take
actions as may be required or recommended by government authorities or as we determine are in the best interests of our employees and
other business partners. We are continuing to monitor the potential impact of the pandemic, but we cannot be certain what the overall
impact will be on our business, financial condition, results of operations and prospects. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Revenue</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have not generated any revenue from the
sale of any products, and we do not expect to generate any revenue until we commercialize our standardized TCM formulae products for
ADHD and ASD patients in Hong Kong. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Selling and Marketing Expenses</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Expenses in marketing were mainly for the sponsorship
of seminars and events with Non-Governmental Organizations (&ldquo;NGOs&rdquo;) and institutions that have a large database of families
with ADHD and ASD children, who are our potential target patients and qualified patients to be enrolled in our research study in the
future. There is no assurance that our ADHD and ASD TCM formulae can obtain regulatory approval for marketing, and when regulatory approval
for marketing is obtained, we expect that we would incur expenses associated with hiring a sales and marketing team. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>General and Administrative Expense</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> General and administrative expenses consist
primarily of salaries, compensation, legal and accounting fees, as well as office rental, computer equipment and software and utilities. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We anticipate that our general and administrative
expenses will increase in the future to support our continued research and development activities and increased costs of operating as
a public company. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside
consultants, lawyers and accountants, among other expenses. Additionally, we anticipate increased costs associated with being a public
company including expenses related to services associated with maintaining compliance with Nasdaq rules and SEC requirements, insurance,
and investor relations costs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Research and Development Expense</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Since our inception, our operations have primarily
been limited to the research studies of the proprietary TCM formulae. Our research and development expenses to date consist mainly of
employee salaries and related benefits, office rental and depreciation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Following the closing of this offering, we
expect to significantly increase our research and development efforts as we will initiate our second research study. Research and development
expenses will include employee-related expenses, such as salaries, share-based compensation, benefits and travel expense for the research
and development personnel that we plan to hire and treatment costs in connection with conducting research studies. Research and development
activities will continue to be central to our business model. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Results of Operations</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Comparison for the six months ended December 31, 2020 and 2019</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The following table sets forth our results of operations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> For the Six Months Ended </TD><TD STYLE="font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> For the Six Months Ended </TD><TD STYLE="font-weight: bold"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> December&nbsp;31, </TD><TD STYLE="font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> December&nbsp;31, </TD><TD STYLE="font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> Change </TD><TD STYLE="font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> Change </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2020 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2019 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Amount </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> % </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold"> OPERATING EXPENSES: </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-left: 9pt"> General and administrative </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 114,944 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 105,083 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 9,861 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 9 </TD><TD STYLE="width: 1%; text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"> Research and development </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 253,521 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 192,933 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 60,588 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"> 31 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"> Total operating expenses </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 368,465 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 298,016 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 70,449 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"> 24 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>General and Administrative Expense</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> General and administrative expenses were $0.11
million and $0.11 million for the six months ended December 31, 2020 and December 31, 2019, respectively, and were primarily attributable
to employee salaries and related benefits, office rental, depreciation, legal, professional fees and consulting services associated with
the formation of our company, corporate matters and certain direct and indirect costs associated with services obtained by the Company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The increased general and administrative expenses
for the six months ended December 31, 2020 compared with same period in 2019 were mainly due to increase in employee salaries and related
benefits, professional fees, and increased depreciation on the renovation cost of our new office space. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Research and Development Expense</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Research and development expenses were $0.25
million and $0.19 million for the six months ended December 31, 2020 and 2019, respectively and were primarily attributable to employee
salaries and related benefits, office rental, depreciation, and other third-party services associated with research studies. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The increased research and development expenses
for the six months ended December 31, 2020 compared with same period in 2019 were mainly due to increase in employee salaries and related
benefits and increased depreciation on the renovation cost of our new office space. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Liquidity and Capital Resources</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In accordance with Accounting Standards Update
(&ldquo;ASU&rdquo;) 2014-15, Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern (Subtopic 205-40),
the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the
Company&rsquo;s ability to continue as a going concern within one year after the date that the consolidated financial statements are
issued. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have incurred recurring negative cash flows
since inception and have funded our operations primarily from shareholder loans. We had an accumulated deficit of approximately
$2.99 million and $2.65 million as of December 31, 2020 and June 30, 2020, respectively. We had net losses of approximately $0.33 million
and $0.29 million for the six months ended December 31, 2020 and 2019. We have received funding in the form of shareholder loans
to support our capital needs, which was provided by our CEO. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On November 10, 2020, we entered into a loan
agreement with Mr. Yat-Gai Au to evidence the existing loan and document our oral agreements of the terms and conditions of such existing
loan when such loan was initially generated. The loan agreement also sets forth that Mr. Yat-Gai Au will continue to make loans to us
for operations and research activities. The maturity date of such loans was June 30, 2021, subject to indefinite extension if agreed
by the parties in writing. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On February 2, 2021, a loan extension agreement
was entered by Mr. Yat-Gai Au and Regencell Bioscience Limited, pursuant to which Mr. Yat-Gai Au agreed to provide up to $3 million in
the form of loans or make payments on behalf of us during the period from January 1, 2021 to June 30, 2022 to support our operations and
research activities for the period from January 1, 2021 to June 30, 2022 and further extend the maturity date of the existing loans from
June 30, 2021 to December 31, 2022. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On March 18, 2021, a supplemental loan agreement
was entered by and between Regencell Bioscience Limited and Mr. Yat-Gai Au, pursuant to which Mr. Yat-Gai Au will waive the amount of
$3.25 million of the outstanding loan upon the receipt of the note issued by the Company in the principal amount of $3,250,000. On March
18, 2021, the Company issued the note to Mr. Yat-Gai Au in the principal amount of $3,250,000, automatically convertible into Ordinary
Shares, upon the completion of the Company&rsquo;s initial public offering at the same price as the offering price per Ordinary Shares
to be issued in the initial public offering. The note does not carry any interest. The note, if not automatically converted, will mature
and become payable twelve months after the issuance date of the note and the date when the Company redeems the note. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company has received additional funding
subsequent to December 31, 2020 in the form of additional shareholder loans of $84,998 as of the date of this prospectus. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We intend to pursue a public offering of our
ordinary shares to fund future operations. If we are unable to complete a public offering for a sufficient amount in a timely manner,
we would need to continue to rely on shareholder loan and/or pursue other financing alternatives such as private financing of debt or
equity or collaboration agreements. There can be no assurances, however, that the current operating plan will be achieved or that additional
funding will be available on terms acceptable to us, or at all. If we are unable to obtain sufficient funding, it could be required to
delay our development efforts, limit activities and reduce research and development costs, which could adversely affect our business
prospects. Therefore, we acknowledge that uncertainty remains over our ability to meet our liabilities as they fall due. If we cannot
secure the financing needed to continue as a viable business, our shareholders may lose some or all of their investment in us. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The accompanying consolidated financial statements
do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements
have been prepared on a basis that assumes we will continue as a going concern and which contemplates the realization of assets and satisfaction
of liabilities and commitments in the ordinary course of business. The following summarizes the key components of our cash flows for
the six months ended December 31, 2020 and 2019.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> For the Six Months Ended <BR>
    December 31, </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2020 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2019 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"> Net cash used in operating activities </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> (373,765 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> (316,734 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"> Net cash used in investing activities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (15,272 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (51,282 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"> Net cash provided by financing activities </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 308,014 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 991,530 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"> Net change in cash </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> (81,023 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 623,514 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Cash Flow in Operating Activities</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> For the six months ended December 31, 2020
and 2019, net cash used in operating activities were $0.37 million and $0.32 million, respectively. Net cash used in operating activities
was primarily attributable to a new office lease, the hiring of our executive staff, research and development and general and administrative
activities. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Cash Flow in Investing Activities</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> For the six months ended December 31, 2020
and 2019, net cash used in investing activities were $0.02 million and $0.05 million, respectively, which was primarily attributable
to the renovation of our new office space. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Cash Flow in Financing Activities</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> For the six months ended December 31, 2020
and 2019, net cash from financing activities were $0.31 million and $0.99 million, respectively. Net cash from financing activities was
primarily attributable to shareholder&rsquo;s loans offset by payments of IPO related costs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Contractual Obligations</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The following table summarizes our contractual
obligations as of December 31, 2020: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Payments due by period </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"> Contractual obligations </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Total </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Less than <BR> 1&nbsp;year </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 1&nbsp;&ndash;&nbsp;3&nbsp;years </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 3&nbsp;&ndash;&nbsp;5&nbsp;years </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-bottom: 1.5pt"> Operating lease obligations </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> 451,667 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> 161,538 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> 224,616 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> 65,513 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt"> Total </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 451,667 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 161,538 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 224,616 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 65,513 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Capital Expenditures</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> For the six months ended December 31, 2020
and 2019, we have capital expenditures of $15,272 and $51,282 in relation to our property and equipment. Subsequent to December 31, 2020
and as of the date of this prospectus, we did not purchase any material equipment for operational use. We do not have any other material
commitments to capital expenditures as of December 31, 2020 or as of the date of this prospectus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Off-Balance Sheet Arrangements</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have no material off-balance sheet arrangements
including arrangements that would affect our liquidity, capital resources, market risk support and credit risk support or other benefits. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Critical Accounting Policies and Estimates</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our financial statements and accompanying notes
have been prepared in accordance with U.S. GAAP. The preparation of these financial statements and accompanying notes requires us to
make estimates and judgments that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets
and liabilities. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under
the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. We have identified certain accounting policies that are significant to the preparation of our
financial statements. These accounting policies are important for an understanding of our financial condition and results of operation.
Critical accounting policies are those that are most important to the portrayal of our financial conditions and results of operations
and require management&rsquo;s difficult, subjective, or complex judgment, often as a result of the need to make estimates about the
effect of matters that are inherently uncertain and may change in subsequent periods. Certain accounting estimates are particularly sensitive
because of their significance to financial statements and because of the possibility that future events affecting the estimate may differ
significantly from management&rsquo;s current judgments. While our significant accounting policies are more fully described in Note 3
to the consolidated financial statements included elsewhere in this prospectus, we believe the following critical accounting policies
involve the most significant estimates and judgments used in the preparation of our financial statements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We are an &ldquo;emerging growth company&rdquo;
as defined under the federal securities laws and, as such, will be subject to reduced public company reporting requirements. Section
107 of the JOBS Act provides that an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period provided
in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting
standards. We have elected to take advantage of the extended transition period for complying with new or revised accounting standards
and acknowledge such election is irrevocable pursuant to Section 107 of the JOBS Act. As a result of our election, our financial statements
may not be comparable to those of companies that comply with public company effective dates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <I>Use of Estimates and assumptions</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The preparation of consolidated financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts
of revenues and expenses during the periods presented. Significant accounting estimates reflected in our consolidated financial statements
required to be made by management include, but not limited to, the useful lives of property and equipment, impairment of long-lived assets
and uncertain tax position. Actual results could differ from these estimates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <I>Fair value measurement </I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> ASC 825-10 requires certain
disclosures regarding the fair value of financial instruments. Fair value is defined as the price that would be received to sell an asset
or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level fair value
hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs
and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-size: 10pt">Level
                                            1 &mdash; inputs to the valuation methodology are quoted prices (unadjusted) for identical
                                            assets or liabilities in active markets.</FONT> </TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-size: 10pt">Level
                                            2 &mdash; inputs to the valuation methodology include quoted prices for similar assets and
                                            liabilities in active markets, quoted market prices for identical or similar assets in markets
                                            that are not active, inputs other than quoted prices that are observable and inputs derived
                                            from or corroborated by observable market data.</FONT> </TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-size: 10pt">Level
                                            3 &mdash; inputs to the valuation methodology are unobservable.</FONT> </TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Unless otherwise disclosed, the fair value
of our financial instruments including cash and shareholder&rsquo;s loans approximates their recorded values due to their short-term
maturities. The fair value of the long-term deposit approximates their carrying amounts because the deposit was paid in cash. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <I>Related Parties </I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Parties, which can be a corporation or individual,
are considered to be related if we have the ability, directly or indirectly, to control the other party or exercise significant influence
over the other party in making financial and operational decisions. Companies are also considered to be related if they are subject to
common control or common significant influence. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> During the six months ended December 31, 2020
and 2019, we have an office rental agreement with Ace United International Limited, which is a company wholly owned by our CEO. According
to this office rental agreement, we pay a monthly rent of $4,103 and the terms of the agreement are renewed on an annual basis from the
1st of January to the 31st of December each year. The rental payment is expensed as incurred. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of December 31, 2020, and June 30, 2020,
we have outstanding shareholder loans amounting to approximately $3.54 million and $3.07 million, respectively, from our CEO.
The amounts borrowed are non-interest bearing. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On February 2, 2021, a loan extension agreement
was entered by Mr. Yat-Gai Au and Regencell Bioscience Limited, pursuant to which Mr. Yat-Gai Au agreed to provide up to $3 million in
the form of loans or make payments on behalf of the Company during the period from January 1, 2021 to June 30, 2022 to support its operations
and research activities for the period from January 1, 2021 to June 30, 2022 and further extend the maturity date of the existing loans
from June 30, 2021 to December 31, 2022. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On March 18, 2021, a supplemental loan agreement
was entered by and between Regencell Bioscience Limited and Mr. Yat-Gai Au, pursuant to which Mr. Yat-Gai Au will waive the amount of
$3.25 million of the outstanding loan upon the receipt of the note issued by the Company in the principal amount of $3,250,000. On March
18, 2021, the Company issued the note to Mr. Yat-Gai Au in the principal amount of $3,250,000, automatically convertible into Ordinary
Shares, upon the completion of the Company&rsquo;s initial public offering at the same price as the offering price per Ordinary Shares
to be issued in the initial public offering. The note does not carry any interest. The note, if not automatically converted, will mature
and become payable twelve months after the issuance date of the note and the date when the Company redeems the Note. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations for the years ended June 30, 2020 and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth our results of operations for
the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">For the Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">For the Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Change</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Change</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">OPERATING EXPENSES:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-left: 0.125in">Selling and marketing</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">114,207</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,638</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">110,569</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,039</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">311,934</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">159,129</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">152,805</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">96</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">386,230</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">228,223</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">158,007</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">69</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">812,371</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">390,990</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">421,381</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">108</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Selling and marketing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Selling and marketing expenses were $0.11
million and $0.03 million for the years ended June 30, 2020 and June 30, 2019, respectively. The expenses were primarily attributable
to employee salaries and related benefits, and incurred by marketing efforts for qualified patients&rsquo; recruitment for our
research study during those periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The increased expenses in marketing in 2020
compared with 2019 were mainly for the sponsorship of seminars and events with NGOs and institutions that have a large database
of families with ADHD and ASD children, who are our potential target patients and qualified patients to be enrolled in our research
study in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>General and Administrative Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">General and administrative expenses were
$0.31 million and $0.16 million for the years ended June 30, 2020 and June 30, 2019, respectively, and were primarily attributable
to employee salaries and related benefits, office rental, depreciation, legal, professional fees and consulting services associated
with the formation of our company, corporate matters and certain direct and indirect costs associated with services obtained by
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The increased general and administrative
expenses in 2020 compared with 2019 were mainly due to increase in employee salaries and related benefits, office rental, legal
expenses, and increased depreciation on the renovation cost of our new office space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development expenses were $0.39
million and $0.23 million for the years ended June 30, 2020 and 2019, respectively and were primarily attributable to employee
salaries and related benefits, office rental, depreciation, and other third-party services associated with research studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The increased research and development expenses
in 2020 compared with 2019 were mainly due to increase in employee salaries and related benefits, office rental, and increased
depreciation on the renovation cost of our new office space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with Accounting Standards
Update (&ldquo;ASU&rdquo;) 2014-15, Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern
(Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise
substantial doubt about the Company&rsquo;s ability to continue as a going concern within one year after the date that the consolidated
financial statements are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have incurred recurring negative cash
flows since inception and have funded our operations primarily from shareholder loans. We had an accumulated deficit of approximately
$2.65 million and $1.84 million as of June 30, 2020 and 2019, respectively. We had net losses of approximately $0.81 million and
$0.39 million for the years ended June 30, 2020 and 2019. We have received funding in the form of shareholder loans to support
our capital needs, which was provided by our CEO. The Company has received additional funding subsequent to June 30, 2020 in the
form of additional shareholder loans of $465,947. We acknowledge that uncertainty remains over our ability to meet our liabilities
as they fall due. If we cannot secure the financing needed to continue as a viable business, our shareholders may lose some or
all of their investment in us. On November 10, 2020, we entered into a loan agreement with Mr. Yat-Gai Au to evidence the existing
loan and document our oral agreements of the terms and conditions of such existing loan when such loan was initially generated.
The loan agreement also sets forth that Mr. Yat-Gai Au will continue to make loan to us for daily operation and research activities.
The maturity date of such loans was June 30, 2021, subject to indefinite extension if agreed by the parties in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February 2, 2021, a loan extension agreement
was entered by Mr. Yat-Gai Au and Regencell Bioscience Limited, pursuant to which Mr. Yat-Gai Au agreed to provide up to $3 million
in the form of loan or make payments on behalf of us during the period from January 1, 2021 to June 30, 2022 to support our operations
and research activities for the period from January 1, 2021 to June 30, 2022 and further extend the maturity date of the existing
loans from June 30, 2021 to December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On March 18, 2021, a supplemental loan agreement was entered by and
between the Regencell Bioscience Limited and Mr. Yat-Gai Au, pursuant to which Mr. Yat-Gai Au will waive the amount of $3.25 million of
the outstanding loan upon the receipt of the Note issued by the Company in the principal amount of $3,250,000. On March 18, the Company
issued the Note to Mr. Yat-Gai Au in the principal amount of $3,250,000, automatically convertible into Ordinary Shares, upon the completion
of the Company&rsquo;s initial public offering, at the same price as the offering price per Ordinary Shares to be issued in the initial
public offering. The Note does not carry any interest. The Note, if not automatically converted, will mature and become payable twelve
months after the issuance date of the Note and the date when the Company redeems the Note. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the years ended June 30, 2020 and
2019, we have an office rental agreement with Ace United International Limited, which is a company wholly owned by our CEO. We
have paid a monthly rent of $4,103 and the terms of the agreement are renewed on an annual basis from the 1<SUP>st</SUP> of January
to the 31<SUP>st</SUP> of December each year. The rental payment is expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to pursue a public offering of our Ordinary Shares
to fund future operations. If we are unable to complete a public offering for a sufficient amount in a timely manner, we would
need to continue to rely on shareholder loan and/or pursue other financing alternatives such as private financing of debt or equity
or collaboration agreements. There can be no assurances, however, that the current operating plan will be achieved or that additional
funding will be available on terms acceptable to us, or at all. If we are unable to obtain sufficient funding, it could be required
to delay our development efforts, limit activities and reduce research and development costs, which could adversely affect our
business prospects.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The accompanying consolidated financial
statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated
financial statements have been prepared on a basis that assumes we will continue as a going concern and which contemplates the
realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. The following summarizes
the key components of our cash flows for the years ended June 30, 2020 and 2019.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended <BR>
    June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net cash used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(726,573</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(390,990</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(117,837</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Net cash provided by financing
    activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">988,082</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">480,994</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net change in cash</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">143,672</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">90,004</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cash Flow in Operating Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the years ended June 30, 2020 and 2019,
net cash used in operating activities were $0.73 million and $0.39 million, respectively. Net cash used in operating activities
was primarily attributable to a new office lease, the hiring of our executive staff, research and development, ramped up marketing
efforts and general and administrative activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cash Flow in Investing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the years ended June 30, 2020, net cash
used in investing activities were $0.12 million, which was primarily attributable to the renovation of our new office space. There
was no cash used in investing activities for the year ended June 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cash Flow in Financing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the years ended June 30, 2020 and 2019,
net cash from financing activities were $0.99 million and $0.48 million, respectively. Net cash from financing activities was primarily
attributable to shareholder loans.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contractual Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes our contractual
obligations as of June 30, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Payments due by period</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Contractual obligations</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Less
                                         than 1</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>year</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">1 &ndash; 3 years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">3 &ndash; 5 years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>More
                                         than 5</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>years</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; padding-bottom: 1.5pt">Operating lease obligations</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">483,206</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">136,923</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">224,616</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">121,667</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">483,206</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">136,923</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">224,616</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">121,667</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Capital Expenditures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the years ended June 30, 2020 and 2019,
we have capital expenditures of $117,837 and nil in relation to our property and equipment. Subsequent to June 30, 2020 and as
of the date of this prospectus, we did not purchase any material equipment for operational use. We do not have any other material
commitments to capital expenditures as of June 30, 2020 or as of the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have no material off-balance sheet arrangements
including arrangements that would affect our liquidity, capital resources, market risk support and credit risk support or other
benefits.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our financial statements and accompanying
notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements and accompanying notes requires
us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses and related disclosure of
contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that are believed
to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of
assets and liabilities that are not readily apparent from other sources. We have identified certain accounting policies that are
significant to the preparation of our financial statements. These accounting policies are important for an understanding of our
financial condition and results of operation. Critical accounting policies are those that are most important to the portrayal of
our financial conditions and results of operations and require management&rsquo;s difficult, subjective, or complex judgment, often
as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent
periods. Certain accounting estimates are particularly sensitive because of their significance to financial statements and because
of the possibility that future events affecting the estimate may differ significantly from management&rsquo;s current judgments.
While our significant accounting policies are more fully described in Note 3 to the consolidated financial statements included
elsewhere in this prospectus, we believe the following critical accounting policies involve the most significant estimates and
judgments used in the preparation of our financial statements.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are an &ldquo;emerging growth company&rdquo;
as defined under the federal securities laws and, as such, will be subject to reduced public company reporting requirements. Section
107 of the JOBS Act provides that an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period
provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised
accounting standards. We have elected to take advantage of the extended transition period for complying with new or revised accounting
standards and acknowledge such election is irrevocable pursuant to Section 107 of the JOBS Act. As a result of our election, our
financial statements may not be comparable to those of companies that comply with public company effective dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Use of Estimates and assumptions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The preparation of consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in
our consolidated financial statements required to be made by management include, but not limited to, the useful lives of property
and equipment, impairment of long-lived assets and uncertain tax position. Actual results could differ from these estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Fair value measurement </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">ASC 825-10 requires certain disclosures
regarding the fair value of financial instruments. Fair value is defined as the price that would be received to sell an asset
or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level fair
value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable
inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 &mdash; inputs to the valuation methodology
    are quoted prices (unadjusted) for identical assets or liabilities in active markets.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 &mdash; inputs to the valuation methodology
    include quoted prices for similar assets and liabilities in active markets, quoted market prices for identical or similar
    assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived from or corroborated
    by observable market data.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 &mdash; inputs to the valuation methodology
    are unobservable.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless otherwise disclosed, the fair value of our financial
instruments including cash and shareholder&rsquo;s loans approximates their recorded values due to their short-term maturities.
The fair value of the long-term deposit approximates their carrying amounts because the deposit was paid in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Related Parties </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Parties, which can be a corporation or
individual, are considered to be related if we have the ability, directly or indirectly, to control the other party or exercise
significant influence over the other party in making financial and operational decisions. Companies are also considered to be
related if they are subject to common control or common significant influence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the years ended June 30, 2020 and
2019, we have an office rental agreement with Ace United International Limited, which is a company wholly owned by our CEO. According
to this office rental agreement, we pay a monthly rent of $4,103 and the terms of the agreement are renewed on an annual basis
from the 1st of January to the 31st of December each year. The rental payment is expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of June 30, 2020, and 2019, we have outstanding
shareholder loans amounting to approximately $3.07 million and $2.08 million, respectively, from our CEO. The amounts borrowed
are non-interest bearing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_011"></A><B>INDUSTRY OVERVIEW</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ADHD Overview and Market Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Attention Deficit and Hyperactivity Disorder (ADHD)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">According to the Centers for Disease Control and Protection
(CDC), ADHD is one of the most common neurodevelopmental&nbsp;disorders of childhood. It is usually first diagnosed in childhood
and often lasts into adulthood. Children with ADHD may have trouble paying attention, controlling impulsive behaviors, or be overly
active. Normal symptoms of ADHD include: having short attention span, easily distracted, constantly fidgeting, excessive physical
movement and little or no sense of danger. Some children may also have signs of anxiety, oppositional defiant and conduct disorder,
depression and sleep problems.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A meta-analysis of 175 research studies
worldwide on ADHD prevalence in children aged 18 and under found an overall pooled estimate of 7.2% (Thomas et al. 2015). Furthermore,
based on the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) screening of 11,422 adults for ADHD in
10 countries in the Americas, Europe and the Middle East, the estimates of worldwide adult ADHD prevalence averaged 3.4% (Fayyad
et al. 2007).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Hong Kong</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The reported prevalence of ADHD is estimated
to be 6.4% in children and adolescents in Hong Kong, according to Li Ka Shing Faculty of Medicine of The University of Hong Kong
(LKS Faculty of Medicine) published in 2018. The estimate of Hong Kong&rsquo;s population of children and adolescents was 1.2
million in mid-2020, based on a population estimate by the Census and Statistics Department of the Hong Kong Government, which
means approximately 76,800 children and adolescents are afflicted with ADHD. Although ADHD is often perceived as a disorder of
childhood and adolescence, an increasing number of evidences suggest that symptoms and impairments of ADHD may persist into adulthood
for up to 65% of children with ADHD, and that ADHD is present in approximately 2.5% of adults in Hong Kong. With a population
of about 6.3 million adults in Hong Kong in 2020 according to the Census and Statistics Department of the Hong Kong Government,
approximately 157,500 adults are living with ADHD in Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>ADHD Market Drivers </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">An increase in
awareness about mental health among the general population and governments is expected to propel the ADHD market. We believe that
products launched across the globe, approval of new drugs, and increased research and development activities are also likely to
drive the market.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> A Lancet Psychiatry
study published in September 2018, which provided the largest population-based evidence on the trend of ADHD medication use across the
world, which was led by a research team from the Li Ka Shing Faculty of Medicine at The University of Hong Kong, shows that there was
an increased use of ADHD medications observed worldwide in the past few decades. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">In Hong Kong, the
use of ADHD medications in children increased from 1 per 2,500 children in 2001 to 1 per 69 children in 2015, a 36 times increase,
while the use of ADHD medications in adults increased 3 times from 1 per 30,000 adults in 2001 to 1 per 10,000 in 2015. It was
also noted that the increasing rate in female patients is faster than that in male patients. Data indicated that adults with ADHD
is likely under-diagnosed and under-treated in Hong Kong. According to the research team, increases in ADHD medication use in both
children and adults reflect improved awareness of ADHD and recognition of the importance of effective treatment to avoid long-term
problems. However, the study said that the current clinical services provided by the Hospital Authority in Hong Kong are unlikely
to be sufficient to deal with the increasing needs of new patients and on-going care of current patients. Also, unlike the UK,
Hong Kong does not have comprehensive guidelines to meet the care of both adults and children with ADHD in terms of the diagnosis,
treatment and education needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">In June 2018, the
Hong Kong government published a press release addressing questions regarding their support for children suffering from ADHD. According
to the press release, additional resources have been allocated to the Child Assessment Service (CAS) under the Department of Health
(DH) to recruit additional manpower in order to shorten the waiting time and to strengthen the assessment service provided. They
planned to recruit additional doctors, nurses and allied health professionals for the CAS. The DH also planned to establish a new
Child Assessment Centre (CAC) with a view to strengthening the manpower support and enhancing service capacity to meet the rising
number of ADHD cases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ADHD Market Leaders</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> According to Market Research Future (MRFR),
the global ADHD therapeutics market comprises a host of key players. This list includes Eli Lilly and Company, Concordia International
Corp., NEOS Therapeutics Inc., Highland Therapeutics Inc., Pfizer Inc., Novartis AG, Noven Pharmaceuticals Inc., Janssen Global Services
LLC, Shire, Teva Pharmaceutical and others. However, we do not compete with these players since they mainly focus on prescription or
over the counter drugs while we focus on TCM. In addition, we will only consider expanding our market to other countries once we have
successfully developed the Hong Kong market. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ADHD Current Treatment Landscape and Therapy Limitations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> The global ADHD drug
market size was valued at $21.5 billion in 2019 and is estimated to exhibit a compound annual group rate (CAGR) of 4.9%, reaching a value
of $36.5 billion in 2030, while Hong Kong ADHD drug market size was valued at $16.8 million in 2019 and is estimated to exhibit a CAGR
of 7.8% to reach a value of $38.5 million in 2029, based on research done by Fortune Business Insights. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">According to the ADHD Parents Medication
Guide of the American Psychiatric Association, medication does not cure ADHD but can alleviate the symptoms of ADHD when it is
taken as prescribed. Ongoing care and treatment monitoring are important since those symptoms may come back once medication is
halted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">Two main types
of medication for ADHD approved by the US Food and Drug Administration (FDA) are: stimulants and non-stimulants. Stimulants include
methylphenidate and amphetamines. Non-stimulants which include atomoxetine and guanfacine, are alternatives for those who do not
respond well to stimulants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">However, these
two types of medication for ADHD have multiple side effects. Common side effects of stimulants include: feeling restless and jittery,
difficulty sleeping, loss of appetite, headaches, upset stomach, irritability, mood swings, depression, dizziness, racing heartbeat
and tics. According to HelpGuide, an independently funded nonprofit organization in the U.S., these stimulant medications may also
cause personality changes, such as becoming withdrawn, listless, rigid, or less spontaneous and talkative, others may develop obsessive-compulsive
symptoms. Beyond the potential side effects, there are a number of safety concerns associated with the use of stimulant medications
such as the effect on developing brain, heart-related problem, psychiatric problem and potential abuse, indicated by experts. Non-stimulants
also have side effects including decreased appetite, nausea, vomiting, fatigue, indigestion, dizziness, and mood swings.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE"> Besides direct medical
cost, there are other costs associated with ADHD including but not limited to <FONT STYLE="background-color: white">other health care
costs, special education and disciplinary costs and costs of parental work loss. </FONT>ADHD persisting into adulthood can lead to significant
burdens on the personal, societal and economical futures of those who suffer from this disorder. Aberrant behaviors can also affect relationships
with friends and families and adult patients may encounter difficulties with employment. Therefore, the social and economic impact of
ADHD beyond drugs can nonetheless be substantial. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ASD Overview and Market Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Autism Spectrum Disorder (ASD)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">According to the CDC, ASD is a&nbsp;developmental disability&nbsp;characterized
by repetitive and characteristic patterns of behavior and difficulties with social communications and interaction. The learning,
thinking, and problem-solving abilities of people with ASD can range from gifted to severely challenged. These symptoms are present
from early childhood and typically last a lifetime, affecting daily functions. The Diagnostic and Statistical Manual of Mental
Disorders 5<SUP>th</SUP> Edition (or DSM-5), published in 2013 includes Asperger syndrome, childhood disintegrative disorder, and
pervasive developmental disorders not otherwise specified (or PDD-NOS) as part of ASD rather than as separate disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">ASD occurs in every racial and ethnical
group, and in both males and females. The World Health Organization (WHO) estimates that 1 in 160 children worldwide has ASD.
A Medscape article estimates the global prevalence of ASD at 7.6 cases per 1000 which was estimated on review of epidemiological
studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Hong Kong</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Hong Kong has the highest rate of ASD prevalence,
1 in 27, among children, according to World Population Review rankings. Based on an approximate children population of about 1.2
million, management estimates approximately 44,000 children with ASD. Fortune Business Insights estimates that 3.7% of the total
population in Hong Kong has ASD, or about 277,000 based on a total population of 7.5 million in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ASD Market Drivers</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">According to Fortune Business Insights,
growing prevalence of ASD globally, rising awareness about the condition and the available options for the treatment are the key
factors which are expected to drive the autism disorder and treatment market. Improved diagnosis rate is also a critical factor
for the growth of ASD drug market. To date, only two drugs are approved by the FDA which are specific to the treatment of ASD,
aripiprazole and risperidone. In January 2018, FDA granted Swiss drug maker Roche breakthrough therapy designation for Balovaptan,
which may improve social interaction and communication in people with ASD, to treat ASD, potentially accelerating the development
and approval of ASD drugs. Other antipsychotic drugs are prescribed as off-label therapy across the globe for management of symptoms
associated with the disease. Growing investments by many key players in the research domain for the development of effective drugs
for the treatment of ASD are expected to fuel the ASD therapeutics market growth.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ASD Market Leaders</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> According to Fortune Business Insights, players
engaged in ASD drug therapy in the global market include AstraZeneca, Eli Lilly and Company, Fusion Autism Center, Pfizer Inc., Otsuka
Holdings Co. Limited, and other prominent players. However, we do not compete with these players since they mainly focus on prescription
or over the counter drugs while we focus on TCM. In addition, we will only consider expanding our market to other countries once we have
successfully developed the Hong Kong market. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ASD Current Treatment Landscape and Therapy Limitations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> The global ASD drug
market size was valued at $3.4 billion in 2019 and is estimated to exhibit a CAGR of 5.9% to reach a value of $6.4 billion in 2030, while
the Hong Kong ASD drug market size was valued at $2.1 million in 2019 and is estimated to exhibit a CAGR of 4.9% to reach a value of
$3.5 million in 2030, based on research by Fortune Business Insights. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no medications that can cure ASD
or treat the core symptoms, according to the CDC. However, there are medications that can help ASD patients with related symptoms
like&nbsp;depression,&nbsp;anxiety, aggression, irritability, seizures, insomnia, and trouble focusing and help them function better.
Medicines for treating the three core symptoms of ASD, communication difficulties, social challenges and repetitive behavior, have
long represented a huge area of unmet need. However, few drugs on the market today effectively relieve these symptoms and individual
reaction to most commonly prescribed medicines can vary materially. Although the FDA has approved two antipsychotic drugs for treating
irritability and aggression associated with autism (risperidone and aripiprazole), the prevalent behavioral problems associated
with ASD have not been able to be improved by these medications.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Today, most medicines
prescribed to ease autism&rsquo;s disabling symptoms are used &ldquo;off-label,&rdquo; meaning the medication is being used in
a manner not specified in the FDA&rsquo;s approved packaging label, or insert. Such off-label use is common in virtually all areas
of medicine and is usually done to relieve significant suffering in the absence of sufficiently large and targeted studies.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Antidepressants
are among the world&rsquo;s most widely prescribed medications for ASD patients, such as selective serotonin reuptake inhibitors
(SSRIs), according to an article in Harvard Health Publishing. The range of their uses has expanded from depression to anxiety,
obsessive-compulsive disorder, eating disorders, and many other psychiatric conditions. Side effects include insomnia, skin rashes,
headaches, joint and muscle pain, stomach upset, nausea, or diarrhea. Anticonvulsants are most commonly prescribed when the patient
also suffers from epilepsy, as about one-third of autism patients do, however, common side effects include confusion, fever, hair
loss, paranoia, impaired judgment and memory, anxiety and depression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> Similar to ADHD, besides
direct medical cost, there are other costs associated with ASD including but not limited to <FONT STYLE="background-color: white">other
health care costs, special education and disciplinary costs and costs of parental work loss. </FONT>ASD persisting into adulthood can
lead to significant burden on the personal, societal and economical futures of those who suffer from this disorder. Aberrant behaviors
can also affect relationships with friends and families and adult patients may encounter difficulties with employment. Therefore, the
social and economic impact of ASD beyond drugs may nonetheless be substantial. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Traditional Chinese Medicine (TCM) Treatment for ADHD and
ASD Patients</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our standardized TCM formulae candidates
aim to address the fundamental cause of the disorders to achieve an optimal outcome compared to available stimulant and non-stimulant
medications currently available in the market. The fundamental properties and treatment process of TCM are different from the mainstream
stimulant and non-stimulant medications. TCM takes a holistic approach, using natural ingredients to treat different elements within
the body. Every bodily function is taken into consideration when preparing the TCM formulae for the patients so that the optimal
results of the treatment could be reached.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Several attempts have been made to reduce
the harmful side effects and increase the efficacy of current drugs used to treat ADHD. Some articles have studied medicinal herbs
as an effective supplement in treating ADHD. Thus far, TCM research related to ADHD has been mainly composed of research based
on original literature, systematic review based on search treatises, and experimental research testing the treatment effect of
herbs on ADHD. However, such research was limited to only listing herbal medicines that frequently appeared in text. On the other
hand, experimental research had difficulty in selecting the right herbal medicines to test.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The volume of research into herbal medicines,
with fewer adverse effects, has increased for the treatment of children with ASD. According to <I>Herbal Medicine Treatment for
Children with Autism Spectrum Disorder: A Systematic Review,</I> Lee, Cho, et al., 2017, &ldquo;a review of herbal medicines reported
that 32 kinds of Chinese herbal medicine have pharmacological effects, which mainly resulted in immune system improvement, memory
enhancement, gastrointestinal tract improvement, and calming of the nerves. However, the study did not provide enough evidence
on the efficacy of the treatment of children with ASD. There is a lack of evidence on the efficacy of herbal medicines in the
treatment of autistic children.&rdquo;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Global acceptance and recognition of TCM</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">More and more people are inclined to treat chronic diseases
using natural medicine due to the obvious side effects of chemical drugs, and TCM is aligned with this development tendency. Moreover,
many national governments have gradually accepted and attached importance to TCM and natural herbal medicine because of, among
other concerns, the high bio-pharmaceutical research and development costs relating to chemical drugs. Average cost from research
and development to commercialization for a new medicine is nearly $4 billion, and can sometimes exceed $10 billion. It is our belief
that the international community continues to accept natural medicine, and market demand will continue to grow. More than 90 countries
and regions are introducing laws and regulations for the registration of TCM. (Ref: SWOT analysis and revelation in traditional
Chinese medicine Internationalization, Haitao Tang <I>et al.</I>, 2018)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">TCM is prevalent in 183 countries and regions
around the world. According to the WHO, 103-member states have approved the practice of acupuncture and moxibustion, 29-member
states have enacted special statutes on traditional medicine, and 18 have included acupuncture and moxibustion treatment in their
medical insurance provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Hong Kong&rsquo;s support of
the TCM development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Highlighted in the 2018 Policy Address, Hong Kong&rsquo;s first
Chinese medicine hospital will be a &ldquo;flagship institution&rdquo; for the sector. The government will subsidize certain in-patient
and out-patient services. A 400-bed hospital is expected to come into operation by phases from late 2024. As announced in the 2018-19
Budget, a Chinese Medicine Development Fund of HK$500 million is set up to facilitate applied research and Chinese medicine specialization.
Part of the fund is dedicated to promoting public awareness and nurturing talents for the Chinese medicine hospital.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The collaboration between Chinese and Western
medicine has been in practice for some years. Under the Hong Kong government&rsquo;s policy direction to promote the development
of &ldquo;evidence-based&rdquo; Chinese medicine (CM) and out-patient CM services in the public sector, as well as to provide
training placements for local CM degree program graduates, the Hong Kong Hospital Authority (HA) was tasked to establish a total
of 18 Chinese Medicine Centers for Training and Research (CMCTRs) in each of the 18 districts of Hong Kong since 2003. In 2018,
the total number of attendances at the 18 CMCTRs was about 1.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>TCM for ADHD and ASD</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Based on research by Persistence Market Research,
key disorders treated with TCM are neurological (insomnia, ADHD, ASD), pain, skin and hair disorders, mild infections and cancer treatment.
Market size of TCM for ADHD was valued at $3.6 billion globally in 2019 and is estimated to exhibit a CAGR of 5.65% to reach a value
of $6.6 billion in 2030. Market size of TCM for ASD was valued at $0.6 billion globally in 2019 and is estimated to exhibit a CAGR of
6.65% to reach a value of $1.2 billion in 2030. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A number of global players have entered
into agreements and collaborations to strengthen their sales footprint and product portfolio in TCM market as supplemental offerings
strategy. Increase profitability and sustainable market share are driving the recent strategic developments from leading Chinese
and global pharmaceutical players as they face stiff competition. North America represents the most lucrative market, followed
by Asia Pacific and Europe. The global TCM ADHD and ASD market is expected to record prominent growth in East Asia and emerging
countries such as China, Australia and other South Asian countries. Manufacturers are focusing on the development of customized
products for end-use industries on the back of policy initiatives such as Belt and Road Initiative and overseas TCM centers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The global TCM therapy market has been
witnessing rising demand due to an increase in the pediatric illnesses, chronic behavioral diseases, growing awareness about mental
well-being and rising incidences of lifestyle diseases and disorders, such as ADHD and ASD. This has been driving the demand for
and production of alternative and off-the-shelf drugs due to added risk with mainstream drugs. Herbal medicines are commonly used
in the treatment of children with ADHD and ASD in conjunction with conventional therapy to improve the Childhood Autism Rating
Scale (CARS) score. Furthermore, continued prioritization of unmet medical needs in herbal extract-based drugs is expected to
drive demand for TCM formulations in the forthcoming years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_012"></A><B>OUR BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are an early-stage bioscience company
that focuses on research, development and commercialization of traditional Chinese medicine for the treatment of neurocognitive
disorders and degeneration, specifically ADHD and ASD. Our goal is to improve the lives of ADHD and ASD patients, their families
and caregivers and become a market leader for the best treatment of ADHD and ASD globally. We started in Hong Kong in 2014 with
main operation and assets in Hong Kong. We aim to launch three liquid-based standardized TCM formulae candidates for mild, moderate
and severe ADHD and ASD patients in Hong Kong first and subsequently to other markets as we deem appropriate.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We strategically partner with Mr. Sik-Kee Au,
our TCM Practitioner, the father of our CEO and director. We have three standardized TCM formulae candidates under development targeting
mild, moderate and severe ADHD and ASD conditions. We plan to commence our second research study using the three standardized TCM formulae
candidates in the third quarter of 2021. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our TCM formulae candidates are derived from
a TCM base formula and an adjustable formula developed by our TCM Practitioner based on his TCM brain theory, known as &ldquo;Sik-Kee
Au TCM Brain Theory&trade;&rdquo;, and has demonstrated reduced severity in patients&rsquo; ADHD and ASD conditions, using the personalized
TCM formula in our first research study, as reflected in lower ATEC, GARS, VADRS and SNAP-IV-26 assessment scores. The activity and specificity
of the TCM base formula have been optimized by the TCM Practitioner in his prior ADHD and ASD treatments. As of the date hereof, the
TCM Practitioner has standardized the adjustable formula into three standardized formulae for mild, moderate and severe ADHD and ASD
conditions. The TCM brain theory is not recognized in general literature of TCM or elsewhere. However, the TCM Practitioner has prescribed
the TCM base formula based on his TCM brain theory for over 30 years to treat ADHD, ASD and many neurological illnesses, disorders and
degeneration and obtained satisfactory clinical treatment results. Such clinical treatment results are not supported by controlled clinical
data or trials. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have been headquartered in Hong Kong since our inception.
In October 2020, we opened our California office. Currently, we are not actively developing the U.S. market and will conduct preliminary
market research once our TCM products obtain regulatory approvals and achieve success in Hong Kong. We have been keeping books
and records in Hong Kong since our inception. Our research study and supply of TCM raw materials are in Hong Kong. As we are still
at the stage of TCM treatment research, we have not applied for regulatory approvals, we have no sales, marketing or distribution
capabilities or experience, and no granted patents or pending patent applications, and we have not generated revenues since inception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our TCM Practitioner </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The TCM Practitioner has been practicing
TCM under the guidance of the Chinese Medicine Ordinance in his clinic in Hong Kong since 1999 and has accumulated in-depth experience
of TCM research and clinical practice. For over 30 years, the TCM Practitioner has focused his TCM study on TCM thesis of his father,
who was a renowned TCM doctor in Hong Kong in the 1950s, and other traditional treatises of TCM. He is experienced in treating
patients suffering from a wide range of neurocognitive disorders and degeneration. In particular, he has treated many children
afflicted with ADHD and ASD. He decided to dedicate all his efforts to treat people afflicted with incurable diseases, illnesses
and disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to starting his TCM clinical practice,
the TCM Practitioner founded a successful technology and property business in California. The TCM Practitioner graduated from the
University of California, Berkeley with Bachelor&rsquo;s and Master&rsquo;s Degrees in Electrical Engineering in Circuit Design
and Network Theory. He was the pioneer who invented the first prototype high-density recording drive on flexible media while working
at IBM, which later became known as Iomega Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our TCM formulae and Sik-Kee Au TCM Brain Theory&trade;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our TCM formulae were developed by the TCM
Practitioner and consist solely of natural ingredients without any synthetic components. We have exclusive ownership over such TCM formulae
and have conducted our first research study based on the personalized TCM formulae in November 2018 and March 2019. As of the date hereof,
the TCM Practitioner has standardized the adjustable formula into three fixed formulae for mild, moderate and severe conditions. As a
result, we have three liquid-based standardized TCM formulae candidates under development targeting mild, moderate and severe ADHD and
ASD patients, each consisting of a standard base formula and a fixed adjusted formula. We plan to commence our second research study
using the three standardized TCM formulae candidates in the third quarter of 2021. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our TCM formulae candidates are derived from a TCM base formula
and an adjustable formula developed by our TCM Practitioner based on his TCM brain theory, known as &ldquo;Sik-Kee Au TCM Brain
Theory&trade;&rdquo;. The TCM brain theory is not recognized in general literature of TCM or elsewhere. However, the TCM Practitioner
has prescribed his TCM formulae based on his TCM brain theory for over 30 years to treat ADHD, ASD and many neurological illnesses,
disorders and degeneration and obtained satisfactory clinical treatment results. Such clinical treatment results are not supported
by controlled clinical data or trials. The TCM brain theory explains why a healthy brain is essential in restoring the body&rsquo;s
systems to normal from disorders and illnesses such as ADHD and ASD. According to the TCM brain theory, the blockage of or reduced
blood flow, and damage of the interconnecting central nervous system, endocrine system and blood circulatory system disrupt the
production of hormones and transmission of neurotransmitters, such as melatonin, dopamine, and norepinephrine, leading to a defective
encoding and decoding of functions, and resulting in deficient or abnormal social behaviors that are the hallmarks of ADHD and
ASD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Also, there are articles that explain and
describe the bases of what Sik-Kee Au TCM Brain Theory&trade;&#65039; has connected and put forward, that blockages in the brain
is connected to the disruption of neurotransmitters, which causes neurological disorders such as ADHD and ASD. In the article &ldquo;Blood
Flow May Be Key Player in Neural Processing&rdquo;, published in Scientific America. It says that <FONT STYLE="background-color: white">Christopher
Moore, an assistant neuroscience professor at the Massachusetts Institute of Technology&rsquo;s McGovern Institute for Brain Research
&lsquo;suggests blood&rsquo;s role in the cortex (a key brain processing center), specifically, is more than just bringing nutrients
to the cell, it can also alter the activity of local neuronal circuits. For instance, in experiments in his lab, Moore has seen
that there is more blood flow arriving in an area that processes information from a presented stimulus to a certain sense (e.g.
touch, visual, auditory) prior to the appearance of the stimulus, implying that the flow can prime a circuit for activity, as well.&rsquo;</FONT>
Also in the article &ldquo;Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing
Therapeutic Agents&rdquo;, published by The National Center for Biotechnology Information (NCBI), states that &lsquo;a<FONT STYLE="background-color: white">utism
spectrum disorder is associated with multiple neurotransmitter abnormalities, most notably abnormalities in monoamine (i.e., dopamine,
norepinephrine and serotonin) and amino acid (i.e., glutamate and GABA) neurotransmitters.&rsquo;</FONT> In the publication &ldquo;ADHD
Neuroscience 101&rdquo; posted in ADDitude digital magazine by Larry Silver, M.D., &lsquo;b<FONT STYLE="background-color: white">rain
scientists have found that deficiencies in specific neurotransmitters underlie many common disorders, including anxiety, mood disorders
and anger-control problems. ADHD was the first disorder found to be the result of a deficiency of a specific neurotransmitter&rsquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that patients under treatments
utilizing our TCM formulae candidates provides progressive holistic improvements over time because it aims to correct the fundamental
cause of illnesses and disorders. According to the assessment of our first research study, patients have better eye contact, appetite,
daily excretion, longer sleep duration, communication, sociability, cognition, awareness and attentiveness, complexion, mood and
temper, which are substantial improvements over common symptoms associated with ADHD and ASD namely poor appetite, constipation
and sleep problems. However, there is no assurance that we can expect similar outcome in our second research study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Corporate History and Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a holding company incorporated in
the Cayman Islands on October 30, 2014. We have no substantive operations other than holding all of the issued and outstanding
shares of Regencell Bioscience Limited and Regencell Limited.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Regencell Bioscience Holding Holdings Limited
is a holding company incorporated in the Cayman Islands, which has no substantive operations other than holding all of the issued
and outstanding shares of Regencell Bioscience Limited and Regencell Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Regencell Bioscience Holdings Limited owns
100% equity interest of Regencell Bioscience Limited, which was incorporated in Hong Kong on May 12, 2015. Currently, we conduct
research and development activities in the TCM industry through Regencell Bioscience Limited, which has entered Partnership Agreements
with the TCM Practitioner. In October 2020, Regencell Bioscience Limited entered into a leasing agreement with Regus in California.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Regencell Bioscience Holdings Limited owns
100% equity interest of Regencell Limited, which was incorporated in Hong Kong on November 20, 2014. Currently, Regencell Limited
has no operation and is reserved for future expansion needs.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our CEO and director, Mr. Yat-Gai Au, beneficially
owns 100% of Regencell Bioscience Holdings Limited through Regencell (BVI) Limited. Regencell (BVI) Limited was incorporated pursuant
to the BVI Business Companies Act, 2004 on May 25, 2017, and has no operation since its inception. Mr. Yat-Gai Au has been the
sole shareholder of Regencell (BVI) Limited since its inception. On September 28, 2020, Regencell (BVI) Limited acquired all equity
interest of Regencell Bioscience Holdings Limited from Mr. Yat-Gai Au.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Regencell Bioscience Limited strategically partners with the TCM Practitioner,
the father of Mr. Yat-Gai Au, our CEO and director. Pursuant to the Partnership Agreements, we have exclusive rights and ownership of
all his TCM formulae and TCM inventions. Under our direction, the TCM Practitioner is authorized to conduct research studies on these
transferred TCM formulae and TCM inventions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The following diagram illustrates our corporate
structure as of the date of this prospectus, assuming over-allotment is not exercised by the underwriter and issuance of 342,105 Ordinary
Shares issuable upon the closing of this offering to Regencell (BVI) Limited, Mr. Yat-Gai Au&rsquo;s designee, under the Note (assuming
an offering price of $9.50, the midpoint of the price range set forth on the cover page of this prospectus). </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_004.jpg" ALT="" STYLE="width: 650px; height: 275px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Business Plan and Growth Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are still a start-up company at an early stage and are committed
to designing standardized TCM formulae candidates for ADHD and ASD patients. The growth of our business highly depends on our research
and commercialization of our three liquid-based standardized TCM formulae candidates. Currently, we aim to conduct research in
the effectiveness and safety of our three standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients
and commercialize these three liquid-based standardized TCM formulae candidates for ADHD and ASD patients in Hong Kong. After obtaining
success of commercialization in the Hong Kong market, we may start to offer our pCm formulae products to other markets. In October
2020, we opened our California office. Currently, we are not actively developing the U.S. market and will conduct preliminary market
research once our TCM products obtain regulatory approvals and achieve success in Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Showing in a quantifiable and systematic way that the
personalized TCM formulae is effective for the treatment of ADHD and ASD in our first research study</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have completed our first research study
in 2019 with our TCM Practitioner and the result showed that, except for one patient in one assessment, the assessment scores of all
participants in our study dropped, which indicated that conditions of their ADHD and ASD symptoms were less severe after three months
of treatment with our personalized TCM formulae, which we believe are significant.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Each of the participants of our first research
study was treated by the TCM Practitioner with a personalized TCM formula. Each personalized TCM formulae is comprised of the TCM base
formula, which remains the same among all participants and an adjustable formula. As of the date hereof, the TCM Practitioner has standardized
the adjustable formula into three fixed formulae for mild, moderate and severe ADHD and ASD conditions. As a result, we have three standardized
TCM formulae candidates under development targeting mild, moderate and severe ADHD and ASD patients, each consisting of a standard base
formula and a fixed adjusted formula. We plan to commence our second research study using the three standardized TCM formulae candidates
in the third quarter of 2021. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>File patent applications in Hong Kong and abroad</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order to protect our intellectual properties,
we will file for patent application for our TCM formulae, including the TCM base formula and the three standardized TCM formulae
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Verify the effectiveness of the standardized TCM formulae in
our second research study</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of the date hereof, the TCM Practitioner
has standardized the adjustable formula into three fixed formulae for mild, moderate and severe conditions. As a result, we have three
liquid-based standardized TCM formulae candidates under development targeting mild, moderate and severe ADHD and ASD patients, each consisting
of a standard base formula and a fixed adjusted formula. We plan to commence our second research study using the three standardized TCM
formulae candidates in the third quarter of 2021 in Hong Kong. We plan to arrange one hundred patients to be treated by TCM practitioner(s)
with the use of our standardized TCM formulae candidates for a period of at least three months and up to twelve months. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Set up centralized production facilities </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To further lower the cost of manufacture of our standardized
TCM formulae candidates together with the anticipated increase in demand and support our application for the approval and registration
of our pCm formulae products, we will set up a centralized production facility for mass production of our standardized TCM formulae
candidates. We will lease an industrial space, purchase new automated equipment and production lines and ensure quality control
of our products.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Brand and commercialize our standardized TCM formulae candidates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">After the first year of our second research
study, we will improve, refine and automate the production process to improve efficiency to scale up our production. We will also
design new packaging and labeling, not only to comply with regulatory requirements but also for branding purposes. We will ensure
that the improved production and packaging process will not compromise the effectiveness of our pCm formulae products. We will
then begin to apply for necessary permits from Hong Kong regulatory agencies. We intend to expand our marketing efforts locally
and globally to gain brand recognition and favorable perception by our consumers in our target markets. Specifically, we will build
a marketing team to develop a strong image that we are a TCM company specializing in the treatment of ADHD and ASD. We plan to
market to those who are afflicted by these disorders, through advertisements in television, live radio stations, newspapers/magazines,
online social media and banner advertising and in-person marketing in various healthcare events and seminars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Expand to other locations globally</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will also consider expanding our market to other countries.
Our plan is to market our pCm formulae products in the U.S. and abroad after obtaining success of commercialization in the Hong
Kong market. Although we opened our California office in October 2020, we will only conduct preliminary market research but we
are not currently actively developing the U.S. market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Conduct further R&amp;D on TCM base formula for other
application</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As the TCM base formula is developed based on Sik-Kee Au TCM
Brain Theory&trade;&#65039;, we believe that his TCM base formula potentially has a wider application. We intend to conduct further
investigation and research on the application of the TCM base formula for other applications for other neurological illnesses,
disorders and degeneration.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Product Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mainstream drugs and treatments available currently in the markets
for ADHD and ASD aim to suppress or alleviate symptoms, whereas our TCM formulae aim to treat the fundamental cause of neurocognitive
disorders. Our TCM formulae contain solely of natural ingredients without any synthetic components. The liquid-based and orally
administered TCM formulae are currently personalized for each patient at different severities and symptoms of ADHD and ASD. According
to Sik-Kee Au TCM Brain Theory&trade;&#65039;, when our TCM formulae with their nutrients and medicinal properties, are absorbed
and circulated throughout the body, the TCM formulae can perform the mechanism of removing deposits, clots and toxins that have
been built up in the body over time and provide better blood circulation to bring sufficient blood supply to the brain. According
to the TCM brain theory, with sufficient blood supply and circulation, the brain and organs will regenerate and as a result brain
activities and organ functions are normalized, metabolism boosted and endocrine system regulated, thereby correcting the neurocognitive
disorders and related symptoms such as attention deficit, hyperactivity, cognitive and social impairment. The TCM brain theory
is not recognized in general literature of TCM or elsewhere. However, the TCM Practitioner has prescribed the formulae based on
his TCM brain theory for over 30 years to treat ADHD, ASD and many neurological illnesses, disorders and degeneration and obtained
satisfactory clinical treatment results. Such clinical treatment results are not supported by controlled clinical data or trials.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our TCM Practitioner prescribes the TCM formulae under the guidance
of TCM fundamental principles in conjunction with his TCM brain theory. Although each herb can be identified by its function in
TCM terms, such as blood circulation, tonifying and qi-regulating herbs, the combination of herbs in each formula also demands
our TCM Practitioner to skillfully apply TCM fundamental principles of compatibility to ensure the roles of each individual herb
do not counteract with each other or become collectively harmful. The resulting combination creates synergetic pharmacological
properties to treat neurological illnesses, disorders and degeneration that disrupted the normal neurological functions in ADHD
and ASD patients. According to the assessment of our first research study, patients have better eye contact, daily excretion, appetite,
longer sleep duration, communication, sociability, cognition, awareness and attentiveness, complexion, mood and temper.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ingredients which our TCM Practitioner
uses are all listed in the Pharmacopoeia of the People&rsquo;s Republic of China, tracing back to Compendium of Materia Medical,
or Ben Cao Gang Mu (&ldquo;&#26412;&#33609;&#32177;&#30446;&rdquo;), more than 400 years ago. All raw materials are sourced under
the Hong Kong Chinese Medicine Regulatory Office guideline, and our TCM Practitioner carefully selects credible TCM herb vendors
that have passed high standard TCM herb inspection. Some of the herbs include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">o</TD><TD>Blood circulation herbs:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#26691;&#20161;
                                         Taoren (Persicae Semen)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#32005;&#33457;
                                         Honghua (Carthami Flos)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#20083;&#39321;
                                         Ruxiang (Olibanum)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#27794;&#34277;
                                         Moyao (Myrrha)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">o</TD><TD>Tonifying herbs:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#40643;&#33450;
                                         Huangqi (Astragali Radix)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#22320;&#40643;
                                         Dihuang (Rehmanniae Radix)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#23665;&#33585;&#33848;
                                         Shanzhuyu (Corni Fructus)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">o</TD><TD>Qi regulating, heat and wind removing herbs:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#33610;&#33445;
                                         Jingjie (Schizonepetae Herba)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#38450;&#39080;
                                         Fangfeng (Saposhnikoviae Radix)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#39321;&#38468;
                                         Xiangfu (Cyperi Rhizoma)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">o</TD><TD>Detoxication herbs:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#28023;&#34299;
                                         Haizao, Algae (Sargassum)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#33970;&#20844;&#33521;
                                         Pugongying (Taraxaci Herba)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#40643;&#33449;
                                         Huangqin (Scutellariae Radix)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">o</TD><TD>Blood clot removing herbs:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#19977;&#19971;
                                         Sanqi (Notoginseng Radix et Rhizoma)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#30070;&#27512;
                                         Danggui (Angelicae Sinensis Radix)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#24029;&#33422;
                                         Chuanxiong (Chuanxiong Rhizoma)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">o</TD><TD>Digestion herbs:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#30333;&#26414;
                                         Baizhu (Atractylodis Macrocephalae Rhizoma)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#23665;&#26946;
                                         Shanzha (Crataegi Fructus)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#38622;&#20839;&#37329;
                                         Jineijin (Galli Gigerii Endothelium Coreneum)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to register our pCm formulae products
with the Hong Kong Chinese Medicines Board, upon successful completion of our second research study, under group II of the non-established
medicines category, a category of pCm that does not contain any newly discovered Chinese herb, new medicinal part(s) of Chinese
herb, active group extracted from Chinese herb or set of active groups extracted from compound prescription.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Research and Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our First Research Study in ADHD and ASD </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have conducted an uncontrolled first research
study, commenced in November 2018 and March 2019, to evaluate the effects of our personalized TCM formulae on seven patients, who were
between five and eleven years old and were clinically diagnosed with ADHD or ASD by their healthcare professionals at different levels
of severity, by arranging them to be treated by the TCM Practitioner with the use of our personalized TCM formulae for up to three months. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To minimize the impacts of patients&rsquo;
existing treatments to our assessment, four of the seven patients had stopped their other medications for more than a year before
they started receiving treatment using our personalized TCM formulae and the other three stopped about a week before they started
receiving treatment using our personalized TCM formulae treatment in our study. Moreover, parents of the three patients who stopped
their medication only a week before our study had indicated that they had given those medications to their child only intermittently
as needed, such as when attending class, because of the adverse side effects the child was experiencing. Parents also noted that
the effect of the medication wore off after a few hours they have taken the medication and their condition would be the same as
before they took the medication until they took another dose again.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Patient Voluntary Participation in the First Research
Study</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Seven of the TCM Practitioner&rsquo;s patients
who were already diagnosed by a doctor or hospital with ADHD and/or ASD and age between three and twelve years old, voluntarily
consented to provide their treatment data to us through their parents or guardians to participate in the first research study of
the TCM Practitioner. Moreover, to isolate the treatment&rsquo;s effectiveness, the parents or primary caretakers must agree that
the children patients would stop all other medical treatments, including both mainstream and Chinese medicine for the duration
of the treatment process, which was expected to last for three months. Children who failed to meet all of the above conditions
were not included in our research study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The seven enrolled patients consumed liquid-based
TCM twice a day, which were prepared based on the personalized TCM formulae by our TCM Practitioner and temporarily stopped consuming
any other medicine. Six of the enrolled patients completed a three-month treatment and one completed a two-month treatment. All the patients
and their parents were required to meet with the TCM Practitioner in his clinic weekly and provide regular reports to update the patients&rsquo;
symptoms and conditions by phone. Quantitative assessments were also conducted using globally accepted assessment tools, described in
the following, together with additional qualitative assessments, written observations, photos, videos and parent testimonials to document
their progress. Within three months of receiving treatment using our personalized TCM formulae, our research showed that patients had
attained better speech, communication, sociability, cognition and behavioral abilities. Their overall health had also improved. As part
of the improvement process, patients had also experienced better bowel movement, sweating and temporary fatigue, which were expected
by our TCM Practitioner. However, there is no assurance that the second research study will show similar improvements in patients&rsquo;
symptoms. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Assessment Methodology</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Each enrolled patient stopped all his or her
existing medical treatment for ADHD or ASD and was treated with a personalized TCM formulae for a period up to three months. Patient&rsquo;s
symptoms were assessed through parent interviews and using the globally accepted assessment tools, which were provided below. The parent&rsquo;s
qualitative and quantitative assessment scores on the patient&rsquo;s behavior were compared before, during and after three months of
treatment. The assessment tools used were the questionnaires filled in by the parents, which included the Autism Treatment Evaluation
Checklist (&ldquo;ATEC&rdquo;), the Gilliam Autism Rating Scale (&ldquo;GARS&rdquo;) and the Vanderbilt ADHD Diagnostic Parent Rating
Scale (&ldquo;VADRS&rdquo;) questionnaire. Based on the results of the VADRS questionnaire, we also used the Swanson, Nolan, and Pelham
(SNAP)-IV 26-item scale (SNAP-IV-26), which covered the first 26 items of the VADRS, for further analysis. The individual assessment
method is explained in detail below. The assessment tools used in our research are globally recognized and accepted methods of scoring
severity levels of ADHD and ASD patients. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The first research study was only the first
phase of our research studies. Our uncontrolled first research study was designed with a small sample size to allow us to collect preliminary
data, monitor the treatment progress, observe the effect of the treatment and note any adverse side effects in a cost-effective and systematic
way. It has helped us better prepare for our second research study we intend to begin in 2021, with a much larger sample size of at least
100 candidates and for a longer duration, between 3 and 12 months. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although these are globally recognized assessment
tools for the assessment of ADHD and ASD, the outcome of our research study may be subject to some biases of parents and caregivers of
patients because we relied on the data provided by them, such biases may come from parental expectations, social desirability and recall
bias. If our understanding and use of these assessment tools is flawed, or if the parents and caregivers of enrolled ADHD and ASD patients
fail to observe and record accurately, then we will not only fail to realize any benefits from using these assessment tools, but may
also be led to invest time and financial resources inefficiently in attempting to develop inappropriate TCM formulae candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Autism Treatment Evaluation Checklist (ATEC) </I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">ATEC is specially designed to measure changes
in autistic severity, making it useful in monitoring behaviors over time as well as tracking the efficacy of a treatment. ATEC
comprises of four subscales: (1) Speech/Language/Communication, (2) Sociability, (3) Sensory/Cognitive Awareness and (4) Health/Physical/Behavior.
ATEC is a caregiver-administered questionnaire designed to measure changes in the severity of autism in response to treatment.
The scores from each subscale are combined in order to calculate a Total Score. A lower score indicates a lower severity of autism
symptoms and a higher score correlates with more severe symptoms of autism.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Gilliam Autism Rating Scale (GARS)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> GARS is one of the most widely used instruments
for the assessment of ASD in the world. It is a 42-item norm-referenced screening instrument used for the assessment of individuals ages
3-22 who have severe behavioral problems that may be indicative of autism. It gathers information about specific characteristics typically
noted in children with ASD in three areas: stereotyped behaviors, communication and social interaction. It also contains a Developmental
Disturbances section. As the questions included in the developmental disturbances section of GARS refer to the condition of the patient
during the patient&rsquo;s first 36 months of age, the total score is calculated by adding the sum of the raw scores of the three subscales
of stereotyped behaviors, communications and social interaction, but excluding the scores of developmental disturbances. A lower score
indicates a lower severity of autism symptoms and a higher score correlates with more severe symptoms of autism. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Vanderbilt ADHD Diagnostic Parent Rating Scale (VADRS) </I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> VADRS is a psychological assessment tool for
parents of children aged 6 to 12 designed to measure the severity of ADHD symptoms. Developed by Mark Wolraich at the Oklahoma Health
Sciences Center, this rating scale also includes items related to other disorders which are frequently comorbid with ADHD. Similar to
ATEC and GARS, a lower score indicates a lower severity of ADHD symptoms and a higher score correlates with more severe symptoms of ADHD. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Swanson, Nolan, and Pelham (SNAP)-IV 26-item Parent Rating
Scale (SNAP-IV-26)</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">SNAP-IV-26, which is an abbreviated version of the SNAP Questionnaire
(Swanson, 1992; Swanson et al., 1983) and the same as the first 26 items of the VADRS, was also used. Items from the <I>DSM-IV
</I>criteria for ADHD are included in the two subsets of symptoms: Inattentive (items 1 &ndash; 9) (score range from 0 &ndash;
27) and Hyperactivity/Impulsivity (items 10 &ndash; 18) (score range from 0 &ndash; 27). Also, items from the <I>DSM-IV </I>criteria
for oppositional defiant disorder (ODD) are included (items 19 &ndash; 26) (score range from 0 &ndash; 24) because ODD is often
present in children with ADHD. The lower the SNAP-IV-26 score, the fewer the problems. The scores provide an interpretation for
severe, moderate, mild and no clinically significant symptoms.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Results</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We had seven enrolled patients in our first
research study. Their ages ranged from five to twelve years old. We collected the data recorded by patients&rsquo; caregivers and parents
in our ATEC, GARS, VADRS and SNAP-IV-26 questionnaires. Percentage change in scores of each patient was calculated by (scores after treatment
- scores before treatment)/scores before treatment x 100%, based on the scores shown in Tables 2 to 5 below. Each participant of our
first research study was treated by the TCM Practitioner with a personalized TCM formula. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each personalized TCM formulae was
comprised of the TCM base formula, which remained the same among all enrolled patients and an adjustable formula. The base formula
is the product of Sik-Kee Au TCM Brain Theory&trade;. The adjustable formula was personalized by TCM Practitioner to each child
based on different severity of symptoms in the first research study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Note that in all the following tables and results,
higher scores represent more severe conditions, hence, a drop in severity will result in a negative percentage change as shown in tables
2 to 5, and Patients 1-6 were treated for three months and Patient 7 was treated for two months. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>ATEC Results<B><SUP></SUP></B></I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Percentage change in ATEC total scores of the
seven patients ranges from -19% to -67%, with a mean of -37% and a median of -35%. However, there is no assurance that we can expect
similar outcomes in our second research study. In addition, the outcome of our research study may be subject to some biases of parents
and caregivers of patients because we relied on the data provided by them. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">ATEC scores can be interpreted by comparing
severity to percentiles with the guidelines in Table 1. Table 1 shows how the scoring is calculated and illustrates the severity
of symptoms based on the scores.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Table 1: Interpretation guidelines for ATEC
scores</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">Speech</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">Sociability</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">Sensory/ Cognitive Awareness</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">Health/ Physical/ Behavior</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">Total</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">Percentile</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">Range: 0-28</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">Range: 0-40</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">Range: 0-36</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">Range: 0-75</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">Range: 0-179</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><I>Mild</I></TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">0-9</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">0-2</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">0-4</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">0-5</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">0-8</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">0-30</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">10-19</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3-5</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">5-7</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">6-8</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">9-12</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">31-41</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">20-29</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">6-7</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-10</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">9-11</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">13-15</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">42-50</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; width: 40%">30-39</TD><TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 11%">8-10</TD><TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center">11</TD><TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 11%">12-13</TD><TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 11%">16-18</TD><TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 11%">51-57</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">40-49</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">11-12</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">12-13</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">14-15</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">19-21</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">58-64</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">50-59</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">13-15</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">14-15</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">16-17</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">22-24</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">65-71</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">60-69</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">16-19</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">16-18</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">18-19</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">25-28</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">72-79</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">70-79</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">20-21</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">19-21</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">20-21</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">29-32</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">80-89</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">80-89</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">22-24</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">22-25</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">22-25</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">33-39</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">90-103</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">90-99</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">25-28</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">26-40</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">26-36</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">40-75</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">104-179</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><I>Severe</I></TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Percentile means how many people out
of 100 the individual would score above; at the 50<SUP>th</SUP> percentile (exactly average), an individual would score higher
than 50 out of 100. Scores falling in the 90<SUP>th</SUP> percentile or above may indicate clinically elevated or clinically significant
concerns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Source: Autism Research Institute, ATEC:
Interpretation and Validity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Table 2: ATEC scores of patients before
and after treatment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt"><B>Patient</B></FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt"><B>&nbsp;Lower
    Scores Indicate Lower Severity </B></FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Scores
    Before Treatment</B></FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Scores After 3 Months
    of Treatment</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Percentage
    Change in Scores</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-size: 10pt">Patient 1</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">ATEC Total (Sum of Sub-Scales, 0 - 179):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">89</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">58</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-35</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">ATEC Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 15%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 6%; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.&nbsp; </FONT> </TD>
    <TD STYLE="width: 42%"> <FONT STYLE="font-size: 10pt">Speech/language/communication (0 &ndash; 28)</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">16</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">14</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">-13</FONT> </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Sociability (0 &ndash; 40)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">21</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">14</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-33</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Sensory/Cognitive Awareness (0 &ndash; 36)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">22</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">14</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-36</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">IV.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Health/Physical/Behavior (0 &ndash; 75)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">30</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">16</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-47</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-size: 10pt">Patient 2</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">ATEC Total (Sum of Sub-Scales, 0 - 179):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">103</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">83</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-19</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">ATEC Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Speech/language/communication (0 &ndash; 28)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">12</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">12</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Sociability (0 &ndash; 40)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">30</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">22</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-27</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Sensory/Cognitive Awareness (0 &ndash; 36)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">27</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">25</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-7</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">IV.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Health/Physical/Behavior (0 &ndash; 75)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">34</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">24</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-29</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-size: 10pt">Patient 3</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">ATEC Total (Sum of Sub-Scales, 0 - 179):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">47</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">36</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-23</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">ATEC Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Speech/language/communication (0 &ndash; 28)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">5</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">4</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-20</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Sociability (0 &ndash; 40)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">11</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">6</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-45</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Sensory/Cognitive Awareness (0 &ndash; 36)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">8</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">6</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-25</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">IV.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Health/Physical/Behavior (0 &ndash; 75)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">23</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">20</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-13</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-size: 10pt">Patient 4</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">ATEC Total (Sum of Sub-Scales, 0 - 179):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">65</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">35</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-46</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">ATEC Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Speech/language/communication (0 &ndash; 28)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">5</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">3</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-40</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Sociability (0 &ndash; 40)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">16</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">9</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-44</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Sensory/Cognitive Awareness (0 &ndash; 36)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">20</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">13</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-35</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">IV.&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Health/Physical/Behavior (0 &ndash; 75)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">24</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">10</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-58</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-size: 10pt">Patient 5</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">ATEC Total (Sum of Sub-Scales, 0 - 179):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">46</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">15</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-67</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">ATEC Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Speech/language/communication (0 &ndash; 28)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">3</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-100</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Sociability (0 &ndash; 40)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">18</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">4</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-78</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Sensory/Cognitive Awareness (0 &ndash; 36)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">4</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">2</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-50</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">IV.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Health/Physical/Behavior (0 &ndash; 75)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">21</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">9</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-57</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-size: 10pt">Patient 6</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">ATEC Total (Sum of Sub-Scales, 0 - 179):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">102</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">52</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-49</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">ATEC Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Speech/language/communication (0 &ndash; 28)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">14</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">13</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-7</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Sociability (0 &ndash; 40)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">24</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">11</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-54</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Sensory/Cognitive Awareness (0 &ndash; 36)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">28</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">17</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-39</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">IV.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Health/Physical/Behavior (0 &ndash; 75)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">36</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">11</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-69</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-size: 10pt">Patient 7</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">ATEC Total (Sum of Sub-Scales, 0 - 179):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">93</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">73</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-22</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">ATEC Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Speech/language/communication (0 &ndash; 28)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">10</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">10</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Sociability (0 &ndash; 40)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">32</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">26</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-19</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Sensory/Cognitive Awareness (0 &ndash; 36)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">22</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">21</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-5</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">IV.&nbsp; </FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Health/Physical/Behavior (0 &ndash; 75)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">29</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">16</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-45</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>GARS Results<B><SUP></SUP></B></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Percentage change in GARS total scores of the
seven patients ranges from 1% to -59%, with a mean of -33% and a median of -34%. However, there is no assurance that we can expect similar
outcomes in our second research study. In addition, the outcome of our research study may be subject to some biases of parents and caregivers
of patients because we relied on the data provided by them. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Table 3: GARS scores of patients before
and after treatment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt"><B>Patient</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">&nbsp;<B>Lower Scores Indicate Lower Severity</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Scores Before Treatment</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Scores After 3 Months
    of Treatment</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Percentage Change
    in Scores</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-size: 10pt">Patient 1</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">GARS Total (Sum of Sub-Scales, 0 - 126):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">70</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">45</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-36</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">GARS Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 15%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 7%; padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">I.&nbsp;&nbsp;</FONT> </TD>
    <TD STYLE="width: 44%; text-align: justify"> <FONT STYLE="font-size: 10pt">Stereotyped behavior (0 &ndash; 42)</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 8%; text-align: right"> <FONT STYLE="font-size: 10pt">19</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 8%; text-align: right"> <FONT STYLE="font-size: 10pt">11</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 8%; text-align: right"> <FONT STYLE="font-size: 10pt">-42</FONT> </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">II.&nbsp; </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Communication (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">26</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">22</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-15</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">III.&nbsp; </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Social interaction (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">25</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">12</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-52</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-size: 10pt">Patient 2</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">GARS Total (Sum of Sub-Scales, 0 - 126):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">78</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">79</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">1</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">GARS Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">I.&nbsp;&nbsp; </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Stereotyped behavior (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">22</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">24</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">9</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">II.&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Communication (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">31</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">30</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-3</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">III. </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Social interaction (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">25</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">25</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-size: 10pt">Patient 3</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">GARS Total (Sum of Sub-Scales, 0 - 126):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">41</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">17</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-59</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">GARS Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">I.&nbsp;&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Stereotyped behavior (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">9</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">5</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-44</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">II.&nbsp;&nbsp; </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Communication (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">14</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">4</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-71</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">III.&nbsp; </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Social interaction (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">18</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">8</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-56</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-size: 10pt">Patient 4</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">GARS Total (Sum of Sub-Scales, 0 - 126):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">82</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">36</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-56</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">GARS Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">I.&nbsp; </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Stereotyped behavior (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">20</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">6</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-70</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">II.&nbsp;&nbsp; </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Communication (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">28</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">16</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-43</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">III.&nbsp; </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Social interaction (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">34</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">14</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-59</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-size: 10pt">Patient 5</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">GARS Total (Sum of Sub-Scales, 0 - 126):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">23</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">16</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-30</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">GARS Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">I.&nbsp;&nbsp;&nbsp; </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Stereotyped behavior (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">10</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">4</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-60</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">II.&nbsp; </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Communication (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">2</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">3</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">50</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">III.&nbsp; </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Social interaction (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">11</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">9</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-18</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-size: 10pt">Patient 6</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">GARS Total (Sum of Sub-Scales, 0 - 126):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">80</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">68</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-15</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">GARS Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">I.&nbsp;&nbsp; </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Stereotyped behavior (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">18</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">13</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-28</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">II.&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Communication (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">35</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">31</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-11</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">III.</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Social interaction (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">27</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">24</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-11</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-size: 10pt">Patient 7</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">GARS Total (Sum of Sub-Scales, 0 - 126):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">73</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">48</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-34</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">GARS Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>

<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">I.&nbsp;&nbsp;&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Stereotyped behavior (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">22</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">15</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-32</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">II.&nbsp;&nbsp; </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Communication (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">23</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">13</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-43</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt; text-align: justify"> <FONT STYLE="font-size: 10pt">III.&nbsp; </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Social interaction (0 - 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">28</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">20</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-29</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>VADRS Results<B><SUP></SUP></B></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 5pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Percentage change in VADRS total scores of
the seven patients ranges from -8% to -49%, with a mean of -30% and a median of -32%. However, there is no assurance that we can expect
similar outcomes in our second research study. In addition, the outcome of our research study may be subject to some biases of parents
and caregivers of patients because we relied on the data provided by them. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Table 4: VADRS scores of patients before
and 3 months after treatment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt"><B>Patient</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">&nbsp;<B>Lower Scores Indicate Lower Severity</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Scores Before Treatment</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Scores After 3 Months
    of Treatment</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Percentage Change
    in Scores</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-size: 10pt">Patient 1</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">VADRS Total (Sum of Sub-Scales, 0 - 141):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">60</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">37</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-38</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">VADRS Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 15%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 7%; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.</FONT> </TD>
    <TD STYLE="width: 44%"> <FONT STYLE="font-size: 10pt">Inattentive (0 &ndash; 27)</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 8%; text-align: right"> <FONT STYLE="font-size: 10pt">21</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 8%; text-align: right"> <FONT STYLE="font-size: 10pt">15</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 8%; text-align: right"> <FONT STYLE="font-size: 10pt">-29</FONT> </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Hyperactive/Impulsivity (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">20</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">11</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-45</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Oppositional-Defiance Disorder (0 &ndash; 24)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">16</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">10</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-38</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">IV.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Conduct Disorder (0 &ndash; 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">1</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-100</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">V.&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Anxiety and Depression</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">2</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">1</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-50</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-size: 10pt">Patient 2</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">VADRS Total (Sum of Sub-Scales, 0 - 141):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">66</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">61</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-8</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">VADRS Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Inattentive (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">27</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">25</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-7</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Hyperactive/Impulsivity (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">15</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">14</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-7</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Oppositional-Defiance Disorder (0 &ndash; 24)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">13</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">13</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">IV.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Conduct Disorder (0 &ndash; 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">2</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">1</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-50</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">V.&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Anxiety and Depression (0 &ndash; 21)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">9</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">8</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-11</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-size: 10pt">Patient 3</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">VADRS Total (Sum of Sub-Scales, 0 - 141):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">57</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">31</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-46</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">VADRS Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Inattentive (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">16</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">11</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-31</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Hyperactive/Impulsivity (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">21</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">9</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-57</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Oppositional-Defiance Disorder (0 &ndash; 24)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">15</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">9</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-40</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">IV.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Conduct Disorder (0 &ndash; 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">2</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">1</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-50</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">V.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Anxiety and Depression (0 &ndash; 21)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">3</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">1</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-67</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-size: 10pt">Patient 4</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">VADRS Total (Sum of Sub-Scales, 0 - 141):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">42</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">34</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-19</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">VADRS Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Inattentive (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">14</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">13</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-7</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Hyperactive/Impulsivity (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">8</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">7</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-13</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Oppositional-Defiance Disorder (0 &ndash; 24)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">11</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">8</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-27</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">IV.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Conduct Disorder (0 &ndash; 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">2</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">1</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-50</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">V.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Anxiety and Depression (0 &ndash; 21)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">7</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">5</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-29</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-size: 10pt">Patient 5</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">VADRS Total (Sum of Sub-Scales, 0 - 141):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">57</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">29</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-49</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">VADRS Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Inattentive (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">14</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">7</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-50</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Hyperactive/Impulsivity (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">15</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">10</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-33</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Oppositional-Defiance Disorder (0 &ndash; 24)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">13</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">9</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-31</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">IV.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Conduct Disorder (0 &ndash; 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">7</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">1</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-86</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">V.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Anxiety and Depression (0 &ndash; 21)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">8</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">2</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-75</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-size: 10pt">Patient 6</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">VADRS Total (Sum of Sub-Scales, 0 - 141):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">57</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">39</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-32</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">VADRS Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Inattentive (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">26</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">21</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-19</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Hyperactive/Impulsivity (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">17</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">7</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-59</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Oppositional-Defiance Disorder (0 &ndash; 24)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">8</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">6</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-25</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">IV.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Conduct Disorder (0 &ndash; 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">2</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">1</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-50</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">V.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Anxiety and Depression (0 &ndash; 21)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">4</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">4</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-size: 10pt">Patient 7</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">VADRS Total (Sum of Sub-Scales, 0 - 141):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">41</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">33</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-20</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">VADRS Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>

<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Inattentive (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">19</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">16</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-16</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Hyperactive/Impulsivity (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">15</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">11</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-27</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Oppositional-Defiance Disorder (0 &ndash; 24)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">7</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">6</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-14</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">IV.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Conduct Disorder (0 &ndash; 42)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">V.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Anxiety and Depression (0 &ndash; 21)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 5pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 5pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>SNAP-IV-26 Results<B><SUP></SUP></B></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Percentage change in SNAP-IV-26 total scores
of the seven patients ranges from -5% to -44%, with a mean of -28% and a median of -33%. However, there is no assurance that we can expect
similar outcomes in our second research study. In addition, the outcome of our research study may be subject to some biases of parents
and caregivers of patients because we relied on the data provided by them. The sub-scales of SNAP-IV-26 are the same as the first three
sub-scales of VADRS, namely I. Inattentive, II. Hyperactive/Impulsivity and III. Oppositional-Defiance Disorder. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Table 5: SNAP-IV-26 scores of patients before
and after treatment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt"><B>Patient</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">&nbsp;<B>Lower Scores Indicate Lower Severity</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Scores Before Treatment</B></FONT> </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Scores After 3 Months
    of Treatment</B></FONT> </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Percentage Change
    in Scores</B></FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-size: 10pt">Patient 1</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">SNAP-IV-26 Total (Sum of Sub-Scales, 0 &ndash; 78):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">57</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">36</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-37</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">SNAP-IV-26 Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 15%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 7%; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.</FONT> </TD>
    <TD STYLE="width: 44%"> <FONT STYLE="font-size: 10pt">Inattentive (0 &ndash; 27)</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 8%; text-align: right"> <FONT STYLE="font-size: 10pt">21</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 8%; text-align: right"> <FONT STYLE="font-size: 10pt">15</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 8%; text-align: right"> <FONT STYLE="font-size: 10pt">-29</FONT> </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Hyperactive/Impulsivity (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">20</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">11</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-45</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Oppositional-Defiance Disorder (0 &ndash; 24)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">16</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">10</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-38</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-size: 10pt">Patient 2</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">SNAP-IV-26 Total (Sum of Sub-Scales, 0 &ndash; 78):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">55</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">52</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-5</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">SNAP-IV-26 Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Inattentive (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">27</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">25</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-7</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Hyperactive/Impulsivity (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">15</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">14</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-7</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Oppositional-Defiance Disorder (0 &ndash; 24)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">13</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">13</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-size: 10pt">Patient 3</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">SNAP-IV-26 Total (Sum of Sub-Scales, 0 &ndash; 78):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">52</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">29</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-44</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">SNAP-IV-26 Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Inattentive (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">16</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">11</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-31</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Hyperactive/Impulsivity (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">21</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">9</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-57</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Oppositional-Defiance Disorder (0 &ndash; 24)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">15</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">9</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-40</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-size: 10pt">Patient 4</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">SNAP-IV-26 Total (Sum of Sub-Scales, 0 &ndash; 78):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">33</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">28</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-15</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">SNAP-IV-26 Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Inattentive (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">14</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">13</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-7</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Hyperactive/Impulsivity (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">8</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">7</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-13</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Oppositional-Defiance Disorder (0 &ndash; 24)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">11</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">8</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-27</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-size: 10pt">Patient 5</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">SNAP-IV-26 Total (Sum of Sub-Scales, 0 &ndash; 78):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">42</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">26</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-38</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">SNAP-IV-26 Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Inattentive (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">14</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">7</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-50</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Hyperactive/Impulsivity (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">15</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">10</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-33</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Oppositional-Defiance Disorder (0 &ndash; 24)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">13</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">9</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-31</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-size: 10pt">Patient 6</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">SNAP-IV-26 Total (Sum of Sub-Scales, 0 &ndash; 78):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">51</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">34</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-33</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">SNAP-IV-26 Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Inattentive (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">26</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">21</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-19</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Hyperactive/Impulsivity (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">17</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">7</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-59</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Oppositional-Defiance Disorder (0 &ndash; 24)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">8</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">6</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-25</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-size: 10pt">Patient 7</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">SNAP-IV-26 Total (Sum of Sub-Scales, 0 &ndash; 78):</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">41</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">33</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-20</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">SNAP-IV-26 Sub-Scale:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>

<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">I.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Inattentive (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">19</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">16</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-16</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">II.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Hyperactive/Impulsivity (0 &ndash; 27)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">15</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">11</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-27</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">III.</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Oppositional-Defiance Disorder (0 &ndash; 24)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">7</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">6</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-14</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Conclusion</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> All enrolled patients treated by the TCM Practitioner
with the use of our personalized TCM formulae showed a drop in scores on our assessments under ATEC, GARS, VADRS and SNAP-IV-26, which
indicated that their conditions of ADHD and ASD symptoms were less severe. Mean 3-month percentage change in scores under assessments
ATEC, GARS, VADRS and SNAP-IV-26 were -37%, -33%, -30% and -28%, respectively. As of the date hereof, the TCM Practitioner has standardized
the adjustable formula into three fixed formulae for mild, moderate and severe conditions. As a result, we have three standardized TCM
formulae candidates under development targeting mild, moderate and severe ADHD and ASD patients, each consisting of a standard base formula
and a fixed adjusted formula. We plan to commence our second research study using the three standardized TCM formulae candidates in the
third quarter of 2021. However, since seven patients were enrolled and observed in our first research study, there is no assurance that
we can expect similar outcomes in our second research study. In addition, we cannot guarantee the accuracy of the initial data provided
by parents or caregivers of the enrolled patients, thus, the results of our first research study may not be accurate. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Competition and Competitive Advantages</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are an early-stage bioscience company
that focuses on research, development and commercialization of our standardized TCM formulae candidates for patients afflicted
with neurocognitive disorders and degeneration, such as ADHD and ASD, for which there are unmet medical needs in the global market.
There are two main types of medication for ADHD: stimulants such as Ritalin and Adderall and non-stimulants. For ASD, there are
only two antipsychotic drugs approved by the FDA for treating irritability and aggression symptoms: risperidone and aripiprazole,
according to Autism Speaks, an organization in the U.S. dedicated to promoting solutions, across the spectrum and throughout the
life span.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Competition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Currently in Hong Kong, there are several drugs
approved by the FDA and Hong Kong Pharmacy and Poisons Board available to treat ADHD and ASD that are manufactured by global pharmaceutical
companies. However, we are a TCM bioscience company focusing on TCM treatments and do not compete directly with those pharmaceutical
companies. Although both pharmaceutical drugs and TCM are regulated by the Import and Export Ordinance and the Undesirable Medical Advertisements
Ordinance, there are several key differences between the regulated pharmaceutical drug industry and the TCM industry in Hong Kong. For
example, pharmaceutical drugs are regulated under the Pharmacy and Poisons Ordinance (&ldquo;PPO&rdquo;) and the Antibiotics and Dangerous
Drugs Ordinance, while TCM is regulated by the HKCMO. Furthermore, all pharmaceutical manufacturers in Hong Kong must comply with the
Hong Kong Good Manufacturing Practices (&ldquo;GMP&rdquo;), whereas TCM manufacturers are not required to have GMP certifications. In
terms of registration, pharmaceutical drug must be registered with the Hong Kong Pharmacy and Poisons Board, while pCm formulae products
registered with the Hong Kong Chinese Medicines Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Most medicines
prescribed to ease ADHD and ASD symptoms are used &ldquo;off-label,&rdquo; meaning the medication is being used in a manner not
specified in the FDA&rsquo;s approved packaging label, or insert. Such off-label use is common in virtually all areas of medicine
and is usually done to relieve significant suffering in the absence of sufficiently large and targeted studies. Further, due to
the complexity of ADHD and ASD, the existing medications approved by the FDA for ADHD and ASD are used to treat a specific symptom
while the comorbid conditions remain present and will persist if no direct medications are available for treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>ADHD Market Leaders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">According to Market Research Future (MRFR),
the global ADHD therapeutics market comprises a host of key players. This list includes Eli Lilly and Company, Concordia International
Corp., NEOS Therapeutics Inc., Highland Therapeutics Inc., Pfizer Inc., Novartis AG, Noven Pharmaceuticals Inc., Janssen Global
Services LLC, Shire, Teva Pharmaceutical and others. However, we are a TCM bioscience company focusing on TCM holistic treatments
and do not compete directly with those pharmaceutical companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">According to the ADHD Parents Medication
Guide of the American Psychiatric Association, medication does not cure ADHD, but can alleviate the symptoms of ADHD when it is
taken as prescribed. Ongoing care and treatment monitoring are important since those symptoms may come back once medication is
halted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">Two main types
of medication for ADHD approved by the FDA are stimulants and non-stimulants. Stimulants include methylphenidate and amphetamines.
Non-stimulants which include atomoxetine and guanfacine, are alternatives for those who do not respond well to stimulants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">However, these
two types of medication for ADHD have multiple side effects. Common side effects of stimulants include: feeling restless and jittery,
difficulty sleeping, loss of appetite, headaches, upset stomach, irritability, mood swings, depression, dizziness, racing heartbeat
and tics. According to Help Guide, these stimulant medications may also cause personality changes, such as becoming withdrawn,
listless, rigid, or less spontaneous and talkative, others may develop obsessive-compulsive symptoms. Beyond the potential side
effects, a number of safety concerns associated with the use of stimulant medications exist such as the effect on developing brain,
heart-related problem, psychiatric problem and potential abuse, indicated by experts. Non-stimulants also have side effects including
decreased appetite, nausea, vomiting, fatigue, indigestion, dizziness and mood swings.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>ASD Market Leaders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> According to Fortune Business Insights, players
engaged in ASD drug therapy in the global market include AstraZeneca, Eli Lilly and Company, Fusion Autism Center, Pfizer Inc., Otsuka
Holdings Co. Limited, and other prominent players. However, we do not compete with these players since they mainly focus on prescription
or over the counter drugs while we focus on TCM. In addition, we will only consider expanding our market to other countries once we have
successfully developed the Hong Kong market. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no medications that can cure ASD
or treat the core symptoms, according to the CDC. However, there are medications that can help ASD patients with related symptoms
like&nbsp;depression,&nbsp;anxiety, aggression, irritability, seizures, insomnia and trouble focusing and help them function better.
Medicines for treating the three core symptoms of ASD, communication difficulties, social challenges and repetitive behavior, have
long represented a huge area of unmet need. However, few drugs on the market today effectively relieve these symptoms and individual
reaction to most commonly prescribed medicines can vary materially. Although the FDA has approved two antipsychotic drugs for treating
irritability and aggression associated with autism (risperidone and aripiprazole), the prevalent behavioral problems associated
with ASD have not been able to be improved by these medications.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;<SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Antidepressants
are among the world&rsquo;s most widely prescribed medications for ASD patients, such as selective serotonin reuptake inhibitors
(SSRIs), according to an article in Harvard Health Publishing. The range of their uses has expanded from depression to anxiety,
obsessive-compulsive disorder, eating disorders and many other psychiatric conditions. Side effects include insomnia, skin rashes,
headaches, joint and muscle pain, stomach upset, nausea, or diarrhea. Anticonvulsants are most commonly prescribed when the patient
also suffers from epilepsy, as about one-third of autism patients do, however, common side effects include confusion, fever, hair
loss, paranoia, impaired judgment and memory, anxiety and depression.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Specialty of Our TCM Formulae</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
core competencies include the specialty of our TCM formulae which is a holistic treatment that may provide progressive improvement
over time and is used specifically for ADHD and ASD</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Our standardized
TCM formulae candidates were created specifically to address this unmet need in the market. We will explore various ways to gain
entry into markets and countries around the world and will research the regulatory and operational requirements as needed. Depending
on the regulatory environment of each country, our product can be sold as either a drug or a dietary supplement, either directly
by us or through partnerships and distributions. We will review and analyze all options to ensure feasibility to meet the demands
of the respective markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our TCM formulae was created based on Sik-Kee
Au TCM Brain Theory&trade;. The TCM brain theory is not recognized in general literature of TCM or elsewhere. However, the TCM Practitioner
has prescribed the personalized TCM formulae based on his TCM brain theory for over 30 years to treat ADHD, ASD and many neurological
illnesses, disorders and degeneration and obtained satisfactory clinical treatment results. Such clinical treatment results are not supported
by controlled clinical data or trials. Treatment using our personalized TCM formulae has shown reduced severity in ADHD and ASD core
symptoms in the first research study. However, there is no assurance that the second research study will show any improvements in patients&rsquo;
symptoms. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Existing ADHD and ASD medications on the
market provide symptomatic relief, with various adverse side effects, such as, feeling restless and jittery, difficulty sleeping,
loss of appetite, headaches, upset stomach, irritability, mood swings, depression, dizziness, racing heartbeat, tics, diarrhea
and other stomach irritation, rashes, hives and itching, dry mouth, fatigue and weight loss. Some other side effects could be serious
and some potentially fatal. Our three standardized TCM formulae candidates target to treat ADHD and ASD patients with fewer side
effects. However, our standardized TCM formulae candidates have not been proven to be safe. We will conduct safety, quality and
stability tests over our three standardized TCM formulae candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We believe treatment using our TCM formulae
can provide progressive improvements over time because it aims to correct the fundamental cause of diseases and disorders such as ADHD
and ASD, whereas the effect of existing ADHD and ASD drugs wear off after a few hours. Short-acting stimulants peak after several hours
and must be taken 2-3 times a day. Long-acting or extended-release stimulants last 8-12 hours and are usually taken just once a day,
some patients may require an increase in dosage over time because the body builds up tolerance and resistance, according to HelpGuide,
an independently funded nonprofit organization in the U.S. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> All parents of the ADHD and ASD children in
our research study have witnessed pronounced changes in their child&rsquo;s symptoms in three months and have testified the benefits
and effectiveness of our TCM Practitioner&rsquo;s treatment and was preferred over their typical mainstream medication. During our study,
all of them stopped their existing medication and switched to treatment with the use of our TCM formulae. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Before the seven patients began their treatment
with our personalized TCM formulae for our first research study, they tried other treatments and therapies for various periods. During
the interviews that we conducted in connection with the study, we asked the parents or caregivers of these patients their impression
of other treatments, therapies or drugs versus our TCM formulae treatment. All of the parents and caregivers that we interviewed advised
us that they felt that their child&rsquo;s temper was more stable, that their child was more attentive and that their awareness of the
environment was higher after treatment with our TCM products. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Currently, according to the CDC, there
is no cure for ADHD and ASD. Given the lack of effective conventional medicine, coupled with adverse side effects associated with
current drugs and rapidly growing patient diagnosis, we are well-positioned to become the leader in providing the treatment for
ADHD and ASD. However, due to the early stage of our research in three standardized TCM formulae candidates, there is no assurance
that the second research study will show similar improvements in patients&rsquo; symptoms.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>TCM Practitioner with Practicing Experiences Over 30
Years</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
TCM Practitioner has treated many children afflicted with ADHD and ASD and other patients suffering from a wide range of neurocognitive
disorders and degeneration with the personalized TCM formulae. However, the treatment results of our TCM Practitioner are not supported
by any controlled clinical data or trials. </FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of the date hereof, the TCM Practitioner
has standardized the adjustable formula into three fixed formulae for mild, moderate and severe conditions. As a result, we have three
standardized TCM formulae candidates under development targeting mild, moderate and severe ADHD and ASD patients, each consisting of
a standard base formula and a fixed adjusted formula. We plan to commence our second research study using the three standardized TCM
formulae candidates in the third quarter of 2021. Based on our TCM Practitioner&rsquo;s practicing experiences, we do not anticipate
high bio-pharmaceutical research and development costs relating to chemical drugs. Average research and development to marketplace cost
for a new medicine is nearly $4 billion, and can sometimes exceed $10 billion. In comparison, our research and development cost were
only $0.39 million and $0.23 million for the years ended June 30, 2020 and June 30, 2019, respectively. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Regulatory Approvals Prior to Commercialization in Hong
Kong</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the outcome of further research
and development, if we commercialize our liquid-based standardized TCM formulae candidates in Hong Kong, we will need to receive
a manufacturer license issued by the Hong Kong Chinese Medicines Board, which was established in 1999 under HKCMO. Once we receive
the licenses and complete pCm registrations for our standardized TCM formulae candidates, our pCm formulae products can be manufactured
and sold over the counter without the supervision and prescription of a TCM practitioner in Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When applying for registration of pCm in
Hong Kong, we will be required to provide sufficient documents to show safety, stability, quality and efficacy of our pCm formulae
products to the Hong Kong Chinese Medicines Board. To show the efficacy of our pCm formulae products, documents required include
reference materials in which the claimed therapeutic functions are supported by research studies, interpretation and principle
of formulating a prescription and a summary report on all the product efficacy documents. To prove safety, stability and quality
of our pCm formulae products, we will work with accredited laboratories, a list of which is provided by the Hong Kong Chinese
Medicines Board, to conduct all the necessary tests, such as heavy metals and toxic element test and pesticide residues test.
As for the application of manufacturer licenses, the major documents required are a brief floor plan of the premise and a list
of manufacturing equipment. GMP certification is not required for the manufacturing of pCm in Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our current primary roles include recruiting
and arranging patients to be treated by the TCM Practitioner, collecting research data from patients, conducting analysis over
research data and planning for commercialization of our standardized TCM formulae candidates.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Estimated Time and Cost Prior to the Commercialization of
Our Standardized TCM Formulae Candidates in Hong Kong</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We estimate that it will take us approximately
four years to commercialize our standardized TCM formulae candidates in Hong Kong, including as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately
                                         one year to complete our second research study, including enrollment of qualified patients
                                         for treatment by qualified TCM practitioner(s) with the use of our standardized TCM formulae
                                         candidates, assessment and analysis;</FONT></TD></TR>                                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately one year to develop an efficient centralized production
process to manufacture our liquid-based standardized TCM formulae, set up our centralized production facility and apply for manufacturer
license with the Hong Kong Chinese Medicines Board after our second research study;</FONT></TD></TR>                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately one year to prepare for efficacy documents and
conduct tests, including safety, quality and stability tests upon completion of our second research study, during which time we
will also apply for manufacturer license for our centralized production process and approval of manufacturer license; and</FONT></TD></TR>                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately
                                         one year or more for review process of our pCm registration application after submission
                                         of our application to the Hong Kong Chinese Medicines Board.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our estimated costs prior to the commercialization
of our pCm formulae products in Hong Kong aggregate to a total amount of approximately $29 million. We will use the proceeds of this
offering for a second research study of our TCM formulae and products, staff salaries, facilities rental, renovations and equipment,
product and intellectual property registrations, and other general and administrative expenses and working capital. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Second Research Study</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We intend to commence our second research study
for our three standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients during the third quarter of 2021
in Hong Kong. Currently, we are planning our second research study which include formulating strategy, designing protocol and reviewing
our candidates&rsquo; qualifications and outcome measures. We intend to arrange for 100 patients to be treated by qualified TCM practitioner(s)
with the use of our standardized TCM formulae candidates. They are to be separated in three different groups with mild, moderate and
severe conditions respectively. Each group will be treated with our different standardized TCM formulae candidates for three months and
up to one year. Our assessments over enrolled patients will be conducted every three months of the treatment. We estimate that our second
research study will take one year to complete and cost is estimated to be approximately $2.9 million. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Setting Up Centralized Production Facility</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> If the results of our second research study
are similar to that of our first research study, we will begin the next step to develop an efficient centralized production process to
manufacture and mass produce our standardized TCM formulae candidates to support the anticipated increase from the over the counter sales
of our pCm formulae products, provided that the application for the pCm registration of our pCm formulae products are approved. In order
for mass production, we will lease an industrial space, purchase new automation equipment and set up the production lines and ensure
quality control of our products. We estimate that this process will take approximately one year, commencing shortly after the conclusion
of our second research study, and the facilities rental, renovations and equipment costs are estimated to be approximately $4.2 million. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon completion of our production facility,
we will obtain regulatory approvals from the Hong Kong Chinese Medicines Board for a manufacturer license. After receiving our
application, the Department of Health of Hong Kong will send officers to inspect our premise and prepare a report for assessment
by the Hong Kong Chinese Medicines Board. If our application to the manufacturer license is approved by the Hong Kong Chinese Medicines
Board, we will pay the prescribed fee and the Department of Health of Hong Kong will issue and send us a manufacturer license.
However, if our application is rejected, we may initiate a review or appeal against that decision.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Preparation of Efficacy Documents and Testing Phase</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Once the Hong Kong Chinese Medicines Board
approves our manufacturer license application, we will prepare for efficacy documents required for application of pCm registration
with the Hong Kong Chinese Medicines Board for our standardized TCM formulae candidates. The Hong Kong Chinese Medicines Board
requires applicants to provide sufficient documents to support the product efficacy of their pCm formulae products. The product
efficacy documents shall include reference materials in which the claimed therapeutic functions are supported by research studies,
interpretation and principle of formulating a prescription and a summary report on all the product efficacy documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In addition, safety, stability and quality
tests documents are also required for the application of pCm registration. We will work with accredited laboratories, a list of which
is provided by the Hong Kong Chinese Medicines Board, to begin the testing phase. Safety test includes test for heavy metals and toxic
element test, pesticide residues test, microbial limit test, acute toxicity test, long-term toxicity test, local toxicity test, mutagenicity
test, carcinogenicity test and reproductive and development toxicity test. Quality test includes manufacturing method, physicochemical
properties of crude drugs, product specification, methods and certificate of analysis. Product and intellectual properties registration
and legal expenses are estimated to be approximately $3.9 million. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>PCM Registration with the Hong Kong Chinese Medicines Board</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When all efficacy documents, tests documents
and other required documents are completed, we will submit an application for the approval of pCm registration of our pCm formulae
products. All applications for registration of pCm will be assessed and approved by the Hong Kong Chinese Medicines Board, or
the Hong Kong Chinese Medicines Committees as delegated by the Hong Kong Chinese Medicines Board. In the course of an application
assessment, the Hong Kong Chinese Medicines Board may, if it considers necessary, require the applicant to provide additional
documents or information for the registration of pCm. Even if such data and information are submitted, the Hong Kong Chinese Medicines
Board may ultimately decide that the pCm does not satisfy the applicable regulatory criteria for approval and reject our application.
If approved, a certificate will be issued, which is valid for 5 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The approval process is lengthy and difficult
and may cost a year or more. According to section 122 of the CMO, in determining the approval of an application for registration
of a pCm, the Hong Kong Chinese Medicines Board shall in particular take into consideration the safety, quality and efficacy of
the pCm. Data obtained from our research study may be inconclusive or the Hong Kong Chinese Medicines Board may interpret the
data different to our interpretation of the same data. The Hong Kong Chinese Medicines Board shall also take into consideration
in particular the methods, standards and conditions of manufacture of the medicine; and may require the production by the applicant
of any one or a combination of the following as they deem appropriate: (i) an undertaking, given by the manufacturer of the pCm,
to permit the premises where it is or is to be manufactured, and the operations carried on or to be carried on in the course of
manufacturing it, to be inspected by or on behalf of the Hong Kong Chinese Medicines Board; (ii) an undertaking, given by the
manufacturer of the pCm, to comply with any conditions as imposed by the Hong Kong Chinese Medicines Board; (iii) a declaration,
given by or on behalf of the manufacturer of the pCm that, in relation to the manufacture of the pCm any requirements imposed
by or under the law of the place in which it is or is to be manufactured have been or will be complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Besides the cost mentioned above, in the course
of our research study, setting up of our centralized production facility, manufacturer license and pCm registration application, we estimate
that the cost of staff salaries will be approximately $14.6 million, working capital and other general corporate expenses will be approximately
$3.2 million.&nbsp; </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The TCM formulae are the core of our
business operation and TCM research and development. We seek to protect the TCM formulae candidates, including the TCM base
formula and the standardized TCM formulae candidates and technology that we consider commercially important by filing patent
applications in Hong Kong and abroad. In addition, we also rely on trade secrets or TCM related regulatory protection to
protect our intellectual property. Our trade secrets and confidential information include unpatented know-how, technology and
other proprietary information, to maintain our competitive position and to protect our TCM formulae candidates. We seek to
protect these trade secrets by limiting access to such confidential information and by entering into non-disclosure and
confidentiality agreements with parties that have access to them, such as our employees, corporate collaborators, outside
scientific collaborators, sponsored researchers, contract manufacturers, consultants, advisers and other third
parties.&nbsp;Further, we also rely on or intend to rely on our trademarks, trade names and brand names to distinguish our
products from the products of our competitors, and have registered or will apply to register a number of these trademarks. We
have received trademark certificates for &ldquo;&#33126;&#36996;&#21407;<SUP>&reg;</SUP>&rdquo; (directly translates as
&ldquo;brain restoration&rdquo;) and &ldquo;RGC Regencell<SUP>&reg;</SUP>&rdquo; from the Hong Kong Registrar of Trade Marks
in July 2020. We also filed a trademark application for &ldquo;Sik-Kee Au TCM Brain Theory&trade;&rdquo; in January 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of the date of the prospectus, we have a
total of seven full-time employees and one part-time employee. Our employees are not represented by a labor organization or covered by
a collective bargaining agreement. We have not experienced any work stoppages. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Description of Office Lease</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We currently maintain offices at Office
A &amp; B on 11th Floor, First Commercial Building, 33-35 Leighton Road, Hong Kong. The Company has entered a five-year fixed term
lease agreement for the office space on July 15, 2019. The lease expires on July 14, 2024. Our commitment for lease payments under
the operating lease as of June 30, 2020 for the next five years are a total of $483,206.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company has a separate office rental
agreement with Ace United International Limited, which is a company wholly-owned by our founder and CEO. The Company has paid a
monthly rent of $4,103 for the premises located at 21<SUP>st</SUP> Floor, EIB Tower, 4-6 Morrison Hill Road, Wan Chai, Hong Kong.
The terms of the agreement are renewed on an annual basis from the 1<SUP>st</SUP> of January to the 31<SUP>st</SUP> of December
each year. The rental payment is expensed as incurred.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company also entered a six-month lease
agreement for an office space at 5201 Great America Pkwy, Suite 320, Santa Clara, California, U.S., on October 1, 2020. The monthly
rent is $394 and we can renew the lease term 3 months prior to the end of the term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Legal
Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may from time to time become a party
to various legal or administrative proceedings arising in the ordinary course of our business. As of the date hereof, neither
we nor any of our subsidiaries is a party to any pending legal proceedings, nor are we aware of any such proceedings threatened
against us or our subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="RB_DRS_013"></A>REGULATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">The
Legislative Council of Hong Kong, Chinese Medicines Council, Chinese Medicines Board and Chinese Medicines Regulatory Office of
Department of Health of Hong Kong are independent and separate entities from China. Whilst Hong Kong is part of the People&rsquo;s
Republic of China (&ldquo;PRC&rdquo;), Hong Kong and the PRC are regarded as two separate jurisdictions in law and markets. Under
the &ldquo;One Country, Two Systems&rdquo;, Hong Kong retains its own systems and way of life after the handover of sovereignty
to the PRC in 1997. The Hong Kong Basic Law (the &ldquo;Basic Law&rdquo;), being Hong Kong&rsquo;s constitutional document, gives
legal effect to the &ldquo;One Country, Two Systems&rdquo; policy.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">Pursuant
to the Basic Law, the laws previously in force in Hong Kong, that is, the common law, rules of equity, ordinances, subordinate
legislation and customary law shall be maintained, except for any that contravene the Basic Law, and subject to any amendment
by the </FONT>Legislative Council <FONT STYLE="background-color: white">of Hong Kong. The socialist system and policies shall
not be practiced in Hong Kong, and the previous capitalist system and way of life shall remain unchanged for 50 years. Further,
Hong Kong residents and other persons in Hong Kong shall have the obligation to abide by the laws in force in Hong Kong. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">As
we have no assets or operation in PRC and operate in Hong Kong, nor have plan to commence operation in PRC, we do not believe
that PRC laws or regulations regarding the TCM industry apply to us. Hence, within Hong Kong&rsquo;s legal system, the laws and
regulations of the PRC do not apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Regulation Related to our Business Operation in Hong Kong</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Chinese Medicine Ordinance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Chinese Medicine Ordinance (&ldquo;CMO&rdquo;)
provides licensing requirements for the sale and distribution of our TCM formulae candidates, registration and licensing requirements
of our Chinese healthcare products, and future operations of our Chinese medicine clinics in Hong Kong. CMO was passed by the Legislative
Council of Hong Kong on July 14, 1999. CMO is not a PRC legislation but is a Hong Kong ordinance. As with all other Hong Kong legislations,
according to the laws of Hong Kong, the Legislative Council of Hong Kong has the power and function to amend the CMO in accordance
with the provisions of the Hong Kong Basic Law and legal procedures. The Hong Kong Government, including but not limited to the
Department of Justice, the Hong Kong Police Force, the Food and Health Bureau, the Department of Health and etc., as well as the
Chinese Medicine Council of Hong Kong, have the implementation rights of CMO. The Chinese Medicine Council of Hong Kong is the
main regulator of CMO.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Registration of TCM products and Chinese
Healthcare Products </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Some of our TCM products and Chinese healthcare
products are classified as proprietary Chinese medicine (&ldquo;pCm&rdquo;), defined below, and others are classified as non-pCm.
The key differences between pCm and non-PCM lie on their ingredients, dosage forms and intended use. Under section 2 of the CMO,
pCm is defined as any proprietary product, which is formulated in a finished dose form and is known or claimed to be used for
the diagnosis, treatment, prevention or alleviation of any disease or any symptom of a disease in human beings, or for the regulation
of the functional states of the human body, composed solely of (i) any Chinese herbal medicines; (ii) any materials of herbal,
animal or mineral origin customarily used by the Chinese, which should be documented in Chinese medicine classics or bibliographies,
including but not limited to Pharmacopeia; or (iii) any medicine and materials referred to above, which is formulated in a finished
dose form and is generally known or claimed to be used for the diagnosis, treatment, prevention or alleviation of any disease
or for the regulation of the functional states of human body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 119 of the CMO provides that no
person shall sell, import or possess any pCm unless the pCm is registered with the Chinese Medicines Board. Application for registration
of a pCm shall be submitted to the Department of Health Chinese Medicines Board in the manner prescribed in section 121 of the
CMO. Pursuant to section 120 of the CMO, the application for registration of any pCm shall be made by the manufacturer of the
pCm manufactured in Hong Kong, or by the importer or local representative or agent of the manufacturer of pCm manufactured outside
Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any person who contravenes section 119 of
the CMO commits an offense and is liable to a maximum fine of HK$100,000 and imprisonment for two years.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Manufacture, Sale and Distribution of TCM Products and
Chinese Healthcare Products </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">CMO provides that manufacturers and traders
in pCm shall obtain a license issued by the Chinese Medicines Board. Section 131 of the CMO provides that no person shall manufacture
any pCm, whether registered or not, without a manufacturer license, or at any place other than the premises specified in such
license. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any person who contravenes section 131 or
134 of the CMO commits an offense and is liable to a maximum fine of HK$100,000 and imprisonment for two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Labeling Requirements and Package Inserts for Chinese
Healthcare Products </I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Chinese Medicines Regulation is not
a PRC legislation but is a Hong Kong legislation. As with all other Hong Kong legislations, according to the laws of Hong Kong,
the Legislative Council of Hong Kong has the power and function to amend the Chinese Medicines Regulation in accordance with the
provisions of the Hong Kong Basic Law and legal procedures. The Hong Kong Government, including but not limited to the Department
of Justice, the Hong Kong Police Force, the Food and Health Bureau, the Department of Health and etc., as well as the Chinese
Medicine Council of Hong Kong, have the implementation rights of Chinese Medicines Regulation. The Chinese Medicine Council of
Hong Kong is the main regulator of Chinese Medicines Regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Sections 143 and 144 of the CMO provide
that a pCm shall not be sold or possessed for the purpose of selling in Hong Kong unless the package of the product is labeled
in the prescribed manner and contains a package insert which complies with the prescribed requirements. Pursuant to Regulations
26 and 28 of the Chinese Medicines Regulation (Chapter 549F of the Laws of Hong Kong) (the &ldquo;Chinese Medicines Regulation&rdquo;),
all pCm shall be properly labeled and attached with package inserts. The label on a package of pCm shall include the following
particulars: the name of the medicine; the name of each active ingredient used (if the pCm is composed of three or more kinds of
active ingredients, the names of more than half of the active ingredients are required); the registration number on the certificate
of registration; the holder of the registration certificate or the manufacturer (if the package is the outermost one, the name
of the holder of the certificate of registration is necessary); the name of the country or territory in which the medicine is produced;
the packing specification; dosage and method of usage; expiry date; and batch number. The package insert of the pCm shall include
the following particulars: the name of the medicine; the name and quantity of each active ingredient used (if the pCm is composed
of three or more kinds of active ingredients, the names and quantities of more than half of the active ingredients are required);
the name of the holder of certificate of registration or the manufacturer; the dosage and method of usage; functions or pharmacological
action; storage instructions; and packing specification. As for the indications, contra-indications, side effects, toxic effects
and precautions, they should be included on the package insert as far as practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any person who contravenes section 143 or
144 of the CMO commits an offense and is liable to a maximum fine of HK$100,000 and imprisonment for two years.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Food Safety Ordinance </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Food Safety Ordinance (Chapter 612 of the
Laws of Hong Kong) (the &ldquo;Food Safety Ordinance&rdquo;) establishes a registration scheme for food importers and food distributors,
to require the keeping of records by persons who acquire, capture, import or supply food and to enable food import controls to
be imposed. Food Safety Ordinance is not a PRC legislation but is a Hong Kong ordinance. As with all other Hong Kong legislations,
according to the laws of Hong Kong, the Legislative Council of Hong Kong has the power and function to amend the Food Safety Ordinance
in accordance with the provisions of the Hong Kong Basic Law and legal procedures. The Hong Kong Government, including but not
limited to the Department of Justice, the Hong Kong Police Force, the Food and Health Bureau, the Food and Environmental Hygiene
Department and etc., has the implementation rights of the Food Safety Ordinance. The Food and Environmental Hygiene Department
is the main regulator of the Food Safety Ordinance. As some of our Chinese healthcare products which are non-pCm fall within the
definition of food, our Company is subject to the regulations under the Food Safety Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Food Safety Ordinance may be applicable
since we cannot determine whether the ultimate product(s) to be commercialized would be classified by the regulatory body as Chinese
herbal medicines, healthcare products, food for ordinary consumption, or otherwise. The precise content of the standardized TCM
formulae candidates are subject to further changes and development along with our second research study. Accordingly, the precise
ingredients of TCM products or product candidates will be determined at a later stage of our research and development.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Registration as Food Importer or Distributor
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Sections 4 and 5 of the Food Safety Ordinance
require any person who carries on a food importation business or food distribution business to register with the Food and Environmental
Hygiene Department of Hong Kong as a food importer or food distributor. Any person who does not register but carries on a food
importation or distribution business, without reasonable excuse, commits an offense and is liable to a maximum fine of HK$50,000
and imprisonment for six months.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Record-keeping Requirement relating
to Supply of Food </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Section 24 of the Food
Safety Ordinance provides that a person who, in the course of business, supplies food in Hong Kong by wholesale must record the
following information about the supply: (i) the date the food was supplied; (ii) the name and contact details of the person to
whom the food was supplied; (iii) the total quantity of the food; and (iv) a description of the food. Such record shall be made
under this section within 72 hours after the time the supply took place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any person, who fails to comply with the
record-keeping requirement without reasonable excuse or knowingly or recklessly includes in the record information that is false
in a material particular, commits an offense and is liable to a maximum fine of HK$10,000 and imprisonment for three months.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Import and Export Ordinance </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Import and Export Ordinance is not a PRC
legislation but is a Hong Kong ordinance. As with all other Hong Kong legislations, according to the laws of Hong Kong, the Legislative
Council of Hong Kong has the power and function to amend the Import and Export Ordinance in accordance with the provisions of
the Hong Kong Basic Law and legal procedures. The Hong Kong Government, including but not limited to the Department of Justice,
the Hong Kong Police Force, the Customs and Excise Department, the Trade and Industry Department and etc., has the implementation
rights of the Import and Export Ordinance. The Customs and Excise Department and the Trade and Industry Department are the main
regulators of the Import and Export Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to sections 6C and 6D of the Import
and Export Ordinance (Chapter 60 of the Laws of Hong Kong) (the &ldquo;Import and Export Ordinance&rdquo;) and Schedules 1 and
2 to the Import and Export (General) Regulations (Chapter 60A of the Laws of Hong Kong), any person who imports or exports any
of the Chinese herbal medicines set out in Schedule 1 to the CMO and five specific types in Schedule 2 to the CMO (namely Flos
Campsis (&#28137;&#38660;&#33457;), Processed Radix Aconiti (&#35069;&#24029;&#28879;), Processed Radix Aconiti Kusnezoffii (&#35069;&#33609;&#28879;),
Radix Clematidis (&#23041;&#38728;&#20185;) and Radix Gentianae (&#40845;&#33213;)) as well as any pCm under the CMO shall apply
for an import or export license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any person importing or exporting of the
aforesaid Chinese herbal medicines and pCm without an import or export license commits an offense and is liable to a fine of HK$500,000
and imprisonment for two years, or on conviction on indictment to a fine of HK$2,000,000 and imprisonment for seven years.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Public Health and Municipal Services Ordinance </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Public Health Ordinance is not a PRC legislation
but is a Hong Kong ordinance. As with all other Hong Kong legislations, according to the laws of Hong Kong, the Legislative Council
of Hong Kong has the power and function to amend the Public Health Ordinance in accordance with the provisions of the Hong Kong
Basic Law and legal procedures. The Hong Kong Government, including but not limited to the Department of Justice, the Hong Kong
Police Force, the Food and Health Bureau, the Home Affairs Bureau, the Drainage Services Department, the Food and Environmental
Hygiene Department, the Leisure and Cultural Services Department, the Department of Health, the Lands Department, the Buildings
Department, etc., has the implementation rights of the Public Health Ordinance. The Food and Environmental Hygiene Department is
the main regulator of the Public Health Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The legal framework for food safety control
in Hong Kong is set out in Part V of the Public Health and Municipal Services Ordinance (Chapter 132 of the Laws of Hong Kong)
(the &ldquo;Public Health Ordinance&rdquo;) and the relevant sub-legislations thereunder. The Public Health Ordinance requires
the manufacturers and sellers of food to ensure that their products are fit for human consumption and comply with the requirements
in respect of food safety, food standards and labeling. As some of our Chinese healthcare products which are non- pCm fall within
the definition of food, our Company is subject to the regulations under the Public Health Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 50 of the Public Health Ordinance
prohibits the manufacture, advertising and sale in Hong Kong of food or drugs that are injurious to health. Any person who fails
to comply with this section commits an offence and is liable to a maximum fine of HK$10,000 and imprisonment for three months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to section 52 of the Public Health
Ordinance, subject to the statutory defenses set out under section 53 of the Public Health Ordinance, where a seller sells to the
prejudice of a purchaser any food or drug which is not of the nature, substance or quality of the food or drug demanded by the
purchaser, the seller commits an offense and is liable to a maximum fine of HK$10,000 and imprisonment for three months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to section 54 of the Public Health
Ordinance, any person who sells or offers for sale any food intended for, but unfit for, human consumption, or any drug intended
for use by human but unfit for the purpose, commits an offense and is liable to a maximum fine of HK$50,000 and imprisonment for
six months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 61(1) of the Public Health Ordinance
provides that it shall be an offense for any person who gives with any food or drug sold by him/her or displays with any food or
drug exhibited for sale by him/her any label which falsely describes the food or drug or is calculated to mislead as to its nature,
substance or quality. Furthermore, pursuant to section 61(2) of the Public Health Ordinance, it shall be an offense if any person
publishes or is a party to the publication of an advertisement falsely describing any food or drug or is likely to mislead as to
the nature, substance or quality of any food or drug. Any person who commits an offense under this section is liable to a maximum
fine of HK$50,000 and imprisonment for six months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Food and Drugs (Composition and Labelling) Regulations
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Food and Drugs (Composition and Labelling)
Regulations (Chapter 132W of the Laws of Hong Kong) (the &ldquo;Food and Drugs Regulations&rdquo;), a subsidiary legislation under
the Public Health Ordinance, regulates the advertising and labeling of food. Food and Drugs Regulations is not a PRC legislation
but is a Hong Kong legislation. As with all other Hong Kong legislations, according to the laws of Hong Kong, the Legislative Council
of Hong Kong has the power and function to amend the Food and Drugs Regulations in accordance with the provisions of the Hong Kong
Basic Law and legal procedures. The Hong Kong Government, including but not limited to the Department of Justice, the Hong Kong
Police Force, the Food and Environmental Hygiene Department, etc., has the implementation rights of the Food and Drugs Regulations.
The Food and Environmental Hygiene Department is the main regulator of the Food and Drugs Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Regulation 3 of the Food and Drugs Regulations
provides that the manufacturing of foods and drugs shall be up to the standards as specified under Schedule 1 to the Food and Drugs
Regulations. Any person who advertises for sale, sells or manufactures for sale any food or drug which does not conform to the
relevant requirements as to composition prescribed in Schedule 1 to the Food and Drugs Regulations commits an offense and is liable
to a fine of HK$50,000 and imprisonment for six months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Regulation 4A of the Food and Drugs Regulations
demands all pre-packaged food and products sold by the Group (except for those listed in Schedule 4 to the Food and Drugs Regulations)
to be marked and labeled in the manner prescribed in Schedule 3 to the Food and Drugs Regulations. Schedule 3 to the Food and Drugs
Regulations contains labeling requirements in respect of stating the product&rsquo;s name or designation, ingredients, &ldquo;best
before&rdquo; or &ldquo;use by&rdquo; date, special conditions for storage or instruction for use, manufacturer&rsquo;s or packer&rsquo;s
name and address, and quantity, weight or volume, and also includes requirements on the appropriate language or languages for marking
or labeling of prepackaged food. Any person who contravenes such requirements commits an offense and is liable to a fine of HK$50,000
and imprisonment for six months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to regulation 4B of the Food and
Drugs Regulations, prepackaged food sold by the Group should be marked or labeled with its energy value and nutrient content in
the manner prescribed in Part 1 of Schedule 5 to the Food and Drugs Regulations, and nutrition claims, if any, made on the label
of the product or in any advertisement for the product should comply with Part 2 of Schedule 5 to the Food and Drugs Regulations.
Contravention of those requirements may result in a conviction liable to a maximum fine of HK$50,000 and imprisonment for six months.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Trade Marks Ordinance </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Trade Marks Ordinance
(Chapter 559 of the Laws of Hong Kong) (the &ldquo;Trade Marks Ordinance&rdquo;) provides for the registration of trademarks,
the use of registered trademarks and related matters. As Hong Kong provides territorial protection for trademarks, trademarks
registered in other countries or regions are not automatically entitled to protection in Hong Kong. In order to enjoy protection
by the laws of Hong Kong, trademarks shall be registered with the Trade Marks Registry of the Intellectual Property Department
under the Trade Marks Ordinance and the Trade Marks Rules (Chapter 599A of the Laws of Hong Kong) (the &ldquo;Trade Marks Rules&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Trade Marks Ordinance is not a PRC legislation
but is a Hong Kong ordinance. As with all other Hong Kong legislations, according to the laws of Hong Kong, the Legislative Council
of Hong Kong has the power and function to amend the Trade Marks Ordinance in accordance with the provisions of the Hong Kong
Basic Law and legal procedures. The Hong Kong Government, including but not limited to the Department of Justice, the Hong Kong
Police Force, the Intellectual Property Department and etc., has the implementation rights of the Trade Marks Ordinance. The Intellectual
Property Department is the main regulator of the Trade Marks Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 10 of the Trade Marks Ordinance
provides that a registered trademark is a property right acquired through due registration under the Trade Marks Ordinance, through
which the owner of a registered trademark is entitled to the statutory rights provided thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">By virtue of section 14 of the Trade Marks
Ordinance, the owner of a registered trademark is conferred exclusive rights in the trademark. The rights of the owner in respect
of the registered trademark come into existence from the date of the registration of the trademark. Pursuant to section 48 of
the Trade Marks Ordinance, the registration date is the filing date of the application for registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the exceptions under sections
19 to 21 of the Trade Marks Ordinance, any use of the trademark by third parties without the consent of the owner is an infringement
of the trademark. Section 18 of the Trade Marks Ordinance further specifies the conducts which amount to infringement of the registered
trademark. In event that infringement by any third party occurs, the owner of the registered trademark is entitled to remedies
under the Trade Marks Ordinance, such as infringement proceedings under sections 23 and 25 of the Trade Marks Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Trademarks which are not registered under
the Trade Marks Ordinance and the Trade Marks Rules may still be protected by the common law action of passing off, which requires
proof of the owner&rsquo;s reputation in the unregistered trademark and that use of the trademark by third parties will cause
damage to the owner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Sale of Goods Ordinance </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Sale of Goods Ordinance (Chapter 26 of
the Laws of Hong Kong) (the &ldquo;Sale of Goods Ordinance&rdquo;) provides, inter alia, that where a seller sells goods in the
course of a business, there is an implied condition that (i) where the goods are purchased by description, the goods shall correspond
with the description; (ii) the goods supplied are of merchantable quality; and (iii) the goods shall be fit for the purpose for
which they are purchased. Otherwise, a buyer has the right to reject the defective goods unless he or she has a reasonable opportunity
to examine the goods. A breach of the implied term may give rise to a civil action for breach of contract by the customers. However,
no criminal liability arises from such breach of implied term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Sale of Goods Ordinance is not a PRC legislation
but is a Hong Kong ordinance. As with all other Hong Kong legislations, according to the laws of Hong Kong, the Legislative Council
of Hong Kong has the power and function to amend the Sale of Goods Ordinance in accordance with the provisions of the Hong Kong
Basic Law and legal procedures. As the Sale of Goods Ordinance only provides for civil courses of action, there is no regulator
or implementer for this ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Employment Ordinance (Chapter 57 of the Laws of Hong
Kong)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Employment Ordinance (Chapter 57of the
Laws of Hong Kong), or the EO, is an ordinance enacted for, amongst other things, the protection of the wages of employees and
the regulation of the general conditions of employment and employment agencies. Employment Ordinance is not a PRC legislation but
is Hong Kong ordinance. As with all other Hong Kong legislations, according to the laws of Hong Kong, the Legislative Council of
Hong Kong has the power and function to amend the Employment Ordinance in accordance with the provisions of the Hong Kong Basic
Law and legal procedures. The Hong Kong Government, including but not limited to the Department of Justice, the Hong Kong Police
Force, the Labor Department, the Department of Health, the Labor Tribunal, etc., has the implementation rights of the Employment
Ordinance. The Labor Department is the main regulator of the Employment Ordinance.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the EO, an employee is generally
entitled to, amongst other things, notice of termination of his or her employment contract; payment in lieu of notice; maternity
protection in the case of a pregnant employee; not less than one rest day in every period of seven days; severance payments or
long service payments; sickness allowance; statutory holidays or alternative holidays; and paid annual leave of up to 14 days
depending on the period of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Employees&rsquo; Compensation Ordinance (Chapter 282
of the Laws of Hong Kong)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Employees&rsquo; Compensation Ordinance
(Chapter 282 of the Laws of Hong Kong), or the ECO, is an ordinance enacted for the purpose of providing for the payment of compensation
to employees injured in the course of employment. The ECO is not a PRC legislation but is a Hong Kong ordinance. As with all other
Hong Kong legislations, according to the laws of Hong Kong, the Legislative Council of Hong Kong has the power and function to
amend the ECO in accordance with the provisions of the Hong Kong Basic Law and legal procedures. The Hong Kong Government, including
but not limited to the Department of Justice, the Hong Kong Police Force, the Labor Department, the Department of Health and etc.,
has the implementation rights of the ECO. The Labor Department is the main regulator of the ECO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As stipulated by the ECO, no employer shall employ any employee
in any employment unless there is in force in relation to such employee a policy of insurance issued by an insurer for an amount
not less than the applicable amount specified in the Fourth Schedule of the ECO in respect of the liability of the employer. According
to the Fourth Schedule of the ECO, the insured amount shall be not less than HK$100,000,000 per event if a company has no more
than 200 employees. Any employer who contravenes this requirement commits a criminal offense and is liable on conviction to a fine
and imprisonment. An employer who has taken out an insurance policy under the ECO is required to display a prescribed notice of
insurance in a conspicuous place on each of its premises where any employee is employed.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_014"></A><B>MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Set forth below is information concerning
our directors, executive officers and other key employees. The following individuals are members of the Board and executive management
of the Registrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 53%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position(s)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yat-Gai Au</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founder, Chief Executive Officer and Director</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Yi-Chung Chao</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Medical Officer and Director</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Wai Hong Chung</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Strategy Officer </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tien Hsiang Chau</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evana Yee Wah Hui</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director Appointee*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul J. Niewiadomski</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director Appointee*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cheung Ming Wong</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director Appointee*</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
                                         accepted an independent director appointment, which will be effective immediately upon
                                         effectiveness of this registration statement.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following is a brief biography of each
of our executive officers and directors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Yat-Gai Au</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Mr. Yat-Gai Au is our CEO and has been our
director since 2014. He began his career in Investment Banking at Deutsche Bank and ING Barings and was one of the core team members
that won Merger and Acquisitions deal of the year awards in Asia from 1998 to 1999 comprising over $4 billion worth of deals. He is a
founding partner of one of California&rsquo;s largest group of property investors. The property group partners with the leading pension
and private equity funds with assets over $250 billion. He is an active investor in biotech and tech startup companies. He funds and
participates in several charity events for thousands of underprivileged families and elderlies in Hong Kong and the U.S. During the COVID-19
outbreak, he has donated over 200,000 masks to hospitals, elderlies and needy families. In September 2018, Mr. Au set up Regencell Foundation
Limited to further his charitable endeavors. Mr. Yat-Gai Au is the son of the TCM Practitioner, Mr. Sik-Kee Au. Mr. Au graduated from
University of California, Berkeley with a Bachelor of Science degree from the Haas School of Business. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Dr. Yi-Chung Chao, Ph.D.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dr. Yi-Chung Chao is our Chief Medical Officer (&ldquo;CMO&rdquo;)
and has served as our director since October 2020. He has joined us as CMO of Regencell Bioscience Limited since November, 2019.
He is a California board certified Chinese medicine doctor and acupuncturist, as well as a successful entrepreneur and a management
leader in Silicon Valley. As the CMO of Regencell Bioscience Limited, he is responsible for including, but not limited to, managing
research projects and preparing research reports; developing a methodology for data collection; collecting, recording data and
presenting the findings. Dr. Chao&rsquo;s journey in TCM started when his then 7-year-old son was diagnosed with ASD and subsequently
received the TCM Practitioner&rsquo;s treatment. Intrigued by the successful treatment using Chinese medicine, Dr. Chao started
learning and eventually obtained a Master of Science in Traditional Chinese Medicine in Silicon Valley. After passing California
board certified Chinese medicine and acupuncture exam in 2017, Dr. Chao has formally immersed himself in the research and development
of the medical cases of our TCM Practitioner and continues to learn under his guidance at his clinical practice in Hong Kong. Prior
to joining Regencell Bioscience Limited, Dr. Chao was a co-founder and Chief Technology Officer of Telenav, Inc. in Silicon Valley.
Dr. Chao obtained his Bachelor&rsquo;s degree in Mechanical Engineering at the National Taiwan University, a Master&rsquo;s degree
in Aerospace Engineering from University of Texas at Austin, and a Ph.D. in Aeronautics and Astronautics at Stanford University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>James Wai Hong Chung </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mr. Chung is our Chief Strategy Officer
(&ldquo;CSO&rdquo;). He has joined Regencell Bioscience Limited as senior vice president since July 2015. He brings 15 years of experience
in various leading roles. Prior to Regencell, Mr. Chung managed the Asia equities and derivatives electronic trading platform
at Investment Technology Group, where he gained extensive banking and finance experience. Prior to that, he worked at Sungard
Financial Systems, providing front to back trading and risk management software solutions for banks. He also gained experiences
in different roles from sales and accounting management, project management, technology and business analyst when he worked at
a startup hedge fund IT consulting business. Mr. Chung started his career as a telecommunication engineer at Hutchison Global
Crossing and eventually led a small team of engineers. Mr. Chung is a graduate of Quantitative Finance from the Management Science
and Engineering Department at Stanford University and Telecommunications Technology from British Columbia Institute of Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Tien Hsiang Chau</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mr. Chau is our Chief Financial Officer
(the &ldquo;CFO&rdquo;). He joined Regencell Bioscience Limited in January 2021. Mr. Chau brings over 15 years of finance experience.
Mr. Chau&rsquo;s CFO experience include four mainboard listed companies on the Hong Kong Stock Exchange and one mainboard listed
company on the Tokyo Stock Exchange. He also brings extensive treasury and risk management experience. Mr. Chau was Philips&rsquo;
Asia Head of Cash Management and Risk and IBM&rsquo;s China Treasurer. Prior to joining IBM, Mr. Chau worked at Merrill Lynch
and Booz Allen &amp; Hamilton where he gained investment banking, capital markets and management consulting experience. Mr. Chau
obtained his Bachelor&rsquo;s degree in finance from the University of Texas at Austin with the highest honor and obtained his
MBA from Massachusetts Institute of Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Evana Yee Wah Hui </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Ms. Evana Yee Wah Hui will serve as our
independent director upon effectiveness of this registration statement. She has over 20 years of retail and brand management experience.
Throughout her 18-year career at the Dairy Farm Company Limited, a leading pan-Asian retailer, she managed various segments of
the business both at the regional and local level. She headed the regional category development team of the Health &amp; Baby
categories across the Greater China and Asian regions covering nine markets, implementing store layout/display, category development
and management strategies. Furthermore, she was responsible for the sales and profitability of a diverse range of categories with
experience in product creation and development, brand building, and customer loyalty. She also spearheaded the launch of both
the GNC and Boots brands in Hong Kong. Prior to that, she spent three years developing and implementing market research at Nielsen,
where her major clients included Unilever, Coca-Cola, HSBC, MSD, and L&rsquo;Oreal. Ms. Hui participated in charitable endeavors,
such as promoting mental health awareness in the community and holding workshops to promote self-awareness and reduce stigma in
local high schools, co-organized by the HK Hospital Authority. She holds an MBA from University of Southern California and graduated
with a Bachelor of Arts, Mathematics (Honors) from Mills College.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Paul J. Niewiadomski</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Mr. Paul J. Niewiadomski will serve as our
independent director upon effectiveness of this registration statement. He is a partner in Lubin Olson &amp; Niewiadomski LLP&rsquo;s
Business, Finance and Workouts Practice Groups. He represents clients in a broad range of business transactions. His practice encompasses
acquisitions, dispositions, joint ventures, and financing. He has advised both publicly traded and private companies on business matters.
Mr. Niewiadomski served on the boards of several non-profit, for profit and civic organizations and is a member of the Urban Land Institute
(San Francisco) and NAIOP (San Francisco Bay Area). He has spoken at a wide range of seminars and conferences on business issues for
Marcus &amp; Millichap, California County Counsels&rsquo; Association, California Mortgage Association, and other organizations. Mr.
Niewiadomski is recognized by Thomson Reuters as a Northern California &ldquo;Super Lawyer&rdquo; and was selected by his peers for the
inclusion of the 2018, 2019 and 2020 Editions of The Best Lawyers in America. He is a Juris Doctor graduate from University of Michigan,
Master of Laws from New York University and a Bachelor of Business Administration from Western Michigan University (Magna Cum Laude). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Cheung Ming Wong </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mr. Cheung Ming Wong will serve as our
independent director upon effectiveness of this registration statement. He has over 20 years of experience in banking and finance.
He has served as General Manager and Head of Treasury and Global Markets for China CITIC Bank International and Managing Director
and Head of Trading for Asia Pacific for Banco Santander S.A., with responsibility for funding and liquidity management as well
as spearheading the development of the markets and trading businesses. He has also served in senior trading and structuring roles
at global institutions including HSBC, Deutsche Bank and Standard Bank PLC. He started his career as an audit professional at
Price Waterhouse and Deloitte Touche Tohmatsu. Mr. Wong is a charter holder of the Chartered Financial Analyst (CFA) and a member
of CPA Australia. He graduated from the University of Melbourne with a Bachelor of Commerce degree. He now runs a fund focused
on derivatives and quantitative strategies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None of our directors or executive officers
have a family relationship as defined in Item 401 of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Involvement in Certain Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To the best of our knowledge, none of our
directors or executive officers has, during the past ten years, been involved in any legal proceedings described in subparagraph
(f) of Item 401 of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Duties of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under Cayman Islands law, all of our directors
owe three types of duties to us: (i) statutory duties, (ii) fiduciary duties, and (iii) common law duties. The Companies Act (2020
Revision) of the Cayman Islands imposes a number of statutory duties on a director. A Cayman Islands director&rsquo;s fiduciary
duties are not codified, however, the courts of the Cayman Islands have held that a director owes the following fiduciary duties:
(a) a duty to act in what the director bona fide considers to be in the best interests of the company, (b) a duty to exercise
their powers for the purposes they were conferred, (c) a duty to avoid fettering his or her discretion in the future and (d) a
duty to avoid conflicts of interest and of duty. The common law duties owed by a director are those to act with skill, care and
diligence that may reasonably be expected of a person carrying out the same functions as are carried out by that director in relation
to the company and, also, to act with the skill, care and diligence in keeping with a standard of care commensurate with any particular
skill they have which enables them to meet a higher standard than a director without those skills. In fulfilling their duty of
care to us, our directors must ensure compliance with our Articles expected to be amended and effective on or before the completion
of this offering. We have the right to seek damages if a duty owed by any of our directors is breached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Amended and Restated Memorandum and
Articles of Association (hereinafter referred as &ldquo;Amended Articles&rdquo;) provide that a director must disclose the nature
and extent of any material interests in any contract or arrangement, provided that the required notice has been given and subject
to any separate requirement for Audit Committee approval under applicable law or the listing rules of Nasdaq, and unless disqualified
by the chairman of the relevant Board meeting, a director may vote in respect of any contract or arrangement in which such director
is interested and may be counted in the quorum at such meeting. However, even if a director discloses his interest and is therefore
permitted to vote, he must still comply with his duty to act bona fide in the best interest of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A director of a Cayman Islands company
also owes to the Company a duty to exercise the powers for the purpose for which they were given and the duty to act with skill
and care. It was previously considered that a director need not exhibit in the performance of his or her duties a greater degree
of skill than may reasonably be expected from a person of his or her knowledge and experience. However, courts are moving towards
an objective standard with regard to the required skill and care and these authorities are likely to be followed in the Cayman
Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Interested Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A director may vote, attend a board meeting
or sign a document on our behalf with respect to any contract or transaction in which he or she is interested. A director must
promptly disclose the interest to all other directors after becoming aware of the fact that he or she is interested in a transaction
we have entered into or are to enter into. A general notice or disclosure to the board or otherwise contained in the minutes of
a meeting or a written resolution of the board or any committee of the board that a director is a shareholder, director, officer
or trustee of any specified firm or company and is to be regarded as interested in any transaction with such firm or company will
be sufficient disclosure, and, after such general notice, it will not be necessary to give special notice relating to any particular
transaction. Any such transaction that would reasonably be likely to affect a Director&rsquo;s status as an &ldquo;Independent
Director&rdquo;, or that would constitute a &ldquo;related party transaction&rdquo; as defined by Item 7.N of Form 20F promulgated
by the SEC, shall require the approval of the Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Remuneration and Borrowing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The directors may receive such remuneration
as our board of directors may determine from time to time and in accordance with the recommendations of the compensation committee of
the Board and the Company&rsquo;s corporate governance documents. Each director is entitled to be repaid or prepaid all traveling, hotel
and incidental expenses reasonably incurred or expected to be incurred in attending meetings of our board of directors or committees
of our board of directors or shareholder meetings or otherwise in connection with the discharge of his or her duties as a director. The
compensation committee will assist the directors in reviewing and approving the compensation structure for the directors. Our board of
directors may exercise all the powers of the company to borrow money and to mortgage or charge our undertakings and property or any part
thereof, to issue debentures, debenture stock and other securities whenever money is borrowed or as security for any debt, liability
or obligation of the company or of any third party. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Terms of Directors and Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each of our directors holds office until
a successor has been duly elected and qualified unless the director was appointed by the board of directors, in which case such
director holds office until the next following annual meeting of shareholders at which time such director is eligible for re-election.
All of our executive officers are appointed by and serve at the discretion of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Qualification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no membership qualifications
for directors. Further, there are no share ownership qualifications for directors unless so fixed by us in a general meeting by
ordinary resolution of our shareholders. There are no other arrangements or understandings pursuant to which our directors are
selected or nominated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Committees of the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to establish an audit committee,
a compensation committee and a nominating and governance committee prior to consummation of this offering. Each of the committees
of the Board shall have the composition and responsibilities described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Audit Committee </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Evana Yee Wah Hui, Paul J. Niewiadomski
and Cheung Ming Wong will be members of our Audit Committee, with Cheung Ming Wong serving as the chairperson. All proposed members
of our Audit Committee satisfy the independence standards promulgated by the SEC and by Nasdaq as such standards apply specifically
to members of audit committees.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have adopted Audit Committee Charter
on December 3, 2020, and the Audit Committee Charter will become effective upon effectiveness of this registration statement.
In accordance with our Audit Committee Charter, our Audit Committee shall perform several functions, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluates the independence
    and performance of, and assesses the qualifications of, our independent auditor, and engages such independent auditor;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approves the plan and fees for the annual audit,
    quarterly reviews, tax and other audit-related services, and approves in advance any non-audit service to be provided by the
    independent auditor;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitors the independence of the independent
    auditor and the rotation of partners of the independent auditor on our engagement team as required by law;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviews the financial statements to be included
    in our Annual Report on Form 20-F and Quarterly Reports on Form 6-K and reviews with management and the independent auditors
    the results of the annual audit and reviews of our quarterly financial statements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">oversees all aspects our systems of internal
    accounting control and corporate governance functions on behalf of the board;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviews and approves in advance any proposed
    related-party transactions and report to the full Board on any approved transactions; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provides oversight assistance in connection
    with legal, ethical and risk management compliance programs established by management and the Board, including Sarbanes-Oxley
    Act implementation, and makes recommendations to the Board regarding corporate governance issues and policy decisions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">It is determined that Cheung Ming Wong,
possesses accounting or related financial management experience that qualifies him as an &ldquo;audit committee financial expert&rdquo;
as defined by the rules and regulations of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Compensation Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Evana Yee Wah Hui, Paul J. Niewiadomski and Cheung Ming Wong
will be members of our Compensation Committee with Evana Yee Wah Hui serving as the chairperson. All members of our Compensation
Committee will be qualified as independent under the current definition promulgated by Nasdaq. We have adopted Compensation Committee
Charter on December 3, 2020, and the Compensation Committee Charter will become effective upon effectiveness of this registration
statement. In accordance with the Compensation Committee&rsquo;s Charter, the Compensation Committee shall be responsible for overseeing
and making recommendations to the Board regarding the salaries and other compensation of our executive officers and general employees
and providing assistance and recommendations with respect to our compensation policies and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Nominating and Governance Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Evana Yee Wah Hui, Paul J. Niewiadomski and Cheung Ming Wong
will be the members of our Nominating and Governance Committee with Paul J. Niewiadomski serving as the chairperson. All members
of our Nominating and Governance Committee will be qualified as independent under the current definition promulgated by Nasdaq.
We have adopted Nominating and Governance on December 3, 2020, and the Nominating and Governance Committee Charter will become effective upon
effectiveness of this registration statement. In accordance with the Nominating and Governance Committee&rsquo;s Charter, the Nominating
and Corporate Governance Committee shall be responsible to identity and propose new potential director nominees to the Board of
Directors for consideration and review our corporate governance policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Governance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our board of directors has adopted a code of business conduct
and ethics, which is applicable to all of our directors, officers and employees. We will make our code of business conduct and
ethics publicly available on our website after the closing of this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Compensation of Directors</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> For the fiscal year ended June 30, 2020, we
did not compensate our executive directors for their services other than to reimburse them for out-of-pocket expenses incurred in connection
with their attendance at meetings of the board of directors. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On June 9, 2021, each independent director
nominee accepted a letter agreement and was awarded share options under the 2021 Share Option Plan to purchase 15,585 Ordinary Shares.
The share options will become effective upon the effectiveness of this registration statement when the nominee&rsquo;s directorship becomes
effective. These options will be exercisable at $9.50 per share, of which 25% vest on each anniversary over four years following the
closing of this offering and is valid for 10 years once vested. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On June 9, 2021, Dr. Chao was awarded share
options under the 2021 Share Option Plan to purchase 324,678 Ordinary Shares. These options will be exercisable at $9.50 per share,
of which 25% vest on each anniversary over four years following the closing of this offering and is valid for 10 years once vested. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </P>

<!-- Field: Page; Sequence: 86; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>2021 Share Option Plan</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We adopted a 2021 Share Option Plan (the &ldquo;Plan&rdquo;)
on May 31, 2021. The Plan is a share-based compensation plan that provides for discretionary grants of share options to key employees,
directors and consultants of the Company. The purpose of the Plan is to recognize contributions made to our company and its subsidiaries
by such individuals and to provide them with additional incentive to achieve the objectives of our Company. No grants have been made
under the plan as of the date hereof. The following is a summary of the Plan and is qualified by the full text of the Plan. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>Administration</I>. The Plan will be administered
by our CEO and Chairman of the board of directors. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>Number of Ordinary Shares.</I>&nbsp;The
number of Ordinary Shares that may be issued under the Plan is the maximum aggregate number of Ordinary Shares reserved and available
pursuant to this Plan shall be the aggregate of (i) 1,235,074 Ordinary Shares, and (ii) on each January 1, starting with January 1, 2022,
an additional number of shares equal to the lesser of (A) 2% of the outstanding number of Ordinary Shares (on a fully-diluted basis)
on the immediately preceding December 31, and (B) such lower number of Ordinary Shares as may be determined by the board of directors.
If there is a forfeiture or termination without the delivery of Ordinary Shares or of other consideration of any option made under the
Plan, the Ordinary Shares underlying such option, or the number of Ordinary Shares otherwise counted against the aggregate number of
Ordinary Shares available under the Plan with respect to the option, to the extent of any such forfeiture or termination, shall again
be, or shall become, available for granting options under the Plan. The number of Ordinary Shares issuable under the Plan is subject
to adjustment, in the event of any reorganization, recapitalization, share split, share distribution, merger, consolidation, split-up,
spin-off, combination, subdivision, consolidation or exchange of shares, any change in the capital structure of the company or any similar
corporate transaction. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>Eligibility</I>. All persons as the CEO
and Chairman of the board may select from among the employees, directors, and consultants of the Company. The grant of options shall
be approved by the Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>Share Options</I>. The Board shall determine
the provisions, terms, and conditions of each option including, but not limited to, the option vesting schedule, repurchase provisions,
rights of first refusal, forfeiture provisions, form of payment (cash, shares, cashless settlement, or other consideration) upon settlement
of the option, payment contingencies and the exercise price; each option will last for the term stated in the option agreement, provided,
however that in the case of an option that is to qualify as an Incentive Share Option as such term is defined in Section 422 of the Code,
the term shall not exceed ten (10) years. It is intended that share options qualify as &ldquo;performance based compensation&rdquo; under
Section 162(m) of the Code and thus be fully deductible by us for federal income tax purposes, to the extent permitted by law. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>Payment for Share Options and Withholding
Taxes</I>. The Board may make one or more of the following methods available for payment of an option, including the exercise price of
a share option, and for payment of the minimum required tax obligation associated with an award: (i) cash&#894; (ii) cheque&#894; (iii)
with respect to options, payment through a broker-dealer sale and remittance procedure pursuant to which the optionee (A) shall provide
written instructions to a Company designated brokerage firm to effect the immediate sale of some or all of the purchased Ordinary Shares
and remit to the Company sufficient funds to cover the aggregate exercise price payable for the purchased Ordinary Shares and (B) shall
provide written directives to the Company to deliver the certificates for the purchased Ordinary Shares directly to such brokerage firm
in order to complete the sale transaction&#894; (iv) cashless election; or (v) any combination of the foregoing methods of payment. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Upon exercise of an option the Company shall
have the right, but not the obligation (except as required by applicable law), to withhold or collect from optionee an amount sufficient
to satisfy such tax obligations. The optionee will be solely responsible for his/her own tax obligations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>Amendment of Award Agreements; Amendment
and Termination of the Plan; Term of the Plan</I>. The board of directors may at any time amend, suspend or terminate the Plan&#894;
provided, however, that no such amendment shall be made without the approval of the Company&rsquo;s shareholders to the extent such approval
is required by applicable laws, or if such amendment would adversely affect the right of any participant under any agreement in any material
way without the written consent of the participant. No option may be granted during any suspension of the Plan or after termination of
the Plan. No suspension or termination of the Plan shall adversely affect any rights under options already granted to an optionee. The
Plan shall become effective on the date of the Company&rsquo;s contemplated initial public offering is effective. It shall continue in
effect for a term of ten (10) years unless sooner terminated or unless renewed for another period not to exceed ten (10) years pursuant
to shareholder approval. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On June 9, 2021, the board of the Company granted
issuance of 1,235,074 options to its certain officers, directors and employees, under the Plan; provided that 46,755 options granted
to the independent director nominees will become effective upon the effectiveness of the Registration Statement when the nominee&rsquo;s
directorship becomes effective. These options will be exercisable at $9.50 per share, of which 25% vest on each anniversary over four
years following the closing of this offering and is valid for 10 years once vested. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><A NAME="RB_DRS_015"></A><B>EXECUTIVE
COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth certain
information with respect to compensation for the year ended June 30, 2020 and 2019 earned by or paid to principal executive officer,
our principal financial officer, and our other most highly compensated executive officers (the &ldquo;named executive officers&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"> Name and Principal Position </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Year </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Salary ($) </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Bonus ($) </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Share Awards ($) </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Option Awards ($) </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Non-Equity Incentive Plan Compensation </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Deferred Compensation Earnings </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Other </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Total ($) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Yat-Gai Au </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in"> CEO </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; width: 21%"> Dr. Yi-Chung Chao </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 6%; text-align: center"> 2020 </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 6%; text-align: right"> 27,360 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 6%; text-align: right"> 6,410 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 6%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 6%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 6%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 6%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 6%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 6%; text-align: right"> 33,770 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in"> CMO </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> James Wai Hong Chung </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 118,685 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 20,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 138,685 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in"> CSO </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 105,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 17,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 122,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>

<TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-size: 10pt">Tien Hsiang Chau</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-size: 10pt">2020</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;-</FONT> </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">CFO</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;-</FONT> </TD>
    <TD> &nbsp; </TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Agreements with Named Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We entered into amended and restated employment agreement with
our CEO, Yat-Gai Au, on February 2, 2021, with retroactive effect to November 12, 2020. Our amended and restated employment agreement
will become effective on the closing date of the initial public offering of our Ordinary Shares in the U.S. Pursuant to such agreement,
he shall receive an annual base salary of $1, and such compensation is subject to annual review and adjustment by the board. The
CEO cannot draw his compensation more than $1 until the Company reaches $1 billion market capitalization. Under this employment
agreement, Mr. Au is employed as our CEO for a term of three years, which automatically renews for additional three-year terms
unless previously terminated on one month written notice by either party. We may terminate the employment for cause, at any time,
without notice or remuneration, for certain acts of the executive officer, such as conviction or plea of guilty to a felony or
grossly negligent or dishonest acts to our detriment, or misconduct or a failure to perform agreed duties. In such case, the executive
officer will not be entitled to receive payment of any severance benefits or other amounts by reason of the termination, and the
executive officer&rsquo;s right to all other benefits will terminate, except as required by any applicable law. We may also terminate
an executive officer&rsquo;s employment without cause upon one-month advance written notice. In such case of termination by us,
we are required to provide compensation to the executive officer, including (1) a lump sum cash payment equal to one month of the
CEO&rsquo;s base salary as of the date of such termination; (2) a lump sum cash payment equal to a pro-rated amount of his target
annual bonus for the year immediately preceding the termination, if any; (3) payment of premiums for continued health benefits
under the Company&rsquo;s health plans for 12 months fo1lowing the termination, if any; and (4) immediate vesting of 100% of the
then-unvested portion of any outstanding equity awards held by Mr. Au. In the event that we or our successor terminates the employment
upon a merger, consolidation, or transfer or sale of all or substantially all of our assets with or to any other individual(s)
or entity (the &ldquo;Change of Control Transaction&rdquo;), Mr. Au shall be entitled to the following severance payments and benefits
upon such termination: (1) a lump sum cash payment equal to 1 month of his base salary at a rate equal to the greater of his annual
salary in effect immediate1y prior to the termination, or his then current annua1 salary as of the date of such termination; (2)
a lump sum cash payment equal to a pro-rated amount of his target annual bonus for the year immediately preceding the termination;
(3) payment of premiums for continued health benefits under the Company&rsquo;s health plans for 12 months fo1lowing the termination;
and (4) immediate vesting of 100% of the then-unvested portion of any outstanding equity awards held by Mr. Au.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On July 15, 2019, we entered into an employment
agreement with our CMO, Dr. Yi-Chung Chao, which became effective on November 1, 2019. Pursuant to such agreement, he shall receive a
monthly base salary of $6,410, which shall be payable in arrears on the last day of each month during the employment. Dr. Chao is also
eligible for bonus, benefits and reasonable expenses reimbursement. Under the employment agreement, Dr. Chao works as our CMO and the
term is annual basis, which automatically renews for additional one-year terms unless previously terminated for cause by the Company,
at any time, without notice or remuneration, for certain acts of the executive officer, such as conviction or plea of guilty to a felony
or grossly negligent or dishonest acts to our detriment, or misconduct or a failure to perform agreed duties. Effective from September
1, 2020, Dr. Chao&rsquo;s base salary was adjusted to $11,538. On June 9, 2021, the board of the Company approved to issue Dr. Chao options
to purchase 324,678 Ordinary Shares under the Plan. These options will be exercisable at $9.50 per share, of which 25% vest on each anniversary
over four years following the closing of this offering and is valid for 10 years once vested. Dr. Chao&rsquo;s main responsibilities
include but not limited to managing research projects and preparing research reports, developing a methodology for data collection, as
well as recording data and presenting the findings. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On July 6, 2015, we entered into an employment
agreement with James Wai Hong Chung, which became effective on July 6, 2015. Pursuant to such agreement, he shall receive a monthly base
salary of $9,615, which shall be payable in arrears on the last day of each month during the employment. Mr. Chung is also eligible for
bonus, benefits and reasonable expenses reimbursement. Under the employment agreement, Mr. Chung works as our senior vice president and
the term is annual basis, which automatically renews for additional one-year terms unless previously terminated for cause by the Company,
at any time, without notice or remuneration, for certain acts of the executive officer, such as conviction or plea of guilty to a felony
or grossly negligent or dishonest acts to our detriment, or misconduct or a failure to perform agreed duties. Effective from September
1, 2020, Mr. Chung&rsquo;s base salary was adjusted to $11,282. On June 9, 2021, the board of the Company approved to issue, immediately
upon the closing of the offering, Mr. Chung options to purchase 311,691 Ordinary Shares under the Plan. These options will be exercisable
at $9.50 per share, of which 25% vest on each anniversary over four years following the closing of this offering and is valid for 10
years once vested. Mr. Chung&rsquo;s responsibilities include but not limited to planning, communicating and executing strategic initiatives
of the Company, exploring and establishing strategic partnerships or joint ventures, identifying risk, opportunities, market research,
projects and investments for the Company, and implementing decisions of the board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On January 18, 2021, we entered into an employment
agreement with Tien Hsiang Chau, who joined Regencell Bioscience Limited as CFO. The employment agreement became effective on January
18, 2021. Pursuant to the employment agreement, he shall receive a monthly base salary of $10,897, which shall be payable in arrears
on the last day of each month during the employment. The employment agreement has a six-month probation period, during which either party
can terminate the agreement with written notice or payment in lieu of notice. After six-month probation, either party may terminate the
employment agreement by giving a three months prior written notice or payment in lieu of notice. The employment term will continue on
an annual basis until terminated in accordance with the agreement. On June 9, 2021, the board of the Company approved to issue, immediately
upon the closing of the offering Mr. Chau options to purchase 259,742 Ordinary Shares under the Plan. These options will be exercisable
at $9.50 per share, of which 25% vest on each anniversary over four years following the closing of this offering and is valid for 10
years once vested. Mr. Chau&rsquo;s main responsibilities include but not limited to identifying and establishing contact with potential
investors, formulating financial policies and strategies for the Company, ensuring effective internal controls, compliance of all accounting
and financial regulations in U.S. and Hong Kong. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_016"></A><B>PRINCIPAL
SHAREHOLDERS</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth information
with respect to beneficial ownership of our Ordinary Shares as of the date of the Prospectus by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each person who is known by us to beneficially own more than 5% of
our outstanding Ordinary Shares;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                         of our director, director nominees and named executive officers; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All directors and named executive officers as
    a group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of the date of this prospectus, our Company
is authorized to issue 100,000,000,000 Ordinary Shares with a par value $0.00001 each. The number and percentage of Ordinary Shares beneficially
owned before the offering are based on 10,000,000 Ordinary Shares issued and outstanding as of the date of this prospectus. The number
and percentage of Ordinary Shares beneficially owned after the offering are based on 12,642,105 Ordinary Shares issued and outstanding
including 2,300,000 Ordinary Shares sold in this offering (assuming that the over-allotment option is not exercised) and 342,105 Ordinary
Shares issued upon conversion of the principal of $3,250,000 under the Note issued to Mr. Au at the same price of the offering price
$9.50 per share, the midpoint of the price range set forth on the cover page of the prospectus. Information with respect to beneficial
ownership has been furnished by each director, officer or beneficial owner of more than 5% of our Ordinary Shares. Beneficial ownership
is determined in accordance with the rules of the SEC and generally requires that such person have voting or investment power with respect
to securities. In computing the number of Ordinary Shares beneficially owned by a person listed below and the percentage ownership of
such person, Ordinary Shares underlying options, warrants or convertible securities held by each such person that are exercisable or
convertible within 60 days are deemed outstanding, but are not deemed outstanding for computing the percentage ownership of any other
person. Except as otherwise indicated in the footnotes to this table, or as required by applicable community property laws, all persons
listed have sole voting and investment power for all Ordinary Shares shown as beneficially owned by them. Unless otherwise indicated
in the footnotes, the address for each beneficial owner is in the care of our Company at 11/F First Commercial Building, 33-35 Leighton
Road, Causeway Bay, Hong Kong. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Ordinary Shares<BR>
    Beneficially Owned<BR>
    Prior to this<BR>
    Offering</B></FONT> </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Ordinary Shares<BR>
    Beneficially Owned<BR>
    Immediately After<BR>
    This Offering</B></FONT> </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Percentage<BR>
    of Votes<BR>
    Held<BR>
    After this<BR>
    Offering</B></FONT> </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Number</B></FONT> </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Percent</B></FONT> </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Number</B></FONT> </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Percent</B></FONT> </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Percent</B></FONT> </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-size: 10pt"><B>Directors and Executive Officers:</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-size: 10pt">Yat-Gai Au <SUP>(1)</SUP></FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 6%; text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;10,000,000&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 6%; text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;100</FONT> </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt"><SUP>(1)</SUP>%</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 6%; padding-right: 2.5pt; text-align: right"> <FONT STYLE="font-size: 10pt">10,342,105<SUP>(3)</SUP></FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 6%"> <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;81.8%</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 6%; padding-right: -1.2pt; padding-left: 1.1pt; text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;81.8</FONT> </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-size: 10pt">Dr. Yi-Chung Chao</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-size: 10pt">James Wai Hong Chung</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-size: 10pt">Tien Hsiang Chau</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-size: 10pt">Evana Yee Wah Hui<SUP>(2)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-size: 10pt">Paul J. Niewiadomski<SUP>(2)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-size: 10pt">Cheung Ming Wong<SUP>(2)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-size: 10pt"><B>5% Shareholders:</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-size: 10pt">Yat-Gai Au <SUP>(1)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;10,000,000&nbsp;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;100</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;10,342,105</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;81.8%</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;81.8</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These Ordinary Shares are held by Regencell (BVI) Limited, a
British Virgin Islands company. Since Mr. Yat-Gai Au is the 100% owner of Regencell (BVI) Limited, he is deemed as the beneficial
owners of these securities.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
                                         accepted an independent director appointment, which will be effective immediately upon
                                         effectiveness of this registration statement.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"> (3) </TD><TD STYLE="text-align: left"> Incudes the Ordinary
                                            Shares issuable to Mr. Yat-Gai Au or his designees upon the automatic conversion of the Note
                                            and assumes the over-allotment option is not exercised by the underwriter. </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of the date of the Prospectus, we have one
shareholder of record. None of our issued and outstanding Ordinary Shares are held by record holders in the United States. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>History of Share Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were incorporated in the Cayman Islands
as an exempted company with limited liability on October 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of the date of this prospectus, our authorized
share capital consists of $1,000,000 divided into 100,000,000,000 shares, par value $0.00001 per share. Holders of Ordinary Shares are
entitled to one vote per share. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On October 30, 2014, the Company issued one
Ordinary Share to Avalon Limited and 9,999 Ordinary Shares to Mr. Yat-Gai Au. On the same day, Avalon Limited transferred its share to
Mr. Yat-Gai Au, who then owned 10,000 Ordinary Shares of the Company. On September 28, 2020, Mr. Yat-Gai Au transferred his 10,000 Ordinary
Shares to Regencell (BVI) Limited, which is wholly owned by Mr. Yat-Gai Au. On May 31, 2021, the Company effectuated a forward split
at a ratio of 1,000-for-1 to increase its authorized capital shares from 100,000,000 Ordinary Shares with a par value of $0.01 per share
to 100,000,000,000 Ordinary Shares with a par value of $0.00001 per share, or the 2021 Forward Split. As a result of the 2021 Forward
Split, we now have 10,000,000 Ordinary Shares issued and outstanding as of the date hereof. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_017"></A><B>RELATED
PARTY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Rental Agreement with Ace United International Limited </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the years ended June 30, 2020 and
2019, the Company has an office rental agreement with Ace United International Limited, which is a company wholly owned by our
founder and CEO. The Company has paid a monthly rent of $4,103 and the terms of the agreement are renewed on an annual basis from
the 1<SUP>st</SUP> of January to the 31<SUP>st</SUP> of December each year. The rental payment is expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Loan Agreement between Regencell Bioscience Limited and Mr.
Yat-Gai Au</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of June 30, 2020, and 2019, the Company has outstanding Shareholder
loans amounting to approximately $3.07 million and $2.08 million, respectively, from Mr. Yat-Gai Au, the Founder and CEO. On November
10, 2020, Regencell Bioscience Limited entered into a loan agreement with Mr. Yat-Gai Au to evidence the existing loan and document
their oral agreements of the terms and conditions of such existing loan when such loan was initially generated (the &ldquo;Loan
Agreement&rdquo;). The Loan Agreement also sets forth that Mr. Yat-Gai Au will continue to make a loan to us for daily operation
and research activities. The use of loan shall be agreed and determined by both parties before granting the loan. All loans shall
bear 0% interest per annual. The maturity date of such loans is June 30, 2021, subject to indefinite extension if agreed by the
parties in writing.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February 2, 2021, a loan extension agreement was entered
by Mr. Yat-Gai Au and Regencell Bioscience Limited, pursuant to which Mr. Yat-Gai Au agreed to provide up to $3 million in the
form of loan or make payments on behalf of Regencell Bioscience Limited during the period from January 1, 2021 to June 30, 2022
to support its operations and research activities for the period from January 1, 2021 to June 30, 2022 and further extend the maturity
date of the existing loans from June 30, 2021 to December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On March 18, 2021, a supplemental loan agreement
was entered by and between Regencell Bioscience Limited and Mr. Yat-Gai Au, pursuant to which Mr. Yat-Gai Au will waive the amount of
$3.25 million of the outstanding loan upon the receipt of the Note issued by the Company in the principal amount of $3,250,000. On March
18, the Company issued the Note to Mr. Yat-Gai Au in the principal amount of $3,250,000, automatically convertible into Ordinary Shares,
upon the completion of the Company&rsquo;s initial public offering, at the same price as the offering price per Ordinary Shares to be
issued in the initial public offering. The Note does not carry any interest. The Note, if not automatically converted, will mature and
become payable twelve months after the issuance date of the Note and the date when the Company redeems the Note. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>2021 Share Option Plan and Issuance of Certain Option under
the Plan upon the Closing of this Offering</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> See &ldquo;Management &ndash; 2021 Share Option
Plan.&rdquo; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Partnership Agreements with TCM Practitioner</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In January 2018, we entered into a Strategic Partnership Agreement
with the TCM Practitioner, the father of our CEO and director. Pursuant to the Strategic Partnership Agreement we have with TCM
Practitioner, we have exclusive rights and ownership of all his TCM formulae for patients suffering from ADHD and ASD, and all
other TCM formulae targeting different kinds of human illnesses, disorders and degeneration as well as the intellectual property
rights of the TCM formulae, including research and development, trademark, copyright, patent, and any other intellectual property
rights in relation to the TCM formulae that he owns. The TCM Practitioner is authorized to conduct research studies on these TCM
formulae. Any inventions, TCM formulae, utilities, models&rsquo; improvements, research, discoveries, designs, processes, methods
of manufacture, and products conceived or made by the TCM Practitioner in relation to TCM shall be the sole and exclusive property
of us.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Strategic Partnership Agreement does
not have a termination date and will remain effective indefinitely under Hong Kong law. The Strategic Partnership Agreement can
be amended or terminated by the mutual written agreement of the parties without breach. Pursuant to the Strategic Partnership
Agreement, in exchange for the rights, the Company is required to donate three percent (3.0%) of net revenue as shown in the audited
financial accounts that the Company generates in association with the use and/or commercialization of the TCM formulae to any
of charitable institutions and/or trusts of a public character anywhere in the world at the sole and absolute choice of the TCM
Practitioner and in such proportion at the sole and absolute discretion of the TCM practitioner on a yearly basis. We also undertake
to pay for all reasonable costs and expenses incurred by the TCM Practitioner in conducting research, testing, attending meetings/seminars,
compiling records, or performing any similar acts in relation to the development of the TCM formulae.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Supplemental Agreement with TCM Practitioner</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In November 2020, we entered into Supplemental
Agreement with the TCM Practitioner. Under the Supplemental Agreement, the TCM Practitioner shall provide his research by using
his best endeavors on his TCM formulae and TCM inventions under our direction and supervision. We shall pay the TCM Practitioner for his expenses on his TCM
research within 30 days upon the receipt of invoice. We have authorized the TCM Practitioner,
his agents, subcontractors, development team, and affiliates to use TCM formulae and TCM inventions to conduct research. However,
the authorized parties, including TCM Practitioner, shall not directly or indirectly publish, disseminate or otherwise disclose,
deliver or make available to any third party any confidential information, without prior written consent and notice given by the
Company. The confidential information includes all information, know-how, and records in any way connected with the Company and
its research, including all TCM inventions, TCM formulae, and intellectual property rights, data, operations and testing procedures,
and all patients and supplier information, etc. The confidentiality obligations shall survive notwithstanding the termination
of the Supplemental Agreement for ten (10) years thereafter. The TCM Practitioner also shall not to be directly or indirectly
concerned with or engaged or interested in any other business which is in any respect in competition with or similar to the TCM
business conducted by the Company for two (2) years after the expiration or termination of the Supplemental Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Supplemental Agreement shall remain
effective until the Strategic Partnership Agreement is expired or terminated. We may terminate this Supplemental Agreement for
any reason in our sole discretion and without any indemnity or damages being due to TCM Practitioner with thirty (30) days prior
written notice. The TCM Practitioner may terminate this Supplemental Agreement in the event that the Company fails to meet its
payment obligations under Supplemental Agreement which is not cured within thirty (30) days of the notification of such by the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_018"></A><B>DESCRIPTION
OF SHARE CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The following description of our share capital
and provisions of our Articles are summaries and do not purport to be complete. Reference is made to our Amended Articles, a copy of
which is filed as an exhibit to this registration statement of which this prospectus is a part (and which is referred to in this section
as, respectively, the &ldquo;memorandum&rdquo; and the &ldquo;articles&rdquo;). </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were incorporated as an exempted company
with limited liability under the Companies Act (2013 Revision) of the Cayman Islands, or the Cayman Companies Act (2020 Revision).
A Cayman Islands exempted company:&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is a company that conducts its business mainly
    outside the Cayman Islands;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is prohibited from trading in the Cayman Islands
    with any person, firm or corporation except in furtherance of the business of the exempted company carried on outside the
    Cayman Islands (and for this purpose can affect and conclude contracts in the Cayman Islands and exercise in the Cayman Islands
    all of its powers necessary for the carrying on of its business outside the Cayman Islands);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">does not have to hold an annual general meeting;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">does not have to make its register of members
    open to inspection by shareholders of that company;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may obtain an undertaking against the imposition
    of any future taxation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may register by way of continuation in another
    jurisdiction and be deregistered in the Cayman Islands;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may register as a limited duration company;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may register as a segregated portfolio company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All of our issued and outstanding Ordinary
Shares are fully paid and non-assessable. Our Ordinary Shares are issued in registered form, and are issued when registered in
our register of members. Unless and until the directors resolve to issue share certificates, no share certificate shall be issued,
and the records of the shareholdings of each shareholder shall be in uncertified book entry form. Our shareholders who are non-residents
of the Cayman Islands may freely hold and vote their Ordinary Shares. We may not issue shares or warrants to bearer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of the date of this prospectus, the authorized
share capital of the Company is $1,000,000 divided into 100,000,000,000 Ordinary Shares of $0.00001 par value each. Subject to the provisions
of the Cayman Companies Act and the provisions, if any, of the Amended Articles, and any directions given by any ordinary resolution
and the rights attaching to any class of existing shares, the directors may issue, allot, grant options over or otherwise dispose of
shares (including any fractions of Shares) and other securities of our company at such times, to such persons, for such consideration
and on such terms as the directors may determine. Such authority could be exercised by the directors to allot shares which carry rights
and privileges that are preferential to the rights attaching to Ordinary Shares. No share may be issued at a discount except in accordance
with the provisions of the Cayman Companies Act. The directors may refuse to accept any application for shares, and may accept any application
in whole or in part, for any reason or for no reason. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have applied to list our Ordinary Shares
on the Nasdaq Capital Market under the symbol &ldquo;RGC.&rdquo; There can be no assurance that we will be successful in listing our
Ordinary Shares on the Nasdaq Capital Market; however, we will not complete this offering unless we receive approval for listing on Nasdaq
Capital Market. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The transfer agent and registrar for the
Ordinary Shares is Vstock Transfer, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the provisions of the Cayman
Companies Act and any rights for the being attaching to any class or classes of shares, the directors may declare dividends or
distributions out of our funds which are lawfully available for that purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the provisions of the Cayman
Companies Act and any rights for the being attaching to any class or classes of shares, the Company may, by ordinary resolution,
declare dividends but no such dividend shall exceed the amount recommended by the directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the requirements of the Cayman
Companies Act regarding the application of a company&rsquo;s share premium account and with the sanction of an ordinary resolution,
dividends may also be declared and paid out of any share premium account. The directors when paying dividends to shareholders
may make such payment either in cash or in specie.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless provided by the rights attached
to a share, no dividend shall bear interest against us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Voting Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to any rights or restrictions as
to voting attached to any shares, unless any share carries special voting rights. On a poll, every shareholder who is present
in person and every person representing a shareholder by proxy shall have one vote for each share of which he or the person represented
by proxy is the holder. In addition, all shareholders holding shares of a particular class are entitled to vote at a meeting of
the holders of that class of shares. Votes may be given either personally or by proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Variation of Rights of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the Cayman Companies Act and
without prejudice to article 8, all or any of the special rights for the time being attached to the shares or any class of shares
may, unless otherwise provided by the terms of issue of the shares of that class, be varied or modified with the sanction of a
special resolution passed at a separate general meeting of the holders of the shares of that class.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless the terms on which a class of shares
was issued state otherwise, the rights conferred on the shareholder holding shares of any class shall not be deemed to be varied
by the creation or issue of further shares ranking pari passu therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Alteration of share capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the Cayman Companies Act, the
Company may, by ordinary resolution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) increase our share capital by such
sum to be divided into shares of such amount and with the attached rights, priorities and privileges and restrictions attached
to them as that ordinary resolution shall prescribe;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) consolidate and divide all or any of
our share capital into shares of larger amount than our existing shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (c) convert all or any of our paid up shares
into stock, and reconvert that stock into paid up shares of any denomination; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (d) sub-divide our shares or any of them into
shares of an amount smaller than that fixed, so, however, that in the sub-division, the proportion between the amount paid and the amount,
if any, unpaid on each reduced share shall be the same as it was in case of the share from which the reduced share is derived; and </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (e) cancel shares which, at the date of the
passing of that ordinary resolution, have not been taken or agreed to be taken by any person and diminish the amount of our share capital
by the amount of the shares so cancelled or, in the case of shares without nominal par value, diminish the number of shares into which
our capital is divided. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the Cayman Companies Act and
to any rights for the time being conferred on the shareholders holding a particular class of shares, the Company may, by special
resolution, reduce its share capital in any lawful way.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Calls on shares and forfeiture</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> Subject to the terms of
allotment, the directors may make calls on the shareholders in respect of any monies unpaid on their shares including any premium and
each shareholder shall (subject to receiving at least 14 clear days&rsquo; notice specifying when and where payment is to be made), pay
to us the amount called on his shares. Shareholders registered as the joint holders of a share shall be jointly and severally liable
to pay all calls in respect of the share. If a call remains unpaid after it has become due and payable the person from whom it is due
and payable shall pay interest on the amount unpaid from the day it became due and payable until it is paid at the rate fixed by the
terms of allotment of the share or in the notice of the call or if no rate is fixed, at the rate of ten percent per annum. The directors
may waive payment of the interest wholly or in part. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> We have a first and paramount
lien on all shares (whether fully paid up or not) registered in the name of a shareholder (whether solely or jointly with others). The
lien is for all monies payable to us by the shareholder or the shareholder&rsquo;s estate: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-bottom: 0pt; text-align: left; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 24px; padding-bottom: 0pt; text-align: left; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT> </TD>
    <TD STYLE="padding-bottom: 0pt; text-align: left; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">either
    alone or jointly with any other person, whether or not that other person is a shareholder; and</FONT> </TD></TR>
  </TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-bottom: 0pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="width: 24px; padding-bottom: 0pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT> </TD>
    <TD STYLE="padding-bottom: 0pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    or not those monies are presently payable.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> &nbsp;At any time the directors
may declare any share to be wholly or partly exempt from the lien on shares provisions of the articles. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> We may sell, in such manner
as the directors may determine, any share on which the sum in respect of which the lien exists is presently payable, if due notice that
such sum is payable has been given (as prescribed by the articles) and, within 14 days of the date on which the notice is deemed to be
given under the articles, such notice has not been complied with. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>Unclaimed Dividend</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> A dividend that remains
unclaimed for a period of six years after it became due for payment shall be forfeited to, and shall cease to remain owing by, the company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>Forfeiture or Surrender of Shares</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> If a shareholder fails
to pay any call, the directors may give to such shareholder not less than 14 clear days&rsquo; notice requiring payment and specifying
the amount unpaid including any interest which may have accrued, any expenses which have been incurred by us due to that person&rsquo;s
default and the place where payment is to be made. The notice shall also contain a warning that if the notice is not complied with, the
shares in respect of which the call is made will be liable to be forfeited. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> If such notice is not complied
with, the directors may, before the payment required by the notice has been received, resolve that any share the subject of that notice
be forfeited (which forfeiture shall include all dividends or other monies payable in respect of the forfeited share and not paid before
such forfeiture). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> A forfeited share may be
sold, re-allotted or otherwise disposed of on such terms and in such manner as the directors determine and at any time before a sale,
re-allotment or disposition the forfeiture may be cancelled on such terms as the directors think fit. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> A person whose shares have
been forfeited shall cease to be a shareholder in respect of the forfeited shares, but shall, notwithstanding such forfeiture, remain
liable to pay to us all monies which at the date of forfeiture were payable by him to us in respect of the shares, together with all
expenses and interest from the date of forfeiture or surrender until payment, but his liability shall cease if and when we receive payment
in full of the unpaid amount. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> A declaration, whether
statutory or under oath, made by a director or the secretary shall be conclusive evidence that the person making the declaration is a
director or secretary and that the particular shares have been forfeited or surrendered on a particular date. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> Subject to the execution
of an instrument of transfer, if necessary, the declaration shall constitute good title to the shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Share premium account</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The directors shall establish a share premium
account and shall carry the credit of such account from time to time to a sum equal to the amount or value of the premium paid
on the issue of any share or capital contributed or such other amounts required by the Cayman Companies Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Redemption and purchase of own shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> Subject to the Cayman Companies Act and any
rights for the time being conferred on the shareholders holding a particular class of shares, we may by action of our directors: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (a) issue
shares that are to be redeemed or liable to be redeemed, at our option or the shareholder holding those redeemable shares, on the terms
and in the manner our directors determine before the issue of those shares; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (b) with
the consent by special resolution of the shareholders holding shares of a particular class, vary the rights attaching to that class of
shares so as to provide that those shares are to be redeemed or are liable to be redeemed at our option on the terms and in the manner
which the directors determine at the time of such variation; and </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (c) purchase
all or any of our own shares of any class including any redeemable shares on the terms and in the manner which the directors determine
at the time of such purchase. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> We may make a payment in respect of the redemption
or purchase of its own shares in any manner authorized by the Cayman Companies Act, including out of any combination of capital, our
profits and the proceeds of a fresh issue of shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 36pt"> When making a payment in respect of the redemption
or purchase of shares, the directors may make the payment in cash or in specie (or partly in one and partly in the other) if so authorized
by the terms of the allotment of those shares or by the terms applying to those shares, or otherwise by agreement with the shareholder
holding those shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> Without limiting the transfer provisions in
the articles, our board of directors would generally decline to register any transfer of any Ordinary Share that has not been fully paid
up or is subject to a company lien. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> Our board of directors may also decline to register
any transfer of any Ordinary Share unless: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) the instrument of transfer is lodged
with us, accompanied by the certificate for the Ordinary Shares to which it relates and such other evidence as our board of directors
may reasonably require to show the right of the transferor to make the transfer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) the instrument of transfer is in respect
of only one class of Ordinary Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) the instrument of transfer is properly
stamped, if required;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) the Ordinary Share transferred is fully
paid and free of any lien in favor of us;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e) any fee related to the transfer has
been paid to us; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f) the transfer is not to more than four
joint holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If our directors refuse to register a transfer,
they are required, within three months after the date on which the instrument of transfer was lodged, to send to each of the transferor
and the transferee notice of such refusal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This, however, is unlikely to affect market
transactions of the Ordinary Shares purchased by investors in the public offering. Once the Ordinary Shares have been listed,
the legal title to such Ordinary Shares and the registration details of those Ordinary Shares in the Company&rsquo;s register
of members will remain with [DTC/Cede &amp; Co]. All market transactions with respect to those Ordinary Shares will then be carried
out without the need for any kind of registration by the directors, as the market transactions will all be conducted through the
DTC systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding the foregoing shares may
be evidenced and transferred in accordance with the rules and regulations of the Designated Stock Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The registration of transfers may, on 14
calendar days&rsquo; notice being given by advertisement in such one or more newspapers or by electronic means, be suspended and
our register of members closed at such times and for such periods as our board of directors may from time to time determine. The
registration of transfers, however, may not be suspended, and the register may not be closed, for more than 30 days in any year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Inspection of Books and Records</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Holders of our Ordinary Shares will have
no general right under the Cayman Companies Act to inspect any account or book or document or obtain copies of our register of
members or our corporate records.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a Cayman Islands exempted company, we
are not obligated by the Cayman Companies Act to call shareholders&rsquo; annual general meetings; however, our articles provide
that the Company shall hold a general meeting as an annual general meeting. Any annual general meeting held shall be held at such
time and place as may be determined by our board of directors. All general meetings other than annual general meetings shall be
called extraordinary general meetings.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> The directors may convene general meetings whenever
they think fit. General meetings shall also be convened on the written requisition of one or more of the shareholders entitled to attend
and vote at our general meetings who (together) hold not less than ten percent of the rights to vote at such general meeting in accordance
with the notice provisions in the articles, specifying the purpose of the meeting and signed by each of the shareholders making the requisition.
If the directors do not convene such meeting for a date not later than 21 clear days&rsquo; after the date of receipt of the written
requisition, those shareholders who requested the meeting may convene the general meeting themselves within three months after the end
of such period of 21 clear days in which case reasonable expenses incurred by them as a result of the directors failing to convene a
meeting shall be reimbursed by us. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> At least 14 days&rsquo; notice of an extraordinary
general meeting and 21 days&rsquo; notice of an annual general meeting shall be given to shareholders entitled to attend and vote at
such meeting. The notice shall specify the place, the day and the hour of the meeting and the general nature of that business. In addition,
if a resolution is proposed as a special resolution, the text of that resolution shall be given to all shareholders. Notice of every
general meeting shall also be given to the directors and our auditors. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> Subject to the Cayman Companies Act and with
the consent of the shareholders who, individually or collectively, hold at least 90 percent of the voting rights of all those who have
a right to vote at a general meeting, a general meeting may be convened on shorter notice. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> A quorum shall consist of the presence (whether
in person or represented by proxy) of one or more shareholders holding shares that represent not less than one-third of the outstanding
shares carrying the right to vote at such general meeting. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> If, within 15 minutes from the time appointed
for the general meeting, or at any time during the meeting, a quorum is not present, the meeting, if convened upon the requisition of
shareholders, shall be cancelled. In any other case it shall stand adjourned to the same time and place seven days or to such other time
or place as is determined by the directors. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> The chairman may, with the consent of a meeting
at which a quorum is present, adjourn the meeting. When a meeting is adjourned for seven days or more, notice of the adjourned meeting
shall be given in accordance with the articles. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> At any general meeting a resolution put to the
vote of the meeting shall be decided on a show of hands, unless a poll is (before, or on, the declaration of the result of the show of
hands) demanded by the chairman of the meeting or by at least two shareholders having the right to vote on the resolutions or one or
more shareholders present who together hold not less than ten percent of the voting rights of all those who are entitled to vote on the
resolution. Unless a poll is so demanded, a declaration by the chairman as to the result of a resolution and an entry to that effect
in the minutes of the meeting, shall be conclusive evidence of the outcome of a show of hands, without proof of the number or proportion
of the votes recorded in favor of, or against, that resolution. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> If a poll is duly demanded it shall be taken
in such manner as the chairman directs and the result of the poll shall be deemed to be the resolution of the meeting at which the poll
was demanded. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> &nbsp; </P>

<P STYLE="text-align: left; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> In the case of an equality of votes, whether on a show of hands
or on a poll, the chairman of the meeting at which the show of hands takes place or at which the poll is demanded, shall not be entitled
to a second or casting vote. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> The Company may by ordinary resolution, from
time to time, fix the maximum and minimum number of directors to be appointed. Under the Articles, we are required to have a minimum
of one director and the maximum number of directors shall be unlimited. </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> A director may be appointed by ordinary resolution
or by the directors. Any appointment may be to fill a vacancy or as an additional director. </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> A director may be appointed
by ordinary resolution or by the directors. Any appointment may be to fill a vacancy or as an additional director. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> Unless the remuneration
of the directors is determined by the shareholders by ordinary resolution, the directors shall be entitled to such remuneration as the
directors may determine. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> The shareholding qualification for directors
may be fixed by our shareholders by ordinary resolution and unless and until so fixed no share qualification shall be required. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> Unless removed or re-appointed, each director
shall be appointed for a term expiring at the next-following annual general meeting, if one is held. At any annual general meeting held,
our directors will be elected by an ordinary resolution of our shareholders. At each annual general meeting, each director so elected
shall hold office for a one-year term and until the election of their respective successors in office or removed. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"> A director may be removed
by ordinary resolution. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> A director may at any time
resign or retire from office by giving us notice in writing. Unless the notice specifies a different date, the director shall be deemed
to have resigned on the date that the notice is delivered to us. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"> Subject to the provisions
of the articles, the office of a director may be terminated forthwith if: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; padding-left: 18pt; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 24px; padding-left: 18pt; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT> </TD>
    <TD STYLE="padding-left: 18pt; text-align: justify; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
    is prohibited by the law of the Cayman Islands from acting as a director;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; padding-left: 18pt; text-align: justify"> &nbsp; </TD>
    <TD STYLE="width: 24px; padding-left: 18pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT> </TD>
    <TD STYLE="padding-left: 18pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
    is made bankrupt or makes an arrangement or composition with his creditors generally;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; padding-left: 18pt; text-align: justify"> &nbsp; </TD>
    <TD STYLE="width: 24px; padding-left: 18pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT> </TD>
    <TD STYLE="padding-left: 18pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
    resigns his office by notice to us;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; padding-left: 18pt; text-align: justify"> &nbsp; </TD>
    <TD STYLE="width: 24px; padding-left: 18pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT> </TD>
    <TD STYLE="padding-left: 18pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
    only held office as a director for a fixed term and such term expires;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; padding-left: 18pt; text-align: justify"> &nbsp; </TD>
    <TD STYLE="width: 24px; padding-left: 18pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT> </TD>
    <TD STYLE="padding-left: 18pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the opinion of a registered medical practitioner by whom he is being treated he becomes physically or mentally incapable of acting
    as a director;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-align: left"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; padding-left: 18pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="width: 24px; padding-left: 18pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT> </TD>
    <TD STYLE="padding-left: 18pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
    is given notice by the majority of the other directors (not being less than two in number) to vacate office (without prejudice to
    any claim for damages for breach of any agreement relating to the provision of the services of such director);</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-align: left"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; padding-left: 18pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="width: 24px; padding-left: 18pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT> </TD>
    <TD STYLE="padding-left: 18pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
    is made subject to any law relating to mental health or incompetence, whether by court order or otherwise; or</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-align: left"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; padding-left: 18pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="width: 24px; padding-left: 18pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT> </TD>
    <TD STYLE="padding-left: 18pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">without
    the consent of the other directors, he is absent from meetings of directors for continuous period of six months.</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each of the compensation committee and
the nominating and corporate governance committee shall consist of at least three directors and the majority of the committee
members shall be independent within the meaning of Section 5605(a)(2) of the Nasdaq Listing Rules. The audit committee shall consist
of at least three directors, all of whom shall be independent within the meaning of Section 5605(a)(2) of the Nasdaq Listing Rules
and will meet the criteria for independence set forth in Rule 10A-3 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Powers and duties of directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the provisions of the Cayman
Companies Act, our memorandum and articles, our business shall be managed by the directors, who may exercise all our powers. No
prior act of the directors shall be invalidated by any subsequent alteration of our memorandum or articles. However, to the extent
allowed by the Cayman Companies Act, shareholders may by special resolution validate any prior or future act of the directors
which would otherwise be in breach of their duties.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The directors may delegate any of their
powers to any committee consisting of one or more persons who need not be shareholders and may include non-directors so long as
the majority of those persons are directors; any committee so formed shall in the exercise of the powers so delegated conform
to any regulations that may be imposed on it by the directors. Upon the initial closing of this offering, our board of directors
will have established an audit committee, compensation committee, and nomination and corporate governance committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The board of directors may establish any
local or divisional board of directors or agency and delegate to it its powers and authorities (with power to sub-delegate) for
managing any of our affairs whether in the Cayman Islands or elsewhere and may appoint any persons to be members of a local or
divisional board of directors, or to be managers or agents, and may fix their remuneration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The directors may from time to time
and at any time by power of attorney or in any other manner they determine to appoint any person, either generally or in
respect of any specific matter, to be our agent with or without authority for that person to delegate all or any of that
person&rsquo;s powers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The directors may from time to time
and at any time by power of attorney or in any other manner they determine to appoint any person, whether nominated directly
or indirectly by the directors, to be our attorney or our authorized signatory and for such period and subject to such
conditions as they may think fit. The powers, authorities and discretions, however, must not exceed those vested in, or
exercisable, by the directors under the articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The board of directors may remove any person
so appointed and may revoke or vary the delegation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The directors may exercise all of our powers
to borrow money and to mortgage or charge its undertaking, property and assets both present and future and uncalled capital or
any part thereof, to issue debentures and other securities whether outright or as collateral security for any debt, liability
or obligation of ours or our parent undertaking (if any) or any subsidiary undertaking of us or of any third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> A director shall not, as
a director, vote in respect of any contract, transaction, arrangement or proposal in which he has an interest which (together with any
interest of any person connected with him) is a material interest (otherwise than by virtue of his interests, direct or indirect, in
shares or debentures or other securities of, or otherwise in or through, us) and if he shall do so his vote shall not be counted, nor
in relation thereto shall he be counted in the quorum present at the meeting, but (in the absence of some other material interest than
is mentioned below) none of these prohibitions shall apply to: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; text-indent: 0pt; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT> </TD>
    <TD STYLE="text-align: justify; text-indent: 0pt; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    giving of any security, guarantee or indemnity in respect of:</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">money lent or obligations
    incurred by him or by any other person for our benefit or any of our subsidiaries; or</FONT> </TD></TR>
  </TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 24px"> &nbsp; </TD>
    <TD STYLE="text-align: left; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a debt or obligation
    of ours or any of our subsidiaries for which the director himself has assumed responsibility in whole or in part and whether alone
    or jointly with others under a guarantee or indemnity or by the giving of security;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where we or any of our
    subsidiaries is offering securities in which offer the director is or may be entitled to participate as a holder of securities or
    in the underwriting or sub-underwriting of which the director is to or may participate;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any contract, transaction,
    arrangement or proposal affecting any other body corporate in which he is interested, directly or indirectly and whether as an officer,
    shareholder, creditor or otherwise howsoever, provided that he (together with persons connected with him) does not to his knowledge
    hold an interest representing one percent or more of any class of the equity share capital of such body corporate (or of any third
    body corporate through which his interest is derived) or of the voting rights available to shareholders of the relevant body corporate;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any act or thing done
    or to be done in respect of any arrangement for the benefit of the employees of us or any of our subsidiaries under which he is not
    accorded as a director any privilege or advantage not generally accorded to the employees to whom such arrangement relates; or</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any matter connected
    with the purchase or maintenance for any director of insurance against any liability or (to the extent permitted by the Cayman Companies
    Act) indemnities in favor of directors, the funding of expenditure by one or more directors in defending proceedings against him
    or them or the doing of anything to enable such director or directors to avoid incurring such expenditure.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> A director may, as a director,
vote (and be counted in the quorum) in respect of any contract, transaction, arrangement or proposal in which he has an interest which
is not a material interest or as described above. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Capitalization of profits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company may, on recommendation of the
Board, resolve to capitalize:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) any part of our profits not required
for paying any preferential dividend, if applicable (whether or not those profits are available for distribution); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) any sum standing to the credit of our
share premium account or capital redemption reserve, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The amount resolved to be capitalized must
be appropriated to the shareholders who would have been entitled to it had it been distributed by way of dividend and in the same
proportions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidation Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we are wound up, the shareholders may,
subject to the articles and any other sanction required by the Cayman Companies Act, pass a special resolution voluntarily winding
up the company. Upon being appointed, a liquidator may do either or both of the following with the authority of a special resolution:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) divide in specie among the shareholders
the whole or any part of our assets and, for that purpose, to value any assets and to determine how the division shall be carried
out as between the shareholders or different classes of shareholders; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) vest the whole or any part of the assets
in trustees for the benefit of shareholders as the liquidator thinks fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The directors have the authority to present
a petition for our winding up to the Grand Court of the Cayman Islands on our behalf without the sanction of a resolution passed
at a general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Register of Members</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Cayman Companies Act, we must
keep a register of members and there should be entered therein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; text-align: justify; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    names and addresses of the members of the company, a statement of the shares held by each member, which:</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; text-align: justify; font-size: 10pt"> &#9675; </TD>
    <TD STYLE="text-align: justify; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">distinguishes
    each share by its number (so long as the share has a number);</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; text-align: justify; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT> </TD>
    <TD STYLE="text-align: justify; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">confirms
    the amount paid, or agreed to be considered as paid, on the shares of each member;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT> </TD>
    <TD STYLE="text-align: justify; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">confirms
    the number and category of shares held by each member; and</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="margin-top: 0; margin-bottom: 0"></P>
        <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT> </TD>
    <TD STYLE="text-align: left; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">confirms
    whether each relevant category of shares held by a member carries voting rights under the Articles, and if so, whether such voting
    rights are conditional;</FONT> </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; text-align: justify; font-size: 10pt"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify; font-size: 10pt"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    date on which the name of any person was entered on the register as a member; and</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; text-align: justify; font-size: 10pt"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify; font-size: 10pt"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    date on which any person ceased to be a member.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> For these purposes, &ldquo;voting
rights&rdquo; means rights conferred on shareholders, including the right to appoint or remove directors, in respect of their shares
to vote at general meetings of the company on all or substantially all matters. A voting right is conditional where the voting right
arises only in certain circumstances. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Cayman Companies Act, the register
of members of our company is prima facie evidence of the matters set out therein (that is, the register of members will raise
a presumption of fact on the matters referred to above unless rebutted) and a shareholder registered in the register of members
is deemed as a matter of the Cayman Companies Act to have legal title to the shares as set against its name in the register of
members. Upon the completion of this offering, the register of members will be immediately updated to record and give effect to
the issuance of shares by us to the custodian or its nominee. Once our register of members has been updated, the shareholders
recorded in the register of members will be deemed to have legal title to the shares set against their name.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the name of any person is incorrectly
entered in or omitted from our register of members, or if there is any default or unnecessary delay in entering on the register
the fact of any person having ceased to be a shareholder of our company, the person or shareholder aggrieved (or any shareholder
of our company or our company itself) may apply to the Grand Court of the Cayman Islands for an order that the register be rectified,
and the Court may either refuse such application or it may, if satisfied of the justice of the case, make an order for the rectification
of the register.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Differences in Corporate Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Cayman Companies Act is derived, to
a large extent, from the older Companies Acts of England and Wales but does not follow recent United Kingdom statutory enactments,
and accordingly there are significant differences between the Cayman Companies Act and the current Companies Act of England. In
addition, the Cayman Companies Act differs from laws applicable to United States corporations and their shareholders. Set forth
below is a summary of certain significant differences between the provisions of the Cayman Companies Act applicable to us and
the comparable laws applicable to companies incorporated in the State of Delaware in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Mergers and Similar Arrangements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Cayman Companies Act permits mergers
and consolidations between Cayman Islands companies and between Cayman Islands companies and non-Cayman Islands companies. For
these purposes, (a) &ldquo;merger&rdquo; means the merging of two or more constituent companies and the vesting of their undertaking,
property and liabilities in one of such companies as the surviving company, and (b) a &ldquo;consolidation&rdquo; means the combination
of two or more constituent companies into a consolidated company and the vesting of the undertaking, property and liabilities
of such companies to the consolidated company. In order to effect such a merger or consolidation, the directors of each constituent
company must approve a written plan of merger or consolidation, which must then be authorized by (a) a special resolution of the
shareholders of each constituent company, and (b) such other authorization, if any, as may be specified in such constituent company&rsquo;s
articles of association. The plan must be filed with the Registrar of Companies together with a declaration as to the solvency
of the consolidated or surviving company, a list of the assets and liabilities of each constituent company and an undertaking
that a copy of the certificate of merger or consolidation will be given to the shareholders and creditors of each constituent
company and that notification of the merger or consolidation will be published in the Cayman Islands Gazette. Court approval is
not required for a merger or consolidation which is affected in compliance with these statutory procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A merger between a Cayman parent company
and its Cayman subsidiary or subsidiaries does not require authorization by a resolution of shareholders. For this purpose, a
subsidiary is a company of which at least 90% of the issued shares entitled to vote are owned by the parent company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The consent of each holder of a fixed or
floating security interest of a constituent company is required unless this requirement is waived by a court in the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Except in certain limited circumstances,
a dissenting shareholder of a Cayman Islands constituent company is entitled to payment of the fair value of his or her shares
upon dissenting from a merger or consolidation. The exercise of such dissenter rights will preclude the exercise by the dissenting
shareholder of any other rights to which he or she might otherwise be entitled by virtue of holding shares, except for the right
to seek relief on the grounds that the merger or consolidation is void or unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, there are statutory provisions
that facilitate the reconstruction and amalgamation of companies, provided that the arrangement is approved by a majority in number
of each class of shareholders and creditors with whom the arrangement is to be made, and who must, in addition, represent three-fourths
in value of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or
by proxy at a meeting, or meetings, convened for that purpose. The convening of the meetings and subsequently the arrangement
must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder has the right to express to the court
the view that the transaction ought not to be approved, the court can be expected to approve the arrangement if it determines
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) the statutory provisions as to the
required majority vote have been met;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) the shareholders have been fairly represented
at the meeting in question and the statutory majority are acting bona fide without coercion of the minority to promote interests
adverse to those of the class;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) the arrangement is such that may be
reasonably approved by an intelligent and honest man of that class acting in respect of his interest; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) the arrangement is not one that would
more properly be sanctioned under some other provision of the Cayman Companies Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When a takeover offer is made and accepted
by holders of 90% of the shares affected within four months the offeror may, within a two-month period commencing on the expiration
of such four-month period, require the holders of the remaining shares to transfer such shares on the terms of the offer. An objection
can be made to the Grand Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so
approved unless there is evidence of fraud, bad faith or collusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If an arrangement and reconstruction is
thus approved, or if a takeover offer is made and accepted, a dissenting shareholder would have no rights comparable to appraisal
rights, which would otherwise ordinarily be available to dissenting shareholders of Delaware corporations, providing rights to
receive payment in cash for the judicially determined value of the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Shareholders&rsquo; Suits </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In principle, we will normally be the proper
plaintiff to sue for a wrong done to us as a company and as a general rule, a derivative action may not be brought by a minority
shareholder. However, based on English law authorities, which would in all likelihood be of persuasive authority in the Cayman
Islands, the Cayman Islands courts can be expected to follow and apply the common law principles (namely the rule in&nbsp;<I>Foss
v. Harbottle</I>&nbsp;and the exceptions thereto) so that a non-controlling shareholder may be permitted to commence a class action
against or derivative actions in the name of the company to challenge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) an act which is illegal or ultra vires
with respect to the company and is therefore incapable of ratification by the shareholders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) an act which, although not ultra vires,
requires authorization by a qualified (or special) majority (that is, more than a simple majority) which has not been obtained;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) an act which constitutes a &ldquo;fraud
on the minority&rdquo; where the wrongdoers are themselves in control of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Indemnification of Directors and Executive Officers and Limitation
of Liability</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> The Cayman Islands law
does not limit the extent to which a company&rsquo;s articles of association may provide for indemnification of officers and directors,
except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide
indemnification against civil fraud or the consequences of committing a crime. Our articles of association provide to the extent permitted
by law, we shall indemnify each existing or former secretary, director (including alternate director), and any of our other officers
(including an investment adviser or an administrator or liquidator) and their personal representatives against: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; padding-bottom: 8pt; text-align: justify; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 24px; padding-bottom: 8pt; text-align: justify; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT> </TD>
    <TD STYLE="padding-bottom: 8pt; text-align: left; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by the existing or former director
    (including alternate director), secretary or officer in or about the conduct of our business or affairs or in the execution or discharge
    of the existing or former director (including alternate director), secretary&rsquo;s or officer&rsquo;s duties, powers, authorities
    or discretions; and</FONT> </TD></TR>
  </TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; padding-bottom: 8pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="width: 24px; padding-bottom: 8pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT> </TD>
    <TD STYLE="padding-bottom: 8pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">without
    limitation to paragraph (a) above, all costs, expenses, losses or liabilities incurred by the existing or former director (including
    alternate director), secretary or officer in defending (whether successfully or otherwise) any civil, criminal, administrative or
    investigative proceedings (whether threatened, pending or completed) concerning us or our affairs in any court or tribunal, whether
    in the Cayman Islands or elsewhere.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> No such existing or former
director (including alternate director), secretary or officer, however, shall be indemnified in respect of any matter arising out of
his own dishonesty. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> To the extent permitted
by law, we may make a payment, or agree to make a payment, whether by way of advance, loan or otherwise, for any legal costs incurred
by an existing or former director (including alternate director), secretary or any of our officers in respect of any matter identified
in above on condition that the director (including alternate director), secretary or officer must repay the amount paid by us to the
extent that it is ultimately found not liable to indemnify the director (including alternate director), the secretary or that officer
for those legal costs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"> This standard of conduct
is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation. In addition, we intend to enter
into indemnification agreements with our directors and executive officers that will provide such persons with additional indemnification
beyond that provided in our articles of association. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Anti-Takeover Provisions in Our Articles</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Some provisions of our articles may discourage,
delay or prevent a change in control of our company or management that shareholders may consider favorable, including provisions
that authorize our board of directors to issue shares at such times and on such terms and conditions as the board of directors
may decide without any further vote or action by our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;<I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Cayman Companies Act, our directors may only exercise the
rights and powers granted to them under our articles for what they believe in good faith to be in the best interests of our company and
for a proper purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Directors&rsquo; Fiduciary Duties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under Delaware corporate law, a director
of a Delaware corporation has a fiduciary duty to the corporation and its shareholders. This duty has two components: the duty
of care and the duty of loyalty. The duty of care requires that a director act in good faith, with the care that an ordinarily
prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of, and disclose to
shareholders, all material information reasonably available regarding a significant transaction. The duty of loyalty requires
that a director act in a manner he or she reasonably believes to be in the best interests of the corporation. He or she must not
use his or her corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates
that the best interests of the corporation and its shareholders take precedence over any interest possessed by a director, officer
or controlling shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have
been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the
corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence
be presented concerning a transaction by a director, a director must prove the procedural fairness of the transaction, and that
the transaction was of fair value to the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 31.5pt"> As a matter of Cayman
Islands law, a director owe three types of duties to the company: (i) statutory duties, (ii) fiduciary duties, and (iii) common law duties.
The Cayman Companies Act imposes a number of statutory duties on a director. A Cayman Islands director&rsquo;s fiduciary duties are not
codified, however the courts of the Cayman Islands have held that a director owes the following fiduciary duties (a) a duty to act in
what the director bona fide considers to be in the best interests of the company, (b) a duty to exercise their powers for the purposes
they were conferred, (c) a duty to avoid fettering his or her discretion in the future and (d) a duty to avoid conflicts of interest
and of duty. The common law duties owed by a director are those to act with skill, care and diligence that may reasonably be expected
of a person carrying out the same functions as are carried out by that director in relation to the company and, also, to act with the
skill, care and diligence in keeping with a standard of care commensurate with any particular skill they have which enables them to meet
a higher standard than a director without those skills. In fulfilling their duty of care to us, our directors must ensure compliance
with our articles of association, as amended and restated from time to time. We have the right to seek damages if a duty owed by any
of our directors is breached.&rsquo; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 31.5pt"> Our independent director nominees will also serve as members of
audit committee, compensation committee, and nomination and corporate governance committee of the board upon the effectiveness of the
registration statement and have additional duties under the charters of committees. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Shareholder Proposals</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Delaware General Corporation
Law, a shareholder has the right to put any proposal before the annual meeting of shareholders, provided it complies with the
notice provisions in the governing documents. The Delaware General Corporation Law does not provide shareholders an express right
to put any proposal before the annual meeting of shareholders, but in keeping with common law, Delaware corporations generally
afford shareholders an opportunity to make proposals and nominations provided that they comply with the notice provisions in the
certificate of incorporation or bylaws. A special meeting may be called by the board of directors or any other person authorized
to do so in the governing documents, but shareholders may be precluded from calling special meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Cayman Companies Act provides shareholders
with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal
before a general meeting. However, these rights may be provided in a company&rsquo;s articles of association. Our articles provide
that general meetings shall be convened on the written requisition of one or more of the shareholders entitled to attend and vote
at our general meetings who (together) hold not less than ten per cent of our paid up voting share capital deposited in accordance
with the notice provisions in the articles, specifying the purpose of the meeting and signed by each of the shareholders making
the requisition. If the directors do not convene such meeting for a date not later than twenty-one clear days&rsquo; after the
date of receipt of the written requisition, those shareholders who requested the meeting may convene the general meeting themselves
within three months after the end of such period of twenty-one clear days in which case reasonable expenses incurred by them as
a result of the directors failing to convene a meeting shall be reimbursed by us. Our articles provide no other right to put any
proposals before annual general meetings or extraordinary general meetings. As a Cayman Islands exempted company, we are not obligated
by law to call shareholders&rsquo; annual general meetings. However, our corporate governance guidelines require us to call such
meetings every year.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cumulative Voting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Delaware General Corporation
Law, cumulative voting for elections of directors is not permitted unless the corporation&rsquo;s certificate of incorporation
specifically provides for it. Cumulative voting potentially facilitates the representation of minority shareholders on a board
of directors since it permits the minority shareholder to cast all the votes to which the shareholder is entitled on a single
director, which increases the shareholder&rsquo;s voting power with respect to electing such director. As permitted under the
Cayman Companies Act, our articles do not provide for cumulative voting. As a result, our shareholders are not afforded any less
protections or rights on this issue than shareholders of a Delaware corporation.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Removal of Directors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Under the Delaware General Corporation Law,
a director of a corporation with a classified board may be removed only for cause with the approval of a majority of the outstanding
shares entitled to vote, unless the certificate of incorporation provides otherwise. Subject to the provisions of our articles of association
(which include the removal of a director by ordinary resolution), the office of a director may be terminated forthwith if (a) he is prohibited
by the laws of the Cayman Islands from acting as a director, (b) he is made bankrupt or makes an arrangement or composition with his
creditors generally, (c) he resigns his office by notice to us, (d) he only held office as a director for a fixed term and such term
expires, (e) in the opinion of a registered medical practitioner by whom he is being treated he becomes physically or mentally incapable
of acting as a director, (f) he is given notice by the majority of the other directors (not being less than two in number) to vacate
office (without prejudice to any claim for damages for breach of any agreement relating to the provision of the services of such director),
(g) he is made subject to any law relating to mental health or incompetence, whether by court order or otherwise, or (h) without the
consent of the other directors, he is absent from meetings of directors for continuous period of six months. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Transactions with Interested Shareholders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Delaware General Corporation Law contains
a business combination statute applicable to Delaware public corporations whereby, unless the corporation has specifically elected
not to be governed by such statute by amendment to its certificate of incorporation or bylaws that is approved by its shareholders,
it is prohibited from engaging in certain business combinations with an &ldquo;interested shareholder&rdquo; for three years following
the date that such person becomes an interested shareholder. An interested shareholder generally is a person or a group who or
which owns or owned 15% or more of the target&rsquo;s outstanding voting stock or who or which is an affiliate or associate of
the corporation and owned 15% or more of the corporation&rsquo;s outstanding voting stock within the past three years. This has
the effect of limiting the ability of a potential acquirer to make a two-tiered bid for the target in which all shareholders would
not be treated equally. The statute does not apply if, among other things, prior to the date on which such shareholder becomes
an interested shareholder, the board of directors approves either the business combination or the transaction which resulted in
the person becoming an interested shareholder. This encourages any potential acquirer of a Delaware corporation to negotiate the
terms of any acquisition transaction with the target&rsquo;s board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Cayman Companies Act has no comparable
statute. As a result, we cannot avail ourselves of the types of protections afforded by the Delaware business combination statute.
However, although the Cayman Companies Act does not regulate transactions between a company and its significant shareholders,
under Cayman Islands law such transactions must be entered into bona fide in the best interests of the company and for a proper
corporate purpose and not with the effect of constituting a fraud on the minority shareholders.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Dissolution; Winding Up</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Delaware General Corporation
Law, unless the board of directors approves the proposal to dissolve, dissolution must be approved by shareholders holding 100%
of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved
by a simple majority of the corporation&rsquo;s outstanding shares. Delaware law allows a Delaware corporation to include in its
certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Cayman Companies Act and our
articles, our company may be wound up by a special resolution of our shareholders, or if the winding up is initiated by our board
of directors, by either a special resolution of our members or, if our company is unable to pay its debts as they fall due, by
an ordinary resolution of our members. In addition, a company may be wound up by an order of the courts of the Cayman Islands.
The court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the
court, just and equitable to do so.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Variation of Rights of Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Delaware General Corporation
Law, a corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such
class, unless the certificate of incorporation provides otherwise. Under the Cayman Companies Act and our articles, if our share
capital is divided into more than one class of shares, the rights attaching to any class of share (unless otherwise provided by
the terms of issue of the shares of that class) may be varied with the sanction of a resolution passed by a majority of not less
than two-thirds of the holders of shares of the class present in person or by proxy at a separate general meeting of the holders
of shares of that class.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Amendment of Governing Documents</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Delaware General Corporation
Law, a corporation&rsquo;s certificate of incorporation may be amended only if adopted and declared advisable by the board of
directors and approved by a majority of the outstanding shares entitled to vote, and the bylaws may be amended with the approval
of a majority of the outstanding shares entitled to vote and may, if so provided in the certificate of incorporation, also be
amended by the board of directors. Under the Cayman Companies Act, our articles may only be amended by special resolution of our
shareholders.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-money Laundering&mdash;Cayman Islands</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0">In order to comply with legislation or
regulations aimed at the prevention of money laundering, we may be required to adopt and maintain anti-money laundering procedures,
and may require subscribers to provide evidence to verify their identity. Where permitted, and subject to certain conditions,
we may also delegate the maintenance of our anti-money laundering procedures (including the acquisition of due diligence information)
to a suitable person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We reserve the right to request such information
as is necessary to verify the identity of a subscriber. In the event of delay or failure on the part of the subscriber in producing
any information required for verification purposes, we may refuse to accept the application, in which case any funds received
will be returned without interest to the account from which they were originally debited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also reserve the right to refuse to
make any redemption payment to a shareholder if our directors or officers suspect or are advised that the payment of redemption
proceeds to such shareholder might result in a breach of applicable anti-money laundering or other laws or regulations by any
person in any relevant jurisdiction, or if such refusal is considered necessary or appropriate to ensure our compliance with any
such laws or regulations in any applicable jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If any person resident in the Cayman Islands
knows or suspects or has reason for knowing or suspecting that another person is engaged in criminal conduct or is involved with
terrorism or terrorist property and the information for that knowledge or suspicion came to their attention in the course of their
business in the regulated sector, or other trade, profession, business or employment, the person will be required to report such
knowledge or suspicion to (i) a nominated officer (appointed in accordance with the Proceeds of Crime Act (Revised) of the Cayman
Islands) or the Financial Reporting Authority of the Cayman Islands, pursuant to the Proceeds of Crime Act (Revised), if the disclosure
relates to criminal conduct or money laundering or (ii) to a police constable or a nominated officer (pursuant to the Terrorism
Act (Revised) of the Cayman Islands) or the Financial Reporting Authority, pursuant to the Terrorism Act (Revised), if the disclosure
relates to involvement with terrorism or terrorist financing and terrorist property. Such a report shall not be treated as a breach
of confidence or of any restriction upon the disclosure of information imposed by any enactment or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Data Protection in the Cayman Islands &ndash; Privacy Notice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> This privacy notice explains the manner in which
the Company collects, processes and maintains personal data about investors of the Company pursuant to the Data Protection Act (Revised)
of the Cayman Islands, as amended from time to time and any regulations, codes of practice or orders promulgated pursuant thereto (DPA). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> The Company is committed to processing personal
data in accordance with the DPA. In its use of personal data, the Company will be characterized under the DPA as a &lsquo;data controller&rsquo;,
whilst certain of the Company&rsquo;s service providers, affiliates and delegates may act as &lsquo;data processors&rsquo; under the
DPA. These service providers may process personal information for their own lawful purposes in connection with services provided to the
Company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">By virtue of making an investment in the
Company, the Company and certain of the Company&rsquo;s service providers may collect, record, store, transfer and otherwise process
personal data by which individuals may be directly or indirectly identified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Your personal data will be processed fairly
and for lawful purposes, including (a) where the processing is necessary for the Company to perform a contract to which you are
a party or for taking pre-contractual steps at your request (b) where the processing is necessary for compliance with any legal,
tax or regulatory obligation to which the Company is subject or (c) where the processing is for the purposes of legitimate interests
pursued by the Company or by a service provider to whom the data are disclosed. As a data controller, we will only use your personal
data for the purposes for which we collected it. If we need to use your personal data for an unrelated purpose, we will contact
you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We anticipate that we will share your personal
data with the Company&rsquo;s service providers for the purposes set out in this privacy notice. We may also share relevant personal
data where it is lawful to do so and necessary to comply with our contractual obligations or your instructions or where it is
necessary or desirable to do so in connection with any regulatory reporting obligations. In exceptional circumstances, we will
share your personal data with regulatory, prosecuting and other governmental agencies or departments, and parties to litigation
(whether pending or threatened), in any country or territory including to any other person where we have a public or legal duty
to do so (e.g. to assist with detecting and preventing fraud, tax evasion and financial crime or compliance with a court order).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Your personal data shall not be held by
the Company for longer than necessary with regard to the purposes of the data processing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> We will not sell your personal data. Any transfer
of personal data outside of the Cayman Islands shall be in accordance with the requirements of the DPA. Where necessary, we will ensure
that separate and appropriate legal agreements are put in place with the recipient of that data. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> The Company will only transfer personal data
in accordance with the requirements of the DPA, and will apply appropriate technical and organizational information security measures
designed to protect against unauthorized or unlawful processing of the personal data and against the accidental loss, destruction or
damage to the personal data. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> If you are a natural person, this will affect
you directly. If you are a corporate investor (including, for these purposes, legal arrangements such as trusts or exempted limited partnerships)
that provides us with personal data on individuals connected to you for any reason in relation to your investment into the Company, this
will be relevant for those individuals and you should inform such individuals of the content. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> You have certain rights under the DPA, including
(a) the right to be informed as to how we collect and use your personal data (and this privacy notice fulfils the Company&rsquo;s obligation
in this respect) (b) the right to obtain a copy of your personal data (c) the right to require us to stop direct marketing (d) the right
to have inaccurate or incomplete personal data correct (e) the right to withdraw your consent and require us to stop processing or restrict
the processing, or not begin the processing of your personal data (f) the right to be notified of a data breach (unless the breach is
unlikely to be prejudicial) (g) the right to obtain information as to any countries or territories outside the Cayman Islands to which
we, whether directly or indirectly, transfer, intend to transfer or wish to transfer your personal data, general measures we take to
ensure the security of personal data and any information available to us as to the source of your personal data (h) the right to complain
to the Office of the Ombudsman of the Cayman Islands and (i) the right to require us to delete your personal data in some limited circumstances. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you consider that your personal data
has not been handled correctly, or you are not satisfied with the Company&rsquo;s responses to any requests you have made regarding
the use of your personal data, you have the right to complain to the Cayman Islands&rsquo; Ombudsman. The Ombudsman can be contacted
by calling +1 (345) 946-6283 or by email at info@ombudsman.ky.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_019"></A><B>SHARES
ELIGIBLE FOR FUTURE SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Before our initial public offering, there has
not been a public market for our Ordinary Shares, and while application has been made for the Ordinary Shares to be listed on the Nasdaq,
a regular trading market for our Ordinary Shares may not develop. Future sales of substantial amounts of our Ordinary Shares in the public
market after our initial public offering, or the possibility of these sales occurring, could cause the prevailing market price for our
Ordinary Shares to fall or impair our ability to raise equity capital in the future. Upon the closing of the offering, we will have 12,642,105
issued and outstanding Ordinary Shares, excluding any exercise of the underwriter&rsquo;s over-allotment option and including the 342,105
Ordinary Shares issuable upon the automatic conversion of the Note, at the same price of the offering price $9.50 per share, the midpoint
of the price range set forth on the cover page of the prospectus. Of that amount, 2,300,000 Ordinary Shares will be publicly held by
investors participating in this offering, and 10,342,105 Ordinary Shares will be held by our existing shareholder, who may be our &ldquo;affiliates&rdquo;
as that term is defined in Rule 144 under the Securities Act. All of the Ordinary Shares sold in this offering will be freely transferable
by persons other than our &ldquo;affiliates&rdquo; without restriction or further registration under the Securities Act. </P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lock-up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our shareholders who own more than 3% of
our shares have agreed that we will not offer, pledge, sell, contract to sell, grant any option, right or warrant to purchase,
sell any option or contract to purchase, purchase any option or contract to sell, lend, or otherwise transfer or dispose of (including
entering into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequence of
ownership interests), directly or indirectly, any of our Ordinary Shares or any securities that are convertible into or exercisable
or exchangeable for our Ordinary Shares, or file any registration statement with the SEC relating to the offering of any Ordinary
Shares or any securities convertible into or exercisable or exchangeable for Ordinary Shares without the prior written consent
of the underwriter for a period ending 180 days after the commencement of sales of the offering, except issuances pursuant to
the exercise of employee share options outstanding on the date hereof and certain other exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each of our directors, officers and existing beneficial owners of
3% or more of our issued and outstanding Ordinary Shares has agreed, subject to some exceptions, not to offer, pledge, sell, contract
to sell, grant, lend or otherwise transfer or dispose of (including entering into any swap or other arrangement that transfers
to another, in whole or in part, any of the economic consequence of ownership interests), directly or indirectly, any of our Ordinary
Shares or any securities convertible into or exercisable or exchangeable for Ordinary Shares or make any demand for or exercise
any right with respect to, the registration of any Ordinary Shares or any security convertible into or exercisable or exchangeable
for Ordinary Shares, without the prior written consent of the underwriter for a period ending 180 days after the IPO is completed.
After the expiration of the 180-day period, Ordinary Shares held by directors, officers, and existing beneficial owners of 3% or
more of our issued and outstanding Ordinary Shares may be sold subject to the restrictions under Rule 144 under the Securities
Act or by means of registered public offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Rule 144</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All of our Ordinary Shares issued and outstanding
prior to this offering are &ldquo;restricted securities&rdquo; as that term is defined in Rule 144 under the Securities Act and
may be sold publicly in the United States only if they are subject to an effective registration statement under the Securities
Act or pursuant to an exemption from the registration requirement such as those provided by Rule 144 and Rule 701 promulgated
under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In general, under Rule 144 as currently
in effect, beginning 90 days after the date of this prospectus, a person who is not deemed to have been our affiliate at any time
during the three months preceding a sale and who has beneficially owned restricted securities within the meaning of Rule 144 for
more than six months would be entitled to sell an unlimited number of those shares, subject only to the availability of current
public information about us. A non-affiliate who has beneficially owned restricted securities for at least one year from the later
of the date these shares were acquired from us or from our affiliate would be entitled to freely sell those shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A person who is deemed to be an affiliate
of ours and who has beneficially owned &ldquo;restricted securities&rdquo; for at least six months would be entitled to sell,
within any three-month period, a number of shares that is not more than the greater of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1% of the number of Ordinary Shares then outstanding,
    in the form of Ordinary Shares or otherwise, which will equal approximately shares immediately after this offering; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         average weekly trading volume of the Ordinary Shares on the Nasdaq Capital Market during
                                         the four calendar weeks preceding the filing of a notice on Form 144 with respect to
                                         such sale.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Sales under Rule 144 by our affiliates
or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements
and to the availability of current public information about us. In addition, in each case, these shares would remain subject to
lock-up arrangements and would only become eligible for sale when the lock-up period expires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_020"></A><B>TAXATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Material U.S. Federal Income Tax Consequences Applicable
to U.S. Holders of Our Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The following sets
forth the material U.S. federal income tax consequences related to an investment in our Ordinary Shares and is the opinion of tax
counsel, Giancarlo A. Messina, Esq. LL.M. It is directed to U.S. Holders (as defined below) of our Ordinary Shares and is based
upon laws and relevant interpretations thereof in effect as of the date of this prospectus, all of which are subject to change.
This description does not deal with all possible tax consequences relating to an investment in our Ordinary Shares or U.S. tax
laws, other than the U.S. federal income tax laws, such as the tax consequences under non-U.S. tax laws, state, local and other
tax laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
following brief description applies only to U.S. Holders (defined below) that hold Ordinary Shares as capital assets and that
have the U.S. dollar as their functional currency. This brief description is based on the federal income tax laws of the United
States in effect as of the date of this prospectus and on U.S. Treasury regulations in effect or, in some cases, proposed, as
of the date of this prospectus, as well as judicial and administrative interpretations thereof available on or before such date.
All of the foregoing authorities are subject to change, which change could apply retroactively and could affect the tax consequences
described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
brief description below of the U.S. federal income tax consequences to &ldquo;U.S. Holders&rdquo; will apply to you if you are
a beneficial owner of Ordinary Shares and you are, for U.S. federal income tax purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual who is
    a citizen or resident of the United States;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a corporation (or other
    entity taxable as a corporation for U.S. federal income tax purposes) organized under the laws of the United States, any state
    thereof or the District of Columbia;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate whose income
    is subject to U.S. federal income taxation regardless of its source; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust that (1) is
    subject to the primary supervision of a court within the United States and the control of one or more U.S. persons for all
    substantial decisions or (2) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a
    U.S. person.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If a partnership (or other entity treated
as a partnership for United States federal income tax purposes) is a beneficial owner of our Ordinary Shares, the tax treatment
of a partner in the partnership will depend upon the status of the partner and the activities of the partnership. Partnerships
and partners of a partnership holding our Ordinary Shares are urged to consult their tax advisors regarding an investment in our
Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">WE
URGE POTENTIAL PURCHASERS OF OUR ORDINARY SHARES TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE U.S. FEDERAL, STATE, LOCAL AND
NON-U.S. TAX CONSEQUENCES OF PURCHASING, OWNING AND DISPOSING OF OUR ORDINARY SHARES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
following does not address the tax consequences to any particular investor or to persons in special tax situations such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial institutions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurance companies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulated investment
    companies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">real estate investment
    trusts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">broker-dealers;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">traders that elect
    to mark-to-market;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. expatriates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt entities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons liable for
    alternative minimum tax;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our
    Ordinary Shares as part of a straddle, hedging, conversion or integrated transaction;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that actually
    or constructively own 10% or more of our voting shares (including by reason of owning our Ordinary Shares);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons who acquired
    our Ordinary Shares pursuant to the exercise of any employee share option or otherwise as compensation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our
    Ordinary Shares through partnerships or other pass-through entities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">events, hip-hop, and
    marketing industries investment trusts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">governments or agencies
    or instrumentalities thereof;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">beneficiaries of a
    Trust holding our Ordinary Shares; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our
    Ordinary Shares through a trust.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
discussion set forth below is addressed only to U.S. Holders that purchase Ordinary Shares in this offering. Prospective purchasers
are urged to consult their own tax advisors about the application of the U.S. federal income tax rules to their particular circumstances
as well as the state, local, foreign and other tax consequences to them of the purchase, ownership and disposition of our Ordinary
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Taxation of Dividends and Other Distributions on our Ordinary
Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">Subject
to the passive foreign investment company rules discussed below, the gross amount of distributions made by us to you with respect
to the Ordinary Shares (including the amount of any taxes withheld therefrom) will generally be includable in your gross income
as dividend income on the date of receipt by you, but only to the extent that the distribution is paid out of our current or accumulated
earnings and profits (as determined under U.S. federal income tax principles). With respect to corporate U.S. Holders, the dividends
will not be eligible for the dividends-received deduction allowed to corporations in respect of dividends received from other
U.S. corporations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">With
respect to non-corporate U.S. Holders, including individual U.S. Holders, dividends will be taxed at the lower capital gains rate
applicable to qualified dividend income, provided that (1) the Ordinary Shares are readily tradable on an established securities
market in the United States, or we are eligible for the benefits of an approved qualifying income tax treaty with the United States
that includes an exchange of information program, (2) we are not a PFIC for either our taxable year in which the dividend is paid
or the preceding taxable year, and (3) certain holding period requirements are met. Because there is no income tax treaty between
the United States and the Cayman Islands, clause (1) above can be satisfied only if the Ordinary Shares are readily tradable on
an established securities market in the United States. Under U.S. Internal Revenue Service authority, Ordinary Shares are considered
for purpose of clause (1) above to be readily tradable on an established securities market in the United States if they are listed
on the OTCQB Market. You are urged to consult your tax advisors regarding the availability of the lower rate for dividends paid
with respect to our Ordinary Shares, including the effects of any change in law after the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">Dividends
will constitute foreign source income for foreign tax credit limitation purposes. If the dividends are taxed as qualified dividend
income (as discussed above), the amount of the dividend considered for purposes of calculating the foreign tax credit limitation
will be limited to the gross amount of the dividend, multiplied by the reduced rate divided by the highest rate of tax normally
applicable to dividends. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific
classes of income. For this purpose, dividends distributed by us with respect to our Ordinary Shares will constitute &ldquo;passive
category income&rdquo; but could, in the case of certain U.S. Holders, constitute &ldquo;general category income.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">To
the extent that the amount of the distribution exceeds our current and accumulated earnings and profits (as determined under U.S.
federal income tax principles), it will be treated first as a tax-free return of your tax basis in your Ordinary Shares, and to
the extent the amount of the distribution exceeds your tax basis, the excess will be taxed as capital gain. We do not intend to
calculate our earnings and profits under U.S. federal income tax principles. Therefore, a U.S. Holder should expect that a distribution
will be treated as a dividend even if that distribution would otherwise be treated as a non-taxable return of capital or as capital
gain under the rules described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Taxation of Dispositions of Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Subject to the
passive foreign investment company rules discussed below, you will recognize taxable gain or loss on any sale, exchange or other
taxable disposition of a share equal to the difference between the amount realized (in U.S. dollars) for the share and your tax
basis (in U.S. dollars) in the Ordinary Shares. The gain or loss will be capital gain or loss. If you are a non-corporate U.S.
Holder, including an individual U.S. Holder, who has held the Ordinary Shares for more than one year, you will be eligible for
reduced tax rates. The deductibility of capital losses is subject to limitations. Any such gain or loss that you recognize will
generally be treated as United States source income or loss for foreign tax credit limitation purposes which will generally limit
the availability of foreign tax credits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Information Reporting and Backup Withholding</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Dividend payments
with respect to our Ordinary Shares and proceeds from the sale, exchange or redemption of our Ordinary Shares may be subject to
information reporting to the U.S. Internal Revenue Service and U.S. backup withholding at a current rate of 24% if an individual
investor does not provide any documentation to the issuer of a U.S. security (or to a broker who holds the security in a custody
account for the individual) so as to identify whether he/she is a U.S. person or a nonresident alien. Backup withholding, under
section 3406, will not apply, however, to a U.S. Holder who furnishes a correct taxpayer identification number and makes any other
required certification on U.S. Internal Revenue Service Form W-9 or who is otherwise exempt from backup withholding. U.S. Holders
who are required to establish their exempt status generally must provide such certification on U.S. Internal Revenue Service Form
W-9. U.S. Holders are urged to consult their tax advisors regarding the application of the U.S. information reporting and backup
withholding rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Backup withholding
is not an additional tax. Amounts withheld as backup withholding may, at taxpayer&rsquo;s discretion, be credited against your
U.S. federal income tax liability, and you may obtain a refund of any excess amounts withheld under the backup withholding rules
by filing the appropriate claim for refund with the U.S. Internal Revenue Service and furnishing any required information. We do
not intend to withhold taxes for individual shareholders. However, transactions effected through certain brokers or other intermediaries
may be subject to withholding taxes (including backup withholding), and such brokers or intermediaries may be required by law to
withhold such taxes. This depends on each broker and their operations, and tax counsel rendering this opinion is not in a place
of authority or knowledge to be able to speak to or opine regarding the operations of those brokers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">Under
the Hiring Incentives to Restore Employment Act of 2010, certain U.S. Holders are required to report information relating to our
Ordinary Shares, subject to certain exceptions (including an exception for Ordinary Shares held in accounts maintained by certain
financial institutions), by attaching a complete Internal Revenue Service Form 8938, Statement of Specified Foreign Financial
Assets, with their tax return for each year in which they hold Ordinary Shares. Failure to report the information could result
in substantial penalties. You should consult your own tax advisor regarding your obligation to file Form 8938.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Passive Foreign Investment Company (&ldquo;PFIC&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Based on our current
and anticipated operations and the composition of our assets, in the opinion of counsel, it is very highly unlikely that we were
a passive foreign investment company, or PFIC, for U.S. federal income tax purposes for the taxable year ended June 30, 2020. While
highly unlikely, there is the outside possibility under Notice 88-22 that certain assets that could have easily been converted
to cash, even if that cash is working capital for an active business, could have been characterized as passive assets, however
for many purposes of the code, cash is treated as a business asset to the extent it is held as working capital to be devoted to
business (e.g., regulations under &sect;&sect;864(c) and 897(c), vic. Treas. Reg. &sect;1-864-4(c)(2)). Depending on the amount
of cash we raise in this offering, together with any other assets held for the production of passive income, it is possible that,
for our taxable year ending June 30, 2021 or for any subsequent year, more than 50% of our assets may be assets which produce passive
income, in which case we would be deemed a PFIC, which could have adverse US federal income tax consequences for US taxpayers who
are shareholders. We will make this determination following the end of any particular tax year. PFIC status is a factual determination
for each taxable year which cannot be made until the close of the taxable year. A non-U.S. corporation is considered a PFIC, as
defined in section 297(a) of the US Internal Revenue Code, for any taxable year if either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least 75% of its
    gross income is passive income; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least 50% of the
    value of its assets (based on an average of the quarterly values of the assets during a taxable year) is attributable to assets
    that produce or are held for the production of passive income (the &ldquo;asset test&rdquo;).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">We
will be treated as owning our proportionate share of the assets and earning our proportionate share of income of any other corporation
in which we own, directly or indirectly, at least 25% (by value) of the stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We must make a separate
determination each year as to whether we are a PFIC, however, and there can be no assurance with respect to our status as a PFIC
for our current taxable year or any future taxable year. Depending on the amount of cash we raise in this offering, together with
any other assets held for the production of passive income, it is possible that, for our current taxable year or for any subsequent
taxable year, more than 50% of our assets may be assets held for the production of passive income. We will make this determination
following the end of any particular tax year. In addition, because the value of our assets for purposes of the asset test will
generally be determined based on the market price of our Ordinary Shares and because cash is generally considered to be an asset
held for the production of passive income, our PFIC status will depend in large part on the market price of our Ordinary Shares
and the amount of cash we raise in this offering. Accordingly, fluctuations in the market price of the Ordinary Shares may cause
us to become a PFIC. In addition, the application of the PFIC rules is subject to uncertainty in several respects and the composition
of our income and assets will be affected by how, and how quickly, we spend the cash we raise in this offering. We are under no
obligation to take steps to reduce the risk of our being classified as a PFIC, and as stated above, the determination of the value
of our assets will depend upon material facts (including the market price of our Ordinary Shares from time to time and the amount
of cash we raise in this offering) that may not be within our control. If we are a PFIC for any year during which you hold Ordinary
Shares, we will continue to be treated as a PFIC for all succeeding years during which you hold Ordinary Shares. If we cease to
be a PFIC and you did not previously make a timely &ldquo;mark-to-market&rdquo; election as described below, however, you may
avoid some of the adverse effects of the PFIC regime by making a &ldquo;purging election&rdquo; (as described below) with respect
to the Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">If
we are a PFIC for any taxable year during which you hold Ordinary Shares, you will be subject to special tax rules with respect
to any &ldquo;excess distribution&rdquo; that you receive and any gain you realize from a sale or other disposition (including
a pledge) of the Ordinary Shares, unless you make a &ldquo;mark-to-market&rdquo; election as discussed below. Distributions you
receive in a taxable year that are greater than 125% of the average annual distributions you received during the shorter of the
three preceding taxable years or your holding period for the Ordinary Shares will be treated as an excess distribution. Under
these special tax rules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the excess distribution
    or gain will be allocated ratably over your holding period for the Ordinary Shares;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated
    to the current taxable year, and any taxable year prior to the first taxable year in which we were a PFIC, will be treated
    as ordinary income, and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated
    to each other year will be subject to the highest tax rate in effect for that year and the interest charge generally applicable
    to underpayments of tax will be imposed on the resulting tax attributable to each such year.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
tax liability for amounts allocated to years prior to the year of disposition or &ldquo;excess distribution&rdquo; cannot be offset
by any net operating losses for such years, and gains (but not losses) realized on the sale of the Ordinary Shares cannot be treated
as capital, even if you hold the Ordinary Shares as capital assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">A
U.S. Holder of &ldquo;marketable stock&rdquo; (as defined below) in a PFIC may make a mark-to-market election for such stock to
elect out of the tax treatment discussed above. If you make a mark-to-market election for the Ordinary Shares, you will include
in income each year an amount equal to the excess, if any, of the fair market value of the Ordinary Shares as of the close of
your taxable year over your adjusted basis in such Ordinary Shares. You are allowed a deduction for the excess, if any, of the
adjusted basis of the Ordinary Shares over their fair market value as of the close of the taxable year. However, deductions are
allowable only to the extent of any net mark-to-market gains on the Ordinary Shares included in your income for prior taxable
years. Amounts included in your income under a mark-to-market election, as well as gain on the actual sale or other disposition
of the Ordinary Shares, are treated as ordinary income. Ordinary loss treatment also applies to the deductible portion of any
mark-to-market loss on the Ordinary Shares, as well as to any loss realized on the actual sale or disposition of the Ordinary
Shares, to the extent that the amount of such loss does not exceed the net mark-to-market gains previously included for such Ordinary
Shares. Your basis in the Ordinary Shares will be adjusted to reflect any such income or loss amounts. If you make a valid mark-to-market
election, the tax rules that apply to distributions by corporations which are not PFICs would apply to distributions by us, except
that the lower applicable capital gains rate for qualified dividend income discussed above under &ldquo;&mdash; Taxation of Dividends
and Other Distributions on our Ordinary Shares&rdquo; generally would not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
mark-to-market election is available only for &ldquo;marketable stock&rdquo;, which is stock that is traded in other than de minimis
quantities on at least 15 days during each calendar quarter (&ldquo;regularly traded&rdquo;) on a qualified exchange or other
market (as defined in applicable U.S. Treasury regulations), including the Nasdaq Capital Market. If the Ordinary Shares are regularly
traded on the Nasdaq Capital Market and if you are a holder of Ordinary Shares, the mark-to-market election would be available
to you were we to be or become a PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">Alternatively,
a U.S. Holder of stock in a PFIC may, at taxpayer&rsquo;s discretion, make a &ldquo;qualified electing fund&rdquo; election with
respect to such PFIC to elect out of the tax treatment discussed above. A U.S. Holder who makes a valid qualified electing fund
election with respect to a PFIC will generally include in gross income for a taxable year such holder&rsquo;s pro rata share of
the corporation&rsquo;s earnings and profits for the taxable year. However, the qualified electing fund election is available only
if such PFIC provides such U.S. Holder with certain information regarding its earnings and profits as required under applicable
U.S. Treasury regulations. We do not currently intend to prepare or provide the information that would enable you to make a qualified
electing fund election. If you hold Ordinary Shares in any year in which we are a PFIC, you will be required to file U.S. Internal
Revenue Service Form 8621 regarding distributions received on the Ordinary Shares and any gain realized on the disposition of the
Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If you do not make a
timely &ldquo;mark-to-market&rdquo; election (as described above), and if we were a PFIC at any time during the period you hold
our Ordinary Shares, then such Ordinary Shares will continue to be treated as stock of a PFIC with respect to you even if we cease
to be a PFIC in a future year, unless you make a &ldquo;purging election&rdquo; for the year we cease to be a PFIC. A &ldquo;purging
election&rdquo; creates a deemed sale of such Ordinary Shares at their fair market value on the last day of the last year in which
we are treated as a PFIC. The gain recognized by the purging election will be subject to the special tax and interest charge rules
treating the gain as an excess distribution, as described above. As a result of the purging election, you will have a new basis
(equal to the fair market value of the Ordinary Shares on the last day of the last year in which we are treated as a PFIC) and
holding period (which new holding period will begin the day after such last day) in your Ordinary Shares for tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">IRC Section 1014(a) provides for a step-up
in basis to the fair market value for our Ordinary Shares when inherited from a decedent that was previously a holder of our Ordinary
Shares. However, if we are determined to be a PFIC and a decedent that was a U.S. Holder did not make either a timely qualified
electing fund election for our first taxable year as a PFIC in which the U.S. Holder held (or was deemed to hold) our Ordinary
Shares, or a mark-to-market election and ownership of those Ordinary Shares are inherited, a special provision in IRC Section 1291(e)
provides that the new U.S. Holder&rsquo;s basis should be reduced by an amount equal to the Section 1014 basis minus the decedent&rsquo;s
adjusted basis just before death. As such if we are determined to be a PFIC at any time prior to a decedent&rsquo;s passing, the
PFIC rules will cause any new U.S. Holder that inherits our Ordinary Shares from a U.S. Holder to not get a step-up in basis under
Section 1014 and instead will receive a carryover basis in those Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">You
are urged to consult your tax advisors regarding the application of the PFIC rules to your investment in our Ordinary Shares and
the elections discussed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U STYLE="text-decoration: none">&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>Hong Kong Profits Taxation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our subsidiaries incorporated in Hong Kong
were subject to 16.5% Hong Kong profits tax on their taxable income assessable profits generated from operations arising in or
derived from Hong Kong for the year of assessment of 2017/2018 and 2018/2019. As from year of assessment of 2019/2020 onwards,
Hong Kong profits tax rates are 8.25% on assessable profits up to HK$2,000,000, and 16.5% on any part of assessable profits over
HK$2,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Under Hong Kong
tax laws, our Hong Kong subsidiaries are exempted from Hong Kong income profits tax on its foreign-derived income profits. In addition,
payments of dividends from our Hong Kong subsidiary to us are not subject to any withholding tax in Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cayman Islands Taxation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"> The following is a discussion
on certain Cayman Islands income tax consequences of an investment in the Ordinary Shares. The discussion is a general summary of the
present law, which is subject to prospective and retroactive change. It is not intended as tax advice, does not consider any investor&rsquo;s
particular circumstances, and does not consider tax consequences other than those arising under Cayman Islands law. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Cayman Islands currently levies no
taxes on individuals or corporations based upon profits, income, gains or appreciation and there is no taxation in the nature
of inheritance tax or estate duty. There are no other taxes likely to be material to our company levied by the Government of the
Cayman Islands except for stamp duties which may be applicable on instruments executed in, or after execution brought within the
jurisdiction of the Cayman Islands. No stamp duty is payable in the Cayman Islands on the issue of shares by, or any transfers
of shares of, Cayman Islands companies (except those which hold interests in land in the Cayman Islands). The Cayman Islands is
not party to any double tax treaties that are applicable to any payments made to or by our company. The Cayman Islands is not
a party to any double tax treaties that are applicable to any payments made to us or by the Company. There are no exchange control
regulations or currency restrictions in the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Payments of dividends and capital in respect
of our Ordinary Shares will not be subject to taxation in the Cayman Islands and no withholding will be required on the payment
of a dividend or capital to any holder of our Ordinary Shares, as the case may be, nor will gains derived from the disposal of
our Ordinary Shares be subject to Cayman Islands income or corporation tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_021"></A><B>UNDERWRITING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are offering our Ordinary Shares described
in this prospectus through the underwriter named below. Maxim Group LLC, or Maxim, is acting as representative of the underwriter.
We have entered into an underwriting agreement with the underwriter. Subject to the terms and conditions of the underwriting agreement,
the underwriter has agreed to purchase, and we have agreed to sell to the underwriter, the number of Ordinary Shares listed next
to its name in the following table.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt"><B>Underwriter</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Number<BR>
    of&nbsp;Shares</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 88%; padding-left: 12pt; text-indent: -12pt"> <FONT STYLE="font-size: 10pt">Maxim Group LLC</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">2,300,000&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0.25in"> <FONT STYLE="font-size: 10pt">Total</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">2,300,000&nbsp;</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The underwriting agreement provides that
the underwriter must buy all of the Ordinary Shares being sold in this offering if they buy any of them. However, the underwriter
is not required to take or pay for the Ordinary Shares covered by the underwriter&rsquo;s option to purchase additional Ordinary
Shares as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Ordinary Shares are offered subject
to a number of conditions, including:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt and acceptance of our Ordinary Shares
    by the underwriter; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the underwriter&rsquo;s right to reject orders
    in whole or in part.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have been advised by Maxim that the underwriter
intends to make a market in our Ordinary Shares but that it is not obligated to do so and may discontinue making a market at any
time without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with this offering, the underwriter
or securities dealers may distribute prospectuses electronically.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Option to Purchase Additional Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have granted the underwriter an option to
buy up to an aggregate of 345,000&nbsp;additional Ordinary Shares. The underwriter has 45 days from the date of this prospectus to exercise
this option. If the underwriter exercises this option, it will purchase additional Ordinary Shares approximately in proportion to the
amounts specified in the table above. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Underwriting Discount</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Shares sold by the underwriter to the public
will initially be offered at the initial offering price set forth on the cover of this prospectus. Any shares sold by the underwriter
to securities dealers may be sold at a discount of up to $0.7125&nbsp;per share from the initial public offering price. The underwriter
may offer the shares through one or more of their affiliates or selling agents. If all the shares are not sold at the initial public
offering price, Maxim may change the offering price and the other selling terms. Upon execution of the underwriting agreement, the underwriter
will be obligated to purchase the shares at the prices and upon the terms stated therein. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The following table shows the per share and
total underwriting discount we will pay to the underwriter assuming both no exercise and full exercise of the underwriter&rsquo;s option
to purchase up to 345,000&nbsp;additional Ordinary Shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
    Share</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    without<BR>
    Over-Allotment<BR>
    Option</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    with<BR>
    Over-Allotment<BR>
    Option</B></FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 67%; padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    offering price</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 8%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 8%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 8%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    discounts and commissions (7.5%)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds,
    before expenses to us</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have agreed to pay Maxim&rsquo;s out-of-pocket
accountable expenses, including Maxim&rsquo;s legal fees, up to a maximum amount of $200,000 if this offering is completed. We
have paid $25,000 to Maxim as an advance to be applied towards reasonable out-of-pocket expenses, or the Advance. Any portion
of the Advance shall be returned back to us to the extent not actually incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We estimate that the total expenses of the
offering payable by us, not including the underwriting discount, will be approximately $0.9 million. We have also agreed to reimburse
the underwriter for certain expenses incurred by them. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Representative&rsquo;s Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have also agreed to issue to Maxim (or
its permitted assignees) warrants to purchase a number of our shares equal to an aggregate of 2.5% of the total number of Ordinary
Shares sold in this offering, or the Representative&rsquo;s Warrants. The Representative&rsquo;s Warrants will have an exercise
price equal to 110% of the offering price of the Ordinary Shares sold in this offering and may be exercised on a cashless basis.
The Representative&rsquo;s Warrants are exercisable commencing six months after the effective date of the registration statement
related to this offering, and will expire five years after the effective date of such registration statement. The Representative&rsquo;s
Warrants are not redeemable by us. We have agreed to a one-time demand registration of the Ordinary Shares underlying the Representative&rsquo;s
Warrants at our expense and an additional demand registration at the holders&rsquo; expense for a period of five years from the
effective date of the registration statement related to this offering. The Representative&rsquo;s Warrants also provide for unlimited
&ldquo;piggyback&rdquo; registration rights at our expense with respect to the underlying Ordinary Shares during the five-year
period commencing from the effective date of the registration statement related to this offering. The Representative&rsquo;s Warrants
and the Ordinary Shares underlying the Representative&rsquo;s Warrants, have been deemed compensation by the Financial Industry
Regulatory Authority, or FINRA, and are therefore subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA. The underwriter
(or permitted assignees under the Rule) may not sell, transfer, assign, pledge or hypothecate the Representative&rsquo;s Warrants
or the securities underlying the Representative&rsquo;s Warrants, nor will they engage in any hedging, short sale, derivative,
put or call transaction that would result in the effective economic disposition of the Representative&rsquo;s Warrants or the underlying
securities for a period of six months from the effective date of this offering, except to any FINRA member participating in the
offering and their bona fide officers or partners. The Representative&rsquo;s Warrants will provide for adjustment in the number
and price of such Representative&rsquo;s Warrants (and the Ordinary Shares underlying such Representative&rsquo;s Warrants) to
prevent dilution in the event of a forward or reverse stock split, stock dividend or similar recapitalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Right of First Refusal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have agreed to grant Maxim, for the
nine-month period following the effective date of the registration statement related to this offering, a right of first refusal
to act as lead left book runner and lead left manager and/or lead left placement agent, with at least 50.0% of the economics for
a two handed deal and 33.3% of the economics for a three handed deal, for any and all future public and private equity, convertible
or debt offerings of the Company&rsquo;s securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Lock-Up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We and our directors, officers any other
holder(s) of three percent (3.0%) or more of our outstanding ordinary share as of the effective date of the Registration Statement
(and all holders of securities exercisable for or convertible into shares of ordinary share) shall enter into customary &ldquo;lock-up&rdquo;
agreements in favor of Maxim pursuant to which such persons and entities shall agree, for a period of one hundred and eighty days
(180) after the IPO is completed, that they shall neither offer, issue, sell, contract to sell, encumber, grant any option for
the sale of or otherwise dispose of any securities of the Company without Maxim&rsquo;s prior written consent, including the issuance
of shares of Ordinary Share upon the exercise of currently outstanding options approved by Maxim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have agreed to indemnify the underwriter
against certain liabilities, including certain liabilities under the Securities Act. If we are unable to provide this indemnification,
we have agreed to contribute to payments the underwriter may be required to make in respect of those liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.45pt"><B>Other Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The underwriter and its affiliates have
engaged in, and may in the future engage in, investment banking and other commercial dealings in the ordinary course of business
with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>No Public Market</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to this offering, there has not been
a public market for our securities in the U.S. and the public offering price for our Ordinary Shares will be determined through
negotiations between us and the underwriter. Among the factors to be considered in these negotiations will be prevailing market
conditions, our financial information, market valuations of other companies that we and the underwriter believe to be comparable
to us, estimates of our business potential, the present state of our development and other factors deemed relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We offer no assurances that the initial
public offering price will correspond to the price at which our Ordinary Shares will trade in the public market subsequent to this
offering or that an active trading market for our Ordinary Shares will develop and continue after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stock Exchange</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have applied to list our Ordinary Shares
on the Nasdaq Capital Market under the symbol &ldquo;RGC.&rdquo; There can be no assurance that we will be successful in listing our
Ordinary Shares on the Nasdaq Capital Market. </P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Electronic Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A prospectus in electronic format may be
made available on websites or through other online services maintained by the underwriter of this offering, or by their affiliates.
Other than the prospectus in electronic format, the information on any underwriter&rsquo;s website and any information contained
in any other website maintained by an underwriter is not part of this prospectus or the registration statement of which this prospectus
forms a part, has not been approved and/or endorsed by us or any underwriter in its capacity as underwriter, and should not be
relied upon by investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Price Stabilization, Short Positions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with this offering, the underwriter
may engage in activities that stabilize, maintain or otherwise affect the price of our Ordinary Shares during and after this offering,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">stabilizing transactions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">short sales;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases to cover positions created by short
    sales;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition of penalty bids; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">syndicate covering transactions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Stabilizing transactions consist of bids or purchases made for
the purpose of preventing or retarding a decline in the market price of our Ordinary Shares while this offering is in progress.
Stabilization transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified
maximum. These transactions may also include making short sales of our Ordinary Shares, which involve the sale by the underwriter
of a greater number of Ordinary Shares than they are required to purchase in this offering and purchasing Ordinary Shares on the
open market to cover short positions created by short sales. Short sales may be &ldquo;covered short sales,&rdquo; which are short
positions in an amount not greater than the underwriter&rsquo;s option to purchase additional shares referred to above, or may
be &ldquo;naked short sales,&rdquo; which are short positions in excess of that amount.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The underwriter may close out any covered
short position by either exercising their option, in whole or in part, or by purchasing shares in the open market. In making this
determination, the underwriter will consider, among other things, the price of shares available for purchase in the open market
as compared to the price at which they may purchase shares through the over-allotment option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Naked short sales are short sales made in excess of the over-allotment
option. The underwriter must close out any naked short position by purchasing shares in the open market. A naked short position
is more likely to be created if the underwriter is concerned that there may be downward pressure on the price of the Ordinary Shares
in the open market that could adversely affect investors who purchased in this offering.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The underwriter also may impose a penalty
bid. This occurs when a particular underwriter repays to the underwriter a portion of the underwriting discount received by it
because Maxim has repurchased shares sold by or for the account of that underwriter in stabilizing or short covering transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These stabilizing transactions, short sales,
purchases to cover positions created by short sales, the imposition of penalty bids and syndicate covering transactions may have
the effect of raising or maintaining the market price of our Ordinary Shares or preventing or retarding a decline in the market
price of our Ordinary Shares. As a result of these activities, the price of our Ordinary Shares may be higher than the price that
otherwise might exist in the open market. The underwriter may carry out these transactions on the Nasdaq Capital Market, in the
over-the-counter market or otherwise. Neither we nor the underwriter make any representation or prediction as to the effect that
the transactions described above may have on the price of the shares. Neither we, nor the underwriter make any representation that
the underwriter will engage in these stabilization transactions or that any transaction, once commenced, will not be discontinued
without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Determination of Offering Price</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to this offering, there was no public
market for our Ordinary Shares. The initial public offering price will be determined by negotiation between us and Maxim. The
principal factors to be considered in determining the initial public offering price include, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the information set forth in this prospectus
    and otherwise available to Maxim;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our history and prospects and the history and
    prospects for the industry in which we compete;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our past and present financial performance;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our prospects for future earnings and the present
    state of our development;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the general condition of the securities market
    at the time of this offering;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the recent market prices of, and demand for,
    publicly traded shares of generally comparable companies; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other factors deemed relevant by the underwriter
    and us.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The estimated public offering price range
set forth on the cover page of this preliminary prospectus is subject to change as a result of market conditions and other factors.
Neither we nor the underwriter can assure investors that an active trading market will develop for our Ordinary Shares or that
the Ordinary Shares will trade in the public market at or above the initial public offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Affiliations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The underwriter and its respective affiliates
are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment
banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage
activities. The underwriter and its affiliates may from time to time in the future engage with us and perform services for us or
in the ordinary course of their business for which they will receive customary fees and expenses. In the ordinary course of their
various business activities, the underwriter and its respective affiliates may make or hold a broad array of investments and actively
trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their
own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or
instruments of us. The underwriter and its respective affiliates may also make investment recommendations and/or publish or express
independent research views in respect of these securities or instruments and may at any time hold, or recommend to clients that
they acquire, long and/or short positions in these securities and instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Offer Restrictions Outside the United States</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">No action has been
taken in any jurisdiction (except in the United States) that would permit a public offering of the Ordinary Shares the possession,
circulation or distribution of this prospectus or any other material relating to us or the Ordinary Shares in any jurisdiction
where action for that purpose is required. Accordingly, the Ordinary Shares may not be offered or sold, directly or indirectly,
and neither this prospectus nor any other material or advertisements in connection with the Ordinary Shares may be distributed
or published, in or from any country or jurisdiction except in compliance with any applicable laws, rules and regulations of any
such country or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>Australia.</I></B>&nbsp;This
prospectus:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left">does
                                         not constitute a product disclosure document or a prospectus under Chapter&nbsp;6D.2
                                         of the Corporations Act 2001 (Cth) (the &ldquo;Corporations Act&rdquo;);</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left">has
                                         not been, and will not be, lodged with the Australian Securities and Investments Commission
                                         (&ldquo;ASIC&rdquo;), as a disclosure document for the purposes of the Corporations Act
                                         and does not purport to include the information required of a disclosure document under
                                         Chapter&nbsp;6D.2 of the Corporations Act;</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left">does
                                         not constitute or involve a recommendation to acquire, an offer or invitation for issue
                                         or sale, an offer or invitation to arrange the issue or sale, or an issue or sale, of
                                         interests to a &ldquo;retail client&rdquo; (as defined in section&nbsp;761G of the Corporations
                                         Act and applicable regulations) in Australia; and</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left">may
                                         only be provided in Australia to select investors who are able to demonstrate that they
                                         fall within one or more of the categories of investors, or Exempt Investors, available
                                         under section&nbsp;708 of the Corporations Act.</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The Ordinary Shares
may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy the
Ordinary Shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating
to any Ordinary Shares may be distributed in Australia, except where disclosure to investors is not required under Chapter&nbsp;6D
of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application
for the Ordinary Shares, you represent and warrant to us that you are an Exempt Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">As any offer of
Ordinary Shares under this prospectus will be made without disclosure in Australia under Chapter&nbsp;6D.2 of the Corporations
Act, the offer of those securities for resale in Australia within 12&nbsp;months may, under section&nbsp;707 of the Corporations
Act, require disclosure to investors under Chapter&nbsp;6D.2 if none of the exemptions in section&nbsp;708 applies to that resale.
By applying for the Ordinary Shares, you undertake to us that you will not, for a period of 12&nbsp;months from the date of issue
of the Ordinary Shares, offer, transfer, assign or otherwise alienate those securities to investors in Australia except in circumstances
where disclosure to investors is not required under Chapter&nbsp;6D.2 of the Corporations Act or where a compliant disclosure document
is prepared and lodged with ASIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">This prospectus
contains general information only and does not take account of the investment objectives, financial situation or particular needs
of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment
decision, investors need to consider whether the information in this prospectus is appropriate to their needs, objectives and circumstances,
and, if necessary, seek expert advice on those matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B><I>Canada.</I></B>&nbsp;The
Ordinary Shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument&nbsp;45-106 Prospectus Exemptions or subsection&nbsp;73.3(1) of the Securities Act (Ontario),
and are permitted clients, as defined in National Instrument&nbsp;31-103 Registration Requirements, Exemptions and Ongoing Registrant
Obligations. Any resale of the Ordinary Shares must be made in accordance with an exemption from, or in a transaction not subject
to, the prospectus requirements of applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">Securities legislation
in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised
by the purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s province or territory.
The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&rsquo;s province or territory
for particulars of these rights or consult with a legal advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Pursuant to section&nbsp;3A.3
of National Instrument&nbsp;33-105 Underwriting Conflicts (NI&nbsp;33-105), the underwriter is not required to comply with the
disclosure requirements of NI&nbsp;33-105 regarding underwriter conflicts of interest in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B><I>Cayman Islands.</I></B>&nbsp;This
prospectus does not constitute a public offer of the Ordinary Shares, whether by way of sale or subscription, in the Cayman Islands.
Ordinary Shares have not been offered or sold, and will not be offered or sold, directly or indirectly, in the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>Dubai International
Financial Centre (&ldquo;DIFC&rdquo;).</I></B>&nbsp;This prospectus relates to an Exempt Offer in accordance with the Markets
Rules&nbsp;2012 of the Dubai Financial Services Authority (the &ldquo;DFSA&rdquo;). This prospectus is intended for distribution
only to persons of a type specified in the Markets Rules&nbsp;2012 of the DFSA. It must not be delivered to, or relied on by,
any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The
DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility
for this prospectus. The securities to which this prospectus relates may be illiquid and/or subject to restrictions on their resale.
Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand
the contents of this prospectus you should consult an authorized financial advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">In relation to
its use in the DIFC, this prospectus is strictly private and confidential and is being distributed to a limited number of investors
and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose.
The interests in the securities may not be offered or sold directly or indirectly to the public in the DIFC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B><I>European
Economic Area.</I></B>&nbsp;In relation to each Member State of the European Economic Area which has implemented the Prospectus
Directive (each, a Relevant Member State), with effect from and including the date on which the Prospectus Directive was implemented
in that Relevant Member State (the Relevant Implementation Date), an offer of the Ordinary Shares to the public may not be made
in that Relevant Member State prior to the publication of a prospectus in relation to the Ordinary Shares which has been approved
by the competent authority in that Relevant Member State or, where appropriate, approved in another Relevant Member State and notified
to the competent authority in that Relevant Member State, all in accordance with the Prospectus Directive, except that, with effect
from and including the Relevant Implementation Date, an offer of Ordinary Shares may be made to the public in that Relevant Member
State at any time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left">to
                                         any legal entity which is a qualified investor as defined under the Prospectus Directive;</TD>
</TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left">to
                                         fewer than 100 or, if the Relevant Member State has implemented the relevant provision
                                         of the 2010 PD Amending Directive, 150 natural or legal persons (other than qualified
                                         investors as defined in the Prospectus Directive); or</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left">in
                                         any other circumstances falling within Article&nbsp;3(2) of the Prospectus Directive,
                                         provided that no such offer of securities described in this prospectus shall result in
                                         a requirement for the publication by us of a prospectus pursuant to Article&nbsp;3 of
                                         the Prospectus Directive.</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">For the purposes
of the above paragraph, the expression &ldquo;an offer of the ordinary shares to the public&rdquo; in relation to any Ordinary
Shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms
of the offer and the Ordinary Shares to be offered so as to enable an investor to decide to purchase or subscribe the Ordinary
Shares, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State.
The expression Prospectus Directive means Directive 2003/71/EC (and any amendments thereto, including the 2010 PD Amending Directive,
to the extent implemented in the Relevant Member State) and includes any relevant implementing measure in each Relevant Member
State, and the expression &ldquo;2010 PD Amending Directive&rdquo; means Directive 2010/73/EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><B><I>Hong Kong</I></B>.&nbsp;The Ordinary Shares may not be
offered or sold by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the public within
the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), (ii)&nbsp;to &ldquo;professional investors&rdquo; within the
meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules promulgated thereunder, or (iii)&nbsp;in
other circumstances which do not result in the document being a &ldquo;prospectus&rdquo; within the meaning of the Companies Ordinance
(Cap.32, Laws of Hong Kong), and no advertisement, invitation or document relating to the Ordinary Shares may be issued or may
be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed
at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under
the laws of Hong Kong) other than with respect to Ordinary Shares which are or are intended to be disposed of only to persons
outside Hong Kong or only to &ldquo;professional investors&rdquo; within the meaning of the Securities and Futures Ordinance (Cap.
571, Laws of Hong Kong) and any rules promulgated thereunder.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B><I>Japan.</I></B>&nbsp;Ordinary
Shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948,
as amended) and, accordingly, will not be offered or sold directly or indirectly in Japan or to, or for the benefit of any Japanese
person or to others, for re-offering or re-sale directly or indirectly in Japan or to any Japanese person, except in each case
pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Securities and Exchange Law
of Japan and any other applicable laws, rules and regulations of Japan. For purposes of this paragraph, &ldquo;Japanese person&rdquo;
means any person resident in Japan, including any corporation or other entity organized under the laws of Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B><I>Kuwait.</I></B>&nbsp;Unless
all necessary approvals from the Kuwait Ministry of Commerce and Industry required by Law No.&nbsp;31/1990 &ldquo;Regulating the
Negotiation of Securities and Establishment of Investment Funds,&rdquo; its Executive Regulations and the various Ministerial Orders
issued pursuant thereto or in connection therewith, have been given in relation to the marketing and sale of the Ordinary Shares,
these may not be marketed, offered for sale, nor sold in the State of Kuwait. Neither this prospectus (including any related document),
nor any of the information contained therein is intended to lead to the conclusion of any contract of whatsoever nature within
Kuwait.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B><I>Malaysia.</I></B>&nbsp;No
prospectus or other offering material or document in connection with the offer and sale of the Ordinary Shares has been or will
be registered with the Securities Commission of Malaysia (the &ldquo;Commission&rdquo;) for the Commission&rsquo;s approval pursuant
to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or material in connection with
the offer or sale, or invitation for subscription or purchase, of the Ordinary Shares may not be circulated or distributed, nor
may the Ordinary Shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly
or indirectly, to persons in Malaysia other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder of a
Capital Markets Services License; (iii)&nbsp;a person who acquires the Ordinary Shares , as principal, if the offer is on terms
that the Ordinary Shares may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies)
for each transaction; (iv)&nbsp;an individual whose total net personal assets or total net joint assets with his or her spouse
exceeds RM3&nbsp;million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual;
(v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum in
the preceding twelve months; (vi)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of RM400,000
(or its equivalent in foreign currencies), per annum in the preceding twelve months; (vii)&nbsp;a corporation with total net assets
exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a partnership
with total net assets exceeding RM10&nbsp;million (or its equivalent in foreign currencies); (ix)&nbsp;a bank licensee or insurance
licensee as defined in the Labuan Financial Services and Securities Act 2010; (x)&nbsp;an Islamic bank licensee or takaful licensee
as defined in the Labuan Financial Services and Securities Act 2010; and (xi)&nbsp;any other person as may be specified by the
Commission; provided that, in the each of the preceding categories&nbsp;(i) to (xi), the distribution of the Ordinary Shares is
made by a holder of a Capital Markets Services License who carries on the business of dealing in securities. The distribution in
Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not constitute and may not be used for the purpose
of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring
the registration of a prospectus with the Commission under the Capital Markets and Services Act 2007.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><B><I>People&rsquo;s Republic of China</I></B>.&nbsp;This
prospectus may not be circulated or distributed in the PRC and the Ordinary Shares may not be offered or sold, and will not offer
or sell to any person for re-offering or resale directly or indirectly to any resident of the PRC except pursuant to applicable
laws, rules and regulations of the PRC. For the purpose of this paragraph only, the PRC does not include Taiwan and the special
administrative regions of Hong Kong and Macau.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>Qatar.</I></B>&nbsp;In
the State of Qatar, the offer contained herein is made on an exclusive basis to the specifically intended recipient thereof, upon
that person&rsquo;s request and initiative, for personal use only and shall in no way be construed as a general offer for the
sale of securities to the public or an attempt to do business as a bank, an investment company or otherwise in the State of Qatar.
This prospectus and the underlying securities have not been approved or licensed by the Qatar Central Bank or the Qatar Financial
Centre Regulatory Authority or any other regulator in the State of Qatar. The information contained in this prospectus shall only
be shared with any third parties in Qatar on a need to know basis for the purpose of evaluating the contained offer. Any distribution
of this prospectus by the recipient to third parties in Qatar beyond the terms hereof is not permitted and shall be at the liability
of such recipient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>Saudi Arabia.</I></B>&nbsp;This
prospectus may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities
Regulations issued by the Capital Market Authority. The Capital Market Authority does not make any representation as to the accuracy
or completeness of this prospectus, and expressly disclaims any liability whatsoever for any loss arising from, or incurred in
reliance upon, any part of this prospectus. Prospective purchasers of the securities offered hereby should conduct their own due
diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this prospectus
you should consult an authorized financial adviser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B><I>Singapore.</I></B>&nbsp;This
prospectus or any other offering material relating to the Ordinary Shares has not been registered as a prospectus with the Monetary
Authority of Singapore under the Securities and Futures Act, Chapter&nbsp;289 of Singapore, or the SFA. Accordingly, (a)&nbsp;the
Ordinary Shares have not been, and will not be, offered or sold or made the subject of an invitation for subscription or purchase
of such Ordinary Shares in Singapore, and (b)&nbsp;this prospectus or any other document or material in connection with the offer
or sale, or invitation for subscription or purchase, of the Ordinary Shares have not been and will not be circulated or distributed,
whether directly or indirectly, to the public or any member of the public in Singapore other than (i)&nbsp;to an institutional
investor as specified in Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275 of the SFA)
and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance
with the conditions of, any other applicable provision of the SFA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Where the Ordinary
Shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">(a) a corporation (which
is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and
the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">(b) a trust (where the trustee
is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who
is an accredited investor, securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&rsquo;
rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that
trust has acquired the Ordinary Shares pursuant to an offer made under Section&nbsp;275 of the SFA except:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">(a) to an institutional investor
or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A)
or Section&nbsp;276(4)(i)(B) of the SFA;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">(b) where no consideration
is or will be given for the traIer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">(c) where the transfer is
by operation of law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">(d) as specified in Section&nbsp;276(7)
of thIFA; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">(e) as specified in Regulation&nbsp;32
of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations&nbsp;2005 of Singapore.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B><I>Switzerland.</I></B>&nbsp;The
Ordinary Shares will not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any
other stock exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure
standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for
listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading
facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to our company or the Ordinary
Shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be
filed with, and the offer of the Ordinary Shares will not be supervised by, the Swiss Financial Market Supervisory Authority, and
the offer of the Ordinary Shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes
(the &ldquo;CISA&rdquo;). The investor protection afforded to acquirers of interests in collective investment schemes under the
CISA does not extend to acquirers of the Ordinary Shares .</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B><I>Taiwan.</I></B>&nbsp;The
Ordinary Shares have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant
securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances
which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval
of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice
regarding or otherwise intermediate the offering and sale of the Ordinary Shares in Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B><I>United Arab
Emirates.</I></B>&nbsp;The Ordinary Shares have not been offered or sold, and will not be offered or sold, directly or indirectly,
in the United Arab Emirates, except: (i)&nbsp;in compliance with all applicable laws and regulations of the United Arab Emirates;
and (ii)&nbsp;through persons or corporate entities authorized and licensed to provide investment advice and/or engage in brokerage
activity and/or trade in respect of foreign securities in the United Arab Emirates. The information contained in this prospectus
does not constitute a public offer of securities in the United Arab Emirates in accordance with the Commercial Companies Law (Federal
Law No.&nbsp;8 of 1984 (as amended)) or otherwise and is not intended to be a public offer and is addressed only to persons who
are sophisticated investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B><I>United Kingdom.</I></B>&nbsp;This
prospectus is only being distributed to and is only directed at, and any offer subsequently made may only be directed at: (i)&nbsp;persons
who are outside the United Kingdom; (ii)&nbsp;investment professionals falling within Article&nbsp;19(5) of the Financial Services
and Markets Act 2000 (Financial Promotion) Order 2005 (the &ldquo;Order&rdquo;); or (iii)&nbsp;high net worth companies, and other
persons to whom it may lawfully be communicated, falling within Article&nbsp;49(2)(a) to (d)&nbsp;of the Order (all such persons
falling within (1)-(3) together being referred to as &ldquo;relevant persons&rdquo;). The Ordinary Shares are only available to,
and any invitation, offer or agreement to subscribe, purchase or otherwise acquire the Ordinary Shares will be engaged in only
with, relevant persons. Any person who is not a relevant person should not act or rely on this prospectus or any of its contents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B><I>Vietnam</I>.</B>
This offering of Ordinary Shares has not been and will not be registered with the State Securities Commission of Vietnam under the Law
on Securities of Vietnam and its guiding decrees and circulars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_022"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The validity of
the Ordinary Shares offered in this offering and certain other legal matters as to Cayman Islands law will be passed upon for us
by Ogier, our counsel as to Cayman Islands law. Certain other legal matters as to United States Federal and New York State law
in connection with this offering will be passed upon for us by Hunter Taubman Fischer &amp; Li LLC, New York, New York. The underwriter
is being represented by Loeb &amp; Loeb LLP, New York, New York, with respect to legal matters of United States federal and New
York State law. Legal matters as to Hong Kong law will be passed upon for us by Fairbairn Catley Low &amp; Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_023"></A><B>CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_024"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">The consolidated
financial statements as of and for the years ended June 30, 2020 and 2019, included in this prospectus have been so included in
reliance on the report of Friedman LLP, an independent registered public accounting firm, given on the authority of said firm
as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The offices of Friedman LLP are located
at One Liberty Plaza, 165 Broadway 21st Floor, New York, NY 10006.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_025"></A><B>INTERESTS
OF NAMED EXPERTS AND COUNSEL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No expert or counsel named in this prospectus
as having prepared or certified any part of this prospectus or having given an opinion upon the validity of the securities being
registered or upon other legal matters in connection with the registration or offering of the Ordinary Shares was employed on
a contingency basis, or had, or is to receive, in connection with the offering, a substantial interest, direct or indirect, in
the registrant. Nor was any such person connected with the registrant as a promoter, managing or principal underwriter, voting
trustee, director, officer, or employee.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_026"></A><B>DISCLOSURE
OF COMMISSION POSITION ON INDEMNIFICATION</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Insofar as indemnification for liabilities
arising under the Securities Act, may be permitted to our directors, officers or persons controlling us, we have been advised
that it is the SEC&rsquo;s opinion that such indemnification is against public policy as expressed in such act and is, therefore,
unenforceable.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_027"></A><B>WHERE
YOU CAN FIND ADDITIONAL INFORMATION</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have filed with the SEC a registration
statement on Form F-1, including relevant exhibits and schedules under the Securities Act, covering the Ordinary Shares offered
by this prospectus, as well as the Ordinary Shares. You should refer to our registration statements and their exhibits and schedules
if you would like to find out more about us and about the Ordinary Shares. This prospectus summarizes material provisions of contracts
and other documents that we refer you to. Since the prospectus may not contain all the information that you may find important,
you should review the full text of these documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Immediately upon the completion of this
offering, we will be subject to periodic reporting and other informational requirements of the Exchange Act, as applicable to
foreign private issuers. Accordingly, we will be required to file reports, including annual reports on Form 20-F, and other information
with the SEC. As a foreign private issuer, we are exempt from the rules of the Exchange Act prescribing the furnishing and content
of proxy statements to shareholders under the federal proxy rules contained in Sections 14(a), (b) and (c) of the Exchange Act,
and our executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery
provisions contained in Section 16 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The registration statements, reports and
other information so filed can be inspected and copied at the public reference facilities maintained by the SEC at 100 F Street,
N.E., Washington, D.C. 20549. You can request copies of these documents upon payment of a duplicating fee, by writing to the SEC.
Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference rooms. The SEC also maintains
a website that contains reports, proxy statements and other information about issuers, such as us, who file electronically with
the SEC. The address of that website is&nbsp;<I>http://www.sec.gov</I>. The information on that website is not a part of this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No dealers, salesperson or other person
is authorized to give any information or to represent anything not contained in this prospectus. You must not rely on any unauthorized
information or representations. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances
and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="RB_DRS_028"></A><B>EXPENSES
RELATING TO THIS OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Set forth below is an itemization of the
total expenses, excluding underwriting discounts, expected to be incurred in connection with the offer and sale of the Ordinary
Shares by us.&nbsp;With the exception of the SEC registration fee and the FINRA filing fee, all amounts are estimates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left"> SEC registration fee </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 3,113 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Nasdaq listing fee </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 5,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> FINRA filing fee </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 4,250 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Transfer agent fees and expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 199 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Printer fees and expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 9,274 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Legal fees and expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 326,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Accounting fees and expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 110,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"> Miscellaneous </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 445,876 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt"> Total </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 903,712 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_029"></A><B>REGENCELL
BIOSCIENCE HOLDINGS LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Index to Consolidated
Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 89%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
    Ended June 30, 2020 and 2019</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#RB_DRS_030"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent
    Registered Public Accounting Firm</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt"><A HREF="#RB_DRS_031"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Balance Sheets</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 9pt"><A HREF="#RB_DRS_032"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Operations and Comprehensive Loss</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt"><A HREF="#RB_DRS_033"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Changes in Shareholder&rsquo;s Deficit</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 9pt"><A HREF="#RB_DRS_034"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Cash Flows</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt"><A HREF="#RB_DRS_035"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    to Consolidated Financial Statements</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7~F-14</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 89%; border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">Six Months Ended December 31, 2020 and
    2019 (Unaudited)</FONT> </TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Page</B></FONT> </TD></TR>
  <TR STYLE="background-color: white">
    <TD> <FONT STYLE="font-size: 10pt">Financial Statements:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"> <A HREF="#f2_001"><FONT STYLE="font-size: 10pt">Unaudited Interim Condensed Consolidated Balance
    Sheets</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-size: 10pt">F-15</FONT> </TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="padding-left: 9pt"> <A HREF="#f2_002"><FONT STYLE="font-size: 10pt">Unaudited Interim Condensed Consolidated Statements
    of Operations and Comprehensive Loss</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-size: 10pt">F-16</FONT> </TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"> <A HREF="#f2_003"><FONT STYLE="font-size: 10pt">Unaudited Interim Condensed Consolidated Statements
    of Changes in Shareholder&rsquo;s Deficit</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-size: 10pt">F-17</FONT> </TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="padding-left: 9pt"> <A HREF="#f2_004"><FONT STYLE="font-size: 10pt">Unaudited Interim Condensed Consolidated Statements
    of Cash Flows</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-size: 10pt">F-18</FONT> </TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"> <A HREF="#f2_005"><FONT STYLE="font-size: 10pt">Notes to Unaudited Interim Condensed Consolidated
    Financial Statements</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-size: 10pt">F-19~F-28</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 121; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_005.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_030"></A><B>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Director and Shareholder of</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regencell Bioscience Holdings Limited</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Opinion on the Financial Statements</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">We have audited the accompanying consolidated
balance sheets of Regencell Bioscience Holdings Limited and Subsidiaries (collectively, the &ldquo;Company&rdquo;) as of June
30, 2020 and 2019, and the related consolidated statements of operations and comprehensive loss, changes in shareholder&rsquo;s
deficit, and cash flows for each of the years in the two-year period ended June 30, 2020, and the related notes (collectively
referred to as the &ldquo;financial statements&rdquo;). In our opinion, the financial statements present fairly, in all material
respects, the financial position of the Company as of June 30, 2020 and 2019, and the results of its operations, and its cash
flows for each of the years in the two-year period ended June 30, 2020, in conformity with accounting principles generally accepted
in the United States of America.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Consideration of the Company&rsquo;s Ability to Continue
as a Going Concern</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">The accompanying financial statements
have been prepared assuming the Company will continue as a going concern. As discussed in Note 2 to the financial statements,
the Company has an accumulated deficit, has incurred recurring losses from operations, has an expectation of continuing operating
losses for the foreseeable future, and needs to raise capital to finance its future operation. These factors raise substantial
doubt about the Company&rsquo;s ability to continue as a going concern. Management&rsquo;s plans in regards to these matters are
also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Basis for Opinion</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">These financial statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based
on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">We conducted our audits in accordance
with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required
to have, nor were we engaged to perform an audit of its internal control over financial reporting. As part of our audits we are
required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made
by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide
a reasonable basis for our opinion.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Friedman LLP</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&rsquo;s auditor since 2020.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> November 13, 2020, except for Note 7, which is
dated June 11, 2021 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_006.jpg" ALT=""></P>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_031"></A><B>REGENCELL
BIOSCIENCE HOLDINGS LIMITED AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CONSOLIDATED
Balance sheets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> <FONT STYLE="font-size: 10pt"><B>June 30,</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> <FONT STYLE="font-size: 10pt"><B>June 30,</B></FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>2020</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>2019</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> <FONT STYLE="font-size: 10pt"><B>ASSETS</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-size: 10pt"><B>CURRENT ASSETS</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; padding-bottom: 1.5pt; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Cash</FONT> </TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">386,979</FONT> </TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">243,307</FONT> </TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.25in"> <FONT STYLE="font-size: 10pt">Total current assets</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">386,979</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">243,307</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> <FONT STYLE="font-size: 10pt"><B>OTHER ASSETS</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Property and equipment, net</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">108,321</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Long-term deposit</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">18,718</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.25in"> <FONT STYLE="font-size: 10pt">Total other assets</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">127,039</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 27pt"> <FONT STYLE="font-size: 10pt">Total assets</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">514,018</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">243,307</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"> <FONT STYLE="font-size: 10pt"><B>LIABILITIES AND SHAREHOLDER&rsquo;S DEFICIT</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-size: 10pt"><B>CURRENT LIABILITIES</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Shareholder&rsquo;s loans</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">3,069,910</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">2,081,828</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Accrued expenses</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">95,000</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.25in"> <FONT STYLE="font-size: 10pt">Total current liabilities</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">3,164,910</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">2,081,828</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.25in"> <FONT STYLE="font-size: 10pt">Total liabilities</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">3,164,910</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">2,081,828</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-size: 10pt">COMMITMENTS AND CONTINGENCIES</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-size: 10pt"><B>SHAREHOLDER&rsquo;S DEFICIT</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"> <FONT STYLE="font-size: 10pt">Ordinary shares, $0.00001 par value, 100,000,000,000
    shares authorized, and 10,000,000 shares issued and outstanding as of June 30, 2020 and 2019 *</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">100</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">100</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Additional paid-in capital</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">256</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">256</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Accumulated deficit</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">(2,651,248</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">(1,838,877</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.25in"> <FONT STYLE="font-size: 10pt">Total shareholder&rsquo;s deficit</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">(2,650,892</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">(1,838,521</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 27pt"> <FONT STYLE="font-size: 10pt">Total liabilities and shareholder&rsquo;s deficit</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">514,018</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">243,307</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"> * </TD><TD STYLE="text-align: justify"> Giving retroactive effect to the 1000-for-1 share split
effected on May 31, 2021 </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying
notes are an integral part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_032"></A><B>REGENCELL
BIOSCIENCE HOLDINGS LIMITED AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"> <FONT STYLE="font-size: 10pt"><B>For the Year Ended</B></FONT> </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"> <FONT STYLE="font-size: 10pt"><B>For the Year Ended</B></FONT> </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"> <FONT STYLE="font-size: 10pt"><B>June 30,</B></FONT> </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"> <FONT STYLE="font-size: 10pt"><B>June 30,</B></FONT> </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>2020</B></FONT> </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>2019</B></FONT> </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-size: 10pt"><B>OPERATING EXPENSES:</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Selling and marketing</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">114,207</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">3,638</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">General and administrative</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">311,934</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">159,129</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Research and development</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">386,230</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">228,223</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.25in"> <FONT STYLE="font-size: 10pt">Total operating expenses</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">812,371</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">390,990</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt"><B>LOSS FROM OPERATIONS</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">(812,371</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">(390,990</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt"><B>LOSS BEFORE INCOME TAXES</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">(812,371</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">(390,990</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt"><B>PROVISION FOR INCOME TAXES</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt"><B>NET LOSS</B></FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">(812,371</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">(390,990</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt"><B>COMPREHENSIVE LOSS</B></FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">(812,371</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">(390,990</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> <FONT STYLE="font-size: 10pt"><B>WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">Basic and diluted *</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">10,000,000</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">10,000,000</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-size: 10pt"><B>LOSS PER SHARE</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Basic and diluted *</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">(0.08</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">(0.04</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"> * </TD><TD STYLE="text-align: justify"> Giving retroactive effect to the 1000-for-1 share split
effected on May 31, 2021 </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying
notes are an integral part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_033"></A><B>REGENCELL
BIOSCIENCE HOLDINGS LIMITED AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CONSOLIDATED
STATEMENTS OF changeS in SHAREHOLDER&rsquo;S DEFICIT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Ordinary
    Shares</B></FONT> </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Additional</B></FONT> </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Accumulated</B></FONT> </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Shares*</B></FONT> </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Par
    value*</B></FONT> </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>paid-in
    capital</B></FONT> </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>deficit</B></FONT> </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Total</B></FONT> </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 40%"> <FONT STYLE="font-size: 10pt"><B>BALANCE, July 1, 2018</B></FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">10,000,000</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;100</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;256</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">(1,447,887</FONT> </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">(1,447,531</FONT> </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Net loss</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">(390,990</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">(390,990</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-size: 10pt"><B>BALANCE, June 30, 2019</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">10,000,000</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">100</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">256</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">(1,838,877</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">(1,838,521</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Net loss</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">(812,371</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">(812,371</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt"><B>BALANCE, June 30, 2020</B></FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">10,000,000</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">100</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">256</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">(2,651,248</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">(2,650,892</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD>
    <TD STYLE="text-align: justify; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Giving
    retroactive effect to the 1000-for-1 share split effected on May 31, 2021</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying
notes are an integral part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_034"></A><B>REGENCELL BIOSCIENCE
HOLDINGS LIMITED AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CONSOLIDATED
STATEMENTS OF cash flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">For the Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">For the Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 76%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(812,371</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(390,990</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,516</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Change in operating assets and liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left">Long-term deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,718</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Accrued expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">95,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(726,573</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(390,990</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Purchase of property and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(117,837</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(117,837</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Proceeds from shareholder&rsquo;s loans</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">988,082</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">480,994</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">988,082</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">480,994</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">NET CHANGE IN CASH</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">143,672</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,004</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH, beginning of year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">243,307</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">153,303</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">CASH, end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">386,979</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">243,307</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">SUPPLEMENTAL CASH FLOW INFORMATION:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Cash paid for income tax</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Cash paid for interest</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral
part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="RB_DRS_035"></A><B>Note 1 &ndash; Nature of business
and organization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Regencell Bioscience Holdings Limited
(&ldquo;Regencell&rdquo; or the &ldquo;Company&rdquo;) is a holding company incorporated as an exempted company on October 30,
2014, under the laws of the Cayman Islands and holding all of the outstanding share capital of Regencell Limited (Hong Kong),
established under the laws of Hong Kong on November 20, 2014, and Regencell Bioscience Limited (Hong Kong), established under
the laws of Hong Kong on May 12, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company, through its controlling interests
in the wholly owned subsidiaries, operates an early-stage bioscience company that focuses on research, development and commercialization
of Traditional Chinese Medicine (&ldquo;TCM&rdquo;) for the global treatment of neurocognitive disorder and degeneration, specifically
for Attention Deficit Hyperactivity Disorder (&ldquo;ADHD&rdquo;) and Autism Spectrum Disorder (&ldquo;ASD&rdquo;). The Company
is in the research and development stage and has not yet generated any revenue since inception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In January 2018, the Company entered into
Strategic Partnership Agreement with Mr. Sik-Kee Au (the &ldquo;TCM Practitioner&rdquo;), the father of Mr. Yat-Gai Au, CEO of
the Company. Pursuant to the Strategic Partnership Agreement, the Company has exclusive rights including the intellectual property
rights and ownership of all his TCM formulae. Any inventions, TCM formulae, utilities, models&rsquo; improvements, research, discoveries,
designs, processes, methods of manufacture, and products conceived or made by the TCM Practitioner in relation to TCM shall be
the sole and exclusive property of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Strategic Partnership Agreement does
not have a termination date and will remain effective indefinitely under Hong Kong law. The Strategic Partnership Agreement can
be amended or terminated by the mutual written agreement of the parties without breach. Pursuant to the Strategic Partnership
Agreement, in exchange for the rights, the Company is required to donate three percent (3.0%) of net revenue that the Company
generates in association with the use and/or commercialization of the TCM formulae to any of charitable institutions and/or trusts
of a public character anywhere in the world at the sole and absolute choice of the TCM Practitioner and in such proportion at
the sole and absolute discretion of the TCM practitioner on a yearly basis. The Company also undertakes to pay for all reasonable
costs and expenses incurred by the TCM Practitioner in relation to the research and development of the TCM formulae for ADHD and
ASD. All research and development costs and expenses incurred by the TCM Practitioner are charged to operations as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company has funded its operations
primarily from shareholder&rsquo;s loans (&ldquo;SH Loans&rdquo;) provided by Mr. Yat-Gai Au (&ldquo;Founder and CEO&rdquo;).
The accompanying consolidated financial statements reflect the activities of the Company and each of the following entities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 14%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Name
                                         of Entity</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal
    Activities</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 30%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Place
    and Date of Incorporation</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: top; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ownership</B></FONT></TD></TR>
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regencell Bioscience Limited (Hong Kong)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&middot; Research and Development</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.05pt; text-indent: -14.05pt">&middot;&nbsp;Day-to-day
        operations</P></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong, incorporated on May 12, 2015</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned Regencell Bioscience Holdings Limited</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regencell Limited (Hong Kong)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&middot; Production and testing laboratory</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&middot; Research and Development</P></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong, incorporated on November 20, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned Regencell Bioscience Holdings Limited</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2 &ndash;Going Concern </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In accordance with Accounting Standards
Update (&ldquo;ASU&rdquo;) 2014-15, Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern
(Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise
substantial doubt about the Company&rsquo;s ability to continue as a going concern within one year after the date that the consolidated
financial statements are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company has incurred recurring negative
cash flows since inception and has funded its operations primarily from shareholder loans. The Company had an accumulated deficit
of approximately $2.65 million and $1.84 million as of June 30, 2020 and 2019, respectively. The Company had net losses of approximately
$0.81 million and $0.39 million for the years ended June 30, 2020 and 2019. The Company has received funding in the form of periodic
shareholders loans to support its capital needs. The Company&rsquo;s ability to continue as a going concern is highly contingent
on the ability to raise additional capital for ongoing research and development as the Company expects to continue incurring losses
for the foreseeable future. The Company has received additional funding subsequent to June 30, 2020 in the form of additional
shareholders loans of $465,947.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company intends to pursue a public offering of its Ordinary
Shares to fund future operations. If the Company is unable to complete a public offering for a sufficient amount in a timely manner,
it would need to pursue other financing alternatives such as private financing of debt or equity or collaboration agreements. There
can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on
terms acceptable to the Company, or at all. If the Company is unable to obtain sufficient funding, it could be required to delay
its development efforts, limit activities and reduce research and development costs, which could adversely affect its business
prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Based on the Company&rsquo;s recurring
losses and negative cash flows from operations since inception, expectation of continuing operating losses and negative cash flows
from operations for the foreseeable future, and the need to raise additional capital to finance its future operations, the Company&rsquo;s
management concluded that there is substantial doubt about the Company&rsquo;s ability to continue as a going concern within one
year after the issuance date of the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The accompanying consolidated financial
statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated
financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates
the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 3 &ndash; Summary of significant accounting policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Basis of presentation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The accompanying consolidated financial
statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&ldquo;U.S.
GAAP&rdquo;) pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Principles of consolidation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The consolidated financial statements
include the financial statements of the Company and its subsidiaries. All intercompany transactions and balances among the Company
and its subsidiaries have been eliminated upon consolidation.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Subsidiaries are those entities in which
the Company, directly or indirectly, controls more than one half of the voting power; or has the power to govern the financial
and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes
at the meeting of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Use of estimates and assumptions</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The preparation of consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in
the Company&rsquo;s consolidated financial statements required to be made by management include, but not limited to, the useful
lives of property and equipment, impairment of long-lived assets and uncertain tax position. Actual results could differ from
these estimates.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Risks and Uncertainties</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company operates in an industry that
is subject to intense competition, government regulations and rapid technological changes. Operations are subject to significant
risk and uncertainties including financial, operational, technological, regulatory, and other risks, including the potential risk
of business failure.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Segment</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Operating segments are defined as components
of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision
maker (&ldquo;CODM&rdquo;), or decision making group, in deciding how to allocate resources and in assessing performance. The
CODM is comprised of certain members of the Company&rsquo;s management team. The Company has one operating segment. The Company&rsquo;s
CODM manages the Company&rsquo;s operations on a consolidated basis for the purpose of allocating resources. All of the Company&rsquo;s
long-lived assets are held in Hong Kong.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Foreign currency translation and transaction
</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The reporting currency of the Company is
the United States dollar (&ldquo;$&rdquo;). The Company conducts its businesses in Hong Kong in the local currency, Hong Kong Dollar
(&ldquo;HK$&rdquo;), as its functional currency. The consolidated balance sheet accounts, statement of operations accounts and
equity accounts are all translated at the exchange rate as quoted by the Hong Kong Monetary Authority (&ldquo;HKMA&rdquo;). The
Company considers the foreign exchange risk in relation to transactions denominated in HK$ with respect to $ is not significant
as HK$ is pegged to $. The HKMA guarantees to exchange US dollars into Hong Kong dollars, or vice versa, at the rate of HK$7.80
to $1.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Monetary assets and liabilities denominated
in currencies other than the functional currency are translated into the functional currency at the rates of exchange existing
at the balance sheet date. Transactions in currencies other than the functional currency during the year are converted into the
functional currency at the applicable rates of exchange prevailing at the transaction date. Transaction gains and losses are recognized
in &ldquo;other income, net&rdquo;. Assets and liabilities denominated in foreign currencies are translated at the exchange rates
at the balance sheet date. Equity accounts are translated at historical exchange rates and revenues, expenses, gains and losses
are translated using the average rate for the year. Translation adjustments are reported as cumulative translation adjustments
and are shown as a separate component of other comprehensive loss in the consolidated statements of changes in shareholders&rsquo;
deficit and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Cash </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Cash represents demand deposits placed
with banks or other financial institutions, which are unrestricted as to withdrawal or use, and which have original maturities
of three months or less and are readily convertible to known amounts of cash. All of the cash balances as at June 30, 2020 and
2019, were maintained at financial institutions in Hong Kong, and were insured by the Hong Kong Deposit Protection Board up to
a limit of HK $500,000 (approximately $64,000).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Property and equipment, net</U></P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Property and equipment are stated at cost
less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the
assets. The estimated useful lives are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; width: 49%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; white-space: nowrap; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Useful&nbsp;Life</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold&nbsp;&nbsp;improvement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Shorter of the remaining lease</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">terms or estimated useful lives</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The cost and related accumulated depreciation
of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the consolidated statements
of operations and comprehensive loss. Expenditures for maintenance and repairs are charged to earnings as incurred, while additions,
renewals and betterments, which are expected to extend the useful life of assets, are capitalized. The Company also re-evaluates
the periods of depreciation to determine whether subsequent events and circumstances warrant revised estimates of useful lives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Long-term deposit</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Long-term deposit presents the deposit
paid to the landlord as required on the signing of the lease agreement and thereafter, to be held by the landlord as security
for the performance of the Company&rsquo;s obligations under the lease agreement. The deposit is classified as either current
or non-current based on the terms of the respective agreement. The deposit is unsecured and is reviewed periodically to determine
whether its carrying value has become impaired.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Impairment for long-lived assets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Long-lived assets, including property
and equipment with finite lives are reviewed for impairment whenever events or changes in circumstances (such as a significant
adverse change to market conditions that will impact the future use of the assets) indicate that the carrying value of an asset
may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted future cash flows the
assets are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows expected to result
from the use of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying value of
the asset. If an impairment is identified, the Company would reduce the carrying amount of the asset to its estimated fair value
based on a discounted cash flows approach or, when available and appropriate, to comparable market values. As of June 30, 2020,
and 2019, no impairment of long-lived assets was recognized.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Fair value measurement </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">ASC 825-10 requires certain disclosures
regarding the fair value of financial instruments. Fair value is defined as the price that would be received to sell an asset
or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level fair
value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable
inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                         1 &mdash; inputs to the valuation methodology are quoted prices (unadjusted) for identical
                                         assets or liabilities in active markets.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 &mdash;
    inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market
    prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable
    and inputs derived from or corroborated by observable market data.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 &mdash; inputs
    to the valuation methodology are unobservable.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Unless otherwise disclosed, the fair value
of the Company&rsquo;s financial instruments including cash and shareholder&rsquo;s loans approximates their recorded values due
to their short-term maturities. The fair value of the long-term deposit approximates their carrying amounts because the deposit
was paid in cash.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Research and development </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Research and development costs are charged
to operations as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in
future research and development activities as expenses when the goods have been received or when the service has been performed
rather than when the payment is made. Research and development expenses consist of costs incurred by the Company for the discovery
and development of the Company&rsquo;s product candidates. Research and development costs include, but not limited to, payroll
and personnel expenses including stock-based compensation, research studies supplies, fees for research studies services, consulting
costs, and allocated overhead, including rent, equipment, and utilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Employee benefit plan</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Employees of the Company located in Hong
Kong participate in a compulsory saving scheme (pension fund) for the retirement of residents in Hong Kong. Employees are required
to contribute monthly to mandatory provident fund schemes provided by approved private organizations, according to their salaries
and the period of employment. The Company is required to contribute to the plan based on certain percentages of the employees&rsquo;
salaries, up to a maximum amount specified by the local government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Operating leases</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">A lease for which substantially all the
benefits and risks incidental to ownership remain with the lessor is classified by the lessee as an operating lease. All leases
of the Company are currently classified as operating leases. The Company records the total expenses on a straight-line basis over
the lease term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Related Parties </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Parties, which can be a corporation or
individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or
exercise significant influence over the other party in making financial and operational decisions. Companies are also considered
to be related if they are subject to common control or common significant influence, such as a family member or relative, shareholder,
or a related corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Income taxes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company accounts for current income
taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences
exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those
temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary,
to reduce deferred tax assets to the amount expected to be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">An uncertain tax position is recognized
as a benefit only if it is &ldquo;more likely than not&rdquo; that the tax position would be sustained in a tax examination. The
amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax
positions not meeting the &ldquo;more likely than not&rdquo; test, no tax benefit is recorded. Penalties and interest incurred
related to underpayment of income tax are classified as income tax expense in the period incurred. No significant penalties or
interest relating to income taxes have been incurred during the years ended June 30, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>(Loss) earnings per share</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company computes (loss) earnings per
share (&ldquo;EPS&rdquo;) in accordance with ASC 260, &ldquo;Earnings per Share&rdquo;. ASC 260 requires companies to present
basic and diluted EPS. Basic EPS is measured as net income (loss) divided by the weighted average ordinary share outstanding for
the period. Diluted EPS presents the dilutive effect on a per share basis of the potential Ordinary Shares (e.g., convertible
securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if
later. Potential Ordinary Shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss
per share) are excluded from the calculation of diluted EPS. For the years ended June 30, 2020 and 2019, there were no dilutive
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Commitments and Contingencies</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In the normal course of business, the
Company is subject to contingencies, including legal proceedings and claims arising out of the business that relate to a wide
range of matters, such as government investigations and tax matters. The Company recognizes a liability for such contingency if
it determines it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may consider
many factors in making these assessments including historical and the specific facts and circumstances of each matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Concentration of credit risk</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Financial instruments that potentially
subject the Company to concentration of credit risks consist primarily of cash, the balances of which are stated on the consolidated
balance sheets which represent the Company&rsquo;s maximum exposure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company places its cash in good credit
quality financial institutions in Hong Kong. The Company deposits its cash in financial institutions that it believes have high
credit quality and have not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk
beyond the normal credit risk associated with commercial banking relationships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Recently issued accounting pronouncements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company considers the applicability
and impact of all accounting standards updates (&ldquo;ASUs&rdquo;). Management periodically reviews new accounting standards
that are issued. Under the Jumpstart Our Business Startups Act of 2012, as amended (&ldquo;the JOBS Act&rdquo;), the Company meets
the definition of an emerging growth company, or EGC, and has elected the extended transition period for complying with new or
revised accounting standards, which delays the adoption of these accounting standards until they would apply to private companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In February 2016, the FASB issued Accounting
Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02). ASU 2016-02 requires an entity to recognize lease assets and lease
liabilities on the balance sheet and to disclose key information about the entity&rsquo;s leasing arrangements. ASU 2016-02 is
effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. A modified retrospective
approach is required. In January 2018, the FASB issued ASU 2018-01, Leases: Land Easement Practical Expedient for Transition.
This ASU clarifies the accounting and reporting of land easements. In July 2018, the FASB issued ASU No. 2018-10, &ldquo;Codification
Improvements to Topic 842, Leases,&rdquo; (&ldquo;ASU 2018-10&rdquo;), to clarify how to apply certain aspects of the new lease
accounting standard. The amendments in this update, among other things, better articulates the requirement for a lessee&rsquo;s
reassessment of lease classification as of the effective date of a modification, clarifies that a change to an index or rate for
variable lease payments does not constitute a resolution of a contingency that would result in the remeasurement of lease payments,
and requires entities that apply Topic 842 retrospectively to each reporting period and do not adopt the practical expedients
to write off any prior unamortized initial direct costs that do not meet the definition under Topic 842 to equity. The amendments
in this update have the same effective date and transition requirements as the new lease standard summarized above. Also, in July
2018, the FASB issued ASU No. 2018-11, &ldquo;Leases (Topic 842): Targeted Improvements,&rdquo; (&ldquo;ASU 2018-11&rdquo;), to
provide an additional transition method. An entity can now elect not to present comparative financial information under Topic
842 if it recognizes a cumulative-effect adjustment to retained earnings upon adoption. On November 15, 2019, the FASB issued
ASU 2019-10, which amends the effective dates for certain major new accounting standards, including Topic 842, to give implementation
relief to certain types of entities. As an emerging growth company, the Company can adopt Topic 842 on July 1, 2021. The Company
is evaluating the impact this ASU will have on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In June 2016, the FASB amended guidance
related to the impairment of financial instruments as part of ASU2016-13 Financial Instruments &ndash; Credit Losses (Topic 326):
Measurement of Credit Losses on Financial Instruments, which was effective from January 1, 2020. The guidance replaces the incurred
loss impairment methodology with an expected credit loss model for which a company recognizes an allowance based on the estimate
of expected credit loss. In November 2018, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Finance&ndash;l
Instruments - Credit Losses, which clarified that receivables from operating leases are not within the scope of Topic 326 and
instead, impairment of receivables arising from operating leases should be accounted for in accordance with Topic 842. On May
15, 2019, the FASB issued ASU 2019-05, 9 which provides transition relief for entities adopting the Board&rsquo;s credit losses
standard, ASU 2016-13. Specifically, ASU 2019-05 amends ASU 2016-13 to allow companies to irrevocably elect, upon adoption of
ASU 2016-13, the fair value option for financial instruments that (1) were previously recorded at amortized cost and (2) are within
the scope of the credit losses guidance in ASC 326-20, (3) are eligible for the fair value option under ASC 825-10, and (4) are
not held-to-maturity debt securities. For entities that have adopted ASU 2016-13, the amendments in ASU 2019-05 are effective
for fiscal years beginning after December 15, 2019, including interim periods therein. An entity may early adopt the ASU in any
interim period after its issuance if the entity has adopted ASU 2016-13. For all other entities, the effective date will be the
same as the effective date of ASU 2016-13. The Company does not expect this guidance will have a material impact on its consolidated
financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In August 2018, the FASB Accounting Standards
Board issued ASU No. 2018-13, &ldquo;Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements
for Fair Value Measurement&rdquo; (&ldquo;ASU 2018-13&rdquo;). ASU 2018-13 modifies the disclosure requirements on fair value
measurements. ASU 2018-13 is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption
permitted for any removed or modified disclosures. The removed and modified disclosures will be adopted on a retrospective basis
and the new disclosures will be adopted on a prospective basis. The Company does not expect this guidance will have a material
impact on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Except for the above-mentioned pronouncements,
there are no new recent issued accounting standards that will have a material impact on the consolidated financial position, statements
of operations and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 4 &ndash; Property and equipment, net</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Property and equipment consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<BR>
    2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<BR>
    2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -19.8pt; padding-left: 19.8pt">Leasehold improvement</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">117,837</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -19.8pt; padding-left: 19.8pt">Less: accumulated depreciation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,516</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">108,321</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Depreciation expense for the years ended
June 30, 2020 and 2019 amounted to $9,516 and nil, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 5 &ndash; Related Party Transaction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">During the years ended June 30, 2020 and
2019, the Company has an office rental agreement with Ace United International Limited, which is a company wholly owned by the
Company&rsquo;s Founder and CEO. The Company has paid a monthly rent of $4,103 and the terms of the agreement are renewed on an
annual basis from the 1<SUP>st</SUP> of January to the 31<SUP>st</SUP> of December each year. The rental payment is expensed as
incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As of June 30, 2020, and 2019, the Company
has outstanding Shareholder Loans amounting to approximately $3.07 million and $2.08 million, respectively, from the Founder and
CEO. The amounts borrowed are non-interest bearing and due on-demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Note 6 &ndash; Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Income tax</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Cayman Islands</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Under the current laws of the Cayman Islands,
the Company is not subject to tax on income or capital gains. Additionally, upon payments of dividends to the shareholders, no
Cayman Islands withholding tax will be imposed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Hong Kong</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Entities incorporated in Hong Kong are
subject to Hong Kong profits tax at a rate of 16.5% on the estimated assessable profit for the years ended June 30, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following table reconciles statutory
tax rates to the Company&rsquo;s effective tax rate for the periods indicated below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For
                                         the year ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June
                                         30,</B></P>
                                                                                                                                                                    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2020</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For
                                         the year ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June
                                         30,<BR>
                                         2019</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -19.8pt; padding-left: 19.8pt">Tax benefit calculated at statutory tax
    rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">16.5</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">16.5</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -19.8pt; padding-left: 19.8pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(16.5</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(16.5</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Effective tax rate</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following table sets forth the significant
components of the aggregate deferred tax assets:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of
    June&nbsp;30, <BR>
    2020</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of
    June&nbsp;30, <BR>
    2019</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Deferred tax assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -19.8pt; padding-left: 19.8pt">Net operating loss carry forwards</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">437,456</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">303,415</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -19.8pt; padding-left: 19.8pt">Less: valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(437,456</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(303,415</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Deferred tax asset, net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The ultimate realization of deferred tax
assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become
deductible. Management considers the cumulative earnings and projected future taxable income in making this assessment. Recovery
of substantially all of the Company&rsquo;s deferred tax assets is dependent upon the generation of future income, exclusive of
reversing taxable temporary differences. Based upon historical operating results and projections for future taxable income, management
provided full valuation allowance for the deferred tax assets for the years ended June 30, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company evaluates each uncertain tax
position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized
benefits associated with the tax positions. As of June 30, 2020, and 2019, the Company did not have any significant unrecognized
uncertain tax positions. The Company did not incur any interest and penalties related to potential underpaid income taxes for
the years ended June 30, 2020 and 2019. The Company also does not anticipate any significant increases or decreases in unrecognized
tax benefits in the next 12 months from June 30, 2020.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Note 7 &ndash; Shareholder&rsquo;s deficit</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Regencell Bioscience Holdings Limited (Cayman) was established
under the laws of Cayman Islands on October 30, 2014. The authorized number of Ordinary Shares is 100,000,000 shares with a par value
of $0.01 per ordinary share, and 10,000 Ordinary Shares were issued and outstanding as of June 30, 2020 and 2019, respectively. On May
31, 2021, the board of directors approved a share split of the Company&rsquo;s authorized number of Ordinary Shares at a ratio of 1,000-for-1.
After the completion of share split, the Company&rsquo;s authorized number of Ordinary Shares was 100,000,000,000 shares with par value
of $0. 00001 per share and 10,000,000 shares were issued and outstanding accordingly. The Company believes it is appropriate to reflect
these share issuances as nominal share issuance on a retroactive basis similar to stock split pursuant to ASC 260. The Company has retroactively
adjusted all shares and per share data for all the periods presented. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As of June 30, 2020, and 2019, additional
paid-in capital in the consolidated balance sheets represented the combined contributed capital of the Company&rsquo;s subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Note 8 &ndash; Commitments and contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Office lease commitments</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company has entered into two lease
agreements for office space with the latest expiring date of July 14, 2024. The Company&rsquo;s commitment for lease payments
under the operating leases as of June 30, 2020 and for the next five years are as follow:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Year ending June 30,</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Office leases</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">2021</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">136,923</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,308</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,308</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,308</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">2025</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,359</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total payments</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">483,206</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Rent expense for the years ended June 30,
2020 and 2019 was $151,538 and $49,231, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Contingencies</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">From time to time, the Company may be
subject to certain legal proceedings, claims and disputes that arise in the ordinary course of business. Although the outcomes
of these legal proceedings cannot be predicted, the Company does not believe these actions, in the aggregate, will have a material
adverse impact on its financial position, results of operations or liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 9 &ndash; Subsequent events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company evaluated all events and transactions
that occurred after June 30, 2020 up through the date the Company issued these consolidated financial statements on November 13,
2020, for disclosure or recognition in the consolidated financial statements of the Company as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Impact of COVID-19</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In December 2019, a novel strain of coronavirus,
or COVID-19, surfaced and it has spread rapidly to many parts of China and other parts of the world, including the United States.
The epidemic has resulted in quarantines, travel restrictions, and the temporary closure of stores and facilities in China and
elsewhere. The COVID-19 pandemic may affect the Company&rsquo;s ability to initiate and complete research studies, delay the initiation
of its future research studies, disrupt regulatory activities or have other adverse effects on its business, results of operations,
financial condition and prospects. In addition, the pandemic has caused substantial disruption in the financial markets and may
adversely impact economies worldwide, both of which could adversely affect its business, operations and ability to raise funds
to support its operations.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Loan Agreement with Mr. Yat-Gai
Au</U></I></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On November 10, 2020, the Company signed a loan agreement to
obtain HK$3,634,387 ($465,947) from Mr. Yat-Gai Au, the Founder and CEO of the Company. The amounts borrowed are non-interest bearing
and due June 30, 2021, but subject to indefinite extension if agreed by Mr. Yat-Gai Au and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="f2_001"></A>REGENCELL
BIOSCIENCE HOLDINGS LIMITED AND SUBSIDIARIES</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNAUDITED
CONDENSED <FONT STYLE="text-transform: uppercase">CONSOLIDATED Balance sheets</FONT></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> <FONT STYLE="font-size: 10pt"><B>December&nbsp;31,</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> <FONT STYLE="font-size: 10pt"><B>June&nbsp;30,</B></FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>2020</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>2020</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> <FONT STYLE="font-size: 10pt"><B>ASSETS</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-size: 10pt"><B>CURRENT ASSETS</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; padding-bottom: 1.5pt; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Cash</FONT> </TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">305,956</FONT> </TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">386,979</FONT> </TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.25in"> <FONT STYLE="font-size: 10pt">Total current assets</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">305,956</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">386,979</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> <FONT STYLE="font-size: 10pt"><B>OTHER ASSETS</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Property and equipment, net</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">110,256</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">108,321</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Deferred offering costs</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">165,056</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Long-term deposit</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">19,106</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">18,718</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.25in"> <FONT STYLE="font-size: 10pt">Total other assets</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">294,418</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">127,039</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 27pt"> <FONT STYLE="font-size: 10pt">Total assets</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">600,374</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">514,018</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center"> <FONT STYLE="font-size: 10pt"><B>LIABILITIES AND SHAREHOLDER&rsquo;S DEFICIT</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> <FONT STYLE="font-size: 10pt"><B>CURRENT LIABILITIES</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Shareholder&rsquo;s loans</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">3,542,980</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">3,069,910</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Accrued expenses</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">42,134</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">95,000</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.25in"> <FONT STYLE="font-size: 10pt">Total current liabilities</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">3,585,114</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">3,164,910</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.25in"> <FONT STYLE="font-size: 10pt">Total liabilities</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">3,585,114</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">3,164,910</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> <FONT STYLE="font-size: 10pt">COMMITMENTS AND CONTINGENCIES</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> <FONT STYLE="font-size: 10pt"><B>SHAREHOLDER&rsquo;S DEFICIT</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"> <FONT STYLE="font-size: 10pt">Ordinary shares, $0. 00001 par value, 100,000,000,000
    shares authorized, and 10, 000,000 shares issued and outstanding as of December 31, 2020 and June 30, 2020*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">100</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">100</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Additional paid-in capital</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">256</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">256</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Accumulated deficit</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">(2,985,096</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">(2,651,248</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.25in"> <FONT STYLE="font-size: 10pt">Total shareholder&rsquo;s deficit</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">(2,984,740</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">(2,650,892</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 27pt"> <FONT STYLE="font-size: 10pt">Total liabilities and shareholder&rsquo;s deficit</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">600,374</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">514,018</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"> * </TD><TD STYLE="text-align: justify"> Giving retroactive effect to the 1000-for-1 share split
effected on May 31, 2021 </TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B></B></FONT>The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="f2_002"></A>REGENCELL
BIOSCIENCE HOLDINGS LIMITED AND SUBSIDIARIES</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNAUDITED
CONDENSED <FONT STYLE="text-transform: uppercase">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</FONT></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>For the Six Months
    Ended</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"> <FONT STYLE="font-size: 10pt"><B>December&nbsp;31,</B></FONT> </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"> <FONT STYLE="font-size: 10pt"><B>December&nbsp;31,</B></FONT> </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>2020</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>2019</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-size: 10pt"><B>OPERATING EXPENSES:</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">General and administrative</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">114,944</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-size: 10pt">105,083</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Research and development</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">253,521</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">192,933</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.25in"> <FONT STYLE="font-size: 10pt">Total operating expenses</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">368,465</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">298,016</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt"><B>LOSS FROM OPERATIONS</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">(368,465</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">(298,016</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-size: 10pt"><B>OTHER INCOME</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">34,617</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt"> <FONT STYLE="font-size: 10pt"><B>LOSS BEFORE INCOME TAXES</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">(333,848</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">(298,016</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt"><B>PROVISION FOR INCOME TAXES</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt"><B>NET LOSS</B></FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">(333,848</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">(298,016</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt"><B>COMPREHENSIVE LOSS</B></FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">(333,848</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">(298,016</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-size: 10pt"><B>WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">Basic and diluted*</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">10,000,000</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">10,000,000</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> <FONT STYLE="font-size: 10pt"><B>LOSS PER SHARE</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 9pt"> <FONT STYLE="font-size: 10pt">Basic and diluted*</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">(0.03</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"> <FONT STYLE="font-size: 10pt">(0.03</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">)</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"> * </TD><TD STYLE="text-align: justify"> Giving retroactive effect to the 1000-for-1 share split
effected on May 31, 2021 </TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="f2_003"></A>REGENCELL
BIOSCIENCE HOLDINGS LIMITED AND SUBSIDIARIES</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNAUDITED
CONDENSED <FONT STYLE="text-transform: uppercase">CONSOLIDATED STATEMENTS OF changeS in SHAREHOLDER&rsquo;S DEFICIT</FONT></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
    shares</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares*</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Par
    value*</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">paid-in
    capital</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">deficit</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 40%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE,
    June 30, 2019</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000,000</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">256</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,838,877</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,838,521</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(298,016</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(298,016</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE,
    December 31, 2019</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000,000</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">256</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,136,893</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,136,537</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
    shares</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Par
    value</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">paid-in
    capital</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">deficit</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 40%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE,
    June 30, 2020</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000,000</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">256</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,651,248</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,650,892</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(333,848</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(333,848</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE,
    December 31, 2020</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000,000</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">256</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,985,096</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,984,740</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"> * </TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> Giving
                                            retroactive effect to the 1000-for-1 share split effected on May 31, 2021 </P></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="f2_004"></A>REGENCELL
BIOSCIENCE HOLDINGS LIMITED AND SUBSIDIARIES</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNAUDITED
CONDENSED <FONT STYLE="text-transform: uppercase">CONSOLIDATED STATEMENTS OF cash flows</FONT></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Six Months Ended</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Six Months Ended</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;31,</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;31,</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    FLOWS FROM OPERATING ACTIVITIES:</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left; padding-left: 9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(333,848</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(298,016</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    to reconcile net loss to net cash used in operating activities:</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,337</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in operating assets and liabilities</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
    deposit</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(388</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,718</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(52,866</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 27pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used in operating activities</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(373,765</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(316,734</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    FLOWS FROM INVESTING ACTIVITIES:</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase
    of property and equipment</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,272</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(51,282</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 27pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used in investing activities</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,272</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(51,282</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    FLOWS FROM FINANCING ACTIVITIES:</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
    of offering costs</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(165,056</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from shareholder&rsquo;s loans</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">473,070</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">991,530</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 27pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by financing activities</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">308,014</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">991,530</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    CHANGE IN CASH</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(81,023</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">623,514</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH,
    beginning of period</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">386,979</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">243,307</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH,
    end of period</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">305,956</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">866,821</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUPPLEMENTAL
    CASH FLOW INFORMATION:</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for income tax</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for interest</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="f2_005"></A>Note
1 &ndash; Nature of business and organization</B></FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regencell
Bioscience Holdings Limited (&ldquo;Regencell&rdquo; or the &ldquo;Company&rdquo;) is a holding company incorporated as an exempted company
on October 30, 2014, under the laws of the Cayman Islands and holding all of the outstanding share capital of Regencell Limited (Hong
Kong), established under the laws of Hong Kong on November 20, 2014, and Regencell Bioscience Limited (Hong Kong), established under
the laws of Hong Kong on May 12, 2015.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, through its controlling interests in the wholly owned subsidiaries, operates an early-stage bioscience company that focuses
on research, development and commercialization of Traditional Chinese Medicine (&ldquo;TCM&rdquo;) for the global treatment of neurocognitive
disorder and degeneration, specifically for Attention Deficit Hyperactivity Disorder (&ldquo;ADHD&rdquo;) and Autism Spectrum Disorder
(&ldquo;ASD&rdquo;). The Company is in the research and development stage and has not yet generated any revenue since inception.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2018, the Company entered into Strategic Partnership Agreement with Mr. Sik-Kee Au (the &ldquo;TCM Practitioner&rdquo;), the
father of Mr. Yat-Gai Au, CEO of the Company. Pursuant to the Strategic Partnership Agreement, the Company has exclusive rights including
the intellectual property rights and ownership of all his TCM formulae. Any inventions, TCM formulae, utilities, models&rsquo; improvements,
research, discoveries, designs, processes, methods of manufacture, and products conceived or made by the TCM Practitioner in relation
to TCM shall be the sole and exclusive property of the Company.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Strategic Partnership Agreement does not have a termination date and will remain effective indefinitely under Hong Kong law. The Strategic
Partnership Agreement can be amended or terminated by the mutual written agreement of the parties without breach. Pursuant to the Strategic
Partnership Agreement, in exchange for the rights, the Company is required to donate three percent (3.0%) of net revenue that the Company
generates in association with the use and/or commercialization of the TCM formulae to any of charitable institutions and/or trusts of
a public character anywhere in the world at the sole and absolute choice of the TCM Practitioner and in such proportion at the sole and
absolute discretion of the TCM practitioner on a yearly basis. The Company also undertakes to pay for all reasonable costs and expenses
incurred by the TCM Practitioner in relation to the research and development of the TCM formulae for ADHD and ASD. All research and development
costs and expenses incurred by the TCM Practitioner are charged to operations as incurred.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Impact
of COVID-19</U></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> In December 2019, a novel strain of coronavirus,
or COVID-19, surfaced and it has spread rapidly to many parts of China and other parts of the world, including the United States. The
epidemic has resulted in quarantines, travel restrictions, and the temporary closure of stores and facilities in China and elsewhere.
To date, the Company has not experienced material business disruptions or impairments of any of its assets as a result of the pandemic.
The Company plans to continue to follow recommendations from local governments regarding workplace policies, practices and procedures.
The Company expects to continue to monitor the situation and take actions as may be required or recommended by government authorities
or as the Company determines are in the best interests of its employees and other business partners. The Company is continuing to monitor
the potential impact of the pandemic, but the Company cannot be certain what the overall impact will be on its business, financial condition,
results of operations and prospects. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has funded its operations primarily from shareholder&rsquo;s loans (&ldquo;SH Loans&rdquo;) provided by Mr. Yat-Gai Au (&ldquo;Founder
and CEO&rdquo;). The accompanying consolidated financial statements reflect the activities of the Company and each of the following entities:</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 13%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of Entity</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 36%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal
    Activities</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; vertical-align: bottom; width: 30%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Place
    and Date of Incorporation</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%; padding-bottom: 1.5pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 18%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ownership</B></FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regencell
    Bioscience Limited (Hong Kong)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
                                            Research and Development</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.05pt; text-indent: -14.05pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;Day-to-day
    operations</FONT> </P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong, incorporated on May 12, 2015</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    owned by Regencell Bioscience Holdings Limited</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regencell
    Limited (Hong Kong)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
                                            Production and testing laboratory</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Research and Development</FONT> </P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong, incorporated on November 20, 2014</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    owned by Regencell Bioscience Holdings Limited</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
2 &ndash;Going Concern </B></FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> In accordance with Accounting Standards Update
(&ldquo;ASU&rdquo;) 2014-15, Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern (Subtopic 205-40),
the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the
Company&rsquo;s ability to continue as a going concern within one year after the date that the consolidated financial statements are
issued. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The Company has incurred recurring negative cash flows since inception
and has funded its operations primarily from shareholder loans. The Company had an accumulated deficit of approximately $2.99 million
and $2.65 million as of December 31, 2020 and June 30, 2020, respectively. The Company had net losses of approximately $0.33 million
and $0.30 million for the six months ended December 31, 2020 and 2019, respectively. The Company has received funding in the form of
shareholders loans to support its capital needs. The Company&rsquo;s ability to continue as a going concern is highly contingent on the
ability to raise additional capital for ongoing research and development as the Company expects to continue incurring losses for the
foreseeable future. The Company has received additional funding subsequent to December 31, 2020 in the form of additional shareholder
loans of $84,998 as of the date of this report. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> The Company intends to pursue a public offering
of its ordinary shares to fund future operations. If the Company is unable to complete a public offering for a sufficient amount in a
timely manner, it would need to pursue other financing alternatives such as private financing of debt or equity or collaboration agreements.
There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on
terms acceptable to the Company, or at all. If the Company is unable to obtain sufficient funding, it could be required to delay its
development efforts, limit activities and reduce research and development costs, which could adversely affect its business prospects. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> Based on the Company&rsquo;s recurring losses
and negative cash flows from operations since inception, expectation of continuing operating losses and negative cash flows from operations
for the foreseeable future, and the need to raise additional capital to finance its future operations, the Company&rsquo;s management
concluded that there is uncertainty in the Company&rsquo;s ability to continue as a going concern within one year after the issuance
date of the consolidated financial statements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> The accompanying unaudited condensed unaudited
condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly,
the unaudited condensed unaudited condensed consolidated financial statements have been prepared on a basis that assumes the Company
will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in
the ordinary course of business. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
3 &ndash; Summary of significant accounting policies</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Basis
of presentation</U></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> The accompanying unaudited condensed consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&ldquo;U.S.
GAAP&rdquo;) pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;). Certain information
and footnote disclosures normally included in financial statements prepared in conformity with U.S. GAAP have been condensed or omitted
pursuant to such rules and regulations. The results of operations are not necessarily indicative of results to be expected for any other
interim period or for the full year. Accordingly, these statements should be read in conjunction with the Company&rsquo;s audited financial
statements as of and for the years ended June 30, 2020 and 2019.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <U>Principles of consolidation</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> The unaudited condensed consolidated financial
statements include the financial statements of the Company and its subsidiaries. All intercompany transactions and balances among the
Company and its subsidiaries have been eliminated upon consolidation.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> Subsidiaries are those entities in which the
Company, directly or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating
policies, to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of
directors. </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <U>Use of estimates and assumptions</U> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> The preparation of unaudited condensed consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the unaudited condensed consolidated
financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates
reflected in the Company&rsquo;s unaudited condensed consolidated financial statements required to be made by management include, but
not limited to, the useful lives of property and equipment, impairment of long-lived assets and uncertain tax position. Actual results
could differ from these estimates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <U>Risks and Uncertainties</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> The Company operates in an industry that is
subject to intense competition, government regulations and rapid technological changes. Operations are subject to significant risk and
uncertainties including financial, operational, technological, regulatory, and other risks, including the potential risk of business
failure. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <U>Segment</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> Operating segments are defined as components
of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision
maker (&ldquo;CODM&rdquo;), or decision making group, in deciding how to allocate resources and in assessing performance. The CODM is
comprised of certain members of the Company&rsquo;s management team. The Company has one operating segment. The Company&rsquo;s CODM
manages the Company&rsquo;s operations on a consolidated basis for the purpose of allocating resources. All of the Company&rsquo;s long-lived
assets are held in Hong Kong. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <U>Foreign currency translation and transaction
</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> The reporting currency of the Company is the
United States dollar (&ldquo;$&rdquo;). The Company conducts its businesses in Hong Kong in the local currency, Hong Kong Dollar (&ldquo;HK$&rdquo;),
as its functional currency. The consolidated balance sheet accounts, statement of operations accounts and equity accounts are all translated
at the exchange rate as quoted by the Hong Kong Monetary Authority (&ldquo;HKMA&rdquo;). The Company considers the foreign exchange risk
in relation to transactions denominated in HK$ with respect to $ is not significant as HK$ is pegged to $. The HKMA guarantees to exchange
US dollars into Hong Kong dollars, or vice versa, at the rate of HK$7.80 to $1.00. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> Monetary assets and liabilities denominated
in currencies other than the functional currency are translated into the functional currency at the rates of exchange existing at the
balance sheet date. Transactions in currencies other than the functional currency during the year are converted into the functional currency
at the applicable rates of exchange prevailing at the transaction date. Transaction gains and losses are recognized in &ldquo;other income,
net&rdquo;. Assets and liabilities denominated in foreign currencies are translated at the exchange rates at the balance sheet date.
Equity accounts are translated at historical exchange rates and revenues, expenses, gains and losses are translated using the average
rate for the year. Translation adjustments are reported as cumulative translation adjustments and are shown as a separate component of
other comprehensive loss in the consolidated statements of changes in shareholders&rsquo; deficit and comprehensive loss. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <U>Cash </U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> Cash represents demand deposits placed with
banks or other financial institutions, which are unrestricted as to withdrawal or use, and which have original maturities of three months
or less and are readily convertible to known amounts of cash. All of the cash balances as at December 31, 2020 and June 30, 2020, were
maintained at financial institutions in Hong Kong, and were insured by the Hong Kong Deposit Protection Board up to a limit of HK $500,000
(approximately $64,000). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <U>Property and equipment, net</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> Property and equipment are stated at cost
less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets.
The estimated useful lives are as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 50%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; width: 49%; border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Useful&nbsp;Life</B></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold&nbsp;&nbsp;improvement</FONT> </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Shorter of the remaining lease </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> terms or estimated useful lives </P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> The cost and related accumulated depreciation
of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the consolidated statements
of operations and comprehensive loss. Expenditures for maintenance and repairs are charged to earnings as incurred, while additions,
renewals and betterments, which are expected to extend the useful life of assets, are capitalized. The Company also re-evaluates the
periods of depreciation to determine whether subsequent events and circumstances warrant revised estimates of useful lives. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <U>Deferred Offering Costs </U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> Deferred offering costs consisted of legal,
accounting, underwriting fees and other costs through the balance sheet date that are directly related to the Initial Public Offering
and that will be charged to shareholders&rsquo; equity upon the completion of the Initial Public Offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <U>Long-term deposit</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> Long-term deposit presents the deposit paid
to the landlord as required on the signing of the lease agreement and thereafter, to be held by the landlord as security for the performance
of the Company&rsquo;s obligations under the lease agreement. The deposit is classified as either current or non-current based on the
terms of the respective agreement. The deposit is unsecured and is reviewed periodically to determine whether its carrying value has
become impaired. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <U>Impairment for long-lived assets</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> Long-lived assets, including property and
equipment with finite lives are reviewed for impairment whenever events or changes in circumstances (such as a significant adverse change
to market conditions that will impact the future use of the assets) indicate that the carrying value of an asset may not be recoverable.
The Company assesses the recoverability of the assets based on the undiscounted future cash flows the assets are expected to generate
and recognize an impairment loss when estimated undiscounted future cash flows expected to result from the use of the asset plus net
proceeds expected from disposition of the asset, if any, are less than the carrying value of the asset. If an impairment is identified,
the Company would reduce the carrying amount of the asset to its estimated fair value based on a discounted cash flows approach or, when
available and appropriate, to comparable market values. For the six months ended December 31, 2020, and 2019, no impairment of long-lived
assets was recognized.&nbsp; </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <U>Fair value measurement </U> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> ASC 825-10 requires certain disclosures regarding
the fair value of financial instruments. Fair value is defined as the price that would be received to sell an asset or paid to transfer
a liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy prioritizes
the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use
of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 48px"> &nbsp; </TD>
    <TD STYLE="text-align: left; width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: left; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 &mdash; inputs to
    the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</FONT> </TD></TR>
  </TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 48px; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: left; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 &mdash; inputs to
    the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for identical
    or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived from or
    corroborated by observable market data.</FONT> </TD></TR>
  </TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 48px"> &nbsp; </TD>
    <TD STYLE="text-align: left; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 &mdash; inputs to the valuation methodology
    are unobservable.</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>


<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> Unless otherwise disclosed, the fair value
of the Company&rsquo;s financial instruments including cash and shareholder&rsquo;s loans approximates their recorded values due to their
short-term maturities. The fair value of the long-term deposit approximates their carrying amounts because the deposit was paid in cash. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <U>Research and development </U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> Research and development costs are charged
to operations as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in future
research and development activities as expenses when the goods have been received or when the service has been performed rather than
when the payment is made. Research and development expenses consist of costs incurred by the Company for the discovery and development
of the Company&rsquo;s product candidates. Research and development costs include, but not limited to, payroll and personnel expenses
including stock-based compensation, research studies supplies, fees for research studies services, consulting costs, and allocated overhead,
including rent, equipment, and utilities. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <U>Employee benefit plan</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> Employees of the Company located in Hong Kong
participate in a compulsory saving scheme (pension fund) for the retirement of residents in Hong Kong. Employees are required to contribute
monthly to mandatory provident fund schemes provided by approved private organizations, according to their salaries and the period of
employment. The Company is required to contribute to the plan based on certain percentages of the employees&rsquo; salaries, up to a
maximum amount specified by the local government. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <U>Operating leases</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> A lease for which substantially all the benefits
and risks incidental to ownership remain with the lessor is classified by the lessee as an operating lease. All leases of the Company
are currently classified as operating leases. The Company records the total expenses on a straight-line basis over the lease term. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <U>Related Parties </U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> Parties, which can be a corporation or individual,
are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant
influence over the other party in making financial and operational decisions. Companies are also considered to be related if they are
subject to common control or common significant influence, such as a family member or relative, shareholder, or a related corporation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <U>Income taxes</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> The Company accounts for current income taxes
in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between
the tax bases of assets and liabilities and their reported amounts in the unaudited condensed consolidated financial statements. Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized
in income in the period including the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets
to the amount expected to be realized. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> An uncertain tax position is recognized as
a benefit only if it is &ldquo;more likely than not&rdquo; that the tax position would be sustained in a tax examination. The amount
recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not
meeting the &ldquo;more likely than not&rdquo; test, no tax benefit is recorded. Penalties and interest incurred related to underpayment
of income tax are classified as income tax expense in the period incurred. No significant penalties or interest relating to income taxes
have been incurred during the six months ended December 31, 2020 and 2019. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <U>(Loss) earnings per share</U> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> The Company computes (loss) earnings per share
(&ldquo;EPS&rdquo;) in accordance with ASC 260, &ldquo;Earnings per Share&rdquo;. ASC 260 requires companies to present basic and diluted
EPS. Basic EPS is measured as net income (loss) divided by the weighted average ordinary share outstanding for the period. Diluted EPS
presents the dilutive effect on a per share basis of the potential Ordinary Shares (e.g., convertible securities, options and warrants)
as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential Ordinary Shares that have
an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of
diluted EPS. For the six months ended December 31, 2020 and 2019, there were no dilutive shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <U>Commitments and Contingencies</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> In the normal course of business, the Company
is subject to contingencies, including legal proceedings and claims arising out of the business that relate to a wide range of matters,
such as government investigations and tax matters. The Company recognizes a liability for such contingency if it determines it is probable
that a loss has occurred and a reasonable estimate of the loss can be made. The Company may consider many factors in making these assessments
including historical and the specific facts and circumstances of each matter. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <U>Concentration of credit risk</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> Financial instruments that potentially subject
the Company to concentration of credit risks consist primarily of cash, the balances of which are stated on the consolidated balance
sheets which represent the Company&rsquo;s maximum exposure. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> The Company places its cash in good credit
quality financial institutions in Hong Kong. The Company deposits its cash in financial institutions that it believes have high credit
quality and have not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the
normal credit risk associated with commercial banking relationships. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <U>Recently issued accounting pronouncements</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> The Company considers the applicability and
impact of all accounting standards updates (&ldquo;ASUs&rdquo;). Management periodically reviews new accounting standards that are issued.
Under the Jumpstart Our Business Startups Act of 2012, as amended (&ldquo;the JOBS Act&rdquo;), the Company meets the definition of an
emerging growth company, or EGC, and has elected the extended transition period for complying with new or revised accounting standards,
which delays the adoption of these accounting standards until they would apply to private companies. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> In February 2016, the FASB issued Accounting
Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02). ASU 2016-02 requires an entity to recognize lease assets and lease liabilities
on the balance sheet and to disclose key information about the entity&rsquo;s leasing arrangements. ASU 2016-02 is effective for fiscal
years beginning after December 15, 2018, and interim periods within those fiscal years. A modified retrospective approach is required.
In January 2018, the FASB issued ASU 2018-01, Leases: Land Easement Practical Expedient for Transition. This ASU clarifies the accounting
and reporting of land easements. In July 2018, the FASB issued ASU No. 2018-10, &ldquo;Codification Improvements to Topic 842, Leases,&rdquo;
(&ldquo;ASU 2018-10&rdquo;), to clarify how to apply certain aspects of the new lease accounting standard. The amendments in this update,
among other things, better articulates the requirement for a lessee&rsquo;s reassessment of lease classification as of the effective
date of a modification, clarifies that a change to an index or rate for variable lease payments does not constitute a resolution of a
contingency that would result in the remeasurement of lease payments, and requires entities that apply Topic 842 retrospectively to each
reporting period and do not adopt the practical expedients to write off any prior unamortized initial direct costs that do not meet the
definition under Topic 842 to equity. The amendments in this update have the same effective date and transition requirements as the new
lease standard summarized above. Also, in July 2018, the FASB issued ASU No. 2018-11, &ldquo;Leases (Topic 842): Targeted Improvements,&rdquo;
(&ldquo;ASU 2018-11&rdquo;), to provide an additional transition method. An entity can now elect not to present comparative financial
information under Topic 842 if it recognizes a cumulative-effect adjustment to retained earnings upon adoption. On November 15, 2019,
the FASB issued ASU 2019-10, which amends the effective dates for certain major new accounting standards, including Topic 842, to give
implementation relief to certain types of entities. As an emerging growth company, the Company can adopt Topic 842 on July 1, 2021. The
Company is evaluating the impact this ASU will have on its unaudited condensed consolidated financial statements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> In June 2016, the FASB amended guidance related
to the impairment of financial instruments as part of ASU2016-13 Financial Instruments &ndash; Credit Losses (Topic 326): Measurement
of Credit Losses on Financial Instruments, which was effective from January 1, 2020. The guidance replaces the incurred loss impairment
methodology with an expected credit loss model for which a company recognizes an allowance based on the estimate of expected credit loss.
In November 2018, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Finance&ndash;l Instruments - Credit Losses,
which clarified that receivables from operating leases are not within the scope of Topic 326 and instead, impairment of receivables arising
from operating leases should be accounted for in accordance with Topic 842. On May 15, 2019, the FASB issued ASU 2019-05, 9 which provides
transition relief for entities adopting the Board&rsquo;s credit losses standard, ASU 2016-13. Specifically, ASU 2019-05 amends ASU 2016-13
to allow companies to irrevocably elect, upon adoption of ASU 2016-13, the fair value option for financial instruments that (1) were
previously recorded at amortized cost and (2) are within the scope of the credit losses guidance in ASC 326-20, (3) are eligible for
the fair value option under ASC 825-10, and (4) are not held-to-maturity debt securities. For entities that have adopted ASU 2016-13,
the amendments in ASU 2019-05 are effective for fiscal years beginning after December 15, 2019, including interim periods therein. An
entity may early adopt the ASU in any interim period after its issuance if the entity has adopted ASU 2016-13. In November 2019, the
FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-02 for private companies, not-for-profit organizations
and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date for these preparers
is for fiscal years beginning after December 15, 2022. For all other entities, the effective date will be the same as the effective date
of ASU 2016-13. The Company does not expect this guidance will have a material impact on its unaudited condensed consolidated financial
statements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> Except for the above-mentioned pronouncements,
there are no new recent issued accounting standards that will have a material impact on the unaudited condensed consolidated financial
position, statements of operations and cash flows. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
4 &ndash; Property and equipment, net</B></FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consist of the following:</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;31,<BR>
    2020</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&nbsp;30,<BR>
    2020</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left; text-indent: -19.8pt; padding-left: 19.8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvement</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">133,109</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">117,837</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -19.8pt; padding-left: 19.8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    accumulated depreciation</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22,853</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,516</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">110,256</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">108,321</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  </TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the six months ended December 31, 2020 and 2019 amounted to $13,337 and nil, respectively.</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5 &ndash; Related Party Transaction</B></FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended December 31, 2020 and 2019, the Company has an office rental agreement with Ace United International Limited, which
is a company wholly owned by the Company&rsquo;s Founder and CEO. The Company has paid a monthly rent of $4,103 and the terms of the
agreement are renewed on an annual basis from the 1<SUP>st</SUP> of January to the 31<SUP>st</SUP> of December each year. The rental
payment is expensed as incurred.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, and June 30, 2020, the Company has outstanding Shareholder Loans amounting to approximately $3.54 million and $3.07
million, respectively, from the Founder and CEO. The amounts borrowed are non-interest bearing and due on-demand.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On February 2, 2021, a loan extension agreement was entered by
Mr. Yat-Gai Au and Regencell Bioscience Limited, pursuant to which Mr. Yat-Gai Au agreed to provide up to $3 million in the form of loans
or to make payments on behalf of the Company during the period from January 1, 2021 to June 30, 2022 to support its operations and research
activities for the period from January 1, 2021 through June 30, 2022 and to further extend the maturity date of the existing loans from
June 30, 2021 to December 31, 2022. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On March 18, 2021, a supplemental loan agreement was entered by
and between Regencell Bioscience Limited and Mr. Yat-Gai Au, pursuant to which Mr. Yat-Gai Au will waive the amount of $3.25 million
of the outstanding loan upon the receipt of a convertible promissory note (the &ldquo;Note&rdquo;) issued by the Company in the principal
amount of $3,250,000. On March 18, 2021, the Company issued the Note to Mr. Yat-Gai Au in the principal amount of $3,250,000, automatically
convertible into Ordinary Shares, upon the completion of the Company&rsquo;s initial public offering at the same price as the offering
price per Ordinary Shares to be issued in the initial public offering. The Note does not carry any interest. The Note, if not automatically
converted, will mature and become payable twelve months after the issuance date of the note and the date when the Company redeems the
Note. </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
6 &ndash; Taxes</B></FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Income
tax</U></FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cayman
Islands</I></FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gains. Additionally, upon payments of
dividends to the shareholders, no Cayman Islands withholding tax will be imposed.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;&nbsp;</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Hong
Kong</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
incorporated in Hong Kong are subject to Hong Kong profits tax at a rate of 16.5% on the estimated assessable profit for the six months
ended December 31, 2020 and 2019.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table reconciles statutory tax rates to the Company&rsquo;s effective tax rate for the periods indicated below:</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the six months ended<BR> December&nbsp;31,<BR> 2020</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the six months ended<BR> December&nbsp;31,<BR> 2019</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left; text-indent: -19.8pt; padding-left: 19.8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    benefit calculated at statutory tax rate</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.5</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.5</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -19.8pt; padding-left: 19.8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
    allowance</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16.5</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16.5</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    tax rate</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the significant components of the aggregate deferred tax assets:</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of <BR> December&nbsp;31, <BR> 2020</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of <BR> June&nbsp;30, <BR> 2020</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    tax assets:</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left; text-indent: -19.8pt; padding-left: 19.8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    operating loss carry forwards</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">492,541</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">437,456</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -19.8pt; padding-left: 19.8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    valuation allowance</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(492,541</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(437,456</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    tax asset, net</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  </TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those
temporary differences become deductible. Management considers the cumulative earnings and projected future taxable income in making this
assessment. Recovery of substantially all of the Company&rsquo;s deferred tax assets is dependent upon the generation of future income,
exclusive of reversing taxable temporary differences. Based upon historical operating results and projections for future taxable income,
management provided full valuation allowance for the deferred tax assets for the six months ended December 31, 2020 and 2019.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical
merits, and measure the unrecognized benefits associated with the tax positions. As of December 31, 2020, and June 30, 2020, the Company
did not have any significant unrecognized uncertain tax positions. The Company did not incur any interest and penalties related to potential
underpaid income taxes for the six months ended December 31, 2020 and 2019. The Company also does not anticipate any significant increases
or decreases in unrecognized tax benefits in the next 12 months from December 31, 2020.</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
7 &ndash; Shareholder&rsquo;s deficit</B></FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Regencell Bioscience Holdings Limited (Cayman) was established
under the laws of Cayman Islands on October 30, 2014. The authorized number of ordinary shares is 100,000,000 shares with a par value
of $0.01 per ordinary share, and 10,000 ordinary shares were issued and outstanding as of December 31, 2020 and June 30, 2020, respectively.
On May 31, 2021, the board of directors approved a share split of the Company&rsquo;s authorized number of Ordinary Shares at a ratio
of 1,000-for-1. After the stock split, the Company&rsquo;s authorized number of Ordinary Shares was 100,000,000,000 shares with par value
of $0. 00001 per share and 10,000,000 shares were issued and outstanding accordingly. The Company believes it is appropriate to reflect
these share issuances as nominal share issuance on a retroactive basis similar to stock split pursuant to ASC 260. The Company has retroactively
adjusted all shares and per share data for all the periods presented. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, and June 30, 2020, additional paid-in capital in the consolidated balance sheets represented the combined contributed
capital of the Company&rsquo;s subsidiaries.</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
8 &ndash; Commitments and contingencies</B></FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Office
lease commitments</U></FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into two lease agreements for office space with the latest expiring date of July 14, 2024. The Company&rsquo;s commitment
for lease payments under the operating leases as of December 31, 2020 and for the next four years are as follow:</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Twelve
    months ending December 31,</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    leases</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">161,538</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">112,308</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">112,308</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65,513</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    payments</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">451,667</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  </TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
expense for the six months ended December 31, 2020 and 2019 was $82,003 and $71,410, respectively.</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Contingencies</U></FONT> </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company may be subject to certain legal proceedings, claims and disputes that arise in the ordinary course of business.
Although the outcomes of these legal proceedings cannot be predicted, the Company does not believe these actions, in the aggregate, will
have a material adverse impact on its financial position, results of operations or liquidity.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
9 &ndash; Subsequent events</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated all events and transactions that occurred after December 31, 2020 up through the date the Company issued these unaudited
condensed consolidated financial statements on April 26, 2021, for disclosure or recognition in the unaudited condensed consolidated
financial statements of the Company as appropriate.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On May 31, 2021, the Company adopted a 2021 Share Option Plan (the
&ldquo;Plan&rdquo;). The Plan is a share-based compensation plan that provides for discretionary grants of share options to key employees,
directors and consultants of the Company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On June 9, 2021, the board of the Company granted issuance of 1,235,074
options to its certain officers, directors and employees, under the Plan; provided that 46,755 options granted to the independent director
nominees will become effective upon the effectiveness of the Registration Statement when the nominee&rsquo;s directorship becomes effective.
These options will be exercisable at $9.50 per share, of which 25% vest on each anniversary over four years following the closing of
this offering and is valid for 10 years once vested. </P>
<P STYLE="margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INFORMATION NOT
REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 6. Indemnification of Directors and Officers</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">Our Amended Articles
provide that the Company shall indemnify each existing or former director (including alternate director), secretary and other
officer of the Company (including an investment adviser or an administrator or liquidator) and their personal representatives
against:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 38.25pt"></TD><TD STYLE="text-align: left; width: 33.75pt">(a)</TD><TD STYLE="text-align: left">all
                                         actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred
                                         or sustained by the existing or former director (including alternate director), secretary
                                         or officer in or about the conduct of the Company&rsquo;s business or affairs or in the
                                         execution or discharge of the existing or former director&rsquo;s (including alternate
                                         director&rsquo;s), secretary&rsquo;s or officer&rsquo;s duties, powers, authorities or
                                         discretions; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 1in; text-indent: -33.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 38.25pt"></TD><TD STYLE="text-align: left; width: 33.75pt">(b)</TD><TD STYLE="text-align: left">all
                                         costs, expenses, losses or liabilities incurred by the existing or former director (including
                                         alternate director), secretary or officer in defending (whether successfully or otherwise)
                                         any civil, criminal, administrative or investigative proceedings (whether threatened,
                                         pending or completed) concerning the Company or its affairs in any court or tribunal,
                                         whether in the Cayman Islands or elsewhere.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 1in; text-indent: -33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">According to our Memorandum
of Association and Articles, no such existing or former director (including alternate director), secretary or officer, however,
shall be indemnified in respect of any matter arising out of his own dishonesty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7. Recent Sales of Unregistered Securities</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On March 18, 2021, the Company issued a convertible
promissory note (the &ldquo;Note&rdquo;) in the principal amount of $3,250,000 to Mr. Yat-Gai Au, the CEO and director of the Company,
in exchange for his waiver of loan at the amount of $3,250,000 owed by Regencell Bioscience Limited, our wholly-owned subsidiary. All
of the Notes shall be converted automatically into the number of fully paid and non-assessable shares of Ordinary Shares, upon the completion
of the Company&rsquo;s initial public offering, at the same price as the offering price per Ordinary Shares to be issued in the initial
public offering. The Note does not carry any interest. The Note, if not automatically converted, will mature and become payable twelve
months after the issuance date of the Note and the date when the Company redeems the Note. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On June 9, 2021, the board of the Company granted
issuance of 1,235,074 options to its certain officers, directors and employees, under the Plan; provided that 46,755 options granted
to the independent director nominees will become effective upon the effectiveness of the Registration Statement when the nominee&rsquo;s
directorship becomes effective. These options will be exercisable at $9.50 per share, of which 25% vest on each anniversary over four
years following the closing of this offering and is valid for 10 years once vested. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8. Exhibits and Financial Statement Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibits and Financial Statement Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(a) Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See Exhibit Index beginning on page II-4
of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(b) Financial Statement Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">Schedules have been
omitted because the information required to be set forth therein is not applicable or is shown in the Consolidated Financial Statements
or the Notes thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9. Undertakings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.25in">(1) To file, during any period
in which offers or sales are being made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(i) To include any prospectus required by Section
10(a)(3) of the Securities Act of 1933;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.5in">(ii) To reflect in the prospectus
any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment
hereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value
of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to
Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate
offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement; and</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.5in">(iii) To include any material
information with respect to the plan of distribution not previously disclosed in this registration statement or any material change
to such information in this registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 149; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.25in">(2) That, for the purpose of
determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.25in">(3) To remove from registration
by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">(4) That, for the purpose of
determining liability under the Securities Act of 1933 to any purchaser:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(i) If the Registrant is relying
on Rule 430B (&sect;230.430B of this chapter):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.9in">(A) Each prospectus filed by
the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus
was deemed part of and included in the registration statement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.9in">(B) Each prospectus required
to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating
to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section
10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier
of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities
in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that
is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to
the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement
or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference
into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of
contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or
prospectus that was part of the registration statement or made in any such document immediately prior to such effective date;
or</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.5in">(ii) If the Registrant is subject
to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other
than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to
be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however,
that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration
statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that
was made in the registration statement or prospectus that was part of the registration statement or made in any such document
immediately prior to such date of first use.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.25in">(5) That, for the purpose of
determining liability of the Registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities,
the undersigned Registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this
registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller
to the purchaser and will be considered to offer or sell such securities to such purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.5in">(i) Any preliminary prospectus
or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.5in">(ii) Any free writing prospectus
relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.5in">(iii) The portion of any other
free writing prospectus relating to the offering containing material information about the undersigned Registrant or its securities
provided by or on behalf of the undersigned registrant; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.5in">(iv) Any other communication
that is an offer in the offering made by the undersigned registrant to the purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.25in">(6) To file a post-effective
amendment to the registration statement to include any financial statements required by item 8.A. of Form 20-F at the start of
any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3)
of the Act need not be furnished, provided, that the Registrant includes in the prospectus, by means of a post-effective amendment,
financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information
in the prospectus is at least as current as the date of those financial statements.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.25in">(7) For purposes of determining
any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration
statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant under Rule 424(b)(1) or (4)
or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.25in">(8) For the purpose of determining
any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> (b) Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions described
in Item 6, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 10%; border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT> </TD>
    <TD STYLE="vertical-align: top; width: 2%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: bottom; width: 88%; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD><A HREF="ea142369ex1-1_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriting Agreement</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> 3.1 </TD>
    <TD> &nbsp; </TD>
    <TD> <A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex3-1_regencell.htm"> Memorandum and Articles
    of Association* </A> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD><A HREF="ea142369ex3-2_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Memorandum and Articles of Association</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD><A HREF="ea142369ex4-1_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Certificate for Ordinary Shares</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD><A HREF="ea142369ex1-1_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representative&rsquo;s Warrants (included in Exhibit 1.1)</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD><A HREF="ea142369ex5-1_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Ogier regarding the validity of the Ordinary Shares being registered</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> 5.2 </TD>
    <TD> &nbsp; </TD>
    <TD><A HREF="ea142369ex5-2_regencell.htm"> Opinion of Hunter Taubman Fischer &amp; Li LLC </A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex8-1_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Messina Madrid Law P.A. regarding certain U.S. Federal Income Taxation matters*</FONT> </A> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex10-1_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deed
    of Rights Transfer, Strategic Partnership and Undertaking between Sik-Kee Au and Regencell Bioscience Limited dated January 1, 2018*
    </FONT></A> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex10-2_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
    and Restated Employment Agreement by and between CEO Yat-Gai Au and the Company dated February 2, 2021*</FONT> </A> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex10-3_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
    Agreement of Deed of Rights Transfer, Strategic Partnership and Undertaking between Sik-Kee Au and Regencell Bioscience Limited dated
    November 10, 2020*</FONT> </A> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <A HREF="https://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex10-4_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan
    Agreement between Yat-Gai Au and the Company dated November 10, 2020*</FONT> </A> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex10-5_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
    Agreement between Dr. Yi-Chung Chao and Regencell Bioscience Limited dated July 15, 2019*</FONT> </A> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex10-6_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
    Agreement between Mr. James Wai Hong Chung and Regencell Bioscience Limited dated July 6, 2019*</FONT> </A> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex10-7_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
    Agreement between Mr. Tien Hsiang Chau and Regencell Bioscience Limited dated January 18, 2021*</FONT> </A> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex10-8_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan
    Extension Agreement between Yat-Gai Au and the Company dated February 2, 2021*</FONT> </A> </TD></TR>

<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-size: 10pt">10.9</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex10-9_regencell.htm"> <FONT STYLE="font-size: 10pt">Supplemental
    Loan Agreement by and between Yat-Gai Au and Regencell Bioscience Limited dated March 18, 2021*</FONT> </A> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-size: 10pt">10.10</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex10-10_regencell.htm"> <FONT STYLE="font-size: 10pt">Convertible
    Promissory Note issued by Regencell Bioscience Holdings Limited dated March 18, 2021*</FONT> </A> </TD></TR>

<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> 10.11 </TD>
    <TD> &nbsp; </TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><A HREF="ea142369ex10-11_regencell.htm"> Form of Director Offer Letter </A></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> 10.12 </TD>
    <TD> &nbsp; </TD>
    <TD><A HREF="ea142369ex10-12_regencell.htm"> Form of Option Agreement </A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 10%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT> </TD>
    <TD STYLE="width: 2%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 88%"> <A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex21-1_regencell.htm">
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries*</FONT> </A> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD><A HREF="ea142369ex23-1_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Friedman LLP</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex8-1_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Messina Madrid Law P.A. (included in Exhibit 8.1)*</FONT> </A> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> 23.3 </TD>
    <TD> &nbsp; </TD>
    <TD><A HREF="ea142369ex5-2_regencell.htm"> Consent of Hunter Taubman Fischer &amp; Li LLC (included in Exhibit 5.2) </A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021022860/ea139606ex99-1_regencellbio.htm">Code
    of Business Conduct and Ethics of the Registrant*</A></FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex99-2_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Evana Yee Wah Hui*</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex99-3_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Paul J. Niewiadomski*</FONT> </A> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex99-4_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Cheung Ming Wong*</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex99-5_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Persistence Market Research*</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.6</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <A HREF="http://www.sec.gov/Archives/edgar/data/1829667/000121390021016917/ea136947ex99-6_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Fortune Business Insights*</FONT> </A> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.35in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD><TD STYLE="padding-left: 1pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed</FONT> </TD>
</TR>
     </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pursuant to the requirements of the Securities
Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form
F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Hong
Kong, June 11, 2021. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regencell Bioscience Holdings Limited</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    <I>Yat-Gai Au</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp; </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yat-Gai Au </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and
    Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Signature</B></FONT> </TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="width: 31%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Capacity</B></FONT> </TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Date</B></FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt"><I>/s/ Yat-Gai
    Au</I></FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt">Chief Executive Officer and Director </FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt">June 11, 2021</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt">Yat-Gai Au</FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt"><I>/s/ Yi-Chung
    Chao</I></FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt">Chief Medical Officer and Director</FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt">June 11, 2021</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt">Yi-Chung Chao</FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt"><I>/s/ James
    Wai Hong Chung</I></FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt">Chief Strategy Officer</FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt">June 11, 2021</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt">James Wai Hong Chung</FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt"><I>/s/ Tien
    Hsiang Chau</I></FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt">Chief Financial Officer </FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt">June 11, 2021</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-size: 10pt">Tien Hsiang Chau</FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE OF AUTHORIZED REPRESENTATIVE
IN THE UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pursuant to the Securities Act of 1933 as amended,
the undersigned, the duly authorized representative in the United States of America, has signed this registration statement thereto in
New Castle, Delaware on June 11, 2021. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 1.8pt">Authorized U.S. Representative</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-bottom: black 1.5pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Donald J. Puglisi</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald J. Puglisi</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; width: 60%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; width: 4%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="padding-right: 0.8pt; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing
Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Puglisi &amp; Associates</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>







































































































</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ea142369ex1-1_regencell.htm
<DESCRIPTION>FORM OF UNDERWRITING AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 1.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">REGENCELL BIOSCIENCE HOLDINGS LIMITED</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNDERWRITING AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MAXIM GROUP LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">405 Lexington Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10174</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">As Representative of the Underwriters</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">named on <U>Schedule I</U> hereto</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned, Regencell
Bioscience Holdings Limited, a corporation incorporated under the laws of the Cayman Islands (the &ldquo;<B>Company</B>&rdquo;), hereby
confirms its agreement (this &ldquo;<B>Agreement</B>&rdquo;) to issue and sell to the underwriter or underwriters, as the case may be,
named in Schedule&nbsp;I hereto (each, an &ldquo;<B>Underwriter</B>&rdquo; and, collectively, the &ldquo;<B>Underwriters</B>;&rdquo;),
for whom Maxim Group LLC is acting as representative (in such capacity, the &ldquo;<B>Representative</B>&rdquo;), (A) an aggregate of
__________ ordinary shares (the &ldquo;<B>Firm Shares</B>&rdquo;) par value $0.00001 per share of the Company (&ldquo;<B>Ordinary Shares</B>&rdquo;)
and (B) at the election of the Representative, (i) up to an additional _______ Ordinary Shares (the &ldquo;<B>Option Shares</B>&rdquo;,
and together with the Firm Shares, the &ldquo;<B>Shares</B>&rdquo;). The offering and sale of the Shares contemplated by this Agreement
is referred to herein as the &ldquo;<B>Offering</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.&nbsp;<U>Securities;
Over-Allotment Option</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;<U>Purchase
of Firm Shares</U>. On the basis of the representations and warranties herein contained, but subject to the terms and conditions herein
set forth, the Company agrees to issue and sell, severally and not jointly, to the several Underwriters, an aggregate of __________ Firm
Shares at a purchase price of $_____ per Firm Share which represents a 7.5% discount to the public offering price per Firm Share (the
&ldquo;<B>Purchase Price</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;
The Underwriters, severally and not jointly, agree to purchase from the Company the number of Firm Shares set forth opposite their respective
names on <U>Schedule I</U> attached hereto and made a part hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;<U>Payment
and Delivery</U>. Delivery and payment for the Firm Shares shall be made at 10:00 a.m., New York time, on the second Business Day following
the effective date (the &ldquo;<B>Effective Date</B>&rdquo;) of the Registration Statement (as hereinafter defined) (or the third Business
Day following the Effective Date, if the Registration Statement is declared effective after 4:30 p.m. New York time) or at such earlier
time as shall be agreed upon by the Representative and the Company at the offices of the Representative or at such other place as shall
be agreed upon by the Representative and the Company. The hour and date of delivery and payment for the Firm Shares is called the &ldquo;<B>Closing
Date</B>.&rdquo; The closing of the payment of the purchase price for, and delivery of certificates representing, the Firm Shares is referred
to herein as the &ldquo;<B>Closing</B>.&rdquo; Payment for the Firm Shares shall be made on the Closing Date by wire transfer in Federal
(same day) funds upon delivery to you of certificates (in form and substance satisfactory to the Underwriters) representing the Firm Shares
(or through the full fast transfer facilities of the Depository Trust Company (the &ldquo;<B>DTC</B>&rdquo;)) for the account of the Underwriters.
The Firm Shares shall be registered in such name or names and in such authorized denominations as the Representative may request in writing
at least one Business Day prior to the Closing Date. The Company will permit the Representative to examine and package the Firm Shares
for delivery, at least one Business Day prior to the Closing Date. The Company shall not be obligated to sell or deliver the Firm Shares
except upon tender of payment by the Representative for all the Firm Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;<U>Over-allotment
Option</U>. For the purposes of covering any over-allotments in connection with the distribution and sale of the Firm Shares, the Representative
on behalf of the Underwriters are hereby granted an option (the &ldquo;<B>Over-Allotment Option&rdquo;)</B> to purchase up to an additional
_______ Option Shares. The purchase price to be paid for the Option Shares subject to the Over-Allotment Option will be equal to $______
per Option Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;<U>Exercise
of Option</U>. The Over-allotment Option granted pursuant to Section 1(d) hereof may be exercised by the Representative as to all (at
any time) or any part (from time to time) of the Option Shares within 45 days after the Closing Date. The Underwriters will not be under
any obligation to purchase any of such Option Shares prior to the exercise of the Over-allotment Option. The Over-allotment Option granted
hereby may be exercised by the giving of written notice to the Company from the Representative, setting forth the number of Option Shares
to be purchased and the date and time for delivery of and payment for such Option Shares, which will not be later than three Business
Days after the date of the notice or such other time as shall be agreed upon by the Company and the Representative, at the offices of
the Representative or at such other place as shall be agreed upon by the Company and the Representative. If such delivery and payment
for all of the Option Shares does not occur on the Closing Date, the date and time of the closing for such Option Shares will be as set
forth in the notice (hereinafter the &ldquo;<B>Option Closing Date</B>&rdquo;). Upon exercise of the Over-allotment Option, the Company
will become obligated to convey to the Underwriters, and, subject to the terms and conditions set forth herein, the Underwriters will
become obligated to purchase, the number of Option Shares specified in such notice. If any Option Shares are to be purchased, each Underwriter
agrees, severally and not jointly, to purchase the number of Option Shares (subject to such adjustments to eliminate fractional securities
as the Representative may determine) that bears the same proportion to the number of Firm Shares to be purchased as set forth on <U>Schedule
I</U> opposite the name of such Underwriter bears to the total number of Firm Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;<U>Payment
and Delivery of Option Shares</U>. Payment for Option Shares shall be made on the Option Closing Date by wire transfer in Federal (same
day) funds by deposit of the price for the Option Shares being purchased to the Company upon delivery to the Underwriters of certificates
(in form and substance satisfactory to the Underwriters) representing such Option Shares (or through the full fast transfer facilities
of DTC) for the account of the Underwriters. The certificates representing the Option Shares to be delivered will be in such denominations
and registered in such names as the Representative requests not less than one Business Day prior to the Closing Date or the Option Closing
Date, as the case may be, and will be made available to the Representative for inspection, checking and packaging at the aforesaid office
of the Company&rsquo;s transfer agent or correspondent not less than one Business Day prior to the Closing Date or the Option Closing
Date, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(g)&nbsp;<U>Representative&rsquo;s
Warrants</U>. The Company hereby agrees to issue to the Representative (and/or its designees) on the Closing Date, Warrants to purchase
______ Ordinary Shares (the &ldquo;<B>Closing Representative&rsquo;s Warrants</B>&rdquo;) and, on each Option Closing Date, Warrants to
purchase a number of Ordinary Shares up to an aggregate of 2.5% of the number of Shares issued at such Option Closing Date (the &ldquo;<B>Option
Representative&rsquo;s Warrants</B>&rdquo; and, together with the Closing Representative&rsquo;s Warrants, the &ldquo;<B>Representative&rsquo;s
Warrants</B>&rdquo;). The Representative&rsquo;s Warrants shall be exercisable, in whole or in part, commencing 180 days from the Effective
Date and expiring on the five-year anniversary of the Effective Date at an initial exercise price of $____ per Ordinary Share, which is
equal to one hundred and ten percent (110%) of the Offering price of a Share. The Representative&rsquo;s Warrants and the Ordinary Shares
issuable upon exercise of the Representative&rsquo;s Warrants are hereinafter referred to collectively as the &ldquo;<B>Representative&rsquo;s
Securities</B>.&rdquo; The Representative&rsquo;s Securities and the Shares shall be collectively referred to as the &ldquo;<B>Securities</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.&nbsp;<U>Representations
and Warranties of the Company</U>. The Company represents, warrants and covenants to, and agrees with, each of the Underwriters that,
as of the date hereof and as of the Closing Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;The
Company has prepared and filed with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) a registration statement
on Form F-1 (Registration No. 333-254571), and amendments thereto, and related preliminary prospectuses for the registration under the
Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), of the Securities which registration statement, as so amended
(including post-effective amendments, if any), has been declared effective by the Commission and copies of which have heretofore been
delivered to the Underwriters. The registration statement, as amended at the time it became effective, including the prospectus, financial
statements, schedules, exhibits and other information (if any) deemed to be part of the registration statement at the time of effectiveness
pursuant to Rule 430A under the Securities Act, is hereinafter referred to as the &ldquo;<B>Registration Statement</B>.&rdquo; If the
Company has filed or is required pursuant to the terms hereof to file a registration statement pursuant to Rule 462(b) under the Securities
Act registering additional Securities (a &ldquo;<B>Rule 462(b) Registration Statement</B>&rdquo;), then, unless otherwise specified, any
reference herein to the term &ldquo;<B>Registration Statement</B>&rdquo; shall be deemed to include such Rule 462(b) Registration Statement.
Other than a Rule 462(b) Registration Statement, which, if filed, becomes effective upon filing, no other document with respect to the
Registration Statement has heretofore been filed with the Commission. All of the Securities have been registered under the Securities
Act pursuant to the Registration Statement or, if any Rule 462(b) Registration Statement is filed, will be duly registered under the Securities
Act with the filing of such Rule 462(b) Registration Statement. The Company has responded to all requests of the Commission for additional
or supplemental information. Based on communications from the Commission, no stop order suspending the effectiveness of either the Registration
Statement or the Rule 462(b) Registration Statement, if any, has been issued and no proceeding for that purpose has been initiated or,
to the Company&rsquo;s knowledge, threatened by the Commission. The Company, if required by the Securities Act and the rules and regulations
of the Commission (the &ldquo;<B>Rules and Regulations</B>&rdquo;), proposes to file the Prospectus with the Commission pursuant to Rule
424(b) under the Securities Act (&ldquo;<B>Rule 424(b)</B>&rdquo;). The prospectus, in the form in which it is to be filed with the Commission
pursuant to Rule 424(b), or, if the prospectus is not to be filed with the Commission pursuant to Rule 424(b), the prospectus in the form
included as part of the Registration Statement at the time the Registration Statement became effective, is hereinafter referred to as
the &ldquo;<B>Prospectus</B>,&rdquo; except that if any revised prospectus or prospectus supplement shall be provided to the Underwriters
by the Company for use in connection with the Offering which differs from the Prospectus (whether or not such revised prospectus or prospectus
supplement is required to be filed by the Company pursuant to Rule 424(b)), the term &ldquo;<B>Prospectus</B>&rdquo; shall also refer
to such revised prospectus or prospectus supplement, as the case may be, from and after the time it is first provided to the Underwriters
for such use. Any preliminary prospectus or prospectus subject to completion included in the Registration Statement or filed with the
Commission pursuant to Rule 424 under the Securities Act is hereafter called a &ldquo;<B>Preliminary Prospectus</B>.&rdquo; Any reference
herein to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the exhibits
incorporated by reference therein pursuant to the Rules and Regulations on or before the Effective Date of the Registration Statement,
the date of such Preliminary Prospectus or the date of the Prospectus, as the case may be. Any reference herein to the terms &ldquo;amend&rdquo;,
&ldquo;amendment&rdquo; or &ldquo;supplement&rdquo; with respect to the Registration Statement, any Preliminary Prospectus or the Prospectus
shall be deemed to refer to and include: (i) the filing of any document under the Securities Exchange Act of 1934, as amended, and together
with the Rules and Regulations promulgated thereunder (the &ldquo;<B>Exchange Act</B>&rdquo;) after the Effective Date, the date of such
Preliminary Prospectus or the date of the Prospectus, as the case may be, which is incorporated therein by reference, and (ii) any such
document so filed. All references in this Agreement to the Registration Statement, the Rule 462(b) Registration Statement, a Preliminary
Prospectus and the Prospectus, or any amendments or supplements to any of the foregoing, shall be deemed to include any copy thereof filed
with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System (&ldquo;<B>EDGAR</B>&rdquo;). The Prospectus
delivered to the Underwriters for use in connection with the Offering was or will be identical to the electronically transmitted copies
thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T promulgated by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;At
the time of the effectiveness of the Registration Statement or any Rule 462(b) Registration Statement or the effectiveness of any post-effective
amendment to the Registration Statement, when the Prospectus is first filed with the Commission pursuant to Rule 424(b), when any supplement
to or amendment of the Prospectus is filed with the Commission, when any document filed under the Exchange Act was or is filed, at all
other subsequent times until the completion of the public offer and sale of the Securities, and at the Closing Date, if any, the Registration
Statement and the Prospectus and any amendments thereof and supplements or exhibits thereto complied or will comply in all material respects
with the applicable provisions of the Securities Act, the Exchange Act and the Rules and Regulations, and did not and will not, as of
the date of such amendment or supplement, contain an untrue statement of a material fact and did not and will not, as of the date of such
amendment or supplement, omit to state any material fact required to be stated therein or necessary in order to make the statements therein:
(i) in the case of the Registration Statement, not misleading, and (ii) in the case of the Prospectus, in light of the circumstances under
which they were made as of its date, not misleading. When any Preliminary Prospectus was first filed with the Commission (whether filed
as part of the registration statement for the registration of the Securities or any amendment thereto or pursuant to Rule 424(a) under
the Securities Act) and when any amendment thereof or supplement thereto was first filed with the Commission, such Preliminary Prospectus
and any amendments thereof and supplements thereto complied in all material respects with the applicable provisions of the Securities
Act, the Exchange Act and the Rules and Regulations and did not contain an untrue statement of a material fact and did not omit to state
any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading. No representation and warranty is made in this subsection (b), however, with respect to any information
contained in or omitted from the Registration Statement or the Prospectus or any related Preliminary Prospectus or any amendment thereof
or supplement thereto in reliance upon and in conformity with information furnished in writing to the Company by or on behalf of any Underwriter
through the Representative specifically for use therein. The parties acknowledge and agree that such information provided by or on behalf
of any Underwriter consists solely of: the statements set forth in the &ldquo;Underwriting&rdquo; section of the Prospectus only insofar
as such statements relate to the names and corresponding share amounts set forth in the table of Underwriters, the amount of selling concession
and re-allowance or to over-allotment and related activities that may be undertaken by the Underwriters and the paragraph relating to
stabilization by the Underwriters (the &ldquo;<B>Underwriters&rsquo; Information</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;Neither:
(i) any Issuer-Represented General Free Writing Prospectus(es) (as defined below) issued at or prior to the Applicable Time (as defined
below) and the Statutory Prospectus (as defined below), all considered together (collectively, the &ldquo;<B>General Disclosure Package</B>&rdquo;),
nor (ii) any individual Issuer-Represented Limited-Use Free Writing Prospectus(es) (as defined below) when considered together with the
General Disclosure Package, includes or included as of the Applicable Time any untrue statement of a material fact or omits or omitted
as of the Applicable Time to state any material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The preceding sentence does not apply to statements in or omissions from any Statutory Prospectus
included in the Registration Statement, the General Disclosure Package or any Issuer-Represented Limited-Use Free Writing Prospectus (as
defined below) in conformity with the Underwriters&rsquo; Information. Each of (i) any electronic road show or investor presentation (including
without limitation any &ldquo;bona fide electronic road show&rdquo; as defined in Rule 433(h)(5) under the Securities Act) delivered to
and approved by the Underwriters for use in connection with the marketing of the Offering as of the time of their use and at the Closing
Date and on each Option Closing Date, if any and (ii) any individual Written Testing-the-Waters Communication (as defined herein), when
considered together with the General Disclosure Package at the Closing Date and on each Option Closing Date, if any, did not and will
not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make
the statements therein, in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;Each
Issuer-Represented Free Writing Prospectus, as of its issue date and at all subsequent times until the Closing Date or until any earlier
date that the Company notified or notifies the Representative as described in the next sentence, did not, does not and will not include
any information that conflicted, conflicts or will conflict with the information contained in the then-current Registration Statement,
Statutory Prospectus or Prospectus. If at any time following issuance of an Issuer-Represented Free Writing Prospectus there occurred
or occurs an event or development as a result of which such Issuer-Represented Free Writing Prospectus conflicted or would conflict with
the information contained in the then-current Registration Statement, Statutory Prospectus or Prospectus relating to the Securities or
included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances prevailing at that subsequent time, not misleading, the Company has
notified or will notify promptly the Representative so that any use of such Issuer-Represented Free Writing Prospectus may cease until
it is promptly amended or supplemented by the Company, at its own expense, to eliminate or correct such conflict, untrue statement or
omission. The preceding two sentences do not apply to statements in or omissions from any Issuer-Represented Free Writing Prospectus in
conformity with the Underwriters&rsquo; Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;The
Company has not distributed and will not distribute any prospectus or other offering material in connection with the offering and sale
of the Securities other than the General Disclosure Package, any Issuer-Represented Limited-Use Free Writing Prospectus or the Prospectus
or other materials permitted by the Securities Act to be distributed by the Company. Unless the Company obtains the prior consent of the
Representative, the Company has not made and will not make any offer relating to the Securities that would constitute an &ldquo;issuer
free writing prospectus,&rdquo; as defined in Rule 433 under the Securities Act, or that would otherwise constitute a &ldquo;free writing
prospectus,&rdquo; as defined in Rule 405 under the Securities Act, required to be filed with the Commission; provided that the prior
written consent of the Representative shall be deemed to have been given in respect of any free writing prospectus referenced on <U>Schedule
II</U> attached hereto. The Company has complied and will comply with the requirements of Rules 164 and 433 under the Securities Act applicable
to any Issuer-Represented Free Writing Prospectus as of its issue date and at all subsequent times through the Closing Date, including
timely filing with the Commission where required, legending and record keeping. To the extent an electronic road show is used, the Company
has satisfied and will satisfy the conditions in Rule 433 under the Securities Act to avoid a requirement to file with the Commission
any electronic road show.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;The
Representative agrees that, unless it obtains the prior written consent of the Company, it will not make any offer relating to the Securities
that would constitute an Issuer-Represented Free Writing Prospectus or that would otherwise (without taking into account any approval,
authorization, use or reference thereto by the Company) constitute a &ldquo;free writing prospectus&rdquo; required to be filed by the
Company with the Commission or retained by the Company under Rule 433 of the Securities Act; provided that the prior written consent of
the Company hereto shall be deemed to have been given in respect of any Issuer-Represented General Free Writing Prospectuses referenced
on <U>Schedule II</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(g)&nbsp;As
used in this Agreement, the terms set forth below shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&ldquo;<B>Applicable
Time</B>&rdquo; means __________, 2021, ____a.m/p.m. (Eastern time) on the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&nbsp;&ldquo;<B>Statutory
Prospectus</B>&rdquo; as of any time means the prospectus that is included in the Registration Statement immediately prior to that time.
For purposes of this definition, information contained in a form of prospectus that is deemed retroactively to be a part of the Registration
Statement pursuant to Rule 430A or 430B shall be considered to be included in the Statutory Prospectus as of the actual time that form
of prospectus is filed with the Commission pursuant to Rule 424(b) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&nbsp;&ldquo;<B>Issuer-Represented
Free Writing Prospectus</B>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 under the Securities
Act, relating to the Securities that (A) is required to be filed with the Commission by the Company, or (B) is exempt from filing pursuant
to Rule 433(d)(5)(i) under the Securities Act because it contains a description of the Securities or of the Offering that does not reflect
the final terms or pursuant to Rule 433(d)(8)(ii) because it is a &ldquo;bona fide electronic road show,&rdquo; as defined in Rule 433
under the Securities Act, in each case in the form filed or required to be filed with the Commission or, if not required to be filed,
in the form retained in the Company&rsquo;s records pursuant to Rule 433(g) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)&nbsp;&ldquo;<B>Issuer-Represented
General Free Writing Prospectus</B>&rdquo; means any Issuer-Represented Free Writing Prospectus that is intended for general distribution
to prospective investors, as evidenced by its being specified in <U>Schedule II</U> to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)&nbsp;&ldquo;<B>Issuer-Represented
Limited-Use Free Writing Prospectus</B>&rdquo; means any Issuer-Represented Free Writing Prospectus that is not an Issuer-Represented
General Free Writing Prospectus. The term Issuer-Represented Limited-Use Free Writing Prospectus also includes any &ldquo;bona fide electronic
road show,&rdquo; as defined in Rule 433 under the Securities Act, that is made available without restriction pursuant to Rule 433(d)(8)(ii),
even though not required to be filed with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(h)&nbsp;Friedman
LLP (the &ldquo;<B>Auditor</B>&rdquo;), whose reports relating to the Company are included in the Registration Statement, the General
Disclosure Package and the Prospectus is an independent registered public accounting firm as required by the Securities Act, the Exchange
Act and the Rules and Regulations and the Public Company Accounting Oversight Board (the &ldquo;<B>PCAOB</B>&rdquo;). To the Company&rsquo;s
knowledge, the Auditor is not in violation of the auditor independence requirements of the Sarbanes-Oxley Act of 2002, as amended (&ldquo;<B>Sarbanes-Oxley</B>&rdquo;).
The Auditor has not, during the periods covered by the financial statements included in the Registration Statement, the General Disclosure
Package and the Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(i)&nbsp;Subsequent
to the respective dates as of which information is presented in the Registration Statement, the General Disclosure Package and the Prospectus,
and except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus: (i) the Company has not declared,
paid or made any dividends or other distributions of any kind on or in respect of its capital stock, and (ii) there has been no material
adverse change (or, to the knowledge of the Company, any development which would reasonably be expected to result in a material adverse
change in the future), whether or not arising from transactions in the ordinary course of business, in or affecting: (A) the business,
condition (financial or otherwise), results of operations, shareholders&rsquo; equity, properties or prospects of the Company; (B) the
long-term debt or capital stock of the Company; or (C) the Offering or consummation of any of the other transactions contemplated by this
Agreement, the Representative Warrants, the Registration Statement, the General Disclosure Package and the Prospectus (a &ldquo;<B>Material
Adverse Change</B>&rdquo;). Since the date of the latest balance sheet presented in the Registration Statement, the General Disclosure
Package and the Prospectus, the Company has not incurred or undertaken any liabilities or obligations, whether direct or indirect, liquidated
or contingent, matured or unmatured, or entered into any transactions, including any acquisition or disposition of any business or asset,
which are material to the Company, except for liabilities, obligations and transactions which are disclosed in the Registration Statement,
the General Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(j)&nbsp;As
of the dates indicated in the Registration Statement, the General Disclosure Package and the Prospectus, the authorized, issued and outstanding
shares of capital stock of the Company were as set forth in the Registration Statement, the General Disclosure Package and the Prospectus
in the column headed &ldquo;Actual&rdquo; under the section thereof captioned &ldquo;Capitalization&rdquo; and, after giving effect to
the Offering and the other transactions (excluding the offer and sale of the Option Shares) contemplated by this Agreement, the Registration
Statement, the General Disclosure Package and the Prospectus, will be as set forth in the column headed &ldquo;As Adjusted&rdquo; in such
section. All of the issued shares of capital stock of the Company, including the outstanding Ordinary Shares of the Company, have been
duly authorized and validly issued and are fully paid and nonassessable and have been issued in compliance with all applicable state,
federal and securities laws and none of those shares was issued in violation of any preemptive rights, rights of first refusal or other
similar rights to the extent any such rights were not waived; the Shares have been duly authorized and, when issued and delivered against
payment therefore as provided in this Agreement, will be validly issued, fully paid and non-assessable, and the issuance of the Securities
is not subject to any preemptive rights, rights of first refusal or other similar rights that have not heretofore been waived (with copies
of such waivers provided to the Underwriters); and no holder of any Shares or any Ordinary Shares is or will be subject to personal liability
by reason of being such a holder. The Securities conform to the descriptions thereof contained in the Registration Statement, the General
Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(k)&nbsp;Except
as described in the Registration Statement, the General Disclosure Package and the Prospectus, (A)&nbsp;there are no outstanding rights
(contractual or otherwise), warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings
with respect to the sale or issuance of, any shares of capital stock of or other equity interest in the Company or any of its Subsidiaries
and (B)&nbsp;there are no contracts, agreements or understandings between the Company and/or any of its Subsidiaries and any person granting
such person the right to require the Company to file a registration statement under the Securities Act or otherwise register any securities
of the Company owned or to be owned by such person and any such rights so disclosed have been waived by the holders thereof in connection
with this Agreement and the transactions contemplated hereby including the Offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(l)&nbsp;The
Company is a &ldquo;foreign private issuer&rdquo; within the meaning of Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(m)&nbsp;The
Ordinary Shares underlying the Representative&rsquo;s Warrants have been duly authorized and reserved for issuance, conform to the description
thereof in the Registration Statement, the General Disclosure Package and the Prospectus and have been validly reserved for issuance and
will, upon exercise of the Representative&rsquo;s Warrants and payment of the exercise price thereof, be duly and validly issued, fully
paid and non-assessable and will not have been issued in violation of or be subject to preemptive or similar rights to subscribe for or
purchase securities of the Company and the holders thereof will not be subject to personal liability by reason of being such holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(n)&nbsp;The
subsidiaries of the Company (the &ldquo;<B>Subsidiaries</B>&rdquo;), together with their respective jurisdictions of incorporation are
listed on Schedule IV hereto. Each of the Subsidiaries is directly or indirectly wholly-owned by the Company and no person or entity has
any right to acquire any equity interest in any of the Subsidiaries. Except as otherwise disclosed in the Registration Statement, the
General Disclosure Package and the Prospectus, the Company holds no ownership or other interest, nominal or beneficial, direct or indirect,
in any corporation, partnership, joint venture or other business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(o)&nbsp;The
Company and each of its Subsidiaries has been duly incorporated and validly exists as a company, in good standing under the laws of the
jurisdiction of its incorporation or has been duly formed and validly exists as a limited liability company under the laws of the jurisdiction
of its formation. The Company and each of its Subsidiaries has all requisite power and authority to carry on its business as it is currently
being conducted and as described in the Registration Statement, the General Disclosure Package and the Prospectus, and to own, lease and
operate its properties. The Company and each of its Subsidiaries is duly qualified to do business and is in good standing as a foreign
corporation, partnership or limited liability company in each jurisdiction in which the character or location of its properties (owned,
leased or licensed) or the nature or conduct of its business makes such qualification necessary, except, in each case, for those failures
to be so qualified or in good standing which (individually and in the aggregate) would not reasonably be expected to have a material adverse
effect on: (i) the business, condition (financial or otherwise), results of operations, shareholders&rsquo; equity, properties or prospects
of the Company and its Subsidiaries, considered as a whole; (ii) the long-term debt or capital stock of the Company; or (iii) the Offering
or consummation of any of the other transactions contemplated by this Agreement, the Registration Statement, the General Disclosure Package
and the Prospectus (any such effect being a &ldquo;<B>Material Adverse Effect</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(p)&nbsp;To
the knowledge of the Company, neither the Company nor any of its Subsidiaries is: (i) in violation of its amended and restated memorandum
and articles of incorporation or bylaws or other organizational documents (ii) in default under any indenture, mortgage, deed of trust,
loan agreement or other agreement or instrument to which it is a party or by which it is bound or to which any of its property or assets
is subject; and no event has occurred which, with notice or lapse of time or both, would constitute a default under or result in the creation
or imposition of any lien, security interest, charge or other encumbrance (a &ldquo;<B>Lien</B>&rdquo;) upon any of its property or assets
pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which it is a party or by which
it is bound or to which any of its property or assets is subject, or (iii) in violation in any respect of any law, rule, regulation, ordinance,
directive, judgment, decree or order of any judicial, regulatory or other legal or governmental agency or body, foreign or domestic, except,
in the case of subsections (ii) and (iii) above, for such violations or defaults which (individually or in the aggregate) would not reasonably
be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(q)&nbsp;The
Company has full right, power and authority to execute and deliver this Agreement, the Representative&rsquo;s Warrants and all other agreements,
documents, certificates and instruments required to be delivered pursuant to this Agreement and the Representative&rsquo;s Warrants. The
Company has duly and validly authorized this Agreement, the Representative&rsquo;s Warrants and each of the transactions contemplated
thereby. This Agreement has been duly and validly executed and delivered by the Company and constitutes the legal, valid and binding obligations
of the Company and are enforceable against the Company in accordance with their terms, except (i)&nbsp;as such enforceability may be limited
by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally; (ii)&nbsp;as enforceability of
any indemnification or contribution provision may be limited under federal and state securities laws; and (iii)&nbsp;that the remedy of
specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion
of the court before which any proceeding therefor may be brought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(r)&nbsp;When
issued, the Representative&rsquo;s Warrants will constitute valid and binding obligations of the Company to issue and sell, upon exercise
thereof and payment of the respective exercise prices therefor, the number and type of securities of the Company called for thereby in
accordance with the terms thereof and the Representative&rsquo;s Warrants are enforceable against the Company in accordance with their
respective terms, except: (i) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting
creditors&rsquo; rights generally; (ii) as enforceability of any indemnification or contribution provision may be limited under foreign,
federal and state securities laws; and (iii) that the remedy of specific performance and injunctive and other forms of equitable relief
may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(s)&nbsp;The
execution, delivery, and performance by the Company of this Agreement, the Representative&rsquo;s Warrants and all other agreements, documents,
certificates and instruments required to be delivered pursuant to this Agreement, and the Representative&rsquo;s Warrants and consummation
of the transactions contemplated hereby and thereby do not and will not: (i) conflict with, require consent under or result in a breach
of any of the terms and provisions of, or constitute a default (or an event which with notice or lapse of time, or both, would constitute
a default) under, or result in the creation or imposition of any Lien upon any property or assets of the Company of any of its Subsidiaries
pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement, instrument, franchise, license or permit to which
the Company or any of its Subsidiaries is a party or by which the Company, any of it Subsidiaries or any of their respective properties,
operations or assets may be bound or (ii) violate or conflict with any provision of the certificate of incorporation, by-laws, or other
organizational documents of the Company or any of its Subsidiaries, or (iii) violate or conflict with any law, rule, regulation, ordinance,
directive, judgment, decree or order of any judicial, regulatory or other legal or governmental agency or body, domestic or foreign applicable
to the Company or any of its Subsidiaries, or (iv) except as disclosed in the Registration Statement, the General Disclosure Package and
the Prospectus, trigger a reset or repricing of any outstanding securities of the Company or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(t)&nbsp;Except
as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company and each of its Subsidiaries
have all material consents, approvals, authorizations, orders, registrations, qualifications, licenses, filings and permits of, with and
from all judicial, regulatory and other legal or governmental agencies and bodies and all third parties, foreign and domestic (collectively,
the &ldquo;<B>Consents</B>&rdquo;), to own, lease and operate their respective properties and conduct their respective businesses as they
are now being conducted and as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, and each such
Consent is valid and in full force and effect, except which (individually or in the aggregate), in each such case, would not reasonably
be expected to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries has received notice of any investigation
or proceedings which results in or, if decided adversely to the Company or any of its Subsidiaries could reasonably be expected to result
in, the revocation of, or imposition of a materially burdensome restriction on, any Consent. No Consent contains a materially burdensome
restriction not adequately disclosed in the Registration Statement, the General Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(u)&nbsp;The
Company and each of its Subsidiaries is in compliance with all material applicable laws, rules, regulations, ordinances, directives, judgments,
decrees and orders, foreign and domestic, except for any non-compliance the consequences of which would not have or reasonably be expected
to have a Material Adverse Effect.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(v)&nbsp;The
Company has filed with the Commission a Form 8-A (File Number 001-________) providing for the registration of the Ordinary Shares (the
&ldquo;<B>Form 8-A Registration Statement</B>&rdquo;). The Ordinary Shares are registered pursuant to Section 12(b) under the Securities
Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;). The Form 8-A Registration Statement was declared effective by
the Commission on or prior to the date hereof. The Company has taken no action designed to, or likely to have the effect of, terminating
the registration of the Ordinary Shares under the Exchange Act, nor has the Company received any notification that the Commission is contemplating
terminating such registration;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(w)&nbsp;The
Ordinary Shares have been approved for listing on the NASDAQ Capital Market, subject to official notice of issuance (the &ldquo;<B>Exchange</B>&rdquo;),
and the Company has taken no action designed to, or likely to have the effect of, delisting the Ordinary Shares from the Exchange, nor
has the Company received any notification that the Exchange is contemplating terminating such listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(x)&nbsp;No
consent of, with or from any judicial, regulatory or other legal or governmental agency or body or any third party, foreign or domestic
is required for the execution, delivery and performance of this Agreement or the Representative&rsquo;s Warrants or the consummation of
each of the transactions contemplated hereby and thereby, including the issuance, sale and delivery of the Securities to be issued, sold
and delivered hereunder, except (i) such as may have previously been obtained (with copies of such consents provided to the Underwriters),
(ii) the registration under the Securities Act of the Securities, which has become effective, (iii) such consents as may be required under
state securities or blue sky laws or the by-laws and rules of the Nasdaq Capital Market, and (iii) the FINRA in connection with the purchase
and distribution of the Securities by the Underwriters, each of which has been obtained and is in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(y)&nbsp;Except
as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, there is no judicial, regulatory, arbitral
or other legal or governmental proceeding or other litigation or arbitration, domestic or foreign, pending to which the Company or any
of its Subsidiaries is a party or of which any property, operations or assets of the Company or any of its Subsidiaries is the subject
which, individually or in the aggregate, if determined adversely to the Company or any of its Subsidiaries would reasonably be expected
to have a Material Adverse Effect. To the Company&rsquo;s knowledge, except as disclosed in the Registration Statement, the General Disclosure
Package and the Prospectus, no such proceeding, litigation or arbitration is threatened or contemplated and the defense of any such proceedings,
litigation and arbitration against or involving the Company or any of its Subsidiaries would not reasonably be expected to have a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(z)&nbsp;The
financial statements, including the notes thereto, and the supporting schedules included in the Registration Statement, the General Disclosure
Package and the Prospectus comply in all material respects with the requirements of the Securities Act and the Exchange Act, and present
fairly in all material respects the financial position as of the dates indicated and the cash flows and results of operations for the
periods specified of the Company. Except as otherwise stated in the Registration Statement, the General Disclosure Package and the Prospectus,
said financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&ldquo;<B>GAAP</B>&rdquo;)
applied on a consistent basis throughout the periods involved, except in the case of unaudited financials which are subject to normal
year end adjustments and do not contain certain footnotes. The supporting schedules included in the Registration Statement, the General
Disclosure Package and the Prospectus present fairly in all material respects the information required to be stated therein. No other
financial statements or supporting schedules are required to be included or incorporated by reference in the Registration Statement, the
General Disclosure Package or the Prospectus. The other financial information included in the Registration Statement, the General Disclosure
Package and the Prospectus present fairly in all material respects the information included therein and have been prepared on a basis
consistent with that of the financial statements that are included in the Registration Statement, the General Disclosure Package and the
Prospectus and the books and records of the respective entities presented therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(aa)&#9;There are
no pro forma or as adjusted financial statements which are required to be included in the Registration Statement, the General Disclosure
Package and the Prospectus in accordance with Regulation S-X which have not been included as so required. The pro forma and pro forma
as adjusted financial information included in the Registration Statement, the General Disclosure Package and the Prospectus has been properly
compiled and prepared in accordance with the applicable requirements of the Securities Act and the Rules and Regulations and include all
adjustments necessary to present fairly in accordance with GAAP the pro forma and as adjusted financial position of the respective entity
or entities presented therein at the respective dates indicated and their cash flows and the results of operations for the respective
periods specified. The assumptions used in preparing the pro forma and pro forma as adjusted financial information included in the Registration
Statement, the General Disclosure Package and the Prospectus provide a reasonable basis for presenting the significant effects directly
attributable to the transactions or events described therein. The related pro forma and pro forma as adjusted adjustments give appropriate
effect to those assumptions; and the pro forma and pro forma as adjusted financial information reflect the proper application of those
adjustments to the corresponding historical financial statement amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(bb)&#9;The statistical,
industry-related and market-related data included in the Registration Statement, the General Disclosure Package and the Prospectus are
based on or derived from sources which the Company reasonably and in good faith believes are reliable and accurate, and such data agree
with the sources from which they are derived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(cc)&#9;The Company
has established and maintains disclosure controls and procedures over financial reporting (as defined in Rules 13a-15 and 15d-15 under
the Exchange Act) and such controls and procedures are designed to ensure that information relating to the Company required to be disclosed
in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&rsquo;s management, including
its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions
regarding required disclosure. The Company has utilized such controls and procedures in preparing and evaluating the disclosures in the
Registration Statement, in the General Disclosure Package and in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(dd)&#9;Except
as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company&rsquo;s board of directors
has validly appointed an audit committee whose composition satisfies the requirements of the rules and regulations of the Nasdaq Stock
Market and the board of directors and/or audit committee has adopted a charter that satisfies the requirements of the rules and regulations
of the Nasdaq Stock Market. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, neither
the board of directors nor the audit committee has been informed, nor is the Company aware, of: (i) any significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
Company&rsquo;s ability to record, process, summarize and report financial information; or (ii) any fraud, whether or not material, that
involves management or other employees who have a significant role in the Company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(ee)&#9;Neither
the Company nor any of its Subsidiaries nor any of their respective Affiliates (as defined in the Securities Act) has taken, directly
or indirectly, any action which constitutes or is designed to cause or result in, or which could reasonably be expected to constitute,
cause or result in, the stabilization or manipulation of the price of any security to facilitate the sale or resale of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(ff)&#9;Neither
the Company nor any of its Subsidiaries nor any of their respective Affiliates has, prior to the date hereof, made any offer or sale of
any securities which are required to be &ldquo;integrated&rdquo; pursuant to the Securities Act or the Rules and Regulations with the
offer and sale of the Securities pursuant to the Registration Statement. Except as disclosed in the Registration Statement, the General
Disclosure Package, and the Prospectus, neither the Company nor any of its Affiliates has sold or issued any securities during the six-month
period preceding the date of the Prospectus, including but not limited to any sales pursuant to Rule 144A or Regulation D or Regulation
S under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(gg)&#9;To the
knowledge of the Company, all information contained in the questionnaires completed by each of the Company&rsquo;s officers and directors
and 5% holders immediately prior to the Offering and provided to the Representative as well as the biographies of such officers and directors
in the Registration Statement are true and correct in all material respects and the Company has not become aware of any information which
would cause the information disclosed in the questionnaires completed by the directors and officers to become inaccurate and incorrect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(hh)&#9;To the
knowledge of the Company, no director or officer of the Company is subject to any non-competition agreement or non-solicitation agreement
with any current employer or prior employer which could materially affect his ability to be and act in his respective capacity of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(ii)&nbsp;The
Company is not and, at all times up to and including consummation of the transactions contemplated by this Agreement, and after giving
effect to application of the net proceeds of the Offering, will not be, subject to registration as an &ldquo;investment company&rdquo;
under the Investment Company Act of 1940, as amended, and is not and will not be an entity &ldquo;controlled&rdquo; by an &ldquo;investment
company&rdquo; within the meaning of such act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(jj)&#9;To the
knowledge of the Company, no relationship, direct or indirect, exists between or among any of the Company or, to the knowledge of the
Company, any Affiliate of the Company, on the one hand, and any director, officer, shareholder, customer or supplier of the Company or,
to the knowledge of the Company, any Affiliate of the Company, on the other hand, which is required by the Securities Act, the Exchange
Act or the Rules and Regulations to be described in the Registration Statement or the Prospectus which is not so described as required.
There are no outstanding loans, advances (except normal advances for business expenses in the ordinary course of business) or guarantees
of indebtedness by the Company to or for the benefit of any of the officers or directors of the Company or any of their respective family
members. The Company has not, in violation of Sarbanes-Oxley directly or indirectly extended or maintained credit, arranged for the extension
of credit, or renewed an extension of credit, in the form of a personal loan to or for any director or executive officer of the Company,
except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(kk)&#9;The Company
is in material compliance with the rules and regulations promulgated by the Nasdaq Stock Market (to the extent applicable to the Company
prior to the listing of the Ordinary Shares on the Nasdaq Capital Market following the Closing) or any other governmental or self regulatory
entity or agency, except for such violations which, singly or in the aggregate, would not have a Material Adverse Effect. Without limiting
the generality of the foregoing: (i) all members of the Company&rsquo;s board of directors who are required to be &ldquo;independent&rdquo;
(as that term is defined under applicable laws, rules and regulations), including, without limitation, all members of the audit committee
of the Company&rsquo;s board of directors, meet the qualifications of independence as set forth under applicable laws, rules and regulations
and (ii)&nbsp; the audit committee of the Company&rsquo;s board of directors has at least one member who is an &ldquo;audit committee
financial expert&rdquo; (as that term is defined under applicable laws, rules and regulations).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(ll)&#9;To the
knowledge of the Company, except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, there
are no contracts, agreements or understandings between the Company or any of its Subsidiaries and any Person that would give rise to a
valid claim against the Company or any of its Subsidiaries or, to the knowledge of the Company, any Underwriter for a brokerage commission,
finder&rsquo;s fee, financial consulting fee or other like payment in connection with the transactions contemplated by this Agreement
or, to the knowledge of the Company, any arrangements, agreements, understandings, payments or issuance with respect to the Company or
any of its officers, directors, shareholders, partners, employees or Affiliates that may affect the Underwriters&rsquo; compensation as
determined by FINRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(mm)&#9;The Company
and each of its Subsidiaries owns or leases all such properties (other than intellectual property, which is covered by Section 2(nn))
as are necessary to the conduct of its business as presently operated as described in the Registration Statement, the General Disclosure
Package and the Prospectus. The Company and each of its Subsidiaries has good and marketable title in fee simple to all real property
and good and marketable title to all personal property owned by it, in each case free and clear of all Liens except such as are described
in the Registration Statement, the General Disclosure Package and the Prospectus or such as do not (individually or in the aggregate)
materially affect the business or prospects of the Company or any of its Subsidiaries. Any real property and buildings held under lease
or sublease by the Company or any of its Subsidiaries are held by it under valid, subsisting and, to the Company&rsquo;s knowledge, enforceable
leases with such exceptions as are not material to, and do not materially interfere with, the use made and proposed to be made of such
property and buildings by the Company or any of its Subsidiaries. Neither the Company nor any of its Subsidiaries has received any notice
of any claim adverse to its ownership of any real or personal property or of any claim against the continued possession of any real property,
whether owned or held under lease or sublease by the Company or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(nn)&#9;The Company
and each of its Subsidiaries: (i) owns, possesses, or has the adequate right to use all patents, patent applications, trademarks, service
marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, formulae, customer lists, and know-how
and other intellectual property (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information,
systems or procedures, &ldquo;<B>Intellectual Property</B>&rdquo;) necessary for the conduct of its businesses as being conducted and
as described in the Registration Statement, the General Disclosure and Prospectus and (ii)&nbsp;has no knowledge that the conduct of its
business conflicts or will conflict with the rights of others, and has not received any notice of any claim of conflict with, any right
of others. Except as set forth in the Registration Statement, the General Disclosure Package or the Prospectus, neither the Company nor
any of its Subsidiaries has granted or assigned to any other Person any right to sell any of the products or services of the Company or
any of its Subsidiaries. To the Company&rsquo;s knowledge, there is no infringement by third parties of any such Intellectual Property;
there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others challenging the rights
of the Company or any of its Subsidiaries in or to any such Intellectual Property, and the Company is unaware of any facts which would
form a reasonable basis for any such claim; and there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding
or claim by others that the Company or any of its Subsidiaries infringes or otherwise violates any patent, trademark, copyright, trade
secret or other proprietary rights of others, and the Company is unaware of any other fact which would form a reasonable basis for any
such claim. Except as set forth in the Registration Statement, the General Disclosure Package and the Prospectus, neither the Company
nor any of its Subsidiaries has received any claim for royalties or other compensation from any Person, including any employee of the
Company or any of its Subsidiaries who made inventive contributions to the technology or products of the Company or any of its Subsidiaries
that are pending or unsettled, and except as set forth in the Registration Statement, the General Disclosure Package and the Prospectus
neither the Company nor any of its Subsidiaries has any obligation to pay material royalties to any Person on account of inventive contributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(oo)&nbsp;The
agreements and documents described in the Registration Statement, the General Disclosure Package and the Prospectus conform in all material
respects to the descriptions thereof contained therein. Each agreement or other instrument (however characterized or described) to which
the Company or any of its Subsidiaries is a party or by which any of their respective properties or business are or may be bound or affected
and (i) that is referred to in the Registration Statement, the General Disclosure Package or the Prospectus or attached as an exhibit
thereto, or (ii) is material to the businesses of the Company and its Subsidiaries, has been duly and validly executed by the Company
or its Subsidiary, as the case may be, is in full force and effect in all material respects and is enforceable against the Company in
accordance with its terms, except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws
affecting creditors&rsquo; rights generally, (y) as enforceability of any indemnification or contribution provision may be limited under
the foreign, federal and state securities laws, and (z) that the remedy of specific performance and injunctive and other forms of equitable
relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought,
and none of such agreements or instruments has been assigned by the Company or any of its Subsidiaries, and neither the Company nor any
of its Subsidiaries, nor, to the Company&rsquo;s knowledge, any other party is in breach or default thereunder and, to the Company&rsquo;s
knowledge, no event has occurred that, with the lapse of time or the giving of notice, or both, would constitute a breach or default thereunder,
in any such case, which would result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(pp)&#9;The disclosures
in the Registration Statement, the General Disclosure Package and the Prospectus concerning the effects of foreign, federal, state and
local regulation on the respective businesses of the Company and each of its Subsidiaries as currently contemplated are correct in all
material respects and do not omit to state a material fact necessary to make the statements therein, in light of the circumstances in
which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(qq)&#9;Except
for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the
Company and each of its Subsidiaries (i) has made or filed all United States federal, state and local income and all Cayman Islands, Hong
Kong and other foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject,
(ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes
for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim.
The provisions for taxes payable, if any, shown on the financial statements filed with or as part of the Registration Statement are sufficient
for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of such consolidated financial
statements. No deficiency assessment with respect to a proposed adjustment of the federal, state, local or foreign taxes of the Company
or any of its Subsidiaries is pending or, to the Company&rsquo;s knowledge, threatened There is no tax lien, whether imposed by any federal,
state, foreign or other taxing authority, outstanding against the assets, properties or business of the Company or any of its Subsidiaries,
other than liens for taxes not yet delinquent, or being contested in good faith by appropriate proceedings and for which reserves in accordance
with GAAP have been established in the Company&rsquo;s books and records. The term &ldquo;taxes&rdquo; mean all federal, state, local,
foreign (including Swiss), and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license,
lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits,
customs, duties or other taxes, fees, assessments, or charges in the nature of taxes, together with any interest and any penalties, additions
to tax, or additional amounts with respect thereto. The term &ldquo;returns&rdquo; means all returns, declarations, reports, statements,
and other documents required to be filed in respect to taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(rr)&#9;No labor
disturbance or dispute by or with the employees of the Company or any of its Subsidiaries which, individually or in the aggregate, would
reasonably be expected to have a Material Adverse Effect, currently exists or, to the Company&rsquo;s knowledge, is threatened. The Company
and each of its Subsidiaries is in compliance in all material respects with the labor and employment laws and collective bargaining agreements
and extension orders applicable to its employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(ss)&#9;As to each
product or product candidate subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<B>FDA</B>&rdquo;) under the
Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<B>FDCA</B>&rdquo;) and/or the jurisdiction of
the non-U.S. counterparts thereof that is tested, sold and/or marketed by the Company or any of its Subsidiaries (each such product, a
&ldquo;<B>Product</B>&rdquo;), such Product is being tested, sold and/or marketed by the Company or any of its Subsidiaries in compliance
with all applicable requirements under FDCA and/or and similar laws, rules and regulations relating to registration, investigational use,
premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices,
product listing, quotas, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have
a Material Adverse Effect. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, neither
the Company nor any of its Subsidiaries currently has any products that have been approved by the FDA or any non-U.S. counterparts thereof
to be manufactured, packaged, labeled, distributed, sold and/or marketed. There is no pending, completed or, to the Company&rsquo;s knowledge,
threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation)
against the Company or any of its Subsidiaries and neither the Company nor any of its Subsidiaries has received any notice, warning letter
or other communication from the FDA or any other governmental entity or any non-U.S. counterparts thereof, which (i) contests the premarket
clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of,
the sale of, or the labeling and promotion of any Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure
of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Product, (iii) imposes a clinical
hold on any clinical investigation by the Company, or its Subsidiaries (iv) enjoins production at any facility of the Company or its Subsidiaries,
(v) enters or proposes to enter into a consent decree of permanent injunction with the Company or its Subsidiaries, or (vi) otherwise
alleges any violation of any laws, rules or regulations by the Company or its Subsidiaries. The properties, business and operations of
the Company and each of its Subsidiaries have been and are being conducted in all material respects in accordance with all applicable
laws, rules and regulations of the FDA and non-U.S. counterparts thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(tt)&#9;The clinical,
pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company and each of its Subsidiaries that are
described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus were and, if still pending,
are being conducted in all material respects accordance with all statutes, laws, rules and regulations, as applicable (including, without
limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions
similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in
the Registration Statement, the General Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly
present the published data derived from such studies and tests. Neither the Company nor any of its Subsidiaries has received any notices
or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions
similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination
or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of
any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company or any of its Subsidiaries will be sufficient
to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority or that
additional studies, tests or preclinical or clinical trials will reach similar results or conclusions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(uu)&#9;Except
as disclosed in the Registration Statement, to the knowledge of the Company the General Disclosure Package and the Prospectus, and would
not be reasonably expected, individually or in the aggregate, to have a Material Adverse Effect, the Company and each of its Subsidiaries
has at all times operated its business in material compliance with all Environmental Laws (as hereinafter defined), and no material expenditures
are or will be required in order to comply therewith. Neither the Company nor any of its Subsidiaries has received any notice or communication
that relates to or alleges any actual or potential violation or failure to comply with any Environmental Laws that would, individually
or in the aggregate, be reasonably expected to have a Material Adverse Effect. As used herein, the term &ldquo;<B>Environmental Laws</B>&rdquo;
means all applicable laws and regulations, including any licensing, permits or reporting requirements, and any action by a federal state
or local government entity pertaining to the protection of the environment, protection of public health, protection of worker health and
safety, or the handling of hazardous materials, including without limitation, the Clean Air Act, 42 U.S.C. &sect; 7401, et seq., the Comprehensive
Environmental Response, Compensation and Liability Act of 1980, 42 U.S.C. &sect; 9601, et seq., the Federal Water Pollution Control Act,
33 U.S.C. &sect; 1321, et seq., the Hazardous Materials Transportation Act, 49 U.S.C. &sect; 1801, et seq., the Resource Conservation
and Recovery Act, 42 U.S.C. &sect; 690-1, et seq., and the Toxic Substances Control Act, 15 U.S.C. &sect; 2601, et seq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(vv)&#9;Except
as would not result in a Material Adverse Effect, neither the Company nor any of its Subsidiaries has failed to file with the applicable
regulatory authorities (including the FDA or any foreign, federal, state or local governmental or regulatory authority performing functions
similar to those performed by the FDA) any filing, declaration, listing, registration, report or submission that is required to be so
filed for the business operation of the Company and its Subsidiaries as currently conducted. All such filings were in material compliance
with applicable laws when filed and no deficiencies have been asserted in writing by any applicable regulatory authority (including, without
limitation, the FDA or any foreign, federal, state or local governmental or regulatory authority performing functions similar to those
performed by the FDA) with respect to any such filings, declarations, listings, registrations, reports or submissions. The Company and
each of its Subsidiaries holds, and is in material compliance with, all franchises, grants, authorizations, licenses, permits, easements,
consents, certificates and orders (&ldquo;<B>Permits</B>&rdquo;) of any governmental or self-regulatory agency, authority or body (including,
without limitation, those administered by FDA or by any foreign, federal, state or local governmental or regulatory authority performing
functions similar to those performed by the FDA) required for the conduct of the business of the Company and its Subsidiaries as currently
conducted, and all such Permits are in full force and effect, in each case except where the failure to hold, or comply with, any of them
is not reasonably likely to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(ww)&#9;Neither
the Company nor any Subsidiary of the Company nor, to the knowledge of the Company, any other person associated with or acting on behalf
of the Company or any Subsidiary including, without limitation, any director, officer, agent or employee of the Company or any Subsidiary,
has, directly or indirectly, while acting on behalf of the Company or such Subsidiary: (i) used any corporate funds for unlawful contributions,
gifts, entertainment or other unlawful expenses relating to political activity; (ii)&nbsp;made any unlawful payment to foreign or domestic
government officials or employees or to foreign or domestic political parties or campaigns from corporate funds; (iii) violated any provision
of the Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any other unlawful payment<FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(xx)&nbsp;
Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the &ldquo;<B>BHCA</B>&rdquo;)
and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<B>Federal Reserve</B>&rdquo;). Neither the Company
nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares
of any class of voting securities or twenty-five percent (25%) or more of the total equity of a bank or any entity that is subject to
the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling
influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(yy)&#9;The operations
of the Company and each of its Subsidiaries are and have been conducted at all times in compliance in all material respects with applicable
financial record keeping and reporting requirements and money laundering statutes of the Cayman Islands, Hong Kong and the United States
and, to the Company&rsquo;s knowledge, all other jurisdictions to which the Company is subject, the rules and regulations thereunder and
any related or similar rules, regulations or guidelines, issued, administered or enforced by any applicable governmental agency (collectively,
the &ldquo;<B>Money Laundering Laws</B>&rdquo;) and no action, suit or proceeding by or before any court or governmental agency, authority
or body or any arbitrator involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to
the best knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(zz)&#9;Neither
the Company nor any of its Subsidiaries nor to the knowledge of the Company, any director, officer, agent, employee or Affiliate of the
Company or any of its Subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of
the U.S. Treasury Department (&ldquo;<B>OFAC</B>&rdquo;), the United Nations Security Council, the European Union, her Majesty&rsquo;s
Treasury (UK HMT), the Swiss Secretariat of Economic Affairs, the Monetary Authority of Singapore or other relevant authorities (collectively,
&ldquo;<B>Sanctions</B>&rdquo;) nor located, organized or resident in a country or territory that is the subject of Sanctions. The Company
will not directly or indirectly use the proceeds of the Offering, or lend, contribute or otherwise make available such proceeds to any
joint venture partner or other person or entity, for the purpose of funding or financing the activities or business of or with any Person
or in any country or territory that. At the time of such funding or facilitation is the subject of to any Sanctions, or in any other manner
that will result in a violation of Sanctions by any Person (including any Person participating in the Offering). For the past five years,
neither the Company nor any of its Subsidiaries has knowingly engaged in, is not now knowingly engaged in, and will not engage in, any
dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the
subject of Sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(aaa)&#9;Except
as set forth in the Registration Statement, the General Disclosure Package and the Prospectus, no brokerage or finder&rsquo;s fees or
commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. To the Company&rsquo;s knowledge,
there are no other arrangements, agreements or understandings of the Company or, to the Company&rsquo;s knowledge, any of its Affiliates
that may affect the Underwriters&rsquo; compensation, as determined by FINRA. The Company has not made any direct or indirect payments
(in cash, securities or otherwise) to (i) any person, as a finder&rsquo;s fee, investing fee or otherwise, in consideration of such person
raising capital for the Company or introducing to the Company persons who provided capital to the Company, (ii) any FINRA member, or (iii)
any person or entity that has any direct or indirect affiliation or association with any FINRA member participating in the Offering within
the 12-month period prior to the date on which the Registration Statement was filed with the Commission (the &ldquo;<B>Filing Date</B>&rdquo;)
or thereafter. To the Company&rsquo;s knowledge, no (i) officer&nbsp;or director of the Company or its Subsidiaries, (ii) owner of 10%
or more of the Company&rsquo;s unregistered securities or that of its Subsidiaries or (iii) owner of any amount of the Company&rsquo;s
unregistered securities acquired within the 180-day period prior to the Filing Date, has any direct or indirect affiliation or association
with any FINRA member participating in the Offering. The Company will advise the Underwriters and their respective counsel if it becomes
aware that any officer, director or stockholder of the Company or its Subsidiaries is or becomes an affiliate or associated person of
a FINRA member participating in the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(bbb)&#9;The Company
and each of its Subsidiaries maintains insurance in such amounts and covering such risks as the Company reasonably considers adequate
for the conduct of their respective businesses and the value of their respective properties and as is customary for companies engaged
in similar businesses in similar industries, all of which insurance is in full force and effect, except where the failure to maintain
such insurance could not reasonably be expected to have Material Adverse Effect. The Company reasonably believes that it and each of its
Subsidiaries will be able to renew its existing insurance as and when such coverage expires or will be able to obtain replacement insurance
adequate for the conduct of its respective business and the value of its respective properties at a cost that would not have a Material
Adverse Effect</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(ccc)&#9; Except
as disclosed in the General Disclosure Package and the Prospectus, under current laws and regulations of the Cayman Islands and any political
subdivision thereof, all dividends and other distributions declared and payable on the Securities may be paid by the Company to the holder
thereof in United States dollars and freely transferred out of the Cayman Islands and all such payments made to holders thereof or therein
who are non-residents of the Cayman Islands will not be subject to income, withholding or other taxes under laws and regulations of the
Cayman Islands or any political subdivision or taxing authority thereof or therein and will otherwise be free and clear of any other tax,
duty, withholding or deduction in the Cayman Islands or any political subdivision or taxing authority thereof or therein and without the
necessity of obtaining any governmental authorization in the Cayman Islands or any political subdivision or taxing authority thereof or
therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(ddd)&#9;The choice
of the laws of the State of New York as the governing law of this Agreement and the Representative&rsquo;s Warrants is a valid choice
of law under the laws of the Cayman Islands and will be honored by courts in the Cayman Islands The Company has the power to submit, and
pursuant to Section 15 of this Agreement, has legally, validly, effectively and irrevocably submitted, to the personal jurisdiction of
each United States federal court and New York state court located in the Borough of Manhattan, in the City of New York, New York, U.S.A.
(each, a &ldquo;<B>New York Court</B>&rdquo;), and the Company has the power to designate, appoint and authorize, and pursuant to Section
15 of this Agreement, has legally, validly, effectively and irrevocably designated, appointed and authorized an agent for service of process
in any action arising out of or relating to this Agreement, the Registration Statement, the Prospectus or the Securities in any New York
Court, and service of process effected on such authorized agent will be effective to confer valid personal jurisdiction over the Company
as provided in Section 15 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(eee)&#9;Except
as provided by laws or statutes generally applicable to transactions of the type described in this Agreement, neither the Company nor
any of its respective properties, assets or revenues has any right of immunity under the Cayman Islands, Hong Kong, New York or United
States law, from any legal action, suit or proceeding, from the giving of any relief in any Cayman Islands, Hong Kong, New York or United
States federal court, from service of process, attachment upon or prior judgment, or attachment in aid of execution of judgment, or from
execution of a judgment, or other legal process or proceeding for the giving of any relief or for the enforcement of a judgment, in any
such court, with respect to its obligations, liabilities or any other matter under or arising out of or in connection with this Agreement.
To the extent that the Company or any of its respective properties, assets or revenues may have or may hereafter become entitled to any
such right of immunity in any such court in which proceedings may at any time be commenced, the Company waives or will waive such right
to the extent permitted by law and has consented to such relief and enforcement as provided in Section 15 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(fff)&#9;Each of
this Agreement and the Representative&rsquo;s Warrants is in proper form under the laws of the Cayman Islands for the enforcement thereof
against the Company, and to ensure the legality, validity, enforceability or admissibility into evidence in the Cayman Islands of this
Agreement and the Representative&rsquo;s Warrants, it is not necessary that this Agreement or the Representative&rsquo;s Warrants be filed
or recorded with any court or other authority in the Cayman Islands or Hong Kong or, except as disclosed in the most recent Preliminary
Prospectus or Prospectus, that any stamp or similar tax in the Cayman Islands or Hong Kong be paid on or in respect of this Agreement,
the Representative&rsquo;s Warrants or any other documents to be furnished hereunder. Any final judgment for a fixed or readily calculable
sum of money rendered by a New York Court having jurisdiction under its own domestic laws in respect of any suit, action or proceeding
against the Company based upon this Agreement or the Representative&rsquo;s Warrants and any instruments or agreements entered into for
the consummation of the transactions contemplated herein and therein would be declared enforceable against the Company, without re-examination
or review of the merits of the cause of action in respect of which the original judgment was given or re-litigation of the matters adjudicated
upon, by the courts of the Cayman Islands or Hong Kong. The Company is not aware of any reason why the enforcement in the Cayman Islands
or Hong Kong of such a New York Court judgment would be, as of the date hereof, contrary to public policy of the Cayman Islands or Hong
Kong</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(ggg)&#9;As used
in this Agreement, references to matters being &ldquo;<B>material</B>&rdquo; with respect to the Company or any of its Subsidiaries shall
mean a material event, change, condition, status or effect related to the condition (financial or otherwise), properties, assets (including
intangible assets), liabilities, business, prospects, operations or results of operations of the Company and such Subsidiaries either
individually or taken as a whole, as the context requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(hhh)&#9;As used
in this Agreement, the term &ldquo;<B>knowledge of the Company</B>&rdquo; (or similar language) shall mean the knowledge of the executive
officers of the Company who are named in the Prospectus, with the assumption that such executive officers shall have made reasonable and
diligent inquiry of the matters presented (with reference to what is customary and prudent for the applicable individuals in connection
with the discharge by the applicable individuals of their duties as executive officers of the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(iii)&nbsp;Any
certificate signed by or on behalf of the Company and delivered to the Underwriters or to Loeb &amp; Loeb LLP (&ldquo;<B>Underwriters&rsquo;
Counsel</B>&rdquo;) shall be deemed to be a representation and warranty by the Company to each Underwriter listed on <U>Schedule A</U>
hereto as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.&nbsp;<U>Offering</U>.
Upon authorization of the release of the Securities by the Representative, the Underwriters propose to offer the Securities for sale to
the public upon the terms and conditions set forth in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.&nbsp;<U>Covenants
of the Company</U>. The Company acknowledges, covenants and agrees with the Representative that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;The
Registration Statement and any amendments thereto have been declared effective, and if Rule 430A is used or the filing of the Prospectus
is otherwise required under Rule 424(b), the Company will file the Prospectus (properly completed if Rule 430A has been used) pursuant
to Rule 424(b) within the prescribed time period and will provide evidence satisfactory to the Representative of such timely filing. The
Company will file with the Commission all Issuer Free Writing Prospectuses in the time and manner required under Rules 433(d) or 163(b)(2),
as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;During
the period beginning on the date hereof and ending on the later of the Closing Date or such date as, in the opinion of Underwriters&rsquo;
Counsel, the Prospectus is no longer required by law to be delivered (or in lieu thereof the notice referred to in Rule 173(a) under the
Securities Act is no longer required to be provided), in connection with sales by an underwriter or dealer (the &ldquo;<B>Prospectus Delivery
Period</B>&rdquo;), prior to amending or supplementing the Registration Statement or the Prospectus, the Company shall furnish to the
Representatives for review a copy of each such proposed amendment or supplement, and the Company shall not file any such proposed amendment
or supplement to which the Representatives reasonably object within 36 hours of delivery thereof to the Representatives and Underwriters&rsquo;
Counsel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;After
the date of this Agreement, the Company shall promptly advise the Representative in writing (i) of the receipt of any comments of, or
requests for additional or supplemental information from, the Commission, (ii) of the time and date of any filing of any post-effective
amendment to the Registration Statement or any amendment or supplement to any prospectus, the General Disclosure Package or the Prospectus,
(iii) of the time and date that any post-effective amendment to the Registration Statement becomes effective, and (iv) of the issuance
by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto
or of any order preventing or suspending its use or the use of any prospectus, the General Disclosure Package, the Prospectus or any Issuer-Represented
Free Writing Prospectus, or of any proceedings to remove, suspend or terminate from listing the Ordinary Shares from any securities exchange
upon which they are listed for trading, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission
shall enter any such stop order at any time, the Company will use its reasonable efforts to obtain the lifting of such order at the earliest
possible moment. Additionally, the Company agrees that it shall comply with the provisions of Rules 424(b), 430A and 430B, as applicable,
under the Securities Act and will use its commercially reasonable efforts to confirm that any filings made by the Company under Rule 424(b)
or Rule 433 were received in a timely manner by the Commission (without reliance on Rule 424(b)(8) or Rule 164(b)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;
During the Prospectus Delivery Period, the Company will comply in all material respects with all requirements imposed upon it by the Securities
Act, as now and hereafter amended, and by the Rules and Regulations, as from time to time in force, and by the Exchange Act so far as
necessary to permit the continuance of sales of or dealings in the Securities as contemplated by the provisions hereof, the General Disclosure
Package, the Registration Statement and the Prospectus. If during such period any event occurs as a result of which the Prospectus (or
if the Prospectus is not yet available to prospective purchasers, the General Disclosure Package ) would include an untrue statement of
a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which
such statements were made, not misleading, or if during such period it is necessary or appropriate in the opinion of the Company or its
counsel or the Representative or Underwriters&rsquo; Counsel to amend the Registration Statement or supplement the Prospectus (or if the
Prospectus is not yet available to prospective purchasers, the General Disclosure Package ) to comply with the Securities Act or to file
under the Exchange Act any document which would be deemed to be incorporated by reference in the Prospectus in order to comply with the
Securities Act or the Exchange Act, the Company will promptly notify the Representative and will amend the Registration Statement or supplement
the Prospectus (or if the Prospectus is not yet available to prospective purchasers, the General Disclosure Package) or file such document
(at the expense of the Company) so as to correct such statement or omission or effect such compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;If
at any time following issuance of an Issuer-Represented Free Writing Prospectus there occurred or occurs an event or development as a
result of which such Issuer-Represented Free Writing Prospectus conflicted or would conflict with the information contained in the Registration
Statement, the Statutory Prospectus or the Prospectus or included or would include an untrue statement of a material fact or omitted or
would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at
that subsequent time, not misleading, the Company has promptly notified or promptly will notify the Representative and has promptly amended
or will promptly amend or supplement, at its own expense, such Issuer-Represented Free Writing Prospectus to eliminate or correct such
conflict, untrue statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;The
Company will promptly deliver to the Underwriters and Underwriters&rsquo; Counsel a signed copy of the Registration Statement, as initially
filed and all amendments thereto, including all consents and exhibits filed therewith, and will maintain in the Company&rsquo;s files
manually signed copies of such documents for at least five (5) years after the date of filing thereof. The Company will promptly deliver
to each of the Underwriters such number of copies of any Preliminary Prospectus, the Prospectus, the Registration Statement, and all amendments
of and supplements to such documents, if any, and all documents which are exhibits to the Registration Statement and Prospectus or any
amendment thereof or supplement thereto, as the Underwriters may reasonably request. Prior to 10:00 a.m., New York time, on the Business
Day next succeeding the date of this Agreement and from time to time thereafter, the Company will furnish the Underwriters with copies
of the Prospectus in New York City in such quantities as the Underwriters may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;The
Company consents to the use and delivery of the Preliminary Prospectus by the Underwriters in accordance with Rule 430 and Section 5(b)
of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(g)&nbsp;If
the Company elects to rely on Rule 462(b) under the Securities Act, the Company shall both file a Rule 462(b) Registration Statement with
the Commission in compliance with Rule 462(b) and pay the applicable fees in accordance with Rule 111 of the Securities Act by the earlier
of: (i) 10:00 p.m., New York City time, on the date of this Agreement, and (ii) the time that confirmations are given or sent, as specified
by Rule 462(b)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(h)&nbsp;The
Company will use its commercially reasonable efforts, in cooperation with the Representative, at or prior to the time of effectiveness
of the Registration Statement, to qualify the Securities for offering and sale under the securities laws relating to the offering or sale
of the Securities of such jurisdictions, domestic or foreign, as the Representative may reasonably designate and to maintain such qualification
in effect for so long as required for the distribution thereof, except that in no event shall the Company be obligated in connection therewith
to qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction, to execute a general consent
to service of process in any such jurisdiction, or to subject itself to taxation in any such jurisdiction if it is otherwise not so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(i)&nbsp;During
the 180 days period following the date of this Agreement (the &ldquo;<B>Company Lock-up Perio</B>d&rdquo;), the Company may not, without
the prior written consent of the Representative, (i) offer, sell, issue, agree or contract to sell or issue or grant any option for the
sale of any securities of the Company, except for (A) the issuance of securities under the Company&rsquo;s 2021 Stock Option Plan, as
described in the Registration Statement, and the Prospectus, (B) the issuance of Ordinary Shares upon the exercise or conversion of securities
that are issued and outstanding on the date of this Agreement and are described in the Registration Statement and the Prospectus, provided
that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the
exercise price or conversion price of such securities (other than in connection with stock splits, adjustments or combinations as set
forth in such securities) or to extend the term of such securities, and (C) the issuance of securities issued pursuant to acquisitions
or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued
as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit the filing of
any registration statement in connection therewith within 180 days following the Closing Date, and provided that any such issuance shall
only be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company or an owner
of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition
to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of
raising capital or to an entity whose primary business is investing in securities; or (ii) file any registration statement relating to
the offer or sale of any of the Company&rsquo;s securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(j)&nbsp;<U>Schedule
II</U> hereto contains a complete and accurate list of the Company&rsquo;s executive officers, directors and holders of 5% or more of
the Company&rsquo;s Ordinary Shares (collectively, the &ldquo;<B>Lock-Up Parties</B>&rdquo;). The Company has caused each of the Lock-Up
Parties to deliver to the Representative an executed Lock-Up Agreement, in the form attached hereto as <U>Annex I</U> <B>(</B>the &ldquo;<B>Lock-Up
Agreement</B>&rdquo;), prior to the execution of this Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(k)&nbsp;If
the Representative, in its sole discretion, agrees to release or waive the restrictions set forth in a Lock-Up Agreement described in
Section 4(j) hereof for an officer or director of the Company and provide the Company with notice of the impending release or waiver at
least three business days before the effective date of the release or waiver, the Company agrees to announce the impending release or
waiver by (i) a press release substantially in the form of <U>Annex VI</U> hereto through a major news service or (ii) any other method
that satisfies the obligations described in FINRA Rule 5131(d)(2) at least two business days before the effective date of the release
or waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(l)&nbsp;For
a period of two years from the Closing Date, the Company shall retain VStock Transfer LLC as the Company&rsquo;s transfer agent and registrar
for the Ordinary Shares or a transfer and registrar agent for the Ordinary Shares reasonably acceptable to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(m)&nbsp;Reserved</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(n)&nbsp;For
a period of at least two (2) years from the Effective Date, the Company shall retain a nationally recognized PCAOB registered independent
public accounting firm reasonably acceptable to the Representative. The Representative acknowledges that the Auditor is acceptable to
the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(o)&nbsp;During
the period of one (1) year from the Effective Date, the Company will make available to the Representative copies of all reports or other
communications (financial or other) furnished to security holders or from time to time published or publicly disseminated by the Company,
and will deliver to the Representative: (i) as soon as practicable after they are available, copies of any reports, financial statements
and proxy or information statements furnished to or filed with the Commission or any national securities exchange on which any class of
securities of the Company is listed; and (ii) such additional information concerning the business and financial condition of the Company
as the Representative may from time to time reasonably request in writing pursuant to a specific regulatory or liability issue or; provided,
that any such item which is available on the EDGAR system (or successor thereto) need not be furnished in physical form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(p)&nbsp;The
Company will not issue press releases or engage in any other publicity, without the Representative&rsquo;s prior written consent, for
a period ending at 5:00 p.m. Eastern time on the first Business Day following the fortieth (40th) day following the Closing Date, other
than normal and customary releases issued in the ordinary course of the Company&rsquo;s business, or as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(q)&nbsp;The
Company hereby grants the Representative the right of first refusal for a period of nine (9) months after the closing of this Offering
to act as lead left bookrunner and lead left manager and/or lead left placement agent with at least 50% of the economics for a two-handed
deal and 33.3% of the economics for a three-handed deal for any and all future <FONT STYLE="font-family: Times New Roman, Times, Serif">private
and public equity, convertible or debt offerings undertaken by the Company or any successor or subsidiary of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(r)&nbsp;The
Company will apply the net proceeds from the sale of the Securities as set forth under the caption &ldquo;Use of Proceeds&rdquo; in the
Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(s)&nbsp;The
Company will use its commercially reasonable efforts to effect and maintain the listing of the Ordinary Shares on the Nasdaq Stock Market,
the NYSE, or the NYSE American for at least three (3) years after the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(t)&nbsp;The
Company, during the Prospectus Delivery Period, will file all documents required to be filed with the Commission pursuant to the Securities
Act, the Exchange Act and the Rules and Regulations within the time periods required thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(u)&nbsp;The
Company will use its commercially reasonable efforts to do and perform all things required to be done or performed under this Agreement
by the Company prior to the Closing Date, and to satisfy all conditions precedent to the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(v)&nbsp;The
Company will not take, and will use its commercially reasonable efforts to cause its Affiliates not to take, directly or indirectly, any
action which constitutes or is designed to cause or result in, or which could reasonably be expected to constitute, cause or result in,
the stabilization or manipulation of the price of any security to facilitate the sale or resale of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(w)&nbsp;The
Company shall cause to be prepared and delivered to the Representative, at its expense, within two (2) Business Days from the effective
date of this Agreement, an Electronic Prospectus to be used by the Underwriters in connection with the Offering. As used herein, the term
&ldquo;Electronic Prospectus&rdquo; means a form of prospectus, and any amendment or supplement thereto, that meets each of the following
conditions: (i) it shall be encoded in an electronic format, satisfactory to the Representative, that may be transmitted electronically
by the other Underwriters to offerees and purchasers of the Securities for at least the period during which a Prospectus relating to the
Securities is required to be delivered under the Securities Act; (ii) it shall disclose the same information as the paper prospectus and
prospectus filed pursuant to EDGAR, except to the extent that graphic and image material cannot be disseminated electronically, in which
case such graphic and image material shall be replaced in the electronic prospectus with a fair and accurate narrative description or
tabular representation of such material, as appropriate; and (iii) it shall be in or convertible into a paper format or an electronic
format, satisfactory to the Representative, that will allow recipients thereof to store and have continuously ready access to the prospectus
at any future time, without charge to such recipients (other than any fee charged for subscription to the Internet as a whole and for
on-line time).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(x)&nbsp;The
Company represents and agrees that, unless it obtains the prior written consent of the Representative, and the Representative represents
and agrees that, unless it obtains the prior written consent of the Company, it has not made and will not make any offer relating to the
Securities that would constitute an &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 under the Securities Act, or
that would otherwise constitute a &ldquo;free writing prospectus,&rdquo; as defined in Rule 405 under the Securities Act, required to
be filed with the Commission; provided that the prior written consent of the parties hereto shall be deemed to have been given in respect
of the free writing prospectuses included in <U>Schedule II</U>. Any such free writing prospectus consented to by the Company and the
Representative is hereinafter referred to as a &ldquo;Permitted Free Writing Prospectus.&rdquo; Each of the Company and the Representative
represents that it has treated or agrees that it will treat each Permitted Free Writing Prospectus as an &ldquo;issuer free writing prospectus,&rdquo;
as defined in Rule 433, and has complied and will comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus,
including timely Commission filing where required, legending and record keeping.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.&nbsp;<U>Payment
of Expenses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;Whether
or not the transactions contemplated by this Agreement, the Registration Statement and the Prospectus are consummated or this Agreement
is terminated, the Company hereby agrees to pay all reasonable and documented costs and expenses incident to the performance of its obligations
hereunder including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;all
filing fees and communication expenses related to the registration of the Securities to be sold in the Offering including all expenses
in connection with the preparation, printing, formatting for EDGAR and filing of the Registration Statement, any Preliminary Prospectus
and the Prospectus and any and all amendments and supplements thereto and the mailing and delivering of copies thereof to the Underwriters
and dealers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&nbsp;all
fees and expenses in connection with filings with FINRA;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&nbsp;all
fees, disbursements and expenses of the Company&rsquo;s counsel and accountants in connection with the registration of the Securities
under the Securities Act and the Offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)&nbsp;all
fees and expenses in connection with listing the Ordinary Shares on the Nasdaq Capital Market;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)&nbsp;the
costs of all mailing and printing of the underwriting documents (including this Agreement, any blue sky surveys and, if appropriate, any
Agreement Among Underwriters, Selected Dealers&rsquo; Agreement, Underwriters&rsquo; Questionnaire and Power of Attorney);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vi)&nbsp;all
reasonable travel expenses of the Company&rsquo;s officers and employees and any other expenses incurred in connection with attending
or hosting meetings with prospective purchasers of the Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vii)&nbsp;any
stock transfer taxes payable upon the transfer of securities by the Company to the Underwriters and any other taxes incurred by the Company
in connection with this Agreement or the Offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(viii)&nbsp;the
costs associated with book building, prospectus tracking and compliance software and the cost of preparing certificates representing the
Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ix)&nbsp;the
cost and charges of any transfer agent or registrar for the Ordinary Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(x)&nbsp;any
reasonable cost and expenses in conducting background checks of the Company&rsquo;s officers and directors by a background search firm
acceptable to the Representative;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(xi)&nbsp;fees
of Underwriters&rsquo; Counsel;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(xii)&nbsp;the
cost of preparing, printing and delivering certificates representing each of the Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(xiii)&nbsp;all
other costs, fees and expenses incident to the performance of the Company obligations hereunder which are not otherwise specifically provided
for in this Section 5;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and the Representative
acknowledge that the Company has previously paid to the Representative advances in an amount of $______ (the &ldquo;<B>Advance&rdquo;</B>)
against the Representative&rsquo;s out-of-pocket expenses. Any portion of the Advance not used shall be returned back to the Company to
the extent not incurred. The Representative&rsquo;s total out-of-pocket accountable expenses (including legal fees and expenses) in connection
with the Offering shall not exceed $200,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Notwithstanding anything
to the contrary in this Section 5, in the event that this Agreement is terminated by the Company, pursuant to Section 11(b) hereof, or
subsequent to a Material Adverse Change, the Company will pay the out-of-pocket expenses actually incurred as allowed under FINRA Rule
5110 by the Underwriters through the date of such termination (including the fees and disbursements of Underwriters&rsquo; Counsel ).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.&nbsp;<U>Conditions
of Underwriters&rsquo; Obligations</U>. The obligations of the Underwriters to purchase and pay for the Firm Shares or the Option Shares,
as the case may be, as provided herein shall be subject to: (i) the accuracy of the representations and warranties of the Company herein
contained, as of the date hereof and as of the Closing Date, (ii) the absence from any certificates, opinions, written statements or letters
furnished to the Representative or to Underwriters&rsquo; Counsel pursuant to this Section 6 of any misstatement or omission, (iii) the
performance by the Company of its obligations hereunder, and (iv) each of the following additional conditions. For purposes of this Section
6, the terms &ldquo;Closing Date&rdquo; and &ldquo;Closing&rdquo; shall refer to the Closing Date for the Firm Shares or the Option Shares,
as the case may be, and each of the foregoing and following conditions must be satisfied as of each Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;The
Registration Statement shall have become effective and all necessary regulatory or listing approvals shall have been received not later
than 5:30 p.m., New York time, on the date of this Agreement, or at such later time and date as shall have been consented to in writing
by the Representative. If the Company shall have elected to rely upon Rule 430A under the Securities Act, the Prospectus shall have been
filed with the Commission in a timely fashion in accordance with the terms hereof and a form of the Prospectus containing information
relating to the description of the Securities and the method of distribution and similar matters shall have been filed with the Commission
pursuant to Rule 424(b) within the applicable time period; and, at or prior to the Closing Date or the actual time of the Closing, no
stop order suspending the effectiveness of the Registration Statement or any part thereof, or any amendment thereof, nor suspending or
preventing the use of the General Disclosure Package, the Prospectus or any Issuer Free Writing Prospectus shall have been issued; no
proceedings for the issuance of such an order shall have been initiated or threatened; any request of the Commission for additional information
(to be included in the Registration Statement, the General Disclosure Package, the Prospectus, any Issuer Free Writing Prospectus or otherwise)
shall have been complied with to the Representative&rsquo;s satisfaction; and FINRA shall have raised no objection to the fairness and
reasonableness of the underwriting terms and arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;The
Representative shall not have reasonably determined, and advised the Company, that the Registration Statement, the General Disclosure
Package or the Prospectus, or any amendment thereof or supplement thereto, or any Issuer Free Writing Prospectus, contains an untrue statement
of fact which, in the Representative&rsquo;s reasonable opinion, is material, or omits to state a fact which, in the Representative&rsquo;s
reasonable opinion, is material and is required to be stated therein or necessary to make the statements therein not misleading; provided,
however, that if in the Representative&rsquo;s opinion such deficiency is curable Representative shall have given the Company reasonable
notice of such deficiency and a reasonable chance to cure such deficiency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;The
Representative shall have received the written opinions of (i) Hunter Taubman Fischer &amp; Li LLP, the U.S., legal counsel for the Company,
dated as of the Closing Date and addressed to the Representative substantially in the form attached hereto as <U>Annex II</U>, (ii) Ogier,
Cayman Islands counsel for the Company dated as of the Closing Date and addressed to the Representative substantially in the form attached
hereto as <U>Annex III,</U> and (iii) Fairbairn Catley Low &amp; Kong, legal advisors as to Hong Kong law for the Company dated as of
the Closing Date and addressed to the Representative substantially in the form attached hereto as <U>Annex IV</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;The
Representative shall have received a certificate of the Chief Executive Officer and Chief Financial Officer of the Company, dated as of
each Closing Date to the effect that: (i) the condition set forth in subsection (a) of this Section 6 has been satisfied, (ii) as of the
date hereof and as of the applicable Closing Date, the representations and warranties of the Company set forth in Sections 1 and 2 hereof
are accurate, (iii) as of the applicable Closing Date, all agreements, conditions and obligations of the Company to be performed or complied
with hereunder on or prior thereto have been duly performed or complied with, (iv) the Company has not sustained any material loss or
interference with their respective businesses, whether or not covered by insurance, or from any labor dispute or any legal or governmental
proceeding, (v) no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereof has been
issued and no proceedings therefor have been initiated or threatened by the Commission, (vi) there are no pro forma or as adjusted financial
statements that are required to be included or incorporated by reference in the Registration Statement and the Prospectus pursuant to
the Rules and Regulations which are not so included or incorporated by reference, and (vii) subsequent to the respective dates as of which
information is given in the Registration Statement and the Prospectus there has not been any Material Adverse Change or any development
involving a prospective Material Adverse Change, whether or not arising from transactions in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;On
the date of this Agreement and on the Closing Date, the Representative shall have received a &ldquo;cold comfort&rdquo; letter from the
Auditor as of the date of delivery and addressed to the Representative and in form and substance satisfactory to the Representative and
Underwriters&rsquo; Counsel, confirming that they are independent certified public accountants with respect to the Company within the
meaning of the Securities Act and the Rules and Regulations, and stating, as of the date of delivery (or, with respect to matters involving
changes or developments since the respective dates as of which specified financial information is given in the Prospectus, as of a date
not more than five (5) days prior to the date of such letter), the conclusions and findings of such firm with respect to the financial
information and other matters relating to the Registration Statement and the Prospectus covered by such letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;Subsequent
to the execution and delivery of this Agreement and prior to the Closing Date, there shall not have been any change in the capital stock
or long-term debt of the Company or any change or development involving a change, whether or not arising from transactions in the ordinary
course of business, in the business, condition (financial or otherwise), results of operations, shareholders&rsquo; equity, properties
or prospects of the Company including but not limited to the occurrence of any fire, flood, storm, explosion, accident, act of war or
terrorism or other calamity, the effect of which, in any such case described above, is, in the sole judgment of the Representative, so
material and adverse as to make it impracticable or inadvisable to proceed with the Offering on the terms and in the manner contemplated
in the Prospectus (exclusive of any supplement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(g)&nbsp;Prior
to the execution and delivery of this Agreement, the Representative shall have received a lock-up agreement from each Lock-Up Party, duly
executed by the applicable Lock-Up Party, in each case substantially in the form attached hereto as <U>Annex I</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(h)&nbsp;The
Ordinary Shares are registered under the Exchange Act and, as of the Closing Date, the Ordinary Shares shall be listed and admitted and
authorized for trading on the Nasdaq Capital Market and satisfactory evidence of such action shall have been provided to the Representative.
The Company shall have taken no action designed to, or likely to have the effect of terminating the registration of the Ordinary Shares
under the Exchange Act or delisting or suspending from trading the Ordinary Shares from the Nasdaq Capital Market, nor has the Company
received any information suggesting that the Commission or the Nasdaq Capital Market is contemplating terminating such registration of
listing. The Shares and the Ordinary Shares underlying the Representative&rsquo;s Warrants shall be DTC eligible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(i)&nbsp;FINRA
shall have confirmed that it has not raised any objection with respect to the fairness and reasonableness of the underwriting terms and
arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(j)&nbsp;No
action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state
or foreign governmental or regulatory authority that would, as of the Closing Date, prevent the issuance or sale of the Securities; and
no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date, prevent the issuance
or sale of the Securities or materially and adversely affect or potentially and adversely affect the business or operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(k)&nbsp;The
Company shall have furnished the Representative with a Certificate of Good Standing for the Company certified by the [Registrar of Companies]
of the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(l)&nbsp;The
Company shall have furnished the Representative and Underwriters&rsquo; Counsel with such other certificates, opinions or other documents
as they may have reasonably requested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(m)&nbsp;On
each Closing Date, there shall have been issued to the Representative, a Representative&rsquo;s Warrant in the form attached hereto as
<U>Annex V.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of the conditions specified
in this Section 6 shall not have been fulfilled when and as required by this Agreement, or if any of the certificates, opinions, written
statements or letters furnished to the Representative or to Underwriters&rsquo; Counsel pursuant to this Section 6 shall not be reasonably
satisfactory in form and substance to the Representative and to Underwriters&rsquo; Counsel, all obligations of the Underwriters hereunder
may be cancelled by the Representative at, or at any time prior to, the consummation of the Closing. Notice of such cancellation shall
be given to the Company in writing or by telephone. Any such telephone notice shall be confirmed promptly thereafter in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">7.&nbsp;<U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;The
Company agrees to indemnify and hold harmless each Underwriter, its officers, directors and employees, and each Person, if any, who controls
such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, against any losses, liabilities,
claims, damages and expenses whatsoever as incurred (including but not limited to reasonable attorneys&rsquo; fees and any and all expenses
whatsoever incurred in investigating, preparing or defending against any litigation, commenced or threatened, or any claim whatsoever,
and any and all amounts paid in settlement of any claim or litigation), joint or several, to which they or any of them may become subject
under the Securities Act, the Exchange Act or otherwise(including in settlement of any litigation if such settlement is effected with
the written consent of the Company), insofar as such losses, liabilities, claims, damages or expenses (or actions in respect thereof)
arise out of or are based upon (i) an untrue statement or alleged untrue statement of a material fact contained in (A) the Registration
Statement, including the information deemed to be a part of the Registration Statement at the time of effectiveness and at any subsequent
time pursuant to Rules 430A and 430B of the Rules and Regulations, the General Disclosure Package, the Prospectus, or any amendment or
supplement thereto (including any documents filed under the Exchange Act and deemed to be incorporated by reference into the Prospectus),
(B) any Issuer Free Writing Prospectus or in any other materials or information provided to investors by, or with the approval of, the
Company in connection with the marketing of the offering of the Securities, including any road show or investor presentations made to
investors by the Company (whether in person or electronically) (collectively &ldquo;<B>Marketing Materials</B>&rdquo;) or (C) any filings
or reports filed by the Company under the Exchange Act or arise out of or are based upon the omission or alleged omission to state therein
a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse such indemnified
party for any legal or other expenses reasonably incurred by it in connection with investigating or defending against such loss, claim,
damage, liability or action; or (ii) in whole or in part upon any inaccuracy in the representations and warranties of the Company contained
herein; or (iii) in whole or in part upon any failure of the Company to perform its obligations hereunder or under law; provided, however,
that the Company shall not be liable in any such case to the extent that any such loss, claim, damage, liability or action arises out
of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement,
any Preliminary Prospectus, the General Disclosure Package, the Prospectus, or any such amendment or supplement, any Issuer Free Writing
Prospectus or any other Marketing Materials, in reliance upon and in conformity with the Underwriters&rsquo; Information. With respect
to any untrue statement or omission or alleged untrue statement or omission made in the Preliminary Prospectus, the indemnity agreement
contained in this Section 7(a) shall not inure to the benefit of an Underwriter to the extent that any loss, liability, claim, damage
or expense of such Underwriter results from the fact that a copy of the Prospectus was not given or sent to the Person asserting any such
loss, liability, claim or damage at or prior to the written confirmation of sale of the Securities to such Person as required by the Securities
Act and the rules and regulations thereunder, and if the untrue statement or omission has been corrected in the Prospectus, unless such
failure to deliver the Prospectus was a result of non-compliance by the Company with its obligations under this Agreement. The Company
agrees promptly to notify each Underwriter of the commencement of any litigation or proceedings against the Company or any of its officers,
directors or Controlling Persons in connection with the issue and sale of the Securities or in connection with the Registration Statement
or Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;Each
Underwriter, severally and not jointly, shall indemnify and hold harmless the Company, each of the directors of the Company, each of the
officers of the Company who shall have signed the Registration Statement, and each other Person, if any, who controls the Company within
the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, against any losses, liabilities, claims, damages and
expenses whatsoever as incurred (including but not limited to attorneys&rsquo; fees and any and all expenses whatsoever incurred in investigating,
preparing or defending against any litigation, commenced or threatened, or any claim whatsoever, and any and all amounts paid in settlement
of any claim or litigation), joint or several, to which they or any of them may become subject under the Securities Act, the Exchange
Act or otherwise, insofar as such losses, liabilities, claims, damages or expenses (or actions in respect thereof) arise out of or are
based upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, as originally
filed or any amendment thereof, or any related Preliminary Prospectus or the Prospectus, or in any amendment thereof or supplement thereto,
or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary
to make the statements therein not misleading, in each case to the extent, but only to the extent, that any such loss, liability, claim,
damage or expense arises out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged omission
made therein in reliance upon and in conformity with the Underwriters&rsquo; Information; provided, however, that in no case shall any
Underwriter be liable or responsible for any amount in excess of the aggregate underwriting discount applicable to the Securities to be
purchased by such Underwriter hereunder. The parties agree that such information provided by or on behalf of any Underwriter through the
Representative consists solely of the material referred to in the last sentence of Section 2(b) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;Promptly
after receipt by an indemnified party under subsection (a) or (b) above of notice of any claims or the commencement of any action, such
indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify each
party against whom indemnification is to be sought in writing of the claim or the commencement thereof (but the failure so to notify an
indemnifying party shall not relieve the indemnifying party from any liability which it may have under this Section 7 to the extent that
it is not materially prejudiced as a result thereof and in any event shall not relieve it from any liability that such indemnifying party
may have otherwise than on account of the indemnity agreement hereunder). In case any such claim or action is brought against any indemnified
party, and it notifies an indemnifying party of the commencement thereof, the indemnifying party will be entitled to participate, at its
own expense in the defense of such action, and to the extent it may elect by written notice delivered to the indemnified party promptly
after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel satisfactory to such indemnified
party; provided however, that counsel to the indemnifying party shall not (except with the written consent of the indemnified party) also
be counsel to the indemnified party. Notwithstanding the foregoing, the indemnified party or parties shall have the right to employ its
or their own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of such indemnified party or
parties unless (i) the employment of such counsel shall have been authorized in writing by one of the indemnifying parties in connection
with the defense of such action, (ii) the indemnifying parties shall not have employed counsel to have charge of the defense of such action
within a reasonable time after notice of commencement of the action, (iii) the indemnifying party does not diligently defend the action
after assumption of the defense, or (iv) such indemnified party or parties shall have reasonably concluded that a conflict may arise between
the positions of the indemnifying party and the indemnified party, or any of them, in conducting the defense of any such action or there
may be legal defenses available to it or them which are different from or additional to those available to one or all of the indemnifying
parties (in which case the indemnifying parties shall not have the right to direct the defense of such action on behalf of the indemnified
party or parties), in any of which events such fees and expenses shall be borne by the indemnifying parties and shall be paid as incurred.
No indemnifying party shall, without the prior written consent of the indemnified parties (which consent shall not be unreasonably delayed,
withhold or denied), effect any settlement or compromise of, or consent to the entry of judgment with respect to, any pending or threatened
claim, investigation, action or proceeding in respect of which indemnity or contribution may be or could have been sought by an indemnified
party under this Section 7 or Section 8 hereof (whether or not the indemnified party is an actual or potential party thereto), unless
(x) such settlement, compromise or judgment (i) includes an unconditional release of the indemnified party from all liability arising
out of such claim, investigation, action or proceeding and (ii) does not include a statement as to or an admission of fault, culpability
or any failure to act, by or on behalf of the indemnified party, and (y) the indemnifying party confirms in writing its indemnification
obligations hereunder with respect to such settlement, compromise or judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">8.&nbsp;<U>Contribution</U>.
In order to provide for contribution in circumstances in which the indemnification provided for in Section 7 is for any reason held to
be unavailable from any indemnifying party or is insufficient to hold harmless a party indemnified thereunder, the Company and the Underwriters
shall contribute to the aggregate losses, claims, damages, liabilities and expenses of the nature contemplated by such indemnification
provision (including any investigation, legal and other expenses incurred in connection with, and any amount paid in settlement of, any
action, suit or proceeding or any claims asserted, but after deducting in the case of losses, claims, damages, liabilities and expenses
suffered by the Company, any contribution received by the Company from Persons, other than the Underwriters, who may also be liable for
contribution, including Persons who control the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange
Act, officers of the Company who signed the Registration Statement and directors of the Company) as incurred to which the Company and
one or more of the Underwriters may be subject, in such proportions as is appropriate to reflect the relative benefits received by the
Company and the Underwriters from the Offering or, if such allocation is not permitted by applicable law, in such proportions as are appropriate
to reflect not only the relative benefits referred to above but also the relative fault of the Company and the Underwriters in connection
with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant
equitable considerations. The relative benefits received by the Company and the Underwriters shall be deemed to be in the same proportion
as (x) the total proceeds from the Offering (net of underwriting discounts and commissions but before deducting expenses) received by
the Company bears to (y) the underwriting discount or commissions received by the Underwriters, in each case as set forth in the table
on the cover page of the Prospectus. The relative fault of each of the Company and of the Underwriters shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state
a material fact relates to information supplied by the Company or the Underwriters and the parties&rsquo; relative intent, knowledge,
access to information and opportunity to correct or prevent such statement or omission. The Company and the Underwriters agree that it
would not be just and equitable if contribution pursuant to this Section 8 were determined by pro rata allocation (even if the Underwriters
were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations
referred to above in this Section. The aggregate amount of losses, liabilities, claims, damages and expenses incurred by an indemnified
party and referred to above in this Section 8 shall be deemed to include any legal or other expenses reasonably incurred by such indemnified
party in investigating, preparing or defending against any litigation, or any investigation or proceeding by any judicial, regulatory
or other legal or governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged
untrue statement or omission or alleged omission. Notwithstanding the provisions of this Section 8: (i) no Underwriter shall be required
to contribute any amount in excess of the aggregate discounts and commissions applicable to the Securities underwritten by it and distributed
to the public and (ii) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall
be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. For purposes of this Section 8, each
Person, if any, who controls an Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act shall
have the same rights to contribution as such Underwriter, and each Person, if any, who controls the Company within the meaning of Section
15 of the Securities Act or Section 20 of the Exchange Act, each officer of the Company who shall have signed the Registration Statement
and each director of the Company shall have the same rights to contribution as the Company, subject in each case to clauses (i) and (ii)
of the immediately preceding sentence. Any party entitled to contribution will, promptly after receipt of notice of commencement of any
action, suit or proceeding against such party in respect of which a claim for contribution may be made against another party or parties,
notify each party or parties from whom contribution may be sought, but the omission to so notify such party or parties shall not relieve
the party or parties from whom contribution may be sought from any obligation it or they may have under this Section 8 or otherwise. The
obligations of the Underwriters to contribute pursuant to this Section 8 are several in proportion to the respective number of Securities
to be purchased by each of the Underwriters hereunder and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">9.&nbsp;<U>Underwriter
Default</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;If
any Underwriter or Underwriters shall default in its or their obligation to purchase Firm Shares hereunder, and if the securities with
respect to which such default relates (the &ldquo;<B>Default Securities</B>&rdquo;) do not (after giving effect to arrangements, if any,
made by the Representative pursuant to subsection (b) below) exceed in the aggregate 10% of the number of Firm Shares, each non-defaulting
Underwriter, acting severally and not jointly, agrees to purchase from the Company that number of Default Securities that bears the same
proportion of the total number of Default Securities then being purchased as the number of Firm Shares set forth opposite the name of
such Underwriter on <U>Schedule I</U> hereto bears to the aggregate number of Firm Shares set forth opposite the names of the non-defaulting
Underwriters, subject, however, to such adjustments to eliminate fractional shares as the Representative in its sole discretion shall
make.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;In
the event that the aggregate number of Default Securities exceeds 10% of the number of Firm Shares, the Representative may in its discretion
arrange for themselves or for another party or parties (including any non-defaulting Underwriter or Underwriters who so agree) to purchase
the Default Securities on the terms contained herein. In the event that within 48 hours after such a default the Representative does not
arrange for the purchase of the Default Securities as provided in this Section 9, this Agreement shall thereupon terminate, without liability
on the part of the Company with respect thereto (except in each case as provided in Sections 5, 7, 8, 9 and 11(d)) or the Underwriters,
but nothing in this Agreement shall relieve a defaulting Underwriter or Underwriters of its or their liability, if any, to the other Underwriters
and the Company for damages occasioned by its or their default hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;In
the event that any Default Securities are to be purchased by the non-defaulting Underwriters, or are to be purchased by another party
or parties as aforesaid, the Representative or the Company shall have the right to postpone the Closing Date for a period, not exceeding
five (5) Business Days, in order to effect whatever changes may thereby be necessary in the Registration Statement or the Prospectus or
in any other documents and arrangements, and the Company agrees to file promptly any amendment or supplement to the Registration Statement
or the Prospectus which, in the reasonable opinion of Underwriters&rsquo; Counsel, may thereby be made necessary or advisable. The term
&ldquo;Underwriter&rdquo; as used in this Agreement shall include any party substituted under this Section 9 with like effect as if it
had originally been a party to this Agreement with respect to such Firm Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">10.&nbsp;<U>Survival
of Representations and Agreements</U>. All representations and warranties, covenants and agreements of the Company and the Underwriters
contained in this Agreement or in certificates of officers of the Company submitted pursuant hereto, including the agreements contained
in Sections 5, 10, 14 and 15, the indemnity agreements contained in Section 7 and the contribution agreements contained in Section 8 hereof,
shall remain operative and in full force and effect regardless of any investigation made by or on behalf of any Underwriter or any controlling
Person thereof or by or on behalf of the Company, any of its officers and directors or any controlling Person thereof, and shall survive
delivery of and payment for the Securities to and by the Underwriters. The representations contained in Section 2 hereof and the covenants
and agreements contained in Sections 5, 7, 8, this Section 10 and Sections 12, 13, 14 and 15 hereof shall survive any termination of this
Agreement, including termination pursuant to Section 9 or 11 hereof. The representations and covenants contained in Sections 2, 3 and
4 hereof shall survive termination of this Agreement if any Securities are purchased pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">11.&nbsp;<U>Effective
Date of Agreement; Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;This
Agreement shall become effective upon the later of: (i) receipt by the Representative and the Company of notification of the effectiveness
of the Registration Statement or (ii) the execution of this Agreement. Notwithstanding any termination of this Agreement, the provisions
of this Section 11 and of Sections 5, 7, 8, 12, 13, 14 and 15, inclusive, shall remain in full force and effect at all times after the
execution hereof. If this Agreement is terminated after any Securities have been purchased hereunder, the provisions of Sections 2, 3
and 4 hereof shall survive termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;The
Representative shall have the right to terminate this Agreement at any time prior to the consummation of the Closing if: (i) any domestic
or international event or act or occurrence has materially disrupted, or in the opinion of the Representative will in the immediate future
materially disrupt, the market for the Company&rsquo;s securities or securities in general; or (ii) trading on the New York Stock Exchange
or the Nasdaq Stock Market shall have been suspended or been made subject to material limitations, or minimum or maximum prices for trading
shall have been fixed, or maximum ranges for prices for securities shall have been required, on the New York Stock Exchange or the Nasdaq
Stock Market or by order of the Commission, FINRA or any other governmental authority having jurisdiction; or (iii) a banking moratorium
has been declared by any state or federal authority or if any material disruption in commercial banking or securities settlement or clearance
services shall have occurred; (iv) any downgrading shall have occurred in the Company&rsquo;s corporate credit rating or the rating accorded
the Company&rsquo;s debt securities by any &ldquo;nationally recognized statistical rating organization&rdquo; (as defined for purposes
of Rule 436(g) under the Securities Act) or if any such organization shall have been publicly announced that it has under surveillance
or review, with material negative implications, its rating of any of the Company&rsquo;s debt securities; or (v) (A) there shall have
occurred any outbreak or escalation of hostilities or acts of terrorism involving the United States or there is a declaration of a national
emergency or war by the United States, excluding a national emergency declared related to the COVID-19 pandemic, or (B) there shall have
been any other calamity or crisis or any change in political, financial or economic conditions if the effect of any such event in (A)
or (B), in the judgment of the Representative, is so material and adverse that such event makes it impracticable or inadvisable to proceed
with the offering, sale and delivery of the Firm Shares on the terms and in the manner contemplated by the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;Any
notice of termination pursuant to this Section 11 shall be in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;If
this Agreement shall be terminated pursuant to any of the provisions hereof or if the sale of the Securities provided for herein is not
consummated because any condition to the obligations of the Underwriters set forth herein is not satisfied or because of any refusal,
inability or failure on the part of the Company to perform any agreement herein or comply with any provision hereof, the Company will,
subject to demand by the Representative, reimburse the Underwriters for those out-of-pocket expenses (including the reasonable fees and
expenses of Underwriters&rsquo; Counsel), actually incurred by the Underwriters in connection herewith less the Advance previously paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">12.&nbsp;<U>Notices</U>.
All communications hereunder, except as may be otherwise specifically provided herein, shall be in writing, and:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;if
sent to the Representative or any Underwriter, shall be mailed, delivered, or faxed and confirmed in writing, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Maxim Group LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">405 Lexington Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">New York, New York 10174</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention: Clifford A. Teller, Executive Managing Director
of Investment Banking,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Fax: 212-895-3555</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">with a copy to Underwriters&rsquo; Counsel at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Loeb &amp; Loeb LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">345 Park Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">New York, New York 10154</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention: Mitchell Nussbaum, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Fax: 212-407-4990</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;if
sent to the Company, shall be mailed, delivered, or faxed and confirmed in writing to the Company and its counsel at the addresses set
forth in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">13.&nbsp;<U>Parties;
Limitation of Relationship</U>. This Agreement shall inure solely to the benefit of, and shall be binding upon, the Underwriters, the
Company and the controlling Persons, directors, officers, employees and agents referred to in Sections 7 and 8 hereof, and their respective
successors and assigns, and no other Person shall have or be construed to have any legal or equitable right, remedy or claim under or
in respect of or by virtue of this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof
are intended to be for the sole and exclusive benefit of the parties hereto and said controlling Persons and their respective successors,
officers, directors, heirs and legal representative, and it is not for the benefit of any other Person. The term &ldquo;successors and
assigns&rdquo; shall not include a purchaser, in its capacity as such, of Securities from any of the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">14.&nbsp;
<U>Governing Law;</U> This Agreement shall be governed by and construed in accordance with the laws of the State of New York without regard
to conflict of laws principles (other than Section 5-1401 of the General Obligations Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">15.&nbsp;<U>Submission
to Jurisdiction, Etc</U><I>.</I> This Agreement shall be governed by and construed in accordance with the laws of the State of New York<I>.</I>
The Company irrevocably (a) submits to the jurisdiction of any court of the State of New York for the purpose of any suit, action, or
other proceeding arising out of this Agreement, or any of the agreements or transactions contemplated by this Agreement, the Registration
Statement and the Prospectus (each, a &ldquo;<B>Proceeding</B>&rdquo;), (b) agrees that all claims in respect of any Proceeding may be
heard and determined in any such court, (c) waives, to the fullest extent permitted by law, any immunity from jurisdiction of any such
court or from any legal process therein, (d) agrees not to commence any Proceeding other than in such courts, and (e) waives, to the fullest
extent permitted by law, any claim that such Proceeding is brought in an inconvenient forum. EACH OF THE COMPANY (ON BEHALF OF ITSELF
AND, TO THE FULLEST EXTENT PERMITTED BY LAW, ON BEHALF OF ITS RESPECTIVE EQUITY HOLDERS AND CREDITORS) HEREBY WAIVES ANY RIGHT IT MAY
HAVE TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM BASED UPON, ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED
BY THIS AGREEMENT, THE REGISTRATION STATEMENT, AND THE PROSPECTUS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">16.&nbsp;<U>Entire
Agreement</U>. This Agreement, together with the exhibits, schedules and annexes attached hereto and as the same may be amended from time
to time in accordance with the terms hereof, constitutes the entire agreement of the parties to this Agreement and supersedes all prior
or contemporaneous written or oral agreements, understandings, promises and negotiations with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">17.&nbsp;<U>Severability</U>.
If any term or provision of this Agreement or the performance thereof shall be invalid or unenforceable to any extent, such invalidity
or unenforceability shall not affect or render invalid or unenforceable any other provision of this Agreement and this Agreement shall
be valid and enforced to the fullest extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">18.&nbsp;<U>Amendment</U>.
This Agreement may only be amended by a written instrument executed by each of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">19.&nbsp;<U>Waiver,
etc</U>. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be deemed or
construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision hereof or the
right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach, non-compliance
or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument executed by
the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment
shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">20.&nbsp;<U>No
Fiduciary Relationship</U>. The Company hereby acknowledges that the Underwriters are acting solely as underwriters in connection with
the offering of the Company&rsquo;s Securities. The Company further acknowledge that the Underwriters are acting pursuant to a contractual
relationship created solely by this Agreement entered into on an arm&rsquo;s length basis and in no event do the parties intend that the
Underwriters act or be responsible as a fiduciary to the Company, its management, shareholders, creditors or any other person in connection
with any activity that the Underwriters may undertake or have undertaken in furtherance of the offering of the Company&rsquo;s Securities,
either before or after the date hereof. The Underwriters hereby expressly disclaim any fiduciary or similar obligations to the Company,
either in connection with the transactions contemplated by this Agreement or any matters leading up to such transactions, and the Company
hereby confirms its understanding and agreement to that effect. The Company hereby further confirms its understanding that no Underwriter
has assumed an advisory or fiduciary responsibility in favor of the Company with respect to the Offering contemplated hereby or the process
leading thereto, including any negotiation related to the pricing of the Securities; and the Company has consulted its own legal and financial
advisors to the extent it has deemed appropriate in connection with this Agreement and the Offering. The Company and the Underwriters
agree that they are each responsible for making their own independent judgments with respect to any such transactions, and that any opinions
or views expressed by the Underwriters to the Company regarding such transactions, including but not limited to any opinions or views
with respect to the price or market for the Company&rsquo;s securities, do not constitute advice or recommendations to the Company. The
Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters
with respect to any breach or alleged breach of any fiduciary or similar duty to the Company in connection with the transactions contemplated
by this Agreement or any matters leading up to such transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">21.&nbsp;<U>Judgment
Currency</U><I>.</I> The obligation of the Company in respect of any sum due to any Underwriter under this Agreement shall, notwithstanding
any judgment in a currency other than U.S. dollars (the &ldquo;<B>Judgment Currency</B>&rdquo;), not be discharged until the first business
day, following receipt by such Underwriter of any sum adjudged to be so due in the Judgment Currency, on which (and only to the extent
that) such Underwriter may in accordance with normal banking procedures purchase U.S. dollars with the Judgment Currency; if the U.S.
dollars so purchased are less than the sum originally due to such Underwriter hereunder, the Company agrees, as a separate obligation
and notwithstanding any such judgment, to indemnify such Underwriter against such loss. If the U.S. dollars so purchased are greater than
the sum originally due to such Underwriter hereunder, such Underwriter agrees to pay to the Company an amount equal to the excess of the
U.S. dollars so purchased over the sum originally due to such Underwriter hereunder</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">22.&nbsp;<U>Counterparts</U>.
This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all such counterparts
shall together constitute one and the same instrument. Delivery of a signed counterpart of this Agreement by facsimile or other electronic
transmission shall constitute valid and sufficient delivery thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">23.&nbsp;<U>Headings</U>.
The headings herein are inserted for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation
of, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">24.&nbsp;<U>Time
is of the Essence</U>. Time shall be of the essence of this Agreement. As used herein, the term &ldquo;Business Day&rdquo; shall mean
any day other than a Saturday, Sunday or any day on which the major stock exchanges in New York, New York are not open for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Signature Pages Follow]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing correctly
sets forth your understanding, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute
a binding agreement among us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>REGENCELL BIOSCIENCE HOLDINGS LIMITED</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: Chief Executive Officer and Chairman of the Board</TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted by the Representative, acting for themselves and as</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Representative of the Underwriters named on <U>Schedule I</U>
attached hereto,</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">as of the date first written above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MAXIM GROUP LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name: Clifford A. Teller</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:&nbsp;Executive Managing Director,</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Investment Banking</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE I</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 88%; padding-bottom: 1.5pt">Name of Underwriter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: center">Number
                                            of Firm Shares Being Purchased</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Maxim Group LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 42; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Schedule I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE II</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>Lock-Up Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Yat-Gai Au</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Yi-Chung Chao</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">James Wai Hong Chung</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Tien Hsiang Chau</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Evana Yee Wah Hui</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Paul J. Niewiadomski</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Cheung Ming Wong</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Regencell (BVI) Ltd</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Schedule II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE III</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Free Writing Prospectus</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Schedule III-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE IV</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 50%"><B>Name</B></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%"><B>Place of Incorporation</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">1. Regencell Limited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Hong Kong</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2. Regencell Bioscience Limited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Hong Kong</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 45; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Schedule IV-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ANNEX I</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form of Lock-Up Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">________, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Maxim Group LLC<BR>
405 Lexington Avenue<BR>
New York, NY 10174</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned understands that Maxim Group LLC
(the &ldquo;<B>Representative</B>&rdquo;) proposes to enter into an Underwriting Agreement (the &ldquo;<B>Underwriting Agreement</B> &ldquo;)
with Regencell Bioscience Holdings Limited, a corporation incorporated under the laws of the Cayman Islands (the &ldquo;<B>Company</B>&rdquo;),
providing for the public offering (the &ldquo;<B>Public Offering</B>&rdquo;) of Ordinary Shares no par value (the &ldquo;<B>Ordinary Shares</B>&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To induce the Representative to continue its efforts
in connection with the Public Offering, the undersigned hereby agrees that, without the prior written consent of the Representative, the
undersigned will not, during the period commencing on the date of the Underwriting Agreement and ending hundred and eighty (180) days
after such date (the &ldquo;<B>Lock-Up Period</B>&rdquo;), (1) offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer
or dispose of, directly or indirectly, any Ordinary Shares or any securities convertible into or exercisable or exchangeable for Ordinary
Shares, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires
the power of disposition (collectively, the &ldquo;<B>Lock-Up Securities</B>&rdquo;); (2) enter into any swap or other arrangement that
transfers to another, in whole or in part, any of the economic consequences of ownership of the Lock-Up Securities, whether any such transaction
described in clause (1) or (2) above is to be settled by delivery of Lock-Up Securities, in cash or otherwise; (3) make any demand for
or exercise any right with respect to the registration of any Lock-Up Securities; or (4) publicly disclose the intention to make any offer,
sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement relating to any Lock-Up Securities. Notwithstanding
the foregoing, and subject to the conditions below, the undersigned may transfer Lock-Up Securities without the prior written consent
of the Representative in connection with (a) transactions relating to Lock-Up Securities acquired in open market transactions after the
completion of the Public Offering; <U>provided</U> that no filing under Section 16(a) of the Securities Exchange Act of 1934, as amended
(the &ldquo;<B>Exchange Act</B>&rdquo;), shall be required or shall be voluntarily made in connection with subsequent sales of Lock-Up
Securities acquired in such open market transactions; (b) transfers of Lock-Up Securities (i) as a <I>bona fide</I> gift, by will or intestacy,
(ii) by operation of law, such as pursuant to a qualified domestic order or as required by a divorce settlement, or (iii) to a family
member or trust for the benefit of a family member (for purposes of this lock-up agreement, &ldquo;family member&rdquo; means any relationship
by blood, marriage or adoption, not more remote than first cousin); (c) transfers of Lock-Up Securities to a charity or educational institution;
or (d) if the undersigned, directly or indirectly, controls a corporation, partnership, limited liability company or other business entity,
any transfers of Lock-Up Securities to any shareholder, partner or member of, or owner of similar equity interests in, the undersigned,
as the case may be; <U>provided</U> that in the case of any transfer pursuant to the foregoing clauses (b), (c) or (d), (i) any such transfer
shall not involve a disposition for value, (ii) each transferee shall sign and deliver to the Representative a lock-up agreement substantially
in the form of this lock-up agreement and (ii) no filing under Section 16(a) of the Exchange Act shall be required or shall be voluntarily
made. The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&rsquo;s transfer agent and
registrar against the transfer of the undersigned&rsquo;s Lock-Up Securities except in compliance with this lock-up agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 46; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the undersigned is an officer or director of
the Company, (i) the undersigned agrees that the foregoing restrictions shall be equally applicable to any Securities that the undersigned
may purchase in the Public Offering; (ii) the Representative agrees that, at least three (3) business days before the effective date of
any release or waiver of the foregoing restrictions in connection with a transfer of Lock-Up Securities, the Representative will notify
the Company of the impending release or waiver; and (iii) the Company has agreed in the Underwriting Agreement to announce the impending
release or waiver by press release through a major news service at least two (2) business days before the effective date of the release
or waiver. Any release or waiver granted by the Representative hereunder to any such officer or director shall only be effective two (2)
business days after the publication date of such press release. The provisions of this paragraph will not apply if (a) the release or
waiver is effected solely to permit a transfer of Lock-Up Securities not for consideration and (b) the transferee has agreed in writing
to be bound by the same terms described in this lock-up agreement to the extent and for the duration that such terms remain in effect
at the time of such transfer.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No provision in this lock-up agreement shall be
deemed to restrict or prohibit the exercise, exchange or conversion by the undersigned of any securities exercisable or exchangeable for
or convertible into Ordinary Shares, as applicable; <U>provided</U> that the undersigned does not transfer the Ordinary Shares acquired
on such exercise, exchange or conversion during the Lock-Up Period, unless otherwise permitted pursuant to the terms of this lock-up agreement.
In addition, no provision herein shall be deemed to restrict or prohibit the entry into or modification of a so-called &ldquo;10b5-1&rdquo;
plan at any time (other than the entry into or modification of such a plan in such a manner as to cause the sale of any Lock-Up Securities
within the Lock-Up Period) or a sale of 100% of the Company&rsquo;s outstanding Ordinary Shares.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned understands that the Company and
the Representative are relying upon this lock-up agreement in proceeding toward consummation of the Public Offering. The undersigned further
understands that this lock-up agreement is irrevocable and shall be binding upon the undersigned&rsquo;s heirs, legal representatives,
successors and assigns.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned understands that, if the Underwriting
Agreement is not executed by ______________, 2021, or if the Underwriting Agreement (other than the provisions thereof which survive termination)
shall terminate or be terminated prior to payment for and delivery of the securities to be sold thereunder, then this lock-up agreement
shall be void and of no further force or effect.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Whether or not the Public Offering actually occurs
depends on a number of factors, including market conditions. Any Public Offering will only be made pursuant to an Underwriting Agreement,
the terms of which are subject to negotiation between the Company and the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">(Name - Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">(Signature)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">(Name of Signatory, in the case of entities - Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">(Title of Signatory, in the case of entities - Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Address:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ANNEX II</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF U.S. SECURITIES COUNSEL OPINION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">[Intentionally Omitted.]</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 49; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ANNEX III</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF CAYMAN ISLANDS COUNSEL OPINION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">[Intentionally Omitted.]</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 50; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex III-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Annex IV</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form of Opinion of
Hong Kong Counsel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Intentionally Omitted.]</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex IV-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ANNEX V</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form of Representative&rsquo;s Warrant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE
UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &quot;<B>SECURITIES ACT</B>&quot;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH
SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES MAY BE PLEDGED
IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THE REGISTERED HOLDER OF THIS PURCHASE WARRANT
BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED
HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD
OF ONE HUNDRED EIGHTY (180) DAYS FOLLOWING THE COMMENCEMENT OF SALES OF THE OFFERING TO ANYONE OTHER THAN (I) MAXIM GROUP LLC, OR A REPRESENTATIVE
OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF MAXIM GROUP LLC, OR OF ANY SUCH UNDERWRITERS
OR SELECTED DEALER.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ORDINARY SHARES PURCHASE WARRANT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">REGENCELL BIOSCIENCE HOLDINGS LIMITED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrant Shares: [&nbsp;&nbsp;&nbsp;] Original Issuance Date: [ ], 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">THIS ORDINARY SHARES PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;)
certifies that, for value received, Maxim Group LLC or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and
subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the &ldquo;<U>Initial
Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on [ ], 2026 (the &ldquo;<U>Termination Date</U>&rdquo;)
<SUP>1</SUP> but not thereafter, to subscribe for and purchase from Regencell Bioscience Holdings Limited. a corporation incorporated
under the laws of the Cayman Islands (the &ldquo;<U>Company</U>&rdquo;), up to [ &nbsp;] Ordinary Shares (as subject to adjustment hereunder,
the &ldquo;<U>Warrant Shares</U>&rdquo;). The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b).</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><SUP>1</SUP> Fifth anniversary
of Effective Date of Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 52; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Section 1</U>. <U>Definitions</U>. Capitalized
terms used and not otherwise defined herein shall have the meanings set forth in that certain Underwriting Agreement (the &ldquo;<U>Agreement</U>&rdquo;),
dated [ &nbsp;], 2021 by and between the Company and Maxim Group, LLC, as representative of the several underwriters.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">a) <U>Exercise of Warrant</U>. Exercise of
the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise
Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy (or e-mail attachment) of the
Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading
Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the
date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice
of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in
Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall
any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein
to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all
of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant
to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company.
Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall
have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number
of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the
date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such
notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this
paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder
at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">b) <U>Exercise Price</U>. The exercise price per
Ordinary Share under this Warrant shall be <B>$[ ] </B>(which is 110% of the offering price per Ordinary Share in the offering contemplated
by the Agreement) (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">c) <U>Cashless Exercise</U>. If at the time of exercise
hereof there is no effective registration statement registering the Warrant Shares, or the prospectus contained therein is not available
for the issuance of the Warrant Shares to the Holder, then, provided that the Trading Price, as defined below, is equal to or greater
than the Exercise Price, on the Termination Date, this Warrant may also be exercised, in whole or in part, at such time by means of a
&ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained
by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(A) = as applicable: (i) the VWAP on the Trading Day immediately
preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section
2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior
to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities
laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of
the applicable Notice of Exercise or (z) the Bid Price of the Ordinary Shares on the principal Trading Market as reported by Bloomberg
L.P. as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during
&ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after
the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the
applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and
delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day (such applicable
price for (a), the &ldquo;Trading Price&rdquo;);</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(B) = the Exercise Price of this Warrant, as adjusted hereunder;
and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(X) = the number of Warrant Shares that would be issuable upon
exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a
cashless exercise.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">If Warrant Shares are issued in such a cashless exercise,
the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the
characteristics of the Warrants being exercised and the holding period of the Warrants being exercised may be tacked on to the holding
period of the Warrant Shares. The Company agrees not to take any position contrary to this Section 2(c).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&ldquo;<U>Bid Price</U>&rdquo; means, for any date,
the price determined by the first of the following clauses that applies: (a) if the Ordinary Shares are then listed or quoted on a Trading
Market, the bid price of the Ordinary Shares for the time in question (or the nearest preceding date) on the Trading Market on which the
Ordinary Shares then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02
p.m. (New York City time)), (b) if the Ordinary Shares are traded on OTCQB or OTCQX, the volume weighted average sales price of the Ordinary
Shares for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Ordinary Shares are not then listed or
quoted for trading on OTCQB or OTCQX and if prices for the Ordinary Shares are then reported in the &ldquo;Pink Sheets&rdquo; published
by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid
price per Ordinary Share so reported, or (d) in all other cases, the fair market value of a Ordinary Share as determined by an independent
appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which shall be paid
by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&ldquo;<U>VWAP</U>&rdquo; means, for any date, the
price determined by the first of the following clauses that applies: (a) if the Ordinary Shares are then listed or quoted on a Trading
Market, the daily volume weighted average price of the Ordinary Shares for such date (or the nearest preceding date) on the Trading Market
on which the Ordinary Shares are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York
City time) to 4:02 p.m. (New York City time)), (b) if the Ordinary Shares are traded on OTCQB or OTCQX , the volume weighted average sales
price of the Ordinary Shares for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Ordinary Shares
are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Ordinary Shares are then reported in the &ldquo;Pink
Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price per Ordinary Share so reported, or (d) in all other cases, the fair market value of a Ordinary Share as determined
by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which
shall be paid by the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Provided that the Trading Price is equal to or greater
than the Exercise Price, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this
Section 2(c).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">d) <U>Mechanics of Exercise</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">i. <U>Delivery of Warrant Shares Upon Exercise</U>. The Company
shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder either by (A) crediting the account
of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian
system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and there is an effective registration statement
permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder, or (B) if there is no effective registration
statement and the Warrant is exercised via cashless exercise at a time when such Warrant Shares would be eligible for resale under Rule
144 by a non-affiliate of the Company, such Warrant Shares are delivered to Holder&rsquo;s broker, and the Company receives a statement
from Holder&rsquo;s broker that it has received instructions to sell the Warrant Shares or that it would take responsibility that the
sales of the Warrant Shares will only be made if the Warrant Shares are eligible to be sold under Rule 144, and otherwise by physical
delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number
of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise
by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1)
Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard
Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of
(i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice
of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant
Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant
Shares subject to such exercise (based on the VWAP of the Ordinary Shares on the date of the applicable Notice of Exercise), $10 per Trading
Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after
such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to use commercially
reasonable efforts to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a
number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Ordinary Shares as in effect on the date of
delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">ii. <U>Delivery of New Warrants Upon Exercise</U>. If this
Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate,
at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the
unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">iii. <U>Rescission Rights</U>. If the Company fails to cause
the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the
Holder will have the right to rescind such exercise.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">iv. <U>Compensation for Buy-In on Failure to Timely Deliver
Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer
Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise
on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market
transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, Ordinary Shares to deliver in satisfaction of a sale
by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the
Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage
commissions, if any) for the Ordinary Shares so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares
that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell
order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant
and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded)
or deliver to the Holder the number of Ordinary Shares that would have been issued had the Company timely complied with its exercise and
delivery obligations hereunder. For example, if the Holder purchases Ordinary Shares having a total purchase price of $11,000 to cover
a Buy-In with respect to an attempted exercise of Ordinary Shares with an aggregate sale price giving rise to such purchase obligation
of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder
shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the
Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available
to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect
to the Company&rsquo;s failure to timely deliver Ordinary Shares upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">v. <U>No Fractional Shares or Scrip</U>. No fractional shares
or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder
would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect
of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round down to the next whole share.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">vi. <U>Charges, Taxes and Expenses</U>. Issuance of Warrant
Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance
of such Warrant Shares, all of which transfer taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued
in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>, that in the event
that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be
accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the
payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required
for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation
performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">vii. <U>Closing of Books</U>. The Company will not close its
stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">e) <U>Holder&rsquo;s Exercise Limitations</U>. The
Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant,
pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable
Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting as a group together with the
Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess
of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of Ordinary Shares beneficially
owned by the Holder and its Affiliates and Attribution Parties shall include the number of Ordinary Shares issuable upon exercise of this
Warrant with respect to which such determination is being made, but shall exclude the number of Ordinary Shares which would be issuable
upon (i) exercise of the remaining, non-exercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or
Attribution Parties and (ii) exercise or conversion of the unexercised or non-converted portion of any other securities of the Company
(including, without limitation, any other Ordinary Share equivalents) subject to a limitation on conversion or exercise analogous to the
limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the
preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission
of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining
the number of outstanding Ordinary Shares, a Holder may rely on the number of outstanding Ordinary Shares as reflected in (A) the Company&rsquo;s
most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company
or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of Ordinary Shares outstanding. Upon
the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number
of Ordinary Shares then outstanding. In any case, the number of outstanding Ordinary Shares shall be determined after giving effect to
the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties
since the date as of which such number of outstanding Ordinary Shares was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of Ordinary Shares issuable
upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions
of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of Ordinary Shares outstanding
immediately after giving effect to the issuance of Ordinary Shares upon exercise of this Warrant held by the Holder and the provisions
of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP>
day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective
or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable
to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Section 3</U>. <U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">a) <U>Stock Dividends and Splits</U>. If the Company,
at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on Ordinary
Shares or any other equity or equity equivalent securities payable in Ordinary Shares (which, for avoidance of doubt, shall not include
any Ordinary Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding Ordinary Shares into a larger number
of shares, (iii) combines (including by way of reverse stock split) outstanding Ordinary Shares into a smaller number of shares, or (iv)
issues by reclassification of Ordinary Shares, any shares of capital stock of the Company, then in each case the Exercise Price shall
be multiplied by a fraction of which the numerator shall be the number of Ordinary Shares (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of Ordinary Shares outstanding immediately after such event,
and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price
of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the
record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">b) <U>Subsequent Rights Offerings</U>. In addition
to any adjustments pursuant to Section 3(a) above, if at any time, the Company grants, issues or sells any Ordinary Share equivalents
or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Ordinary Shares (the
&ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights,
the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of Ordinary Shares acquirable upon
complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights,
or, if no such record is taken, the date as of which the record holders of Ordinary Shares are to be determined for the grant, issue or
sale of such Purchase Rights (<U>provided</U>, <U>however</U>, to the extent that the Holder&rsquo;s right to participate in any such
Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Purchase Right to such extent (or beneficial ownership of such Ordinary Shares as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not
result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">c) <U>Pro Rata Distributions</U>. During such time
as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire
its assets) to holders of Ordinary Shares, by way of return of capital or otherwise, other than cash (including, without limitation, any
distribution of stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement,
scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant,
then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have
participated therein if the Holder had held the number of Ordinary Shares acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Ordinary
Shares are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, to the extent that the Holder's
right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Ordinary Shares as a result
of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">d) <U>Fundamental Transaction</U>. If, at any time
while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or
consolidation of the Company with or into another Person (other than solely with respect to a name change of the Company), (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Ordinary Shares are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Ordinary Shares, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Ordinary Shares or any compulsory share exchange pursuant to which the Ordinary Shares are effectively converted
into or exchanged for other securities, cash or property (other than a reclassification in which the Company&rsquo;s shareholders remain
the same), or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with
another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding Ordinary Shares (not including
any Ordinary Shares held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making
or party to, such stock or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of Ordinary Shares of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of Ordinary Shares for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one Ordinary Share in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Ordinary Shares are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the
event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable
at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the
public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount
of cash equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the date of the consummation of such
Fundamental Transaction; <U>provided</U>, <U>however</U>, if the Fundamental Transaction is not within the Company's control, including
not approved by the Company's Board of Directors or the consideration is not in all stock of the Successor Entity, Holder shall only be
entitled to receive from the Company or any Successor Entity, as of the date of consummation of such Fundamental Transaction, the same
type or form of consideration (and in the same proportion), at the Black Scholes Value (as defined below) of the unexercised portion of
this Warrant, that is being offered and paid to the holders of Ordinary Shares of the Company in connection with the Fundamental Transaction,
whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Ordinary Shares are given
the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction. &ldquo;<U>Black Scholes
Value</U>&rdquo; means the value of this Warrant based on the Black and Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo;
function on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of the day of consummation of the applicable Fundamental Transaction
for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate as of the Trading Day immediately
following the public announcement of the applicable Fundamental Transaction, (B) an expected volatility equal to the greater of 100% and
the 100 day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement
of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the
sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such
Fundamental Transaction and (ii) the greater of (x) the last VWAP immediately prior to the public announcement of such Fundamental Transaction
and (y) the last VWAP immediately prior to the consummation of such Fundamental Transaction and (D) a remaining option time equal to the
time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date. The payment of the
Black Scholes Value will be made by wire transfer of immediately available funds within five Business Days of the Holder&rsquo;s election
(or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction
in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the
Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to written
agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to
such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of
the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Ordinary Shares
acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such
Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking
into account the relative value of the Ordinary Shares pursuant to such Fundamental Transaction and the value of such shares of capital
stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to
the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so
that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring
to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall
assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor
Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">e) <U>Calculations</U>. All calculations under this
Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the
number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares (excluding
treasury shares, if any) issued and outstanding.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">f) <U>Notice to Holder</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">i. <U>Adjustment to Exercise Price</U>. Whenever the Exercise
Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email
a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting
forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">ii. <U>Notice to Allow Exercise by Holder</U>. If (A) the Company
shall declare a dividend (or any other distribution in whatever form) on the Ordinary Shares, (B) the Company shall declare a special
nonrecurring cash dividend on or a redemption of the Ordinary Shares, (C) the Company shall authorize the granting to all holders of the
Ordinary Shares rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval
of any stockholders of the Company shall be required in connection with any reclassification of the Ordinary Shares, any consolidation
or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory
share exchange whereby the Ordinary Shares are converted into other securities, cash or property, or (E) the Company shall authorize the
voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause
to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant
Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating
(x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a
record is not to be taken, the date as of which the holders of the Ordinary Shares of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer
or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Ordinary Shares
of record shall be entitled to exchange their Ordinary Shares for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in
the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that
any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Report on Form 6-K. The Holder shall remain entitled
to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice
except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Section 4</U>. <U>Transfer of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">a) <U>Transferability</U>. Pursuant to FINRA Rule
5110(g)(1) and the Agreement, neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant shall be sold, transferred,
assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result
in the effective economic disposition of the securities by any person for a period of one hundred eighty (180) days immediately following
the date of effectiveness or commencement of sales of the offering pursuant to which this Warrant is being issued, except the transfer
of any security:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(i) by operation of law or by reason of reorganization of the
Company;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(ii) to any FINRA member firm participating in the offering
and the officers and partners thereof, if all securities so transferred remain subject to the lock-up restriction in this Section 4(a)
for the remainder of the time period;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(iii) if the aggregate amount of securities of the Company
held by the Holder or related person do not exceed 1% of the securities being offered;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(iv) that is beneficially owned on a pro-rata basis by all
equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund, and participating
members in the aggregate do not own more than 10% of the equity in the fund; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(v) the exercise or conversion of any security, if all securities
received remain subject to the lock-up restriction in this Section 4(a) for the remainder of the time period.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to the foregoing restrictions, compliance with any applicable
securities laws, and the conditions set forth in Section 4(d) hereof, this Warrant and all rights hereunder (including, without limitation,
any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company
or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by
the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such
surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee
or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the
assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days
of the date the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in
accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">b) <U>New Warrants</U>. This Warrant may be divided
or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying
the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance
with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new
Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued
on transfers or exchanges shall be dated the Original Issuance Date of this Warrant and shall be identical with this Warrant except as
to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">c) <U>Warrant Register</U>. The Company shall register
this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;), in the name of
the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner
hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the
contrary.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">d) <U>Representation by the Holder</U>. The Holder,
by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant
Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant or Warrant
Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered
or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 5. Registration Rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">a) <U>Demand Registration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">i. <U>Grant of Right</U>. Unless all of the Registrable Securities
(defined as below) are included in an effective registration statement with a current prospectus or are not eligible for resale pursuant
to Rule 144 of the Securities Act, the Company, upon written demand (&ldquo;<U>Initial Demand Notice</U>&rdquo;) of the Holder(s) of at
least 51% of the Warrant Shares (&ldquo;<U>Majority Holders</U>&rdquo;), agrees to register on two occasions only (each, a &ldquo;<U>Demand
Registration</U>&rdquo;) under the Securities Act all or any portion of the Warrant Shares requested by the Majority Holders in the Initial
Demand Notice (the &ldquo;<U>Registrable Securities</U>&rdquo;). On such occasion, the Company will file a registration statement covering
the Registrable Securities within 60 days after receipt of the Initial Demand Notice and use its commercially reasonable efforts to have
such registration statement declared effective as soon as possible thereafter. A demand for registration may be made at any time during
which the Majority Holders hold any of the Warrant Shares. Notwithstanding the foregoing, the Company shall not be required to effect
a registration pursuant to this Section 5 a): (A) with respect to securities that are not Registrable Securities; (B) during any Scheduled
Black-Out Period; (C) if the aggregate offering price of the Registrable Securities to be offered is less than $250,000, unless the Registrable
Securities to be offered constitute all of the then-outstanding Registrable Securities; or (D) within 180 days after the effective date
of a prior registration in respect of the Ordinary Shares, including a Demand Registration (or, in the event that Holders were prevented
from including any Registrable Securities requested to be included in a Piggyback Registration pursuant to Section 5(b), within 90 days
after the effective date of such prior registration in respect of the Ordinary Shares. For purposes of this Agreement, a &ldquo;<U>Scheduled
Black-Out Period</U>&rdquo; shall means the periods from and including the day that is ten days prior to the last day of a fiscal quarter
of the Company to and including the day that is two days after the day on which the Company publicly releases its earnings for such fiscal
quarter. The Initial Demand Notice shall specify the number of shares of Registrable Securities proposed to be sold and the intended method(s)
of distribution thereof. The Company will notify all holders of the Warrant Shares of the demand within ten days from the date of the
receipt of any such Initial Demand Notice. Each holder of the Warrant Shares who wishes to include all or a portion of such holder&rsquo;s
Warrant Shares in the Demand Registration (each such holder including shares of Registrable Securities in such registration, a &ldquo;<U>Demanding
Holder</U>&rdquo;) shall so notify the Company within 15 days after the receipt by the holder of the notice from the Company. Upon any
such request, the Demanding Holders shall be entitled to have their Warrant Shares included in the Demand Registration. The term of the
Demand Registration shall not be more than five-years from the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">ii. <U>Effective Registration</U>. A registration will not
count as a Demand Registration until the registration statement filed with the Commission with respect to such Demand Registration has
been declared effective and the Company has complied with all of its obligations under this Warrant with respect thereto.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">iii. <U>Terms.</U> In connection with the first Demand Registration,
the Company shall bear all fees and expenses attendant to registering the Registrable Securities, including the reasonable expenses of
one legal counsel selected by the Holders to represent them in connection with the sale of the Registrable Securities. In connection with
the second Demand Registration, the Holders shall bear all fees and expenses attendant to registering the Registrable Securities including
the reasonable expenses of the Company&rsquo;s legal counsel. The Company agrees to qualify or register the Registrable Securities in
such states as are reasonably requested by the Majority Holder(s); provided, however, that in no event shall the Company be required to
register the Registrable Securities in a state in which such registration would cause (i) the Company to be obligated to qualify to do
business in such state, or would subject the Company to taxation as a foreign corporation doing business in such jurisdiction or (ii)
the principal shareholders of the Company to be obligated to escrow their shares of Ordinary Shares of the Company. The Company shall
cause any registration statement filed pursuant to the demand rights granted under Section 5(a)(iii) to remain effective until all Registrable
Securities are sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">iv. <U>Deferred Filing</U>. Notwithstanding
the foregoing, if the Board of Directors of the Company determines in its good faith judgment that the filing of a registration statement
in connection with a Demand Registration (i) would be seriously detrimental to the Company in that such registration would interfere with
a material corporate transaction or (ii) would require the disclosure of material non-public information concerning the Company that at
the time is not, in the good faith judgment of the Board of Directors, in the best interests of the Company to disclose and is not, in
the opinion of the Company&rsquo;s counsel, otherwise required to be disclosed, then the Company shall have the right to defer such filing
for the period during which such registration would be seriously detrimental under clause (i) or would require such disclosure under clause
(ii); provided, however, that (x) the Company may not defer such filing for a period of more than one hundred and twenty (120) days after
receipt of any demand by the Holders and (y) the Company shall not exercise its right to defer a Demand Registration more than once in
any 12-month period. The Company shall give written notice of its determination to the Holders to defer the filing and of the fact that
the purpose for such deferral no longer exists, in each case, promptly after the occurrence thereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">v. <U>No Cash Settlement Option</U>. The
Company is only required to use its commercially reasonable efforts to cause a registration statement covering issuance of the Registrable
Securities to be declared effective, and once effective, only to use its commercially reasonable efforts to maintain the effectiveness
of the registration statement. The Company will not be obligated to deliver securities, and there are no contractual penalties for failure
to deliver securities, if a registration statement is not effective at the time of exercise. Additionally, in no event is the Company
obligated to settle any Warrants, in whole or in part, for cash in the event it is unable to register the Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">b) <U>Piggy-Back Registration.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">i. <U>Piggy-Back Rights</U>. If at any time during the five
year period after the Effective Date, the registration statement filed pursuant to this Section 5(a) is no longer effective and the Registrable
Securities are not eligible for resale pursuant to Rule 144 of the Securities Act, the Company proposes to file a registration statement
under the Securities Act with respect to an offering of equity securities, or securities or other obligations exercisable or exchangeable
for, or convertible into, equity securities, by the Company for its own account or for shareholders of the Company for their account (or
by the Company and by shareholders of the Company including, without limitation, pursuant to Section 5(a)), other than a registration
statement (i) filed in connection with any employee share option or other benefit plan, (ii) for an exchange offer or offering of securities
solely to the Company&rsquo;s existing shareholders, or (iii) for a dividend reinvestment plan, then the Company shall (x) give written
notice of such proposed filing to the holders of Registrable Securities as soon as practicable but in no event less than ten days before
the anticipated filing date, which notice shall describe the amount and type of securities to be included in such offering, the intended
method(s) of distribution, and the name of the proposed managing underwriter or underwriters, if any, of the offering, and (y) offer to
the holders of Registrable Securities in such notice the opportunity to register the sale of such number of Warrant Shares held by such
holder (the &ldquo;<U>Piggy-Back Registrable Securities</U>&rdquo;), as such holders may request in writing within five days following
receipt of such notice (a &ldquo;<U>Piggy-Back Registration</U>&rdquo;). The Company shall cause such Piggy-Back Registrable Securities
to be included in such registration and shall use its commercially reasonable efforts to cause the managing underwriter or underwriters
of a proposed underwritten offering to permit the Piggy-Back Registrable Securities requested to be included in a Piggy-Back Registration
on the same terms and conditions as any similar securities of the Company and to permit the sale or other disposition of such Piggy-Back
Registrable Securities in accordance with the intended method(s) of distribution thereof. All holders of Piggy-Back Registrable Securities
proposing to distribute their securities through a Piggy-Back Registration that involves an underwriter or underwriters shall enter into
an underwriting agreement in customary form with the underwriter or underwriters selected for such Piggy-Back Registration.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">ii. <U>Reduction of Offering</U>. If the managing underwriter
or underwriters for a Piggy-Back Registration that is to be an underwritten offering advises the Company and the holders of Registrable
Securities in writing that the dollar amount or number of Ordinary Shares which the Company desires to sell, taken together with Ordinary
Shares, if any, as to which registration has been requested pursuant to written contractual arrangements with persons other than the holders
of Piggy-Back Registrable Securities hereunder, the Piggy-Back Registrable Securities as to which registration has been requested under
this Section 5(b), and the Ordinary Shares, if any, as to which registration has been requested pursuant to the written contractual piggy-back
registration rights of other shareholders of the Company, exceeds the maximum dollar amount or maximum number of shares that can be sold
in such offering without adversely affecting the proposed offering price, the timing, the distribution method, or the probability of success
of such offering (such maximum dollar amount or maximum number of shares, as applicable, the &ldquo;<U>Maximum Number of Shares</U>&rdquo;),
then the Company shall include in any such registration:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(x) If the registration is undertaken for the Company&rsquo;s
account: (A) first, the Ordinary Shares or other securities that the Company desires to sell that can be sold without exceeding the Maximum
Number of Shares; and (B) second, subject to the requirements of registration rights granted by the Company prior to the date hereof,
to the extent that the Maximum Number of Shares has not been reached under the foregoing clause (A), up to the amount of Ordinary Shares
or other securities that can be sold without exceeding the Maximum Number of Shares, on a pro rata basis, from (i) Piggy-Back Registrable
Securities as to which registration has been requested and (ii) the Ordinary Shares or other securities for the account of other persons
that the Company is obligated to register pursuant to written contractual piggy-back registration rights with such persons;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(y) If the registration is a Demand Registration undertaken
at the demand of holders of Registrable Securities, subject to the requirements of registration rights granted by the Company prior to
the date hereof, (A) first, the Ordinary Shares or other securities for the account of the demanding persons that can be sold without
exceeding the Maximum Number of Shares; (B) second, to the extent that the Maximum Number of Shares has not been reached under the foregoing
clause (A), the Ordinary Shares or other securities comprised of Piggy-Back Registrable Securities, pro rata, as to which registration
has been requested pursuant to the terms hereof that can be sold without exceeding the Maximum Number of Shares; and (C) third, to the
extent that the Maximum Number of Shares has not been reached under the foregoing clauses (A) and (B), the Ordinary Shares or other securities
for the account of other persons that the Company is obligated to register pursuant to written contractual arrangements with such persons,
that can be sold without exceeding the Maximum Number of Shares.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">iii. <U>Withdrawal</U>. Any holder of Piggy-Back Registrable
Securities may elect to withdraw such holder&rsquo;s request for inclusion of such Piggy-Back Registrable Securities in any Piggy-Back
Registration by giving written notice to the Company of such request to withdraw prior to the effectiveness of the registration statement.
The Company (whether on its own determination or as the result of a withdrawal by persons making a demand pursuant to written contractual
obligations) may withdraw a registration statement at any time prior to the effectiveness of the registration statement. Notwithstanding
any such withdrawal, the Company shall pay all expenses incurred by the holders of Piggy-Back Registrable Securities in connection with
such Piggy-Back Registration as provided in Section 5(b)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">iv. <U>Terms</U>. The Company shall bear all fees and expenses
attendant to registering the Piggy-Back Registrable Securities, including the expenses of one legal counsel selected by the Holders to
represent them in connection with the sale of the Piggy-Back Registrable Securities but the Holders shall pay any and all underwriting
commissions related to the Piggy-Back Registrable Securities. In the event of such a proposed registration, the Company shall furnish
the then Holders of outstanding Piggy-Back Registrable Securities with not less than fifteen days written notice prior to the proposed
date of filing of such registration statement. Such notice to the Holders shall continue to be given for each applicable registration
statement filed (during the period in which the Warrant is exercisable) by the Company until such time as all of the Piggy-Back Registrable
Securities have been registered and sold. The Holders of the Piggy-Back Registrable Securities shall exercise the &ldquo;piggy-back&rdquo;
rights provided for herein by giving written notice, within ten days of the receipt of the Company&rsquo;s notice of its intention to
file a registration statement. The Company shall cause any registration statement filed pursuant to the above &ldquo;piggyback&rdquo;
rights to remain effective for at least nine (9) months from the date that the Holders of the Piggy-Back Registrable Securities are first
given the opportunity to sell all of such securities.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">c) <U>General Terms</U>. These additional terms shall
relate to registration under Sections 5(a) above:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">i. <U>Indemnification</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(w) The Company shall, to the fullest extent permitted by applicable
law, indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration statement hereunder and each person,
if any, who controls such Holders within the meaning of Section 15 of the Act or Section 20(a) of the Exchange Act against all loss, claim,
damage, expense or liability (including all reasonable attorneys&rsquo; fees and other expenses reasonably incurred in investigating,
preparing or defending against litigation, commenced or threatened, or any claim whatsoever whether arising out of any action between
the underwriter and the Company or between the underwriter and any third party or otherwise) to which any of them may become subject under
the Act, the Exchange Act or otherwise, arising from such registration statement; <U>provided</U>, <U>however</U>, that, with respect
to any Holder of Registrable Securities, this indemnity shall not apply to any loss, liability, claim, damage or expense to the extent
arising out of an untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with written
information furnished to the Company by such Holder expressly for use in the registration statement (or any amendment thereto), or any
preliminary prospectus or the prospectus (or any amendment or supplement thereto).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(x) The Holder(s) of the Registrable Securities to be sold
pursuant to such registration statement, and their successors and assigns, shall severally, and not jointly, indemnify the Company, its
officers and directors and each person, if any, who controls the Company within the meaning of Section 15 of the Act or Section 20(a)
of the Exchange Act, against all loss, claim, damage, expense or liability (including all reasonable attorneys&rsquo; fees and other expenses
reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which they may become subject under the
Act, the Exchange Act or otherwise, arising from information furnished by or on behalf of such Holders, or their successors or assigns,
in writing, for specific inclusion in such registration statement(or any amendment thereto), or any preliminary prospectus or the prospectus
(or any amendment or supplement thereto).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(y) Each indemnified party shall give prompt notice to each
indemnifying party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify
an indemnifying party shall not relieve the indemnifying party from any liability it may have under this Agreement, except to the extent
that the indemnifying party is prejudiced thereby. If it so elects, after receipt of such notice, an indemnifying party, jointly with
any other indemnifying parties receiving such notice, may assume the defense of such action with counsel chosen by it; <U>provided</U>,
<U>however</U>, that the indemnified party shall be entitled to participate in (but not control) the defense of such action with counsel
chosen by it, the reasonable fees and expenses of which shall be paid by such indemnified party, unless a conflict would arise if one
counsel were to represent both the indemnified party and the indemnifying party, in which case the reasonable fees and expenses of counsel
to the indemnified party shall be paid by the indemnifying party or parties. In no event shall the indemnifying party or parties be liable
for a settlement of an action with respect to which they have assumed the defense if such settlement is effected without the written consent
of such indemnifying party, or for the reasonable fees and expenses of more than one counsel for (i) the Company, its officers, directors
and controlling persons as a group, and (ii) the selling Holders and their controlling persons as a group, in each case, in connection
with any one action or separate but similar or related actions in the same jurisdiction arising out of the same general allegations or
circumstances; <U>provided</U>, <U>however</U>, that if, in the reasonable judgment of an indemnified party, a conflict of interest may
exist between such indemnified party and the Company or any other of such indemnified parties with respect to such claim, the indemnifying
party shall be obligated to pay the reasonable fees and expenses of such additional counsel.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(z) If the indemnification provided for in or pursuant
to Section 5(b)(i) is due in accordance with the terms hereof, but held by a court of competent jurisdiction to be unavailable or unenforceable
in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each applicable indemnifying party, in lieu
of indemnifying such indemnified party, shall contribute to the amount paid or payable by such indemnified party as a result of such losses,
claims, damages, liabilities or expenses in such proportion as is appropriate to reflect the relative fault of the indemnifying party
on the one hand and of the indemnified party on the other in connection with the statements or omissions which result in such losses,
claims, damages, liabilities or expenses as well as any other relevant equitable considerations. The relative fault of the indemnifying
party on the one hand and of the indemnified party on the other shall be determined by reference to, among other things, whether the untrue
or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied
by the indemnifying party or by the indemnified party, and by such party&rsquo;s relative intent, knowledge, access to information and
opportunity to correct or prevent such statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">ii. [<U>Intentionally Omitted</U>]</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">iii. <U>Supplemental Prospectus</U>. Each Holder
agrees, that upon receipt of any notice from the Company of the happening of any event as a result of which the prospectus included in
the registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required
to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing, such Holder
will immediately discontinue disposition of Registrable Securities pursuant to the registration statement covering such Registrable Securities
until such Holder&rsquo;s receipt of the copies of a supplemental or amended prospectus, and, if so desired by the Company, such Holder
shall deliver to the Company (at the expense of the Company) or destroy (and deliver to the Company a certificate of such destruction)
all copies, other than permanent file copies then in such Holder&rsquo;s possession, of the prospectus covering such Registrable Securities
current at the time of receipt of such notice. Immediately after discovering of such an event which causes the prospectus included in
the registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required
to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing, the Company
shall prepare and file, as soon as practicable, a supplement or amendment to the prospectus so that such registration statement does not
include any untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the
statements therein not misleading in light of the circumstances then existing and distribute such supplement or amendment to each Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 6. Miscellaneous.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">a) <U>No Rights as Stockholder Until Exercise</U>.
This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the
exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">b) <U>Loss, Theft, Destruction or Mutilation of Warrant</U>.
The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation
of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security
reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation
of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor
and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">c) <U>Saturdays, Sundays, Holidays, etc</U>. If the
last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day,
then, such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">d) <U>Authorized Shares</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">The Company covenants that, during the period the
Warrant is outstanding, it will reserve from its authorized and unissued Ordinary Shares a sufficient number of shares to provide for
the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its
issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant
Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary
to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements
of the Trading Market upon which the Ordinary Shares may be listed. The Company covenants that all Warrant Shares which may be issued
upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant
and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and non-assessable and free
from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
occurring contemporaneously with such issue).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Except and to the extent as waived or consented to
by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through
any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in
the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder
as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the
par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value,
(ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable
Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations
under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Before taking any action which would result in an
adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all
such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction
thereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">e) <U>Jurisdiction</U>. All questions concerning
the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the
Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">f) <U>Restrictions</U>. The Holder acknowledges that
the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will
have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">g) <U>Non-waiver and Expenses</U>. No course of dealing
or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice
the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Agreement, if the Company willfully
and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall
pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo;
fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing
any of its rights, powers or remedies hereunder.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">h) <U>Notices</U>. Any notice, request or other document
required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions
of the Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">i) <U>Limitation of Liability</U>. No provision hereof,
in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein
of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Ordinary Shares
or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">j) <U>Remedies</U>. The Holder, in addition to being
entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights
under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach
by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance
that a remedy at law would be adequate.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">k) <U>Successors and Assigns</U>. Subject to applicable
securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors
and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to
be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">l) <U>Amendment</U>. This Warrant may be modified
or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">m) <U>Severability</U>. Wherever possible, each provision
of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant
shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity,
without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">n) <U>Headings</U>. The headings used in this Warrant
are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">IN WITNESS WHEREOF, the Company has caused this Warrant
to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>REGENCELL BIOSCIENCE HOLDINGS LIMITED</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 3%">By:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 37%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Name:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Title:</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTICE OF EXERCISE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TO: REGENCELL BIOSCIENCE HOLDINGS LIMITED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(1) The undersigned hereby elects to purchase ________
Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment
of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(2) Payment shall take the form of (check applicable
box):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#9744; in lawful money of the United States; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#9744; if permitted the cancellation of such number of Warrant
Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum
number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(3) Please issue said Warrant Shares in the name
of the undersigned or in such other name as is specified below:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 1.6in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Warrant Shares shall be delivered to the following DWAC Account
Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 1.6in">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[SIGNATURE OF HOLDER]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 1.5in; font-size: 10pt">Name of Investing Entity:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 3.15in; font-size: 10pt"><I>Signature of Authorized Signatory of Investing Entity:&nbsp;</I></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 1.8in; font-size: 10pt">Name of Authorized Signatory:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 1.75in; font-size: 10pt">Title of Authorized Signatory:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">Date:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT B</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">(To assign the foregoing Warrant, execute this form and supply
required information. Do not use this form to purchase shares.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced
thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">Name:</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Address:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Phone Number:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Email Address:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Dated: ___________ __, _____</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Holder&rsquo;s Signature:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Holder&rsquo;s Address:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Warrant Exercise Log</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 25%">Date</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 24%; text-align: left">Number of Warrant Shares Available to be Exercised</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 24%">Number of Warrant Shares Exercised</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 24%; text-align: left">Number of Warrant Shares Remaining to be Exercised</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">REGENCELL
BIOSCIENCE HOLDINGS LIMITED<BR>
WARRANT DATED __________, 2021<BR>
WARRANT NO. [ ]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">FORM OF
ASSIGNMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">[To be completed and signed
only upon transfer of Warrant]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FOR VALUE RECEIVED, the undersigned
hereby sells, assigns and transfers unto ________________________________ the right represented by the above-captioned Warrant to purchase
____________ share of Company Ordinary Shares and appoints ________________ attorney to transfer said right on the books of the Company
with full power of substitution in the premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated:&nbsp;_______________, ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(Signature must conform in all respects to name of holder as specified on the face of the Warrant)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Address of Transferee</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the presence of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex V-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ANNEX VI</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">FORM OF PRESS RELEASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regencell Bioscience Holdings Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">__________, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regencell Bioscience Holdings Limited (the &ldquo;Company&rdquo;) announced
today that Maxim Group LLC, the sole book-running manager in the Company&rsquo;s recent public sale of _____ Ordinary Shares, are [waiving][releasing]
a lock-up restriction with respect to ____ Ordinary Shares held by [certain officers or directors] [an officer or director] of the Company.
The [waiver][release] will take effect on ____, 2021 and the Ordinary Shares may be sold on or after such date.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>This press release is not an offer for sale of the securities in
the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United
States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[to be attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Annex VI-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>ea142369ex3-2_regencell.htm
<DESCRIPTION>AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
3.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies
Law (Revised)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
Limited by Shares</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 60%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMENDED
AND RESTATED<BR>
memorandum of association<BR>
OF<BR>
REGENCELL BIOSCIENCE HOLDINGS LIMITED</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 60%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Adopted
by special resolution passed on May 31, 2021)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="vertical-align: bottom; width: 34%; text-align: center"><P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><I>www.verify.gov.ky
                                            File#: 293256</I></P></TD><TD STYLE="text-align: right; width: 33%"><I><IMG SRC="ex3-2_01.jpg" ALT=""><BR> Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies
Law (Revised)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
Limited by Shares</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
and Restated<BR>
Memorandum of Association</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regencell
Bioscience Holdings Limited</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(Adopted
by special resolution passed on May 31, 2021)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            name of the Company is Regencell Bioscience Holdings Limited.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company&rsquo;s registered office will be situated at the offices of 1<SUP>st</SUP> Floor, Landmark
                                            Square, 64 Earth Clos, Grand Cayman KY1-1107, Cayman Islands or at such other place in the
                                            Cayman Islands as the directors may at any time decide.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company&rsquo;s objects are unrestricted. As provided by section 7(4) of the Companies Law (Revised),
                                            the Company has full power and authority to carry out any object not prohibited by any law
                                            of the Cayman Islands.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has unrestricted corporate capacity. Without limitation to the foregoing, as provided
                                            by section 27 (2) of the Companies Law (Revised), the Company has and is capable of exercising
                                            all the functions of a natural person of full capacity irrespective of any question of corporate
                                            benefit.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
                                            in any of the preceding paragraphs permits the Company to carry on any of the following businesses
                                            without being duly licensed, namely:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            business of a bank or trust company without being licensed in that behalf under the Banks
                                            and Trust Companies Law (Revised); or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurance
                                            business from within the Cayman Islands or the business of an insurance manager, agent, sub-agent
                                            or broker without being licensed in that behalf under the Insurance Law (Revised);or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            business of company management without being licensed in that behalf under the Companies
                                            Management Law (Revised).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company will not trade in the Cayman Islands with any person, firm or corporation except
                                            in furtherance of its business carried on outside the Cayman Islands. Despite this, the Company
                                            may effect and conclude contracts in the Cayman Islands and exercise in the Cayman Islands
                                            any of its powers necessary for the carrying on of its business outside the Cayman Islands.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --><BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company is a company limited by shares and accordingly the liability of each member is limited
                                            to the amount (if any) unpaid on that member&rsquo;s shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            share capital of the Company is US$1,000,000 divided into 100,000,000,000 Ordinary Shares
                                            of US$000001 par value each. Subject to the Companies Law (Revised) and the Company&rsquo;s articles
                                            of association, the Company has power to do any one or more of the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            redeem or repurchase any of its shares; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            increase or reduce its capital; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            issue any part of its capital (whether original, redeemed, increased or reduced):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
                                            or without any preferential, deferred, qualified or special rights, privileges or conditions;
                                            or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
                                            to any limitations or restrictions</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
unless the condition of issue expressly declares otherwise, every issue of shares (whether declared to be ordinary, preference or otherwise)
is subject to this power; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            alter any of those rights, privileges, conditions, limitations or restrictions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has power to register by way of continuation as a body corporate limited by shares
                                            under the laws of any jurisdiction outside the Cayman Islands and to be deregistered in the
                                            Cayman Islands.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --><BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Companies Law (Revised)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Company Limited By Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 60%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AMENDED
AND RESTATED<BR>
articles of association<BR>
of<BR>
REGENCELL BIOSCIENCE HOLDINGS LIMITED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 60%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Adopted by special resolution passed on May 31,
2021)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contents</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1</B></FONT></TD>
    <TD STYLE="width: 87%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Definitions, interpretation and exclusion of Table A</B></FONT></TD>
    <TD STYLE="text-align: center; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpretation</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusion of Table A Articles</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power to issue Shares and options, with or without special rights</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power to pay commissions and brokerage fees</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trusts not recognised</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security interests</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power to vary class rights</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of new Share issue on existing class rights</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No bearer Shares or warrants</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treasury Shares</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights attaching to Treasury Shares and related matters</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Register of Members</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual Return</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share certificates</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of share certificates</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renewal of lost or damaged share certificates</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lien on Shares</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nature and scope of lien</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company may sell Shares to satisfy lien</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority to execute instrument of transfer</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consequences of sale of Shares to satisfy lien</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Application of proceeds of sale</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Calls on Shares and forfeiture</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power to make calls and effect of calls</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time when call made</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liability of joint holders</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest on unpaid calls</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deemed calls</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power to accept early payment</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power to make different arrangements at time of issue of Shares</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of default</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeiture or surrender of Shares</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposal of forfeited or surrendered Share and power to cancel forfeiture or surrender</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of forfeiture or surrender on former Member</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evidence of forfeiture or surrender</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale of forfeited or surrendered Shares</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer of Shares</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right to transfer</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suspension of transfers</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company may retain instrument of transfer</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of refusal to register</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transmission of Shares</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persons entitled on death of a Member</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration of transfer of a Share following death or bankruptcy</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnity</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights of person entitled to a Share following death or bankruptcy</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8</B></FONT></TD>
    <TD STYLE="width: 87%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alteration of capital</B></FONT></TD>
    <TD STYLE="text-align: center; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increasing, consolidating, converting, dividing and cancelling share capital</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dealing with fractions resulting from consolidation of Shares</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reducing share capital</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Redemption and purchase of own Shares</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power to issue redeemable Shares and to purchase own Shares</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power to pay for redemption or purchase in cash or in specie</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of redemption or purchase of a Share</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Meetings of Members</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual and extraordinary general meetings</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power to call meetings</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Content of notice</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period of notice</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persons entitled to receive notice</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accidental omission to give notice or non-receipt of notice</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proceedings at meetings of Members</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quorum</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack of quorum</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right of a Director to attend and speak</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accommodation of Members at meeting</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjournment</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method of voting</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outcome of vote by show of hands</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Withdrawal of demand for a poll</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taking of a poll</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman&rsquo;s casting vote</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written resolutions</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sole-Member Company</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Voting rights of Members</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>24</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right to vote</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights of joint holders</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representation of corporate Members</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member with mental disorder</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Objections to admissibility of votes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of proxy</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">How and when proxy is to be delivered</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting by proxy</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Directors</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>28</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Appointment, disqualification and removal of Directors</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>28</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Directors</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No age limit</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Directors</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No shareholding qualification</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment of Directors</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board&rsquo;s power to appoint Directors</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eligibility</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment at annual general meeting</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Removal of Directors</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resignation of Directors</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination of the office of Director</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15</B></FONT></TD>
    <TD STYLE="width: 87%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alternate Directors</B></FONT></TD>
    <TD STYLE="text-align: center; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>31</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment and removal</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights of alternate Director</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment ceases when the appointor ceases to be a Director</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Status of alternate Director</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Status of the Director making the appointment</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Powers of Directors</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>33</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Powers of Directors</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors below the minimum number</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointments to office</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions for employees</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of voting rights</FONT></TD>
    <TD STYLE="text-align: center">34</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remuneration</FONT></TD>
    <TD STYLE="text-align: center">34</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure of information</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delegation of powers</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>35</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power to delegate any of the Directors&rsquo; powers to a committee</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Local boards</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power to appoint an agent of the Company</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power to appoint an attorney or authorised signatory of the Company</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowing Powers</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Governance</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Meetings of Directors</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>37</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation of Directors&rsquo; meetings</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calling meetings</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of meetings</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of technology</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quorum</FONT></TD>
    <TD STYLE="text-align: center">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman or deputy to preside</FONT></TD>
    <TD STYLE="text-align: center">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting</FONT></TD>
    <TD STYLE="text-align: center">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recording of dissent</FONT></TD>
    <TD STYLE="text-align: center">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written resolutions</FONT></TD>
    <TD STYLE="text-align: center">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Validity of acts of Directors in spite of formal defect</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Permissible Directors&rsquo; interests and disclosure</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>39</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Minutes</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>40</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accounts and audit</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>40</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditors</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Record dates</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>41</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>23</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividends</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>41</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Source of dividends</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Declaration of dividends by Members</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of interim dividends and declaration of final dividends by Directors</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apportionment of dividends</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right of set off</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power to pay other than in cash</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">How payments may be made</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends or other monies not to bear interest in absence of special rights</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends unable to be paid or unclaimed</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>24</B></FONT></TD>
    <TD STYLE="width: 87%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capitalisation of profits</B></FONT></TD>
    <TD STYLE="text-align: center; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>44</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalisation of profits or of any share premium account or capital redemption reserve;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applying an amount for the benefit of Members</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>25</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share Premium Account</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>45</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors to maintain share premium account</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debits to share premium account</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>26</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Seal</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>45</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company seal</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duplicate seal</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When and how seal is to be used</FONT></TD>
    <TD STYLE="text-align: center">46</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If no seal is adopted or used</FONT></TD>
    <TD STYLE="text-align: center">46</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power to allow non-manual signatures and facsimile printing of seal</FONT></TD>
    <TD STYLE="text-align: center">46</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Validity of execution</FONT></TD>
    <TD STYLE="text-align: center">46</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>27</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnity</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>47</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Release</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>28</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notices</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>48</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of notices</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electronic communications</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persons entitled to notices</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persons authorised to give notices</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery of written notices</FONT></TD>
    <TD STYLE="text-align: center">50</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint holders</FONT></TD>
    <TD STYLE="text-align: center">50</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signatures</FONT></TD>
    <TD STYLE="text-align: center">50</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Giving notice to a deceased or bankrupt Member</FONT></TD>
    <TD STYLE="text-align: center">50</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of giving notices</FONT></TD>
    <TD STYLE="text-align: center">51</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saving provision</FONT></TD>
    <TD STYLE="text-align: center">51</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>29</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authentication of Electronic Records</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>51</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Application of Articles</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authentication of documents sent by Members by Electronic means</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authentication of document sent by the Secretary or Officers of the Company by Electronic means</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manner of signing</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saving provision</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>30</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer by way of continuation</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>53</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>31</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Winding up</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>53</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution of assets in specie</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No obligation to accept liability</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>32</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment of Memorandum and Articles</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>54</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power to change name or amend Memorandum</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power to amend these Articles</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies
Law (Revised)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
Limited by Shares</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
and Restated<BR>
Articles of Association</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regencell
Bioscience Holdings Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Adopted
by special resolution passed on May 31, 2021)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions,
interpretation and exclusion of Table A</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            these Articles, the following definitions apply:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Articles
</B>means, as appropriate:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">these
                                            articles of association as amended from time to time: or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">two
                                            or more particular articles of these Articles;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
<B>Article</B> refers to a particular article of these Articles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Auditors
</B>means the auditor or auditors for the time being of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
</B>means the board of Directors from time to time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
Day</B> means a day when banks in Grand Cayman, the Cayman Islands are open for the transaction of normal banking business and for the
avoidance of doubt, shall not include a Saturday, Sunday or public holiday in the Cayman Islands;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cayman
Islands</B> means the British Overseas Territory of the Cayman Islands;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clear
Days</B>, in relation to a period of notice, means that period excluding:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            day when the notice is given or deemed to be given; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            day for which it is given or on which it is to take effect;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
</B>means Securities and Exchange Commission of the United States of America or other federal agency for the time being administering
the U.S. Securities Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
</B>means the above-named company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Default
Rate</B> means ten per cent per annum;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Designated
Stock Exchanges</B> means the Nasdaq Stock Market in the United States of America for so long as the Company&rsquo;s Shares are there
listed and any other stock exchange on which the Company&rsquo;s Shares are listed for trading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Designated
Stock Exchange Rules</B> means the relevant code, rules and regulations, as amended, from time to time, applicable as a result of the
original and continued listing of any Shares on the Designated Stock Exchanges;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors
</B>means the directors for the time being of the Company and the expression Director shall be construed accordingly;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
</B>has the meaning given to that term in the Electronic Transactions Law (Revised) of the Cayman Islands;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Record</B> has the meaning given to that term in the Electronic Transactions Law (Revised) of the Cayman Islands;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Signature</B> has the meaning given to that term in the Electronic Transactions Law (Revised) of the Cayman Islands;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fully
Paid Up</B> means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            relation to a Share with par value, means that the par value for that Share and any premium
                                            payable in respect of the issue of that Share, has been fully paid or credited as paid in
                                            money or money&rsquo;s worth; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            relation to a Share without par value, means that the agreed issue price for that Share has
                                            been fully paid or credited as paid in money or money&rsquo;s worth;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
Meeting</B> means a general meeting of the Company duly constituted in accordance with the Articles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Independent
Director</B> means a Director who is an independent director as defined in the Designated Stock Exchange Rules as determined by the Board;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Law
</B>means the Companies Law (Revised) of the Cayman Islands, including any statutory modification or re-enactment thereof for the time
being in force;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Member
</B>means any person or persons entered on the register of Members from time to time as the holder of a Share;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Memorandum
</B>means the memorandum of association of the Company as amended from time to time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>month
</B>means a calendar month;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Officer
</B>means a person appointed to hold an office in the Company including a Director, alternate Director or liquidator and excluding the
Secretary;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary
Resolution</B> means a resolution of a General Meeting passed by a simple majority of Members who (being entitled to do so) vote in person
or by proxy at that meeting. The expression includes a unanimous written resolution;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary
Share </B>means an ordinary share in the capital of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Partly
Paid Up</B> means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            relation to a Share with par value, that the par value for that Share and any premium payable
                                            in respect of the issue of that Share, has not been fully paid or credited as paid in money
                                            or money&rsquo;s worth; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            relation to a Share without par value, means that the agreed issue price for that Share has
                                            not been fully paid or credited as paid in money or money&rsquo;s worth;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Secretary
</B>means a person appointed to perform the duties of the secretary of the Company, including a joint, assistant or deputy secretary;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
</B>means a share in the capital of the Company and the expression:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">includes
                                            stock (except where a distinction between shares and stock is expressed or implied); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
                                            the context permits, also includes a fraction of a Share;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Special
Resolution</B> means a resolution of a General Meeting or a resolution of a meeting of the holders of any class of Shares in a class
meeting duly constituted in accordance with the Articles in each case passed by a majority of not less than two-thirds of Members who
(being entitled to do so) vote in person or by proxy at that meeting. The expression includes a unanimous written resolution;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Treasury
Shares</B> means Shares held in treasury pursuant to the Law and Article 2.12; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>U.S.
Securities Act</B> means the Securities Act of 1933 of the United States of America, as amended, or any similar federal statute and the
rules and regulations of the Commission thereunder, all as the same shall be in effect at the time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpretation</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            the interpretation of these Articles, the following provisions apply unless the context otherwise
                                            requires:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            reference in these Articles to a statute is a reference to a statute of the Cayman Islands
                                            as known by its short title, and includes:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            statutory modification, amendment or re-enactment; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            subordinate legislation or regulations issued under that statute.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
limitation to the preceding sentence, a reference to a revised Law of the Cayman Islands is taken to be a reference to the revision of
that Law in force from time to time as amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Headings
                                            are inserted for convenience only and do not affect the interpretation of these Articles,
                                            unless there is ambiguity.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            a day on which any act, matter or thing is to be done under these Articles is not a Business
                                            Day, the act, matter or thing must be done on the next Business Day.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            word which denotes the singular also denotes the plural, a word which denotes the plural
                                            also denotes the singular, and a reference to any gender also denotes the other genders.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            reference to a <B>person</B> includes, as appropriate, a company, trust, partnership, joint
                                            venture, association, body corporate or government agency.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
                                            a word or phrase is given a defined meaning another part of speech or grammatical form in
                                            respect to that word or phrase has a corresponding meaning.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            references to time are to be calculated by reference to time in the place where the Company&rsquo;s
                                            registered office is located.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            words <B>written</B> and <B>in writing</B> include all modes of representing or reproducing
                                            words in a visible form, but do not include an Electronic Record where the distinction between
                                            a document in writing and an Electronic Record is expressed or implied.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            words <B>including</B>, <B>include</B> and <B>in particular</B> or any similar expression
                                            are to be construed without limitation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            headings in these Articles are intended for convenience only and shall not affect the interpretation
                                            of these Articles.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusion
of Table A Articles</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            regulations contained in Table A in the First Schedule of the Law and any other regulations
                                            contained in any statute or subordinate legislation are expressly excluded and do not apply
                                            to the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
to issue Shares and options, with or without special rights</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the provisions of the Law and these Articles about the redemption and purchase of the
                                            Shares, the Directors have general and unconditional authority to allot (with or without
                                            confirming rights of renunciation), grant options over or otherwise deal with any unissued
                                            Shares to such persons, at such times and on such terms and conditions as they may decide.
                                            No Share may be issued at a discount except in accordance with the provisions of the Law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
                                            limitation to the preceding Article, the Directors may so deal with the unissued Shares:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">either
                                            at a premium or at par; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
                                            or without preferred, deferred or other special rights or restrictions, whether in regard
                                            to dividend, voting, return of capital or otherwise.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
                                            limitation to the two preceding Articles, the Directors may refuse to accept any application
                                            for Shares, and may accept any application in whole or in part, for any reason or for no
                                            reason.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
to pay commissions and brokerage fees</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company may pay a commission to any person in consideration of that person:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subscribing
                                            or agreeing to subscribe, whether absolutely or conditionally; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">procuring
                                            or agreeing to procure subscriptions, whether absolute or conditional,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
any Shares. That commission may be satisfied by the payment of cash or the allotment of Fully Paid Up or Partly Paid Up Shares or partly
in one way and partly in another.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company may employ a broker in the issue of its capital and pay him any proper commission
                                            or brokerage.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trusts
not recognised</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
                                            as required by Law:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
                                            person shall be recognised by the Company as holding any Share on any trust; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
                                            person other than the Member shall be recognised by the Company as having any right in a
                                            Share.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security
interests</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
                                            the preceding Article, the Company may (but shall not be obliged to) recognise a security
                                            interest of which it has actual notice over shares. The Company shall not be treated as having
                                            recognised any such security interest unless it has so agreed in writing with the secured
                                            party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
to vary class rights</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the share capital is divided into different classes of Shares then, unless the terms on which
                                            a class of Shares was issued state otherwise, the rights attaching to a class of Shares may
                                            only be varied if one of the following applies:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Members holding not less than two-thirds of the issued Shares of that class consent in writing
                                            to the variation; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            variation is made with the sanction of a Special Resolution passed at a separate general
                                            meeting of the Members holding the issued Shares of that class.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the purpose of Article 2.8(b), all the provisions of these Articles relating to general meetings
                                            apply, mutatis mutandis, to every such separate meeting except that:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            necessary quorum shall be one or more persons holding, or representing by proxy, not less
                                            than one third of the issued Shares of the class; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            Member holding issued Shares of the class, present in person or by proxy or, in the case
                                            of a corporate Member, by its duly authorised representative, may demand a poll.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
of new Share issue on existing class rights</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
                                            the terms on which a class of Shares was issued state otherwise, the rights conferred on
                                            the Member holding Shares of any class shall not be deemed to be varied by the creation or
                                            issue of further Shares ranking <I>pari passu</I> with the existing Shares of that class.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
bearer Shares or warrants</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company shall not issue Shares or warrants to bearers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treasury
Shares</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            that the Company purchases, redeems or acquires by way of surrender in accordance with the
                                            Law shall be held as Treasury Shares and not treated as cancelled if:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Directors so determine prior to the purchase, redemption or surrender of those shares; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            relevant provisions of the Memorandum and Articles and the Law are otherwise complied with.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights
attaching to Treasury Shares and related matters</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            dividend may be declared or paid, and no other distribution (whether in cash or otherwise)
                                            of the Company&rsquo;s assets (including any distribution of assets to Members on a winding
                                            up) may be made to the Company in respect of a Treasury Share.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company shall be entered in the register of Members as the holder of the Treasury Shares.
                                            However:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company shall not be treated as a Member for any purpose and shall not exercise any right
                                            in respect of the Treasury Shares, and any purported exercise of such a right shall be void;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            Treasury Share shall not be voted, directly or indirectly, at any meeting of the Company
                                            and shall not be counted in determining the total number of issued shares at any given time,
                                            whether for the purposes of these Articles or the Law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
                                            in Article 2.14 prevents an allotment of Shares as Fully Paid Up bonus shares in respect
                                            of a Treasury Share and Shares allotted as Fully Paid Up bonus shares in respect of a Treasury
                                            Share shall be treated as Treasury Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.16</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treasury
                                            Shares may be disposed of by the Company in accordance with the Law and otherwise on such
                                            terms and conditions as the Directors determine.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Register
of Members</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors shall keep or cause to be kept a register of Members as required by the Law and
                                            may cause the Company to maintain one or more branch registers as contemplated by the Law,
                                            provided that where the Company is maintaining one or more branch registers, the Directors
                                            shall ensure that a duplicate of each branch register is kept with the Company&rsquo;s principal
                                            register of Members and updated within such number of days of any amendment having been made
                                            to such branch register as may be required by the Law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
Return</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.18</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors in each calendar year shall prepare or cause to be prepared an annual return and
                                            declaration setting forth the particulars required by the Law and shall deliver a copy thereof
                                            to the registrar of companies for the Cayman Islands.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
certificates</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
of share certificates</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Member shall only be entitled to a share certificate if the Directors resolve that share
                                            certificates shall be issued. Share certificates representing Shares, if any, shall be in
                                            such form as the Directors may determine. If the Directors resolve that share certificates
                                            shall be issued, upon being entered in the register of Members as the holder of a Share,
                                            the Directors may issue to any Member:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">without
                                            payment, one certificate for all the Shares of each class held by that Member (and, upon
                                            transferring a part of the Member&rsquo;s holding of Shares of any class, to a certificate
                                            for the balance of that holding); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
                                            payment of such reasonable sum as the Directors may determine for every certificate after
                                            the first, several certificates each for one or more of that Member&rsquo;s Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
                                            certificate shall specify the number, class and distinguishing numbers (if any) of the Shares
                                            to which it relates and whether they are Fully Paid Up or Partly Paid Up. A certificate may
                                            be executed under seal or executed in such other manner as the Directors determine.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
                                            certificate shall bear legends required under the applicable laws, including the U.S. Securities
                                            Act.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company shall not be bound to issue more than one certificate for Shares held jointly by
                                            several persons and delivery of a certificate for a Share to one joint holder shall be a
                                            sufficient delivery to all of them.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renewal
of lost or damaged share certificates</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            a share certificate is defaced, worn-out, lost or destroyed, it may be renewed on such terms
                                            (if any) as to:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evidence;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">indemnity;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
                                            of the expenses reasonably incurred by the Company in investigating the evidence; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
                                            of a reasonable fee, if any for issuing a replacement share certificate,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
the Directors may determine, and (in the case of defacement or wearing-out) on delivery to the Company of the old certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lien
on Shares</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nature
and scope of lien</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has a first and paramount lien on all Shares (whether Fully Paid Up or not) registered
                                            in the name of a Member (whether solely or jointly with others). The lien is for all monies
                                            payable to the Company by the Member or the Member&rsquo;s estate:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">either
                                            alone or jointly with any other person, whether or not that other person is a Member; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            or not those monies are presently payable.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
                                            any time the Board may declare any Share to be wholly or partly exempt from the provisions
                                            of this Article.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
may sell Shares to satisfy lien</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company may sell any Shares over which it has a lien if all of the following conditions are
                                            met:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            sum in respect of which the lien exists is presently payable;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company gives notice to the Member holding the Share (or to the person entitled to it in
                                            consequence of the death or bankruptcy of that Member) demanding payment and stating that
                                            if the notice is not complied with the Shares may be sold; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                            sum is not paid within fourteen Clear Days after that notice is deemed to be given under
                                            these Articles,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
Shares to which this Article 4.3 applies shall be referred to as Lien Default Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Lien Default Shares may be sold in such manner as the Board determines.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            the maximum extent permitted by law, the Directors shall incur no personal liability to the
                                            Member concerned in respect of the sale.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority
to execute instrument of transfer</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            give effect to a sale, the Directors may authorise any person to execute an instrument of
                                            transfer of the Lien Default Shares sold to, or in accordance with the directions of, the
                                            purchaser.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            title of the transferee of the Lien Default Shares shall not be affected by any irregularity
                                            or invalidity in the proceedings in respect of the sale.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consequences
of sale of Shares to satisfy lien</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            a sale pursuant to the preceding Articles:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            name of the Member concerned shall be removed from the register of Members as the holder
                                            of those Lien Default Shares; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                            person shall deliver to the Company for cancellation the certificate (if any) for those Lien
                                            Default Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
                                            the provisions of Article 4.8, such person shall remain liable to the Company for all monies
                                            which, at the date of sale, were presently payable by him to the Company in respect of those
                                            Lien Default Shares. That person shall also be liable to pay interest on those monies from
                                            the date of sale until payment at the rate at which interest was payable before that sale
                                            or, failing that, at the Default Rate. The Board may waive payment wholly or in part or enforce
                                            payment without any allowance for the value of the Lien Default Shares at the time of sale
                                            or for any consideration received on their disposal.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Application
of proceeds of sale</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            net proceeds of the sale, after payment of the costs, shall be applied in payment of so much
                                            of the sum for which the lien exists as is presently payable. Any residue shall be paid to
                                            the person whose Lien Default Shares have been sold:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            no certificate for the Lien Default Shares was issued, at the date of the sale; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            a certificate for the Lien Default Shares was issued, upon surrender to the Company of that
                                            certificate for cancellation</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">but,
in either case, subject to the Company retaining a like lien for all sums not presently payable as existed on the Lien Default Shares
before the sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calls
on Shares and forfeiture</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
to make calls and effect of calls</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the terms of allotment, the Board may make calls on the Members in respect of any monies
                                            unpaid on their Shares including any premium. The call may provide for payment to be by instalments.
                                            Subject to receiving at least 14 Clear Days&rsquo; notice specifying when and where payment is
                                            to be made, each Member shall pay to the Company the amount called on his Shares as required
                                            by the notice.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
                                            receipt by the Company of any sum due under a call, that call may be revoked in whole or
                                            in part and payment of a call may be postponed in whole or in part. Where a call is to be
                                            paid in instalments, the Company may revoke the call in respect of all or any remaining instalments
                                            in whole or in part and may postpone payment of all or any of the remaining instalments in
                                            whole or in part.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Member on whom a call is made shall remain liable for that call notwithstanding the subsequent
                                            transfer of the Shares in respect of which the call was made. He shall not be liable for
                                            calls made after he is no longer registered as Member in respect of those Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time
when call made</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            call shall be deemed to have been made at the time when the resolution of the Directors authorising
                                            the call was passed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liability
of joint holders</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
                                            registered as the joint holders of a Share shall be jointly and severally liable to pay all
                                            calls in respect of the Share.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
on unpaid calls</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            a call remains unpaid after it has become due and payable the person from whom it is due
                                            and payable shall pay interest on the amount unpaid from the day it became due and payable
                                            until it is paid:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
                                            the rate fixed by the terms of allotment of the Share or in the notice of the call; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            no rate is fixed, at the Default Rate.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors may waive payment of the interest wholly or in part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deemed
calls</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            amount payable in respect of a Share, whether on allotment or on a fixed date or otherwise,
                                            shall be deemed to be payable as a call. If the amount is not paid when due the provisions
                                            of these Articles shall apply as if the amount had become due and payable by virtue of a
                                            call.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
to accept early payment</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company may accept from a Member the whole or a part of the amount remaining unpaid on Shares
                                            held by him although no part of that amount has been called up.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
to make different arrangements at time of issue of Shares</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the terms of allotment, the Directors may make arrangements on the issue of Shares to
                                            distinguish between Members in the amounts and times of payment of calls on their Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
of default</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            a call remains unpaid after it has become due and payable the Directors may give to the person
                                            from whom it is due not less than 14 Clear Days&rsquo; notice requiring payment of:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            amount unpaid;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            interest which may have accrued;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            expenses which have been incurred by the Company due to that person&rsquo;s default.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            notice shall state the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            place where payment is to be made; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            warning that if the notice is not complied with the Shares in respect of which the call is
                                            made will be liable to be forfeited.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeiture
or surrender of Shares</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the notice given pursuant to Article 5.10 is not complied with, the Directors may, before
                                            the payment required by the notice has been received, resolve that any Share the subject
                                            of that notice be forfeited. The forfeiture shall include all dividends or other monies payable
                                            in respect of the forfeited Share and not paid before the forfeiture. Despite the foregoing,
                                            the Board may determine that any Share the subject of that notice be accepted by the Company
                                            as surrendered by the Member holding that Share in lieu of forfeiture.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposal
of forfeited or surrendered Share and power to cancel forfeiture or surrender</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            forfeited or surrendered Share may be sold, re-allotted or otherwise disposed of on such
                                            terms and in such manner as the Board determine either to the former Member who held that
                                            Share or to any other person. The forfeiture or surrender may be cancelled on such terms
                                            as the Directors think fit at any time before a sale, re-allotment or other disposition.
                                            Where, for the purposes of its disposal, a forfeited or surrendered Share is to be transferred
                                            to any person, the Directors may authorise some person to execute an instrument of transfer
                                            of the Share to the transferee.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
of forfeiture or surrender on former Member</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            forfeiture or surrender:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            name of the Member concerned shall be removed from the register of Members as the holder
                                            of those Shares and that person shall cease to be a Member in respect of those Shares; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                            person shall surrender to the Company for cancellation the certificate (if any) for the forfeited
                                            or surrendered Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
                                            the forfeiture or surrender of his Shares, that person shall remain liable to the Company
                                            for all monies which at the date of forfeiture or surrender were presently payable by him
                                            to the Company in respect of those Shares together with:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            expenses; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interest
                                            from the date of forfeiture or surrender until payment:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
                                            the rate of which interest was payable on those monies before forfeiture; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            no interest was so payable, at the Default Rate.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors, however, may waive payment wholly or in part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evidence
of forfeiture or surrender</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            declaration, whether statutory or under oath, made by a Director or the Secretary shall be
                                            conclusive evidence of the following matters stated in it as against all persons claiming
                                            to be entitled to forfeited Shares:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                            the person making the declaration is a Director or Secretary of the Company, and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                            the particular Shares have been forfeited or surrendered on a particular date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the execution of an instrument of transfer, if necessary, the declaration shall constitute good title to the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale
of forfeited or surrendered Shares</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            person to whom the forfeited or surrendered Shares are disposed of shall not be bound to
                                            see to the application of the consideration, if any, of those Shares nor shall his title
                                            to the Shares be affected by any irregularity in, or invalidity of the proceedings in respect
                                            of, the forfeiture, surrender or disposal of those Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer
of Shares</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
to transfer</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            instrument of transfer of any Share shall be in writing and in any usual or common form or
                                            such other form as the Directors may, in their absolute discretion, approve and be executed
                                            by or on behalf of the transferor and if in respect of a nil or Partly Paid Up Share, or
                                            if so required by the Directors, shall also be executed on behalf of the transferee and shall
                                            be accompanied by the certificate (if any) of the Shares to which it relates and such other
                                            evidence as the Directors may reasonably require to show the right of the transferor to make
                                            the transfer. The transferor shall be deemed to remain a Member until the name of the transferee
                                            is entered in the register of Members in respect of the relevant Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors may in their absolute discretion decline to register any transfer of Shares which
                                            is not Fully Paid Up or on which the Company has a lien.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors may also, but are not required to, decline to register any transfer of any Share
                                            unless:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            instrument of transfer is lodged with the Company, accompanied by the certificate (if any)
                                            for the Shares to which it relates and such other evidence as the Board may reasonably require
                                            to show the right of the transferor to make the transfer;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            instrument of transfer is in respect of only one class of Shares;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            instrument of transfer is properly stamped, if required;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            the case of a transfer to joint holders, the number of joint holders to whom the Share is
                                            to be transferred does not exceed four;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Shares transferred are Fully Paid Up and free of any lien in favour of the Company; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            applicable fee of such maximum sum as the Designated Stock Exchanges may determine to be
                                            payable, or such lesser sum as the Board may from time to time require, related to the transfer
                                            is paid to the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suspension
of transfers</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registration of transfers may, on 14 days&rsquo; notice being given by advertisement in such
                                            one or more newspapers or by electronic means, be suspended and the register of Members closed
                                            at such times and for such periods as the Directors may, in their absolute discretion, from
                                            time to time determine, provided always that such registration of transfer shall not be suspended
                                            nor the register of Members closed for more than 30 days in any year.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
may retain instrument of transfer</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            instruments of transfer that are registered shall be retained by the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
of refusal to register</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the Directors refuse to register a transfer of any Shares, they shall within three months
                                            after the date on which the instrument of transfer was lodged with the Company send to each
                                            of the transferor and the transferee notice of the refusal.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transmission
of Shares</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persons
entitled on death of a Member</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            a Member dies, the only persons recognised by the Company as having any title to the deceased
                                            Members&rsquo; interest are the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
                                            the deceased Member was a joint holder, the survivor or survivors; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
                                            the deceased Member was a sole holder, that Member&rsquo;s personal representative or representatives.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
                                            in these Articles shall release the deceased Member&rsquo;s estate from any liability in
                                            respect of any Share, whether the deceased was a sole holder or a joint holder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
of transfer of a Share following death or bankruptcy</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            person becoming entitled to a Share in consequence of the death or bankruptcy of a Member
                                            may elect to do either of the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            become the holder of the Share; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            transfer the Share to another person.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
                                            person must produce such evidence of his entitlement as the Directors may properly require.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the person elects to become the holder of the Share, he must give notice to the Company to
                                            that effect. For the purposes of these Articles, that notice shall be treated as though it
                                            were an executed instrument of transfer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the person elects to transfer the Share to another person then:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Share is Fully Paid Up, the transferor must execute an instrument of transfer; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Share is nil or Partly Paid Up, the transferor and the transferee must execute an instrument
                                            of transfer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            the Articles relating to the transfer of Shares shall apply to the notice or, as appropriate,
                                            the instrument of transfer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnity</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            person registered as a Member by reason of the death or bankruptcy of another Member shall
                                            indemnify the Company and the Directors against any loss or damage suffered by the Company
                                            or the Directors as a result of that registration.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights
of person entitled to a Share following death or bankruptcy</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            person becoming entitled to a Share by reason of the death or bankruptcy of a Member shall
                                            have the rights to which he would be entitled if he were registered as the holder of the
                                            Share. But, until he is registered as Member in respect of the Share, he shall not be entitled
                                            to attend or vote at any meeting of the Company or at any separate meeting of the holders
                                            of that class of Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alteration
of capital</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increasing,
consolidating, converting, dividing and cancelling share capital</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            the fullest extent permitted by the Law, the Company may by Ordinary Resolution do any of
                                            the following and amend its Memorandum for that purpose:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
                                            its share capital by new Shares of the amount fixed by that Ordinary Resolution and with
                                            the attached rights, priorities and privileges set out in that Ordinary Resolution;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidate
                                            and divide all or any of its share capital into Shares of larger amount than its existing
                                            Shares;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">convert
                                            all or any of its Paid Up Shares into stock, and reconvert that stock into Paid Up Shares
                                            of any denomination;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sub-divide
                                            its Shares or any of them into Shares of an amount smaller than that fixed by the Memorandum,
                                            so, however, that in the sub-division, the proportion between the amount paid and the amount,
                                            if any, unpaid on each reduced Share shall be the same as it was in case of the Share from
                                            which the reduced Share is derived; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancel
                                            Shares which, at the date of the passing of that Ordinary Resolution, have not been taken
                                            or agreed to be taken by any person, and diminish the amount of its share capital by the
                                            amount of the Shares so cancelled or, in the case of Shares without nominal par value, diminish
                                            the number of Shares into which its capital is divided.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dealing
with fractions resulting from consolidation of Shares</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever,
                                            as a result of a consolidation of Shares, any Members would become entitled to fractions
                                            of a Share the Directors may on behalf of those Members deal with the fractions as it thinks
                                            fit, including (without limitation):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">either
                                            round up or down the fraction to the nearest whole number, such rounding to be determined
                                            by the Directors acting in their sole discretion; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sell
                                            the Shares representing the fractions for the best price reasonably obtainable to any person
                                            (including, subject to the provisions of the Law, the Company); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">distribute
                                            the net proceeds in due proportion among those Members.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the purposes of Article 8.2, the Directors may authorise some person to execute an instrument
                                            of transfer of the Shares to, in accordance with the directions of, the purchaser. The transferee
                                            shall not be bound to see to the application of the purchase money nor shall the transferee&rsquo;s
                                            title to the Shares be affected by any irregularity in, or invalidity of, the proceedings
                                            in respect of the sale.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reducing
share capital</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the Law and to any rights for the time being conferred on the Members holding a particular
                                            class of Shares, the Company may, by Special Resolution, reduce its share capital in any
                                            way.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redemption
and purchase of own Shares</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
to issue redeemable Shares and to purchase own Shares</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the Law and to any rights for the time being conferred on the Members holding a particular
                                            class of Shares, the Company may by its Directors:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
                                            Shares that are to be redeemed or liable to be redeemed, at the option of the Company or
                                            the Member holding those redeemable Shares, on the terms and in the manner its Directors
                                            determine before the issue of those Shares;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
                                            the consent by Special Resolution of the Members holding Shares of a particular class, vary
                                            the rights attaching to that class of Shares so as to provide that those Shares are to be
                                            redeemed or are liable to be redeemed at the option of the Company on the terms and in the
                                            manner which the Directors determine at the time of such variation; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchase
                                            all or any of its own Shares of any class including any redeemable Shares on the terms and
                                            in the manner which the Directors determine at the time of such purchase.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may make a payment in respect of the redemption or purchase of its own Shares in any manner authorised by the Law, including
out of any combination of the following: capital, its profits and the proceeds of a fresh issue of Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
to pay for redemption or purchase in cash or in specie</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
                                            making a payment in respect of the redemption or purchase of Shares, the Directors may make
                                            the payment in cash or <I>in specie</I> (or partly in one and partly in the other) if so
                                            authorised by the terms of the allotment of those Shares or by the terms applying to those
                                            Shares in accordance with Article 9.1, or otherwise by agreement with the Member holding
                                            those Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
of redemption or purchase of a Share</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
                                            the date of redemption or purchase of a Share:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Member holding that Share shall cease to be entitled to any rights in respect of the Share
                                            other than the right to receive:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            price for the Share; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            dividend declared in respect of the Share prior to the date of redemption or purchase;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Member&rsquo;s name shall be removed from the register of Members with respect to the Share;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Share shall be cancelled or held as a Treasury Share, as the Directors may determine.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the purpose of Article 9.3, the date of redemption or purchase is the date when the Member&rsquo;s
                                            name is removed from the register of Members with respect to the Shares the subject of the
                                            redemption or purchase.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Meetings
of Members</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
and extraordinary general meetings</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company may, but shall not (unless required by the Designated Stock Exchange Rules) be obligated
                                            to, in each year hold a general meeting as an annual general meeting, which, if held, shall
                                            be convened by the Board, in accordance with these Articles.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            general meetings other than annual general meetings shall be called extraordinary general
                                            meetings.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
to call meetings</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors may call a general meeting at any time.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            there are insufficient Directors to constitute a quorum and the remaining Directors are unable
                                            to agree on the appointment of additional Directors, the Directors must call a general meeting
                                            for the purpose of appointing additional Directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors must also call a general meeting if requisitioned in the manner set out in the
                                            next two Articles.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            requisition must be in writing and given by one or more Members who together hold at least
                                            ten per cent of the rights to vote at such general meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            requisition must also:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">specify
                                            the purpose of the meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
                                            signed by or on behalf of each requisitioner (and for this purpose each joint holder shall
                                            be obliged to sign). The requisition may consist of several documents in like form signed
                                            by one or more of the requisitioners; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
                                            delivered in accordance with the notice provisions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
                                            the Directors fail to call a general meeting within 21 Clear Days&rsquo; from the date of
                                            receipt of a requisition, the requisitioners or any of them may call a general meeting within
                                            three months after the end of that period.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
                                            limitation to the foregoing, if there are insufficient Directors to constitute a quorum and
                                            the remaining Directors are unable to agree on the appointment of additional Directors, any
                                            one or more Members who together hold at least five per cent of the rights to vote at a general
                                            meeting may call a general meeting for the purpose of considering the business specified
                                            in the notice of meeting which shall include as an item of business the appointment of additional
                                            Directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the Members call a meeting under the above provisions, the Company shall reimburse their
                                            reasonable expenses.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Content
of notice</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
                                            of a general meeting shall specify each of the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            place, the date and the hour of the meeting;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the meeting is to be held in two or more places, the technology that will be used to facilitate
                                            the meeting;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
                                            to paragraph (d) and the requirements of (to the extent applicable) the Designated Stock
                                            Exchange Rules, the general nature of the business to be transacted; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            a resolution is proposed as a Special Resolution, the text of that resolution.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            each notice there shall appear with reasonable prominence the following statements:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                            a Member who is entitled to attend and vote is entitled to appoint one or more proxies to
                                            attend and vote instead of that Member; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                            a proxyholder need not be a Member.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period
of notice</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
                                            least twenty-one Clear Days&rsquo; notice of an annual general meeting must be given to Members.
                                            For any other general meeting, at least fourteen Clear Days&rsquo; notice must be given to
                                            Members.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the Law, a meeting may be convened on shorter notice, subject to the Law with the consent
                                            of the Member or Members who, individually or collectively, hold at least ninety per cent
                                            of the voting rights of all those who have a right to vote at that meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persons
entitled to receive notice</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the provisions of these Articles and to any restrictions imposed on any Shares, the notice
                                            shall be given to the following people:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Members</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
                                            entitled to a Share in consequence of the death or bankruptcy of a Member;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Directors; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Auditors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Board may determine that the Members entitled to receive notice of a meeting are those persons
                                            entered on the register of Members at the close of business on a day determined by the Board.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accidental
omission to give notice or non-receipt of notice</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceedings
                                            at a meeting shall not be invalidated by the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            accidental failure to give notice of the meeting to any person entitled to notice; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">non-receipt
                                            of notice of the meeting by any person entitled to notice.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            addition, where a notice of meeting is published on a website proceedings at the meeting
                                            shall not be invalidated merely because it is accidentally published:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            a different place on the website; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
                                            part only of the period from the date of the notification until the conclusion of the meeting
                                            to which the notice relates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceedings
at meetings of Members</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quorum</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Save
                                            as provided in the following Article, no business shall be transacted at any meeting unless
                                            a quorum is present in person or by proxy. A quorum is as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Company has only one Member: that Member;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Company has more than one Member: one or more Members holding Shares that represent not
                                            less than one-third of the outstanding Shares carrying the right to vote at such general
                                            meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
of quorum</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            a quorum is not present within fifteen minutes of the time appointed for the meeting, or
                                            if at any time during the meeting it becomes inquorate, then the following provisions apply:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the meeting was requisitioned by Members, it shall be cancelled.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            any other case, the meeting shall stand adjourned to the same time and place seven days hence,
                                            or to such other time or place as is determined by the Directors. If a quorum is not present
                                            within fifteen minutes of the time appointed for the adjourned meeting, then the Members
                                            present in person or by proxy shall constitute a quorum.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            chairman of a general meeting shall be the chairman of the Board or such other Director as
                                            the Directors have nominated to chair Board meetings in the absence of the chairman of the
                                            Board. Absent any such person being present within fifteen minutes of the time appointed
                                            for the meeting, the Directors present shall elect one of their number to chair the meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            no Director is present within fifteen minutes of the time appointed for the meeting, or if
                                            no Director is willing to act as chairman, the Members present in person or by proxy and
                                            entitled to vote shall choose one of their number to chair the meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
of a Director to attend and speak</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
                                            if a Director is not a Member, he shall be entitled to attend and speak at any general meeting
                                            and at any separate meeting of Members holding a particular class of Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accommodation
of Members at meeting</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lf
                                            it appears to the chairman of the meeting that the meeting place specified in the notice
                                            convening the meeting is inadequate to accommodate all Members entitled and wishing to attend,
                                            the meeting will be duly constituted and its proceedings valid if the chairman is satisfied
                                            that adequate facilities are available to ensure that a Member who is unable to be accommodated
                                            is able (whether at the meeting place or elsewhere):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            participate in the business for which the meeting has been convened;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            hear and see all persons present who speak (whether by the use of microphones, loud-speakers,
                                            audio-visual communications equipment or otherwise); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            be heard and seen by all other persons present in the same way.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            addition to any measures which the Board may be required to take due to the location or venue
                                            of the meeting, the Board may make any arrangement and impose any restriction it considers
                                            appropriate and reasonable in the circumstances to ensure the security of a meeting including,
                                            without limitation, the searching of any person attending the meeting and the imposing of
                                            restrictions on the items of personal property that may be taken into the meeting place.
                                            The Board may refuse entry to, or eject from, a meeting a person who refuses to comply with
                                            any such arrangements or restrictions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjournment</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            chairman may at any time adjourn a meeting with the consent of the Members constituting a
                                            quorum. The chairman must adjourn the meeting if so directed by the meeting. No business,
                                            however, can be transacted at an adjourned meeting other than business which might properly
                                            have been transacted at the original meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
                                            a meeting be adjourned for more than 7 Clear Days, whether because of a lack of quorum or
                                            otherwise, Members shall be given at least seven Clear Days&rsquo; notice of the date, time and
                                            place of the adjourned meeting and the general nature of the business to be transacted. Otherwise
                                            it shall not be necessary to give any notice of the adjournment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method
of voting</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            resolution put to the vote of the meeting shall be decided on a show of hands unless before,
                                            or on, the declaration of the result of the show of hands, a poll is duly demanded. Subject
                                            to the Law, a poll may be demanded:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            the chairman of the meeting;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            at least two Members having the right to vote on the resolutions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            any Member or Members present who, individually or collectively, hold at least ten per cent
                                            of the voting rights of all those who have a right to vote on the resolution.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outcome
of vote by show of hands</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
                                            a poll is duly demanded, a declaration by the chairman as to the result of a resolution and
                                            an entry to that effect in the minutes of the meeting shall be conclusive evidence of the
                                            outcome of a show of hands without proof of the number or proportion of the votes recorded
                                            in favour of or against the resolution.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Withdrawal
of demand for a poll</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            demand for a poll may be withdrawn before the poll is taken, but only with the consent of
                                            the chairman. The chairman shall announce any such withdrawal to the meeting and, unless
                                            another person forthwith demands a poll, any earlier show of hands on that resolution shall
                                            be treated as the vote on that resolution; if there has been no earlier show of hands, then
                                            the resolution shall be put to the vote of the meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taking
of a poll</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            poll demanded on the question of adjournment shall be taken immediately.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            poll demanded on any other question shall be taken either immediately or at an adjourned
                                            meeting at such time and place as the chairman directs, not being more than thirty Clear
                                            Days after the poll was demanded.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            demand for a poll shall not prevent the meeting continuing to transact any business other
                                            than the question on which the poll was demanded.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.16</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            poll shall be taken in such manner as the chairman directs. He may appoint scrutineers (who
                                            need not be Members) and fix a place and time for declaring the result of the poll. If, through
                                            the aid of technology, the meeting is held in more than place, the chairman may appoint scrutineers
                                            in more than place; but if he considers that the poll cannot be effectively monitored at
                                            that meeting, the chairman shall adjourn the holding of the poll to a date, place and time
                                            when that can occur.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman&rsquo;s
casting vote</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            the case of an equality of votes, whether on a show of hands or on a poll, the Chairman of
                                            the meeting at which the show of hands takes place or at which the poll is demanded shall
                                            not be entitled to a second or casting vote.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
resolutions</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.18</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
                                            may pass a resolution in writing without holding a meeting if the following conditions are
                                            met:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            Members entitled to vote are given notice of the resolution as if the same were being proposed
                                            at a meeting of Members;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            Members entitled so to vote;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sign
                                            a document; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sign
                                            several documents in the like form each signed by one or more of those Members; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            signed document or documents is or are delivered to the Company, including, if the Company
                                            so nominates, by delivery of an Electronic Record by Electronic means to the address specified
                                            for that purpose.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
                                            written resolution shall be as effective as if it had been passed at a meeting of the Members
                                            entitled to vote duly convened and held.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.19</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            a written resolution is described as a Special Resolution or as an Ordinary Resolution, it
                                            has effect accordingly.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.20</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors may determine the manner in which written resolutions shall be put to Members.
                                            In particular, they may provide, in the form of any written resolution, for each Member to
                                            indicate, out of the number of votes the Member would have been entitled to cast at a meeting
                                            to consider the resolution, how many votes he wishes to cast in favour of the resolution
                                            and how many against the resolution or to be treated as abstentions. The result of any such
                                            written resolution shall be determined on the same basis as on a poll.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sole-Member
Company</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.21</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the Company has only one Member, and the Member records in writing his decision on a question,
                                            that record shall constitute both the passing of a resolution and the minute of it.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting
rights of Members</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
to vote</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
                                            their Shares carry no right to vote, or unless a call or other amount presently payable has
                                            not been paid, all Members are entitled to vote at a general meeting, whether on a show of
                                            hands or on a poll, and all Members holding Shares of a particular class of Shares are entitled
                                            to vote at a meeting of the holders of that class of Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
                                            may vote in person or by proxy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            a show of hands, every Member shall have one vote. For the avoidance of doubt, an individual
                                            who represents two or more Members, including a Member in that individual&rsquo;s own right,
                                            that individual shall be entitled to a separate vote for each Member.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            a poll a Member shall have one vote for each Share he holds, unless any Share carries special
                                            voting rights.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            Member is bound to vote on his Shares or any of them; nor is he bound to vote each of his
                                            Shares in the same way.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights
of joint holders</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            Shares are held jointly, only one of the joint holders may vote. If more than one of the
                                            joint holders tenders a vote, the vote of the holder whose name in respect of those Shares
                                            appears first in the register of Members shall be accepted to the exclusion of the votes
                                            of the other joint holder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representation
of corporate Members</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Save
                                            where otherwise provided, a corporate Member must act by a duly authorised representative.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            corporate Member wishing to act by a duly authorised representative must identify that person
                                            to the Company by notice in writing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            authorisation may be for any period of time, and must be delivered to the Company before
                                            the commencement of the meeting at which it is first used.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors of the Company may require the production of any evidence which they consider necessary
                                            to determine the validity of the notice.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
                                            a duly authorised representative is present at a meeting that Member is deemed to be present
                                            in person; and the acts of the duly authorised representative are personal acts of that Member.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            corporate Member may revoke the appointment of a duly authorised representative at any time
                                            by notice to the Company; but such revocation will not affect the validity of any acts carried
                                            out by the duly authorised representative before the Directors of the Company had actual
                                            notice of the revocation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
with mental disorder</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Member in respect of whom an order has been made by any court having jurisdiction (whether
                                            in the Cayman Islands or elsewhere) in matters concerning mental disorder may vote, whether
                                            on a show of hands or on a poll, by that Member&rsquo;s receiver, <I>curator bonis</I> or
                                            other person authorised in that behalf appointed by that court.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the purpose of the preceding Article, evidence to the satisfaction of the Directors of the
                                            authority of the person claiming to exercise the right to vote must be received not less
                                            than 24 hours before holding the relevant meeting or the adjourned meeting in any manner
                                            specified for the delivery of forms of appointment of a proxy, whether in writing or by Electronic
                                            means. In default, the right to vote shall not be exercisable.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Objections
to admissibility of votes</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
                                            objection to the validity of a person&rsquo;s vote may only be raised at the meeting or at
                                            the adjourned meeting at which the vote is sought to be tendered. Any objection duly made
                                            shall be referred to the chairman whose decision shall be final and conclusive.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of proxy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.16</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
                                            instrument appointing a proxy shall be in any common form or in any other form approved by
                                            the Directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            instrument must be in writing and signed in one of the following ways:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            the Member; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            the Member&rsquo;s authorised attorney; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Member is a corporation or other body corporate, under seal or signed by an authorised
                                            officer, secretary or attorney.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Directors so resolve, the Company may accept an Electronic Record of that instrument delivered in the manner specified below and
otherwise satisfying the Articles about authentication of Electronic Records.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.18</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors may require the production of any evidence which they consider necessary to determine
                                            the validity of any appointment of a proxy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.19</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Member may revoke the appointment of a proxy at any time by notice to the Company duly signed
                                            in accordance with Article 12.17.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.20</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            revocation by a Member of the appointment of a proxy made in accordance with Article 12.19
                                            will affect the validity of any acts carried out by the relevant proxy before the Directors
                                            of the Company had actual notice of the revocation.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">How
and when proxy is to be delivered</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.21</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the following Articles, the Directors may, in the notice convening any meeting or adjourned
                                            meeting, or in an instrument of proxy sent out by the Company, specify the manner by which
                                            the instrument appointing a proxy shall be deposited and the place and the time (being not
                                            later than the time appointed for the commencement of the meeting or adjourned meeting to
                                            which the proxy relates) at which the instrument appointing a proxy shall be deposited. In
                                            the absence of any such direction from the Directors in the notice convening any meeting
                                            or adjourned meeting or in an instrument of proxy sent out by the Company, the form of appointment
                                            of a proxy and any authority under which it is signed (or a copy of the authority certified
                                            notarially or in any other way approved by the Directors) must be delivered so that it is
                                            received by the Company before the time for holding the meeting or adjourned meeting at which
                                            the person named in the form of appointment of proxy proposes to vote. They must be delivered
                                            in either of the following ways:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            the case of an instrument in writing, it must be left at or sent by post:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            the registered office of the Company; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            such other place within the Cayman Islands specified in the notice convening the meeting
                                            or in any form of appointment of proxy sent out by the Company in relation to the meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
                                            pursuant to the notice provisions, a notice may be given to the Company in an Electronic
                                            Record, an Electronic Record of an appointment of a proxy must be sent to the address specified
                                            pursuant to those provisions unless another address for that purpose is specified:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            the notice convening the meeting; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            any form of appointment of a proxy sent out by the Company in relation to the meeting; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            any invitation to appoint a proxy issued by the Company in relation to the meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
                                            Article 12.21(a) and Article 12.21(b), the chairman of the Company may, in any event at his
                                            discretion, direct that an instrument of proxy shall be deemed to have been duly deposited.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.22</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
                                            a poll is taken:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            it is taken more than seven Clear Days after it is demanded, the form of appointment of a
                                            proxy and any accompanying authority (or an Electronic Record of the same) must be delivered
                                            in accordance with Article 12.21 before the time appointed for the taking of the poll;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            it to be taken within seven Clear Days after it was demanded, the form of appointment of
                                            a proxy and any accompanying authority (or an Electronic Record of the same) must be delivered
                                            in accordance with Article 12.21 before the time appointed for the taking of the poll.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.23</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the form of appointment of proxy is not delivered on time, it is invalid.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.24</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
                                            two or more valid but differing appointments of proxy are delivered or received in respect
                                            of the same Share for use at the same meeting and in respect of the same matter, the one
                                            which is last validly delivered or received (regardless of its date or of the date of its
                                            execution) shall be treated as replacing and revoking the other or others as regards that
                                            Share. lf the Company is unable to determine which appointment was last validly delivered
                                            or received, none of them shall be treated as valid in respect of that Share.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Board may at the expense of the Company send forms of appointment of proxy to the Members
                                            by post (that is to say, pre-paying and posting a letter), or by Electronic communication
                                            or otherwise (with or without provision for their return by pre-paid post) for use at any
                                            general meeting or at any separate meeting of the holders of any class of Shares, either
                                            blank or nominating as proxy in the alternative any one or more of the Directors or any other
                                            person. lf for the purpose of any meeting invitations to appoint as proxy a person or one
                                            of a number of persons specified in the invitations are issued at the Company&rsquo;s expense,
                                            they shall be issued to all (and not to some only) of the Members entitled to be sent notice
                                            of the meeting and to vote at it. The accidental omission to send such a form of appointment
                                            or to give such an invitation to, or the non-receipt of such form of appointment by, any
                                            Member entitled to attend and vote at a meeting shall not invalidate the proceedings at that
                                            meeting</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting
by proxy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.26</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            proxy shall have the same voting rights at a meeting or adjourned meeting as the Member would
                                            have had except to the extent that the instrument appointing him limits those rights. Notwithstanding
                                            the appointment of a proxy, a Member may attend and vote at a meeting or adjourned meeting.
                                            If a Member votes on any resolution a vote by his proxy on the same resolution, unless in
                                            respect of different Shares, shall be invalid.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.27</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            instrument appointing a proxy to vote at a meeting shall be deemed also to confer authority
                                            to demand or join in demanding a poll and, for the purposes of Article 11.11, a demand by
                                            a person as proxy for a Member shall be the same as a demand by a Member. Such appointment
                                            shall not confer any further right to speak at the meeting, except with the permission of
                                            the chairman of the meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                            of Directors</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            shall be a Board consisting of not less than one person provided however that the Company
                                            may by Ordinary Resolution increase or reduce the limits in the number of Directors. Unless
                                            fixed by Ordinary Resolution, the maximum number of Directors shall be unlimited.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Appointment,
                                            disqualification and removal of Directors</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            first Directors shall be appointed in writing by the subscriber or subscribers to the Memorandum,
                                            or a majority of them.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
age limit</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            is no age limit for Directors save that they must be at least eighteen years of age.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
                                            prohibited by law, a body corporate may be a Director. If a body corporate is a Director,
                                            the Articles about representation of corporate Members at general meetings apply, mutatis
                                            mutandis, to the Articles about Directors&rsquo; meetings.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
shareholding qualification</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
                                            a shareholding qualification for Directors is fixed by Ordinary Resolution, no Director shall
                                            be required to own Shares as a condition of his appointment.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
of Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Director may be appointed by Ordinary Resolution or by the Directors. Any appointment may
                                            be to fill a vacancy or as an additional Director.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            remaining Director may appoint a Director even though there is not a quorum of Directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            appointment can cause the number of Directors to exceed the maximum (if one is set); and
                                            any such appointment shall be invalid.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            so long as Shares are listed on a Designated Stock Exchange, the Directors shall include
                                            at least such number of Independent Directors as applicable law, rules or regulations or
                                            the Designated Stock Exchange Rules require as determined by the Board.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board&rsquo;s
power to appoint Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
                                            prejudice to the Company&rsquo;s power to appoint a person to be a Director pursuant to these
                                            Articles, the Board shall have power at any time to appoint any person who is willing to
                                            act as a Director, either to fill a vacancy or as an addition to the existing Board, subject
                                            to the total number of Directors not exceeding any maximum number fixed by or in accordance
                                            with these Articles.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            Director so appointed shall, if still a Director, retire at the next annual general meeting
                                            after his appointment and be eligible to stand for election as a Director at such meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eligibility</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            person (other than a Director retiring in accordance with these Articles) shall be appointed
                                            or re-appointed a Director at any general meeting unless:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
                                            is recommended by the Board; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
                                            less than seven nor more than forty-two Clear Days before the date appointed for the meeting,
                                            a Member (other than the person to be proposed) entitled to vote at the meeting has given
                                            to the Company notice of his intention to propose a resolution for the appointment of that
                                            person, stating the particulars which would, if he were so appointed, be required to be included
                                            in the Company&rsquo;s register of Directors and a notice executed by that person of his
                                            willingness to be appointed.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
at annual general meeting</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
                                            re-appointed pursuant to the provisions of Article 14.5 or removed from office pursuant to
                                            the provisions of Article 14.13, each Director shall be appointed for a term expiring at
                                            the next-following annual general meeting of the Company. At any such annual general meeting,
                                            Directors will be elected by Ordinary Resolution. At each annual general meeting of the Company,
                                            each Director elected at such meeting shall be elected to hold office for a one-year term
                                            and until the election of their respective successors in office or removal pursuant to Articles
                                            14.5 and 14.13.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Removal
of Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Director may be removed by Ordinary Resolution.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resignation
of Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Director may at any time resign office by giving to the Company notice in writing or, if
                                            permitted pursuant to the notice provisions, in an Electronic Record delivered in either
                                            case in accordance with those provisions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
                                            the notice specifies a different date, the Director shall be deemed to have resigned on the
                                            date that the notice is delivered to the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
of the office of Director</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.16</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Director may retire from office as a Director by giving notice in writing to that effect
                                            to the Company at the registered office, which notice shall be effective upon such date as
                                            may be specified in the notice, failing which upon delivery to the registered office.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
                                            prejudice to the provisions in these Articles for retirement (by rotation or otherwise),
                                            a Director&rsquo;s office shall be terminated forthwith if:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
                                            is prohibited by the law of the Cayman Islands from acting as a Director; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
                                            is made bankrupt or makes an arrangement or composition with his creditors generally; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
                                            resigns his office by notice to the Company; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
                                            only held office as a Director for a fixed term and such term expires; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            the opinion of a registered medical practitioner by whom he is being treated he becomes physically
                                            or mentally incapable of acting as a Director; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
                                            is given notice by the majority of the other Directors (not being less than two in number)
                                            to vacate office (without prejudice to any claim for damages for breach of any agreement
                                            relating to the provision of the services of such Director); or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
                                            is made subject to any law relating to mental health or incompetence, whether by court order
                                            or otherwise; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">without
                                            the consent of the other Directors, he is absent from meetings of Directors for a continuous
                                            period of six months.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alternate
                                            Directors</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
and removal</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            Director may appoint any other person, including another Director, to act in his place as
                                            an alternate Director. No appointment shall take effect until the Director has given notice
                                            of the appointment to the Board.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Director may revoke his appointment of an alternate at any time. No revocation shall take
                                            effect until the Director has given notice of the revocation to the Board.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            notice of appointment or removal of an alternate Director shall be effective only if given
                                            to the Company by one or more of the following methods:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            notice in writing in accordance with the notice provisions contained in these Articles;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Company has a facsimile address for the time being, by sending by facsimile transmission
                                            to that facsimile address a facsimile copy or, otherwise, by sending by facsimile transmission
                                            to the facsimile address of the Company&rsquo;s registered office a facsimile copy (in either case,
                                            the facsimile copy being deemed to be the notice unless Article 29.7 applies), in which event
                                            notice shall be taken to be given on the date of an error-free transmission report from the
                                            sender&rsquo;s fax machine;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Company has an email address for the time being, by emailing to that email address a
                                            scanned copy of the notice as a PDF attachment or, otherwise, by emailing to the email address
                                            provided by the Company&rsquo;s registered office a scanned copy of the notice as a PDF attachment
                                            (in either case, the PDF version being deemed to be the notice unless Article 29.7 applies),
                                            in which event notice shall be taken to be given on the date of receipt by the Company or
                                            the Company&rsquo;s registered office (as appropriate) in readable form; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            permitted pursuant to the notice provisions, in some other form of approved Electronic Record
                                            delivered in accordance with those provisions in writing.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            notices of meetings of Directors shall continue to be given to the appointing Director and
                                            not to the alternate.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights
of alternate Director</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
                                            alternate Director shall be entitled to attend and vote at any Board meeting or meeting of
                                            a committee of the Directors at which the appointing Director is not personally present,
                                            and generally to perform all the functions of the appointing Director in his absence. An
                                            alternate Director, however, is not entitled to receive any remuneration from the Company
                                            for services rendered as an alternate Director.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
ceases when the appointor ceases to be a Director</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
                                            alternate Director shall cease to be an alternate Director if:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Director who appointed him ceases to be a Director; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Director who appointed him revokes his appointment by notice delivered to the Board or to
                                            the registered office of the Company or in any other manner approved by the Board; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            any event happens in relation to him which, if he were a Director of the Company, would cause
                                            his office as Director to be vacated.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Status
of alternate Director</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
                                            alternate Director shall carry out all functions of the Director who made the appointment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Save
                                            where otherwise expressed, an alternate Director shall be treated as a Director under these
                                            Articles.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
                                            alternate Director is not the agent of the Director appointing him.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
                                            alternate Director is not entitled to any remuneration for acting as alternate Director.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Status
of the Director making the appointment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Director who has appointed an alternate is not thereby relieved from the duties which he
                                            owes the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Powers
                                            of Directors</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Powers
of Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the provisions of the Law, the Memorandum and these Articles the business of the Company
                                            shall be managed by the Directors who may for that purpose exercise all the powers of the
                                            Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            prior act of the Directors shall be invalidated by any subsequent alteration of the Memorandum
                                            or these Articles. However, to the extent allowed by the Law, Members may, by Special Resolution,
                                            validate any prior or future act of the Directors which would otherwise be in breach of their
                                            duties.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
below the minimum number</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lf
                                            the number of Directors is less than the minimum prescribed in accordance with these Articles,
                                            the remaining Director or Directors shall act only for the purposes of appointing an additional
                                            Director or Directors to make up such minimum or of convening a general meeting of the Company
                                            for the purpose of making such appointment. lf there are no Director or Directors able or
                                            willing to act, any two Members may summon a general meeting for the purpose of appointing
                                            Directors. Any additional Director so appointed shall hold office (subject to these Articles)
                                            only until the dissolution of the annual general meeting next following such appointment
                                            unless he is re-elected during such meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointments
to office</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors may appoint a Director:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                            chairman of the Board;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                            managing Director;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            any other executive office,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
such period, and on such terms, including as to remuneration as they think fit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            appointee must consent in writing to holding that office.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
                                            a chairman is appointed he shall, unless unable to do so, preside at every meeting of Directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            there is no chairman, or if the chairman is unable to preside at a meeting, that meeting
                                            may select its own chairman; or the Directors may nominate one of their number to act in
                                            place of the chairman should he ever not be available.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the provisions of the Law, the Directors may also appoint and remove any person, who need
                                            not be a Director:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                            Secretary; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            any office that may be required</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
such period and on such terms, including as to remuneration, as they think fit. In the case of an Officer, that Officer may be given
any title the Directors decide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Secretary or Officer must consent in writing to holding that office.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Director, Secretary or other Officer of the Company may not the hold the office, or perform
                                            the services, of auditor.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
for employees</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Board may make provision for the benefit of any persons employed or formerly employed by
                                            the Company or any of its subsidiary undertakings (or any member of his family or any person
                                            who is dependent on him) in connection with the cessation or the transfer to any person of
                                            the whole or part of the undertaking of the Company or any of its subsidiary undertakings.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
of voting rights</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Board may exercise the voting power conferred by the Shares in any body corporate held or
                                            owned by the Company in such manner in all respects as it thinks fit (including, without
                                            limitation, the exercise of that power in favour of any resolution appointing any Director
                                            as a Director of such body corporate, or voting or providing for the payment of remuneration
                                            to the Directors of such body corporate).</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remuneration</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
                                            Director may be remunerated by the Company for the services he provides for the benefit of
                                            the Company, whether as Director, employee or otherwise, and shall be entitled to be paid
                                            for the expenses incurred in the Company&rsquo;s business including attendance at Directors&rsquo;
                                            meetings.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
                                            otherwise determined by the Company by Ordinary Resolution, the Directors (other than alternate
                                            Directors) shall be entitled to such remuneration by way of fees for their services in the
                                            office of Director as the Directors may determine.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remuneration
                                            may take any form and may include arrangements to pay pensions, health insurance, death or
                                            sickness benefits, whether to the Director or to any other person connected to or related
                                            to him.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.16</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
                                            his fellow Directors determine otherwise, a Director is not accountable to the Company for
                                            remuneration or other benefits received from any other company which is in the same group
                                            as the Company or which has common shareholdings.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
of information</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors may release or disclose to a third party any information regarding the affairs
                                            of the Company, including any information contained in the register of Members relating to
                                            a Member, (and they may authorise any Director, Officer or other authorised agent of the
                                            Company to release or disclose to a third party any such information in his possession) if:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company or that person, as the case may be, is lawfully required to do so under the laws
                                            of any jurisdiction to which the Company is subject; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            disclosure is in compliance with the Designated Stock Exchange Rules; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            disclosure is in accordance with any contract entered into by the Company; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Directors are of the opinion such disclosure would assist or facilitate the Company&rsquo;s
                                            operations.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delegation
                                            of powers</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
to delegate any of the Directors&rsquo; powers to a committee</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors may delegate any of their powers to any committee consisting of one or more persons
                                            who need not be Members. Persons on the committee may include non-Directors so long as the
                                            majority of those persons are Directors. Any such committee shall be made up of such number
                                            of Independent Directors as required from time to time by the Designated Stock Exchange Rules
                                            or otherwise required by applicable law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            delegation may be collateral with, or to the exclusion of, the Directors&rsquo; own powers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            delegation may be on such terms as the Directors think fit, including provision for the committee
                                            itself to delegate to a sub-committee; save that any delegation must be capable of being
                                            revoked or altered by the Directors at will.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
                                            otherwise permitted by the Directors, a committee must follow the procedures prescribed for
                                            the taking of decisions by Directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Board shall establish an audit committee, a compensation committee and a nominating and corporate
                                            governance committee. Each of these committees shall be empowered to do all things necessary
                                            to exercise the rights of such committee set forth in these Articles. Each of the audit committee,
                                            compensation committee and nominating and corporate governance committee shall consist of
                                            at least three Directors (or such larger minimum number as may be required from time to time
                                            by the Designated Stock Exchange Rules). The majority of the committee members on each of
                                            the compensation committee and nominating and corporate governance committee shall be Independent
                                            Directors. The audit committee shall be made up of such number of Independent Directors as
                                            required from time to time by the Designated Stock Exchange Rules or otherwise required by
                                            applicable law.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Local
boards</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Board may establish any local or divisional board or agency for managing any of the affairs
                                            of the Company whether in the Cayman Islands or elsewhere and may appoint any persons to
                                            be members of a local or divisional Board, or to be managers or agents, and may fix their
                                            remuneration.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Board may delegate to any local or divisional board, manager or agent any of its powers and
                                            authorities (with power to sub-delegate) and may authorise the members of any local or divisional
                                            board or any of them to fill any vacancies and to act notwithstanding vacancies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            appointment or delegation under this Article 17.8 may be made on such terms and subject to
                                            such conditions as the Board thinks fit and the Board may remove any person so appointed,
                                            and may revoke or vary any delegation.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
to appoint an agent of the Company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors may appoint any person, either generally or in respect of any specific matter,
                                            to be the agent of the Company with or without authority for that person to delegate all
                                            or any of that person&rsquo;s powers. The Directors may make that appointment:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            causing the Company to enter into a power of attorney or agreement; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            any other manner they determine.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
to appoint an attorney or authorised signatory of the Company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors may appoint any person, whether nominated directly or indirectly by the Directors,
                                            to be the attorney or the authorised signatory of the Company. The appointment may be:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
                                            any purpose;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
                                            the powers, authorities and discretions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
                                            the period; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
                                            to such conditions</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
they think fit. The powers, authorities and discretions, however, must not exceed those vested in, or exercisable, by the Directors under
these Articles. The Directors may do so by power of attorney or any other manner they think fit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            power of attorney or other appointment may contain such provision for the protection and
                                            convenience for persons dealing with the attorney or authorised signatory as the Directors
                                            think fit. Any power of attorney or other appointment may also authorise the attorney or
                                            authorised signatory to delegate all or any of the powers, authorities and discretions vested
                                            in that person.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Board may remove any person appointed under Article 17.10 and may revoke or vary the delegation.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowing
Powers</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors may exercise all the powers of the Company to borrow money and to mortgage or charge
                                            its undertaking, property and assets both present and future and uncalled capital, or any
                                            part thereof, and to issue debentures and other securities, whether outright or as collateral
                                            security for any debt, liability or obligation of the Company or its parent undertaking (if
                                            any) or any subsidiary undertaking of the Company or of any third party.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
Governance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Board may, from time to time, and except as required by applicable law or the Designated
                                            Stock Exchange Rules, adopt, institute, amend, modify or revoke the corporate governance
                                            policies or initiatives of the Company, which shall be intended to set forth the guiding
                                            principles and policies of the Company and the Board on various corporate governance related
                                            matters as the Board shall determine by resolution from time to time.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Meetings
                                            of Directors</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation
of Directors&rsquo; meetings</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the provisions of these Articles, the Directors may regulate their proceedings as they
                                            think fit.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calling
meetings</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            Director may call a meeting of Directors at any time. The Secretary must call a meeting of
                                            the Directors if requested to do so by a Director.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
of meetings</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
                                            of a Board meeting may be given to a Director personally or by word of mouth or given in
                                            writing or by Electronic communications at such address as he may from time to time specify
                                            for this purpose (or, if he does not specify an address, at his last known address). A Director
                                            may waive his right to receive notice of any meeting either prospectively or retrospectively.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
of technology</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Director may participate in a meeting of Directors through the medium of conference telephone,
                                            video or any other form of communications equipment providing all persons participating in
                                            the meeting are able to hear and speak to each other throughout the meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Director participating in this way is deemed to be present in person at the meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quorum</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            quorum for the transaction of business at a meeting of Directors shall be two unless the
                                            Directors fix some other number.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
or deputy to preside</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Board may appoint a chairman and one or more deputy chairman or chairmen and may at any time
                                            revoke any such appointment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            chairman, or failing him any deputy chairman (the longest in office taking precedence if
                                            more than one is present), shall preside at all Board meetings. If no chairman or deputy
                                            chairman has been appointed, or if he is not present within five minutes after the time fixed
                                            for holding the meeting, or is unwilling to act as chairman of the meeting, the Directors
                                            present shall choose one of their number to act as chairman of the meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            question which arises at a Board meeting shall be decided by a majority of votes. If votes
                                            are equal the chairman may, if he wishes, exercise a casting vote.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recording
of dissent</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Director present at a meeting of Directors shall be presumed to have assented to any action
                                            taken at that meeting unless:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">his
                                            dissent is entered in the minutes of the meeting; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
                                            has filed with the meeting before it is concluded signed dissent from that action; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
                                            has forwarded to the Company as soon as practical following the conclusion of that meeting
                                            signed dissent.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Director who votes in favour of an action is not entitled to record his dissent to it.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
resolutions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors may pass a resolution in writing without holding a meeting if all Directors sign
                                            a document or sign several documents in the like form each signed by one or more of those
                                            Directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            written resolution signed by a validly appointed alternate Director need not also be signed
                                            by the appointing Director.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">
&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            written resolution signed personally by the appointing Director need not also be signed by
                                            his alternate.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            resolution in writing passed pursuant to Article 18.11, Article 18.12 and/or Article 18.13
                                            shall be as effective as if it had been passed at a meeting of the Directors duly convened
                                            and held; and it shall be treated as having been passed on the day and at the time that the
                                            last Director signs (and for the avoidance of doubt, such day may or may not be a Business
                                            Day).</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Validity
of acts of Directors in spite of formal defect</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            acts done by a meeting of the Board, or of a committee of the Board, or by any person acting
                                            as a Director or an alternate Director, shall, notwithstanding that it is afterwards discovered
                                            that there was some defect in the appointment of any Director or alternate Director or member
                                            of the committee, or that any of them were disqualified or had vacated office or were not
                                            entitled to vote, be as valid as if every such person had been duly appointed and qualified
                                            and had continued to be a Director or alternate Director and had been entitled to vote.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Permissible
                                            Directors&rsquo; interests and disclosure</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Director shall not, as a Director, vote in respect of any contract, transaction, arrangement
                                            or proposal in which he has an interest which (together with any interest of any person connected
                                            with him) is a material interest (otherwise then by virtue of his interests, direct or indirect,
                                            in Shares or debentures or other securities of, or otherwise in or through, the Company)
                                            and if he shall do so his vote shall not be counted, nor in relation thereto shall he be
                                            counted in the quorum present at the meeting, but (in the absence of some other material
                                            interest than is mentioned below) none of these prohibitions shall apply to:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            giving of any security, guarantee or indemnity in respect of:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">money
                                            lent or obligations incurred by him or by any other person for the benefit of the Company
                                            or any of its subsidiaries; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            debt or obligation of the Company or any of its subsidiaries for which the Director himself
                                            has assumed responsibility in whole or in part and whether alone or jointly with others under
                                            a guarantee or indemnity or by the giving of security;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
                                            the Company or any of its subsidiaries is offering securities in which offer the Director
                                            is or may be entitled to participate as a holder of securities or in the underwriting or
                                            sub-underwriting of which the Director is to or may participate;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            contract, transaction, arrangement or proposal affecting any other body corporate in which
                                            he is interested, directly or indirectly and whether as an officer, shareholder, creditor
                                            or otherwise howsoever, provided that he (together with persons connected with him) does
                                            not to his knowledge hold an interest representing one per cent or more of any class of the
                                            equity share capital of such body corporate (or of any third body corporate through which
                                            his interest is derived) or of the voting rights available to members of the relevant body
                                            corporate (any such interest being deemed for the purposes of this Article 19.1 to be a material
                                            interest in all circumstances);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            act or thing done or to be done in respect of any arrangement for the benefit of the employees
                                            of the Company or any of its subsidiaries under which he is not accorded as a Director any
                                            privilege or advantage not generally accorded to the employees to whom such arrangement relates;
                                            or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            matter connected with the purchase or maintenance for any Director of insurance against any
                                            liability or (to the extent permitted by the Law) indemnities in favour of Directors, the
                                            funding of expenditure by one or more Directors in defending proceedings against him or them
                                            or the doing of any thing to enable such Director or Directors to avoid incurring such expenditure.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Director may, as a Director, vote (and be counted in the quorum) in respect of any contract,
                                            transaction, arrangement or proposal in which he has an interest which is not a material
                                            interest or which falls within Article 19.1.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Minutes</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company shall cause minutes to be made in books of:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            appointments of Officers and committees made by the Board and of any such Officer&rsquo;s
                                            remuneration; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            names of Directors present at every meeting of the Directors, a committee of the Board, the
                                            Company or the holders of any class of shares or debentures, and all orders, resolutions
                                            and proceedings of such meetings.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            such minutes, if purporting to be signed by the chairman of the meeting at which the proceedings
                                            were held or by the chairman of the next succeeding meeting or the Secretary, shall be prima
                                            facie evidence of the matters stated in them.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accounts
                                            and audit</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors must ensure that proper accounting and other records are kept, and that accounts
                                            and associated reports are distributed in accordance with the requirements of the Law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            books of account shall be kept at the registered office of the Company and shall always be
                                            open to inspection by the Directors. No Member (other than a Director) shall have any right
                                            of inspecting any account or book or document of the Company except as conferred by the Law
                                            or as authorised by the Directors or by Ordinary Resolution.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
                                            the Directors otherwise prescribe, the financial year of the Company shall end on 30 September
                                            in each year and begin on 1 October in each year.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors may appoint an Auditor of the Company who shall hold office on such terms as the
                                            Directors determine.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
                                            any general meeting convened and held at any time in accordance with these Articles, the
                                            Members may, by Ordinary Resolution, remove the Auditor before the expiration of his term
                                            of office. If they do so, the Members shall, by Ordinary Resolution, at that meeting appoint
                                            another Auditor in his stead for the remainder of his term.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Auditors shall examine such books, accounts and vouchers; as may be necessary for the performance
                                            of their duties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Auditors shall, if so requested by the Directors, make a report on the accounts of the Company
                                            during their tenure of office at the next annual general meeting following their appointment,
                                            and at any time during their term of office, upon request of the Directors or any general
                                            meeting of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Record
                                            dates</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
                                            to the extent of any conflicting rights attached to Shares, the resolution declaring a dividend
                                            on Shares of any class, whether it be an Ordinary Resolution of the Members or a Director&rsquo;s
                                            resolution, may specify that the dividend is payable or distributable to the persons registered
                                            as the holders of those Shares at the close of business on a particular date, notwithstanding
                                            that the date may be a date prior to that on which the resolution is passed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the resolution does so specify, the dividend shall be payable or distributable to the persons
                                            registered as the holders of those Shares at the close of business on the specified date
                                            in accordance with their respective holdings so registered, but without prejudice to the
                                            rights <I>inter se</I> in respect of the dividend of transferors and transferees of any of
                                            those Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            provisions of this Article apply, <I>mutatis mutandis</I>, to bonuses, capitalisation issues,
                                            distributions of realised capital profits or offers or grants made by the Company to the
                                            Members.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>23</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividends</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Source
of dividends</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
                                            may be declared and paid out of any funds of the Company lawfully available for distribution.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the requirements of the Law regarding the application of a company&rsquo;s Share premium
                                            account and with the sanction of an Ordinary Resolution, dividends may also be declared and
                                            paid out of any share premium account.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Declaration
of dividends by Members</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the provisions of the Law, the Company may by Ordinary Resolution declare dividends in
                                            accordance with the respective rights of the Members but no dividend shall exceed the amount
                                            recommended by the Directors.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
of interim dividends and declaration of final dividends by Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors may declare and pay interim dividends or recommend final dividends in accordance
                                            with the respective rights of the Members if it appears to them that they are justified by
                                            the financial position of the Company and that such dividends may lawfully be paid.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the provisions of the Law, in relation to the distinction between interim dividends and
                                            final dividends, the following applies:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
                                            determination to pay a dividend or dividends described as interim by the Directors in the
                                            dividend resolution, no debt shall be created by the declaration until such time as payment
                                            is made.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
                                            declaration of a dividend or dividends described as final by the Directors in the dividend
                                            resolution, a debt shall be created immediately following the declaration, the due date to
                                            be the date the dividend is stated to be payable in the resolution.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the resolution fails to specify whether a dividend is final or interim, it shall be assumed to be interim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            relation to Shares carrying differing rights to dividends or rights to dividends at a fixed
                                            rate, the following applies:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the share capital is divided into different classes, the Directors may pay dividends on Shares
                                            which confer deferred or non-preferred rights with regard to dividends as well as on Shares
                                            which confer preferential rights with regard to dividends but no dividend shall be paid on
                                            Shares carrying deferred or non-preferred rights if, at the time of payment, any preferential
                                            dividend is in arrears.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors may also pay, at intervals settled by them, any dividend payable at a fixed rate
                                            if it appears to them that there are sufficient funds of the Company lawfully available for
                                            distribution to justify the payment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the Directors act in good faith, they shall not incur any liability to the Members holding
                                            Shares conferring preferred rights for any loss those Members may suffer by the lawful payment
                                            of the dividend on any Shares having deferred or non-preferred rights.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apportionment
of dividends</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
                                            as otherwise provided by the rights attached to Shares all dividends shall be declared and
                                            paid according to the amounts Paid Up on the Shares on which the dividend is paid. All dividends
                                            shall be apportioned and paid proportionately to the amount Paid Up on the Shares during
                                            the time or part of the time in respect of which the dividend is paid. But if a Share is
                                            issued on terms providing that it shall rank for dividend as from a particular date, that
                                            Share shall rank for dividend accordingly.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
of set off</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors may deduct from a dividend or any other amount payable to a person in respect of
                                            a Share any amount due by that person to the Company on a call or otherwise in relation to
                                            a Share.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
to pay other than in cash</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the Directors so determine, any resolution declaring a dividend may direct that it shall
                                            be satisfied wholly or partly by the distribution of assets. If a difficulty arises in relation
                                            to the distribution, the Directors may settle that difficulty in any way they consider appropriate.
                                            For example, they may do any one or more of the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
                                            fractional Shares;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fix
                                            the value of assets for distribution and make cash payments to some Members on the footing
                                            of the value so fixed in order to adjust the rights of Members; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vest
                                            some assets in trustees.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">How
payments may be made</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            dividend or other monies payable on or in respect of a Share may be paid in any of the following
                                            ways:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Member holding that Share or other person entitled to that Share nominates a bank account
                                            for that purpose - by wire transfer to that bank account; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            cheque or warrant sent by post to the registered address of the Member holding that Share
                                            or other person entitled to that Share.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the purposes of Article 23.10(a), the nomination may be in writing or in an Electronic Record
                                            and the bank account nominated may be the bank account of another person. For the purposes
                                            of Article 23.10(b), subject to any applicable law or regulation, the cheque or warrant shall
                                            be made to the order of the Member holding that Share or other person entitled to the Share
                                            or to his nominee, whether nominated in writing or in an Electronic Record, and payment of
                                            the cheque or warrant shall be a good discharge to the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            two or more persons are registered as the holders of the Share or are jointly entitled to
                                            it by reason of the death or bankruptcy of the registered holder (<B>Joint Holders</B>),
                                            a dividend (or other amount) payable on or in respect of that Share may be paid as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            the registered address of the Joint Holder of the Share who is named first on the register
                                            of Members or to the registered address of the deceased or bankrupt holder, as the case may
                                            be; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            the address or bank account of another person nominated by the Joint Holders, whether that
                                            nomination is in writing or in an Electronic Record.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            Joint Holder of a Share may give a valid receipt for a dividend (or other amount) payable
                                            in respect of that Share.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
or other monies not to bear interest in absence of special rights</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
                                            provided for by the rights attached to a Share, no dividend or other monies payable by the
                                            Company in respect of a Share shall bear interest.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
unable to be paid or unclaimed</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            a dividend cannot be paid to a Member or remains unclaimed within six weeks after it was
                                            declared or both, the Directors may pay it into a separate account in the Company&rsquo;s
                                            name. If a dividend is paid into a separate account, the Company shall not be constituted
                                            trustee in respect of that account and the dividend shall remain a debt due to the Member.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.16</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            dividend that remains unclaimed for a period of six years after it became due for payment
                                            shall be forfeited to, and shall cease to remain owing by, the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>24</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capitalisation
                                            of profits</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalisation
of profits or of any share premium account or capital redemption reserve;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors may resolve to capitalise:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            part of the Company&rsquo;s profits not required for paying any preferential dividend (whether
                                            or not those profits are available for distribution); or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            sum standing to the credit of the Company&rsquo;s share premium account or capital redemption reserve,
                                            if any.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            amount resolved to be capitalised must be appropriated to the Members who would have been
                                            entitled to it had it been distributed by way of dividend and in the same proportions. The
                                            benefit to each Member so entitled must be given in either or both of the following ways::</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            paying up the amounts unpaid on that Member&rsquo;s Shares;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            issuing Fully Paid Up Shares, debentures or other securities of the Company to that Member
                                            or as that Member directs. The Directors may resolve that any Shares issued to the Member
                                            in respect of Partly Paid Up Shares (<B>Original Shares</B>) rank for dividend only to the
                                            extent that the Original Shares rank for dividend while those Original Shares remain Partly
                                            Paid Up.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applying
an amount for the benefit of Members</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            amount capitalised must be applied to the benefit of Members in the proportions to which
                                            the Members would have been entitled to dividends if the amount capitalised had been distributed
                                            as a dividend.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the Law, if a fraction of a Share, a debenture or other security is allocated to a Member,
                                            the Directors may issue a fractional certificate to that Member or pay him the cash equivalent
                                            of the fraction.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>25</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
                                            Premium Account</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
to maintain share premium account</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors shall establish a share premium account in accordance with the Law. They shall
                                            carry to the credit of that account from time to time an amount equal to the amount or value
                                            of the premium paid on the issue of any Share or capital contributed or such other amounts
                                            required by the Law.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debits
to share premium account</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            following amounts shall be debited to any share premium account:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
                                            the redemption or purchase of a Share, the difference between the nominal value of that Share
                                            and the redemption or purchase price; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            other amount paid out of a share premium account as permitted by the Law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
                                            the preceding Article, on the redemption or purchase of a Share, the Directors may pay the
                                            difference between the nominal value of that Share and the redemption purchase price out
                                            of the profits of the Company or, as permitted by the Law, out of capital.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>26</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Seal</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
seal</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company may have a seal if the Directors so determine.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duplicate
seal</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the provisions of the Law, the Company may also have a duplicate seal or seals for use
                                            in any place or places outside the Cayman Islands. Each duplicate seal shall be a facsimile
                                            of the original seal of the Company. However, if the Directors so determine, a duplicate
                                            seal shall have added on its face the name of the place where it is to be used.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
and how seal is to be used</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            seal may only be used by the authority of the Directors. Unless the Directors otherwise determine,
                                            a document to which a seal is affixed must be signed in one of the following ways:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            a Director (or his alternate) and the Secretary; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            a single Director (or his alternate).</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
no seal is adopted or used</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the Directors do not adopt a seal, or a seal is not used, a document may be executed in the
                                            following manner:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            a Director (or his alternate) and the Secretary; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            a single Director (or his alternate); or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            any other manner permitted by the Law.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
to allow non-manual signatures and facsimile printing of seal</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors may determine that either or both of the following applies:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                            the seal or a duplicate seal need not be affixed manually but may be affixed by some other
                                            method or system of reproduction;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                            a signature required by these Articles need not be manual but may be a mechanical or Electronic
                                            Signature.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Validity
of execution</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            a document is duly executed and delivered by or on behalf of the Company, it shall not be
                                            regarded as invalid merely because, at the date of the delivery, the Secretary, or the Director,
                                            or other Officer or person who signed the document or affixed the seal for and on behalf
                                            of the Company ceased to be the Secretary or hold that office and authority on behalf of
                                            the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>27</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnity</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            the extent permitted by law, the Company shall indemnify each existing or former Director
                                            (including alternate Director), Secretary and other Officer of the Company (including an
                                            investment adviser or an administrator or liquidator) and their personal representatives
                                            against:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or
                                            sustained by the existing or former Director (including alternate Director), Secretary or
                                            Officer in or about the conduct of the Company&rsquo;s business or affairs or in the execution
                                            or discharge of the existing or former Director&rsquo;s (including alternate Director&rsquo;s), Secretary&rsquo;s
                                            or Officer&rsquo;s duties, powers, authorities or discretions; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">without
                                            limitation to paragraph (a), all costs, expenses, losses or liabilities incurred by the existing
                                            or former Director (including alternate Director), Secretary or Officer in defending (whether
                                            successfully or otherwise) any civil, criminal, administrative or investigative proceedings
                                            (whether threatened, pending or completed) concerning the Company or its affairs in any court
                                            or tribunal, whether in the Cayman Islands or elsewhere.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
such existing or former Director (including alternate Director), Secretary or Officer, however, shall be indemnified in respect of any
matter arising out of his own dishonesty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            the extent permitted by Law, the Company may make a payment, or agree to make a payment,
                                            whether by way of advance, loan or otherwise, for any legal costs incurred by an existing
                                            or former Director (including alternate Director), Secretary or Officer of the Company in
                                            respect of any matter identified in Article 27.1 on condition that the Director (including
                                            alternate Director), Secretary or Officer must repay the amount paid by the Company to the
                                            extent that it is ultimately found not liable to indemnify the Director (including alternate
                                            Director), Secretary or that Officer for those legal costs.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Release</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            the extent permitted by Law, the Company may by Special Resolution release any existing or
                                            former Director (including alternate Director), Secretary or other Officer of the Company
                                            from liability for any loss or damage or right to compensation which may arise out of or
                                            in connection with the execution or discharge of the duties, powers, authorities or discretions
                                            of his office; but there may be no release from liability arising out of or in connection
                                            with that person&rsquo;s own dishonesty.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            the extent permitted by Law, the Company may pay, or agree to pay, a premium in respect of
                                            a contract insuring each of the following persons against risks determined by the Directors,
                                            other than liability arising out of that person&rsquo;s own dishonesty:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            existing or former Director (including alternate Director), Secretary or Officer or auditor
                                            of:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            company which is or was a subsidiary of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            company in which the Company has or had an interest (whether direct or indirect); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            trustee of an employee or retirement benefits scheme or other trust in which any of the persons
                                            referred to in paragraph (a) is or was interested.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>28</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notices</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of notices</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Save
                                            where these Articles provide otherwise, and subject to the Designated Stock Exchange Rules,
                                            any notice to be given to or by any person pursuant to these Articles shall be:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            writing signed by or on behalf of the giver in the manner set out below for written notices;
                                            or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
                                            to the next Article, in an Electronic Record signed by or on behalf of the giver by Electronic
                                            Signature and authenticated in accordance with Articles about authentication of Electronic
                                            Records; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
                                            these Articles expressly permit, by the Company by means of a website.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electronic
communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            notice may only be given to the Company in an Electronic Record if:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Directors so resolve;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            resolution states how an Electronic Record may be given and, if applicable, specifies an
                                            email address for the Company; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            terms of that resolution are notified to the Members for the time being and, if applicable,
                                            to those Directors who were absent from the meeting at which the resolution was passed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the resolution is revoked or varied, the revocation or variation shall only become effective when its terms have been similarly notified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            notice may not be given by Electronic Record to a person other than the Company unless the
                                            recipient has notified the giver of an Electronic address to which notice may be sent.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the Law, the Designated Stock Exchange Rules and to any other rules which the Company
                                            is bound to follow, the Company may also send any notice or other document pursuant to these
                                            Articles to a Member by publishing that notice or other document on a website where:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company and the Member have agreed to his having access to the notice or document on a website
                                            (instead of it being sent to him);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            notice or document is one to which that agreement applies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Member is notified (in accordance with any requirements laid down by the Law and, in a manner
                                            for the time being agreed between him and the Company for the purpose) of:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            publication of the notice or document on a website;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            address of that website; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70.9pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            place on that website where the notice or document may be accessed, and how it may be accessed;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            notice or document is published on that website throughout the publication period, provided
                                            that, if the notice or document is published on that website for a part, but not all of,
                                            the publication period, the notice or document shall be treated as being published throughout
                                            that period if the failure to publish that notice of document throughout that period is wholly
                                            attributable to circumstances which it would not be reasonable to have expected the Company
                                            to prevent or avoid. For the purposes of this Article 28.4 &ldquo;publication period&rdquo;
                                            means a period of not less than twenty-one days, beginning on the day on which the notification
                                            referred to in Article 28.4(c) is deemed sent.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persons
entitled to notices</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            notice or other document to be given to a Member may be given by reference to the register
                                            of Members as it stands at any time within the period of twenty-one days before the day that
                                            the notice is given or (where and as applicable) within any other period permitted by, or
                                            in accordance with the requirements of, (to the extent applicable) the Designated Stock Exchange
                                            Rules and/or the Designated Stock Exchanges. No change in the register of Members after that
                                            time shall invalidate the giving of such notice or document or require the Company to give
                                            such item to any other person.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persons
authorised to give notices</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            notice by either the Company or a Member pursuant to these Articles may be given on behalf
                                            of the Company or a Member by a Director or company secretary of the Company or a Member.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery
of written notices</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Save
                                            where these Articles provide otherwise, a notice in writing may be given personally to the
                                            recipient, or left at (as appropriate) the Member&rsquo;s or Director&rsquo;s registered
                                            address or the Company&rsquo;s registered office, or posted to that registered address or
                                            registered office.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint
holders</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
                                            Members are joint holders of a Share, all notices shall be given to the Member whose name
                                            first appears in the register of Members.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signatures</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            written notice shall be signed when it is autographed by or on behalf of the giver, or is
                                            marked in such a way as to indicate its execution or adoption by the giver.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
                                            Electronic Record may be signed by an Electronic Signature.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Evidence
of transmission</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            notice given by Electronic Record shall be deemed sent if an Electronic Record is kept demonstrating
                                            the time, date and content of the transmission, and if no notification of failure to transmit
                                            is received by the giver.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            notice given in writing shall be deemed sent if the giver can provide proof that the envelope
                                            containing the notice was properly addressed, pre-paid and posted, or that the written notice
                                            was otherwise properly transmitted to the recipient.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Member present, either in person or by proxy, at any meeting of the Company or of the holders
                                            of any class of Shares shall be deemed to have received due notice of the meeting and, where
                                            requisite, of the purposes for which it was called.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Giving
notice to a deceased or bankrupt Member</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            notice may be given by the Company to the persons entitled to a Share in consequence of the
                                            death or bankruptcy of a Member by sending or delivering it, in any manner authorised by
                                            these Articles for the giving of notice to a Member, addressed to them by name, or by the
                                            title of representatives of the deceased, or trustee of the bankrupt or by any like description,
                                            at the address, if any, supplied for that purpose by the persons claiming to be so entitled.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
                                            such an address has been supplied, a notice may be given in any manner in which it might
                                            have been given if the death or bankruptcy had not occurred.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of giving notices</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.16</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            notice is given on the date identified in the following table</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; padding-right: 0; padding-left: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;Method
for giving notices</B></FONT></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>When
    taken to be given</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
    Personally</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    the time and date of delivery</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
    By leaving it at the Member&rsquo;s registered address</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    the time and date it was left</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)
    By posting it by prepaid post to the street or postal address of that recipient</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48
    hours after the date it was posted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(D)
    By Electronic Record (other than publication on a website), to recipient&rsquo;s Electronic address</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48
    hours after the date it was sent</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(E)
    By publication on a website</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24
    hours after the date on which the Member is deemed to have been notified of the publication of the notice or document on the website</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saving
provision</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
                                            of the preceding notice provisions shall derogate from the Articles about the delivery of
                                            written resolutions of Directors and written resolutions of Members.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>29</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authentication
                                            of Electronic Records</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Application
of Articles</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
                                            limitation to any other provision of these Articles, any notice, written resolution or other
                                            document under these Articles that is sent by Electronic means by a Member, or by the Secretary,
                                            or by a Director or other Officer of the Company, shall be deemed to be authentic if either
                                            Article 29.2 or Article 29.4 applies.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authentication
of documents sent by Members by Electronic means</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
                                            Electronic Record of a notice, written resolution or other document sent by Electronic means
                                            by or on behalf of one or more Members shall be deemed to be authentic if the following conditions
                                            are satisfied:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Member or each Member, as the case may be, signed the original document, and for this purpose
                                            <B>Original Document</B> includes several documents in like form signed by one or more of
                                            those Members; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Electronic Record of the Original Document was sent by Electronic means by, or at the direction
                                            of, that Member to an address specified in accordance with these Articles for the purpose
                                            for which it was sent; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
                                            29.7 does not apply.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            example, where a sole Member signs a resolution and sends the Electronic Record of the original
                                            resolution, or causes it to be sent, by facsimile transmission to the address in these Articles
                                            specified for that purpose, the facsimile copy shall be deemed to be the written resolution
                                            of that Member unless Article 28.7 applies.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authentication
of document sent by the Secretary or Officers of the Company by Electronic means</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
                                            Electronic Record of a notice, written resolution or other document sent by or on behalf
                                            of the Secretary or an Officer or Officers of the Company shall be deemed to be authentic
                                            if the following conditions are satisfied:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Secretary or the Officer or each Officer, as the case may be, signed the original document,
                                            and for this purpose <B>Original Document</B> includes several documents in like form signed
                                            by the Secretary or one or more of those Officers; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Electronic Record of the Original Document was sent by Electronic means by, or at the direction
                                            of, the Secretary or that Officer to an address specified in accordance with these Articles
                                            for the purpose for which it was sent; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
                                            29.7 does not apply.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Article 29.4 applies whether the document is sent by or on behalf of the Secretary or Officer in his own right or as a representative
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            example, where a sole Director signs a resolution and scans the resolution, or causes it
                                            to be scanned, as a PDF version which is attached to an email sent to the address in these
                                            Articles specified for that purpose, the PDF version shall be deemed to be the written resolution
                                            of that Director unless Article 29.7 applies.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manner
of signing</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the purposes of these Articles about the authentication of Electronic Records, a document
                                            will be taken to be signed if it is signed manually or in any other manner permitted by these
                                            Articles.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saving
provision</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            notice, written resolution or other document under these Articles will not be deemed to be
                                            authentic if the recipient, acting reasonably:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">believes
                                            that the signature of the signatory has been altered after the signatory had signed the original
                                            document; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">believes
                                            that the original document, or the Electronic Record of it, was altered, without the approval
                                            of the signatory, after the signatory signed the original document; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">otherwise
                                            doubts the authenticity of the Electronic Record of the document</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
the recipient promptly gives notice to the sender setting the grounds of its objection. If the recipient invokes this Article, the sender
may seek to establish the authenticity of the Electronic Record in any way the sender thinks fit.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>30</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
                                            by way of continuation</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company may, by Special Resolution, resolve to be registered by way of continuation in a
                                            jurisdiction outside:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Cayman Islands; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            other jurisdiction in which it is, for the time being, incorporated, registered or existing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            give effect to any resolution made pursuant to the preceding Article, the Directors may cause
                                            the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            application be made to the Registrar of Companies of the Cayman Islands to deregister the
                                            Company in the Cayman Islands or in the other jurisdiction in which it is for the time being
                                            incorporated, registered or existing; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            such further steps as they consider appropriate to be taken to effect the transfer by way
                                            of continuation of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>31</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Winding
                                            up</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution
of assets in specie</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the Company is wound up the Members may, subject to these Articles and any other sanction
                                            required by the Law, pass a Special Resolution allowing the liquidator to do either or both
                                            of the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            divide in specie among the Members the whole or any part of the assets of the Company and,
                                            for that purpose, to value any assets and to determine how the division shall be carried
                                            out as between the Members or different classes of Members; and/or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            vest the whole or any part of the assets in trustees for the benefit of Members and those
                                            liable to contribute to the winding up.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><BR> <BR> <BR> <BR> <BR> <BR> <BR> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --><BR> <BR> <BR> <I>www.verify.gov.ky File#: 293256</I></TD><TD STYLE="text-align: right; width: 33%"><IMG SRC="ex3-2_01.jpg" ALT=""><BR> <I>Filed: 04-Jun-2021 09:51 EST<BR> Auth Code: B00676975210</I></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
obligation to accept liability</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            Member shall be compelled to accept any assets if an obligation attaches to them.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors are authorised to present a winding up petition</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Directors have the authority to present a petition for the winding up of the Company to the
                                            Grand Court of the Cayman Islands on behalf of the Company without the sanction of a resolution
                                            passed at a general meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>32</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment
                                            of Memorandum and Articles</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
to change name or amend Memorandum</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the Law, the Company may, by Special Resolution:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">change
                                            its name; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">change
                                            the provisions of its Memorandum with respect to its objects, powers or any other matter
                                            specified in the Memorandum.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
to amend these Articles</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the Law and as provided in these Articles, the Company may, by Special Resolution, amend
                                            these Articles in whole or in part.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 35%; font-size: 10pt; text-align: center">54<BR>
<BR>
<BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif"><I>www.verify.gov.ky File#: 293256</I></FONT></TD>
    <TD STYLE="width: 35%; font-size: 10pt; text-align: right"><IMG SRC="ex3-2_01.jpg" ALT=""><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Filed: 04-Jun-2021 09:51 EST<BR>
Auth Code: B00676975210</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>4
<FILENAME>ea142369ex4-1_regencell.htm
<DESCRIPTION>SPECIMEN CERTIFICATE FOR ORDINARY SHARES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 246.7pt 0pt 248.75pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Share Certificate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; padding-right: 28.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of certificate</FONT></TD>
    <TD STYLE="width: 40%">&nbsp;</TD>
    <TD STYLE="width: 30%; padding-right: 28.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1.5pt solid; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: Black 1.5pt solid; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid; border-right: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid; border-right: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGENCELL BIOSCIENCE HOLDINGS LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>COMPANY
NUMBER [NUMBER]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 207pt 0pt 208.65pt; text-align: center; text-indent: 0.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS SHARE CERTIFICATE CERTIFIES
THAT as of [Transfer date], [Name] of [Address] is the registered holder of [Number] fully paid Ordinary Share(s) of US$0.00001 par value
per share in the above named Company which are held subject to, and transferable in accordance with, the Memorandum and Articles of Association
of the Company (as Revised).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.7pt 0pt 14pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In Witness Whereof the Company has
authorized this certificate to be issued on [Transfer date].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; padding-right: 0; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%; padding-right: 0; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>ea142369ex5-1_regencell.htm
<DESCRIPTION>OPINION OF OGIER REGARDING THE VALIDITY OF THE ORDINARY SHARES BEING REGISTERED
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="5" STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regencell Bioscience Holdings Limited</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sanne Trustees (Cayman) Limited, 3rd Floor, Citrus Grove, 106 Goring
    Avenue, PO Box 492, Grand Cayman KY1-1106, Cayman Islands</P></TD>
    <TD STYLE="width: 10%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>D&nbsp;&nbsp;+1 345 815 1877</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>E&nbsp;&nbsp;bradley.kruger@ogier.com</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference: 427450.00001/BKR/RZD</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11 June 2021</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Sirs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regencell Bioscience Holdings Limited (Company)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have acted as Cayman Islands legal advisers
to the Company in connection with the Company&rsquo;s registration statement on Form F-1, including all amendments or supplements thereto
(the <B>Registration Statement</B>), filed with the Securities and Exchange Commission (the <B>Commission</B>) under the U.S. Securities
Act of 1933, as amended (the <B>Act</B>) to date relating to the offering by the Company of up to 2,645,000 ordinary shares of the Company
of par value US$0.00001 each, including the ordinary shares issuable upon exercise of underwriter&rsquo;s over-allotment option (the <B>Shares</B>)
and the offering of ordinary shares issuable upon exercise of the Underwriter Warrants (as defined in the Registration Statement). This
opinion is given in accordance with the terms of the legal matters section of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless a contrary intention appears, all capitalised
terms used in this opinion have the respective meanings set forth in the Registration Statement. A reference to a Schedule is a reference
to a schedule to this opinion and the headings herein are for convenience only and do not affect the construction of this opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.1pt"></TD><TD STYLE="width: 34.9pt">1</TD><TD STYLE="text-align: justify">Documents examined</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">For the purposes of giving this opinion,
we have examined a copy of the Registration Statement. In addition, we have examined the corporate and other documents and conducted the
searches listed in Schedule 1. We have not made any searches or enquiries concerning, and have not examined any documents entered into
by or affecting the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 55%">
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">{HTFL00098252; 1}&#9;Ogier</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">89 Nexus Way</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Camana Bay</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Grand Cayman, KY1-9009</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cayman Islands</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T +1 345 949 9876</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">F +1 345 949 9877</P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">ogier.com</P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 43%">A list of Partners may be inspected on our website</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 40%; font-size: 10pt; text-align: center"></TD><TD STYLE="width: 30%; font-size: 10pt; text-align: right">BTLG3-11722361-1</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.1pt"></TD><TD STYLE="width: 34.9pt">2</TD><TD STYLE="text-align: justify">Assumptions</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">In giving this opinion we have relied
upon the assumptions set forth in Schedule 2 without having carried out any independent investigation or verification in respect of those
assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.1pt"></TD><TD STYLE="width: 34.9pt">3</TD><TD STYLE="text-align: justify">Opinions</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">On the basis of the examinations and
assumptions referred to above and subject to the qualifications set forth in Schedule 24 and the limitations set forth below, we are of
the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><B>Corporate status</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.65pt"></TD><TD STYLE="width: 34.35pt">(a)</TD><TD STYLE="text-align: justify">The Company has been duly incorporated as an exempted company and is validly existing and in good standing
with the Registrar of Companies of the Cayman Islands (the <B>Registrar</B>).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><B>Issue of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.65pt"></TD><TD STYLE="width: 34.35pt">(b)</TD><TD STYLE="text-align: justify">The issue and allotment of the Shares has been authorised by all requisite corporate action of the Company
and when allotted, issued and paid for as contemplated in the Registration Statement, the Shares will be validly issued and allotted,
fully paid and non-assessable. As a matter of Cayman Islands law, the Shares are only issued when they have been entered into the register
of members of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in"><B>Shares underlying
the Underwriter Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.65pt"></TD><TD STYLE="width: 34.35pt">(c)</TD><TD STYLE="text-align: justify">The ordinary shares issuable upon exercise of the Underwriter Warrants will, when issued and paid for
as contemplated in the Registration Statement, be validly issued as fully paid and non-assessable. As a matter of Cayman Islands law,
such ordinary shares are only issued when they have been entered into the register of members of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><B>Registration Statement &ndash;
&ldquo;Cayman Islands Taxation&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.65pt"></TD><TD STYLE="width: 34.35pt">(d)</TD><TD STYLE="text-align: justify">Insofar as the statements set forth in the Registration Statement under the caption &ldquo;Cayman Islands
Taxation&rdquo; purport to summarise certain tax laws of the Cayman Islands, such statements are accurate in all material respects and
such statements constitute our opinion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 40%; font-size: 10pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 30%; font-size: 10pt; text-align: right">BTLG3-11722361-1</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.1pt"></TD><TD STYLE="width: 34.9pt">4</TD><TD STYLE="text-align: justify">Matters not covered</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">We offer no opinion as to any laws
other than the laws of the Cayman Islands, and we have not, for the purposes of this opinion, made any investigation of the laws of any
other jurisdiction, and we express no opinion as to the meaning, validity, or effect of references in the memorandum and articles of association
of the Company to statutes, rules, regulations, codes or judicial authority of any jurisdiction other than the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.1pt"></TD><TD STYLE="width: 34.9pt">5</TD><TD STYLE="text-align: justify">Governing law of this opinion</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.1pt"></TD><TD STYLE="width: 34.9pt">5.1</TD><TD STYLE="text-align: justify">This opinion is:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.65pt"></TD><TD STYLE="width: 34.35pt">(a)</TD><TD STYLE="text-align: justify">governed by, and shall be construed in accordance with, the laws of the Cayman Islands;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.65pt"></TD><TD STYLE="width: 34.35pt">(b)</TD><TD STYLE="text-align: justify">limited to the matters expressly stated in it; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.65pt"></TD><TD STYLE="width: 34.35pt">(c)</TD><TD STYLE="text-align: justify">confined to, and given on the basis of, the laws and practice in the Cayman Islands at the date of this
opinion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.1pt"></TD><TD STYLE="width: 34.9pt">5.2</TD><TD STYLE="text-align: justify">Unless otherwise indicated, a reference to any specific Cayman Islands legislation is a reference to that
legislation as amended to, and as in force at, the date of this opinion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.1pt"></TD><TD STYLE="width: 34.9pt">6</TD><TD STYLE="text-align: justify">Consent</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">We hereby consent to the filing of
this opinion as an exhibit to the Registration Statement and to the references to our firm in the Registration Statement. In the giving
of our consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or
the Rules and Regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yours faithfully</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ogier</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 40%; font-size: 10pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 30%; font-size: 10pt; text-align: right">BTLG3-11722361-1</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Schedule
1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Documents examined</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Corporate and other documents</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">1</FONT></TD><TD STYLE="text-align: justify">The Certificate of Incorporation of the Company dated 30 October 2014 and the Certificates of Incorporation
on Change of Name of the Company dated 7 July 2015 and 6 June 2017, each such certificate issued by the Registrar.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">2</FONT></TD><TD STYLE="text-align: justify">The amended and restated memorandum and articles or association of the Company adopted by special resolution
passed on 31 May 2021 (the <B>M&amp;A</B>).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">3</FONT></TD><TD STYLE="text-align: justify">A Certificate of Good Standing dated 9 June 2021 (<B>Good Standing Certificate</B>) issued by the
                                                                                                Registrar in respect of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">4</FONT></TD><TD STYLE="text-align: justify">A certificate dated on the date hereof as to certain matters of fact signed by a director of the Company
in the form annexed hereto (the <B>Director&rsquo;s Certificate</B>), having attached to it the written resolutions of the directors of
the Company passed on 4 March 2021 (the <B>Board Resolutions</B>).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 40%; font-size: 10pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 30%; font-size: 10pt; text-align: right">BTLG3-11722361-1</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Schedule
2</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Assumptions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">1</TD><TD STYLE="text-align: justify">All original documents examined by us are authentic and complete.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">2</TD><TD STYLE="text-align: justify">All copy documents examined by us (whether in facsimile, electronic or other form) conform to the originals
and those originals are authentic and complete.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">3</TD><TD STYLE="text-align: justify">All signatures, seals, dates, stamps and markings (whether on original or copy documents) are genuine.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">4</TD><TD STYLE="text-align: justify">Each of the Certificate of Incorporation, the M&amp;A, the Good Standing Certificate, the Director's Certificate
and the Board Resolutions is accurate and complete as at the date of this opinion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">5</TD><TD STYLE="text-align: justify">The M&amp;A is in full force and effect and has not been amended, varied, supplemented or revoked in any
respect.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Status and Authorisation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">6</TD><TD STYLE="text-align: justify">In authorising the issue and allotment of Shares, each director of the Company has acted in good faith
with a view to the best interests of the Company and has exercised the standard of care, diligence and skill that is required of him or
her.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">7</TD><TD STYLE="text-align: justify">Any individuals who sign or have signed documents or give information on which we rely, have the legal
capacity under all relevant laws (including the laws of the Cayman Islands) to sign such documents and give such information.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">8</TD><TD STYLE="text-align: justify">None of the opinions expressed herein will be adversely affected by the laws or public policies of any
jurisdiction other than the Cayman Islands. In particular, but without limitation to the previous sentence, the laws or public policies
of any jurisdiction other than the Cayman Islands will not adversely affect the capacity or authority of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">9</TD><TD STYLE="text-align: justify">There are no agreements, documents or arrangements (other than the documents expressly referred to in
this opinion as having been examined by us) that materially affect or modify the Registration Statement or the transactions contemplated
by it or restrict the powers and authority of the Company in any way.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 40%; font-size: 10pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 30%; font-size: 10pt; text-align: right">BTLG3-11722361-1</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Schedule
3</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Qualifications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good Standing</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">1</TD><TD STYLE="text-align: justify">Under the Companies Act (Revised) (<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Companies
Law</B></FONT>) of the Cayman Islands annual returns in respect of the Company must be filed with the Registrar, together with payment
of annual filing fees. A failure to file annual returns and pay annual filing fees may result in the Company being struck off the Register
of Companies, following which its assets will vest in the Financial Secretary of the Cayman Islands and will be subject to disposition
or retention for the benefit of the public of the Cayman Islands.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">2</TD><TD STYLE="text-align: justify"><B>In good standing</B> means only that as of the date of the Good Standing Certificate the Company is
up-to-date with the filing of its annual returns and payment of annual fees with the Registrar. We have made no enquiries into the Company's
good standing with respect to any filings or payment of fees, or both, that it may be required to make under the laws of the Cayman Islands
other than the Companies Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">3</TD><TD STYLE="text-align: justify">In this opinion the phrase &ldquo;non-assessable&rdquo; means, with respect to Shares, that a member of
the Company shall not, by virtue of its status as a member of the Company, be liable for additional assessments or calls on the Shares
by the Company or its creditors (except in exceptional circumstances, such as involving fraud, the establishment of an agency relationship
or an illegal or improper use or other circumstance in which a court may be prepared to pierce or lift the corporate veil).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt; text-align: center">6</TD>
    <TD STYLE="width: 30%; font-size: 10pt; text-align: right">BTLG3-11722361-1</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>6
<FILENAME>ea142369ex5-2_regencell.htm
<DESCRIPTION>OPINION OF HUNTER TAUBMAN FISCHER & LI LLC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex5-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">June 11, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Regencell Bioscience Holdings Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11/F First Commercial Building</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">33-35 Leighton Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Causeway Bay, Hong Kong</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have acted as U.S. securities counsel to Regencell
Bioscience Holdings Limited, a Cayman Islands exempted company with limited liability (the &ldquo;<B>Company</B>&rdquo;) in connection
with the Registration Statement on Form F-1 (File No. 333-254571) (as amended, the &ldquo;<B>Registration Statement</B>&rdquo;) filed
with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;<B>Securities
Act</B>&rdquo;), for the registration of 2,300,000 ordinary shares, par value $0.00001 per share, up to 345,000 ordinary shares, par value
$0.00001 per share, issuable upon exercise of an over-allotment option granted to the underwriter by the Company, and up to 66,125 ordinary
shares, par value $0.00001 per share, underlying warrants issuable to the underwriter upon exercise of such warrants (the &ldquo;<B>Warrants</B>&rdquo;),
pursuant to the Underwriting Agreement between the Company and the underwriter named therein (the &ldquo;<B>Underwriting Agreement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this opinion letter, we have
examined originals or copies, certified or otherwise identified to our satisfaction, of (i) the Registration Statement; (ii) the most
recent prospectus included in the Registration Statement on file with the Commission as of the date of this opinion letter; (iii) the
form of Underwriting Agreement attached as an exhibit to the Registration Statement; (iv) the form of Warrants attached as an exhibit
to the Registration Statement and (v) the records of corporate actions of the Company relating to the Registration Statement, the Underwriting
Agreement and the Warrants and matters in connection therewith. We have also made such other investigation as we have deemed appropriate.
We have examined and relied upon certificates of public officials and, as to certain matters of fact that are material to our opinion,
we have also relied on certificates of officers of the Company. In our examination, we have assumed the legal capacity of all natural
persons, the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original
documents of all documents submitted to us as certified or photostatic copies and the authenticity of all originals of such latter documents.
In making our examination of the documents executed by the parties, we have assumed that such parties had the power, corporate or other,
to enter into and perform all obligations thereunder and have also assumed the due authorization by all requisite action, corporate or
other, and execution and delivery by such parties of such documents and the validity and binding effect thereof. Except as expressly set
forth herein, we have not undertaken any independent investigation to determine the existence or absence of facts material to the opinions
expressed herein and no inference as to our knowledge concerning such facts should be drawn from the fact that such representation has
been relied upon by us in connection with the preparation and delivery of this opinion letter. As to any facts material to the opinions
expressed herein which were not independently established or verified, we have relied upon oral or written statements and representations
of officers and other representatives of the Company and others, in each case as we have deemed relevant and appropriate. We have not
independently verified the facts so relied on.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion letter is limited to the laws of
the State of New York and United States federal law as in effect on the date hereof. We expressly disclaim any responsibility to advise
of any development or circumstance of any kind, including any change of law or fact that may occur after the date of this opinion letter
that might affect the opinion expressed herein. We express no opinion with respect to the applicability to, or the effect on, the subject
transaction of the laws of any other jurisdiction or as to any matters of municipal law or the laws of any local agencies within any state
other than the State of New York. We express no opinion as to whether the laws of any other jurisdiction are applicable to the subject
matter hereof, and we express no opinion as to compliance with any federal or other state law, rule or regulation relating to securities,
or to the sale or issuance thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">www.htflawyers.com | info@htflawyers.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">800 Third Avenue, Suite
2800, New York, NY 10022 | Office: (212) 530-2210 | Fax: (212) 202-6380</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the foregoing, and having regard to legal
considerations which we deem relevant, and subject to the qualifications, limitations and assumptions set forth herein, we are of the
opinion that when the Warrants are duly executed and authenticated in accordance with the Underwriting Agreement and when issued, delivered
and paid for, as contemplated by the Registration Statement and the Underwriting Agreement, such Warrants will constitute valid and binding
obligations of the Company, enforceable in accordance with their terms, except: (a) as such enforceability may be limited by bankruptcy,
insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally and by general equitable principles (regardless
of whether enforceability is considered in a proceeding in equity or at law), including but not limited to principles limiting the availability
of specific performance and injunctive relief, and concepts of materiality, reasonableness, good faith and fair dealing; (b) as enforceability
of any indemnification or contribution provision may be limited under the federal and state securities laws, and (c) that the remedy of
specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion
of the court before which any proceeding therefor may be brought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We express no opinion as to the enforceability
of (i) provisions that relate to choice of law, forum selection or submission to jurisdiction (including, without limitation, any express
or implied waiver of any objection to venue in any court or of any objection that a court is an inconvenient forum) to the extent that
the validity, binding effect or enforceability of any such provision is to be determined by any court other than a state court of the
State of New York, (ii) waivers by the Company of any statutory or constitutional rights or remedies, or (iii) terms which excuse any
person or entity from liability for, or require the Company to indemnify such person or entity against, such person&rsquo;s or entity&rsquo;s
negligence or willful misconduct. We draw your attention to the fact that, under certain circumstances, the enforceability of terms to
the effect that provisions may not be waived or modified except in writing may be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the filing of this opinion letter
as an exhibit to the Registration Statement, the discussion of this opinion letter in the Registration Statement and to the references
to our firm in the Registration Statement and the Prospectus. In giving this consent, we do not hereby admit that we are in the category
of persons whose consent is required under Section 7 of the Securities Act, or the rules and regulations promulgated thereunder, nor do
we admit that we are experts with respect to any part of the Registration Statement within the meaning of the term &ldquo;expert&rdquo;
as used in the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><IMG SRC="ex5-2_002.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-top: 3pt; text-align: justify">Hunter Taubman Fischer and Li LLC</TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">www.htflawyers.com | info@htflawyers.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">800 Third Avenue, Suite 2800 | Office: (212) 530-2210
| Fax: (212) 202-6380</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>7
<FILENAME>ea142369ex10-11_regencell.htm
<DESCRIPTION>FORM OF DIRECTOR OFFER LETTER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.11</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Regencell Bioscience Holdings Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">11/F First Commercial Building</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">33-35 Leighton Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Causeway Bay, Hong Kong</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">+ 852 2155 0823</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">[&nbsp;&nbsp;&nbsp;&nbsp;], 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Director
Offer Letter</U></B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear [&nbsp;&nbsp;&nbsp;&nbsp;],</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regencell Bioscience Holdings Limited, a Cayman
Islands company (the &ldquo;<B>Company</B>&rdquo;), is pleased to offer you a position as a member of its Board of Directors (the &ldquo;<B>Board</B>&rdquo;).
We believe your background and experience will be a significant asset to the Company and we look forward to your participation on the
Board. Should you choose to accept this position as a member of the Board, this letter agreement (the &ldquo;<B>Agreement</B>&rdquo;)
shall constitute an agreement between you and the Company and contains all the terms and conditions relating to the services you agree
to provide to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1. <U>Term</U>.</B> Your
term as director shall begin upon the effectiveness of the Form S-1 registration statement (File No. 333-254571) in connection with the
Company&rsquo;s initial public offering and continue subject to the provisions in Section 8 below or until your successor is duly elected and
qualified. The position shall be up for re-election each year at the annual shareholder&rsquo;s meeting and upon re-election, the terms
and provisions of this Agreement shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2. <U>Services</U>.</B>
You shall render services as a member of the Board and the Board&rsquo;s committees set forth on <B><U>Schedule A</U></B> attached hereto
(hereinafter your &ldquo;<B>Duties</B>&rdquo;). During the term of this Agreement, you shall attend and participate in such number of
meetings of the Board and of the committee(s) of which you are a member as regularly or specially called. You may attend and participate
at each such meeting via teleconference, video conference or in person. You shall consult with the other members of the Board and committee(s)
as necessary via telephone, electronic mail or other forms of correspondence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3. <U>Compensation</U>.</B>
As compensation for your services to the Company, you will receive compensation as set forth on <B><U>Schedule B</U></B> attached hereto
(hereinafter, the &ldquo;<B>Compensation</B>&rdquo;) per year for serving on the Board during your term as a director, which shall be
paid to you quarterly in arrears as determined by the Company. You shall be reimbursed for reasonable and approved expenses incurred by
you in connection with the performance of your Duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4. <U>No Assignment</U>.</B>
Because of the personal nature of the services to be rendered by you, this Agreement may not be assigned by you without the prior written
consent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5. <U>Confidential Information;
Non-Disclosure</U>.</B> In consideration of your access to certain Confidential Information (as defined below) of the Company, in connection
with your business relationship with the Company, you hereby represent and agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>a. <U>Definition</U>.</B>
For purposes of this Agreement the term &ldquo;Confidential Information&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>i.</B> Any information which the Company
possesses that has been created, discovered or developed by or for the Company, and which has or could have commercial value or utility
in the business in which the Company is engaged; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>ii.</B> Any information which is related
to the business of the Company and is generally not known by non-Company personnel.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>iii.</B> Confidential Information includes,
without limitation, trade secrets and any information concerning services provided by the Company, concepts, ideas, improvements, techniques,
methods, research, data, know-how, software, formats, marketing plans, and analyses, business plans and analyses, strategies, forecasts,
customer and supplier identities, characteristics and agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>b. <U>Exclusions</U>.</B>
Notwithstanding the foregoing, the term Confidential Information shall not include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>i.</B> Any information which becomes
generally available to the public other than as a result of a breach of the confidentiality portions of this Agreement, or any other agreement
requiring confidentiality between the Company and you;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>ii.</B> Information received from a
third party in rightful possession of such information who is not restricted from disclosing such information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>iii.</B> Information known by you
prior to receipt of such information from the Company, which prior knowledge can be documented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>c. <U>Documents</U>.</B> You agree
that, without the express written consent of the Company, you will not remove from the Company&rsquo;s premises, any notes, formulas, programs,
data, records, machines or any other documents or items which in any manner contain or constitute Confidential Information, nor will you
make reproductions or copies of same. You shall promptly return any such documents or items, along with any reproductions or copies, to
the Company upon the earliest of Company&rsquo;s demand, termination of this Agreement, or your termination or Resignation, as defined in Section
8 herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>d. <U>Confidentiality</U>.</B> You
agree that you will hold in trust and confidence all Confidential Information and will not disclose to others, directly or indirectly,
any Confidential Information or anything relating to such information without the prior written consent of the Company, except as maybe
necessary in the course of your business relationship with the Company. You further agree that you will not use any Confidential Information
without the prior written consent of the Company, except as may be necessary in the course of your business relationship with the Company,
and that the provisions of this paragraph (d) shall survive termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>e. <U>Ownership</U>.</B> You agree
that Company shall own all right, title and interest (including patent rights, copyrights, trade secret rights, mask work rights, trademark
rights, and all other intellectual and industrial property rights of any sort throughout the world) relating to any and all inventions
(whether or not patentable), works of authorship, mask works, designations, designs, know-how, ideas and information made or conceived
or reduced to practice, in whole or in part, by you during the term of this Agreement and that arise out of your Duties (collectively,
&ldquo;<B>Inventions&rdquo;</B>) and you will promptly disclose and provide all Inventions to the Company. You agree to assist the Company,
at its expense, to further evidence, record and perfect such assignments, and to perfect, obtain, maintain, enforce, and defend any rights
assigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6. <U>Non-Competition</U></B>.
You agree and undertake that you will not, so long as you are a member of the Board and for a period of 12 months following termination
of this Agreement for whatever reason, directly or indirectly as owner, partner, joint venture, stockholder, employee, broker, agent principal,
corporate officer, director, licensor or in any other capacity whatsoever, engage in, become financially interested in, be employed by,
or have any connection with any business or venture that is engaged in any activities involving services or products which compete, directly
or indirectly, with the services or products provided or proposed to be provided by the Company or its subsidiaries or affiliates; <I><U>provided</U></I>,
<I><U>however</U></I>, that you may own securities of any public corporation which is engaged in such business but in an amount not to
exceed at any one time, one percent of any class of stock or securities of such company, so long as you has no active role in the publicly
owned company as director, employee, consultant or otherwise.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7. <U>Non-Solicitation</U>.</B>
So long as you are a member of the Board and for a period of 12 months thereafter, you shall not directly or indirectly solicit for employment
any individual who was an employee of the Company during your tenure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8. <U>Termination and Resignation</U>.</B>
Your membership on the Board may be terminated for any or no reason by a vote of the stockholders holding at least a majority of the shares
of the Company&rsquo;s issued and outstanding shares entitled to vote. Your membership on the Board or on a Board committee may be terminated
for any or no reason by a majority of the Board at any time, if you have been declared incompetent by an order of a court of competent
jurisdiction or convicted of a felony. You may also terminate your membership on the Board or on a committee for any or no reason by delivering
your written notice of resignation to the Company (&ldquo;<B>Resignation</B>&rdquo;), and such Resignation shall be effective upon the
time specified therein or, if no time is specified, upon receipt of the notice of resignation by the Company. Upon the effective date
of the termination or Resignation, your right to compensation hereunder will terminate subject to the Company&rsquo;s obligations to pay you
any compensation (including the vested portion of the Shares) that you have already earned and to reimburse you for approved expenses
already incurred in connection with your performance of your Duties as of the effective date of such termination or Resignation. Any Shares
that have not vested as of the effective date of such termination or Resignation shall be forfeited and cancelled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9. <U>Governing Law</U>.</B>
All questions with respect to the construction and/or enforcement of this Agreement, and the rights and obligations of the parties hereunder,
shall be determined in accordance with the law of the State of New York applicable to agreements made and to be performed entirely in
the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10. <U>Entire Agreement;
Amendment; Waiver; Counterparts</U>.</B> This Agreement expresses the entire understanding with respect to the subject matter hereof and
supersedes and terminates any prior oral or written agreements with respect to the subject matter hereof. Any term of this Agreement may
be amended and observance of any term of this Agreement may be waived only with the written consent of the parties hereto. Waiver of any
term or condition of this Agreement by any party shall not be construed as a waiver of any subsequent breach or failure of the same term
or condition or waiver of any other term or condition of this Agreement. The failure of any party at any time to require performance by
any other party of any provision of this Agreement shall not affect the right of any such party to require future performance of such
provision or any other provision of this Agreement. This Agreement may be executed in separate counterparts each of which will be an original
and all of which taken together will constitute one and the same agreement, and may be executed using facsimiles of signatures, and a
facsimile of a signature shall be deemed to be the same, and equally enforceable, as an original of such signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11. <U>Indemnification</U></B>.
The Company shall, to the maximum extent provided under applicable law, indemnify and hold you harmless from and against any expenses,
including reasonable attorney&rsquo;s fees, judgments, fines, settlements and other legally permissible amounts (&ldquo;<B>Losses</B>&rdquo;),
incurred in connection with any proceeding arising out of, or related to, your performance of your Duties, other than any such Losses
incurred as a result of your negligence or willful misconduct. The Company shall advance to you any expenses, including reasonable attorneys&rsquo;
fees and costs of settlement, incurred in defending any such proceeding to the maximum extent permitted by applicable law. Such costs
and expenses incurred by you in defense of any such proceeding shall be paid by the Company in advance of the final disposition of such
proceeding promptly upon receipt by the Company of (a) written request for payment; (b) appropriate documentation evidencing the incurrence,
amount and nature of the costs and expenses for which payment is being sought; and (c) an undertaking adequate under applicable law made
by or on your behalf to repay the amounts so advanced if it shall ultimately be determined pursuant to any non-appealable judgment or
settlement that you are not entitled to be indemnified by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12. <U>Not an Employment
Agreement</U>.</B> This Agreement is not an employment agreement, and shall not be construed or interpreted to create any right for you
to continue employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>13. <U>Acknowledgement</U>.</B>
You accept this Agreement subject to all the terms and provisions of this Agreement. You agree to accept as binding, conclusive, and final
all decisions or interpretations of the Board of Directors of the Company of any questions arising under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Agreement has been executed and delivered by the undersigned and
is made effective as of the date set first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGENCELL BIOSCIENCE HOLDINGS LIMITED</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yat-Gai Au</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AGREED AND ACCEPTED:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 39%; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 61%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Schedule A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Director is offered to serve on the following Board committee(s):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 60%; text-align: left"><B>Committee</B></TD><TD STYLE="text-align: center; width: 40%"><B>Title</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audit Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Compensation Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nominating and Corporate Governance Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During your term as a member of Board of Directors
of the Company, you will receive cash compensation in the amount of $[&nbsp;&nbsp;&nbsp;&nbsp;], payable quarterly and [share]/[option] compensation as set forth
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 1pt 4pt; width: 25%; border: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">[Share]/[Options]</FONT></TD>
    <TD STYLE="padding: 1pt 4pt; width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD>
    <TD STYLE="padding: 1pt 4pt; width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercise Price</FONT></TD>
    <TD STYLE="padding: 1pt 4pt; width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Vesting Schedule</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 1pt 4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1pt 4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1pt 4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1pt 4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 1pt 4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1pt 4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1pt 4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1pt 4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 1pt 4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1pt 4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1pt 4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1pt 4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 1pt 4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1pt 4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1pt 4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1pt 4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>8
<FILENAME>ea142369ex10-12_regencell.htm
<DESCRIPTION>FORM OF OPTION AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.12</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AGREEMENT OF </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OPTION TO PURCHASE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ORDINARY SHARE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Regencell
Bioscience Holdings Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>(the
&ldquo;COmpany&rdquo;)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, the Company has approved 2021
Share Option Plan on May 31, 2021, pursuant to which the Chief Executive Officer (&ldquo;<B>CEO</B>&rdquo;) of the Company may grant options
to consultants, employees, and directors (collectively, &ldquo;<B>Service Provider</B>&rdquo;) of the Company with the approval of the
Board of Directors (the &ldquo;<B>Board</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, the Chairman of the Board of Directors
(the &ldquo;<B>Chairman</B>&rdquo;) may grant options to directors (the &ldquo;<B>Directors</B>&rdquo;) of the Company with the approval
of the Board of Directors (the &ldquo;<B>Board</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOW, THEREFORE,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DATE OF GRANT (&ldquo;<B>Grant Date</B>&rdquo;): [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EXPIRATION DATE: Ten years from the date that the Options become vested
in accordance with the Vesting Schedule set forth in <B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regencell Bioscience Holdings Limited, hereby grants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>[NAME OF THE INDIVIDUAL]</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(the &ldquo;<B>Optionee</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">an opportunity to purchase Company&rsquo;s ordinary
shares, par value of $0.00001 per share (&ldquo;<B>Ordinary Share</B>&rdquo;), on the terms and subject to the conditions hereinafter
in connection with the Company&rsquo;s 2021 Share Option Plan (the &ldquo;<B>Plan</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company's board of directors, referred to
as the Board, has determined that it would be to the advantage and best interests of the Company and its shareholders to grant the options
provided for in this agreement to the Optionee in recognition of services rendered by the Optionee to the Company and to give the Optionee
additional incentive in furthering the business success of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now, therefore, in consideration of the promises
and the mutual covenants contained in this agreement, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. <B><U>Grant
of Options</U>.</B> The Company hereby grants to the Optionee&rsquo;s compensation, [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] options (hereinafter each called the &ldquo;<B>Option</B>&rdquo;
or collectively the &ldquo;<B>Options</B>&rdquo;), each Option to purchase one Ordinary Share of the Company (collectively, the &ldquo;<B>Option
Shares</B>&rdquo;), such number being subject to adjustment as provided in Section 9 hereof) on the terms and conditions set forth herein
and in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. <B><U>Exercise
Price</U>.</B> The Exercise Price of the Option Shares shall be the (US$9.50 ) per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. <B><U>Term
of Options</U>.</B> Except as provided in paragraphs 8 and 9 hereof, the term of the Options shall be ten (10) years from the date that
the Options become vested in accordance with the Vesting Schedule (defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. <B><U>Vesting.</U></B>
The Options shall vest according to the vesting conditions set forth in <B><U>Exhibit A</U></B> (the &ldquo;<B>Vesting Schedule</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5. <B><U>Exercise
of Options</U>.</B> The Options or such portion of them as is applicable, may be exercised beginning on the date on which they vest. Except
as herein after provided, the Options may not be exercised at any time unless the Optionee shall have been a Service Provider of the Company
on the date of the exercise of the Option; provided, however, that Optionee shall have twelve (12) months from the date of the Optionee&rsquo;s
termination of consultancy, termination of employment, or termination of directorship, or in which to exercise the unexercised Options
provided such Options are vested at the time of the termination. The Optionee shall not have any rights of a shareholder with respect
to the Option Shares except to the extent that one or more certificates for such shares shall be delivered to him or her upon the due
exercise of the Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6. <B><U>Transferability</U>.</B>
The Options shall be transferable; provided, however, that the transferee must agree in writing to be bound by the terms of the Options
and the Plan at the time of the transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7. <B><U>Death
of Optionee and Transfer of Options</U>.</B> If the Optionee shall die while in his or her period of being a Service Provider of the Company
or a subsidiary or within a period of twelve (12) months after the termination of his or her employment, consultancy, or directorship
with the Company and all subsidiaries, and shall not have fully exercised the Options, such Options may be exercised to the extent that
the Optionee&rsquo;s right to exercise such Options have been accrued pursuant to the terms of the Options at the time of his or her death
and had not been previously exercised, at any time within twelve (12) months after the Optionee&rsquo;s death, by the executors or administrators
of the Optionee or by any person or persons who shall have acquired the Options directly from the Optionee by bequest or inheritance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8. <B><U>Changes
in Capital Structure</U>. </B> If all or any portion of the Options shall be exercised subsequent to any share dividend, share split-up,
recapitalization, reclassification, merger, consolidation, combination or exchange of shares, separation, reorganization, or liquidation
occurring after the date hereof, as a result of which Ordinary Shares shall be changed into the same or a different number of shares of
the same or another class of classes, the person or persons so exercising the Options shall receive, for the aggregate price paid upon
such exercise, the aggregate number and class of shares which, as if Ordinary Shares (as authorized at the date hereof) had been purchased
at the date hereof for the same aggregate price (on the basis of price per share set forth in Section 2 hereof) and had not been disposed
of, such person or persons would be holding at the time of such exercise as a result of such purchase and all such share dividends, share
split-ups, recapitalization, mergers, consolidations, combinations or exchanges of shares, separations, reorganizations or liquidations;
provided, however, that no fractional share shall be issued upon any such exercise, and any aggregate price paid shall be appropriately
reduced on account of any fractional share not issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9. <B><U>Method
of Exercising Options</U>.</B> Subject to the terms and conditions of this agreement, the Options may be exercised by a duly executed
copy of Notice of Exercise Form annexed hereto (&ldquo;<B>Notice of Exercise Form</B>&rdquo;) to the Company&rsquo;s Option Administer
presented any time prior to the termination of the Options. The exercise date will be the date of the Notice of Exercise Form to the Option
Administer. Such notice shall state the election to exercise the Options and the number of shares in respect of which it is being exercised
and shall be signed by the person or persons so exercising the Options. The Company shall have received payment of an amount of consideration
equal to the Exercise Price in effect on the date of such exercise multiplied by the number of Option Shares with respect to which the
Options are then being exercised, payable at the Optionee&rsquo;s election by certified or official bank check or money order payable
to the order of the Company. If someone other than the Optionee is exercising the Options pursuant to the provisions providing for the
contingency of death of the Optionee, such notice shall be accompanied by the appropriate proof of right of such person or persons to
exercise the Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10. <B><U>Restrictions
on Issuance of Shares</U>.</B> The Company shall at all times during the term of the Options reserve and keep available such number of
Ordinary Shares as will be sufficient to satisfy the requirements of the Options. The Company shall pay all original issue and transfer
taxes with respect to the issuance and transfer of shares pursuant thereto and all other fees and expenses necessarily incurred by the
Company in connection therewith; and it will from time to time use its best efforts to comply with all laws and regulations which shall
be applicable thereto. Delivery of these certificates of shares may be deferred by the Company in order to comply with any and all applicable
law, regulation or requirement of any regulatory body. The Company shall not be obligated to sell or issue any shares pursuant to the
Options unless the shares, with respect to which the Options are being exercised are at the time effectively registered or exempt from
registration under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.
<B><U>Options Subject to All of the Plan Terms</U>.</B> This agreement and the Options shall be subject to the Plan, the terms of which
are hereby incorporated herein by reference, and in the event of any conflict or inconsistency between the Plan and this Agreement, shall
be governed by the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12. <B><U>Legends
and Stop-Transfer Orders</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <B>Legends</B>. The Optionee
understands and agrees that the Company shall cause the legends set forth below or legends substantially similar thereto, to be placed
upon any certificate(s) evidencing ownership of the Ordinary Shares acquired upon exercise of the Options together with any other legends
that may be required by state or federal securities laws:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THE SECURITIES REPRESENTED
HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE &ldquo;ACT&rdquo;) OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY
NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT AND SUCH LAWS OR, IN
THE OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION
IS IN COMPLIANCE THEREWITH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <B>Stop-Transfer Notices</B>.
Optionee agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may issue appropriate &ldquo;stop
transfer&rdquo; instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate
notations to the same effect in its own records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) <B>Refusal to Transfer</B>.
The Company shall not be required (i) to transfer on its books any Ordinary Shares that have been sold or otherwise transferred in violation
of any of the provisions of this Agreement or (ii) to treat as owner of such shares or to accord the right to vote or pay dividends to
any purchaser or other transferee to whom such shares shall have been so transferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13. <B><U>Optionee&rsquo;s
Representations</U></B>. If the Ordinary Shares purchasable pursuant to the exercise of this Options have not been registered under the
Securities Act or any applicable state laws at the time the Options are exercised, the Optionee shall, if required by the Company, concurrently
with the exercise of all or any portion of the Options, deliver to the Company his or her Investment Representation Statement in the form
attached hereto as <B><U>Exhibit B</U></B> and shall make such other written representations as are deemed necessary or appropriate by
the Company and/or its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14. <B><U>Governing
Law; Severability</U></B>. The laws of the New York shall govern the interpretation, validity, administration, enforcement and performance
of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15. <B><U>Conformity
to Securities Laws</U></B>. The Optionee acknowledges that the Plan and this Agreement are intended to conform to the extent necessary
with all provisions of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and any and all regulations
and rules promulgated by the U.S. Securities and Exchange Commission thereunder, and U.S. state securities laws and regulations. Notwithstanding
anything herein to the contrary, the Plan shall be administered, and the Options are granted and may be exercised, only in such a manner
as to conform to such laws, rules and regulations. To the extent permitted by applicable law, the Plan and this Agreement shall be deemed
amended to the extent necessary to conform to such laws, rules and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16. <B><U>Amendments,
Suspension and Termination</U></B>. To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise
modified, suspended or terminated at any time or from time to time by the Committee or the Board, provided, that, except as may otherwise
be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall adversely effect the Options in
any material way without the prior written consent of the Optionee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17. <B><U>Disclaimer</U></B>.
The Company will <B><U>not</U></B> advise Optionee as to the tax consequences resulting from the execution of the designated Options.
It is solely the responsibility of the Optionee to consult with the Optionee&rsquo;s tax and/or financial advisors regarding any financial
or tax liabilities that may result due to the execution of the designated Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">[intentionally left blank on
the rest of this page]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0">IN WITNESS WHEREOF, the Company has executed this Option as of the
Date of Grant set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="width: 40%; layout-grid-mode: line"><FONT STYLE="font-size: 10pt"><B>Regencell Bioscience Holdings Limited</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Yat-Gai Au</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 202.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Exhibit
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Vesting
Schedule</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Options shall vest based on the following schedules:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] options shall vest immediately following first year anniversary of the closing of the initial public offering of the Company.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] options shall vest immediately following second year anniversary of the closing of the initial public offering of the Company.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] options shall vest immediately following the third year anniversary of the closing of the initial public offering of the Company.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] options shall vest immediately following the fourth year anniversary of the closing of the initial public offering of the Company.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any unvested Options during the Term of the Options shall expire and
become void on the Expiration Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INVESTMENT REPRESENTATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="width: 0.15in; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; width: 2.25in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-size: 10pt">OPTIONEE</FONT></TD>
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-size: 10pt">:</FONT></TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-size: 10pt">COMPANY</FONT></TD>
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-size: 10pt">:</FONT></TD>
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Regencell Bioscience Holdings Limited</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-size: 10pt">SECURITY</FONT></TD>
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-size: 10pt">:</FONT></TD>
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Ordinary Shares</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-size: 10pt">AMOUNT</FONT></TD>
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-size: 10pt">:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-size: 10pt">DATE</FONT></TD>
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-size: 10pt">:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">In connection with the purchase
of the above-listed ordinary shares (the &ldquo;<U>Securities</U>&rdquo;) of Regencell Bioscience Holdings Limited (the &ldquo;<U>Company</U>&rdquo;),
the undersigned (the &ldquo;<U>Optionee</U>&rdquo;) represents to the Company the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">(a) Optionee is aware of
the Company&rsquo;s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed
and knowledgeable decision to acquire the Securities. Optionee is acquiring these Securities for investment for Optionee&rsquo;s own account
only and not with a view to, or for resale in connection with, any &ldquo;distribution&rdquo; thereof within the meaning of the Securities
Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">(b) Optionee acknowledges
and understands that the Securities constitute &ldquo;restricted securities&rdquo; under the Securities Act and have not been registered
under the Securities Act, in each case, in reliance upon specific exemptions therefrom, which exemptions depend upon, among other things,
the bona fide nature of Optionee&rsquo;s investment intent as expressed herein. Optionee understands that the Securities must be held
indefinitely unless they are subsequently registered under the Securities Act, or an exemption from such registration and qualification
is available. Optionee further acknowledges and understands that the Company is under no obligation to register the Securities. Optionee
understands that the certificate evidencing the Securities will be imprinted with a legend which prohibits the transfer of the Securities
unless they are registered and qualified, or such registration and qualification is not required in the opinion of counsel satisfactory
to the Company. Optionee acknowledges and understands that the California Commissioner of Corporations has made no finding or determination
relating to the fairness for investment of the Securities offered by the Company and that the Commissioner has not and will not recommend
or endorse the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">(c) Optionee is familiar
with the provisions of Rule&nbsp;701 and Rule&nbsp;144, each promulgated under the Securities Act, which, in substance, permit limited
public resale of &ldquo;restricted securities&rdquo; acquired, directly or indirectly from the issuer thereof, in a non-public offering
subject to the satisfaction of certain conditions. Rule&nbsp;701 provides that if the issuer qualifies under Rule&nbsp;701 at the time
of the grant of the Option to Optionee, the exercise will be exempt from registration under the Securities Act. In the event the Company
becomes subject to the reporting requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, ninety (90)&nbsp;days
thereafter (or such longer period as any market stand-off agreement may require) the Securities exempt under Rule&nbsp;701 may be resold,
subject to the satisfaction of certain of the conditions specified by Rule&nbsp;144, including: (1)&nbsp;the resale being made through
a broker in an unsolicited &ldquo;broker&rsquo;s transaction&rdquo; or in transactions directly with&nbsp;a market maker (as said term
is defined under the Securities Exchange Act of 1934); and, in the case of an affiliate, (2)&nbsp;the availability of certain public information
about the Company, (3)&nbsp;the amount of Securities being sold during any three (3)&nbsp;month period not exceeding the limitations specified
in Rule&nbsp;144(e), and (4)&nbsp;the timely filing of a Form 144, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">(d) In the event that the
Company does not qualify under Rule 701 at the time of grant of the Option, then the Securities may be resold in certain limited circumstances
subject to the provisions of Rule 144, which requires (i)&nbsp;the resale to occur not less than six months, or, in the event the Company
is not subject to the reporting requirements of Section&nbsp;13 or 15(d) of the Exchange Act, not less than one year, after the later
of the date the Securities were sold by the Company or the date the Securities were sold by an affiliate of the Company, (ii)&nbsp;in
the case of resales by persons who are not affiliates of the Company (within the meaning of Rule 144), the satisfaction of the conditions
set forth in section (2)&nbsp;of the paragraph immediately above, and (iii)&nbsp;in the case of resales by affiliates of the Company,
the satisfaction of the conditions set forth in sections (1), (2), (3)&nbsp;and (4)&nbsp;of the paragraph immediately above. Optionee
acknowledges that a copy of Rule 144 will be delivered to Optionee upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">(e) Optionee further understands
that in the event all of the applicable requirements of Rule&nbsp;701 or 144 are not satisfied, registration under the Securities Act,
compliance with Regulation A, or some other registration exemption will be required; and that, notwithstanding the fact that Rules 144
and 701 are not exclusive, the Staff of the Securities and Exchange Commission has expressed its opinion that persons proposing to sell
private placement securities other than in a registered offering and otherwise than pursuant to Rules 144 or 701 will have a substantial
burden of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their
respective brokers who participate in such transactions do so at their own risk. Optionee understands that no assurances can be given
that any such other registration exemption will be available in such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">(f) Optionee is a resident
and domiciliary of the state or other jurisdiction hereinafter set forth opposite the Optionee&rsquo;s signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">(g) Optionee understands
and acknowledges that the Company will rely upon the accuracy and truth of the foregoing representations and Optionee hereby consents
to such reliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">IN WITNESS WHEREOF, the undersigned Optionee has
executed this Investment Representation Statement as of  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-size: 10pt; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line; width: 7%"><FONT STYLE="font-size: 10pt">Address:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line; width: 29%">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGENCELL BIOSCIENCE HOLDINGS LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned _______________, pursuant to the
provisions of the Option, hereby elects to purchase __________ Ordinary Shares (the &ldquo;<B>Option Shares</B>&rdquo;) of Regencell Bioscience
Holdings Limited covered by the accompanying Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of Ordinary Shares beneficially owned or
deemed beneficially owned by the Optionee on the date of Exercise: _______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned intends that payment of the Exercise
Price shall be made as cash exercise:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Optionee shall pay the sum of $______________
by certified or official bank check (or via wire transfer) to the Company in accordance with the terms of the Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The certificate(s) representing the Option Shares shall be delivered
by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>certified mail to the designated address, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>certified mail to the prime broker of the Holder at</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse; margin-left: 0.5in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; font-size: 10pt; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line; width: 80%">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Attention:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Tel. No.:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>electronically (DWAC Instructions: ___________________), or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD>other (specify) _____________________________________</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the number of Option Shares shall not be all the Option Shares purchasable
upon exercise of the Option, that a new Option for the balance of the Option Shares purchasable upon exercise of this Option be registered
in the name of the undersigned Optionee or the undersigned&rsquo;s Assignee as below indicated and delivered to the address stated below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note: The signature must correspond with the name of the Optionee
as written on the first page of the Option in every particular, without alteration or enlargement or any change whatever, unless the
Option has been assigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Optionee:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse; margin-left: 0.5in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 25%; font-size: 10pt; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line; width: 75%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Name (please print)&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">National ID</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Email</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Address</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Date</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Assignee:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse; margin-left: 0.5in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 25%; font-size: 10pt; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line; width: 75%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Name (please print)&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">National ID</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Email</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Address</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Date</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; layout-grid-mode: line">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>9
<FILENAME>ea142369ex23-1_regencell.htm
<DESCRIPTION>CONSENT OF FRIEDMAN LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><IMG SRC="image_010.jpg" ALT="" STYLE="height: 44pt; width: 259.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We consent to the inclusion in this Registration
Statement of <FONT STYLE="font-size: 10pt">Regencell Bioscience Holdings Ltd.</FONT> on Form F-1 of our report dated November 13,
2020, except for Note 7, which is dated June 11, 2021, which includes an explanatory paragraph as to the Company&rsquo;s ability to
continue as a going concern, with respect to our audits of consolidated financial statements of <FONT STYLE="font-size: 10pt">Regencell
Bioscience Holdings Ltd.</FONT> and Subsidiaries as of and for the years then ended June 30, 2020 and 2019. We also consent to the
reference to our Firm under the heading &ldquo;Experts&rdquo; in the prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ Friedman LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">New York, New
York</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">June 11, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<IMG SRC="image_008.jpg" ALT=""></P>
<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex3-2_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-2_01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "* (@# 2(  A$! Q$!_\0
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MWX/'BR2X^/ME\/OB9HGP>UGPMX]^./\ :NF:5\0[S]GOQ%XR_9W\ :U+XO\
M"]I\'[>?2K+Q39_#?%^+GQ[^$_[7VF^+_A?;_M"_"'Q7\+_'GQ.^$WB#]D[X
MS6^BZ+9>)?V.?VR/!.H:;X@^%/[._P"UE\)/$EK9>+O"$7Q!\?\ @#49?!D_
MCOPWX$\0_$'1_$'Q)_9B\4KX1\<7_P *=6^*7:_!_P =^)/VKO#/[..D>/\
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M[?%?X>_#S]H#]B;]HNW^%_Q-_8L\)?LVZ?<> ].^*9\0Z?IMYXT^#-A:>%]
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MA>7E_<1V5E D][=7-U*'GGED?L'=(T:21E1$5G=W8*B(H+,S,Q 55 )9B0
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MJ=-DU3_@G5';[3\JW=E\ /B+8:VN -ID/B"VU9IN0PS'N#,S;?W%)"@LQ 4
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M,OVD_@]\"QXB^-O[&_PP\-?#[PI^T?\ $MIK#]G3]GWX6^%/V3%_:"\1^*O
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MIS]BW5-8_:D_X)D>*?&>C6.O^#?'_P %M?\ "?CGX8W/P0\665S;>';.70_
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M$^/+6^G3>'KKP-\+)='T+4(OTC^#WP9^&OP$\!Z7\-OA3X8M_"WA32Y;N\,
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@ZRDMI3;DUZ7TC_V[&/K;0****^=+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P '8# 2(  A$! Q$!_\0
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M .T9/)Q6</%.F&W:8O(,-M"%?F/T% &U169IFNVNJRO' DRL@W'>H''X$T4
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6$D7G^;O;=G9MQQ]36G12 **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex5-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "% 8 # 2(  A$! Q$!_\0
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M;R\D.OZKI6CV][K;6KP:>VH2S&PL[2VV0K]45^=7_!-G_D0OVJO^TC/[??\
MZTIXWK]%: "BBOXW_P#@H=^W7^V7\//^"G'CWX&_#W]I/XD^!OA6/B=\#O"]
MGX3\.-X8AM=*TCQCX<^''_"01Z9<W_AO4+VWGNY]<U.\2>6XN#!=W)DC78B1
M#R<WS>CDU"C7KTJM:-;$0PT8T734E.<7)2DZDHQY5:SM=Z[63/G.)N)<+PO@
M\-C<7AL3BH8K'4<!3AA704XU:\9RA.;KSA!4URVDTW)-IJ+29_9!17QX?V0[
M\$C_ (:U_;(X./\ DK/AO^OP\-)_PR)?_P#1VO[9'_AV?#7_ ,[RNOVV*_Z
MG_X687_Y ]+ZSF'_ $*7_P"'/ ?_ "D^Q**\I^%'PMG^%FG:OI\_Q/\ BQ\4
M#JVH17ZZA\6/$^G^)]1TD16L=J;#1Y]/T'08[33Y2GVF:"2&X=[IWD$JJ1&/
M5JZ8.4HISA[.3WASQGRZO3G@E&6EG=+K;=,[:4JDZ<95:7L:C7O4O:0K<CNU
M;VE-1A.Z2=XI+6VZ8HY('J17S'^QY\;_ !'^T7^S]X5^+GBS2-$T+7=>\3_%
MK0[K3/#OV\:1#;?#_P",/C[X=:5-;C4KF\O//O=)\)V-]J'F7#Q_VC<W?V98
M;;R88_IQ>H^H_G7Y^_\ !+S_ ),I^'/_ &4']I;_ -:A^,U4:=/N_4_0&BBB
M@ HK^.C_ (*,_MZ_ME_"C_@IYXV^#OPW_:*\?^#OA=I_Q$^ 6E6/@C24\-'1
M[73?$_AWX<7?B"SB:]\/W=_Y.K7.K:E-=;[UG#WDODO$NP)_8P>"?J:\K+LW
MH9E7S'#TJ5:G++<3]6JRJ>SY:DU*K'FI\DF^6]*7QI2LUIN?.9'Q+A,]QF>8
M+#8?$T:F18[ZAB)UW1Y*]3FKQYZ'LIRDJ=\/+^*HSM*.F]DHHHKU3Z,****
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M&^(7_95/V9?_ %%?A/7]Y[=3]3_.OBN%?^1EQ3_V-7_Z=QA^4^'?_(^\1/\
MLHW_ .G<R$HHHK[4_5@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /CS_@H5_P F)_M@_P#9N'Q?_P#4(UBOYM_^#:<D?'[]I[!(_P"+,^ O_4VU
M3_$_G7])'_!0K_DQ/]L'_LW#XO\ _J$:Q7\VW_!M/_R7[]I[_LC/@+_U-M4K
MXK-_^2OX:_Z\XG_TK$GY3Q-_R<S@+_L%S#_TK&G]AN3ZG\S2@G(Y/4=SZTVE
M7J/J/YU]J?JQ_!;^PZ2?^"V7A$DY)_:W_:'))ZDX^,')K^]&OX+OV'/^4V7A
M'_L[?]H?^7Q@K^]&OBN"/]SS3_L;XC_TAGY3X3?\BOB'_LJ,P_\ 2&%?!G[%
M'_)1/^"BO_9_.O\ _K*_[*5?>=?!G[%'_)1/^"BO_9_.O_\ K*_[*5?:GZL?
M>=%%% !7\7?_  <J?\G:?!C_ +-?C_\ 5E_$"O[1*_B[_P"#E3_D[3X,?]FO
MQ_\ JR_B!7R7&W_(@K_]A6"_].U#\U\6O^2*Q?\ V,,J_P#4FN?UC_LH_P#)
MK/[-'_9OWP:_]5UX<KWVO OV4?\ DUG]FC_LW[X-?^JZ\.5[[7TV&_W;#?\
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M/4?%J77PKTKP9J6BQ^%]?MO%&FZ7I-OJC^*YXM9&J>'-=E\NPMO[/>TDFGD
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M;5?V=/VR]5:&]U/XE_##5M$^%6F:5\(OV@IX(XC#^TO\,TL9(+KQE';P:/\
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ML?'/]G/]HU]4T=M.":?J>D^#;S4_^%H>%/$?A77_  CK]];_ $Q^VWX=\9>
M_P!H;]A#]N&+PEK_ (K\!?LUWWQU^'?[0_A[P3I&I>,/%G@OX6_M*^!_"NEW
MGQ>T7PWHMK=ZYXKT7X4>/OAWX.E\=V'AS3M2\06_P[UOQ/XKT_2=1C\-W-H_
MZ=O:6DEU#>O:VSWMO')#;WCP1-=00RX,L4-PR&:**7:/,C1U1\#<#BK% [GQ
MSXX_;1^#<OA*.'X$>//!WQ\^+/C.U&G?"OX;_"GQ'HOCG7=<\0ZI&L6FZEK]
MMH=]=IX/\$Z!).NL>-_%_BR31]#\-:%8:C+?70O4MK"Y^8O^"E2>$=6^,?\
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M[&RUR]FD&G:7>W,$%U>1FX@,OZQ!B  ,        <   8  Z"DP#G(!R"IR
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MZNEZ-)GN]-6UNYP#L***\3^./Q/UWX2:3X#\466AZ3J_A;4?BS\._ WQ%O\
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;444 =K1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex5-2_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-2_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ? 4H# 2(  A$! Q$!_\0
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M7BFPU+5/#/@W4->TNS\4>(=-T=X4U6^T30;BYCU/5+73VN(A=S65M,D(8ER
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M[:&2W\MHUP7;W=Q65[V5^Y_,-\(OVZ_B[^Q+\&_VTK_]I_P)X*^$W[5'Q?\
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MEI9K?S_JQ\F?L@^)?V@_''P\USQ!^TKX/L?"WBZQ^(GC+0?!D4^CPZ/XFO/
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M7*K)7=NW?R9\Y?#']DC]G#X/?"GQ%\$_ /PD\*Z3\-/&9U&7QSX<O+>;7O\
MA/+[6+2.RU?5_&^JZ]-J.L>*]9U."&(7>K:W?7=^YCC*31^6@7X^U;_@E%\,
M-6T2[^%DG[0_[6-K^S%?B<7G[+]G\8+F#X<M;2ZDNJ)X?M?$0TL_$JQ\%P7"
MA(O"-MXQ33$@"0(4AC1!^IU%*[WN][_/N.R[=+?+L9FBZ/IWA[1M(\/Z/;FT
MTC0M+L-&TJU:>XNFMM-TNUBLK&W:ZO)9[NY,-K!%&;BZGFN9BOF3S22LSMIT
%44AG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !L ',# 2(  A$! Q$!_\0
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M9\I%A0^A;D_H!^=>?FF)^K86=1;V.O!4O:UE$]*AABM;>.W@0)%$H1%'8 8
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(B@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVD/^@YX:_P#!#!1_P_W_ &D/^@YX:_\ !#!7Q911_J_EO_/B/_@*#_63-?\
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MVD/^@YX:_P#!#!1_P_W_ &D/^@YX:_\ !#!7Q911_J_EO_/B/_@*#_63-?\
MH(G_ .!,^T_^'^_[2'_0<\-?^"&"C_A_O^TA_P!!SPU_X(8*^+**/]7\M_Y\
M1_\  4'^LF:_]!$__ F?:?\ P_W_ &D/^@YX:_\ !#!1_P /]_VD/^@YX:_\
M$,%?%E%'^K^6_P#/B/\ X"@_UDS7_H(G_P"!,^T_^'^_[2'_ $'/#7_@A@H_
MX?[_ +2'_0<\-?\ @A@KXLHH_P!7\M_Y\1_\!0?ZR9K_ -!$_P#P)GVG_P /
M]_VD/^@YX:_\$,%'_#_?]I#_ *#GAK_P0P5\644?ZOY;_P ^(_\ @*#_ %DS
M7_H(G_X$S[3_ .'^_P"TA_T'/#7_ ((8*/\ A_O^TA_T'/#7_@A@KXLHH_U?
MRW_GQ'_P%!_K)FO_ $$3_P# F?:?_#_?]I#_ *#GAK_P0P4?\/\ ?]I#_H.>
M&O\ P0P5\644?ZOY;_SXC_X"@_UDS7_H(G_X$S[3_P"'^_[2'_0<\-?^"&"C
M_A_O^TA_T'/#7_@A@KXLHH_U?RW_ )\1_P# 4'^LF:_]!$__  )GVG_P_P!_
MVD/^@YX:_P#!#!1_P_W_ &D/^@YX:_\ !#!7Q911_J_EO_/B/_@*#_63-?\
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M  _W_:0_Z#GAK_P0P4?\/]_VD/\ H.>&O_!#!7Q911_J_EO_ #XC_P" H/\
M63-?^@B?_@3/M/\ X?[_ +2'_0<\-?\ @A@H_P"'^_[2'_0<\-?^"&"OBRBC
M_5_+?^?$?_ 4'^LF:_\ 01/_ ,"9]I_\/]_VD/\ H.>&O_!#!1_P_P!_VD/^
M@YX:_P#!#!7Q911_J_EO_/B/_@*#_63-?^@B?_@3/M/_ (?[_M(?]!SPU_X(
M8*/^'^_[2'_0<\-?^"&"OBRBC_5_+?\ GQ'_ ,!0?ZR9K_T$3_\  F?:?_#_
M '_:0_Z#GAK_ ,$,%'_#_?\ :0_Z#GAK_P $,%?%E%'^K^6_\^(_^ H/]9,U
M_P"@B?\ X$S[3_X?[_M(?]!SPU_X(8*/^'^_[2'_ $'/#7_@A@KXLHH_U?RW
M_GQ'_P !0?ZR9K_T$3_\"9]I_P##_?\ :0_Z#GAK_P $,%'_  _W_:0_Z#GA
MK_P0P5\644?ZOY;_ ,^(_P#@*#_63-?^@B?_ ($S[3_X?[_M(?\ 0<\-?^"&
M"C_A_O\ M(?]!SPU_P""&"OBRBC_ %?RW_GQ'_P%!_K)FO\ T$3_ / F?:?_
M  _W_:0_Z#GAK_P0P4?\/]_VD/\ H.>&O_!#!7Q911_J_EO_ #XC_P" H/\
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M]!SPU_X(8*/^'^_[2'_0<\-?^"&"OBRBC_5_+?\ GQ'_ ,!0?ZR9K_T$3_\
M F?:?_#_ '_:0_Z#GAK_ ,$,%'_#_?\ :0_Z#GAK_P $,%?%E%'^K^6_\^(_
M^ H/]9,U_P"@B?\ X$S[3_X?[_M(?]!SPU_X(8*/^'^_[2'_ $'/#7_@A@KX
MLHH_U?RW_GQ'_P !0?ZR9K_T$3_\"9]I_P##_?\ :0_Z#GAK_P $,%'_  _W
M_:0_Z#GAK_P0P5\644?ZOY;_ ,^(_P#@*#_63-?^@B?_ ($S[3_X?[_M(?\
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M]!SPU_X(8*/^'^_[2'_0<\-?^"&"OBRBC_5_+?\ GQ'_ ,!0?ZR9K_T$3_\
M F?:?_#_ '_:0_Z#GAK_ ,$,%'_#_?\ :0_Z#GAK_P $,%?%E%'^K^6_\^(_
M^ H/]9,U_P"@B?\ X$S[3_X?[_M(?]!SPU_X(8*/^'^_[2'_ $'/#7_@A@KX
MLHH_U?RW_GQ'_P !0?ZR9K_T$3_\"9]I_P##_?\ :0_Z#GAK_P $,%'_  _W
M_:0_Z#GAK_P0P5\644?ZOY;_ ,^(_P#@*#_63-?^@B?_ ($S[3_X?[_M(?\
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M]!SPU_X(8*/^'^_[2'_0<\-?^"&"OBRBC_5_+?\ GQ'_ ,!0?ZR9K_T$3_\
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MVD/^@YX:_P#!#!1_P_W_ &D/^@YX:_\ !#!7Q911_J_EO_/B/_@*#_63-?\
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MVD/^@YX:_P#!#!1_P_W_ &D/^@YX:_\ !#!7Q911_J_EO_/B/_@*#_63-?\
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M .!,^T_^'^_[2'_0<\-?^"&"C_A_O^TA_P!!SPU_X(8*^+**/]7\M_Y\1_\
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MQ'_P%!_K)FO_ $$3_P# F?:?_#_?]I#_ *#GAK_P0P4?\/\ ?]I#_H.>&O\
MP0P5\644?ZOY;_SXC_X"@_UDS7_H(G_X$S[3_P"'^_[2'_0<\-?^"&"C_A_O
M^TA_T'/#7_@A@KXLHH_U?RW_ )\1_P# 4'^LF:_]!$__  )GVG_P_P!_VD/^
M@YX:_P#!#!1_P_W_ &D/^@YX:_\ !#!7Q911_J_EO_/B/_@*#_63-?\ H(G_
M .!,^T_^'^_[2'_0<\-?^"&"C_A_O^TA_P!!SPU_X(8*^+**/]7\M_Y\1_\
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MQ'_P%!_K)FO_ $$3_P# F?:?_#_?]I#_ *#GAK_P0P4?\/\ ?]I#_H.>&O\
MP0P5\644?ZOY;_SXC_X"@_UDS7_H(G_X$S[3_P"'^_[2'_0<\-?^"&"C_A_O
M^TA_T'/#7_@A@KXLHH_U?RW_ )\1_P# 4'^LF:_]!$__  )GVG_P_P!_VD/^
M@YX:_P#!#!1_P_W_ &D/^@YX:_\ !#!7Q911_J_EO_/B/_@*#_63-?\ H(G_
M .!,^T_^'^_[2'_0<\-?^"&"C_A_O^TA_P!!SPU_X(8*^+**/]7\M_Y\1_\
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MQ'_P%!_K)FO_ $$3_P# F?:?_#_?]I#_ *#GAK_P0P4?\/\ ?]I#_H.>&O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7P=_P '$O\ R8+;_P#8T6'_ *#-7WC7P=_P<2_\
MF"V__8T6'_H,U>MD/_(QI?XD>+Q'_P BVM_A9^&%%%%?T$?S9'8****!A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_M.BO?C_ !$NCZ37KU/C.B@_>., $YP.U%?3'RH4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG6B\/B-*L'9K\FO)[G5G66QH2CB,-K2J:Q?;NGYK8HT445[1X84444 %%%%
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MG"BBB@ HHHH **** "BBB@ HHHH **** "OJ;_@DI^TYX9^ 7[3-MIGCK1]
MU;P7XP:'3[Q]4LH;D:=.'S!.NX$J-QP<@^H[5\LT;/,C;YF7JIV?>&>AKEQV
M$CBJ$J%39K_AON.S XJ>%Q$<1#=._?3T/N;_ (+A_L(P_LS?':'QSX3L8[?P
M)X_9IU2W 6*PU$@&1$ XVR@-)GU<^E?$.E:5=:YJ%O:6$#7MY=.L-M:G_EJ[
M-B*/_OILU^NG_!._XNZ#_P %5/V"?$OP!^(5TA\6>';,)9W9.)I85/\ HUTO
M^W"^V-@,94+_ 'C7FG_!'S_@G-J'P\_:)\8?$CXM65OI.E_!JYGMK=9O]1)J
M$:[WNU_Z9QPE77WDKY3!YY+ X:KA\7K4HZ+^\G\+1]=C,ACC<72Q&#5J5;5]
MH-?$GVMTV/1OBK\/_ __  2%_P""9VEV.J>'?#NO?%SQ:CB&:_L(KF1;^9,2
M.I89588B$R#SL'4<5^1#2M,=[,LCMRS+MP3WQMXQ["OI#]O#]J/Q!_P4I_;*
M^T:+%+=6E[>+H'A2P[10LX57/NY!D/N]?8WB7]G[]F'_ ()(_#_P_#\5?#K_
M !8^)WB" W#6<P^THB@_/Y<;GRD13D9()8@GCOK@<1++:<7B%*IB*SYG&.K_
M !T21GCL,LSK..'<:>'HKE4GHOP3;;W/RIHK]6_A;X2_9'_X*RV>I>%?"?@E
MOA)\0X+66?3!:PQVI<*J@2J(CY;@9Y  (YY)XK\W/C/^SSXC^"'QYU;X:ZI#
MCQ!I.HKIJ)*,><S[/)F'^^DBOGONKV,#G$,1.=&I%TYQ5VI;V[JUT_D>'F&2
M5,-"-:G-5(2=E*-[7[6=FF</17ZS?$#X!?LN?\$A_AEX7C^)7@V3XH?$/Q%!
MYACN8OM0=Q]_8DA\I$!.WH2=N>,U/^SKJW['O_!4+7]1\!Z?\)5^'7BJ2T>Z
MLW@MHK5F5."\30D(<%N1CJ#DYKSWQ/'D=>%";I+[:2MZVO>QZ,>%9<ZP\Z\%
M5?V&W?TO:U_*Y^25%=I^T9\%KC]G?X^>+O \TRW4GA;4Y]/CD;K-$K[4S]4V
MU^I7QI_X)=? 7P?\,OA7\3O%%IIO@?X<^&_#W]H^+O*N)%FUZ>6&U$$!09W;
MG#9"]>G'6N['9[A\*J<IW:J7Y;*_2_KKT.#+^'\3BW5C%J+IVYKNUM;/[C\@
M:*^GO^"F'Q_^!WQO\1^%8_@CX*G\(V7A^"YM]2+:0FGB];C;ED8R-CIEQ].,
M&OF'.?0>P.<?H/Y5Z.$Q$JU)5)0<&[Z/=?=<\W&8>-"LZ4)J:75;/[S[ _X)
M$_\ !.S2?VW?B)KVL>-IWMOA[X)A634H=VW^TG<;@A?^!%";C]#7T#XN_P""
ME?[&_P ._$]QX>T;]G/2?$6CV4CP3:M_8FGO-. V"Z-)NG9<YY)''3C%?)'[
M,7_!27Q3^RO^S5XY^&>B:#X?OM/\>"[%U?7CR+<6WGV?D?(%.#PG>O/_ (-?
ML=?%/]H33EOO!?@'Q1XFTXW+6KWEG9RFV255!V/(WR;>021TSSS7SV)RUU\3
M4JYC4<::MR)3Y5YMV:U/I,)F2P^&IT,LIJ55WYVX<S\DKIZ=S[4_X*6?\$_?
MA7XJ_9(LOVC/@/;K8^&V19]0TJ#,5NT1E,#.L?\ "T<JLK#U!(S7YQ,K*S!B
MS,"<EAR:_6;XU67_  [K_P"")DGPK\;7U@GQ!\:^=';Z3%('\E[B[#D CJ$3
M&3_>X&<$U^2Z',:G&-P!K;ABM5G1J*4G*,9-1D];Q7GU]>ICQ50I4Z].4(*$
MY03E%:)2?ET%HHHKZ0^7"BBB@ HHHH **** "BBB@#M?V=_V@O$G[,'QBT/Q
MOX2N&M]:T&?SL'_5W4)XEMW_ -EUR*^^_P#@I#\!_#__  4&_9TT_P#:B^%%
MNSZM#:I#XOTF _OU,*A3(P_O1*%7MF,*?7'YGU]0?\$M_P!OZZ_8=^-&W59'
MNOAWXJ=;/Q%8L-RQ(PVK=QCNR='']P5X.<8.HI1Q^%_B0Z?S1ZQ?Z'T62YA2
M<99?C/X4_P#R6722_4^7QT_AP>057:I'J!Z'J**^R/\ @KK^P!:_LP_$.S\<
M>"56X^%?Q"Q?:;=0MNBT^>11)Y6>Z299E/HP':OCACD_X=J]3 XRGBZ*KTMG
M^#ZI^AY688"K@Z[P]7=?BNC7J)11174<04444 %%%% !1110 4444 %%%% !
M1110 5Z5^R)\?X_V9OV@- \6W6EZ?KVDV<WE:MIU[:0S1RV3<2.-W/ )Z^E>
M:T5E7HQK4W3GLU8VH5I4:D:D-XNY^HO_  6E_8I\+^//@CX8_:"^%.EZ='H+
M644>KVFF6ZP036<F/)N-B_*#&V%( ';OFOR\*J/,WLK;",X[]2[CZXK]+_\
M@A+^V?I^JV6K?LY^/##<^&_%44[:")ON[Y0WVBT/HKYWK_MLP[URGPF_X(P:
MK:_\%/;KX=ZI;377PW\-LFOB]D/[N\TLO_HUK[NCJ4;_ &D8]*^2RW,?[-57
M!8V7\-.46_M1[>O0^RS+*UF;I8_ K^(U&27V9=7Z=3UK_@G1^S?X)_85_8!\
M0_'OXNZ#I>J:IXFM%NM,L]2LX9I(;0Y-M F\9+3.3*?]AQV!K\O?BA\0KKXL
M?$36O$E[;6-G<ZW=R7;VUE;K;VUMN.1%&B\!$&%'J%![U]G_ /!<_P#;HB^/
M?QI3X;^&+A7\"_#>0P2+#S'J.H( I"^T1W1X]4;UKT;]G_\ 84^"?["'[*^C
M_&3]I*SF\3:QX@ ETKPX8O/CB#@E$$(.)69=KDMPN['-9X'$_5(/'XQ.56L_
M=BM6ET27IN]"\PPJQE19=@N6-*@O>F]%?JV]]]DC\S**_4[X0?'K]BG]NKQK
M%\/=8^#</PWU'7#]GTC4(TBM=\G\(6:W;$4N>BL#[^E?$_\ P42_8BU#]@W]
MHF[\)W-]+JFA7D0O])U*5 C7-JV[*N!_$K*4)_B*Y[U[F"SJ-:O]6JTY4YVN
ME*VJ\FFU^)X&.R.=&A]:H5(U:=[-QOH_--)GA-%?IO\ LT?L7_ G]C/]B'P]
M\=OC]I<WB[4O%<$5Q8Z0\9F@A6;+0HD60'+1[6);@;JV?A%^UU^Q=^U9\1=-
M\!ZE\ K7P;<>()O[.L;X:=;1 NQ^4%X""I/7G.,URRXB3<I4*$YPBVG))6TW
MM=W=O([(\,-*$<17A"<TFHMN^NU[*R/ROHKZ,_X*C?L7V/[$/[5U]X0TF[EN
M/#NHV,6L:6+F3S)T@E<Q%"W?;+&ZCV KZZ_9/_X)??#W]J;_ ();> _%UU9Z
M;X;\17FI75WXC\3S3RK.FFV]_=B55 .T'RT50./4FNG%9_A:&&IXMW<9M)67
M=7_X?S.7"\.XJOBJF#C93@FW?;1I;_._H?ES17VY_P %"/CY^RGKG[/5OX!^
M!O@F2WUS2=1@D3Q*-+B1;VV1)=[?:7D\Z0-VW*.G  Q7Q'G+,0 JLQ8 >A)(
M_2N_ 8N6)I^TE3E#7:6]NYY^88..&J^RA4C/NXZJ_8*]$_97_9J\0?M;?'+0
M_ OAR.1;S5YL3W"?\N%L/];<GZ#*_A7GL%K-?W*0V\3W%Q,5ACAC^_.['"(/
M]IF./I7Z;016_P#P1+_8<6Z?R_\ A?WQ=MSY:G&-$M05R/\ MFI&?5_]WGDS
MC,)4*:I45>K/2*_5^2.S)<MAB:CJXAVI4]9/R[>K9TG_  6M_8_^'_[*/_!/
M_P"'5CX/\,Z#I]]8^*+2REU6.RB2^O@;2[WO)*!O8L>>2< @#  K\HDQL 4,
M HQ\P.>.._-?JO\ \%7KVXU+_@BC^S?<W4YNKFX_L"668_\ +9FT*Y);\22?
MQK\J1TKS>$*E26";JOFESRN_F>EQA"E''+V4>6/)&R[:(****^I/DPHHHH *
M*** "BBB@ HHHH L:7K-YX=U.UU#3[E[&^LYEG@NH_\ 66\B'<CCVSQ7ZF,=
M+_X+G_L1<1VMK\?/A?!RL@PFIH#D ]RDBD$?W9?8FORKKT3]E?\ :;\1?LB?
M&W1_''AMO]*TF0?:+=3N_M&W<X>W(]P":\?-\OE7A&M0TJPUB_\ VU^3/<R7
M,HX>;HUU>E4TDO+NO-'":QI%YX>UB[T_4+>6SOK&=[>X@E_UD+HQ5E?_ &@1
M@^^:K5^D'_!4C]F?P[^U9\%M-_:J^$<2W-CJ$0;Q;IL/WDD4"-IV']^(C:P]
M@>]?F^?0?,J@*#MV[@. <>_6M\MS&.,H^TVDM)+JFMT<V:Y;+!5_9MWB]8OO
M%[,****]$\P**** "BBB@ HHHH **** "BBB@ HHHH *T/"?B>Z\#>*]-UNQ
MCM9;S2[A+NW2ZC62%WC.XHZMPRL/EK/HJ914DXO9E1DXRYH[GZ_?M)? 7P+_
M ,%2O^";VE_$[X6^'](T#QUX522^>RTZRCM9?M*KMNK215[.N67.25*GO7Y
M[=@5?+>$* !$W6( ?<_X#T_"OL#_ ((V_M[S?L<?M%QZ1K%TJ^!?&TT-GJ*-
MTL[ACLBN/H.A]LUZS_P4=_X)'ZO<?M_^'+?P!9K'X4^,5VTRW42[DT2?A[TY
M])5+R9_VSZ5\CE^(_LO$SP&)E^[=Y0;[;M7\C[;,,+_:^%AC\+']XFHS2[[)
MV\R7_@A3^Q%HOB*?7_CI\1K73SX,\)0S1:4NHQ+)!)<!3]HN6# @I%& J_[;
M.>U?(/[<O[16F_M,_M(ZSXD\/:+IOA_PS:O]CT2QLK5+6..TC8A6D"?Q/RY
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?!W_!Q+_P F"V__ &-%A_Z#
M-7WC7P=_P<2_\F"V_P#V-%A_Z#-7K9#_ ,C&E_B1XO$?_(MK?X6?AA1117]!
M'\V1V"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Z*?\
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M7Y5)]Q?H*_56Z_Y5A;/_ *^#_P"I2U?E4GW%^@KY?AG;$_\ 7V9]9Q1OA?\
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MB^(WB'2=3GU+2=.N!.UE/=:>8;:VQG(+QHAY R7.,C!/Y_\ _!(;P!KOPO\
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M8;12M%>O=^9\RL26^8Y;OQT/<?A12NNQV!W;LY.1@Y[TE?7'Q@4444 %%%%
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M965V4%P>I;'S'\3D_C7["^'O!=O_ ,$:?^"4_C+3_&U]I\GC_P"(1O?)L(9
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ML=^?8^G7J0H4-8TH\J?5VW?IV04445[AX(4444 %%%% !1110 4444 %%%%
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M<)&TJL/WUN3_ ,LW5]S+G&Y6![UGQ'!PQN&K2FZ<%S+F27NM[7NGN5PS453
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M\&QQ/L9NHX\EY;7O>_Y'9QI+"^WA[*,N?ECNU:UM--[^9DT445]H?#A1110
M4444 %%%% !1110 445[O_P3S_8@U?\ ;O\ CY:^&;43VWAZQ"W/B"_ RMM;
M9Y0#N9,;<5ABL13P]*5:L[11T87"U<15C1HJ\I'V7_P0ATKQ#\(O@G\4/B#X
MTOH]+^!\UC(D]M=J&CO[E!MFG3V\O$)'=EQ7YL_$[5M$U[XCZ]>>&;*33?#E
MUJ$\FE6K];>T,C>2GX1[0/85]H_\%@OVY-'\6_8?@+\+_)LOAC\/=MK="WQY
M>J7,.!Y8(_@C;=N/=@QKX2YR2<DL2Q)[YYR/8]O:O$R/#U)SJ9A67*ZMK1\E
MM?S[GO9_B*4*=/+J+YE2O>7]Y[V\K[!1117T6Y\R%%%% !1110 4444 %%%%
M !1110 4444 %%%% "2-^Y8?,QP0P7[R(W&?SK]Q_P#@D]^V+XB\:_\ !+?Q
M1XFUU8M2U;X5C4=.M9I.M]%9V45U#O\ H)1'QV05^'-?K1_P1\_Y0W?'[_KZ
MU_\ ],EK7Q_&E&$\'!S5[3C^)]IP3B*E/&SC!V3@S\LOB=\3-:^,?Q!UGQ9K
M]W)>:YX@NGO;MI/O R')7Z+G:/8"OVA^-WP-^&?C7_@D_P#!'PCXX^)$/PM\
M+_V7H]V+QU5OMDHL=YA^8C&3(S?A7X@A/,M_+_OQ\?BI4_H:_6KX%^'=+_X*
M]?\ !)?3OAA8ZO;Z?\2OA>((84F8 J;?*VY[GRI(=B$XZCGM4<34%".&J*7+
M"$M6K>[?9V=T7PK7YY8FFXJ=2<79-OWM;VTLSQZ7_@FW^R3Y4D4G[6%DJ,'3
M;Y$(V@C;CENV*]/_ ."BWQ?^#<7_  2IT[X7>$_BMH/CS6/"=U8_8Y%D5;B5
M5F<*Q5>%PI*]?X17R;X>_P"",G[1OBGQ_'H,W@&XT+[1<&)]2GN5;3[1<Y:4
M..&P/E4#G %>E_\ !7+]FKX(?L8^ / WP]\&Z?;S?%0K#=^(-5_M"XF:.%8F
MYDA\S8GF2MD#8.,'DDDX5%0JXNC3>)E6E?F2CR-*W5V2L=,)5Z.#KU/JD*,>
M7E;?.F[](IMW.,_8._X)S?&3]MGX;73Z9XHN/"/PP25DN;C5+^=M/NG4EI#%
M;*527:VX$L0 P.:]*U#_ ()O_LI_!&61OB'^U!9ZXUGO>ZL-!@AW2*/O1 PO
M*<>H/(/%>\Z'\/M<_:Y_X(&>&_"_P?F7^W=*B2'4--MI LLTD-Q(UQ;D=C(3
MO /4.*^)/@[_ ,$=/CI\4?&,6GZOX)U#P'H,,F^]U;7BEO;Z=;\^=(AZL1$H
M7\/2BGCY5Y5I5L0J,82:Y4HJ6G5MW;OY()Y;##1H1H89UY3BGS2<G%>24;)6
M\V?77_!P =$/['OP'_X1HR-X=WD:89%96-J+.,19# $'9MZ@55_X(+:_)X0_
M8J_:&UB'_7:>CW$?UCL9G'ZUVW_!;+X :Q\0?V(_A#'\.M,OO&_A_P &A)I;
MS366138QVBHLY()!4A<Y%>;_ /!$AM__  3R_:5;(^;39F&!C:#IDW&/4=/P
MKR8SA+A[E3NU/7O\?4]BI"I#B/G:M>'R^#H?E_+,US-)*_WYF,C?5CD_SIM
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M5I.=X)[J/5VZ(\"1=L2 =E'\J6D3[B^NT$_7'-+7V!\6%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5^N7_  ;=_#;XA:)X5\7>)KRZ^R_#76'$
M5C9S+DWEZA"R7$1[*JJ8SZLOMQ\%_P#!.3]A75OV\_V@+7P]#YEGX7TW;<>(
M-00_\>\ .X(/]N7[@]AFOZ*/ '@32_A?X+TSP_H=G#8:3I%NMM:V\0PL2*,
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MW^W*02/16 [5\SF%26/Q']G4G^[C;VC7_I*]>I]3EM..6X?^TJZ_>2NJ:_\
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MK[_CUHHHKZ@^3W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1U
MC9F/&,;2N"5/&0?K77:C\>/'NK_#N+P?=>,_%UUX3A(6+1)]6G.G@J2PQ#YF
MP<DGA1DDGDDFN2HJ)TX3MSI.VUTG8J%24+\C:OO9M!O$GS+D!N<%=N/;'M7<
M?!#]I/QY^S?K<FH>!?%>M>&+J;'FFQG*I/CIO0DHX]F6N'HI5*<*D>2HDUV:
MN52JSIR4Z;::ZK1_@?0WQ._X*M_M#?&+PS-I6N?%#6O[/D4QO%86EKIK3*>H
M=K=5+ ^YKYY+,[,S;BSL68MU8DY)/)Y)YZT45GA\+1H+EH04?1)&V)QE?$2Y
MJ\W)^;;/8_V>_P#@H!\9/V6=";2O WCW6-'TIG,B6+B.[M;?));9%.K1IN8E
MCM')8D\DUF_'W]M;XL?M2RPMX\\<:UKT=K*+F"!C';V\,BX 9(HU50>!G &3
MD\]:\NHJ5@<,JOMO9QYN]E?[[ \?BG2]BZDN7MS.WW7/:/BQ_P %#?C)\:_@
MTO@'Q1X[OM6\*E(U%I+9V^YRARH,GE^8<>['\L"O/Y?CIXUF^&2^"O\ A+O%
MB^#8SN70O[6N#I@<R-(<0_<7+,6('5B3U)KEZ**>"P\(\L(12O?9;]_453&8
MBI+FG-MVM>[V[;["N0SL5QACGA=H&>>E)1174<P4V3!C;=M9<'*N PP!\WRC
MDJ0<9[&G44!&Z=T=5XK^./C;Q_X-L?#.O>,O%FM>'=(\O['IE_JMQ=6EBL:A
M8Q'$?D554  #TKEF.YV/S?,2>1C/OCWI**F$8P5HI(N52<M9-OUU"BBBJ("B
MBB@ HHHH **** "BBESE?NM(3D!4^][#\31MN"3;LC<^%OPSUSXS_$71_"OA
MJQ;4M<UZY%E909^\[8R3_L*#N/OFOTJ_:X^)6A_\$@/V/;/X$_#Z]CG^*/C2
MV-YXGU:/'FVR.H#R,.O*GRT]%&>_#/V//A?HO_!);]D&[^/?Q!LUD^)7C*U^
MQ>%M*?'F6R."44?[XQ(?0-C^+C\V_BK\4=<^-?Q&UCQ7XDO9M0UO7KEKJZFE
M^]D]$_X H51[**^7E?-<5;_EQ3?RG)?HOS/KK_V/A-/]XJ+YPB_U?Y'/@;1Q
MYA]2_P!XGOFBBBOJ-.A\B%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5UOA#X]^._A[X,U#P_X<\:>+]!T/4O,-]8:=J\]M:W!D18V,D*. ^Y%"
M\@5R5%1.G">DDGZJYI"K.&L&UZ 1M)  50<*!CY1V'!/0<=:W/AU\4/$/PA\
M66^N>%]<U;P_K5I_J;RPN&MI(QZ%UX(/HW6L.BG*,9+EDDUZ$QG*,E*+LUV_
MS/IC6?\ @L/^TMK?A_\ LV7XIZI#!MV^=;Z=9PW(]O,2/><^I8GZ=*^<]>U^
M^\4ZU=:CJEY=ZAJ%Y(9;BYNIC+-,YZLS-R?Z=*IT5SX?!X>A_!@HW[)(Z,1C
ML1B$E7FY6[MO\V>@_L__ +5_Q&_99UFYO_ 'B[5O#DMR1]HCMV1H)\=/,216
M0_E77?'?_@I#\</VD?#;:+XP^(>K:EI,R[9[.".*PMKA>NV2.V1 _L37B%%$
ML#AI5/;2IQ<N]E?[[!3Q^*A3]C"I)1[)NWW'MG@?_@HM\:_AW\&9/A[I?CS4
MH?!\UO+:#3I+6WN#'#)N+1)(59P"6;JQQG' XKSOP)\<?&OPS\-:CI/AOQAX
ME\/Z3JP$6H6.FZI/;6]\=NW]Z(V56X)!! [BN7HIQP>'C?E@M=7HM7W?F$L;
MB)6YIMVT6KT79:@<Y.0 V3G '7\"?SSS11172<HA9HV5ATKV7X#_ /!0'XR?
MLQ:,NF^!_'^MZ/I88NMBX2[M+?));9%*K(FYB6/')8GO7C=%8UL/2K1Y*L5)
M>:3-J&(JT9<]&3B^Z;7Y'KWQ\_;U^,?[4>E-I_CCX@:UKFGL=QLE:&TMF]-\
M,2JC_@![Y.37D."HP<<#''0444Z&'I48\E&*BNR5@K8BK6ESU9.3[MMO\0HH
MHK4Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KH?A-\+=<^-OQ&T?PG
MX9LVU#7M>N19V4&< L<$L?\ 80?,?QKGE)5AM5I&ZA4^][#\37[=_P#!$+_@
MFU_PS3\.%^)7BRS7_A./%D :UA<Y;2;-B<(#ZN,.?3?BO#S[.89=AG5?Q/2*
M\SWN'<CJ9GBU3CI%:R?D?2O[ ?[%>@_L.? '3?"FEJD^J2@76LW^/GO[IA\S
M'V481?\ 945[?C'TI$X7BG5^$8BO4K5'6JN\F[L_H?#8>GAZ4:-)6C%60#I1
M1161N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %?!W_!Q+_R8+;_]C18?^@S5]XU\'?\ !Q+_ ,F"V_\ V-%A_P"@S5ZV0_\
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MH **** "BBB@ HHHH **** "BBB@ HHHH  X!8-E-JF1I%^\$'\(^IK]-OV
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M:)'S52I*I-U)N[>K844451F%%%% !1110 4444 %%%% !1110 4444 %%%%
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MC_D'^HN3?\^W_P"!2_S/R _XAD_%'_15M"_\%$G_ ,51_P 0R?BC_HJVA?\
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MS\@/^(9/Q1_T5;0O_!1)_P#%4?\ $,GXH_Z*MH7_ (*)/_BJ_7^BC_7+-O\
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M]<LV_P"?B_\  8_Y!_J+DW_/M_\ @4O\S\@/^(9/Q1_T5;0O_!1)_P#%4?\
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M ,51_P 0R?BC_HJVA?\ @HD_^*K]?Z*/]<LV_P"?B_\  8_Y!_J+DW_/M_\
M@4O\S\@/^(9/Q1_T5;0O_!1)_P#%4?\ $,GXH_Z*MH7_ (*)/_BJ_7^BC_7+
M-O\ GXO_  &/^0?ZBY-_S[?_ (%+_,_(#_B&3\4?]%6T+_P42?\ Q5'_ !#)
M^*/^BK:%_P""B3_XJOU_HH_URS;_ )^+_P !C_D'^HN3?\^W_P"!2_S/R _X
MAD_%'_15M"_\%$G_ ,51_P 0R?BC_HJVA?\ @HD_^*K]?Z*/]<LV_P"?B_\
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M\0R?BC_HJVA?^"B3_P"*K]?Z*/\ 7+-O^?B_\!C_ )!_J+DW_/M_^!2_S/R
M_P"(9/Q1_P!%6T+_ ,%$G_Q5'_$,GXH_Z*MH7_@HD_\ BJ_7^BC_ %RS;_GX
MO_ 8_P"0?ZBY-_S[?_@4O\S\@/\ B&3\4?\ 15M"_P#!1)_\51_Q#)^*/^BK
M:%_X*)/_ (JOU_HH_P!<LV_Y^+_P&/\ D'^HN3?\^W_X%+_,_(#_ (AD_%'_
M $5;0O\ P42?_%4?\0R?BC_HJVA?^"B3_P"*K]?Z*/\ 7+-O^?B_\!C_ )!_
MJ+DW_/M_^!2_S/R _P"(9/Q1_P!%6T+_ ,%$G_Q5'_$,GXH_Z*MH7_@HD_\
MBJ_7^BC_ %RS;_GXO_ 8_P"0?ZBY-_S[?_@4O\S\@/\ B&3\4?\ 15M"_P#!
M1)_\51_Q#)^*/^BK:%_X*)/_ (JOU_HH_P!<LV_Y^+_P&/\ D'^HN3?\^W_X
M%+_,_(#_ (AD_%'_ $5;0O\ P42?_%4?\0R?BC_HJVA?^"B3_P"*K]?Z*/\
M7+-O^?B_\!C_ )!_J+DW_/M_^!2_S/R _P"(9/Q1_P!%6T+_ ,%$G_Q5'_$,
MGXH_Z*MH7_@HD_\ BJ_7^BC_ %RS;_GXO_ 8_P"0?ZBY-_S[?_@4O\S\@/\
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MQ?\ @,?\@_U%R;_GV_\ P*7^9^0'_$,GXH_Z*MH7_@HD_P#BJ/\ B&3\4?\
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M57Z_T4?ZY9M_S\7_ (#'_(/]1<F_Y]O_ ,"E_F?D!_Q#)^*/^BK:%_X*)/\
MXJC_ (AD_%'_ $5;0O\ P42?_%5^O]%'^N6;?\_%_P" Q_R#_47)O^?;_P#
MI?YGY ?\0R?BC_HJVA?^"B3_ .*H_P"(9/Q1_P!%6T+_ ,%$G_Q5?K_11_KE
MFW_/Q?\ @,?\@_U%R;_GV_\ P*7^9^0'_$,GXH_Z*MH7_@HD_P#BJ/\ B&3\
M4?\ 15M"_P#!1)_\57Z_T4?ZY9M_S\7_ (#'_(/]1<F_Y]O_ ,"E_F?D!_Q#
M)^*/^BK:%_X*)/\ XJC_ (AD_%'_ $5;0O\ P42?_%5^O]%'^N6;?\_%_P"
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MO^":&N?%C]ECPW\'/AGXLTKX?^"=) CU&%M.>22_P<GD-_$Q9CZD^F*^1O\
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MQ?\ @,?\@_U%R;_GV_\ P*7^9^0'_$,GXH_Z*MH7_@HD_P#BJ/\ B&3\4?\
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M57Z_T4?ZY9M_S\7_ (#'_(/]1<F_Y]O_ ,"E_F?D!_Q#)^*/^BK:%_X*)/\
MXJC_ (AD_%'_ $5;0O\ P42?_%5^O]%'^N6;?\_%_P" Q_R#_47)O^?;_P#
MI?YGY ?\0R?BC_HJVA?^"B3_ .*H_P"(9/Q1_P!%6T+_ ,%$G_Q5?K_11_KE
MFW_/Q?\ @,?\@_U%R;_GV_\ P*7^9^0'_$,GXH_Z*MH7_@HD_P#BJ/\ B&3\
M4?\ 15M"_P#!1)_\57Z_T4?ZY9M_S\7_ (#'_(/]1<F_Y]O_ ,"E_F?D!_Q#
M)^*/^BK:%_X*)/\ XJC_ (AD_%'_ $5;0O\ P42?_%5^O]%'^N6;?\_%_P"
MQ_R#_47)O^?;_P# I?YGY ?\0R?BC_HJVA?^"B3_ .*H_P"(9/Q1_P!%6T+_
M ,%$G_Q5?K_11_KEFW_/Q?\ @,?\@_U%R;_GV_\ P*7^9^0'_$,GXH_Z*MH7
M_@HD_P#BJ/\ B&3\4?\ 15M"_P#!1)_\57Z_T4?ZY9M_S\7_ (#'_(/]1<F_
MY]O_ ,"E_F?D!_Q#)^*/^BK:%_X*)/\ XJE'_!LGXH/_ #5C0UYZKHS9P1SR
M37Z_44?ZY9M_S\7_ (#'_(/]1<F_Y]O_ ,"E_F?(7PC_ ."9U]^S+^Q#JWPU
M^&?B;3]%\8>) PU7Q1<V)9KG=N&1&#P5C*H/8$]37QZW_!LOXID;=)\6M%FD
M;YGD?1W#.QY)X;N<U^O]%<N&XFS'#RE.E-7D[MV3;?W;>6QUXKA3+<1"%.K!
M\L59+FDDE]^_=GY #_@V3\3G_FJVA?\ @HD_^*H_XAD_%'_15M"_\%$G_P 5
M7Z_T5U?ZY9M_S\7_ (#'_(Y/]1<F_P"?;_\  I?YGY ?\0R?BC_HJVA?^"B3
M_P"*H_XAD_%'_15M"_\ !1)_\57Z_P!%'^N6;?\ /Q?^ Q_R#_47)O\ GV__
M  *7^9^0'_$,GXH_Z*MH7_@HD_\ BJ/^(9/Q1_T5;0O_  42?_%5^O\ 11_K
MEFW_ #\7_@,?\@_U%R;_ )]O_P "E_F?D!_Q#)^*/^BK:%_X*)/_ (JC_B&3
M\4?]%6T+_P %$G_Q5?K_ $4?ZY9M_P _%_X#'_(/]1<F_P"?;_\  I?YGY ?
M\0R?BC_HJVA?^"B3_P"*H_XAD_%'_15M"_\ !1)_\57Z_P!%'^N6;?\ /Q?^
M Q_R#_47)O\ GV__  *7^9^0'_$,GXH_Z*MH7_@HD_\ BJ/^(9/Q1_T5;0O_
M  42?_%5^O\ 11_KEFW_ #\7_@,?\@_U%R;_ )]O_P "E_F?D!_Q#)^*/^BK
M:%_X*)/_ (JC_B&3\4?]%6T+_P %$G_Q5?K_ $4?ZY9M_P _%_X#'_(/]1<F
M_P"?;_\  I?YGY ?\0R?BC_HJVA?^"B3_P"*H_XAD_%'_15M"_\ !1)_\57Z
M_P!%'^N6;?\ /Q?^ Q_R#_47)O\ GV__  *7^9^0'_$,GXH_Z*MH7_@HD_\
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M^"B3_P"*H_XAD_%'_15M"_\ !1)_\57Z_P!%'^N6;?\ /Q?^ Q_R#_47)O\
MGV__  *7^9^0'_$,GXH_Z*MH7_@HD_\ BJ/^(9/Q1_T5;0O_  42?_%5^O\
M11_KEFW_ #\7_@,?\@_U%R;_ )]O_P "E_F?D!_Q#)^*/^BK:%_X*)/_ (JC
M_B&3\4?]%6T+_P %$G_Q5?K_ $4?ZY9M_P _%_X#'_(/]1<F_P"?;_\  I?Y
MGY ?\0R?BC_HJVA?^"B3_P"*H_XAD_%'_15M"_\ !1)_\57Z_P!%'^N6;?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+*WTG23>8MQ(8RS-N4#YD;CV- 'U[&V]?Q(_+BG5^6?_ !& _L@C_EM\3/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BH;VY6SMY)I'CCAC4M([MM6-1DE
MB?I3-&UBV\0:3;7UG-'<V=Y$LT,L9W+(C#((/N* +-%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#17O O_@R2OYMZ*/\ B'N$_P"?LOP_R#_B)6-_Y]1_'_,_I(_X><?L^_\
M17O O_@R2C_AYQ^S[_T5[P+_ .#)*_FWHH_XA[A/^?LOP_R#_B)6-_Y]1_'_
M #/Z2/\ AYQ^S[_T5[P+_P"#)*/^'G'[/O\ T5[P+_X,DK^;>BC_ (A[A/\
MG[+\/\@_XB5C?^?4?Q_S/Z2/^'G'[/O_ $5[P+_X,DH_X><?L^_]%>\"_P#@
MR2OYMZ*/^(>X3_G[+\/\@_XB5C?^?4?Q_P S^DC_ (><?L^_]%>\"_\ @R2C
M_AYQ^S[_ -%>\"_^#)*_FWHH_P"(>X3_ )^R_#_(/^(E8W_GU'\?\S^DC_AY
MQ^S[_P!%>\"_^#)*/^'G'[/O_17O O\ X,DK^;>BC_B'N$_Y^R_#_(/^(E8W
M_GU'\?\ ,_I(_P"'G'[/O_17O O_ (,DH_X><?L^_P#17O O_@R2OYMZ*/\
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M_P#17O O_@R2OYMZ*/\ B'N$_P"?LOP_R#_B)6-_Y]1_'_,_I(_X><?L^_\
M17O O_@R2C_AYQ^S[_T5[P+_ .#)*_FWHH_XA[A/^?LOP_R#_B)6-_Y]1_'_
M #/Z2/\ AYQ^S[_T5[P+_P"#)*/^'G'[/O\ T5[P+_X,DK^;>BC_ (A[A/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% !1110!^=__  <I?\F6>#_^QVMO_2"_K\3SUK]L/^#E+_DRSP?_ -CM;?\
MI!?U^)YZU^S<#_\ (L_[>9^$\?\ _(T?^%!1117V1\2%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7TC_P $A_\ E(_\*/\ L)7'_H@5\W5](_\ !(?_ )2/_"C_
M +"5Q_Z(%>;G'^XUO\,OR/2R7_?Z/^./YG]%XZ44#I17\\G]-!1110!^ O\
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M/^O27_T U^?/_!M?_P F>>,O^QRG_P#2&SK]!O%__(IZI_UZ2_\ H!K\^?\
M@VO_ .3//&7_ &.4_P#Z0V=>W@_^17B/6!\[CO\ D;8;_#/_ -M/LW]J?]EK
MPC^V%\(M2\&>,M.6\TV\&Z*7@2VDH'RS1GLRD_I7YW_LZ?M'>./^"-/QXA^#
MOQDO)-6^$NLSL?#?B<IB.P5CNY_V2SG?Z-N/U_5AJ\U_:E_9:\(?MB_"/4O!
M7C/35O-/NANAEP!+9R@?+-$W9E)_2HRW,HTH/#8I<U*6ZZI]X^?<TS7*YU)K
M%X1\M:.SZ27\LO)GH6B:Q:^(-'M;^QN([JSO(EG@FC;<DJ, 58'N""#5JORE
M_9R_:0\<_P#!&KX[P?!WXS7DFL?"76;ASX<\3E<1V"L=W/\ LEG._/1LGZ_J
M?HFKVOB#2+6_L9XKJSO(EG@FC.Y)4895@>X(.:QS++9862:?-3EK&2V:_P ^
MZ.C*LTCC(-27+4CI*+W3_5=F6Z* >**\T]8**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU^TB?"OB1K[Q!^SSXWO6EL=2VC.AN<?-_O+T=.Z*K5T>[F]/MB(K_P #2_\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?2/\
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M?P;_ . ^D?X4?V/_ ,%*/^@OX-_\!](_PH_L!?\ 032_\#?^0?ZQ/_H%K?\
M@"_^2/TLHK\T_P"Q_P#@I1_T%_!O_@/I'^%']C_\%*/^@OX-_P# ?2/\*/[
M7_032_\  W_D'^L3_P"@6M_X O\ Y(_2RBOS3_L?_@I1_P!!?P;_ . ^D?X4
M?V/_ ,%*/^@OX-_\!](_PH_L!?\ 032_\#?^0?ZQ/_H%K?\ @"_^2/TLHK\T
M_P"Q_P#@I1_T%_!O_@/I'^%']C_\%*/^@OX-_P# ?2/\*/[ 7_032_\  W_D
M'^L3_P"@6M_X O\ Y(_2RBOS3_L?_@I1_P!!?P;_ . ^D?X4?V/_ ,%*/^@O
MX-_\!](_PH_L!?\ 032_\#?^0?ZQ/_H%K?\ @"_^2/TLHK\T_P"Q_P#@I1_T
M%_!O_@/I'^%']C_\%*/^@OX-_P# ?2/\*/[ 7_032_\  W_D'^L3_P"@6M_X
M O\ Y(_2RBOS3_L?_@I1_P!!?P;_ . ^D?X4?V/_ ,%*/^@OX-_\!](_PH_L
M!?\ 032_\#?^0?ZQ/_H%K?\ @"_^2/TLHK\T_P"Q_P#@I1_T%_!O_@/I'^%'
M]C_\%*/^@OX-_P# ?2/\*/[ 7_032_\  W_D'^L3_P"@6M_X O\ Y(_2RBOS
M3_L?_@I1_P!!?P;_ . ^D?X4?V/_ ,%*/^@OX-_\!](_PH_L!?\ 032_\#?^
M0?ZQ/_H%K?\ @"_^2/TLHK\T_P"Q_P#@I1_T%_!O_@/I'^%']C_\%*/^@OX-
M_P# ?2/\*/[ 7_032_\  W_D'^L3_P"@6M_X O\ Y(_2RBOS3_L?_@I1_P!!
M?P;_ . ^D?X4?V/_ ,%*/^@OX-_\!](_PH_L!?\ 032_\#?^0?ZQ/_H%K?\
M@"_^2/TLHK\T_P"Q_P#@I1_T%_!O_@/I'^%']C_\%*/^@OX-_P# ?2/\*/[
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M "'1_JSC^T?_  .'_P D'^MF7]Y?^ 3_ /D3]+J*_-'_ (?/?M!?]&D^-/\
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M-2_^0Z/]6<?VC_X'#_Y(/];,O[R_\ G_ /(GZ745^:/_  ^>_:"_Z-)\:?\
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M^-2_^0Z/^'SW[07_ $:3XT_[\:E_\AT?ZLX_M'_P.'_R0?ZV9?WE_P" 3_\
MD3]+J*_-'_A\]^T%_P!&D^-/^_&I?_(='_#Y[]H+_HTGQI_WXU+_ .0Z/]6<
M?VC_ .!P_P#D@_ULR_O+_P  G_\ (GZ745^:/_#Y[]H+_HTGQI_WXU+_ .0Z
M/^'SW[07_1I/C3_OQJ7_ ,AT?ZLX_M'_ ,#A_P#)!_K9E_>7_@$__D3]+J*_
M-'_A\]^T%_T:3XT_[\:E_P#(='_#Y[]H+_HTGQI_WXU+_P"0Z/\ 5G']H_\
M@</_ )(/];,O[R_\ G_\B?I=17YH_P##Y[]H+_HTGQI_WXU+_P"0Z/\ A\]^
MT%_T:3XT_P"_&I?_ "'1_JSC^T?_  .'_P D'^MF7]Y?^ 3_ /D3]+J*_-'_
M (?/?M!?]&D^-/\ OQJ7_P AT?\ #Y[]H+_HTGQI_P!^-2_^0Z/]6<?VC_X'
M#_Y(/];,O[R_\ G_ /(GZ745^:/_  ^>_:"_Z-)\:?\ ?C4O_D.C_A\]^T%_
MT:3XT_[\:E_\AT?ZLX_M'_P.'_R0?ZV9?WE_X!/_ .1/TNHK\T?^'SW[07_1
MI/C3_OQJ7_R'1_P^>_:"_P"C2?&G_?C4O_D.C_5G']H_^!P_^2#_ %LR_O+_
M , G_P#(GTG_ ,%CO^4:GQ8_[!L/_I3#5W_@DA_RCG^%?_8*;_T?)7PU^UO_
M ,%%/CY^UA^SGXJ^'MS^RWXZT>'Q1:K;_:UT[4)M@$J,3@VP]*^\_P#@EYX5
MU3P1^P/\--*UK3]0TK4K+3"DUK?6S6UQ"?.D(#1LJE>"",@9!![UOCL'4PF5
MJC6MS.I>RDGIRVZ-G+E^/I8W-W6H7Y53M=QDM>;S2/?CR>U<1^T3^SWX9_:B
M^$>K>"_%MA'?Z/JT95@?OP./N2H>SJ>0:[D=**^:IU)0DIP=FM4?55:4*D'3
MFKI[H_*?]F_X\>+_ /@C%^T;'\&?BM=3:E\(/$ET[^&O$DI_=:=N.XANRJ6=
MBX/\98CK7ZGZ7J%OJ^FV]Y:S1W%M=1K-#+&=RR(PRK ]P0<YKS;]KO\ 9-\(
M_MF_!K4/!?C"S6:SN@9+6Y4#S].G ^2:,]F4_F*^"_V(?VL_%W_!,SXZ-^SM
M\=KF63PS))_Q2/B24?NC$[X0,W]QB<DG[KEO>OI*U..:TG7HJU>*]Z/\R_F7
MGW1\OAZL\HK+#5G>A+2,OY'_ "M]NQ^HPZ44V"99X4DC97C<!E93D,#T(IU?
M,GU@4444 %%%% 'YW_\ !RE_R99X/_[':V_](+^OQ//6OVP_X.4O^3+/!_\
MV.UM_P"D%_7XGGK7[-P/_P BS_MYGX3Q_P#\C1_X4%%%%?9'Q(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %?2/_  2'_P"4C_PH_P"PE<?^B!7S=7TC_P $A_\
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M_P!HKX':K\"_B/XGM&O?#V=174=/U=0&)5)5&"2%;[I(!4J<$5Z1_P %1?\
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M/QK^%?AOQAH,QN-%\5:9;ZM8R'&6AGC61,X[[6&1ZT =%1110 4444 %%%%
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MG_P3-_Y3'?M1?[\W_I<U?I8_W#]*_-/_ ()F_P#*8[]J+_?F_P#2YJ]O*O\
M=L3_ (?U1\[G/^]X7_'^A^EHZ44#I17B'T04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#[':V_](+^OQ//6OV;@?\ Y%G_ &\S\)X__P"1H_\ "@HHHK[(^)"BBB@
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MXW[-_P >=(M]('P\^&/A_4-+U>2:ZV3QR307ZKLCQR!YJ<].>: .K_X.$_\
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M+9X22:?-"6L9+9K_ #[HZ,JS2.,@U)<M2.DHO=/]5V9;?[A^E?FG_P $S?\
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MMW9XQGK7T%;S1W<2S0NLL4H61)$;<K@]"#TP1CIZT 345\^_%/\ X*N?LU_
M_P ?77A7Q=\</AIX?\16+A+G3[S78$GMV/0.N?E.".#BO;O!OC/1_B%X9L];
MT'4]/UK1]2036M]8SI<6]RO3<CH2&&1C.>Q':@#4HKR77OV\O@GX7^'WB7Q5
M??%CX=Q^'?!M^=*UW4$U^VE@TF\!P;:9D<[)L_\ +,_-[5WWPT^).A_&+X?Z
M/XJ\,ZG:ZSX?\06D=]I]];-NBNH7&5=3W!% &Y17YJ_\'9.HW.F?\$<O$TMI
M-+;SKXATG#Q2>6X'G$G!^@KQ7]F?_@U"_9Y^-/[-WP^\8:EX^^/%OJ7BKPUI
MNKW26?B2UCA66XM8Y6VJ]H[ 9<\%C[8&  #]E**_G[_X*._L=^+/^#:/5OAK
M\9O@7\7_ (EZOX"U;Q)#X?USPOXDU1+N*X#QR7!&$2.-E86[](P0=O.,Y_?+
M3M>M[OPQ;ZO<-'9V\MJMW(\KA5@4H&))/  '4^U &E17S?8_\%@/V7-2^(0\
M*V_Q\^%MQK[7'V1;2/7X&+S9QL#!MI;/! /!!'45]%1W<=U;1S0NL\<@#(T9
M#*ZGD$'I@@YSZ4 345\\?$W_ (*T?LR_!?QQ=^&?%7QT^&6AZ_I\GE7-A<Z[
M"LUN_P#==0?E//0U[GX*\;Z/\2/"MCKGA_5-/UO1=2C\VTOK&X6XM[A,D91U
M)!&01P>H(H U**\C_:2_;T^#'['=Q9P_%'XG>"_ MQJ0+VEOJVJ1P3W"C&66
M,G<1[@8K?^ '[4/P[_:J\)MKWPV\;>&?'&C1OY<EUHVH1W21/_=;:25/L<&@
M#O:*XOXW_M#^!OV:O!<GB3X@>+?#O@O0(7$;ZAK-_'9P;CT 9R Q]AS7FOP&
M_P""IW[.?[3OC.+PYX!^,WP^\3:_<;O)TZSU>(W4V#@[(R0S?@#G- 'OU%<M
M\6?C5X-^ GAR/6_'7BSPQX-TF:YCL8;[7-3ATZW>>3A(1),RJ78@X4')QP.*
MYP?MD_"MOVB8_A*OC_PJ_P 2IK7[<GAN/4$;4/)\L2!VC!RN48.,]5((X- '
MIE%>2?M-_MX_!O\ 8U6R7XI?$SP?X$FU-#)9P:MJ,<%Q<J#@LD9.Y@#QD BM
M_P#9]_:A^'/[5O@Y_$'PT\;>&?'.BQR>5)=Z+J$=W'"_]U]A)5NO#8- '>45
M^0G_  24^-^@_!C_ (*M?\%)_$?C;Q+8>'_#&B>*]+,]_JE^(K>S4W&J  !C
M@ _YZU^B/[.?_!1WX#_M=>)YM$^&?Q:\#>-=:MX3/)8:7JD<URL8."WEYW8'
MKCWH ]JHH!S7YL_\'+?[=WC[]C[]F?P'X7^&.K2^&?&'QC\31^&X==A \W3(
M1M+E3V9O, SU SB@#]&KKQ#8V.H1VL][:0W,W^KB>95DD^BGFK@Z5^4W@C_@
MT2_9OG\$1_\ "P-:^)/CCQM>0?\ $RU^;73$\LYY+HFT@ ' &2<@#/>J/_!-
M/PE\<?\ @F!_P5/O_P!F'6-6\>_%'X">(M!;6?"OB/5[>>Y_L%XUW& SG]VB
M[MZD XR4XSG !^L]%?EO\1O^"W>D^%?^"Z/AGX:K\;OA;:?L_OX)GGUNZDU;
M3FLK?6XWNE\F2_+?N9 5C!C+CD8(YX_1+5OVC?A[X>\6^&=!U#QYX-L=<\;1
M^;X=T^XUNVCNM>0@,'M(B^ZX7!ZQ@T =M167XQ\9:/\ #?PMJ&N^(-6T[0]#
MTN%KJ^U'4;M+:TLHE&6DDED(5$ ZDD 57^'GQ)\._%SP1I_B;PGX@T;Q-X;U
M:,SV6JZ3?17ME>)D@M'-&S(ZY!&5)&01VH W**^<];_X*Z_LQ>&OB8W@V_\
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MG?CCKCISTKT3XF?%/PW\&/!M[XD\7:_H_AGP_IJ[[K4-3NTM;:W'^T[D+^M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[L>K4?M(?M&>./\ @L[\=I/@U\'+B]T7X1Z7*#XE\2,FU+]%(R_^U&>0D?\
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MPG\8_C1I#?$6\CN[O3?!VGZK<RR6'AJPM;V5F6&(,%!>]-U*<C&9#W)KLO\
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M_P %J?VLOB)KVAWOANZ\<:%9Z[:Z?=Q-'-%87$L$MBQ5N</:-;R#L0X(X(H
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M#^-/AW]F[_@L!^Q#\0/%EQ-8^&_!][-JVJ7,4+S/%;PWUL6(1>O7ZU](S_\
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M_0!7XQ?\',?[+?PZ_P"&KOV3/$W_  AOAT^(OB5\5=/TCQ/?M8JUQK=J&L(
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M"CQC:P[=7T/Q#9SQM:3J2KHDBH4DZ9 !R P!&017S+_P4Y_X*TG_ (++6/\
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MX\3?M@^.-'L? 7P9U&?PCX)\(:X\K6,[VL[6T\OEJ"&W20O(0, F3G@5@?\
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MS#9^!_$WPST/Q1X@O+#_ (G/BB^3S-8N[YP6EN%GQE2)'<KC@ *#G&:^+O\
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MGX3UN6#PT^OZ=_:.FZO8B1O)FE,BNL;R1>5(I^48?J* .Y_88_X)X?LYZO\
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M'TVXD5)%'_;01CZ.:XG_ (*/>/+'_@K'_P %7OV4?@+H-RMYX%T&PA^+?BI
MQVF(QB6UB<C@DQA1@_\ />@#]5/@%X^U;XJ_!+PGXGUW05\+ZOXBTJWU*ZT@
M7GVS^S6FC$GDF78F]E# $[1R".<9/74V-M\:MSR,\TZ@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BF]#5/6]:MO#FE76H7UQ!:6-E$TT\\SA
M(XD499F8\  <\T:MV0FTE=CM;UFU\.:3=:A?7$-G96433SSRN%2%%&69B>
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M<\1/:\0-J>FPWAA_W3(IV_A6%%^RC\+(I%>/X:_#]64Y#+X>M 0?KY=>@44
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M,?@OI7Q6^''A+QM#IEYKLEM;^(M'M[\6Q;6;XY3S%.W.?\\5^BOP9^ '@?\
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M[!S110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/^(EGX6_]"'\0/\ OFW_ /BZ/]5<V_Y\/\/\P_UNR?\ Y_K\?\C])**_-O\
MXB6?A;_T(?Q _P"^;?\ ^+H_XB6?A;_T(?Q _P"^;?\ ^+H_U5S;_GP_P_S#
M_6[)_P#G^OQ_R/TDHK\VQ_P<M_"W_H0?'W_?-O\ _%U]7_L%?MU>'?V_/A?J
MOBKPWH^L:-:Z7JC:5+#J*J)&=8HI<C:2,8E%<>,R/'X6G[7$4W&/=V.O!<09
M=BZGLL/54I=E?_(]UHHHKRSV HII.#5/6M9M/#NE76HW]Q!9V-E$TT\\SA(X
M44$LS,>  !GGTH6KL@DTE=CM=UBV\.Z5=:A?7$%G8V,333SS.$CA11EF9CP
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M-F&85,744GI%:1CT2[(Z\KRRG@J7)'63UE+K)]_^  -%%%<!Z04444 ?G?\
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M:6\+^'?&.G^%;SPCXHU6/1+C3K+33%_9GF';L#Y^;;G'.0<5X#_P61^!VA_
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M$<T__GQL_P#ORO\ A1_PCFG_ //C9_\ ?E?\*N44<S#E13_X1S3_ /GQL_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*"YJT](K]7V2+'P:^%?C#_@N'^TD/B5X]MK[0?@7X3NWCT/1W.T:N5.W!/\
M$#MRQ[%L>@K]5-!T*S\,:%9Z;I]O%9V-C"EO;PQC:D4:@*J@>@  JMX$\$:3
M\-O"&GZ%H=C;Z;I.EQ""UMH5VI$@[ ?J?<FM:C,\R>)DHP7+3CI&/9=WYOJ7
ME.5K"1<ZCYJDM92[OMZ+H"\"BBBO+/7"BBB@ HHHH _._P#X.4O^3+/!_P#V
M.UM_Z07]?B>>M?MA_P '*7_)EG@__L=K;_T@OZ_$\]:_9N!_^19_V\S\)X__
M .1H_P#"@HHHK[(^)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M1N_U'\GK]/\ ]J;4KG3/^#>_X0R6LTEO)_:EL-Z?> W7U?F$9,(!V8X8?WL
M_P"-?6'QE_X*(Z+\2O\ @F7X-^!<'AS4[?4_"]W%<2:@9$^SS!#<.-H//'F
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[-P/_P BS_MYGX3Q_P#\C1_X4%%%%?9'Q(4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %?2/_  2'_P"4C_PH_P"PE<?^B!7S=7TC_P $A_\ E(_\*/\ L)7'_H@5
MYN<?[C6_PR_(]+)?]_H_XX_F?T7CI10.E%?SR?TT%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFP4444 %%%% !1110!^=_P#P<I?\F6>#_P#L=K;_ -(+^OQ//6OVP_X.4O\
MDRSP?_V.UM_Z07]?B>>M?LW _P#R+/\ MYGX3Q__ ,C1_P"%!1117V1\2%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7TC_P2'_Y2/\ PH_["5Q_Z(%?-U?2/_!(
M?_E(_P#"C_L)7'_H@5YN<?[C6_PR_(]+)?\ ?Z/^./YG]%XZ44#I17\\G]-!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!\^_\%4/^4>WQ8_[ 4G_ *$M<C_P12A6
MY_X)??"^.15:-[:_5E89# W]T""*[#_@JC_RCU^+'_8"D_\ 0EKD_P#@B9_R
MC!^%G_7"^_\ 3A<U[B_Y$_\ W%_]M/G):YXE_P!.O_;CYC_;2_9'\7?\$NOC
MC)^T/\";.2Z\'S2%_%WA6+_5QHS!GE7TC9LLW<,V?2OO#]D']K;PA^V?\'-/
M\8>$;R.2"0"*\LV8>=ITP',4@[>H/&5(->H7UC#J5I-;SQ1S6]PICECD3<LJ
MD8((/!!'&#7Y9?M2_LW^,O\ @CU\>9OCC\%;.XU+X6ZI*/\ A*?#"MF*U5F&
MX?[,><LDG\#-M/&,]-&I3S2FJ%=VK15HR?VE_++S[,YL12J914>)H*]"3O**
M^R_YH^7='ZJ*,"EKS;]EW]I[PE^UQ\(-/\8^#]02\TZZ'ESQE\S64Z@;X91V
M9<_CP1D&O1=@C4!> . *^=J4I4Y.G-6:T9]11K0JP52F[IJZ?D244BGY:6H-
M HHHH **** /SO\ ^#E+_DRSP?\ ]CM;?^D%_7XGGK7[8?\ !RE_R99X/_['
M:V_](+^OQ//6OV;@?_D6?]O,_">/_P#D:/\ PH****^R/B0HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P B4?\ $-_\#?\ H8OBE_X-++_Y$H^JY-_T$3_\ _\ M@^N9W_T#0_\&?\
MVI]M?\+P\%_]#=X7_P#!K!_\51_PO#P7_P!#=X7_ /!K!_\ %5\2_P#$-_\
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M .*H_P"%X>"_^AN\+_\ @U@_^*KXE_XAO_@;_P!#%\4O_!I9?_(E'_$-_P#
MW_H8OBE_X-++_P"1*/JN3?\ 01/_ , _^V#ZYG?_ $#0_P#!G_VI]M?\+P\%
M_P#0W>%__!K!_P#%4?\ "\/!?_0W>%__  :P?_%5\2_\0W_P-_Z&+XI?^#2R
M_P#D2C_B&_\ @;_T,7Q2_P#!I9?_ ")1]5R;_H(G_P" ?_;!]<SO_H&A_P"#
M/_M3[:_X7AX+_P"AN\+_ /@U@_\ BJ/^%X>"_P#H;O"__@U@_P#BJ^)?^(;_
M .!O_0Q?%+_P:67_ ,B4?\0W_P #?^AB^*7_ (-++_Y$H^JY-_T$3_\  /\
M[8/KF=_] T/_  9_]J?;7_"\/!?_ $-WA?\ \&L'_P 51_PO#P7_ -#=X7_\
M&L'_ ,57Q+_Q#?\ P-_Z&+XI?^#2R_\ D2C_ (AO_@;_ -#%\4O_  :67_R)
M1]5R;_H(G_X!_P#;!]<SO_H&A_X,_P#M3[:_X7AX+_Z&[PO_ .#6#_XJC_A>
M'@O_ *&[PO\ ^#6#_P"*KXE_XAO_ (&_]#%\4O\ P:67_P B4?\ $-_\#?\
MH8OBE_X-++_Y$H^JY-_T$3_\ _\ M@^N9W_T#0_\&?\ VI]M?\+P\%_]#=X7
M_P#!K!_\51_PO#P7_P!#=X7_ /!K!_\ %5\2_P#$-_\  W_H8OBE_P"#2R_^
M1*/^(;_X&_\ 0Q?%+_P:67_R)1]5R;_H(G_X!_\ ;!]<SO\ Z!H?^#/_ +4^
MVO\ A>'@O_H;O"__ (-8/_BJ/^%X>"_^AN\+_P#@U@_^*KXE_P"(;_X&_P#0
MQ?%+_P &EE_\B4?\0W_P-_Z&+XI?^#2R_P#D2CZKDW_01/\ \ _^V#ZYG?\
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M]J?;7_"\/!?_ $-WA?\ \&L'_P 51_PO#P7_ -#=X7_\&L'_ ,57Q+_Q#?\
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M0W_P-_Z&+XI?^#2R_P#D2CZKDW_01/\ \ _^V#ZYG?\ T#0_\&?_ &I]M?\
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MA?\ \&L'_P 51_PO#P7_ -#=X7_\&L'_ ,57Q+_Q#?\ P-_Z&+XI?^#2R_\
MD2C_ (AO_@;_ -#%\4O_  :67_R)1]5R;_H(G_X!_P#;!]<SO_H&A_X,_P#M
M3[:_X7AX+_Z&[PO_ .#6#_XJC_A>'@O_ *&[PO\ ^#6#_P"*KXE_XAO_ (&_
M]#%\4O\ P:67_P B4?\ $-_\#?\ H8OBE_X-++_Y$H^JY-_T$3_\ _\ M@^N
M9W_T#0_\&?\ VI]M?\+P\%_]#=X7_P#!K!_\51_PO#P7_P!#=X7_ /!K!_\
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M8OBE_P"#2R_^1*/^(;_X&_\ 0Q?%+_P:67_R)1]5R;_H(G_X!_\ ;!]<SO\
MZ!H?^#/_ +4^VO\ A>'@O_H;O"__ (-8/_BJ/^%X>"_^AN\+_P#@U@_^*KXE
M_P"(;_X&_P#0Q?%+_P &EE_\B4?\0W_P-_Z&+XI?^#2R_P#D2CZKDW_01/\
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M(;_X&_\ 0Q?%+_P:67_R)1]5R;_H(G_X!_\ ;!]<SO\ Z!H?^#/_ +4^VO\
MA>'@O_H;O"__ (-8/_BJ/^%X>"_^AN\+_P#@U@_^*KXE_P"(;_X&_P#0Q?%+
M_P &EE_\B4?\0W_P-_Z&+XI?^#2R_P#D2CZKDW_01/\ \ _^V#ZYG?\ T#0_
M\&?_ &I]M?\ "\/!?_0W>%__  :P?_%4?\+P\%_]#=X7_P#!K!_\57Q+_P 0
MW_P-_P"AB^*7_@TLO_D2C_B&_P#@;_T,7Q2_\&EE_P#(E'U7)O\ H(G_ . ?
M_;!]<SO_ *!H?^#/_M3[:_X7AX+_ .AN\+_^#6#_ .*H_P"%X>"_^AN\+_\
M@U@_^*KXE_XAO_@;_P!#%\4O_!I9?_(E'_$-_P# W_H8OBE_X-++_P"1*/JN
M3?\ 01/_ , _^V#ZYG?_ $#0_P#!G_VI]M?\+P\%_P#0W>%__!K!_P#%4?\
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M (-++_Y$H^JY-_T$3_\  /\ [8/KF=_] T/_  9_]J?;7_"\/!?_ $-WA?\
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M#_XJC_A>'@O_ *&[PO\ ^#6#_P"*KXE_XAO_ (&_]#%\4O\ P:67_P B4?\
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M^*KXE_XAO_@;_P!#%\4O_!I9?_(E'_$-_P# W_H8OBE_X-++_P"1*/JN3?\
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M+_Z&[PO_ .#6#_XJC_A>'@O_ *&[PO\ ^#6#_P"*KXE_XAO_ (&_]#%\4O\
MP:67_P B4?\ $-_\#?\ H8OBE_X-++_Y$H^JY-_T$3_\ _\ M@^N9W_T#0_\
M&?\ VI]M?\+P\%_]#=X7_P#!K!_\51_PO#P7_P!#=X7_ /!K!_\ %5\2_P#$
M-_\  W_H8OBE_P"#2R_^1*/^(;_X&_\ 0Q?%+_P:67_R)1]5R;_H(G_X!_\
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M^(;_ .!O_0Q?%+_P:67_ ,B4?\0W_P #?^AB^*7_ (-++_Y$H^JY-_T$3_\
M /\ [8/KF=_] T/_  9_]J?;7_"\/!?_ $-WA?\ \&L'_P 51_PO#P7_ -#=
MX7_\&L'_ ,57Q+_Q#?\ P-_Z&+XI?^#2R_\ D2C_ (AO_@;_ -#%\4O_  :6
M7_R)1]5R;_H(G_X!_P#;!]<SO_H&A_X,_P#M3[:_X7AX+_Z&[PO_ .#6#_XJ
MC_A>'@O_ *&[PO\ ^#6#_P"*KXE_XAO_ (&_]#%\4O\ P:67_P B4?\ $-_\
M#?\ H8OBE_X-++_Y$H^JY-_T$3_\ _\ M@^N9W_T#0_\&?\ VI]M?\+P\%_]
M#=X7_P#!K!_\51_PO#P7_P!#=X7_ /!K!_\ %5\2_P#$-_\  W_H8OBE_P"#
M2R_^1*/^(;_X&_\ 0Q?%+_P:67_R)1]5R;_H(G_X!_\ ;!]<SO\ Z!H?^#/_
M +4^VO\ A>'@O_H;O"__ (-8/_BJ/^%X>"_^AN\+_P#@U@_^*KXE_P"(;_X&
M_P#0Q?%+_P &EE_\B4?\0W_P-_Z&+XI?^#2R_P#D2CZKDW_01/\ \ _^V#ZY
MG?\ T#0_\&?_ &I]M?\ "\/!?_0W>%__  :P?_%4?\+P\%_]#=X7_P#!K!_\
M57Q+_P 0W_P-_P"AB^*7_@TLO_D2C_B&_P#@;_T,7Q2_\&EE_P#(E'U7)O\
MH(G_ . ?_;!]<SO_ *!H?^#/_M3[:_X7AX+_ .AN\+_^#6#_ .*H_P"%X>"_
M^AN\+_\ @U@_^*KXE_XAO_@;_P!#%\4O_!I9?_(E'_$-_P# W_H8OBE_X-++
M_P"1*/JN3?\ 01/_ , _^V#ZYG?_ $#0_P#!G_VI]M?\+P\%_P#0W>%__!K!
M_P#%4?\ "\/!?_0W>%__  :P?_%5\2_\0W_P-_Z&+XI?^#2R_P#D2C_B&_\
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M_P#;!]<SO_H&A_X,_P#M3[:_X7AX+_Z&[PO_ .#6#_XJC_A>'@O_ *&[PO\
M^#6#_P"*KXE_XAO_ (&_]#%\4O\ P:67_P B4?\ $-_\#?\ H8OBE_X-++_Y
M$H^JY-_T$3_\ _\ M@^N9W_T#0_\&?\ VI]M?\+P\%_]#=X7_P#!K!_\51_P
MO#P7_P!#=X7_ /!K!_\ %5\2_P#$-_\  W_H8OBE_P"#2R_^1*/^(;_X&_\
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M ")1]5R;_H(G_P" ?_;!]<SO_H&A_P"#/_M3[:_X7AX+_P"AN\+_ /@U@_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5](_\ !(?_ )2/_"C_ +"5Q_Z(%?-U?2/_  2'_P"4C_PH_P"P
ME<?^B!7FYQ_N-;_#+\CTLE_W^C_CC^9_1>.E% Z45_/)_304444 -D^X:_-?
M_@A%_P G-?M7_P#8R6G_ *5ZM7Z42?<-?FO_ ,$(O^3FOVK_ /L9+3_TKU:O
M<R__ )%V*](?^E'SF:?\C/!^L_\ TD_2H=**!THKPSZ,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?2/_  2'_P"4C_PH
M_P"PE<?^B!7S=7TC_P $A_\ E(_\*/\ L)7'_H@5YN<?[C6_PR_(]+)?]_H_
MXX_F?T7CI10.E%?SR?TT%%%% #9/N&OS7_X(1?\ )S7[5_\ V,EI_P"E>K5^
ME$GW#7YK_P#!"+_DYK]J_P#[&2T_]*]6KW,O_P"1=BO2'_I1\YFG_(SP?K/_
M -)/TJ'2B@=**\,^C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:?L]_LW>-/%_]J:/I]_I.A7U]IC7\ZI#<W,5M))$O7Y\E1P,DBO@S]I3_@W
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M0!^A/_!37X0K^W/^POK7AKP;\:M-^%ZZI>VS1^,+2^5H(##,&:'S$E3EL;2
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M'_A04445]D?$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5](_\ !(?_ )2/_"C_
M +"5Q_Z(%?-U?2/_  2'_P"4C_PH_P"PE<?^B!7FYQ_N-;_#+\CTLE_W^C_C
MC^9_1>.E% Z45_/)_304444 -D^X:_-?_@A%_P G-?M7_P#8R6G_ *5ZM7Z4
M2?<-?FO_ ,$(O^3FOVK_ /L9+3_TKU:O<R__ )%V*](?^E'SF:?\C/!^L_\
MTD_2H=**!THKPSZ,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8:]I<&HVJS(<I((YE90ZGH<9%=+96D.GV<4%O''#;PH$BCC4*D:C@*H'  &
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MS_CC\1O^"5OP=_9DU+XAVOA/]EOQ1Y=A+=Z9HNF:=IDFK:C(%(CA6VQYR,2
M"64 ?>]*XWXU_LC77[;G_!MAXJN/!OP'\/\ P0UGQ-)_PG&G>"_#T0A-VEK+
MMAEE!5?GFMHA*!Z%.^2?N;P)_P $/_V2_AMX_C\4:/\  ;X?VNLPSK<02M8^
M;';.N,&.)B8TQC/RJ.<GJ37U);PK%:I'#&L,<8"(BJ $ X& .,8QP.U 'Y\_
M\$QO^"Z7[.OQ0_8/\$7GBGXI>"O 7BCPCX>M=-\1Z)XBUB&QO[2>UA$$CI%(
M0\RNT>Y=@)PXSSP=[_@C9_P4\\??\%1/'?QJ\376@^']*^#/A;75T;P+?6]E
M<17^M*ID,LTLCRM&XVB,@(B8W@')!)],^*W_  17_97^-_Q)N/%WBCX'^ ]4
M\07DIGNKDV/E"[D/5I$0A6)]2.:^AOAU\./#OP?\%Z?X;\*Z)I/AOP_I:>39
MZ=IMJEK:VRY+$)&@"C+%B<#DDGJ2: /R5_X--/C7X/T/X._&KP)<^)-%L_%>
MI?%G5[_3]$GOHEOKJV%K:+YD</!*CRVR0.JDU6_X((_#S_A='A?_ (**>#=_
MES>*/B/KNE!B1A!<K>Q*<]."S$^]?HCX!_X)<_L__##]IB3XR>'/A;X;T/XE
M7$T]S)K5DLD4C23H5F?RU?R@7#-DA.2Q/4DGTSX7_ 'P+\#KG6I?!?@OPGX1
ME\17AO\ 4WT72(+!]3N#UFG,2J97Y/S/DT ?DS_P;I?\%$_A_P#L6_LW^(OV
M8_CAXL\/_##QY\(?$VH6<,'B*_CLEU""6=[AFC+D#AG?@GD,".*R_P!J;X_>
M'?\ @LG_ ,%Y_P!F7PQ\'-4@\9^"OV;[[_A,O$'B#3IUFTQI#/9W $<H.&(-
MM$A]6+ 9Q7Z8?M4_\$O?@#^VYKL.K?%+X5^%?%VLVZ>4FHW%MY=YL& %,L95
MV    ). !78?LR_L<?"[]C+PA-H/PM\">&_ VE74HFN(M*M%B>Z<# :60Y>0
M@< L20.!Q0!^=/Q9_P"5P7X8?]D9G_\ 0M3KV+_@Z._Y06_&_P#WM _]2#3:
M^TKCX#>!;[XN6_Q"E\&^%)O'=I:-80>)&TFW;5H;9OO0K=;/-$9Y^4-CD^M7
M/B=\)O"GQR\%7GAOQIX9T#Q?X=U K]JTK7--BO[*Y*L&7?#,K(V& (R#@@$4
M >1?LG?$C2_@S_P2[^&?C#6VFCT?PO\ "W2M6OWAC,D@M[?28I9"%'4A5; K
M6_8/_;X^'O\ P4<^!:_$7X9W>IWGAIK^;30]_9M:S>=$%+@H<XQN%>HS?#S0
M+CP)_P (O)H>CMX9^Q#3?[(:RC-A]E">6+?R-OE^4$PNS&W QC'%8OP?^ 7@
MG]G;PN-!^'_@_P +^!=!,K7']F>']+@TVS,K#YG\J%50$XR<#D\GF@#LJ_'/
M_@RI_P"4='Q._P"RE7/_ *;-.K]AG2.ZA99%5T88*L.'!XY'<'IS7'_!;]G;
MP#^S?HM[I?P]\%>$/ NFZA=&^NK/P]H\&FP7,[*$,LB0JH9RJJ"Q&3B@#MJ_
M-/\ X.K_ (D^-OA?_P $NGF\'7^K:38Z]XHL=(\5WFF!OM":-)#=&=<CHA8(
M#VY]Z_2J,Y3_ #Q[5E^._ FB_$[PAJ'A_P 1:58ZWH>KPM;7EC>PB:"YC88*
MLK @B@#\K_AAX-_X)9?L0?LS:;XULT^ OBQ+?3UGA;4+JS\2:_JDN#\B6\K/
M(92^1P@VG'08(Y?_ (-$?C)X9UWX5?'S0XKNQTKQ!J_Q*OM?M= D=8;N&PD@
MMPC"#@JBD%< 8&WL,5]X?!O_ ((P?LK_  !^)]OXT\(? _P+I'B:RE6>UO5M
M6F-E(O1X4D9DB8>J*#GWKL?AC_P3D^!_P4_:2UCXN^$_AOX?\/\ Q&\1"9=0
MUBR62-[GSB&E)C#>6I<KN8JH))).222 ?G)_P;G?&KPEX*_;-_;=\(ZSXHT3
M3/$^N?&"_DT[2[R_CBO+]5O+]6:*(D%N2 =N><UX'_P3^^$7[,_[&/\ P4-_
M:$^!7[7G@+X:V^JZCXHE\1^"?$GC;3[:2QO-.N'+1PI<3C8"5D1N<#<''4$#
M]A4_X)<?L_I^TS%\98?A;X9M_B7'=F_778$>.8SD8\TJK!-V.^WDDDY)-='^
MU-^PA\'?VWM!M=/^+'P\\->.(+$DVKZC;;I[3.<^5,I$B Y/"L!0!^87[2'Q
M'_8CTW]KGX6?!O\ 9W_9Q_9[^.?CKQKK,<.K3:%I]G-IOANR5E,ER]Q K1ET
MR20&&W85)W?+78_\'']K%8_M7?\ !/.&WCCAMX?C)9)''&H5447FF   <  =
MA7Z ?LL?\$\/@G^Q'#<K\)_AKX5\#S7HVW-U8VNZZN%!)VM/(6D8<]"Q Z=A
M7<_$SX > _C7J.@WGC#P7X3\5W7A>[%_H\VL:3!?2:3<C&)K=I%8Q2# ^9,'
M@<\4 9?[77_)J'Q/_P"Q2U7_ -(Y:_,__@AC_P JM&N?]BUXV_\ 1E_7ZTZU
MHEGXDT>ZT_4;.UO]/OHFAN+:YB66&XC889'1@0RD$@@C!KG_ (;_  0\%_![
MX>KX2\(>$_#/A?PJ@E5='TC3(;&P42LS2XAB54&]G=FX^8LQ.22: /ST_P"#
M47XX>#?$/_!(;X:^";+Q5X?N_&6@RZW+J&AQ:C#)J-C&^KW4BO) #YB*5FC8
M%A@AP<X(KZ=_X*]_MAV_["7_  3P^*7Q&6XBM=:T_1GL]&9A]_4+@-#:C_OX
M^?P-;_[-W_!,GX$?L@?%O6?'/PQ^&?A_P7XHU^U>RU"^L/-'VB%Y(Y6387**
M"\:GY5'(^N?3?B_\!O O[0WA-=!\?>#/"?CG0UE6==.\0:1;ZG:"1?NOY4R,
MFX=CC(H _*'_ ((A?\&]_P "O&/_  3@^'WC#XV?"W2_%GC[QW _B*XGO[NY
M4V]M<.SVH58Y%49MS"Q&,$MGK7G_ /P<._\ !%WX5?L6_L/Z?\;/V>_ UC\/
M_%/PL\2V.JWMUIT\S.;9Y$B5SYCL3Y<YA88_OMVX'[A:3I5KH6EVUC8V\%G9
M6<2P6\$$8CB@C4 *B*H 55    P !5'QQX$T/XG>$[[0/$FC:5X@T+5(C!>Z
M=J5I'=VEW&>J212 HZ^S B@#\0?^#D;]JR#]JW_@CE^RK\8O#D9N'\3>,--U
MB.*(':+H:?=M-;XZ_+-%(O\ VSK[Z^#7_!?O]E_XD?LI6/Q*U7XM^"=!NO[-
M6ZU'0+O5X(]6M;D+E[=;;=YK$NI"X'S J>AKY5_X.=_A)X3^ W[)/[,_AGP/
MX7\.^#?#>F?&33Y+/2M&TR&QTZV9X[IW"P0JJ*'=W=MH&6+$\DFON#XI?\$4
M/V5?C5\3[KQEXG^!_@G5?$-],;BZN7MV5;MSU:2-6",?JM 'YK?\$H-#U[]H
MGX+?\%#_ -JK4-+NM-T'XTZ5KL/AJ*9=HN[2&VOWW*#SQO1#GN#VJY_P:R?\
M%=/A)\+?V&;7X+_$WQIH/P[UKPMJ-Y>Z+/XDOTTZTU>QN9WE+1SS%8\I<-.A
M4-U7UR*_57]L_P (Z7X"_P""=GQ>T71-/L])TG3?A[K<%I9VD*PPV\8TZ?"J
MJ@ #Z5^??_!!?_@GA\%?VZO^"%GP/3XL?#KPWXUETR77X[*YO;?%U9H==OR5
MCF0AU4G)QG'/TH \^_:#_:#T#_@LS_P7_P#V=-!^$-XOBCP-^S5=/XHUWQ%9
MR"33Y9A/!-MC?N ]M&@/1B3C(%>E_L[_ /*X3\>/^R,VO\]"K]&/V7OV,?A9
M^Q7X-F\/_"OP+X=\#Z3=2":YBTRU$<EW(!@/+(<O(0. 7)P.!QQ706/P"\":
M;\7KWXA6O@OPG;^/M2M5L;OQ+%I%NFL75NH4+#)=A/.>,!$ 4L0 J\<"@#\S
M_P#@F9*H_P"#E7]NB/< TFEZ.P Z_+!:#/\ Y$Q7DW_!!S]I[P;_ ,$A_C=\
M>OV4_CGK^C_#/4;7QM)XB\-7NNWBV=AJMM<Q0PQ[)I"(_FBAA<'('+#)(./V
M*\-? 7P/X,^)>N>,M'\&^%=)\7>)P@U?7+/28(-1U4(JJHN+A5$DN%50-Y.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.5XHI:*\D]H_._\ X.4O^3+/!_\ V.UM_P"D%_7XGGK7[8?\'*7_ "99X/\
M^QVMO_2"_K\3SUK]FX'_ .19_P!O,_">/_\ D:/_  H****^R/B0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *^D?^"0_P#RD?\ A1_V$KC_ -$"OFZOI'_@D/\
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MK_\ (U']CYA_SXG_ . 2_P @_MW+?^@B'_@<?\SZNHKY1_X?;_LP?]%.C_\
M!!JO_P C4?\ #[?]F#_HIT?_ ((-5_\ D:C^Q\P_Y\3_ / )?Y!_;N6_]!$/
M_ X_YGU=17RC_P /M_V8/^BG1_\ @@U7_P"1J/\ A]O^S!_T4Z/_ ,$&J_\
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M5\H_\/M_V8/^BG1_^"#5?_D:C_A]O^S!_P!%.C_\$&J__(U']CYA_P ^)_\
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M_P#D:C^Q\P_Y\3_\ E_D']NY;_T$0_\  X_YGU=17RC_ ,/M_P!F#_HIT?\
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M_(U'_#[?]F#_ **='_X(-5_^1J/['S#_ )\3_P# )?Y!_;N6_P#01#_P./\
MF?5U%?*/_#[?]F#_ **='_X(-5_^1J/^'V_[,'_13H__  0:K_\ (U']CYA_
MSXG_ . 2_P @_MW+?^@B'_@<?\SZNHKY1_X?;_LP?]%.C_\ !!JO_P C4?\
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MBG1_^"#5?_D:C_A]O^S!_P!%.C_\$&J__(U']CYA_P ^)_\ @$O\@_MW+?\
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M?^'V_P"S!_T4Z/\ \$&J_P#R-1_P^W_9@_Z*='_X(-5_^1J/['S#_GQ/_P
ME_D']NY;_P!!$/\ P./^9]745\H_\/M_V8/^BG1_^"#5?_D:C_A]O^S!_P!%
M.C_\$&J__(U']CYA_P ^)_\ @$O\@_MW+?\ H(A_X''_ #/JZBOE'_A]O^S!
M_P!%.C_\$&J__(U'_#[?]F#_ **='_X(-5_^1J/['S#_ )\3_P# )?Y!_;N6
M_P#01#_P./\ F?5U%?*/_#[?]F#_ **='_X(-5_^1J/^'V_[,'_13H__  0:
MK_\ (U']CYA_SXG_ . 2_P @_MW+?^@B'_@<?\SZNHKY1_X?;_LP?]%.C_\
M!!JO_P C4?\ #[?]F#_HIT?_ ((-5_\ D:C^Q\P_Y\3_ / )?Y!_;N6_]!$/
M_ X_YGU=17RC_P /M_V8/^BG1_\ @@U7_P"1J/\ A]O^S!_T4Z/_ ,$&J_\
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M5\H_\/M_V8/^BG1_^"#5?_D:C_A]O^S!_P!%.C_\$&J__(U']CYA_P ^)_\
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M_P#D:C^Q\P_Y\3_\ E_D']NY;_T$0_\  X_YGU=17RC_ ,/M_P!F#_HIT?\
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M_(U'_#[?]F#_ **='_X(-5_^1J/['S#_ )\3_P# )?Y!_;N6_P#01#_P./\
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ML?,/^?$__ )?Y!_;N6_]!$/_  ./^9]745\H_P##[?\ 9@_Z*='_ ."#5?\
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M!JO_ ,C4?V/F'_/B?_@$O\@_MW+?^@B'_@<?\SZNHKY1_P"'V_[,'_13H_\
MP0:K_P#(U'_#[?\ 9@_Z*='_ ."#5?\ Y&H_L?,/^?$__ )?Y!_;N6_]!$/_
M  ./^9]745\H_P##[?\ 9@_Z*='_ ."#5?\ Y&H_X?;_ +,'_13H_P#P0:K_
M /(U']CYA_SXG_X!+_(/[=RW_H(A_P"!Q_S/JZBOE'_A]O\ LP?]%.C_ /!!
MJO\ \C4?\/M_V8/^BG1_^"#5?_D:C^Q\P_Y\3_\  )?Y!_;N6_\ 01#_ ,#C
M_F?5U%?*/_#[?]F#_HIT?_@@U7_Y&H_X?;_LP?\ 13H__!!JO_R-1_8^8?\
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M_13H_P#P0:K_ /(U']CYA_SXG_X!+_(/[=RW_H(A_P"!Q_S/JZBOE'_A]O\
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M_8^8?\^)_P#@$O\ (/[=RW_H(A_X''_,^KJ*^4?^'V_[,'_13H__  0:K_\
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ML?,/^?$__ )?Y!_;N6_]!$/_  ./^9]745\H_P##[?\ 9@_Z*='_ ."#5?\
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M_P":7GV['/E.63IR>+Q;YJTMWTBOY8^2_$;%_JQBG49S17CGN!1110!\=?\
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M4-E1_P .&/VF/^A1T7_PH;*OWXHH_P!?<Q_EA]S_ /D@_P"(<Y7_ #3^]?\
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M?_%4?\.K/V=_^B1^#_\ P%;_ .*KZ HH_M+&?\_9?^!/_,/[*P7_ #YA_P"
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M /1(_!__ ("M_P#%4?\ #JS]G?\ Z)'X/_\  5O_ (JOH"BC^TL9_P _9?\
M@3_S#^RL%_SYA_X"O\CY_P#^'5G[._\ T2/P?_X"M_\ %4?\.K/V=_\ HD?@
M_P#\!6_^*KZ HH_M+&?\_9?^!/\ S#^RL%_SYA_X"O\ (^?_ /AU9^SO_P!$
MC\'_ /@*W_Q5'_#JS]G?_HD?@_\ \!6_^*KZ HH_M+&?\_9?^!/_ ##^RL%_
MSYA_X"O\CY__ .'5G[.__1(_!_\ X"M_\51_PZL_9W_Z)'X/_P# 5O\ XJOH
M"BC^TL9_S]E_X$_\P_LK!?\ /F'_ ("O\CY__P"'5G[._P#T2/P?_P" K?\
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M*W_Q5'_#JS]G?_HD?@__ ,!6_P#BJ^@**/[2QG_/V7_@3_S#^RL%_P ^8?\
M@*_R/G__ (=6?L[_ /1(_!__ ("M_P#%4?\ #JS]G?\ Z)'X/_\  5O_ (JO
MH"BC^TL9_P _9?\ @3_S#^RL%_SYA_X"O\CY_P#^'5G[._\ T2/P?_X"M_\
M%4?\.K/V=_\ HD?@_P#\!6_^*KZ HH_M+&?\_9?^!/\ S#^RL%_SYA_X"O\
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MX/\ _ 5O_BJ^@**/[2QG_/V7_@3_ ,P_LK!?\^8?^ K_ "/G_P#X=6?L[_\
M1(_!_P#X"M_\51_PZL_9W_Z)'X/_ / 5O_BJ^@**/[2QG_/V7_@3_P P_LK!
M?\^8?^ K_(^?_P#AU9^SO_T2/P?_ . K?_%4?\.K/V=_^B1^#_\ P%;_ .*K
MZ HH_M+&?\_9?^!/_,/[*P7_ #YA_P" K_(^?_\ AU9^SO\ ]$C\'_\ @*W_
M ,51_P .K/V=_P#HD?@__P !6_\ BJ^@**/[2QG_ #]E_P"!/_,/[*P7_/F'
M_@*_R/G_ /X=6?L[_P#1(_!__@*W_P 51_PZL_9W_P"B1^#_ /P%;_XJOH"B
MC^TL9_S]E_X$_P#,/[*P7_/F'_@*_P CY_\ ^'5G[.__ $2/P?\ ^ K?_%4?
M\.K/V=_^B1^#_P#P%;_XJOH"BC^TL9_S]E_X$_\ ,/[*P7_/F'_@*_R/G_\
MX=6?L[_]$C\'_P#@*W_Q5'_#JS]G?_HD?@__ ,!6_P#BJ^@**/[2QG_/V7_@
M3_S#^RL%_P ^8?\ @*_R/G__ (=6?L[_ /1(_!__ ("M_P#%4?\ #JS]G?\
MZ)'X/_\  5O_ (JOH"BC^TL9_P _9?\ @3_S#^RL%_SYA_X"O\CY_P#^'5G[
M._\ T2/P?_X"M_\ %4?\.K/V=_\ HD?@_P#\!6_^*KZ HH_M+&?\_9?^!/\
MS#^RL%_SYA_X"O\ (^?_ /AU9^SO_P!$C\'_ /@*W_Q5'_#JS]G?_HD?@_\
M\!6_^*KZ HH_M+&?\_9?^!/_ ##^RL%_SYA_X"O\CY__ .'5G[.__1(_!_\
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MA_X"O\CY_P#^'5G[._\ T2/P?_X"M_\ %4?\.K/V=_\ HD?@_P#\!6_^*KZ
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M_P" K_(^?_\ AU9^SO\ ]$C\'_\ @*W_ ,51_P .K/V=_P#HD?@__P !6_\
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M9?\ @3_S#^RL%_SYA_X"O\CY_P#^'5G[._\ T2/P?_X"M_\ %4?\.K/V=_\
MHD?@_P#\!6_^*KZ HH_M+&?\_9?^!/\ S#^RL%_SYA_X"O\ (^?_ /AU9^SO
M_P!$C\'_ /@*W_Q5'_#JS]G?_HD?@_\ \!6_^*KZ HH_M+&?\_9?^!/_ ##^
MRL%_SYA_X"O\CY__ .'5G[.__1(_!_\ X"M_\51_PZL_9W_Z)'X/_P# 5O\
MXJOH"BC^TL9_S]E_X$_\P_LK!?\ /F'_ ("O\CY__P"'5G[._P#T2/P?_P"
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M5G[._P#T2/P?_P" K?\ Q5'_  ZL_9W_ .B1^#__  %;_P"*KZ HH_M+&?\
M/V7_ ($_\P_LK!?\^8?^ K_(^?\ _AU9^SO_ -$C\'_^ K?_ !5'_#JS]G?_
M *)'X/\ _ 5O_BJ^@**/[2QG_/V7_@3_ ,P_LK!?\^8?^ K_ "/G_P#X=6?L
M[_\ 1(_!_P#X"M_\51_PZL_9W_Z)'X/_ / 5O_BJ^@**/[2QG_/V7_@3_P P
M_LK!?\^8?^ K_(^?_P#AU9^SO_T2/P?_ . K?_%4?\.K/V=_^B1^#_\ P%;_
M .*KZ HH_M+&?\_9?^!/_,/[*P7_ #YA_P" K_(^?_\ AU9^SO\ ]$C\'_\
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M!_\ X"M_\51_PZL_9W_Z)'X/_P# 5O\ XJOH"BC^TL9_S]E_X$_\P_LK!?\
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M/V=_^B1^#_\ P%;_ .*KZ HH_M+&?\_9?^!/_,/[*P7_ #YA_P" K_(^?_\
MAU9^SO\ ]$C\'_\ @*W_ ,51_P .K/V=_P#HD?@__P !6_\ BJ^@**/[2QG_
M #]E_P"!/_,/[*P7_/F'_@*_R/G_ /X=6?L[_P#1(_!__@*W_P 51_PZL_9W
M_P"B1^#_ /P%;_XJOH"BC^TL9_S]E_X$_P#,/[*P7_/F'_@*_P CY_\ ^'5G
M[.__ $2/P?\ ^ K?_%4?\.K/V=_^B1^#_P#P%;_XJOH"BC^TL9_S]E_X$_\
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M_9W_ .B1^#__  %;_P"*KZ HH_M+&?\ /V7_ ($_\P_LK!?\^8?^ K_(^?\
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M ##^RL%_SYA_X"O\CY__ .'5G[.__1(_!_\ X"M_\51_PZL_9W_Z)'X/_P#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!\_?\%4#_QKV^+'_8"D_P#0EKDO^"*#;/\ @F!\+>G_ ![WW?J?[0NJZW_@
MJ>P'_!/?XL%NBZ%(?_'EK\T?@M_P4 \777[!OPE_9S^"%K/>?$[Q-:7<&IWL
M?_,'@DO+B3"_W6,<BNTG1$/KT^JR_+ZF,ROV5/\ Y^7;Z)<N[9\;F>84L'FW
MM:F_LK)+5M\VR1])_P#!2#_@H)XD^-WQ/_X9Q_9Y<ZEXRUUWL_$&MVC@QZ1&
M!^\C1LXW!3\[?PJ"*^F/^">O_!/_ ,,?L%_""/2--5;[Q+J@6?7=78?O+V;K
MM4]1&G11W !/-9/_  3?_P""<WA[]@?X8;59-6\;ZZBRZ]J[C<\SGDP1GJ(D
M8\9^]C<>3Q]+QMO';WP:X<RQU.-/ZC@?X:W?6;[OR[(]'+,MJSJ_VACOXCV7
M2"[+S[L<A!7Y>E+0.E%>&?0A1110 4444 %%%% !17@O_!0+XY^)/@#\*M-U
M;PQ<P6M]=:K':2/+;K,OEF*5CPW'517R&W_!2OXM9/\ Q/-/Z]M,MA_,U]=D
MO!>/S3#_ %G#RBHWMJVGIZ)GQ>><=9=E6*^J8F,W*U]$FM?-M'Z;45^9(_X*
M6?%H?\QRP_\ !;:_XT?\/+?BW_T'+#_P6VO^->M_Q#'-OYJ?_@3_ /D3Q_\
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M?\0QS;^:G_X$_P#Y$/\ B*V3_P E3_P&/_R1^FU%?F3_ ,/+?BW_ -!RP_\
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M\%MK_C1_Q#'-OYJ?_@3_ /D0_P"(K9/_ "5/_ 8__)'Z;45^9/\ P\M^+?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#Y5_X*W_\D"T+_L/Q?^DUS7Y\U^@W_!6_
M_D@6A?\ 8?B_])KFOSYK]_\ #?\ Y%*_QO\ 0_FWQ._Y'4O\*"BBBOT$_/0H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *]8_8<_Y.L\%_P#7W-_Z*KR>O6/V'/\
MDZSP7_U]S?\ HJO)S[_D75_\$OR/8X?_ .1E0_QQ_,_5=/NTM(GW:6OY5/Z\
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#Y5_P""M_\ R0+0O^P_%_Z37-?GS7Z#?\%;_P#D@6A?]A^+_P!)KFOSYK]_
M\-_^12O\;_0_FWQ._P"1U+_"@HHHK]!/ST**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "O6/V'/\ DZSP7_U]S?\ HJO)Z]8_8<_Y.L\%_P#7W-_Z*KR<^_Y%U?\
MP2_(]CA__D94/\<?S/U73[M+2)]VEK^53^O HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BFF-68-CE>GZ_XFOY<_\ @K3^TCXH\5_\%X?%WQ:TF]NAX-^"?Q0\*>%V
M16^6.>W9)) /K<:9<'\O>@#^HZBF+*) &7YMPR/?_.:_F^_X.I_V^O$'[4'Q
MIU+P%X"U"Z7X:_ 6^M+'7]1M#F&[\27JS&.$,.3Y44,R=3AUEH _I$HKQ?\
M8P^'ME^Q]^P-\,?#?B*_L]'A\#>#M.M=6O+^X6&&":.VC^T222,0JCS=Y))
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% 'RK_P5O_Y(%H7_ &'XO_2:YK\^:_0;_@K?_P D"T+_ +#\7_I-<U^?
M-?O_ (;_ /(I7^-_H?S;XG?\CJ7^%!1117Z"?GH4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>L?L.?\G6>"_P#K[F_]%5Y/7K'[#G_)UG@O_K[F_P#15>3GW_(N
MK_X)?D>QP_\ \C*A_CC^9^JZ?=I:1/NTM?RJ?UX%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS\1_%W2O^"2O[,7[(>K>%(KSX.^,=:L]#DM8]1TC;K6MWUT(CB9)U:0[S)R
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M6A?]A^+_ -)KFOSYK]_\-_\ D4K_ !O]#^;?$[_D=2_PH****_03\]"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KUC]AS_DZSP7_P!?<W_HJO)Z]8_8<_Y.L\%_
M]?<W_HJO)S[_ )%U?_!+\CV.'_\ D94/\<?S/U73[M+2)]VEK^53^O HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?L8?L#>!_"GPQ_9!T/QIX4OEFUFU\0WOB"&TFU6*ZD>X5VB:X1EVB38,J,A
M><YKV3XM?L??MR?\%O=8\.^$?VAO"_A/]GWX'Z;?Q:AK>B:1J*WFHZZT;!E5
MF260<8X^90OIGF@#]*O^";GQTUG]IK]@+X.?$#Q$JKKWB_PCIVIZ@0,!YY+=
M"[C_ 'FRWXU:_;O_ &SO"O\ P3__ &7/%GQ4\8S,ND^&[;?%;HW[R_NF^6&V
M3_:=]H_$GM7IG@'P1I_PT\#:+X<TB'[/I6@V,.G6<6<^7#%&L:#/LJBOR/\
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M'A?X5^$/#<^GGXB7EY=&S@\7_9X426".::6,@/(&8;LGD'FOA_\ X*A>)/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %>L?L.?\ )UG@O_K[F_\
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M?P\\/>+KAK70!:#;B81N?+8RQD3 $X8R,3NX Y'_ (+Q?\%!OV;O'_[+EO\
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M"^#/PWTB3PQ\+X-27;+JDK%DGO@O!53OE8=<;T!Y4Y_0#QE_P37_ &>?B/\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RK_P5O\
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M^./YGZKI]VEI$^[2U_*I_7@4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% #&7DX[]_3I7\P'_  =X_L"?
M\,Z_MT6/Q=T.Q,/ASXQ6PDN3$-L<&KVZJDP ]9(PDG^\SU_4%7QC_P %[_V#
MQ_P4!_X)K>.O#-G;B7Q1X<@/B3P^=VTF[ME9C'GT>,NOU84 ?QJO@,2,[<_*
M#Z5_2+_P9K?L"R?#']G3Q7\?-:LQ'J?Q#N&T709"=VW3K64K.X'8O<QLN?\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O6/V'/^3K/!?\
MU]S?^BJ\GKUC]AS_ ).L\%_]?<W_ **KR<^_Y%U?_!+\CV.'_P#D94/\<?S/
MU73[M+2)]VEK^53^O HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "D*A@<C.X8.>]+10!^>O[&O_  ;[
M^ _V-/\ @ISX[_:)TO6YM2B\0O=3Z#H,EF-N@7%XV;J02%CN'S.%& 0KD9X&
M?T&MG#P*5.Y2/E.=VX=CGWZU)10 4444 %%%% !1110 4444 %%%% !1110
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M'Q$_XJS76SDJ;A1]FB_X!:K""/[Y>@#[XHHS10 4444 %%%% !1110 4444
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MPW_Y%*_QO]#^=_$[_D=2_P *"BBBOT$_/0HHHH **** "BBB@ HHHH ****
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M'_Z"VF?^!2?XU^>E%?2_ZCT_^?S^[_@GR_\ K]4_Y\K_ ,"_X!^A?_"<:/\
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M/_GZ_N_X(?Z_5/\ GRO_  +_ (!^A?\ PG&C_P#06TS_ ,"D_P :/^$XT?\
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M"D_QH_X3C1_^@MIG_@4G^-?GI11_J/3_ .?K^[_@A_K]4_Y\K_P+_@'Z%_\
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M?%WB;XG:+:Z/\3/'U\(YK99EEDTS3H?]7$60E#OD+R$ \ KZ5^H>: "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %>L?L.?\G6>"_\ K[F_]%5Y/7K'[#G_ "=9X+_Z
M^YO_ $57DY]_R+J_^"7Y'L</_P#(RH?XX_F?JNGW:6D3[M+7\JG]>!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% #)ON?A7Y\_$#_D?M<_["-Q_Z-:OT&F^Y^%?GS\0/^1^
MUS_L(W'_ *-:OM^"?XM7T1\!QY_"I>K,BBBBOT4_,@HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*V#Q;UV3_1GT*AR/6EH'2BOA3]#"BBB@ HHHH **** "BBB@ HHHH ****
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M ."7Y'L</_\ (RH?XX_F?JNGW:6D3[M+7\JG]>!1110 4444 %%%% !1110
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M_8JMAITXJ4K:W6^NG?L%%%%;'.%%%% !117S5JG[:/B"T_X*?Z?\#8],T?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC:^&;B=?$'C"[@CAN=1GDD#1VENJ# 'D>6I  R03GGGZ._;9^*?[0'B3X_\
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M@9Q7RK_P6,_8H\3?![]E"/Q9X[^/7CWXD:Q)K5I9V&FWR+:Z<QD$I>18!PF
M.W4Y/>OIK_@M4=W_  21U/TVZ)CG/'FIBHE*K&&)HM-)15DWS6O?S?YFT8TY
M5<)7@TY.;3<8\J=K/:R^^Q5_;A_:@\<?LQ_LP?LXW'@G6VT67Q)JVD:1J6+.
M&;[3;-;1DIE@2,G_ /6*]T_:^^%GQV^)>J:#-\'?BKI/PYMK>.3^U4O=$MK[
M[8Q.5.UH6 P.,;C^'2ODO_@J^<?LH?LI_P#8TZ/_ .DD5?7/[=W[;&A?L/?!
M!O$%Y&=3\1:DJV>@:+@EM5O"!Y:C )VJ3DX':NRC4C^^563C%*+T;73I9G%6
MH-*@Z$$YRE-:I.^O6_;N?"/[6OQ9_;!_9=^('@WP3:?M Z/XX\>^-IO(L-!T
MOPE81RV\)Z3NWV?Y>^.^!GM7UK^W/^VCXF_8;_98\'^99VGB?XN^+1:Z%86[
M1HT4NH-$HEF*QJJY$A(P .>#SS63_P $U/V)-=\ :CJWQN^+#+JWQH^(*K<2
MF0_\B_;. !;_ %$808[8QDXR?%?^"\?A*^U?X_?LPWL>O:AX9TN/Q!=6+:U"
MNYM'F>>P*7 '^SU_X#6$HXC#X6>)BY>]9).3;2?75Z-_@;Q>'Q6,I8648M1N
MY244E)I-VT6RM;S.BU3]F?\ ;D\-^!Y/'$?QZTG4/%<%NU[)X0?2T%LX2,2-
M%'*1\VT<$8&&!&>,UZI^S#_P5#TGXL?L!^(OC!XDTV/2]2\ _:+/Q'I=NFQ)
M+Z% R+&?XMX*N1V+D=JP9?\ @G%\8K."YFG_ &Q/B*UNJ/+/,-,$D<D(#,SG
M)Z$9//K7S+XK_9E\*>#?^"/7[0DWPS^(UY\4K;6=;L+S4KR72C:;)[:ZM7F4
M'^+B0GCTJ>?$X9N5/F2Y9-J4D[M:W2NV7&GA<4E3J.+?-%)Q@XV3=FF^5+^M
MST'X!Z)^V-_P4&\')\4[/XN6'PA\-ZO*\GA[2(]-AF$D =E61L_, 74\MG.<
MC .*XK]CKXD?$;Q]_P %Q['3OBM9:=9^//#'A6;0]1EL8Q'#J!4>=%. ./GB
ME1CZDD\=*^]_^"<_C#2?'?["_P ([_1)%N+&'PM8681/NQS0P+;RJ?=)(W4^
MZU\F>'O%VD>*_P#@XWGCT^:.X_LWPA]AO)(_N&86Z-@?0.H/TI5L.H1P]5U)
M2<I1;N[IW[)["P^,=2>)HJE&*C&5K))JVEF^OSN?HQ$V^)&Z[E#?F,U^9O[?
M/Q3\/_!+_@O'\$?%?B;5(='T+1_!1>\NYQ^[A#G64&?Q('U-?IE$6,,>[KL7
M^0K\T_VZ?A]H?Q6_X+X_ SP[XDTBQUW0]4\%,MW87L2S0W(4ZRP!0]0" <'N
M,UZ.?<WLH<MK\T;7VW\CS.&^7V]1SVY)WMO;YGTKXA_X+$_LV>&M&FNS\4-%
MOOLT9Q9V<;N]S@JP&!QSMKYR_P""'>CZM\6/VEOCW\;H])N-)\(>.M8;^R1,
MC1Q7;RWLDK%=W!PK<^^1VKZ\M/\ @G)\ ;6Z$D/P:^&Y"_=8:!;#:>HQNYX]
M_2O8=&TFTT'3;6RL+6SLK.UVQ0P6L"00Q*"H 5$^4?AU.35?4L54K1K8J4;0
MO9136MM[LCZ]@Z5"='"QE[]DW)K:^R2/S!^$G[7G[47[8WQ:^*_PG\!^(],T
MRY\,^++\2^+-0MH5CT+3$D>"&VAVH6,K.N0>3@_B/7_VP?VNOBQ^SAX<^$/P
M*\$W5IXG^.7C;3X8;S6KI/,2V" I),00,,2C'IQ@]<8./_P1$MU7XU_M4R_Q
M-\0I!_Y,7E4?C]>0^ /^#@GX/ZMKB[--UKP:]G87#_=@G*:@@Q_P+_T*O*IR
MK+"1JNI+FG+EO?9.5M%T/:JQH/&RH*G'EIQYK6W:BGJ_T*7QB^&7[9G[$WPZ
MOOB:OQJTOXH6OAU/[0UOP[/I7EQ>2#B1D;'S;0".,8(/7I7N?Q#_ ."H?AWP
ME_P3:LOC_86*SMK5HL.FZ;*^X2ZCO:%XF]%25'_!:]D_:_\ %.F^!?V5OB1J
M>M2-%I]IX=O8IL]99/+('YU^/_Q*^'NL6W_!OS\,=0N899-/@^(+ZM(N,B*S
M8WT*X^LC.?QK7'5*F!G*%"3:<&]6W9IVOJ8X"C2S"G&>)BDU-+1*-TU>S2\T
M?6'PH^"/[<7QK\$6/Q+G^-&E^&=:U.%;_2_"$FFB>W=6R\=O*V"(R5VD#G[W
M6N/_ .",_P 2?$'QE_X*/_'[6_&.DPZ3XDN-*LK+5[2+_5QW$,D5M*R^S/$6
MQVW5^EW@#QAIOCWP5HVO:+<1S:1K-E!?6LO\)BD$;K^2D#\*_/C_ ()E>+=+
M\;_\%?\ ]J34=&*MI\ACC0J."T=U'&__ (^K4ZV$5&OAVIRE>6MW>[MOKM\A
M8?&RKX?%1=.,;1TM%*RYEIIO\SU__@G;^U+X]^/O[5W[3WAOQ5K7]JZ7X!\3
MQ6.B0^5%']D22?4(R/, WM\J=#G'3IBI/^"E_P"U'XX_9Z^.?[.NE>#]9;2]
M.\=^-8M.UF,6D4WVRV:YL_ERX+=#WQ['%><_\$CIE_X;X_;44_\ 0YVW_I9J
M=4_^"R7BBS3]L3]C_1HY";Q/'4%](O\ =0WE@G]*IXBI_9O/S._-:_7XB886
MG+-E2Y5R\J=K:? G>QZ=_P %)/VT?&WPN^*?@GX+_!NUL6^)GQ"<B*]NXED3
M1;169#*$7Y5;Y&/T!/)X/C'QWL/VNO\ @G)X!;XH:C\8-/\ B]X=TFYC_P"$
MCT6ZTD0)'"S[24;'(]QC'7GI6W\5KN#X?_\ !Q#X#O=< 6PU[P:]MI$K]%E$
M=VG'_ E?\Z^V/V@?CQX>_9D^$NK>-O&%Y-:Z'X?2%[MHXO.FE+RH@ 7U+#BJ
MITWB75J3JN+B[*S=E9;VV=_,RJ5%A(T:5.E&:FDW=)N5WLGNK;:'YK_\%H[O
MQW\6OA]\(?'^F^.K>#X?^,M9TEM$\.G28&?1]0EM'?[09F^:8 EL \ ,%["O
MH+]MSXH?&S]B'_@F=K6O7_Q+7Q)\2-.U2T6/7X-'M[8"WEN-I0(!@84A>G.W
M/>O/_P#@M7\1M/\ B_\ LD? #Q5I*WB:7XB\;Z9J-H+J'R9C%+:3.A*]LJ01
MZ@@UZ;_P7S_Y1I>+?^PCIG_I0M<TERSQ-6,FWRK6[MJNUSMC)3CA*4X*SF]&
METDM-OO[G1_MH_MZWG[(?[$OAGQ>MNNN>./&%K9V6DV;0J([N]F@1VG9%XX)
M)P.OU->-1?LP?MR:AX#C\=?\+[TVW\5R6AU"/PHFG)]G">4)#")"/[I&>.#D
M>]<I_P %:I1X5^&/['OBS45V^&/#^O:<=2;U/E6LH_\ (<,M?IG:7]O-;1W&
MZ/['($F+GO'D22?^.**ZJ<)8JO.%6<DH)6LVMU>^G4XJLHX/#TYT81;G*5VX
MJ6B=DM=OE8^1?V0?^"ANJ_M7_L%_$#Q1<6MOX?\ B+X!T_4;#5884C^S+=PV
MSLEPB/\ *3PI(_O$UXA^Q9\5_P!J;_@IK^SYIFH:?\3+'X9:1H,LMKJ/B7^P
MX;K4?$5_YTD@,4* "*..%XXBPQDQECRQKG_^"<%VOBSPA^WEXNTD[M \07NH
MR6!]=J:I./\ QR45]&?\$'H%B_X)C^ =D?[R:[U,L_KB_NA7/A)U<7.E"I-V
MY97L[7L[=#JQM.C@X5JM*G&ZG"UTG:ZN]SF?V ?VC_B_X"_;;\:?L[_&'Q!8
M^,KS0=&&N:5X@6W5&GBS PZ=,K(!CL017W0J[$5?[H _*O@GPG_RL+^(.<_\
M6ZCY_P" 15]['K7KY34G[.<9-OEDTFW=VOW/$SJ,%4IS@DN:*;MHKM;V1^7_
M /P4=^._AW]F3_@N+\&?'7BBXN+7P_X?\$>9>O%"T[#S'UF,80>NX<"O<7_X
M+]?LSQ [?%&M8C) _P"*?N5Z# X7C\J\R_:XT>S\1?\ !PI\!K._M;>]M)O!
M4BR17$:R1M@:TV"I[=^>]?>*_!#P2ZHR^#_"JG ; TJ$#U[\UYV!IXJ56NZ$
MXI<^SBWT]4>KF53!QHX=8F$I/D6TDNO^%G,6/[56B^./V3;SXM>"[/4O%NFK
MI-SJ6FVJ6<D<^HM$7C$'E'Y\>:C=>OTKX_\ @U\'_P!LW]LCP)9_$#5OC7'\
M(WUN0MIGAE/#R;K*,2,B&59 '3)&1NSD,#T(%?6'[:7[0-I^Q%^R%XL\=:?H
M=G-'X;MD2RTZ)%CMA-+,D2L47@#=<9..O)KYK^"/[./[3'[8OPTT3QGXV_:-
MU3P/8^,;*/4+?1/"6F1026]O<;'7-SP2"C*2"3M)(R0*Z,;S3JQHOFE)*[47
MRKM=NZZ]-3DR_DA0G7BHP3E92FN9][)6?3K9'7?\$K_VL_B1\6_&WQ4^%GQ6
MN=-U7QA\)KZ&T&K0PK$NH1S&:(M(%XR%0,, 5YYXA_:0^.7_  4C_:3\<^$_
M@?XPM?AC\.?AS='3]2\126R7%_J5R'VL IY(WA@/]D+]*Y[_ ((P>!;?X:?M
MU?M1>'=+UO4O$EOI-Y96YU*_N%N+B\E#W2;G=>&;SF/TQ@\@UO?\&[T]KH?P
M<^+'A&^=?^$DT'QU/)J*M_SR:!(!_P"18FKAPU:K6A1P]23M)ROKK9.R5ST\
M50HT)U\33@FXJ%KK1.23;Y7HO0UO@M^T-\</V-/VWO"7P6^-GB6S^)GA?XBQ
MLNB>(H;$6]S;S*S JZ@87#@KCG. >YQW_P"RO^U)XV^(_P#P4Y^.GPZUS6?M
MWA7P/9V4FEV/V>WC^S.XMB_[W'F-EV8X.<9P.,"O:?C!^V)X,^"WQJ\!^ =<
MN-1_X2GX@3LNFV]C:^=@@C<\A[?-G\*^4OV'1L_X+6_M2+\NY=.TX-M&,G%K
M^OK[UU:T:M.C"HY+GM;JM+V;ZZZG'3Y:]*I6G147R732T=I)<R5E;1VT%_X)
M1C?_ ,%"_P!M!&.[_BJ[))#M5\#SM4]?0UO?L-?M _&#]L'P]^T5HO\ PG<>
ME>)/#GB^71_"^KRZ7:SQZ,%N& )B89DRH R<X^G%8'_!*+_E(=^VG_V--I_Z
M/U.I_P#@B'_R/O[3G_929_\ T=-7+@Y2M1A=I.52]G;JSLQU.'[ZIRIN,:5K
MJ]M$>,_\$:OA1\8+_P#:+^+UQI_Q4M+'3=$\;O;^*[0:#;2#Q%=++,JSB1E8
M0_O6+;1QS7TU_P $LOVK/&WQ9\5?&#X<_%+6#JOC;X:^(GMUGDM8[=I+!SY*
M?+&JI]Z,'(49!!.223Q'_!%0@?&/]JS=]UOB//\ ^C[JLC]J'Q3IO[ /_!8G
MPG\5-4D^R^!_BQX>GTGQ#-_TTMD )_%(K5?SJ<'_ ++AZ6(BWRJ34E=VLVU?
MY%X_EQ>+K8645S.*<79)W23M\STWXB_M3^._B/\ \%:/"OP9\#Z[_97AOPWI
M)UGQJB644_VHLOFK$2PR,QO$>O\ %7V&)1/^\7=MD^90RJI"GD#"\<# XKX.
M_P""(_A.^^*&F_%+]H/Q%'(^K?%[Q!.]D[-UL;>5B>.V)05_X *^\223\WWO
MXOKWKV\JE*I3=:;?O-M>2Z?>?.9Q&%.M'#TTO<23\Y;N_HPHHHKTSR0HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *]8_8<_Y.L\%_P#7W-_Z*KR>O6/V'/\ DZSP7_U]S?\
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M)U/]JOQE-\-6@%L=+736^V/;#@1&8GY@.G/ &!C Q7UQ\%_V6_!/P#^ %O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !115K0]"O/%.LV]A8PM<W5RPBBA3^)CW;Z5,I**YI;=65&$I248[O9!H>A
M7GBG6;>PL86N;JY8110I_$Q[M]*^R/V>OV>K/X/:1]HN EUKERO[^X(SY8_N
M)Z#^9H_9[_9ZL_@[H_VBXV76N7*XGN"/]6/[B>@'?U->F!J_,>(N(GBI/#X=
MV@MWW_X!^K<,\,QPB6)Q*O-[+M_P1R]**%X%%?)GV@4444 %%%% !1110 44
M44 %%%% !1110 &H9_\ CV?Z'^53&H9_^/9_H?Y4(FI\+/Q5[?A11V_"BOZ]
MI_ O0_C&K\;]0HHHJS,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ II^XW_  +^0IU-/W&_X%_(5,OA
M8X_$OE^A^QGP9_Y))X9_[!=M_P"BEHH^#/\ R23PS_V"[;_T4M%?R3BOXT_5
M_F?V3@O]WAZ+\CY[_P""M_\ R0+0O^P_%_Z37-?GS7Z#?\%;_P#D@6A?]A^+
M_P!)KFOSYK]W\-_^12O\;_0_G?Q._P"1U+_"@HHHK]!/ST**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "O6/V'/\ DZSP7_U]S?\ HJO)Z]8_8<_Y.L\%_P#7W-_Z
M*KR<^_Y%U?\ P2_(]CA__D94/\<?S/U73[M+2)]VEK^53^O HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@".3A6^E?%OC?]GOQI?>--7GA\/:A-%/>S2HZX(8,Y(/ZU]K45
MZV4YQ5R^4I4DGS=[GBYQDE+,8QC5;7+VL?"O_#./CC_H6=2_(4?\,X^./^A9
MU+_OD5]U45[G^NF*_P"?<?Q_S/G_ /4/!_\ /R7X?Y'PK_PSCXX_Z%G4O^^1
M1_PSCXX_Z%G4O^^17W511_KIBOY(_C_F'^H>#_Y^2_#_ "/A7_AG'QQ_T+.I
M?]\BC_AG'QQ_T+.I?]\BONJBC_73%?R1_'_,/]0\'_S\E^'^1\*_\,X^./\
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M?"O_  SCXX_Z%G4O^^11_P ,X^./^A9U+_OD5]U44?ZZ8K^2/X_YA_J'@_\
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M+\/\CX5_X9Q\<?\ 0LZE_P!\BC_AG'QQ_P!"SJ7_ 'R*^ZJ*/]=,5_)'\?\
M,/\ 4/!_\_)?A_D?"O\ PSCXX_Z%G4O^^11_PSCXX_Z%G4O^^17W511_KIBO
MY(_C_F'^H>#_ .?DOP_R/A7_ (9Q\<?]"SJ7_?(H_P"&<?''_0LZE_WR*^ZJ
M*/\ 73%?R1_'_,/]0\'_ ,_)?A_D?"O_  SCXX_Z%G4O^^11_P ,X^./^A9U
M+_OD5]U44?ZZ8K^2/X_YA_J'@_\ GY+\/\CX5_X9Q\<?]"SJ7_?(H_X9Q\<?
M]"SJ7_?(K[JHH_UTQ7\D?Q_S#_4/!_\ /R7X?Y'PK_PSCXX_Z%G4O^^11_PS
MCXX_Z%G4O^^17W511_KIBOY(_C_F'^H>#_Y^2_#_ "/A7_AG'QQ_T+.I?]\B
MC_AG'QQ_T+.I?]\BONJBC_73%?R1_'_,/]0\'_S\E^'^1\*_\,X^./\ H6=2
M_P"^11_PSCXX_P"A9U+_ +Y%?=5%'^NF*_DC^/\ F'^H>#_Y^2_#_(^%?^&<
M?''_ $+.I?\ ?(H_X9Q\<?\ 0LZE_P!\BONJBC_73%?R1_'_ ##_ %#P?_/R
M7X?Y'PK_ ,,X^./^A9U+_OD4?\,X^./^A9U+_OD5]U44?ZZ8K^2/X_YA_J'@
M_P#GY+\/\CX5_P"&<?''_0LZE_WR*/\ AG'QQ_T+.I?]\BONJBC_ %TQ7\D?
MQ_S#_4/!_P#/R7X?Y'PK_P ,X^./^A9U+_OD4?\ #./CC_H6=2_[Y%?=5%'^
MNF*_DC^/^8?ZAX/_ )^2_#_(^%?^&<?''_0LZE_WR*/^&<?''_0LZE_WR*^Z
MJ*/]=,5_)'\?\P_U#P?_ #\E^'^1\*_\,X^./^A9U+_OD4?\,X^./^A9U+_O
MD5]U44?ZZ8K^2/X_YA_J'@_^?DOP_P CX5_X9Q\<?]"SJ7_?(H_X9Q\<?]"S
MJ7_?(K[JHH_UTQ7\D?Q_S#_4/!_\_)?A_D?"O_#./CC_ *%G4O\ OD4?\,X^
M./\ H6=2_P"^17W511_KIBOY(_C_ )A_J'@_^?DOP_R/A7_AG'QQ_P!"SJ7_
M 'R*/^&<?''_ $+.I?\ ?(K[JHH_UTQ7\D?Q_P P_P!0\'_S\E^'^1\*_P##
M./CC_H6=2_[Y%'_#./CC_H6=2_[Y%?=5%'^NF*_DC^/^8?ZAX/\ Y^2_#_(^
M%?\ AG'QQ_T+.I?]\BC_ (9Q\<?]"SJ7_?(K[JHH_P!=,5_)'\?\P_U#P?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"12O\ &_T/YW\3O^1U+_"@HHHK]!/ST**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O6/V'/^3K/!?_ %]S?^BJ\GKUC]AS_DZSP7_U]S?^BJ\G/O\ D75_\$OR
M/8X?_P"1E0_QQ_,_5=/NTM(GW:6OY5/Z\"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQJ_&_4****LS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOAV+5%N+75M2U2,2_;XF62,QM\RB-AD%",'(.#G/2O@+]I/_ ((7?L_?"_\
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MM1-HJRY+'O<L2 , 8%?+?_!$K_@WL\+?M5_L)?#WX@?M&:EXD\8V.H6]S?\
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ML=:!X+USXF:A\7M:^T76H7?BNZE=SJ7GS.\>S?+*0B1&-!\Y!V9& 0!W&O\
M[:7P<\'^/CX5UCXM_#/3/%'FB$:/=^*+&"_#G!">0T@DW$$'&,\U^>__  5J
M^,/CKX,?#S]FK]A_X(ZK<>&_'7Q2L++P_=ZO;Y5]%T*T@2VGD5AT+*C\\'$;
M $$UVUK_ ,&LO[)=K^SR_@^?P9>ZIXDDLVC?Q;<ZG<#5)[HC)G;:VP OSM"X
MQQSU(!^C1N%EMUDC;=&X#*Z$$%3SG/3%<OK'Q^\"^&_!E_XBU+QIX3T_P_I4
MQM[W4[G5[>&SM) <;))F8(C>Q(-?EG_P;K?MP^)- _X(:?%SQ3XRUBZUR/X
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MH44459F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'Q7_P<.?'9?V?_ /@C[\9M1622
M.^UW2D\.V7EC+-+>RI;X_P"^'<_A7SS_ ,&^7_!3OX"?"G_@EKX)^'7C+XD>
M"/AOXT^%HOM,\0:+XDUF#3+B*3[=<R^;&)F7SE=9 V4SAB0>@RW_ (.AY?\
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M'-==-_QZO]#03/X6?BKV_"BCM^%%?U[3^!>A_&-7XWZA1115F84444 %%%%
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MXX_F?JNGW:6D3[M+7\JG]>!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 5]4U&'2+":ZN&$<-NC22.>BJ!DFH]$UBW\0:7;WEG-'
M<6UR@DC=3D,#6;\3O^2=Z[_UX3_^BVKY0_9V_:.N/A%JOV#4'>X\/W#Y=<<V
M;$_?7V/<5[&!R>IC*$ZE'XH].Z/"S'/*>"Q-.C6^&?7LS[-HJMI&K6^N:;#=
MVDT=Q;7"AXY$.58&K->.TT[,]N,E)76P4444%!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% $,UE%-.LK1J\L?W">HJ8444 %%%% !1110!YO\
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MVVC#T!'7/:A$3^%GXJ]OPHH[?A17]>T_@7H?QE5^-^H44459F%%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!A_$[_DG.O?]@^?_P!%M7Y^/]\_6OT#^)W_ "3G7O\ L'S_ /HM
MJ_/Q_OGZU^A<#_!5]4?FG'G\2EZ,]1_9S_:.N/A%J0L-0=[CP_</EU[V9/\
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MXL\+_$+PW_:UCJNBW\-]8W<VW3+F4I-"3&[!Y9E;:3AU8'D&M[_@Y]_X2_\
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M[F_]%5Y.??\ (NK_ ."7Y'L</_\ (RH?XX_F?JNGW:6D3[M+7\JG]>!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8?Q._Y)SKW_
M &#Y_P#T6U?GX_WS]:_0/XG?\DYU[_L'S_\ HMJ_/Q_OGZU^A<#_  5?5'YI
MQY_$I>C$HHHK[H_/CU#]G7]HVX^#^I_8=0>2X\.W#Y=<<V;'^-?8]Z^QM'U>
MVUW3(;RSFCN+:X4/'(AR&!K\Z:]0_9T_:.N/@_JGV'4&DN/#MP^77'-FQ_C7
MV/>OC>(^'5B$\3AE[_5=_P#@GVW#/$SPS6%Q+O![/M_P#[0!R**JZ-J]MKVE
MPWEG-'<6UPN^.1#E7!]*M5^:M-.S/U2,E)76P4444%!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'UC!_P#)^H1_P>D_M/P2,L7@#]G]8TRQ']BZLN1@<#_B8CG.>U '[Y?LO_\
M!*C]G7]C;Q3_ &]\-OA'X-\,Z_AD74X;3SKR,$Y*I+(69!V^4C@5\2_M;_9_
MVL_^#H3X">!/]=IGP0\$7OBO4(G7?&;BXWJJLIXY4VY&?4&OM/\ X)0_M5^-
M_P!MS]@7X??%#XA>'=-\+>*?%UM<7-S8:?%)%;1HMW-%$R++)(X#Q1QO\SD_
M/VZ#Z%2SA2X:98U$LGWFQR<<4 ?+<_\ P1!_9+F^*5QXT;X"_#^;Q%=71OI)
M9;1GMVG)W&3[.6,(8M\QPG)YZG-?3-WX3TO4_"\FB76GV%UHTT!M)+"6W1[5
MX,;?),9&TIM^7;C&!BM$=** .9^%_P '_"?P*\%6OAOP3X9\.^#?#=B[O;Z7
MHNGPZ?8VY=VD?9#$JHNYV9S@#+,S'))-9/Q^_9D^'O[5W@*7PS\2/!WA_P :
M:#,V_P"QZI:+<(A'1D)&5;W4@UWE% 'SW^S+_P $K/V=?V-?%3:[\,OA#X-\
M+:]AE74H+/SKV%6ZA)IBSH#Z*0,<=.*]_>/>OR^XX4;@?49X]ZEHH X?X9_L
MT_#GX->*]=\0>#_ 7@OPOKWBJ=[G6=3TG1;:SO-7D=S(SW$T:!YF+L6RY/)K
M7^)GPM\._&?P1JGAGQ;H>E^)/#NM0FWO=-U&V2XM;F,]0Z-D'V/;CN*Z&B@#
MY?\ @E_P1=_97_9[\=VWBGP?\#_ VEZ]9SBZM+YK1KF2SD!R&B\UF$9';:!7
M:?#/_@G)\#_@U\>/$_Q.\+_#7P[HOCCQE#-;ZSJ5LCC^T(YF#RJ\18Q#>PRV
M$&[OUKVRB@#D?A+\#/!?[/OAN71? GA/PSX+T>:Y>\>PT+3(=/MFG?[\ICB5
M5+M@9.,D\G)KIW;?9LW(W G!&,<5.:AG_P"/9_H?Y4(FI\+/Q5[?A11V_"BO
MZ]I_ O0_C&K\;]0HHHJS,**** "BBB@ HHHH 9<W<=C TTT@A@@1IW<_<3;]
MYV^B_P J^1-=_P""H^K>//&6I:/\(?A)XE^)=KI<I2XU-9_)MPP[Q_NGQZ<^
MF:^B_P!HWPAJ'C_]G_QMH>DAWU35M OK6SCB^_),\) 'Y+7Q3_P3?_;S^'/[
M.7PBM_A?X\:;P3XET*_GCO)KRV:2"]D::1PTC+RFT,%RW&%':OE,\S.I2Q=/
M">U]C"2;<VEJUM%.2:1]EP_E5*K@JN,]C[><&DH7:LFKN346I,]A^%?_  4W
MCNOB?I_@WXG_  _\3?"O6]:8)8S7DIFMIV)Q@-L0')QT7 )QUKZI<DMSL]BG
MW6'8_B.:\(_: ^#?P[_X*-_"FPTZT\7Z?>V^F:C'?0:EH5['=26[['4*3Z'/
MU'3J*W?VLOVC[7]CK]G:X\2W%JVM7%J(;#3[>3 -Y<, %+8[$?,<>]=6#Q6(
MPU.I4QM13I15XSTU6MTU'3II;<X\9A<-BZE*E@*3IUI.TH:V3TLTY:I:ZIO2
MW4]9JKK>J?V)H]Y>M&TBV=M),RK)Y3-M5FQN_P" U\<I\0/VRI?")\8+H?PQ
MM]/^RF__ +$,;"[$ 7=C@XW8]^]>S?LO?M-K^UI^RS<>+CIL>CWVR\L-1LT8
MLL,\2$\$\X((/XUI0SZC7DZ48SA-Q;CS1M==UNG^9EB>'J^'@JTI0G!249<D
MN:S[/9K8U?V-_P!J"/\ :Z^#/_"80Z*VBQM?36(M6F\XMY8!)W=\DY]LXKU4
M\'\<?2OCO_@CIXCL_"7[!%UJVIS_ &73]+U74;NYF/6&)$!<CZBL_P ,_M4_
MM$?M<W6I:W\(/#/@WP_X%M+EX+*^\0[O-U,@D#:1_$2",5R8+/XQP="=?FG4
MJ1O:,;OS=ELO/0[<PX;E+'XBGAW&%*G*W-*5DM=%=[OR/M2BOF_]D']M'7_B
M;\4M9^&/Q*\/6_A?XE:%&+@Q0 BWU&':"2F?52#^/U ^D% 5<*"%[ ]AV%>Y
M@,PHXRE[:B]+V=U9I]FNY\_F&75\%5]C76MDTT[II[-/JF%%?+O[4/[:GC2Q
M^/4/P>^#OAVQ\0>.C;K=ZA=:D,V^DJR!UQ[%&5B?5JXV_P#VQ/CG^R)XNT+_
M (7EH'A34O!OB"[6T_MKP^.;*1@#ACZC/(] :\NMQ)A*=1PDI<L79R46XI]F
M_+KN>M1X5QM6G&47%2DN:,')*<EW2_*]KGTQ^TM^T1HW[+GP>U/QEKL-S<V>
MGE(8[6U.)+N1SA03^.*H?LM_&_7/CW\.YM<U[P/J?@=VN3';65\29KNW:)'C
MG4'TR*^8O^"U.J>.+WX'V+:;#X;F^'%Q+9S27+"3^T7O&>1H]G\.W81G\:^G
M/V5;SXB7OPLB_P"%E6OA6UU577["FB>;]GEL_(CYESQYN[.??-84<SK5LWGA
MES*$8K[.C;OJWO;32UKG5B,IH4<DABWRNI*37Q.Z2MHHK1O76]['IA8N26Y;
M/)V[<GN<>]%.D)+G.[.>_6FU].?(A1110 4444 %%%% !33]QO\ @7\A3J:?
MN-_P+^0J9?"QQ^)?+]#]C/@S_P DD\,_]@NV_P#12T4?!G_DDGAG_L%VW_HI
M:*_DG%?QI^K_ #/[)P7^[P]%^1\]_P#!6_\ Y(%H7_8?B_\ 2:YK\^:_0;_@
MK?\ \D"T+_L/Q?\ I-<U^?-?N_AO_P BE?XW^A_._B=_R.I?X4%%%%?H)^>A
M1110 4444 %%%% !7U9_P2O\(V\WC3Q=XHG422>'=.CCA]4,ID+?F(OUKY3K
MZV_X)4ZK;W^I_$#PW,V)-9TV&5!_LH98Y/\ T?'7RG&TIQR>JX?W;^G,KW/K
M.!XPEG-)3\VO7ETM\SY?\=>,[OXB^,M3UV^D\RZU:Y>Z9AZ,<@?@,#\*HZ3J
M$^CZG;WEJWEW%G,D\,C+N4.AR 14GB#0[KPQKEYIM\GEWEC,T$R^C*<'^55%
MA:5E5%W32$(@V[LDE0JX_P!YLU]'3C25!15N2WRM;_(^=KRJNO)N_.W\[W_S
M.^_:!_:,U[]I/5M-O]>L]-CN]-MS;Q&S4K)<*6X#9Z?-GBO==%^ WPU_94^$
MNC^)OBC9W'B/Q%KO[VRTF-MT<1*YVCD=B"2>YZ&N ^,W[(O_  S5XE\!_P!H
M:XNI7'B.Z4RVK6X3R=K1%@#Z9-=5_P %7'D?X]Z&K<6JZ#$5Q_>^TR5\-6Q-
M#%5<+E^73=.A/G;<6XM\O1/=:]C[BCAZ^$I8K,<S@JE>'(DI^\ES=6MG9=SH
M?!G@'X*_MI:=J&D>%="NO GC"SA:>W"_=<#T.2&&>N ".>M>(_LY?"*S\2_M
M3:/X-\3Z>MU;O?3VM[:EF4/Y4<I#97GDX/XU8_8-N[BW_:O\'^3UDEE1_P#<
M\L@_I7KICAMO^"L[+!]QM1#'_>-EEO\ QXFE7G6R^MBL!2J2E#V+G'F;;B]M
M'OUON:X>G0S&CA<?5I1C/VRA+E22DG9W:6GEL,^)V@?!']DGXAZEI^J^'-0\
M;:U-</<&S^TM]GTB)CNC3+')<QLK<YZ\5TWC?]EGX-^+/ FE_%:TN+SP[X,6
M%IM1L+?)^U[6*A%!)VN) 1UYKYU_;3;=^U-XT_Z_\?\ CBUZ]XN_Y1-^'O\
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M4-@<=LUP7P3^!L?QF_:$B\(P2-9V/VN999$RS10Q$Y&X\G@5Z]_P3-DU"?\
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MQXB\^2,V"V4I#6XRV03YJ'KFO<?A!#^SS\:?'5CX?T#X7^,IKR\RS-)?2+'
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MB\)?#6X\/Z:MC<>(-,>XOF$\C><0D#9Q[DFLS_@HC_R=[XN^EI_Z1V]>A?\
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M_P $^N/^&ZO!O_/KKW_@,G_Q='_#=7@W_GUU[_P&3_XNOD>BC_4_+NTOO_X
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M_P $^N/^&ZO!O_/KKW_@,G_Q='_#=7@W_GUU[_P&3_XNOD>BC_4_+NTOO_X
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M_P $^N/^&ZO!O_/KKW_@,G_Q='_#=7@W_GUU[_P&3_XNOD>BC_4_+NTOO_X
M?ZZYEWC]W_!/KC_ANKP;_P ^NO?^ R?_ !='_#=7@W_GUU[_ ,!D_P#BZ^1Z
M*/\ 4_+NTOO_ . '^NN9=X_=_P $^N/^&ZO!O_/KKW_@,G_Q='_#=7@W_GUU
M[_P&3_XNOD>BC_4_+NTOO_X ?ZZYEWC]W_!/KC_ANKP;_P ^NO?^ R?_ !='
M_#=7@W_GUU[_ ,!D_P#BZ^1Z*/\ 4_+NTOO_ . '^NN9=X_=_P $^N/^&ZO!
MO_/KKW_@,G_Q='_#=7@W_GUU[_P&3_XNOD>BC_4_+NTOO_X ?ZZYEWC]W_!/
MKC_ANKP;_P ^NO?^ R?_ !='_#=7@W_GUU[_ ,!D_P#BZ^1Z*/\ 4_+NTOO_
M . '^NN9=X_=_P $^N/^&ZO!O_/KKW_@,G_Q='_#=7@W_GUU[_P&3_XNOD>B
MC_4_+NTOO_X ?ZZYEWC]W_!/KC_ANKP;_P ^NO?^ R?_ !='_#=7@W_GUU[_
M ,!D_P#BZ^1Z*/\ 4_+NTOO_ . '^NN9=X_=_P $^N/^&ZO!O_/KKW_@,G_Q
M='_#=7@W_GUU[_P&3_XNOD>BC_4_+NTOO_X ?ZZYEWC]W_!/KC_ANKP;_P ^
MNO?^ R?_ !='_#=7@W_GUU[_ ,!D_P#BZ^1Z*/\ 4_+NTOO_ . '^NN9=X_=
M_P $^I_%?[:'A'Q%X;U"PAM]<$UY;20KNME49*D==Q'>OE=.(UXQ@  <=.W3
MBEHKU<MRG#X%25"^O=W/&S3.,1CY1EB+7CM96"BBBO3/+"BBB@#U#]G7]HVX
M^#^I_8=0>2X\.W#Y=<<V;'^-?8]Z^QM'U>VUW3(;RSFCN+:X4/'(AR&!K\Z:
M]0_9T_:.N/@_JGV'4&DN/#MP^77'-FQ_C7V/>OC>(^'5B$\3AE[_ %7?_@GV
MW#/$SPS6%Q+O![/M_P  ^T <BBJNC:O;:]I<-Y9S1W%M<+OCD0Y5P?2K5?FK
M33LS]4C)25UL%%%%!0F>:\6_;4\8ZKX-\&Z3+I6H7VGS37NQWM7*,PVG@D=O
MK7M#=:\'_;U_Y$G0?^PA_P"R-7K9#&,LPI1DKJYXO$4Y1RZK*+L['@0^.'C(
M ?\ %5:]T'_,084?\+Q\9?\ 0UZ]_P"#%JY9?NK]!17ZY]2P_P#S[C]R/QCZ
M]B?^?DO_  )_YG4_\+Q\9?\ 0UZ]_P"#%J/^%X^,O^AKU[_P8M7+44?4L/\
M\^X_<A?7L3_S\E_X$_\ ,ZG_ (7CXR_Z&O7O_!BU'_"\?&7_ $->O?\ @Q:N
M6HH^I8?_ )]Q^Y!]>Q/_ #\E_P"!/_,ZG_A>/C+_ *&O7O\ P8M1_P +Q\9?
M]#7KW_@Q:N6HH^I8?_GW'[D'U[$_\_)?^!/_ #.I_P"%X^,O^AKU[_P8M1_P
MO'QE_P!#7KW_ (,6KEJ*/J6'_P"?<?N0?7L3_P _)?\ @3_S.I_X7CXR_P"A
MKU[_ ,&+4?\ "\?&7_0UZ]_X,6KEJ*/J6'_Y]Q^Y!]>Q/_/R7_@3_P SJ?\
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M\+Q\9?\ 0UZ]_P"#%JY:BCZEA_\ GW'[D'U[$_\ /R7_ ($_\SJ?^%X^,O\
MH:]>_P#!BU'_  O'QE_T->O?^#%JY:BCZEA_^?<?N0?7L3_S\E_X$_\ ,ZG_
M (7CXR_Z&O7O_!BU'_"\?&7_ $->O?\ @Q:N6HH^I8?_ )]Q^Y!]>Q/_ #\E
M_P"!/_,ZG_A>/C+_ *&O7O\ P8M1_P +Q\9?]#7KW_@Q:N6HH^I8?_GW'[D'
MU[$_\_)?^!/_ #.I_P"%X^,O^AKU[_P8M1_PO'QE_P!#7KW_ (,6KEJ*/J6'
M_P"?<?N0?7L3_P _)?\ @3_S.I_X7CXR_P"AKU[_ ,&+4?\ "\?&7_0UZ]_X
M,6KEJ*/J6'_Y]Q^Y!]>Q/_/R7_@3_P SJ?\ A>/C+_H:]>_\&+4?\+Q\9?\
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M $->O?\ @Q:N6HH^I8?_ )]Q^Y!]>Q/_ #\E_P"!/_,ZG_A>/C+_ *&O7O\
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MG!+1)*S3MO?9G-?\%#!<+_P2.^'_ -JW?:/L7A_S-W7=]DYK[C\*?\BMIO\
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M;^R%H_Q<U+38O!MEJ4%[/=037GVN'3X[:XFA>0OL3)80[A\HQNQSC)^:H?\
M@KA\6?CWJNIW_P !/V>]4\>>"=%G:V;6KS43 +XIP=B= #@X R>.QK.IF6&A
M",W*_,KI)-MKO9:G13RG%3J2II)<KLVVDD^UWI^)]\%O+;=G&WJ=RC:O<Y;A
M16/X.^(.@_$JVNIO#>NZ-KD5G<O97$VGW<5U#;7"[/W3XXW8;\#Q7S)\"?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.?)KGK8JC2J0I5'9RT7G97_ ".JA@JU:G.K3C>,+.6VB;LOQ/7J*\F_8_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\Z:]0_9T_:.N?@_J?V'4'DN/#MP^77'-FQ_C7V/>OC>(^'5B$\3AE[_5=_\
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M7B*%/VM1*U[.S3L^SLW;YGJ-%  4!57:JC"CT Z45W'GA1110 4444 %%%%
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MT4\PQLL(J:J2C+VRA>5G+E=M[75]0J97E\<9[5THRBZ#J-1NH\RZJ]FD[?\
M ,_XP?M*_M.?LD:9:^,O'VC_  WUOP;+=QPW]GI1+7&G[R %)8YR/QY]N:^@
M_P!HK]K_ $']GW]FR'XC744UY#J4$+Z98O\ ?O)9HPZI_NC=CZ"N'_X*X+M_
MX)]^.A_V#_\ TX6U>"?\% U*_LO?LR-=9_L/[3IWVW'][[);_P#LN:Z<=C,3
MET\12IU)3]R+BY:N+E*S_P [''E^7X3-*6&KU*48-U)1DH7BI*,5)=7KTON=
MIX9^-/[8&N>&H?'4?@OP&^@3(+Q?#Q7&I36V0Y"C/]U,Y]#T[5E_\$?_ (EP
M?&3XW_M#>*A9SZ=!KVJ:;J,MJQ^>'>]^[)^!)'T K[L@:!_+,?E_8\+LSUV[
ME_\ 9,5\._\ !,;6=+\.?M%_M6:@LGEZ+I_B&&Y=O6%9]38K^.*>(P=3"YA@
MY3KRFFY7YK/7D>JLE9>5[#P^.I8S*\=&GAXTVE!+D36CJ15G=M-^>YH:=^UQ
M\=OVL/B!XHM?@WHO@O1?"OA6_:PFU77MV^XE';([YR!QTQ75?LS?M<?$I?VE
MYO@_\8_#^BZ?XBN-/_M#3]1TD$072KDY&>QP1]5/M7+_  F_:,^/7[8=MJ&J
M?"O1?AYX'\"+=M;P7^LQ2SSWDB<;E5<C(*GJOI7$> ? 7CCP1_P5S\#Q?$'Q
MI!XR\1WGA>>[>ZMK<6\=JACNU6!8P  ,KGISNSWKDCC\3&I1KTZE62E-)R:4
M:;3=O=B]=MFMSKEEN&G3KX>K2I0<*;DHIN55226LI)6WW3VVL>J_M3_\%"?$
MG[/?[5L/@'3O#-GX@35M!CN]*MH8Y5O+G4I962--^\)Y?RY.!V/?-:4?[5/Q
M$_9?_9?\1>-OCII>D6^O?VF(=%TG3&4B9VC&8I"K,/E;@\G!!KD?'&F1W?\
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M;=MC7.<5R6F?M@?'+]K_ ,4:Q+\#O#_A/2?!&C7)LHM:\0*P.H,.A&. 3C@
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MK#/S*"<^I&3^N:*]0\@**** "BBB@ HHHH **** "BBB@ HHHH *W/A[\/\
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M"4JL:]Y2E#X7*3=DU:ROY'H8KBG&UJ,\/:$8SMS<L(QYFG>[LM[_ /#'S'\
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MU,:/$6)ISG)1ARSMS0Y(\CML^5))/S1\U_LL?L7^*?!_QHN_BG\6/%5KXO\
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M^#/_ "23PS_V"[;_ -%+17\DXK^-/U?YG]DX+_=X>B_(^>_^"M__ "0+0O\
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M9)0=E%MZ)=;VU.>_X)N_M.ZO^RW_ ,$0%^(^L://X@M_"EQ=R:?9W%X;?[=
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M=8\+V^L73:-I;:HTVFW\J7%B$A>=G8L"V5.6.W.WMBOH&\^-_P"VI.D]O-\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_I-<U^?-?N_AO_R*5_C?Z'\[^)W_ ".I?X4%%%%?H)^>A1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAP-2E0J0K*W-.;^3;L_Q/H^(LPHU\31JT'S<L*:]'&*37X'Q)_P18\20^&/
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M:79)WM;>UR,;G&+JU9*564H.6SE)JU]-+GQ5_P $7S%#X4^*BW6W^W!XL?\
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MI:*/@S_R23PS_P!@NV_]%+17\DXK^-/U?YG]E8+_ '>'HOR/GO\ X*W_ /)
MM"_[#\7_ *37-?GS7Z#?\%;_ /D@6A?]A^+_ -)KFOSYK]W\-_\ D4K_ !O]
M#^=_$[_D=2_PH****_03\]"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KUC]AS_D
MZSP7_P!?<W_HJO)Z]8_8<_Y.L\%_]?<W_HJO)S[_ )%U?_!+\CV.'_\ D94/
M\<?S/U73[M+2)]VEK^53^O HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP9XE_P"@IH?_ 'W-_P#$5]744?ZVYE_,O_ 4'^IN5_RO_P "9\H_\,&>)?\
MH*:'_P!]S?\ Q%'_  P9XE_Z"FA_]]S?_$5]744?ZVYE_,O_  %!_J;E?\K_
M / F?*/_  P9XE_Z"FA_]]S?_$4?\,&>)?\ H*:'_P!]S?\ Q%?5U%'^MN9?
MS+_P%!_J;E?\K_\  F?*/_#!GB7_ *"FA_\ ?<W_ ,11_P ,&>)?^@IH?_?<
MW_Q%?5U%'^MN9?S+_P !0?ZFY7_*_P#P)GRC_P ,&>)?^@IH?_?<W_Q%'_#!
MGB7_ *"FA_\ ?<W_ ,17U=11_K;F7\R_\!0?ZFY7_*__  )GRC_PP9XE_P"@
MIH?_ 'W-_P#$4?\ #!GB7_H*:'_WW-_\17U=11_K;F7\R_\  4'^IN5_RO\
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MNQ#]@A_YYQ_]\T?8(?\ GG'_ -\U-11S,.5=B'[!#_SSC_[YH^P0_P#/./\
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M&6PE*$IOW6T_=E9-:.[Y;?B?24^$<UJ0C.%->\DTN:%VFKJRYK_@?:5%<?\
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M"DN:H[+S-:-&=5\M.+?717VW^5CK** =R@_+R,G ( /X\T5H9!1110 4444
M%%%% !33]QO^!?R%.II^XW_ OY"IE\+''XE\OT/V,^#/_))/#/\ V"[;_P!%
M+11\&?\ DDGAG_L%VW_HI:*_DG%?QI^K_,_LG!?[O#T7Y'SW_P %;_\ D@6A
M?]A^+_TFN:_/FOT&_P""M_\ R0+0O^P_%_Z37-?GS7[OX;_\BE?XW^A_._B=
M_P CJ7^%!1117Z"?GH4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *]8_8<_Y.L\%_\ 7W-_Z*KR>O6/V'/^3K/!
M?_7W-_Z*KR<^_P"1=7_P2_(]CA__ )&5#_''\S]5T^[2TB?=I:_E4_KP****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.L\%_P#7W-_Z*KR<^_Y%U?\ P2_(]CA__D94/\<?S/U73[M+2)]VEK^53^O
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"&]O(=/MI)YI$CCA&YW;^$5)!,MQ DD;!HY%#*1T(/(-<
M[\7B!\+?$F[_ *!EQT_ZY-7SI^R_^TZ?!AM_#OB"4'2R1';W+<-:L>S?[)/?
MMFO4P>4UL30G7I:\EKKK;R/'QV=4<)B84*^BGUZ)]F?5]%-AE6>)9(V5D<!E
M8'((/0TZO+/8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ -0S_\ 'L_T/\JF-0S_ /'L_P!#_*A$U/A9^*O;\**.WX45_7M/X%Z'
M\8U?C?J%%%%69A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %-/W&_X%_(4ZFG[C?\"_D*F7PL<?B7R_
M0_8SX,_\DD\,_P#8+MO_ $4M%'P9_P"22>&?^P7;?^BEHK^2<5_&GZO\S^R<
M%_N\/1?D?/?_  5O_P"2!:%_V'XO_2:YK\^:_0;_ (*W_P#) M"_[#\7_I-<
MU^?-?N_AO_R*5_C?Z'\[^)W_ ".I?X4%%%%?H)^>A1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_) M"_[#\7_I-<U^?-?N_AO_ ,BE?XW^A_._B=_R.I?X4%%%%?H)^>A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5ZQ^PY_R=9X+_P"ON;_T57D]>L?L.?\ )UG@
MO_K[F_\ 15>3GW_(NK_X)?D>QP__ ,C*A_CC^9^JZ?=I:1/NTM?RJ?UX%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 -/6FLZQ(S,=J@9)IYZTR3_5_@:
M=['GMU^U7X"L[F2&37D62%BC@6LS@$'!Y5"/R-1_\-9_#_\ Z&!?_ .X_P#C
M=?&>N?\ (:O/^N[_ /H1JK7Z53X-P<HJ3G+[U_D?E=3CG'1DTH0^Y_\ R1]K
M?\-9_#__ *&!?_ .X_\ C='_  UG\/\ _H8%_P# .X_^-U\4T57^I>"_GG]Z
M_P#D2/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
M[C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\
MD?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\ [C_ .-U\4T4?ZEX+^>?
MWK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P  [C_XW1_PUG\/_P#H8%_\
M [C_ .-U\4T4?ZEX+^>?WK_Y$/\ 7K'_ ,D/NE_\D?:W_#6?P_\ ^A@7_P
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M_0_RH1-3X6?BKV_"BCM^%%?U[3^!>A_&-7XWZA1115F84444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAO\ \BE?XW^A_._B=_R.I?X4%%%%?H)^>A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5ZQ^PY_R=9X+_ .ON;_T57D]>L?L.?\G6>"_^ON;_ -%5Y.??\BZO_@E^
M1['#_P#R,J'^./YGZKI]VEI$^[2U_*I_7@4444 %%%% !1110 4444 %%%%
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MMAX<KYH6O%:-K6RZ'W+H]A_96CV=J)))EM8(X1(X(:0*H 8YYR0,Y[U^:_\
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MPPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\>FPR)L_=8'UQZ9K[.HKGJ9;A*D_:U*:<O,Z*.:XRE2]C3J-1\G_ %;Y')?
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MY'M"+YR_Q80*OT45Y_\ M8?\$F/AI^U1\2O^$V-UXG\">-L!)-7\+WB6L]\
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MM'U?57N(X9!R"JC@D?SKZLHKAAE."A+FC2C?T/1J9UCYQ<95I6?FSCOC_P#
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ML;^TX1;;.NTC'0^O7FOORBL,1EN%KRYZL$WW_P"&L=.&S3%X>'LZ-1Q7:_\
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MLJ=1J/:_]-?*QB>-_AIX?^(_@&\\*ZYH]CJ?AO4+464VG3C_ $<Q!=JJ/[I
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MN?,C:1F+G:/3+FO4**VCAZ4>7EBO=V\C!XJN^;FFWS;^?J>8_&_]DGP?\?\
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M^;/USASAV&!A[:LKU'^'DAU%"]**^:/K HHHH **** "BBB@ HHHH ****
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M ."7Y'L</_\ (RH?XX_F?JNGW:6D3[M+7\JG]>!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 (>M,D_U?X&GGK3)/]7^!I,4
MMC\[=<_Y#5Y_UW?_ -"-5:M:Y_R&KS_KN_\ Z$:JU^\T?X:]#^>*WQOU"BBB
MM#,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KUC]AS_DZSP7_U]S?^BJ\G
MKUC]AS_DZSP7_P!?<W_HJO)S[_D75_\ !+\CV.'_ /D94/\ ''\S]5T^[2TB
M?=I:_E4_KP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@!K<@TV1=\3>K"I** >JL?'^I_L<^-[W4[J:.WLVCFF=U+72J<%B1
MQBJ__#%_CK_GUL?_  ,7_"OLBBOJH\88^*LE'[G_ )GR,N"LOD^9N7WK_(^-
M_P#AB_QU_P ^MC_X&+_A1_PQ?XZ_Y];'_P #%_PK[(HJO]<L?VC]S_S)_P!2
M,N[R^]?Y'QO_ ,,7^.O^?6Q_\#%_PH_X8O\ '7_/K8_^!B_X5]D44?ZY8_M'
M[G_F'^I&7=Y?>O\ (^-_^&+_ !U_SZV/_@8O^%'_  Q?XZ_Y];'_ ,#%_P *
M^R**/]<L?VC]S_S#_4C+N\OO7^1\;_\ #%_CK_GUL?\ P,7_  H_X8O\=?\
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M ,#%_P */^&+_'7_ #ZV/_@8O^%?9%%'^N6/[1^Y_P"8?ZD9=WE]Z_R/C?\
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M,7_"C_AB_P =?\^MC_X&+_A7V111_KEC^T?N?^8?ZD9=WE]Z_P CXW_X8O\
M'7_/K8_^!B_X4?\ #%_CK_GUL?\ P,7_  K[(HH_URQ_:/W/_,/]2,N[R^]?
MY'QO_P ,7^.O^?6Q_P# Q?\ "C_AB_QU_P ^MC_X&+_A7V111_KEC^T?N?\
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M/^&+_'7_ #ZV/_@8O^%?9%%'^N6/[1^Y_P"8?ZD9=WE]Z_R/C?\ X8O\=?\
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M&+_'7_/K8_\ @8O^%?9%%'^N6/[1^Y_YA_J1EW>7WK_(^-_^&+_'7_/K8_\
M@8O^%'_#%_CK_GUL?_ Q?\*^R**/]<L?VC]S_P P_P!2,N[R^]?Y'QO_ ,,7
M^.O^?6Q_\#%_PH_X8O\ '7_/K8_^!B_X5]D44?ZY8_M'[G_F'^I&7=Y?>O\
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MR/C?_AB_QU_SZV/_ (&+_A1_PQ?XZ_Y];'_P,7_"OLBBC_7+']H_<_\ ,/\
M4C+N\OO7^1\;_P##%_CK_GUL?_ Q?\*/^&+_ !U_SZV/_@8O^%?9%%'^N6/[
M1^Y_YA_J1EW>7WK_ "/C?_AB_P =?\^MC_X&+_A1_P ,7^.O^?6Q_P# Q?\
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MC_X&+_A7V111_KEC^T?N?^8?ZD9=WE]Z_P CXW_X8O\ '7_/K8_^!B_X4?\
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M_P!<L?VC]S_S#_4C+N\OO7^1\;_\,7^.O^?6Q_\  Q?\*/\ AB_QU_SZV/\
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M*_KVG\"]#^,:OQOU"BBBK,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "FG[C?\"_D*=33]QO\ @7\A
M4R^%CC\2^7Z'[&?!G_DDGAG_ +!=M_Z*6BCX,_\ ))/#/_8+MO\ T4M%?R3B
MOXT_5_F?V3@O]WAZ+\CY[_X*W_\ ) M"_P"P_%_Z37-?GS7Z#?\ !6__ )(%
MH7_8?B_])KFOSYK]W\-_^12O\;_0_G?Q._Y'4O\ "@HHHK]!/ST**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_7P[_P"!C?X4?\.L/B?Z^'?_  ,;_"OTBHH_XB7G']S_ ,!_X(?\0MR7^_\
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M_7P[_P"!C?X4?\.L/B?Z^'?_  ,;_"OTBHH_XB7G']S_ ,!_X(?\0MR7^_\
M^!?\ _-W_AUA\3_7P[_X&-_A1_PZP^)_KX=_\#&_PK](J*/^(EYQ_<_\!_X(
M?\0MR7^__P"!?\ _-W_AUA\3_7P[_P"!C?X4?\.L/B?Z^'?_  ,;_"OTBHH_
MXB7G']S_ ,!_X(?\0MR7^_\ ^!?\ _-W_AUA\3_7P[_X&-_A1_PZP^)_KX=_
M\#&_PK](J*/^(EYQ_<_\!_X(?\0MR7^__P"!?\ _-W_AUA\3_7P[_P"!C?X4
M?\.L/B?Z^'?_  ,;_"OTBHH_XB7G']S_ ,!_X(?\0MR7^_\ ^!?\ _-W_AUA
M\3_7P[_X&-_A1_PZP^)_KX=_\#&_PK](J*/^(EYQ_<_\!_X(?\0MR7^__P"!
M?\ _-W_AUA\3_7P[_P"!C?X4?\.L/B?Z^'?_  ,;_"OTBHH_XB7G']S_ ,!_
MX(?\0MR7^_\ ^!?\ _-W_AUA\3_7P[_X&-_A1_PZP^)_KX=_\#&_PK](J*/^
M(EYQ_<_\!_X(?\0MR7^__P"!?\ _-W_AUA\3_7P[_P"!C?X4?\.L/B?Z^'?_
M  ,;_"OTBHH_XB7G']S_ ,!_X(?\0MR7^_\ ^!?\ _-W_AUA\3_7P[_X&-_A
M1_PZP^)_KX=_\#&_PK](J*/^(EYQ_<_\!_X(?\0MR7^__P"!?\ _-W_AUA\3
M_7P[_P"!C?X4?\.L/B?Z^'?_  ,;_"OTBHH_XB7G']S_ ,!_X(?\0MR7^_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<_\  ?\ @A_Q"W)?[_\ X%_P#\W?^'6'Q/\ 7P[_ .!C?X4?\.L/B?Z^'?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"617AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0=NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 &5F:6QE+F5D
M9V%R   !ZAP !P  " P   AH     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                  !E &8 :0!L &4 +@!E &0 9P!A '(   #_X0ID:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X])^^[
MOR<@:60])U<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"<_/@T*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(^/')D9CI21$8@>&UL;G,Z<F1F
M/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C
M(CX\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB
M83-D+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P.B\O
M<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(O/CQR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W
M-3$X,F8Q8B(@>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT
M<R\Q+C$O(CX\9&,Z8W)E871O<CX\<F1F.E-E<2!X;6QN<SIR9&8](FAT=' Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/CQR9&8Z
M;&D^969I;&4N961G87(\+W)D9CIL:3X\+W)D9CI397$^#0H)"0D\+V1C.F-R
M96%T;W(^/"]R9&8Z1&5S8W)I<'1I;VX^/"]R9&8Z4D1&/CPO>#IX;7!M971A
M/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^
M_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8%1@7&QXG(1L=
M)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4"PL4*AP8'"HJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ_\  $0@!HP/G P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           !
M @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-1
M80<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$
M149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8
MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;G
MZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*
M"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"
MD:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-4
M55976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6F
MIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V
M]_CY^O_:  P# 0 "$0,1 #\ ^D:*** "BN-MK;6->\2>)%7Q5JFFV^GZA':P
M6]G#:%%4VEO*23) [$EI6[^E7O\ A%]7_P"A[\0?]^-/_P#D6@#I**YO_A%]
M7_Z'OQ!_WXT__P"1:/\ A%]7_P"A[\0?]^-/_P#D6@#I**YO_A%]7_Z'OQ!_
MWXT__P"1:/\ A%]7_P"A[\0?]^-/_P#D6@#I**YO_A%]7_Z'OQ!_WXT__P"1
M:/\ A%]7_P"A[\0?]^-/_P#D6@#I**YO_A%]7_Z'OQ!_WXT__P"1:/\ A%]7
M_P"A[\0?]^-/_P#D6@#I**YO_A%]7_Z'OQ!_WXT__P"1:/\ A%]7_P"A[\0?
M]^-/_P#D6@#I**YO_A%]7_Z'OQ!_WXT__P"1:/\ A%]7_P"A[\0?]^-/_P#D
M6@#I**YO_A%]7_Z'OQ!_WXT__P"1:/\ A%]7_P"A[\0?]^-/_P#D6@#I**YO
M_A%]7_Z'OQ!_WXT__P"1:/\ A%]7_P"A[\0?]^-/_P#D6@#I**YO_A%]7_Z'
MOQ!_WXT__P"1:/\ A%]7_P"A[\0?]^-/_P#D6@#I**YO_A%]7_Z'OQ!_WXT_
M_P"1:/\ A%]7_P"A[\0?]^-/_P#D6@#I**YO_A%]7_Z'OQ!_WXT__P"1:/\
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M]K\FJWQ>Y:6;SFBFM;5R6SG_ %QA\\ 'IB3@8 XXKN**-G<.E@HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** .;\+_\ (Q>,_P#L-1_^F^SKI*YOPO\ \C%XS_[#4?\ Z;[.NDH
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MC2O"?AS0;IKK0] TO3;AT,;2V=E'"[*2"5)4 XR <>PK7HHH **** "BBB@
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M+I5D-49=AOA;IYY7&,>9C=C''6LK_A/-(_Y\_$'_ (3FH?\ QBC_ (3S2/\
MGS\0?^$YJ'_QB@#03POH$=S>7,>AZ:L]^K)=RK:1AKA6Y(D.,L#WSG-(?"WA
M]KFSN&T+33/8*$M)39Q[K=1R!&<94#L!BJ'_  GFD?\ /GX@_P#"<U#_ .,4
M?\)YI'_/GX@_\)S4/_C% &D_AO0Y$NT?1M/9;Y0MTIM4(N .@?CY@.V<U7LO
M!OAC3;V&\T[PYI%I=6X(AG@L8D>,'/"L%R.IZ>IJK_PGFD?\^?B#_P )S4/_
M (Q1_P )YI'_ #Y^(/\ PG-0_P#C% '1LH=2K@,K#!!&014/V&T&G_8!:P_8
M_+\G[-Y8\O9C&W;TVXXQTK"_X3S2/^?/Q!_X3FH?_&*/^$\TC_GS\0?^$YJ'
M_P 8H L#P3X56V@MU\,Z.(+>0RPQ"PBVQ.<991MP"<#D<\"L+XA_#.S^($EE
M)>&Q;[(&"I>6LLB_-C)!BFB<'CH6*^V<$7A\2O#IU!K +K1O%B$S6_\ PC]_
MY@C)(#[?)SM)!&>F0:G_ .$\TC_GS\0?^$YJ'_QBAZAL0^'OAUX?T+3=/MY-
M.M+ZXT_/V:ZN8!));@L6"1L^YU52>!N)'J>M61\/_!J[=OA+0AM?>N--AX;U
M^[UX'-,_X3S2/^?/Q!_X3FH?_&*/^$\TC_GS\0?^$YJ'_P 8IW=[@:^J:-IF
MN68M=:TVTU&V#!Q#=P+*@8=#M8$9Y/-5H_"GAV&RBLX=!TR.UAD$L4"V<81'
M!R&"XP#DYR*H_P#">:1_SY^(/_"<U#_XQ1_PGFD?\^?B#_PG-0_^,4@-%O#.
MA/J4^HOHFG-?7,9CGNC:(994(P59\9(( &#V%,'A3PZL91=!TP(UO]E*BSCP
M8?\ GET^Y_L]*H_\)YI'_/GX@_\ "<U#_P",4?\ ">:1_P ^?B#_ ,)S4/\
MXQ0!9M/!7A;3[R"[L/#6CVMS;_ZF:&PB1XNOW6"Y'4]/4TY_!WAF5'63PYI+
MK)-Y[AK&(AI>3O/R\MR>>O)JI_PGFD?\^?B#_P )S4/_ (Q1_P )YI'_ #Y^
M(/\ PG-0_P#C% &I+HUD+F6^LK2TM]3>(Q+>_9E,B@G.">"1DYQG%&B:+;Z#
MI@L[4O(2[2RS28WS2.=SNV !DDYX '8<5E_\)YI'_/GX@_\ "<U#_P",4?\
M">:1_P ^?B#_ ,)S4/\ XQ0!TE%<W_PGFD?\^?B#_P )S4/_ (Q1_P )YI'_
M #Y^(/\ PG-0_P#C% !X7_Y&+QG_ -AJ/_TWV==)7+>#)C>:AXHOUMKR"WO-
M662#[9:2VSR*+*V0L$D56QN1AG'\)KJ: "BBB@ HHHH **** "BBB@ HHHH
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M%OCKYA!^7&#UQ5J&_L[BU@N;>[@E@N,>3*D@99<\C:1P<^U %BBBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1_T)OA__ ,%<'_Q- '245S?_  KCP1_T)OA__P %<'_Q-'_"N/!'_0F^'_\
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MC_H3?#__ (*X/_B:/^%<>"/^A-\/_P#@K@_^)H Z2BN;_P"%<>"/^A-\/_\
M@K@_^)H_X5QX(_Z$WP__ ."N#_XF@#I**YO_ (5QX(_Z$WP__P""N#_XFC_A
M7'@C_H3?#_\ X*X/_B: .DHKF_\ A7'@C_H3?#__ (*X/_B:/^%<>"/^A-\/
M_P#@K@_^)H Z2BN;_P"%<>"/^A-\/_\ @K@_^)H_X5QX(_Z$WP__ ."N#_XF
M@#I**YO_ (5QX(_Z$WP__P""N#_XFC_A7'@C_H3?#_\ X*X/_B: .DHKF_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH X?X;?\A#QQ_V,\_\ Z(@KN*X?
MX;?\A#QQ_P!C//\ ^B(*[B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME5C"V,[6 /RG'.#4T,T=Q"DT$B2Q2*&1T8%6!Z$$=10 ^BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBL'QMHU]K_ (,U+3]'U"YTW4)(
MB;6YM9VB=)%Y4;E(."1@^Q- &+\-O^0AXX_[&>?_ -$05W%?,7[.6F>*M6\:
MZIJ6L:QJZV&G2L;JWEO)-MS>,-I\Q<X8JJ\YR>$KZ=H **** "BBB@ HHHH
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M[W3M0T?6%M_M*VM\L9\V+.-RO$[H>>,9SQTKIZ .;_X1?5_^A[\0?]^-/_\
MD6C_ (1?5_\ H>_$'_?C3_\ Y%KI** .;_X1?5_^A[\0?]^-/_\ D6C_ (1?
M5_\ H>_$'_?C3_\ Y%KI** .;_X1?5_^A[\0?]^-/_\ D6C_ (1?5_\ H>_$
M'_?C3_\ Y%K3\0:U%X=\/7VL7%M/<PV4+32Q6X4R%%Y8C<RC@9/7M6#I_P 2
M-,U'6O#^G16.H1MX@L#?6<TB1^6$"[BK8<L& ([$<]>M"UV_K?\ R8/17?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTW_T??5TE<W8_P#)4]=_[ NF_P#H^^H Z2BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF_\ A ](_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^@#I**YO_ (0/2/\
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M7-_\('I'_/YX@_\ "CU#_P"/T?\ "!Z1_P _GB#_ ,*/4/\ X_0!TE<W8_\
M)4]=_P"P+IO_ */OJ/\ A ](_P"?SQ!_X4>H?_'ZNZ-X8TW0;JYNK#[8]Q=)
M''-+>7\]T[*A<HH,KL0 9'.!C[QH UZ*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#F_"_P#R,7C/_L-1_P#IOLZZ2N;\+_\
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M /P:0?\ Q5'_  L?P1_T.7A__P &D'_Q5 '245S?_"Q_!'_0Y>'_ /P:0?\
MQ5'_  L?P1_T.7A__P &D'_Q5 '245S?_"Q_!'_0Y>'_ /P:0?\ Q5'_  L?
MP1_T.7A__P &D'_Q5 '245S?_"Q_!'_0Y>'_ /P:0?\ Q5'_  L?P1_T.7A_
M_P &D'_Q5 '245S?_"Q_!'_0Y>'_ /P:0?\ Q5'_  L?P1_T.7A__P &D'_Q
M5 '245S?_"Q_!'_0Y>'_ /P:0?\ Q5'_  L?P1_T.7A__P &D'_Q5 '245S?
M_"Q_!'_0Y>'_ /P:0?\ Q5'_  L?P1_T.7A__P &D'_Q5 '245S?_"Q_!'_0
MY>'_ /P:0?\ Q5'_  L?P1_T.7A__P &D'_Q5 '245ST'Q \'75U#;6GBO1+
MBXGD6***'4(G>1V. H ;)))Q70T %%%% !1110 4444 %%%% !1110 4444
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MP ' 8+P"02 :Z"BG<#*U/PY8:Q;ZA!J DE34+?[-)\V-D>/NKCIR<YZDX[
M.T#0H/#VFM:03SW323//-<7)4R32,<EFVA5_    "M.BD&YY1\7/''ANRN-%
MTJ[U:&&^LM?T^ZN('#!HXEE5V<\= O/%>CZ'KVF>)-*34M#NTO+*1BJ3Q@[6
M(.#C(YP>*\E^/?PFNO'%UHNJ:#$/MZSI973 =(';B0^H0D_@WM7K>A:-:>'=
M L='TU-EK90K#&.^ ,9/N>I]S0!?HHHH **** "BBB@ HHHH **** "BBB@
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M7[ TJWX"']WYN,1D$ALYR<56_P"%I^#E6=Y=7:".WO/L-Q)/:31I!-_=D9D
M3ZL0#ZT@_K^ON.NHKC;_ .(&@7_@_7+_ $G7VM%TY3%/>KI\LS6;L/ED,17+
MKR&SC:1SG%-_X6'I]MXA\/Z!NN[^?5+,7/VN*PE*LF %?"J=NXG)[*.I'%.S
M;M_7</Z_K[SM**Q;/Q?H6H:I+I]I?K)<1!\GRW$;[#APDA&QRIX8*3M[XKB[
M_P ?C5/&_@QO"NN3R:3JUQ/!<0-9A(YU1&.]&DC#GYA@E6QP/Q2U:7<-D_(]
M.HHHH **** .;^(__)+/%?\ V!;S_P!$/725S?Q'_P"26>*_^P+>?^B'KI*
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MHP2]XMRAA7'!R^<#'UI#,O\ X5QX(_Z$WP__ ."N#_XFC_A7'@C_ *$WP_\
M^"N#_P")K1_X270CHG]LC6M._LLG OOM:>1UQ_K,[>O'7K5*Y\1Q2>(M%M--
MUG0VAO4>62"6Z!N)X]IV- H.&&0<GD8!Q1UL!'_PKCP1_P!";X?_ /!7!_\
M$T?\*X\$?]";X?\ _!7!_P#$UK+KFDM>75HNJ61N;-/,N81<)O@7KN=<Y4>Y
MJ"Q\4^']4FAATS7=-O);A6:%+>\CD:0*<,5 )R!WQTH H?\ "N/!'_0F^'__
M  5P?_$T?\*X\$?]";X?_P#!7!_\36M%KFDSZM+I<&IV<FHPKNDLTN$,R#U*
M Y _"GV>KZ;J%S<6]AJ%K=3VK;+B*&97:%O1@#E3]: ,;_A7'@C_ *$WP_\
M^"N#_P")H_X5QX(_Z$WP_P#^"N#_ .)KI** .;_X5QX(_P"A-\/_ /@K@_\
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M?VE'>Z;:/8*'GM6M98RX;='Y:B0\C/[PY&3US7I]%"=G?^OZU8GKOZA1112
M*YOQ1_R,7@S_ +#4G_IOO*Z2N;\4?\C%X,_[#4G_ *;[R@#I**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H[FY@L[66ZO)HX+>%#
M)++*X5(U R68G@  9)-25S?Q'_Y)9XK_ .P+>?\ HAZ #_A8_@C_ *'+P_\
M^#2#_P"*H_X6/X(_Z'+P_P#^#2#_ .*KI** .;_X6/X(_P"AR\/_ /@T@_\
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M6/X(_P"AR\/_ /@T@_\ BJ/^%C^"/^AR\/\ _@T@_P#BJZ2B@#F_^%C^"/\
MH<O#_P#X-(/_ (JC_A8_@C_H<O#_ /X-(/\ XJNDHH YO_A8_@C_ *'+P_\
M^#2#_P"*H_X6/X(_Z'+P_P#^#2#_ .*KI** .;_X6/X(_P"AR\/_ /@T@_\
MBJ/^%C^"/^AR\/\ _@T@_P#BJZ2B@#F_^%C^"/\ H<O#_P#X-(/_ (JC_A8_
M@C_H<O#_ /X-(/\ XJNDHH YO_A8_@C_ *'+P_\ ^#2#_P"*H_X6/X(_Z'+P
M_P#^#2#_ .*KI*YOXC_\DL\5_P#8%O/_ $0] '24444 %%%% !1110 5S?PX
M_P"26>%/^P+9_P#HA*Z2N;^''_)+/"G_ &!;/_T0E '24444 %%%% !1110
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M&BKNWAI(V(/;DD=,#UZ70I[SQ/>0>)-/\0W*:%,H-O81I;LDX&1O9C&77/\
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M<G@^P["E@^&?A.VTE],BTV4VK7HU#:][.[+< Y$JN7+*V>N",]ZTO'FOT_\
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MSDX8XZ<]:3^%]]?R7_!*5KZ[:?F[_@:UCX[M-9U3PF!JUSI<VJ0/-_9DVDS
M7O[O)"RN@"A#DY!^88[$5O67C3P_J.I1V%GJ DFE9TA8Q.L<S(2'5)"H1V7!
MR%)(Q7('P+XED\0> ;V3^RO)\-6SPW86ZDW2%XA&=@\K! "YY*YSCC&3#I?P
MRUC3I?#FG"XLCI.@ZQ-J$<XE?SYD<.50ILV@AI,$[CD#/'2K?+?3N_S_ ,B-
M>2_6R_)_\#[SIX/B=X2N+K[.FJ.L@OQIS"6SGC"7)Z1L60!2<<$X![&M.?Q9
MHEOKJZ/+? 7I=8RHC<HCL,JC.!L5F'(5B">P->67GPN\9S_;_+&A?Z3XG374
MW7\PPJ_\LS^XZ].?K701_"^7_A8&IZI?>7?:9J%W#J"HVIW4+6T\8&/W*'RY
M1E006P1[CBICK:_]:+_@_<7/2_+_ %J_^!]YU%AX^\-ZG?/9V5]))<1WIL)(
MS:3*8YP"=C90;> <$\''!KHZXSP#X7U?PWJ'B>;5Q8[-6U62_@-K.\C*K #:
MX9%P1@=,]3Z<]G2Z+T7Y?YB>[L%%%% !7-_$?_DEGBO_ + MY_Z(>NDKF_B/
M_P DL\5_]@6\_P#1#T =)1110 4444 %%%% !7-_#C_DEGA3_L"V?_HA*Z2N
M;^''_)+/"G_8%L__ $0E '24444 %%%% !1110!QNLV#Z9\4-+\4,K&REL)-
M,N7 R("75XW/HI(92>Q*YXYK+T/PMXMTGXE>)_$LEKHLD&LQ1K%"NHRAHS$A
M5-Q\C&&XSC[O;=W]&HH6BMZ_CJ-N]_.WX?\ #(\BT3X7>(HOAW>^'=6ETN*X
M&JC5;2>VN))4:02B3RW5HU(7C&02><XXYM:K\//$FIZ9XZD+:7'?^*4MXHH?
MM4AA@1(PK$OY62<[L87G Z5ZG10]5;IM^7^2$M'?^N_YL\BC\$Z_IE[KFKZ_
M::1<:?-X:337MH+N>1G,2=P(0=K'(XY'&,FLWX/ZJ;OQ=_I.C&2X33Q9Q:A%
MK]KJ*VT"<K"5@4&-<]&?<Q/!)KV^BJ4G>_\ 77_-D\JY;+^MO\D<!X_\*^(_
M$7BKPU?Z-!I+VNB7)NG6\O)(VG)&TIA87 &.^3UZ<<U?"W@SQ1X+\8:BFA+I
M1\(7\XF6PEO91+:LWWVB AV@=?DSC@?,*])HJ5I_7?\ X8IZ_P!?UW9Y;IGP
MRUC39/#NGK<6+:3H.L3ZA'.)7$\R.'*H4V;00TF"=QR!GCI6)%\+/&B>1N&@
M_N_%3>(&Q?S?=/\ RR_U'7K\WZ5[;15*33O_ %T_R0/6]^O_  ?\V?/>NZBF
MG_$N_M!X>%_8_P!KKJ#6-MK]O"\TZ ?OOLLB"=WX)VJP1L# /6O4K6R;6OBL
M=>B#BRTK3GL$=E($LSR!G SU"A%!(XR2.QKLJ*4=$EV_RM^7]:!+5M]_\[_F
M%%%%( HHHH **** .;^(_P#R2SQ7_P!@6\_]$/725S?Q'_Y)9XK_ .P+>?\
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M'_0Y>'__  :0?_%4?\+'\$?]#EX?_P#!I!_\57244 <W_P +'\$?]#EX?_\
M!I!_\51_PL?P1_T.7A__ ,&D'_Q5=)10!S?_  L?P1_T.7A__P &D'_Q5'_"
MQ_!'_0Y>'_\ P:0?_%5TE% '-_\ "Q_!'_0Y>'__  :0?_%4?\+'\$?]#EX?
M_P#!I!_\57244 <W_P +'\$?]#EX?_\ !I!_\51_PL?P1_T.7A__ ,&D'_Q5
M=)10!S?_  L?P1_T.7A__P &D'_Q5'_"Q_!'_0Y>'_\ P:0?_%5TE% '-_\
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MZ;[R@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ,*/4/\ X_1_P@>D?\_GB#_PH]0_^/T =)17-_\ "!Z1_P _GB#_ ,*/4/\
MX_1_P@>D?\_GB#_PH]0_^/T =)17-_\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D
M?\_GB#_PH]0_^/T =)17-_\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D?\_GB#_P
MH]0_^/T =)17-_\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D?\_GB#_PH]0_^/T
M=)7-^*/^1B\&?]AJ3_TWWE'_  @>D?\ /YX@_P#"CU#_ ./U):>"='L]3M;]
M6U2>XLW:2#[9K%W<I&Q1D+!))67.UV&<?Q&@#H**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"617AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0=NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 &5F:6QE+F5D
M9V%R   !ZAP !P  " P   AH     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_P"1:/\ A%]7_P"A[\0?]^-/_P#D6@#I**YO_A%]7_Z'OQ!_WXT__P"1:/\
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M]K\FJWQ>Y:6;SFBFM;5R6SG_ %QA\\ 'IB3@8 XXKN**-G<.E@HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** .;\+_\ (Q>,_P#L-1_^F^SKI*YOPO\ \C%XS_[#4?\ Z;[.NDH
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MC2O"?AS0;IKK0] TO3;AT,;2V=E'"[*2"5)4 XR <>PK7HHH **** "BBB@
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M+I5D-49=AOA;IYY7&,>9C=C''6LK_A/-(_Y\_$'_ (3FH?\ QBC_ (3S2/\
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M8?\ GET^Y_L]*H_\)YI'_/GX@_\ "<U#_P",4?\ ">:1_P ^?B#_ ,)S4/\
MXQ0!9M/!7A;3[R"[L/#6CVMS;_ZF:&PB1XNOW6"Y'4]/4TY_!WAF5'63PYI+
MK)-Y[AK&(AI>3O/R\MR>>O)JI_PGFD?\^?B#_P )S4/_ (Q1_P )YI'_ #Y^
M(/\ PG-0_P#C% &I+HUD+F6^LK2TM]3>(Q+>_9E,B@G.">"1DYQG%&B:+;Z#
MI@L[4O(2[2RS28WS2.=SNV !DDYX '8<5E_\)YI'_/GX@_\ "<U#_P",4?\
M">:1_P ^?B#_ ,)S4/\ XQ0!TE%<W_PGFD?\^?B#_P )S4/_ (Q1_P )YI'_
M #Y^(/\ PG-0_P#C% !X7_Y&+QG_ -AJ/_TWV==)7+>#)C>:AXHOUMKR"WO-
M662#[9:2VSR*+*V0L$D56QN1AG'\)KJ: "BBB@ HHHH **** "BBB@ HHHH
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M%OCKYA!^7&#UQ5J&_L[BU@N;>[@E@N,>3*D@99<\C:1P<^U %BBBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ I&4.I5P&5A@@C((I:* /EO3?@:T7[1DFF26Q/AVV(
MU121\K0EODB_[[!7']U2:^I*R-5\)^'->NENM<T#2]2N$01K+>64<SJH)(4%
M@3C))Q[FJ7_"N/!'_0F^'_\ P5P?_$T =)17-_\ "N/!'_0F^'__  5P?_$T
M?\*X\$?]";X?_P#!7!_\30!TE%<W_P *X\$?]";X?_\ !7!_\31_PKCP1_T)
MOA__ ,%<'_Q- '245S?_  KCP1_T)OA__P %<'_Q-'_"N/!'_0F^'_\ P5P?
M_$T =)17-_\ "N/!'_0F^'__  5P?_$T?\*X\$?]";X?_P#!7!_\30!TE%<W
M_P *X\$?]";X?_\ !7!_\31_PKCP1_T)OA__ ,%<'_Q- '245S?_  KCP1_T
M)OA__P %<'_Q-'_"N/!'_0F^'_\ P5P?_$T =)17-_\ "N/!'_0F^'__  5P
M?_$T?\*X\$?]";X?_P#!7!_\30!TE%<W_P *X\$?]";X?_\ !7!_\31_PKCP
M1_T)OA__ ,%<'_Q- '245S?_  KCP1_T)OA__P %<'_Q-'_"N/!'_0F^'_\
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MC_H3?#__ (*X/_B:/^%<>"/^A-\/_P#@K@_^)H Z2BN;_P"%<>"/^A-\/_\
M@K@_^)H_X5QX(_Z$WP__ ."N#_XF@#I**YO_ (5QX(_Z$WP__P""N#_XFC_A
M7'@C_H3?#_\ X*X/_B: .DHKF_\ A7'@C_H3?#__ (*X/_B:/^%<>"/^A-\/
M_P#@K@_^)H Z2BN;_P"%<>"/^A-\/_\ @K@_^)H_X5QX(_Z$WP__ ."N#_XF
M@#I**YO_ (5QX(_Z$WP__P""N#_XFC_A7'@C_H3?#_\ X*X/_B: .DHKF_\
MA7'@C_H3?#__ (*X/_B:/^%<>"/^A-\/_P#@K@_^)H Z2BN;_P"%<>"/^A-\
M/_\ @K@_^)H_X5QX(_Z$WP__ ."N#_XF@#=OK*WU+3[BQOHEGMKF)HIHG&0Z
M,,$'Z@U\U?"SX+7&E_'+4O[7A:33?#<HEMI9%XN7?F ],'"_,<=&4"O>/^%<
M>"/^A-\/_P#@K@_^)K2TCPYH?A_SO[!T;3],\_;YOV*U2'S-N<;MH&<9.,^I
MH TJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH X?X;?\A#QQ_V,\_\ Z(@KN*X?
MX;?\A#QQ_P!C//\ ^B(*[B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME5C"V,[6 /RG'.#4T,T=Q"DT$B2Q2*&1T8%6!Z$$=10 ^BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBL'QMHU]K_ (,U+3]'U"YTW4)(
MB;6YM9VB=)%Y4;E(."1@^Q- &+\-O^0AXX_[&>?_ -$05W%?,7[.6F>*M6\:
MZIJ6L:QJZV&G2L;JWEO)-MS>,-I\Q<X8JJ\YR>$KZ=H **** "BBB@ HHHH
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M[W3M0T?6%M_M*VM\L9\V+.-RO$[H>>,9SQTKIZ .;_X1?5_^A[\0?]^-/_\
MD6C_ (1?5_\ H>_$'_?C3_\ Y%KI** .;_X1?5_^A[\0?]^-/_\ D6C_ (1?
M5_\ H>_$'_?C3_\ Y%KI** .;_X1?5_^A[\0?]^-/_\ D6C_ (1?5_\ H>_$
M'_?C3_\ Y%K3\0:U%X=\/7VL7%M/<PV4+32Q6X4R%%Y8C<RC@9/7M6#I_P 2
M-,U'6O#^G16.H1MX@L#?6<TB1^6$"[BK8<L& ([$<]>M"UV_K?\ R8/17?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTW_T??5TE<W8_P#)4]=_[ NF_P#H^^H Z2BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF_\ A ](_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^@#I**YO_ (0/2/\
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M7-_\('I'_/YX@_\ "CU#_P"/T?\ "!Z1_P _GB#_ ,*/4/\ X_0!TE<W8_\
M)4]=_P"P+IO_ */OJ/\ A ](_P"?SQ!_X4>H?_'ZNZ-X8TW0;JYNK#[8]Q=)
M''-+>7\]T[*A<HH,KL0 9'.!C[QH UZ*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#F_"_P#R,7C/_L-1_P#IOLZZ2N;\+_\
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M /P:0?\ Q5'_  L?P1_T.7A__P &D'_Q5 '245S?_"Q_!'_0Y>'_ /P:0?\
MQ5'_  L?P1_T.7A__P &D'_Q5 '245S?_"Q_!'_0Y>'_ /P:0?\ Q5'_  L?
MP1_T.7A__P &D'_Q5 '245S?_"Q_!'_0Y>'_ /P:0?\ Q5'_  L?P1_T.7A_
M_P &D'_Q5 '245S?_"Q_!'_0Y>'_ /P:0?\ Q5'_  L?P1_T.7A__P &D'_Q
M5 '245S?_"Q_!'_0Y>'_ /P:0?\ Q5'_  L?P1_T.7A__P &D'_Q5 '245S?
M_"Q_!'_0Y>'_ /P:0?\ Q5'_  L?P1_T.7A__P &D'_Q5 '245S?_"Q_!'_0
MY>'_ /P:0?\ Q5'_  L?P1_T.7A__P &D'_Q5 '245ST'Q \'75U#;6GBO1+
MBXGD6***'4(G>1V. H ;)))Q70T %%%% !1110 4444 %%%% !1110 4444
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MP ' 8+P"02 :Z"BG<#*U/PY8:Q;ZA!J DE34+?[-)\V-D>/NKCIR<YZDX[
M.T#0H/#VFM:03SW323//-<7)4R32,<EFVA5_    "M.BD&YY1\7/''ANRN-%
MTJ[U:&&^LM?T^ZN('#!HXEE5V<\= O/%>CZ'KVF>)-*34M#NTO+*1BJ3Q@[6
M(.#C(YP>*\E^/?PFNO'%UHNJ:#$/MZSI973 =(';B0^H0D_@WM7K>A:-:>'=
M L='TU-EK90K#&.^ ,9/N>I]S0!?HHHH **** "BBB@ HHHH **** "BBB@
MHHJO?7]GIEG)>:E=06=M$,R3W$@C1!ZECP* +%%06E[:W]NEQ8W,-S#(H=)(
M9 ZLIZ$$<$'UJ>@ HHHH ***.G6@ HJ"SOK34;5;G3[J&ZMV)"RP2!U.#@X(
MXX((J666."%Y9W6..-2SNYPJ@<DDGH*-@'45AV/CCPGJ=Y'::;XGT:\N9#A(
M;?4(I'<^RALFMR@ HHHH **** "BBJ6H:SIFDR6Z:IJ-I9/=2>5 MS.L9F?^
MZNXC<>>@H NT5#>7EMI]G+=W]S#:VT*[I)IG"(@]2QX J565T#(P96&00<@B
M@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KF_AQ_R2SPI_P!@6S_]$)725S?P
MX_Y)9X4_[ MG_P"B$H Z2BBB@ HHHH **\@USQ/>Z;\7M3T/5_B%-H.DKIBW
MMLTJ6*;96<CRP9(26  X'+>]=-X*\5:HGP]75_B%MLIDG:))F@:)KF/=B-_*
MQN#/GA ,GC YQ0M5?^M[ ]';^MKG<T5@R^-_#\.CPZG)?-Y%Q/\ 9XD6WE:9
MYLD&,0A?,WC!RNW(P<BH+/X@^&K_ $*36+>]F^Q1S_9@\EE/&TDN<>6B,@:1
ML\84$YXZT =+17-7?Q"\,V-KIEQ=:BR0ZK.;>T<6LQ#2@X,;83Y'SD;7P<@^
MAJQ:>-?#U[H-SK4&I(+"UF:">26-XVCD5MI0HP#!LD#&,G(QUH W:*YZ/QWX
M=ETI]06^D$27)M#$UK,L_G8SY0@*>87QSM"YQS7.^)/%MW_PEG@63P[JY.E:
MS=RP7$2Q(5E4(2.67>K C! (]"*.J0='_6QZ'17!?"S7M7UM?%$6N:@]^VFZ
M[/96\CQ1HPB0+@'8J@GD\XJGHFIZ_-\=-:T*Y\17D^DV%E'=Q6K6]L 3(<;"
MPB#%1GCD'@9)YR[:I=U?\+A+W;WZ.WXV/2:*YKQ#KD-AXJ\/:<^MOITMY.^+
M7[ TJWX"']WYN,1D$ALYR<56_P"%I^#E6=Y=7:".WO/L-Q)/:31I!-_=D9D
M3ZL0#ZT@_K^ON.NHKC;_ .(&@7_@_7+_ $G7VM%TY3%/>KI\LS6;L/ED,17+
MKR&SC:1SG%-_X6'I]MXA\/Z!NN[^?5+,7/VN*PE*LF %?"J=NXG)[*.I'%.S
M;M_7</Z_K[SM**Q;/Q?H6H:I+I]I?K)<1!\GRW$;[#APDA&QRIX8*3M[XKB[
M_P ?C5/&_@QO"NN3R:3JUQ/!<0-9A(YU1&.]&DC#GYA@E6QP/Q2U:7<-D_(]
M.HHHH **** .;^(__)+/%?\ V!;S_P!$/725S?Q'_P"26>*_^P+>?^B'KI*
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MHP2]XMRAA7'!R^<#'UI#,O\ X5QX(_Z$WP__ ."N#_XFC_A7'@C_ *$WP_\
M^"N#_P")K1_X270CHG]LC6M._LLG OOM:>1UQ_K,[>O'7K5*Y\1Q2>(M%M--
MUG0VAO4>62"6Z!N)X]IV- H.&&0<GD8!Q1UL!'_PKCP1_P!";X?_ /!7!_\
M$T?\*X\$?]";X?\ _!7!_P#$UK+KFDM>75HNJ61N;-/,N81<)O@7KN=<Y4>Y
MJ"Q\4^']4FAATS7=-O);A6:%+>\CD:0*<,5 )R!WQTH H?\ "N/!'_0F^'__
M  5P?_$T?\*X\$?]";X?_P#!7!_\36M%KFDSZM+I<&IV<FHPKNDLTN$,R#U*
M Y _"GV>KZ;J%S<6]AJ%K=3VK;+B*&97:%O1@#E3]: ,;_A7'@C_ *$WP_\
M^"N#_P")H_X5QX(_Z$WP_P#^"N#_ .)KI** .;_X5QX(_P"A-\/_ /@K@_\
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M?VE'>Z;:/8*'GM6M98RX;='Y:B0\C/[PY&3US7I]%"=G?^OZU8GKOZA1112
M*YOQ1_R,7@S_ +#4G_IOO*Z2N;\4?\C%X,_[#4G_ *;[R@#I**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H[FY@L[66ZO)HX+>%#
M)++*X5(U R68G@  9)-25S?Q'_Y)9XK_ .P+>?\ HAZ #_A8_@C_ *'+P_\
M^#2#_P"*H_X6/X(_Z'+P_P#^#2#_ .*KI** .;_X6/X(_P"AR\/_ /@T@_\
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M6/X(_P"AR\/_ /@T@_\ BJ/^%C^"/^AR\/\ _@T@_P#BJZ2B@#F_^%C^"/\
MH<O#_P#X-(/_ (JC_A8_@C_H<O#_ /X-(/\ XJNDHH YO_A8_@C_ *'+P_\
M^#2#_P"*H_X6/X(_Z'+P_P#^#2#_ .*KI** .;_X6/X(_P"AR\/_ /@T@_\
MBJ/^%C^"/^AR\/\ _@T@_P#BJZ2B@#F_^%C^"/\ H<O#_P#X-(/_ (JC_A8_
M@C_H<O#_ /X-(/\ XJNDHH YO_A8_@C_ *'+P_\ ^#2#_P"*H_X6/X(_Z'+P
M_P#^#2#_ .*KI*YOXC_\DL\5_P#8%O/_ $0] '24444 %%%% !1110 5S?PX
M_P"26>%/^P+9_P#HA*Z2N;^''_)+/"G_ &!;/_T0E '24444 %%%% !1110
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M&BKNWAI(V(/;DD=,#UZ70I[SQ/>0>)-/\0W*:%,H-O81I;LDX&1O9C&77/\
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M<G@^P["E@^&?A.VTE],BTV4VK7HU#:][.[+< Y$JN7+*V>N",]ZTO'FOT_\
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MSDX8XZ<]:3^%]]?R7_!*5KZ[:?F[_@:UCX[M-9U3PF!JUSI<VJ0/-_9DVDS
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M%%%%( HHHH **** .;^(_P#R2SQ7_P!@6\_]$/725S?Q'_Y)9XK_ .P+>?\
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M'_0Y>'__  :0?_%4?\+'\$?]#EX?_P#!I!_\57244 <W_P +'\$?]#EX?_\
M!I!_\51_PL?P1_T.7A__ ,&D'_Q5=)10!S?_  L?P1_T.7A__P &D'_Q5'_"
MQ_!'_0Y>'_\ P:0?_%5TE% '-_\ "Q_!'_0Y>'__  :0?_%4?\+'\$?]#EX?
M_P#!I!_\57244 <W_P +'\$?]#EX?_\ !I!_\51_PL?P1_T.7A__ ,&D'_Q5
M=)10!S?_  L?P1_T.7A__P &D'_Q5'_"Q_!'_0Y>'_\ P:0?_%5TE% '-_\
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MZ;[R@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "N;\>?\ (NVO_8:TK_TX6]=)5'6-'LM>
MTQ[#4TD>W=XY/W4SPNK(ZNC*Z$,I#*I!!'2@"]17-_\ "!Z1_P _GB#_ ,*/
M4/\ X_1_P@>D?\_GB#_PH]0_^/T =)17-_\ "!Z1_P _GB#_ ,*/4/\ X_1_
MP@>D?\_GB#_PH]0_^/T =)17-_\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D?\_G
MB#_PH]0_^/T =)17-_\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D?\_GB#_PH]0_
M^/T =)17-_\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D?\_GB#_PH]0_^/T =)17
M-_\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D?\_GB#_PH]0_^/T =)17-_\ "!Z1
M_P _GB#_ ,*/4/\ X_1_P@>D?\_GB#_PH]0_^/T =)17-_\ "!Z1_P _GB#_
M ,*/4/\ X_1_P@>D?\_GB#_PH]0_^/T =)17-_\ "!Z1_P _GB#_ ,*/4/\
MX_1_P@>D?\_GB#_PH]0_^/T =)17-_\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D
M?\_GB#_PH]0_^/T =)17-_\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D?\_GB#_P
MH]0_^/T =)17-_\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D?\_GB#_PH]0_^/T
M=)7-^*/^1B\&?]AJ3_TWWE'_  @>D?\ /YX@_P#"CU#_ ./U):>"='L]3M;]
M6U2>XLW:2#[9K%W<I&Q1D+!))67.UV&<?Q&@#H**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  U 5L# 2(  A$! Q$!_\0
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M[LOY9?REC]ALY_X+^_%7_KYUO_T9%7ZVMUK\DOV&&\S_ (+]_%0]0;G6R/\
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M;>>.WD<R>9'G>?ZU]/?\1-GAS/\ R2G7<'_J-0?_ !%?H9KG[/?@'7]4GO\
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M<R.#[-_P5]_Y,9U3_L:/"G_J1Z;110!]#>*+"\OO"NI0:;>KIFH36LBVUYY
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1 'WK1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  W G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]DOCK^V=;
M?"+XE:=X)T7P;XN^(?C._L'U:32_#T,+?V=9*X03W,LLB)$'<[4!.YR&P,*2
M+_PI_;8\ ?$KX3R>+;W6+?P5;65Q<6.JV/BB:+2[S1+JW(6>WN5D?:CIN4DA
MBI5T8$A@3Y]\5O WQ*^!?[4VN?$WX?>#+;XCZ5X^T:QTC7]$;5HM+O\ 3Y[!
MK@VMS;R2CRWB9;F59$)# A&&1N%>5>$?^">_BOXD_&GPGX^^)_A'PE?7&L^(
MO$'BWQ#HDDL=_9^'Y[G2K;3;&",LNVX=8;6/?)MQO=R!C!H ^R?%/QM\&>![
MK1H=:\7>&-'F\1,%TF.^U6"W;4R<8$ =@92=RXV9^\/6LCXU?M":1\"]<\"V
M.K6][-)\0?$T/A73C;QAQ'=2VUQ<*TG(VQ[;:0$\\E>.:_,S6O\ @D/\5K_0
M_"-AXAT#5O$MG/\ #O3_  7):Z-XITZQ7PO+!/,T@=[NUG<P/YL<@DM"LBF+
M&#A2/LK]LSX&^.I?AK\ V\#^''\;ZG\)?&FEZS?V$VLI;SWEK;Z9>VCLMQ.
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MC?ZSI,VMZ5)XA:V%MJ5K (VG998I'5&C66-F#[>#G/%>BQ?M+?#F9-#*>/\
MP2P\32M!HY&N6I&K2*VQDM_G_>L&^4A,D'CK7YZZ9_P3U^(WB*UU>#P[\*-6
M^'4=W\/=6\-ZLWB/X@GQ)_PD,EQ:K';VT"222_90LZK(\JE053800>-CXO\
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M_/\ ?_@'_P!L'M\=_P ^E_X%_P  ^N_M(_R:/M(_R:^1/^'+?PN_Z&+XN?\
MA;WW_P 71_PY;^%W_0Q?%W_PM[[_ .+H^K8#_G^__ /_ +8/;X[_ )]+_P "
M_P" ?7?VD?Y-'VD?Y-?(G_#EOX7?]#%\7/\ PM[[_P"+H_X<M_"[_H8OBY_X
M6]]_\71]6P'_ #_?_@'_ -L'M\=_SZ7_ (%_P#Z[^TC_ ":/M(_R:^0_^'+?
MPN_Z&'XN?^%O??\ Q=+_ ,.6_A=_T,7Q<_\ "WOO_BZ/JV _Y_O_ , _^V#V
M^._Y]+_P+_@'UW]I'^35:]LK349H7G@AF:W<2Q&1 WE.,X9<]&Y/(]:^3?\
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M_P#"WOO_ (NC_ARW\+O^AB^+G_A;WW_Q='U; ?\ /]_^ ?\ VP>WQW_/I?\
M@7_ /KO[2/\ )IAD4N&ST]Z^1_\ ARW\+O\ H8OB[_X6]]_\71_PY;^%W_0Q
M?%W_ ,+>^_\ BZ/JV _Y_O\ \ _^V#V^._Y]+_P)?Y'UW]I'^31]I'^37R)_
MPY;^%W_0Q?%S_P +>^_^+H_X<M_"[_H8OBY_X6]]_P#%T?5L!_S_ '_X!_\
M;![?'?\ /I?^!?\  /KO[2/:C[4/:OD3_ARU\+O^AB^+G_A<7W_Q='_#EKX7
M?]#%\7/_  N+[_XNCZM@/^?[_P# /_M@]OCO^?2_\"_X!]=_:1_DT?:1_DU\
MB?\ #EOX7?\ 0Q?%S_PM[[_XNC_ARW\+O^AB^+G_ (6]]_\ %T?5L!_S_?\
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M\.6_A=_T,7Q<_P#"WOO_ (NC_ARW\+O^AB^+G_A;WW_Q='U; ?\ /]_^ ?\
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M:1_DT?:1_DU\B?\ #EOX7?\ 0Q?%S_PM[[_XNC_ARW\+O^AB^+O_ (6]]_\
M%T?5L!_S_?\ X!_]L'M\=_SZ7_@7_ /KO[2/\FC[2/\ )KY$_P"'+?PN_P"A
MB^+G_A;WW_Q='_#EOX7?]#%\7/\ PM[[_P"+H^K8#_G^_P#P#_[8/;X[_GTO
M_ O^ ?7?VD?Y-'VD?Y-?(G_#EOX7?]#%\7?_  M[[_XNC_ARW\+O^AB^+G_A
M;WW_ ,71]6P'_/\ ?_@'_P!L'M\=_P ^E_X%_P  ^N_M(_R:/M(]J^1/^'+?
MPN_Z&+XN_P#A;WW_ ,71_P .6_A=_P!#%\7?_"WOO_BZ/JV _P"?[_\  /\
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MU>:;XK64O;17EI$\\]E<KC]V[PJ7A()\PHZ?>VAN8\-_\%1O!'@KX5^%=?\
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M^+$U+XM:E#J&N3:GX@BN[>"9K>>Y9D4 ,J)=2&$CDD,&' H _&<>'_B9HO\
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ME%% !B@C(HHH ,48YHHH ,4N*** $Q2T44 )BEQ110 F.:7%%% !BDQFBB@
MVT8HHH ,48HHH ,9I<444 )BC%%% "TF*** %QFDQ110 8YHQ110 8HQ110!
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] G # 2(  A$! Q$!_\0
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M-Q%"&. 9'"Y_.A*^P7L<K<>&=4U>Y^WZJU@MSY]J%AAW/&D$4PE898 LS'V
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M38% ?)0X=N@(&W@$=CI\\]S8Q37-N;>9L[HB<[>3C],'\:C_ +8TS_H(V?\
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MU6O/ ;WNE3Z9-<@VTVI17+LKLCF%84C(W#D.=N?3FNJ_MC3/^@C9_P#?]?\
M&C^V-,_Z"-G_ -_U_P :.278.:/<I:!'J5E"NEWT<+I:PJL5U"-JRC+  K@!
M6VJI('&3QQBL35/!-U?:/K,4-W##?W-S<36LVTE525 C(X[@@<X[A3VKJ/[8
MTS_H(V?_ '_7_&C^V-,_Z"-G_P!_U_QHY)=@YH]RC/H7G>(=&U,B$_V?;S1$
MD?.2X0 @^VUOSJSXATZ75_#FI:;"Z)+=6TD*,^=H+*0"<=JE_MC3/^@C9_\
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M@#I__?A:WJ*/;5?YG][_ ,P]E#^5?<8/_"$^%_\ H Z?_P!^%H_X0GPO_P!
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M ]31[:K_ #/[W_F'LH?RK[C"_P"$)\+_ /0!T_\ [\+1_P (3X7_ .@#I_\
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M" ,@CL#U JA)\/M*> P+=ZC'')&J7(2XYN2':0-(2"2V]V)QC.X@@CBNKHH
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&Q110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Z X0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#G]>_Y&+4_
M^ON7_P!#-9]:&O?\C%J?_7W+_P"AFNP^%V@:7KMSJ2ZG:+<+$D90,Q&W);/0
MCT%?32J*E2YWT2_0^3A2=6MR1W;?ZGG]%?1/_"O?"G_0'B_[^/\ _%4?\*]\
M*?\ 0'B_[^/_ /%5R?VG2[,[?[*J]U^)\[45]$_\*]\*?] >+_OX_P#\51_P
MKWPI_P! >+_OX_\ \51_:=+LP_LJKW7XGF7PC_Y'-_\ KT?^:U[G6-I?A/0]
M%NS=:=IZ03E2F]68\'J.3[5LUYN*K1K5.>)ZN#H2H4N27<*J:I_R"+W_ *X/
M_P"@FK=5-4_Y!%[_ -<'_P#037/'='1+X6?+=%%>N?"W0-(U7PQ<SW^G6US*
MMXR!Y8PQ"[$./U/YU]-7K*C#G:N?*X>@Z\^1.QY'17TI_P (=X;_ .@'8?\
M?D4?\(=X;_Z =A_WY%<7]IP_E?X'?_9-3^9?B?-=:5CX@UC37#6>IW4..RRG
M:?J.AKWR;P+X7G!#Z+:C/]P%/Y$5YK\0O -KX?M$U32VD%L9 DD+MNV$]"#U
MQQCFM*>-I5I<C6_<RJX"M0BYI[=CH/ WQ*?5;N/2M:V+<R';#<*-HD;^ZPZ
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M#C?9/V=3X?R_X![W14<$\5S!'/!(LD4BAD=#D,#T(-25X9] %?*MU_Q]S?\
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M&BN/^S*?\S_ [?[6J_RK\3Z._P"$Z\,?]!JU_,_X4Z/QMX:ED6--8MF=R%4
MGDG\*^;ZMZ7_ ,A>R_Z[I_Z$*'EM-*]W^ UFM5NW*OQ/J2BBBO%/="JFJ?\
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MUZ=7COP9S_:VJ=<>0G_H5>Q5RXY)5Y6.O+Y-X>-PKYF\4?\ (W:U_P!?\_\
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M0?E'YX_ &N5N;F6\NIKF=R\TSF1V/=B<DU[I\+]#_LGPJMU(N+B_(F;/4)_
M/RR?^!5ZU=K#8;D6^W^9X^'3Q6*YWMO_ )'A=U_Q]S?]=&_G7N?PI_Y$B/\
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MHH **** /F;Q1_R-VM?]?\__ *,:N\^"_P#Q^:Q_USB_FU<'XH_Y&[6O^O\
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M%# _@:NE/DFI=C.K#VE-P[H^5:*^G_[ T;_H$V'_ (#)_A1_8&C?] FP_P#
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MM(A%;01PQ@Y"1H%'Y"O1K8]2I>SA&W^1YE'+G"K[2<K]?F2T445YIZ@4444
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M6]I;IODE<\*/ZGL!W)KS:'XI>(O$CN_@SP3<W]FK%1>7DRP(^.N,X'_CV>G
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MK/QQ\%H;>1A!J$%W-)9W:CYHGR._7:>,C\>H% 'O5<IK/C3^R/'>A>&?[/\
M-_M5';[3YVWRMH)^[M.[IZBN>^'/CN\GO9?!WBW_ $?Q)8_(K2'_ (^U'<'N
MV,'_ &ASZXJ^,_\ DNW@7_KE-_Z"U 'JU<;\0/'4O@B#3&@T@ZG-?W'V>.(7
M'E'=CCG:V<DXKLJ\I^,W_(0\$?\ 8:C_ )K0!8_X6+XX_P"B6WW_ (,!_P#&
MZ2T^,UM:ZA#8^+/#NI^'99CA);A2\7XMA3CW ('?%>GUC^*/#UGXI\.7FD7L
M2.D\9",PR8WQ\KCT(- &M'(DL:R1NKHX#*RG((/0@TZO,_@1JT^J?#6**=V<
MV-S):H6.3M 5P/P#X'L!7IE !1110 5Y=XB^--CH'C&311I4ES8VTL<-[J*S
M86!FZC;M.<#/<9(([5UOCSQ5#X-\(7NKN5,RKY=LA_CF;[H^G<^P-<9X-^&T
M=S\*;VRU@$ZGX@4W=S-(,NCGYHL^Z\,1ZLPH ]61UD171@R,,JP.01ZTM>;?
M!SQ#<7GA^X\-ZIE-7T&4VDJ,>3&"0A]\8*_11ZUZ30!RGQ"\:?\ "">&UU?^
MS_MVZX6#RO.\K[P8YSM;^[Z5S:?$?QM(BNOPNO2K#(/]H#D?]^Z@_:#_ .2;
MQ?\ 80B_]!>O3K#_ )!]M_UR7^0H \T'QDDTNYCC\6^#]6T*&1MHN6!FC!^N
MU<_AD^U>F6=Y;:A9PWEG.D]M,@>.6,Y5E/0@TS4=.M-6T^>PO[=+BUG0I)&X
MR&!_SUKS'X'R7%E!XG\-R2-)!H^IO%"6.2 2P(^F4S]6- '?^*]:NO#OAF]U
M>TT[^T'M$\UK?S?+)0?>(.UN@R>G:D\*>)+7Q;X9LM:M!L2X3+Q;MQB<<,A/
ML<\X&1@]ZV6570HZAE88((R"*\<\%L?AW\5-2\&3$KI.K'[7IA8\*W/RC\ 5
M^J+ZT >R5QDOCTR?$N/P;IVF?:W2'SKV[^T;%MAC.-NT[C@KW'+ 5M^*O$-O
MX5\,7^LW."EM$65"<;W/"K^)(%<9\&_#ES9Z'<^)]5R^KZ])]JD9ARL9)*C\
M<EOH5]* /2ZY#1_'/]K?$/6O"G]G>5_9D0D^U>?N\S.SC9M&/O\ J>E=?7D/
M@_\ Y.&\9_\ 7JG_ +2H ]>KAO%_Q)@\.ZQ%H.F:5=:UKLJ;Q9VW C!Z%VP<
M>O0\<G'%=S7C&NV_B/P'\5]2\7VF@S:UI6I0K')]FR9(<! > "1@IZ8(/4'H
M ;)\6?%-09C\/+;R>NT:C'OQ_P!]9S^%:/A?XIZ?K>L_V%JVGW6A:YG M+SH
MY]%; R?J!GMFLA/C[X61Q'?6&LV4G=9K9>/R;/Z5T&B>*? GCC6+6ZL;BSN]
M6M%8P":(I-&#][:& )_#.* .TK+\0>(=+\+Z1+JFKW*P6T?&3RSL>BJ.Y..G
M]*U*\=\8VZ>+_CGH/AN]_>:786IO)8#T=^3SZCB,?3/K0!>M_B5XQ\1(;GPM
MX"FFL"<QW-]<K#YJ^H!P/R8T/\5=;\.3Q+XW\&W6F6KMM^VVLHGB4GH#C(_\
M>)]J]350BA5 "@8  X J&]LK;4;*:SO($GMIT*21.,JRGJ#0 W3]0M-5L(+Z
MQN$N+6= \<L9R&%6:\C^#$DNE:KXN\(F9I;72K[-J6.2%9G!'M]Q3CU)KUR@
M#R>'XNZ]J.JZI9:-X"GU%=.N6MY)(K\#D,0"1Y?&=I.*LO\ $?QNBEF^%FH8
M'7;?;C^0CKB_ 'CWP_X,\2^-(];NI(&N=39HMD+/D*\F?N@XZBN\/QS\!A21
MJ5P2.PM).?TH$:/@[XE6'BK4Y]'GL+S2=9@7<]E>+AB.^T\9QD<$ \]Z[:O&
MO#]Y-\0_C%8^+M,TVYM=$TNT> W5Q'L-RQ#J /7[^>^ .<9 KV6@9R7C7Q_I
M_@P6MN]M<7^J7IQ:V-L,O(<XY]!DXZ$GL#@USH\7?%*X7S[?X>0)"PRJ3:A&
M' ]P6!S^%5?B/I'B'3/B#HGCK1=*.KQ6-L;>:SC&9 ,R<@ $\B0\@'!'/%/7
MX]:!;X35=%US3YNC++;K@'TSN!_2@1=TGXMQ+K,6C>+=#N_#E_,<1-.=\,AZ
M</@=^_(]Z])KSZR\<_#OQ]<6EE+<6EQ<QRB2WM[^ H1)T&W<,$^P)^E>@T#"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \,\8P:C\5?B6WAS2;U
M+;3M 3S);AH_,3[1D9R.YS\H!_NO72_\(3\2?^BD_P#E.2LG]G?Y_#6MW#_-
M-)J)WR'EF^13R>IY)_,U[)0!X#J>E^(/A5XUT_QGJVKC5[:_E^R:E+'!Y1"$
M#&0."<+N'NF.]>^1R)-$DD;J\;@,K*<@@]"*X7XSHC_"?6RRJQ40E<C.#YR<
MBM'X9N\GPT\/,[,Q^QH,DYX' _2@#F_C-HVH2:?H_BC28C->^'[K[28P,YCR
MI)QWP47/L373^%OB#X=\6Z=%<66H01SE09+2:0++&V.00>H]QP:ZBOE'XX6%
MGI_CQH[*T@MD:(.RPQA 6/4D =: /I#7_&GA[PS8/=ZGJEO& I*Q*X:23V51
MR?Y>N*ROAQXHUOQ?I%UJNJ:9%8V<DY_L_:3ODBR>6!].!D8SSP._S=\*+*TU
M#X@Z?;WMM#<P,W,<T8=3R.QXK[#50BA5 "@8  X H J:MI\>KZ-?:;,Q6*\M
MY+=R.H#J5/\ .O)/A?XO@\'Q3> _%DJ:;?6$S_9I9SMBE1F+<,>.I)!/!!'<
M5[/7E_QUL+.;P))>26D#W43A8YFC!= >H#=0* /1)-6TV* SR:A:)"!N,C3*
M% ]<YQBN!A^)TNO_ !"LM \)6L.HZ='EM2OFW!$7U1AZ<CD$,3@>M?*%?9GP
MVL;.R\#Z<;6U@@,L8>0Q1A=[>IQU/O0(ZVO&O' N_ 'Q4M/'J6TD^CWL0M-2
M,0R8^ N3^"H1ZE2.,BO9:9-#%<P/!/$DL4BE7C=0RL#U!!ZB@9EZ3XHT+7+-
M;O3=6M+B)AGY90"OLRGE3[$5@>-OB9H?A+3)MEY!>:JRE;>RA<.S.>FX#[JY
M]?PR:^7_ !Y;6]GXTU."U@B@A29@L<2!549/0#@5Z/\ L\V%G=:U?SW%I!--
M H:&22,,T9]5)&0?I0*YZ9\'?"U]X;\(23:JK)J6I3F[F1_O(" %#>_4GTW8
M[5Z'110,\4^&>M6W@3Q-X@\&>()UL7>]:YLYISM28,,?>/'(52/7D=>*]EDO
M+6*V^TR7,*08SYK. N/KTKS7XZV-G-X#DNY;6![F)PL<S1@N@/4!NHKY6H$?
M2&IZI#\0_C5X?@T1_M.F^'RUQ<7D?,>\D' /0@E$4$=>>PS7M-<=\+[&TL_
M6FM:VL$#31AY3%&%+MTRV.I]S78T#/*?CC_R#_"__8:B_D:]6KRGXX_\@_PO
M_P!AJ+^1KU:@#Q?Q5H.H?"[Q&_C7PK 9-'G(&JZ8F0J@GEP.PYX_ND_W20+7
MP*O(M1'BV^@#"*YU0S)N&#M;)&??!KUR6*.:)XI462-U*NC#(8'J".XKQ[X
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3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
